16198049	Gold	El-Sayed IH	Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles.	Cancer letters	2006	170
16464114	Gold	Huang X	Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods.	Journal of the American Chemical Society	2006	489
17430005	Gold	Chen J	Immuno gold nanocages with tailored optical properties for targeted photothermal destruction of cancer cells.	Nano letters	2007	143
17465586	Gold	Chithrani BD	Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes.	Nano letters	2007	281
17474783	Gold	Huang X	Cancer cells assemble and align gold nanorods conjugated to antibodies to produce highly enhanced, sharp, and polarized surface Raman spectra: a potential cancer diagnostic marker.	Nano letters	2007	59
18339879	Gold	Patra CR	Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.	Cancer research	2008	79
18566244	Gold	Melancon MP	In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy.	Molecular cancer therapeutics	2008	83
19216571	Gold	Mani V	Ultrasensitive immunosensor for cancer biomarker proteins using gold nanoparticle film electrodes and multienzyme-particle amplification.	ACS nano	2009	53
19706948	Gold	Roa W	Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle.	Nanotechnology	2009	50
20080552	Gold	Choi CH	Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles.	Proceedings of the National Academy of Sciences of the United States of America	2010	144
20410458	Gold	Chanda N	Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity.	Proceedings of the National Academy of Sciences of the United States of America	2010	54
20550178	Gold	Kim D	A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.	ACS nano	2010	86
20707386	Gold	Guo S	Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte.	ACS nano	2010	45
20863096	Gold	Huang X	A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands.	ACS nano	2010	91
20876255	Gold	Libutti SK	Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine.	Clinical cancer research 	2010	103
21081567	Gold	Hainfeld JF	Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions.	The British journal of radiology	2011	39
21275772	Gold	Jungwirth U	Anticancer activity of metal complexes: involvement of redox processes.	Antioxidants & redox signaling	2011	38
21591812	Gold	Agarwal A	Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods.	ACS nano	2011	38
22424173	Gold	Dam DH	Direct observation of nanoparticle-cancer cell nucleus interactions.	ACS nano	2012	38
23160926	Gold	Chattopadhyay N	Molecularly targeted gold nanoparticles enhance the radiation response of breast cancer cells and tumor xenografts to X-radiation.	Breast cancer research and treatment	2013	26
24821383	Gold	Sykes EA	Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency.	ACS nano	2014	54
25519743	Gold	Dixit S	Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors.	Nanoscale	2015	15
25652893	Gold	Wolfe T	Targeted gold nanoparticles enhance sensitization of prostate tumors to megavoltage radiation therapy in vivo.	Nanomedicine 	2015	20
25733851	Gold	Conde J	Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance.	Proceedings of the National Academy of Sciences of the United States of America	2015	16
26318788	Gold	Jolly P	Aptamer-MIP hybrid receptor for highly sensitive electrochemical detection of prostate specific antigen.	Biosensors & bioelectronics	2016	10
26761620	Gold	Liu Y	Human Induced Pluripotent Stem Cells for Tumor Targeted Delivery of Gold Nanorods and Enhanced Photothermal Therapy.	ACS nano	2016	15
8261513	ADP	Brown HA	ADP-ribosylation factor, a small GTP-dependent regulatory protein, stimulates phospholipase D activity.	Cell	1993	177
9428522	ADP	Gradia S	The human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch.	Cell	1997	108
10078208	ADP	Gradia S	hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on mismatched DNA.	Molecular cell	1999	110
10328216	ADP	Fritz G	Rho GTPases are over-expressed in human tumors.	International journal of cancer	1999	171
10455009	ADP	D'Amours D	Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.	The Biochemical journal	1999	444
11048711	ADP	Lamers MH	The crystal structure of DNA mismatch repair protein MutS binding to a G x T mismatch.	Nature	2000	209
11069113	ADP	Smith S	Tankyrase promotes telomere elongation in human cells.	Current biology 	2000	98
11259441	ADP	Vander Heiden MG	Bcl-xL promotes the open configuration of the voltage-dependent anion channel and metabolite passage through the outer mitochondrial membrane.	The Journal of biological chemistry	2001	108
12121659	ADP	Frauwirth KA	The CD28 signaling pathway regulates glucose metabolism.	Immunity	2002	296
12223530	ADP	Vir√°g L	The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.	Pharmacological reviews	2002	280
12237774	ADP	Fritz G	Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters.	British journal of cancer	2002	102
12440774	ADP	Hassa PO	The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders.	Cellular and molecular life sciences 	2002	100
14578449	ADP	Shiio Y	Histone sumoylation is associated with transcriptional repression.	Proceedings of the National Academy of Sciences of the United States of America	2003	155
15052340	ADP	McDermott M	Phospholipase D.	Biochemistry and cell biology = Biochimie et biologie cellulaire	2004	88
15087504	ADP	Hashimoto S	Requirement for Arf6 in breast cancer invasive activities.	Proceedings of the National Academy of Sciences of the United States of America	2004	82
15304223	ADP	Snowden T	hMSH4-hMSH5 recognizes Holliday Junctions and forms a meiosis-specific sliding clamp that embraces homologous chromosomes.	Molecular cell	2004	129
16051170	ADP	Bryce NS	Cortactin promotes cell motility by enhancing lamellipodial persistence.	Current biology 	2005	113
16418332	ADP	Hideshima T	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.	Blood	2006	124
16507573	ADP	Skoufias DA	S-trityl-L-cysteine is a reversible, tight binding inhibitor of the human kinesin Eg5 that specifically blocks mitotic progression.	The Journal of biological chemistry	2006	72
16860662	ADP	Sharp S	Inhibitors of the HSP90 molecular chaperone: current status.	Advances in cancer research	2006	84
17259553	ADP	Powers MV	Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.	Endocrine-related cancer	2006	81
17303126	ADP	Dawson RJ	Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP.	FEBS letters	2007	109
17310282	ADP	Roche TE	Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer.	Cellular and molecular life sciences 	2007	78
17332279	ADP	Ratnam K	Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.	Clinical cancer research 	2007	65
17456799	ADP	Yamamoto H	Sirtuin functions in health and disease.	Molecular endocrinology	2007	98
17505006	ADP	Albert JM	Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.	Clinical cancer research 	2007	80
17694089	ADP	Saunders LR	Sirtuins: critical regulators at the crossroads between cancer and aging.	Oncogene	2007	181
17891139	ADP	Kanai M	Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation.	Nature cell biology	2007	59
17981777	ADP	Hassa PO	The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases.	Frontiers in bioscience 	2008	159
18591545	ADP	Ashworth A	A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.	Journal of clinical oncology 	2008	174
19464286	ADP	Kumar V	Adenosine: an endogenous modulator of innate immune system with therapeutic potential.	European journal of pharmacology	2009	48
19759537	ADP	Huang SM	Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.	Nature	2009	512
19858214	ADP	Zhang T	Characterization of celastrol to inhibit hsp90 and cdc37 interaction.	The Journal of biological chemistry	2009	55
19879981	ADP	Zhang T	SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions.	Biochimica et biophysica acta	2010	59
20011104	ADP	Richards JB	A genome-wide association study reveals variants in ARL15 that influence adiponectin levels.	PLoS genetics	2009	62
20125064	ADP	Park KS	Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation.	Transplantation	2010	53
20421936	ADP	Scherag A	Two new Loci for body-weight regulation identified in a joint analysis of genome-wide association studies for early-onset extreme obesity in French and german study groups.	PLoS genetics	2010	105
20606085	ADP	Hennessy BT	Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.	Journal of clinical oncology 	2010	81
20823146	ADP	Redon CE	Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.	Clinical cancer research 	2010	84
21095583	ADP	L√∂nn P	PARP-1 attenuates Smad-mediated transcription.	Molecular cell	2010	41
21159641	ADP	Maldonado EN	Free tubulin modulates mitochondrial membrane potential in cancer cells.	Cancer research	2010	46
21211721	ADP	Rulten SL	PARP-3 and APLF function together to accelerate nonhomologous end-joining.	Molecular cell	2011	88
21257746	ADP	Chen D	Identification of macrodomain proteins as novel O-acetyl-ADP-ribose deacetylases.	The Journal of biological chemistry	2011	42
21265739	ADP	Hardie DG	AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer.	Biochemical Society transactions	2011	41
21270334	ADP	Boehler C	Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression.	Proceedings of the National Academy of Sciences of the United States of America	2011	65
21317875	ADP	Ali MM	Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response.	The EMBO journal	2011	56
21326243	ADP	Khan OA	A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.	British journal of cancer	2011	38
21892188	ADP	Slade D	The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase.	Nature	2011	69
21900744	ADP	Van Meter M	SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells.	Cell cycle	2011	42
21937710	ADP	Hardie DG	AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function.	Genes & development	2011	370
21974986	ADP	Otvos L Jr	Design and development of a peptide-based adiponectin receptor agonist for cancer treatment.	BMC biotechnology	2011	37
22022533	ADP	Egan K	Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells.	PloS one	2011	38
22233320	ADP	Narwal M	Structural basis of selective inhibition of human tankyrases.	Journal of medicinal chemistry	2012	34
22262760	ADP	Santo L	Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.	Blood	2012	107
22319497	ADP	Carafa V	Sirtuins and disease: the road ahead.	Frontiers in pharmacology	2012	34
22391446	ADP	Luo X	On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1.	Genes & development	2012	153
22582261	ADP	Langelier MF	Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1.	Science	2012	100
22702974	ADP	Carling D	AMP-activated protein kinase: new regulation, new roles?	The Biochemical journal	2012	94
22738915	ADP	Cas√°s-Selves M	Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.	Cancer research	2012	36
22753495	ADP	Mao Z	Sirtuin 6 (SIRT6) rescues the decline of homologous recombination repair during replicative senescence.	Proceedings of the National Academy of Sciences of the United States of America	2012	46
22915752	ADP	Ibrahim YH	PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.	Cancer discovery	2012	114
23022210	ADP	Di Vizio D	Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease.	The American journal of pathology	2012	67
23102217	ADP	Hardie DG	AMP-activated protein kinase: a target for drugs both ancient and modern.	Chemistry & biology	2012	99
23103912	ADP	Jwa M	PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK- and IRE1Œ±-mediated unfolded protein response.	Nature cell biology	2012	34
23144924	ADP	Bao R	Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells.	PloS one	2012	39
23168256	ADP	Kami≈Ñski MM	T cell activation is driven by an ADP-dependent glucokinase linking enhanced glycolysis with mitochondrial reactive oxygen species generation.	Cell reports	2012	33
23230278	ADP	Tauro BJ	Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids.	Molecular & cellular proteomics 	2013	75
23319653	ADP	Robu M	Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair.	Proceedings of the National Academy of Sciences of the United States of America	2013	49
23423489	ADP	Plummer R	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.	Cancer chemotherapy and pharmacology	2013	32
23471966	ADP	Maldonado EN	Voltage-dependent anion channels modulate mitochondrial metabolism in cancer cells: regulation by free tubulin and erastin.	The Journal of biological chemistry	2013	36
23481255	ADP	Sharifi R	Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease.	The EMBO journal	2013	66
23601906	ADP	Antonioli L	CD39 and CD73 in immunity and inflammation.	Trends in molecular medicine	2013	135
23604120	ADP	Roth M	Sorting out functions of sirtuins in cancer.	Oncogene	2014	67
23622245	ADP	Cho-Park PF	Proteasome regulation by ADP-ribosylation.	Cell	2013	29
23648170	ADP	Lehti√∂ L	Tankyrases as drug targets.	The FEBS journal	2013	38
23680151	ADP	Li M	Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation.	Cancer cell	2013	69
23736681	ADP	Feijs KL	Macrodomain-containing proteins: regulating new intracellular functions of mono(ADP-ribosyl)ation.	Nature reviews. Molecular cell biology	2013	29
23747347	ADP	Russo GL	AMP-activated protein kinase: a target for old drugs against diabetes and cancer.	Biochemical pharmacology	2013	35
23917125	ADP	Vyas S	A systematic analysis of the PARP protein family identifies new functions critical for cell physiology.	Nature communications	2013	40
24185178	ADP	Reiling JH	A CREB3-ARF4 signalling pathway mediates the response to Golgi stress and susceptibility to pathogens.	Nature cell biology	2013	33
24196964	ADP	Tang WK	Altered intersubunit communication is the molecular basis for functional defects of pathogenic p97 mutants.	The Journal of biological chemistry	2013	25
24395786	ADP	Vozza A	UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation.	Proceedings of the National Academy of Sciences of the United States of America	2014	64
24438746	ADP	Kugel S	Chromatin and beyond: the multitasking roles for SIRT6.	Trends in biochemical sciences	2014	56
24550317	ADP	Khoury-Haddad H	PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair.	Proceedings of the National Academy of Sciences of the United States of America	2014	25
24569222	ADP	Zhao Y	Crosstalk between ubiquitin and other post-translational modifications on chromatin during double-strand break repair.	Trends in cell biology	2014	21
24816114	ADP	Swan MK	Structure of human Bloom's syndrome helicase in complex with ADP and duplex DNA.	Acta crystallographica. Section D, Biological crystallography	2014	20
24824502	ADP	Grahame Hardie D	AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease.	Journal of internal medicine	2014	39
24829859	ADP	Yadav BS	Systemic treatment strategies for triple-negative breast cancer.	World journal of clinical oncology	2014	28
24850385	ADP	Hardie DG	AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels.	Annual review of nutrition	2014	28
24875882	ADP	Daugherty MD	Rapid evolution of PARP genes suggests a broad role for ADP-ribosylation in host-virus conflicts.	PLoS genetics	2014	26
24919149	ADP	Xu H	Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome.	Nature	2014	101
24975604	ADP	Haikarainen T	Tankyrases: structure, function and therapeutic implications in cancer.	Current pharmaceutical design	2014	21
25043379	ADP	Vyas S	Family-wide analysis of poly(ADP-ribose) polymerase activity.	Nature communications	2014	60
25209998	ADP	Atherton J	Conserved mechanisms of microtubule-stimulated ADP release, ATP binding, and force generation in transport kinesins.	eLife	2014	22
25244928	ADP	Bruntz RC	Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer.	Pharmacological reviews	2014	28
25253741	ADP	Eades G	lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6.	Molecular cancer research 	2015	38
25403716	ADP	Bastid J	Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.	Cancer immunology research	2015	19
25533949	ADP	Sajish M	A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol.	Nature	2015	22
25547115	ADP	Li N	Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growth.	Genes & development	2015	16
25567907	ADP	Jewell JL	Metabolism. Differential regulation of mTORC1 by leucine and glutamine.	Science	2015	114
25678824	ADP	Coward JI	New perspectives on targeted therapy in ovarian cancer.	International journal of women's health	2015	23
25695398	ADP	Jensen TE	PT-1 selectively activates AMPK-Œ≥1 complexes in mouse skeletal muscle, but activates all three Œ≥ subunit complexes in cultured human cells by inhibiting the respiratory chain.	The Biochemical journal	2015	15
26091343	ADP	Bai P	Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance.	Molecular cell	2015	32
26152739	ADP	Hardie DG	Molecular Pathways: Is AMPK a Friend or a Foe in Cancer?	Clinical cancer research 	2015	22
26277545	ADP	Israelsen WJ	Pyruvate kinase: Function, regulation and role in cancer.	Seminars in cell & developmental biology	2015	34
26300261	ADP	Hosios AM	Lack of Evidence for PKM2 Protein Kinase Activity.	Molecular cell	2015	21
26822609	ADP	Banerjee S	2.3 √Ö resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition.	Science	2016	58
26824338	ADP	Zakraoui O	Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression.	Molecular carcinogenesis	2017	7
26865365	ADP	Radons J	The human HSP70 family of chaperones: where do we stand?	Cell stress & chaperones	2016	26
27064283	ADP	Haemmerle M	FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.	The Journal of clinical investigation	2016	12
27067600	ADP	Gibbs-Seymour I	HPF1/C4orf27 Is a PARP-1-Interacting Protein that Regulates PARP-1 ADP-Ribosylation Activity.	Molecular cell	2016	16
27138857	ADP	Yang E	Wnt pathway activation by ADP-ribosylation.	Nature communications	2016	12
27240471	ADP	Wei H	Functions of PARylation in DNA Damage Repair Pathways.	Genomics, proteomics & bioinformatics	2016	14
27321181	ADP	Di Virgilio F	Extracellular purines, purinergic receptors and tumor growth.	Oncogene	2017	14
27828775	ADP	Schuetz AK	A Dynamic molecular basis for malfunction in disease mutants of p97/VCP.	eLife	2016	11
28001384	ADP	Thorsell AG	Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.	Journal of medicinal chemistry	2017	8
28202539	ADP	Gupte R	PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes.	Genes & development	2017	19
28232179	ADP	Carling D	AMPK signalling in health and disease.	Current opinion in cell biology	2017	15
1360704	Adenosine triphosphate	Cole SP	Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line.	Science	1992	351
2175676	Adenosine triphosphate	Scheffner M	The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.	Cell	1990	935
7630397	Adenosine triphosphate	Jeffrey PD	Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex.	Nature	1995	336
7988572	Adenosine triphosphate	Benson FE	Purification and characterization of the human Rad51 protein, an analogue of E. coli RecA.	The EMBO journal	1994	151
8465201	Adenosine triphosphate	Schaeffer L	DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor.	Science	1993	207
8684460	Adenosine triphosphate	Russo AA	Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.	Nature	1996	238
8929543	Adenosine triphosphate	Baumann P	Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro.	Cell	1996	207
9009268	Adenosine triphosphate	Hu J	Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids.	The EMBO journal	1997	112
9054934	Adenosine triphosphate	Allikmets R	A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy.	Nature genetics	1997	296
9157970	Adenosine triphosphate	Eguchi Y	Intracellular ATP levels determine cell death fate by apoptosis or necrosis.	Cancer research	1997	166
9351836	Adenosine triphosphate	Evans E	Mechanism of open complex and dual incision formation by human nucleotide excision repair factors.	The EMBO journal	1997	145
9450758	Adenosine triphosphate	Benson FE	Synergistic actions of Rad51 and Rad52 in recombination and DNA repair.	Nature	1998	128
9774334	Adenosine triphosphate	Mohammadi M	Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.	The EMBO journal	1998	115
9790534	Adenosine triphosphate	Zhang Y	The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities.	Cell	1998	247
9817203	Adenosine triphosphate	Yin MJ	The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta.	Nature	1998	270
9850061	Adenosine triphosphate	Allikmets R	A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.	Cancer research	1998	122
9861027	Adenosine triphosphate	Doyle LA	A multidrug resistance transporter from human MCF-7 breast cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	1998	376
9892175	Adenosine triphosphate	Miyake K	Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.	Cancer research	1999	127
10224048	Adenosine triphosphate	Guo S	SAC1-like domains of yeast SAC1, INP52, and INP53 and of human synaptojanin encode polyphosphoinositide phosphatases.	The Journal of biological chemistry	1999	124
10233156	Adenosine triphosphate	Andrei C	The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles.	Molecular biology of the cell	1999	118
10369688	Adenosine triphosphate	Masutani C	Xeroderma pigmentosum variant (XP-V) correcting protein from HeLa cells has a thymine dimer bypass DNA polymerase activity.	The EMBO journal	1999	121
10395545	Adenosine triphosphate	Riballo E	Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient.	Current biology 	1999	96
10438458	Adenosine triphosphate	Boulares AH	Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells.	The Journal of biological chemistry	1999	154
10825162	Adenosine triphosphate	Brosh RM Jr	Replication protein A physically interacts with the Bloom's syndrome protein and stimulates its helicase activity.	The Journal of biological chemistry	2000	118
10934467	Adenosine triphosphate	Saleh A	Negative regulation of the Apaf-1 apoptosome by Hsp70.	Nature cell biology	2000	147
11030347	Adenosine triphosphate	Rathmell JC	In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability.	Molecular cell	2000	132
11274139	Adenosine triphosphate	Kamradt MC	The small heat shock protein alpha B-crystallin negatively regulates cytochrome c- and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation.	The Journal of biological chemistry	2001	89
11387316	Adenosine triphosphate	Ananthanarayanan M	Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor.	The Journal of biological chemistry	2001	115
11431468	Adenosine triphosphate	Chao SH	Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo.	The Journal of biological chemistry	2001	222
11583616	Adenosine triphosphate	Xiao H	Dual functions of largest NURF subunit NURF301 in nucleosome sliding and transcription factor interactions.	Molecular cell	2001	91
11694888	Adenosine triphosphate	Favelyukis S	Structure and autoregulation of the insulin-like growth factor 1 receptor kinase.	Nature structural biology	2001	97
11717429	Adenosine triphosphate	Bennett BL	SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.	Proceedings of the National Academy of Sciences of the United States of America	2001	619
11739410	Adenosine triphosphate	Madesh M	VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release.	The Journal of cell biology	2001	114
11751413	Adenosine triphosphate	Moulder SL	Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.	Cancer research	2001	99
11801536	Adenosine triphosphate	Kim M	The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.	Clinical cancer research 	2002	95
12176997	Adenosine triphosphate	Basso AD	Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function.	The Journal of biological chemistry	2002	163
12231511	Adenosine triphosphate	Gardella S	The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway.	EMBO reports	2002	237
12370334	Adenosine triphosphate	Harton JA	Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains.	Journal of immunology	2002	82
12429862	Adenosine triphosphate	Jonker JW	The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.	Proceedings of the National Academy of Sciences of the United States of America	2002	127
12438266	Adenosine triphosphate	Cuezva JM	The bioenergetic signature of cancer: a marker of tumor progression.	Cancer research	2002	96
12535572	Adenosine triphosphate	Schinkel AH	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.	Advanced drug delivery reviews	2003	207
12578958	Adenosine triphosphate	Bermudez VP	Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro.	Proceedings of the National Academy of Sciences of the United States of America	2003	121
12665508	Adenosine triphosphate	Reddy RK	Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation.	The Journal of biological chemistry	2003	193
12743604	Adenosine triphosphate	Bianco R	Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.	Oncogene	2003	92
12835412	Adenosine triphosphate	Reid G	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.	Proceedings of the National Academy of Sciences of the United States of America	2003	92
12953102	Adenosine triphosphate	Xue Y	The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies.	Proceedings of the National Academy of Sciences of the United States of America	2003	129
14522923	Adenosine triphosphate	French KJ	Discovery and evaluation of inhibitors of human sphingosine kinase.	Cancer research	2003	180
14530494	Adenosine triphosphate	Leonard GD	The role of ABC transporters in clinical practice.	The oncologist	2003	147
14576842	Adenosine triphosphate	Doyle L	Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).	Oncogene	2003	165
14576852	Adenosine triphosphate	Ambudkar SV	P-glycoprotein: from genomics to mechanism.	Oncogene	2003	169
14612533	Adenosine triphosphate	Christensen JG	A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.	Cancer research	2003	137
14612543	Adenosine triphosphate	Hasmann M	FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.	Cancer research	2003	157
14713298	Adenosine triphosphate	Bijur GN	Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation.	Journal of neurochemistry	2003	94
14740253	Adenosine triphosphate	Wegele H	Hsp70 and Hsp90--a relay team for protein folding.	Reviews of physiology, biochemistry and pharmacology	2004	142
14985505	Adenosine triphosphate	Shaw RJ	The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress.	Proceedings of the National Academy of Sciences of the United States of America	2004	523
15001581	Adenosine triphosphate	Xu J	Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2.	The Journal of biological chemistry	2004	71
15031492	Adenosine triphosphate	Noble ME	Protein kinase inhibitors: insights into drug design from structure.	Science	2004	212
15044640	Adenosine triphosphate	Shulenin S	ABCA3 gene mutations in newborns with fatal surfactant deficiency.	The New England journal of medicine	2004	135
15099516	Adenosine triphosphate	Nagaich AK	Rapid periodic binding and displacement of the glucocorticoid receptor during chromatin remodeling.	Molecular cell	2004	75
15118073	Adenosine triphosphate	Lynch TJ	Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2004	2399
15158434	Adenosine triphosphate	Roskoski R Jr	The ErbB/HER receptor protein-tyrosine kinases and cancer.	Biochemical and biophysical research communications	2004	71
15173008	Adenosine triphosphate	Rabindran SK	Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.	Cancer research	2004	101
15192144	Adenosine triphosphate	Andrei C	Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes.	Proceedings of the National Academy of Sciences of the United States of America	2004	105
15205346	Adenosine triphosphate	Zhu J	From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.	Cancer research	2004	83
15223063	Adenosine triphosphate	Galati G	Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties.	Free radical biology & medicine	2004	84
15236194	Adenosine triphosphate	Tamborini E	A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.	Gastroenterology	2004	70
15241474	Adenosine triphosphate	Garcia PL	Human RECQ5beta, a protein with DNA helicase and strand-annealing activities in a single polypeptide.	The EMBO journal	2004	91
15456405	Adenosine triphosphate	Barnett SF	Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors.	The Biochemical journal	2005	132
15485900	Adenosine triphosphate	Stark JM	Genetic steps of mammalian homologous repair with distinct mutagenic consequences.	Molecular and cellular biology	2004	172
15543203	Adenosine triphosphate	de Kok JB	Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes.	Laboratory investigation; a journal of technical methods and pathology	2005	148
15559249	Adenosine triphosphate	Meijer L	Pharmacological inhibitors of glycogen synthase kinase 3.	Trends in pharmacological sciences	2004	136
15585581	Adenosine triphosphate	Palmer AE	Bcl-2-mediated alterations in endoplasmic reticulum Ca2+ analyzed with an improved genetically encoded fluorescent sensor.	Proceedings of the National Academy of Sciences of the United States of America	2004	211
15604286	Adenosine triphosphate	Hickson I	Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.	Cancer research	2004	432
15695406	Adenosine triphosphate	Xu RH	Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.	Cancer research	2005	181
15705904	Adenosine triphosphate	Smith JA	Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.	Cancer research	2005	104
15717060	Adenosine triphosphate	L√∂scher W	Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.	NeuroRx 	2005	111
15753456	Adenosine triphosphate	Baselga J	Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.	Journal of clinical oncology 	2005	130
15766665	Adenosine triphosphate	Gumireddy K	ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.	Cancer cell	2005	84
15845415	Adenosine triphosphate	Leslie EM	Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.	Toxicology and applied pharmacology	2005	197
15894266	Adenosine triphosphate	Plescia J	Rational design of shepherdin, a novel anticancer agent.	Cancer cell	2005	67
15899824	Adenosine triphosphate	Frank NY	ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma.	Cancer research	2005	139
15899831	Adenosine triphosphate	Wedge SR	AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.	Cancer research	2005	165
15899892	Adenosine triphosphate	Sharma S	Biochemical analysis of the DNA unwinding and strand annealing activities catalyzed by human RECQ1.	The Journal of biological chemistry	2005	83
15937217	Adenosine triphosphate	Losada A	Dynamic molecular linkers of the genome: the first decade of SMC proteins.	Genes & development	2005	123
15937340	Adenosine triphosphate	Bali P	Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.	The Journal of biological chemistry	2005	238
15988001	Adenosine triphosphate	Sofer A	Regulation of mTOR and cell growth in response to energy stress by REDD1.	Molecular and cellular biology	2005	145
15998811	Adenosine triphosphate	Dannenberg JH	mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival.	Genes & development	2005	86
16024622	Adenosine triphosphate	Patrawala L	Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic.	Cancer research	2005	281
16098463	Adenosine triphosphate	Moeller BJ	Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity.	Cancer cell	2005	111
16124856	Adenosine triphosphate	Dean M	Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates.	Annual review of genomics and human genetics	2005	132
16146333	Adenosine triphosphate	Mao Q	Role of the breast cancer resistance protein (ABCG2) in drug transport.	The AAPS journal	2005	86
16214424	Adenosine triphosphate	Macris MA	Biochemical characterization of the RECQ4 protein, mutated in Rothmund-Thomson syndrome.	DNA repair	2006	63
16226706	Adenosine triphosphate	Hatzivassiliou G	ATP citrate lyase inhibition can suppress tumor cell growth.	Cancer cell	2005	252
16227410	Adenosine triphosphate	Safaei R	Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells.	Molecular cancer therapeutics	2005	98
16239320	Adenosine triphosphate	Haraguchi N	Characterization of a side population of cancer cells from human gastrointestinal system.	Stem cells	2006	170
16251956	Adenosine triphosphate	Myong S	Repetitive shuttling of a motor protein on DNA.	Nature	2005	110
16305368	Adenosine triphosphate	Glavinas H	The role of ABC transporters in drug resistance, metabolism and toxicity.	Current drug delivery	2004	91
16397263	Adenosine triphosphate	Schittenhelm MM	Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.	Cancer research	2006	95
16402910	Adenosine triphosphate	Krishnamurthy P	Role of ABCG2/BCRP in biology and medicine.	Annual review of pharmacology and toxicology	2006	82
16415863	Adenosine triphosphate	Adri√°n FJ	Allosteric inhibitors of Bcr-abl-dependent cell proliferation.	Nature chemical biology	2006	76
16518375	Adenosine triphosphate	Szak√°cs G	Targeting multidrug resistance in cancer.	Nature reviews. Drug discovery	2006	621
16520385	Adenosine triphosphate	Kruhlak MJ	Changes in chromatin structure and mobility in living cells at sites of DNA double-strand breaks.	The Journal of cell biology	2006	166
16622124	Adenosine triphosphate	Yaguchi S	Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.	Journal of the National Cancer Institute	2006	70
16640460	Adenosine triphosphate	Levinson NM	A Src-like inactive conformation in the abl tyrosine kinase domain.	PLoS biology	2006	102
16644802	Adenosine triphosphate	Viollet B	Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders.	The Journal of physiology	2006	96
16721371	Adenosine triphosphate	Weisberg E	AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.	British journal of cancer	2006	69
16728978	Adenosine triphosphate	Li H	Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF.	Nature	2006	266
16756493	Adenosine triphosphate	Pearl LH	Structure and mechanism of the Hsp90 molecular chaperone machinery.	Annual review of biochemistry	2006	299
16778563	Adenosine triphosphate	Swinnen JV	Increased lipogenesis in cancer cells: new players, novel targets.	Current opinion in clinical nutrition and metabolic care	2006	140
16787253	Adenosine triphosphate	Shoshan-Barmatz V	The voltage-dependent anion channel (VDAC): function in intracellular signalling, cell life and cell death.	Current pharmaceutical design	2006	80
16816140	Adenosine triphosphate	Deeley RG	Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.	Physiological reviews	2006	164
16842198	Adenosine triphosphate	P√©rez-Tom√°s R	Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.	Current medicinal chemistry	2006	100
16873062	Adenosine triphosphate	Kadyrov FA	Endonucleolytic function of MutLalpha in human mismatch repair.	Cell	2006	220
16880519	Adenosine triphosphate	Griswold IJ	Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.	Molecular and cellular biology	2006	62
16890793	Adenosine triphosphate	Mendelsohn J	Epidermal growth factor receptor targeting in cancer.	Seminars in oncology	2006	155
16892079	Adenosine triphosphate	Brandon M	Mitochondrial mutations in cancer.	Oncogene	2006	206
16892090	Adenosine triphosphate	Mathupala SP	Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria.	Oncogene	2006	166
16935882	Adenosine triphosphate	Fuller-Pace FV	DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation.	Nucleic acids research	2006	127
17015488	Adenosine triphosphate	Sarkadi B	Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system.	Physiological reviews	2006	142
17062895	Adenosine triphosphate	Vandenabeele P	Caspase inhibitors promote alternative cell death pathways.	Science's STKE 	2006	79
17095747	Adenosine triphosphate	Fernando SL	A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis.	American journal of respiratory and critical care medicine	2007	60
17114456	Adenosine triphosphate	Mambula SS	Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes.	Journal of immunology	2006	97
17158952	Adenosine triphosphate	Pelicano H	Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism.	The Journal of cell biology	2006	126
17244528	Adenosine triphosphate	H√∏yer-Hansen M	Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2.	Molecular cell	2007	314
17307971	Adenosine triphosphate	Towler MC	AMP-activated protein kinase in metabolic control and insulin signaling.	Circulation research	2007	317
17318448	Adenosine triphosphate	Kuo MT	The roles of copper transporters in cisplatin resistance.	Cancer metastasis reviews	2007	67
17322922	Adenosine triphosphate	Lou H	Targeted therapy for cancer stem cells: the patched pathway and ABC transporters.	Oncogene	2007	62
17323127	Adenosine triphosphate	Robey RW	ABCG2: determining its relevance in clinical drug resistance.	Cancer metastasis reviews	2007	87
17332304	Adenosine triphosphate	Yeh TC	Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.	Clinical cancer research 	2007	172
17332438	Adenosine triphosphate	Arad M	AMP-activated protein kinase in the heart: role during health and disease.	Circulation research	2007	92
17333344	Adenosine triphosphate	Assaraf YG	Molecular basis of antifolate resistance.	Cancer metastasis reviews	2007	69
17353904	Adenosine triphosphate	Sims-Mourtada J	Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport.	Oncogene	2007	76
17367763	Adenosine triphosphate	Roskoski R Jr	Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.	Biochemical and biophysical research communications	2007	73
17386261	Adenosine triphosphate	Larochelle S	Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells.	Molecular cell	2007	77
17428165	Adenosine triphosphate	Fox E	Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.	Expert review of anticancer therapy	2007	75
17457036	Adenosine triphosphate	H√∏yer-Hansen M	AMP-activated protein kinase: a universal regulator of autophagy?	Autophagy	2007	72
17483355	Adenosine triphosphate	Zou HY	An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.	Cancer research	2007	171
17510412	Adenosine triphosphate	Ho MM	Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells.	Cancer research	2007	281
17519960	Adenosine triphosphate	Brendel C	Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.	Leukemia	2007	55
17572300	Adenosine triphosphate	Gillet JP	Chemotherapy-induced resistance by ATP-binding cassette transporter genes.	Biochimica et biophysica acta	2007	61
17573453	Adenosine triphosphate	Ryan JL	Mechanisms of cancer-related fatigue.	The oncologist	2007	88
17588518	Adenosine triphosphate	Li X	Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway.	Molecular cell	2007	96
17609380	Adenosine triphosphate	Bey EA	An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.	Proceedings of the National Academy of Sciences of the United States of America	2007	68
17620360	Adenosine triphosphate	Hislop AD	A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates.	The Journal of experimental medicine	2007	65
17699718	Adenosine triphosphate	Davies BR	AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models.	Molecular cancer therapeutics	2007	141
17713585	Adenosine triphosphate	Williams RS	Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template.	Biochemistry and cell biology = Biochimie et biologie cellulaire	2007	155
17879147	Adenosine triphosphate	Pedersen PL	Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen.	Journal of bioenergetics and biomembranes	2007	117
17911267	Adenosine triphosphate	Zhou J	Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance.	Proceedings of the National Academy of Sciences of the United States of America	2007	193
17942911	Adenosine triphosphate	Pyrko P	The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.	Cancer research	2007	125
17952660	Adenosine triphosphate	Wirkner K	P2X3 receptor involvement in pain states.	Molecular neurobiology	2007	59
18003859	Adenosine triphosphate	Hu Y	RECQL5/Recql5 helicase regulates homologous recombination and suppresses tumor formation via disruption of Rad51 presynaptic filaments.	Genes & development	2007	144
18006696	Adenosine triphosphate	Chen L	SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.	Blood	2008	103
18006847	Adenosine triphosphate	Shi Z	Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.	Cancer research	2007	91
18077363	Adenosine triphosphate	Fedorov O	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	Proceedings of the National Academy of Sciences of the United States of America	2007	80
18154452	Adenosine triphosphate	Sharom FJ	ABC multidrug transporters: structure, function and role in chemoresistance.	Pharmacogenomics	2008	173
18193822	Adenosine triphosphate	Hoye AT	Targeting mitochondria.	Accounts of chemical research	2008	91
18202014	Adenosine triphosphate	Clem B	Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.	Molecular cancer therapeutics	2008	85
18212047	Adenosine triphosphate	Auger A	Eaf1 is the platform for NuA4 molecular assembly that evolutionarily links chromatin acetylation to ATP-dependent exchange of histone H2A variants.	Molecular and cellular biology	2008	55
18230700	Adenosine triphosphate	Ye J	Nuclear myosin I acts in concert with polymeric actin to drive RNA polymerase I transcription.	Genes & development	2008	52
18290764	Adenosine triphosphate	Pearl LH	The Hsp90 molecular chaperone: an open and shut case for treatment.	The Biochemical journal	2008	144
18336669	Adenosine triphosphate	Lu SC	S-Adenosylmethionine in cell growth, apoptosis and liver cancer.	Journal of gastroenterology and hepatology	2008	50
18339875	Adenosine triphosphate	Roberts WG	Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.	Cancer research	2008	123
18349109	Adenosine triphosphate	Pegg AE	Spermidine/spermine-N(1)-acetyltransferase: a key metabolic regulator.	American journal of physiology. Endocrinology and metabolism	2008	62
18393293	Adenosine triphosphate	Komuta M	Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.	Hepatology	2008	74
18408761	Adenosine triphosphate	Li D	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.	Oncogene	2008	282
18414044	Adenosine triphosphate	Morrish F	The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry.	Cell cycle	2008	52
18439900	Adenosine triphosphate	Gwinn DM	AMPK phosphorylation of raptor mediates a metabolic checkpoint.	Molecular cell	2008	938
18454141	Adenosine triphosphate	Tasdemir E	Regulation of autophagy by cytoplasmic p53.	Nature cell biology	2008	333
18468555	Adenosine triphosphate	Szak√°cs G	The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox).	Drug discovery today	2008	79
18523012	Adenosine triphosphate	Piccini A	ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way.	Proceedings of the National Academy of Sciences of the United States of America	2008	128
18559531	Adenosine triphosphate	Yang Y	Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion.	Cancer research	2008	73
18560012	Adenosine triphosphate	Miller DS	Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.	Pharmacological reviews	2008	79
18568041	Adenosine triphosphate	Ow YP	Cytochrome c: functions beyond respiration.	Nature reviews. Molecular cell biology	2008	155
18591380	Adenosine triphosphate	Rao R	HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.	Blood	2008	52
18606717	Adenosine triphosphate	Maira SM	Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.	Molecular cancer therapeutics	2008	380
18623623	Adenosine triphosphate	Liegl B	Heterogeneity of kinase inhibitor resistance mechanisms in GIST.	The Journal of pathology	2008	80
18624356	Adenosine triphosphate	Franchi L	The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity.	European journal of immunology	2008	133
18680391	Adenosine triphosphate	Huang D	Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines.	Stem cells and development	2009	48
18691045	Adenosine triphosphate	Guerra B	Protein kinase CK2 in human diseases.	Current medicinal chemistry	2008	55
18691054	Adenosine triphosphate	Zhou SF	Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development.	Current medicinal chemistry	2008	75
18723486	Adenosine triphosphate	Blasina A	Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.	Molecular cancer therapeutics	2008	70
18752326	Adenosine triphosphate	Ma KL	Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice.	Hepatology	2008	59
18790776	Adenosine triphosphate	Zabludoff SD	AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.	Molecular cancer therapeutics	2008	131
18829454	Adenosine triphosphate	Sharlow ER	Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone.	The Journal of biological chemistry	2008	66
18829547	Adenosine triphosphate	Dai CL	Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.	Cancer research	2008	95
18829551	Adenosine triphosphate	Clark EL	The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer.	Cancer research	2008	58
18922930	Adenosine triphosphate	Migita T	ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer.	Cancer research	2008	78
18938156	Adenosine triphosphate	Day E	Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.	European journal of pharmacology	2008	61
18957201	Adenosine triphosphate	Barber LJ	RTEL1 maintains genomic stability by suppressing homologous recombination.	Cell	2008	137
18971320	Adenosine triphosphate	Shukla S	Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.	Drug metabolism and disposition	2009	53
18991631	Adenosine triphosphate	Donnelly A	Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.	Current medicinal chemistry	2008	74
19010870	Adenosine triphosphate	Bean J	Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.	Clinical cancer research 	2008	84
19050078	Adenosine triphosphate	Wang X	Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins.	Proceedings of the National Academy of Sciences of the United States of America	2008	232
19056914	Adenosine triphosphate	Polli JW	An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-(3-fluorobenzyl)oxyphenyl}-6-5-({2-(methylsulfonyl)ethylamino}methyl)-2-furyl-4-quinazolinamine; GW572016).	Drug metabolism and disposition	2009	66
19079736	Adenosine triphosphate	Wu CP	Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.	Current molecular pharmacology	2008	55
19094056	Adenosine triphosphate	Dauchy S	ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier.	Journal of neurochemistry	2008	53
19101634	Adenosine triphosphate	Mathupala SP	Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.	Seminars in cancer biology	2009	138
19101635	Adenosine triphosphate	Olovnikov IA	Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense.	Seminars in cancer biology	2009	51
19118021	Adenosine triphosphate	Chiche J	Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH.	Cancer research	2009	121
19118027	Adenosine triphosphate	Banerji U	Heat shock protein 90 as a drug target: some like it hot.	Clinical cancer research 	2009	73
19177149	Adenosine triphosphate	Xu X	Dual DNA unwinding activities of the Rothmund-Thomson syndrome protein, RECQ4.	The EMBO journal	2009	55
19185005	Adenosine triphosphate	Schaap FG	High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis.	Hepatology	2009	54
19196867	Adenosine triphosphate	Nahimana A	The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.	Blood	2009	47
19208652	Adenosine triphosphate	Park JS	A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis.	Human molecular genetics	2009	60
19216841	Adenosine triphosphate	Gills JJ	Perifosine: update on a novel Akt inhibitor.	Current oncology reports	2009	64
19219026	Adenosine triphosphate	Gao P	c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.	Nature	2009	572
19234488	Adenosine triphosphate	Reisman D	The SWI/SNF complex and cancer.	Oncogene	2009	188
19236062	Adenosine triphosphate	AshaRani PV	Cytotoxicity and genotoxicity of silver nanoparticles in human cells.	ACS nano	2009	293
19243571	Adenosine triphosphate	Wang W	AMP-activated protein kinase and cancer.	Acta physiologica	2009	47
19245654	Adenosine triphosphate	Shaw RJ	LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.	Acta physiologica	2009	147
19245656	Adenosine triphosphate	Viollet B	AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives.	Acta physiologica	2009	89
19249331	Adenosine triphosphate	Fang J	Therapeutic strategies by modulating oxygen stress in cancer and inflammation.	Advanced drug delivery reviews	2009	71
19251738	Adenosine triphosphate	Schnetz MP	Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns.	Genome research	2009	87
19258498	Adenosine triphosphate	Samudio I	Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism.	Cancer research	2009	73
19270741	Adenosine triphosphate	Gegg ME	Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells.	PloS one	2009	60
19292913	Adenosine triphosphate	Sparvero LJ	RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.	Journal of translational medicine	2009	133
19296866	Adenosine triphosphate	Johnson LN	Protein kinase inhibitors: contributions from structure to clinical compounds.	Quarterly reviews of biophysics	2009	59
19303847	Adenosine triphosphate	Carreira A	The BRC repeats of BRCA2 modulate the DNA-binding selectivity of RAD51.	Cell	2009	92
19383919	Adenosine triphosphate	Dong X	Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.	Cancer research	2009	56
19417105	Adenosine triphosphate	Cheng Z	Structural insights into eRF3 and stop codon recognition by eRF1.	Genes & development	2009	50
19427995	Adenosine triphosphate	Tiwari AK	Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.	Biochemical pharmacology	2009	50
19448666	Adenosine triphosphate	Morrish F	c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry.	Oncogene	2009	57
19450601	Adenosine triphosphate	Mandapathil M	Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression.	Journal of immunological methods	2009	53
19454274	Adenosine triphosphate	Yalcin A	Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer.	Experimental and molecular pathology	2009	81
19461003	Adenosine triphosphate	Wellen KE	ATP-citrate lyase links cellular metabolism to histone acetylation.	Science	2009	450
19515901	Adenosine triphosphate	Guilbert A	Evidence that TRPM7 is required for breast cancer cell proliferation.	American journal of physiology. Cell physiology	2009	53
19525936	Adenosine triphosphate	Peng G	BRIT1/MCPH1 links chromatin remodelling to DNA damage response.	Nature cell biology	2009	74
19558545	Adenosine triphosphate	Donnelly-Roberts DL	Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors.	British journal of pharmacology	2009	58
19583815	Adenosine triphosphate	Carew JS	Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.	Journal of cellular and molecular medicine	2010	72
19584280	Adenosine triphosphate	Yu K	Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.	Cancer research	2009	119
19589128	Adenosine triphosphate	Casero RA	Polyamine catabolism and disease.	The Biochemical journal	2009	81
19593530	Adenosine triphosphate	Kostenko S	Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology.	Cellular and molecular life sciences 	2009	89
19598259	Adenosine triphosphate	Hong SP	CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.	International journal of cancer	2009	80
19651622	Adenosine triphosphate	Pan C	Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics.	Molecular & cellular proteomics 	2009	65
19666485	Adenosine triphosphate	Gottschalk AJ	Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler.	Proceedings of the National Academy of Sciences of the United States of America	2009	126
19689244	Adenosine triphosphate	Hartmann JT	Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.	Current drug metabolism	2009	63
19693011	Adenosine triphosphate	Schafer ZT	Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment.	Nature	2009	234
19697319	Adenosine triphosphate	Zuehlke A	Hsp90 and co-chaperones twist the functions of diverse client proteins.	Biopolymers	2010	61
19711346	Adenosine triphosphate	Zhu Z	Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.	International journal of cancer	2010	106
19717510	Adenosine triphosphate	Mu√±oz-Planillo R	A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome.	Journal of immunology	2009	111
19737566	Adenosine triphosphate	Lin JE	The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.	Gastroenterology	2010	40
19753307	Adenosine triphosphate	Chen Y	Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect.	PloS one	2009	55
19762091	Adenosine triphosphate	Hall MD	Is resistance useless? Multidrug resistance and collateral sensitivity.	Trends in pharmacological sciences	2009	46
19769945	Adenosine triphosphate	Yu Y	Withaferin A targets heat shock protein 90 in pancreatic cancer cells.	Biochemical pharmacology	2010	63
19778642	Adenosine triphosphate	Fogarty S	Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer.	Biochimica et biophysica acta	2010	100
19782152	Adenosine triphosphate	Menendez JA	Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives.	Biochimica et biophysica acta	2010	43
19788499	Adenosine triphosphate	V√§h√§kangas K	Drug transporters in the human blood-placental barrier.	British journal of pharmacology	2009	51
19789351	Adenosine triphosphate	Wang X	Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.	Cancer research	2009	53
19815529	Adenosine triphosphate	Hoppe S	AMP-activated protein kinase adapts rRNA synthesis to cellular energy supply.	Proceedings of the National Academy of Sciences of the United States of America	2009	56
19825957	Adenosine triphosphate	Mandapathil M	Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.	Clinical cancer research 	2009	56
19840943	Adenosine triphosphate	Demory ML	Epidermal growth factor receptor translocation to the mitochondria: regulation and effect.	The Journal of biological chemistry	2009	51
19843643	Adenosine triphosphate	Furuta M	miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.	Carcinogenesis	2010	176
19858205	Adenosine triphosphate	Mandapathil M	Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells.	The Journal of biological chemistry	2010	111
19901542	Adenosine triphosphate	Shor B	Targeting mTOR globally in cancer: thinking beyond rapamycin.	Cell cycle	2009	63
19922818	Adenosine triphosphate	Manley PW	Extended kinase profile and properties of the protein kinase inhibitor nilotinib.	Biochimica et biophysica acta	2010	50
19939921	Adenosine triphosphate	Chambers JW	Glutamine metabolism is essential for human cytomegalovirus infection.	Journal of virology	2010	59
20028854	Adenosine triphosphate	Chresta CM	AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.	Cancer research	2010	215
20038799	Adenosine triphosphate	Samudio I	Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction.	The Journal of clinical investigation	2010	138
20068177	Adenosine triphosphate	Yu K	Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.	Cancer research	2010	58
20072125	Adenosine triphosphate	Zhang J	Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.	Nature	2010	140
20081827	Adenosine triphosphate	Berndt A	The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.	Nature chemical biology	2010	44
20086177	Adenosine triphosphate	Aymeric L	Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity.	Cancer research	2010	79
20087650	Adenosine triphosphate	Martin FT	Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT).	Breast cancer research and treatment	2010	59
20103563	Adenosine triphosphate	Klaassen CD	Xenobiotic, bile acid, and cholesterol transporters: function and regulation.	Pharmacological reviews	2010	166
20130576	Adenosine triphosphate	Hatzivassiliou G	RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.	Nature	2010	402
20133848	Adenosine triphosphate	Le A	Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression.	Proceedings of the National Academy of Sciences of the United States of America	2010	276
20159023	Adenosine triphosphate	Ding XW	ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy.	Life sciences	2010	80
20179222	Adenosine triphosphate	Wainberg ZA	Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.	Clinical cancer research 	2010	49
20179705	Adenosine triphosphate	Poulikakos PI	RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.	Nature	2010	469
20215500	Adenosine triphosphate	Ben Sahra I	Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.	Cancer research	2010	133
20215513	Adenosine triphosphate	Dry JR	Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).	Cancer research	2010	64
20347038	Adenosine triphosphate	Qian W	Alterations in bioenergetics due to changes in mitochondrial DNA copy number.	Methods	2010	47
20350531	Adenosine triphosphate	Fuchs D	Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells.	Biochemical and biophysical research communications	2010	49
20360943	Adenosine triphosphate	Gandhirajan RK	Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.	Neoplasia	2010	45
20378837	Adenosine triphosphate	Hu W	Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function.	Proceedings of the National Academy of Sciences of the United States of America	2010	217
20381449	Adenosine triphosphate	Mathupala SP	The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies.	Biochimica et biophysica acta	2010	46
20399660	Adenosine triphosphate	Feng Z	The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein.	Trends in cell biology	2010	114
20409745	Adenosine triphosphate	Porter JR	Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.	Current opinion in chemical biology	2010	49
20415579	Adenosine triphosphate	Phang JM	Proline metabolism and microenvironmental stress.	Annual review of nutrition	2010	42
20423956	Adenosine triphosphate	Dohse M	Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.	Drug metabolism and disposition	2010	44
20439741	Adenosine triphosphate	Murray BW	Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.	Proceedings of the National Academy of Sciences of the United States of America	2010	79
20442200	Adenosine triphosphate	Yang XR	High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma.	Gut	2010	73
20444419	Adenosine triphosphate	Kalender A	Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner.	Cell metabolism	2010	214
20453110	Adenosine triphosphate	Adinolfi E	Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor.	FASEB journal 	2010	42
20460169	Adenosine triphosphate	Smolkov√° K	Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells.	The international journal of biochemistry & cell biology	2011	43
20466882	Adenosine triphosphate	Najafi-Shoushtari SH	MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis.	Science	2010	279
20484018	Adenosine triphosphate	Munshi N	ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.	Molecular cancer therapeutics	2010	93
20538613	Adenosine triphosphate	S√°nchez-Cenizo L	Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype.	The Journal of biological chemistry	2010	52
20558731	Adenosine triphosphate	Mandapathil M	Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.	The Journal of biological chemistry	2010	49
20562527	Adenosine triphosphate	Migneco G	Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling.	Cell cycle	2010	58
20571029	Adenosine triphosphate	Xiao D	Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells.	The Journal of biological chemistry	2010	51
20593179	Adenosine triphosphate	Xi H	2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion.	Cancer chemotherapy and pharmacology	2011	46
20595235	Adenosine triphosphate	Igal RA	Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer.	Carcinogenesis	2010	68
20616036	Adenosine triphosphate	Yang H	Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation.	Proceedings of the National Academy of Sciences of the United States of America	2010	74
20622997	Adenosine triphosphate	Liu Q	mTOR Mediated Anti-Cancer Drug Discovery.	Drug discovery today. Therapeutic strategies	2009	47
20644254	Adenosine triphosphate	Imtiyaz HZ	Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation.	The Journal of clinical investigation	2010	98
20667897	Adenosine triphosphate	Kefas B	Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells.	Neuro-oncology	2010	57
20671266	Adenosine triphosphate	Park JT	Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.	The American journal of pathology	2010	44
20682318	Adenosine triphosphate	Cheung ST	Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance.	Gastroenterology	2011	40
20682644	Adenosine triphosphate	Singh A	Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.	Molecular cancer therapeutics	2010	43
20683952	Adenosine triphosphate	Wang XQ	Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway.	Hepatology	2010	56
20724478	Adenosine triphosphate	Pittelli M	Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool.	The Journal of biological chemistry	2010	41
20729832	Adenosine triphosphate	Jensen RB	Purified human BRCA2 stimulates RAD51-mediated recombination.	Nature	2010	201
20805324	Adenosine triphosphate	Larsen DH	The chromatin-remodeling factor CHD4 coordinates signaling and repair after DNA damage.	The Journal of cell biology	2010	88
20812900	Adenosine triphosphate	Zhou H	Updates of mTOR inhibitors.	Anti-cancer agents in medicinal chemistry	2010	48
20812902	Adenosine triphosphate	Ni Z	Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).	Current drug metabolism	2010	48
20819940	Adenosine triphosphate	Tang D	Endogenous HMGB1 regulates autophagy.	The Journal of cell biology	2010	236
20838378	Adenosine triphosphate	Pi√±eiro R	The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.	Oncogene	2011	48
20847263	Adenosine triphosphate	Vander Heiden MG	Evidence for an alternative glycolytic pathway in rapidly proliferating cells.	Science	2010	207
20876799	Adenosine triphosphate	Mi YJ	Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.	Cancer research	2010	63
20884625	Adenosine triphosphate	Chapuis N	Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.	Clinical cancer research 	2010	56
20930850	Adenosine triphosphate	Tang Y	Short-chain fatty acids induced autophagy serves as an adaptive strategy for retarding mitochondria-mediated apoptotic cell death.	Cell death and differentiation	2011	39
20935265	Adenosine triphosphate	Calcagno AM	Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.	Journal of the National Cancer Institute	2010	76
20971042	Adenosine triphosphate	Holthausen JT	Regulation of DNA strand exchange in homologous recombination.	DNA repair	2010	60
21039338	Adenosine triphosphate	Shukla S	Improving cancer chemotherapy with modulators of ABC drug transporters.	Current drug targets	2011	42
21062993	Adenosine triphosphate	Fan QW	Akt and autophagy cooperate to promote survival of drug-resistant glioma.	Science signaling	2010	111
21085683	Adenosine triphosphate	Awad O	High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.	PloS one	2010	54
21103974	Adenosine triphosphate	Keppler D	Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy.	Handbook of experimental pharmacology	2011	55
21132003	Adenosine triphosphate	Morris MR	Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma.	Oncogene	2011	56
21147915	Adenosine triphosphate	Yu Y	Human cytomegalovirus activates glucose transporter 4 expression to increase glucose uptake during infection.	Journal of virology	2011	43
21172662	Adenosine triphosphate	Lan L	The ACF1 complex is required for DNA double-strand break repair in human cells.	Molecular cell	2010	74
21205825	Adenosine triphosphate	Copsel S	Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation.	The Journal of biological chemistry	2011	35
21212411	Adenosine triphosphate	Frank NY	VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth.	Cancer research	2011	51
21224349	Adenosine triphosphate	R√©role AL	Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy.	Cancer research	2011	45
21242969	Adenosine triphosphate	Jelassi B	P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness.	Oncogene	2011	50
21249425	Adenosine triphosphate	Kepp O	Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy.	Cancer metastasis reviews	2011	70
21278237	Adenosine triphosphate	Kim TH	NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1Œ±.	Cancer research	2011	65
21283107	Adenosine triphosphate	Quint√°s-Cardama A	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.	Nature reviews. Drug discovery	2011	80
21284981	Adenosine triphosphate	Tennessen JM	The Drosophila estrogen-related receptor directs a metabolic switch that supports developmental growth.	Cell metabolism	2011	60
21317208	Adenosine triphosphate	Prasad G	Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.	Neuro-oncology	2011	48
21331075	Adenosine triphosphate	Evangelisti C	Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.	Leukemia	2011	37
21336310	Adenosine triphosphate	Jiang P	p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase.	Nature cell biology	2011	151
21351087	Adenosine triphosphate	Tang SC	Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.	International journal of cancer	2012	37
21358755	Adenosine triphosphate	Hargreaves DC	ATP-dependent chromatin remodeling: genetics, genomics and mechanisms.	Cell research	2011	239
21363918	Adenosine triphosphate	Falcon BL	Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.	Cancer research	2011	38
21374643	Adenosine triphosphate	Nobili S	Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.	Medicinal research reviews	2012	30
21383145	Adenosine triphosphate	Chou TF	Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways.	Proceedings of the National Academy of Sciences of the United States of America	2011	109
21383285	Adenosine triphosphate	Yap TA	Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.	Journal of clinical oncology 	2011	73
21396365	Adenosine triphosphate	Alexander A	The role of LKB1 and AMPK in cellular responses to stress and damage.	FEBS letters	2011	46
21414251	Adenosine triphosphate	Krukenberg KA	Conformational dynamics of the molecular chaperone Hsp90.	Quarterly reviews of biophysics	2011	70
21441910	Adenosine triphosphate	Brennan DF	A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK.	Nature	2011	73
21459328	Adenosine triphosphate	Porat S	Control of pancreatic Œ≤ cell regeneration by glucose metabolism.	Cell metabolism	2011	112
21480217	Adenosine triphosphate	Kryczek I	Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.	International journal of cancer	2012	78
21531766	Adenosine triphosphate	Jeon HM	ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2.	Cancer research	2011	54
21555003	Adenosine triphosphate	Russell RG	Bisphosphonates: the first 40 years.	Bone	2011	112
21571596	Adenosine triphosphate	Fuss JO	XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase.	DNA repair	2011	60
21576264	Adenosine triphosphate	Zaugg K	Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress.	Genes & development	2011	123
21592869	Adenosine triphosphate	Egly JM	A history of TFIIH: two decades of molecular biology on a pivotal transcription/repair factor.	DNA repair	2011	61
21620960	Adenosine triphosphate	Hers I	Akt signalling in health and disease.	Cellular signalling	2011	223
21622723	Adenosine triphosphate	Maugeri-Sacc√† M	Cancer stem cells and chemosensitivity.	Clinical cancer research 	2011	45
21625222	Adenosine triphosphate	Singh RR	ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.	Oncogene	2011	51
21647434	Adenosine triphosphate	Pramanik KC	Role of mitochondrial electron transport chain complexes in capsaicin mediated oxidative stress leading to apoptosis in pancreatic cancer cells.	PloS one	2011	39
21677139	Adenosine triphosphate	Clayton A	Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production.	Journal of immunology	2011	91
21692052	Adenosine triphosphate	Sandulache VC	Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.	Cancer	2011	40
21698063	Adenosine triphosphate	Varum S	Energy metabolism in human pluripotent stem cells and their differentiated counterparts.	PloS one	2011	166
21709020	Adenosine triphosphate	Avivar-Valderas A	PERK integrates autophagy and oxidative stress responses to promote survival during extracellular matrix detachment.	Molecular and cellular biology	2011	71
21734725	Adenosine triphosphate	Saxena M	Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters.	Cell death & disease	2011	56
21740521	Adenosine triphosphate	Chen ZS	Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases.	The FEBS journal	2011	52
21750219	Adenosine triphosphate	Yuan J	PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.	Molecular cancer therapeutics	2011	49
21812414	Adenosine triphosphate	Cui JJ	Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).	Journal of medicinal chemistry	2011	110
21813754	Adenosine triphosphate	Chan DA	Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality.	Science translational medicine	2011	92
21822277	Adenosine triphosphate	Kashatus DF	RALA and RALBP1 regulate mitochondrial fission at mitosis.	Nature cell biology	2011	99
21873242	Adenosine triphosphate	Aung T	Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3.	Proceedings of the National Academy of Sciences of the United States of America	2011	41
21892209	Adenosine triphosphate	Mamo A	An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer.	Oncogene	2012	44
21900104	Adenosine triphosphate	Visscher H	Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.	Journal of clinical oncology 	2012	57
21900605	Adenosine triphosphate	Vlashi E	Metabolic state of glioma stem cells and nontumorigenic cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	113
21932399	Adenosine triphosphate	Borel F	Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs.	Hepatology	2012	44
21947008	Adenosine triphosphate	Jiang F	Structural basis of RNA recognition and activation by innate immune receptor RIG-I.	Nature	2011	136
21948564	Adenosine triphosphate	Bitarte N	MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells.	Stem cells	2011	70
21960526	Adenosine triphosphate	Dang CV	Therapeutic targeting of Myc-reprogrammed cancer cell metabolism.	Cold Spring Harbor symposia on quantitative biology	2011	45
21967057	Adenosine triphosphate	Sharom FJ	The P-glycoprotein multidrug transporter.	Essays in biochemistry	2011	73
21967058	Adenosine triphosphate	Slot AJ	Mammalian multidrug-resistance proteins (MRPs).	Essays in biochemistry	2011	37
21969607	Adenosine triphosphate	Fan J	Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells.	Molecular and cellular biology	2011	37
21975038	Adenosine triphosphate	Karkhanis V	Versatility of PRMT5-induced methylation in growth control and development.	Trends in biochemical sciences	2011	48
22037041	Adenosine triphosphate	Benjamin D	Rapamycin passes the torch: a new generation of mTOR inhibitors.	Nature reviews. Drug discovery	2011	220
22037302	Adenosine triphosphate	Frankland-Searby S	The 26S proteasome complex: an attractive target for cancer therapy.	Biochimica et biophysica acta	2012	46
22052357	Adenosine triphosphate	Menendez JA	mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging.	Cell cycle	2011	58
22062686	Adenosine triphosphate	Jhaveri K	Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.	Biochimica et biophysica acta	2012	118
22072639	Adenosine triphosphate	Bresler SC	Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.	Science translational medicine	2011	70
22077634	Adenosine triphosphate	Sheng B	Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease.	Journal of neurochemistry	2012	66
22084398	Adenosine triphosphate	Zhou Y	Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells.	Cancer research	2012	59
22098950	Adenosine triphosphate	Nakanishi T	Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.	Chinese journal of cancer	2012	49
22098952	Adenosine triphosphate	Sodani K	Multidrug resistance associated proteins in multidrug resistance.	Chinese journal of cancer	2012	35
22101433	Adenosine triphosphate	Metallo CM	Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.	Nature	2011	435
22113612	Adenosine triphosphate	Poulikakos PI	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).	Nature	2011	385
22123234	Adenosine triphosphate	Bayley JP	The Warburg effect in 2012.	Current opinion in oncology	2012	64
22130229	Adenosine triphosphate	Takeuchi K	Receptor tyrosine kinases and targeted cancer therapeutics.	Biological & pharmaceutical bulletin	2011	36
22134189	Adenosine triphosphate	Whitaker-Menezes D	Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue.	Cell cycle	2011	79
22156303	Adenosine triphosphate	Rottiers V	MicroRNAs in metabolism and metabolic diseases.	Cold Spring Harbor symposia on quantitative biology	2011	36
22195962	Adenosine triphosphate	Hitosugi T	Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism.	Molecular cell	2011	72
22198378	Adenosine triphosphate	Gusdon AM	ATP13A2 regulates mitochondrial bioenergetics through macroautophagy.	Neurobiology of disease	2012	39
22203527	Adenosine triphosphate	Del Barco S	Metformin: multi-faceted protection against cancer.	Oncotarget	2011	100
22215907	Adenosine triphosphate	Neckers L	Hsp90 molecular chaperone inhibitors: are we there yet?	Clinical cancer research 	2012	247
22223645	Adenosine triphosphate	Liu Q	Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics.	The Journal of biological chemistry	2012	36
22248732	Adenosine triphosphate	Natarajan K	Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.	Biochemical pharmacology	2012	80
22252128	Adenosine triphosphate	Garg AD	A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death.	The EMBO journal	2012	123
22262166	Adenosine triphosphate	Zhang Y	mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.	Cell cycle	2012	36
22266115	Adenosine triphosphate	Zaytseva YY	Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer.	Cancer research	2012	35
22277784	Adenosine triphosphate	Katayama R	Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.	Science translational medicine	2012	305
22294766	Adenosine triphosphate	Hlavata I	The role of ABC transporters in progression and clinical outcome of colorectal cancer.	Mutagenesis	2012	42
22323447	Adenosine triphosphate	Bernstein SH	The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives.	Blood	2012	32
22333578	Adenosine triphosphate	Vazquez-Martin A	Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells.	Cell cycle	2012	38
22342343	Adenosine triphosphate	Formentini L	The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response.	Molecular cell	2012	48
22360810	Adenosine triphosphate	Filipp FV	Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells.	Pigment cell & melanoma research	2012	52
22367541	Adenosine triphosphate	Hsieh AC	The translational landscape of mTOR signalling steers cancer initiation and metastasis.	Nature	2012	343
22396493	Adenosine triphosphate	Diaconu I	Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.	Cancer research	2012	52
22449631	Adenosine triphosphate	Garrido C	The small heat shock proteins family: the long forgotten chaperones.	The international journal of biochemistry & cell biology	2012	48
22460906	Adenosine triphosphate	Liu L	Deregulated MYC expression induces dependence upon AMPK-related kinase 5.	Nature	2012	83
22461509	Adenosine triphosphate	Miyamoto S	Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma.	Cancer research	2012	45
22469988	Adenosine triphosphate	Peschiaroli A	miR-143 regulates hexokinase 2 expression in cancer cells.	Oncogene	2013	40
22474384	Adenosine triphosphate	Kang YH	Properties of the human Cdc45/Mcm2-7/GINS helicase complex and its action with DNA polymerase epsilon in rolling circle DNA synthesis.	Proceedings of the National Academy of Sciences of the United States of America	2012	53
22505653	Adenosine triphosphate	Adinolfi E	Expression of P2X7 receptor increases in vivo tumor growth.	Cancer research	2012	67
22509477	Adenosine triphosphate	Mo W	Human ABCG2: structure, function, and its role in multidrug resistance.	International journal of biochemistry and molecular biology	2012	37
22525272	Adenosine triphosphate	Galavotti S	The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells.	Oncogene	2013	55
22532167	Adenosine triphosphate	Huang X	An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.	Cancer research	2012	34
22539746	Adenosine triphosphate	Thomas HE	mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.	Science translational medicine	2012	32
22544066	Adenosine triphosphate	Perciavalle RM	Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion¬†to respiration.	Nature cell biology	2012	110
22544529	Adenosine triphosphate	Franke H	Pathophysiology of astroglial purinergic signalling.	Purinergic signalling	2012	34
22552292	Adenosine triphosphate	Xu L	Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.	Cancer research	2012	41
22561706	Adenosine triphosphate	Dhar SK	Manganese superoxide dismutase regulation and cancer.	Free radical biology & medicine	2012	51
22564882	Adenosine triphosphate	Martelli AM	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.	Oncotarget	2012	50
22588883	Adenosine triphosphate	Vivanco I	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.	Cancer discovery	2012	91
22605616	Adenosine triphosphate	Goldman JW	Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.	Cancer	2012	38
22626470	Adenosine triphosphate	Johnson RF	Nuclear factor-Œ∫B, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect.	Trends in biochemical sciences	2012	35
22689530	Adenosine triphosphate	Liu Y	A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.	Molecular cancer therapeutics	2012	78
22698286	Adenosine triphosphate	Suijkerbuijk SJ	The vertebrate mitotic checkpoint protein BUBR1 is an unusual pseudokinase.	Developmental cell	2012	42
22705370	Adenosine triphosphate	Yuan J	The HARP-like domain-containing protein AH2/ZRANB3 binds to PCNA and participates in cellular response to replication stress.	Molecular cell	2012	32
22722202	Adenosine triphosphate	Banerji S	Sequence analysis of mutations and translocations across breast cancer subtypes.	Nature	2012	352
22727666	Adenosine triphosphate	Xu W	Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine.	Molecular cell	2012	41
22761435	Adenosine triphosphate	Marino ML	Autophagy is a protective mechanism for human melanoma cells under acidic stress.	The Journal of biological chemistry	2012	40
22787121	Adenosine triphosphate	Zaidi N	ATP-citrate lyase: a key player in cancer metabolism.	Cancer research	2012	68
22797058	Adenosine triphosphate	Chau WK	c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/Œ≤-catenin-ATP-binding cassette G2 signaling.	Oncogene	2013	53
22814620	Adenosine triphosphate	Jouan-Lanhouet S	TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation.	Cell death and differentiation	2012	85
22820988	Adenosine triphosphate	Bandaranayake RM	Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.	Nature structural & molecular biology	2012	42
22869150	Adenosine triphosphate	Kilbride SM	Central roles of apoptotic proteins in mitochondrial function.	Oncogene	2013	27
22886304	Adenosine triphosphate	Carracedo A	A metabolic prosurvival role for PML in breast cancer.	The Journal of clinical investigation	2012	65
22888144	Adenosine triphosphate	Solca F	Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.	The Journal of pharmacology and experimental therapeutics	2012	109
22892846	Adenosine triphosphate	van den Heuvel AP	Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth.	Cancer biology & therapy	2012	55
22913968	Adenosine triphosphate	Adekola K	Glucose transporters in cancer metabolism.	Current opinion in oncology	2012	40
22919677	Adenosine triphosphate	Pessione E	Lactic acid bacteria contribution to gut microbiota complexity: lights and shadows.	Frontiers in cellular and infection microbiology	2012	33
22948162	Adenosine triphosphate	Juliana C	Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation.	The Journal of biological chemistry	2012	116
22963440	Adenosine triphosphate	Volont√© C	P2X7 receptors: channels, pores and more.	CNS & neurological disorders drug targets	2012	48
22990239	Adenosine triphosphate	Rampelt H	Metazoan Hsp70 machines use Hsp110 to power protein disaggregation.	The EMBO journal	2012	88
23000902	Adenosine triphosphate	Jin MS	Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans.	Nature	2012	117
23049731	Adenosine triphosphate	Lodola F	Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients.	PloS one	2012	37
23071355	Adenosine triphosphate	Teicher BA	Targeting cancer metabolism.	Clinical cancer research 	2012	34
23090120	Adenosine triphosphate	Di Virgilio F	Purines, purinergic receptors, and cancer.	Cancer research	2012	69
23128392	Adenosine triphosphate	Zhao J	Mitochondrial dynamics regulates migration and invasion of breast cancer cells.	Oncogene	2013	102
23142078	Adenosine triphosphate	Kim SG	Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex.	Molecular cell	2013	50
23151605	Adenosine triphosphate	Krysko DV	Immunogenic cell death and DAMPs in cancer therapy.	Nature reviews. Cancer	2012	210
23168408	Adenosine triphosphate	von Schwarzenberg K	Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition.	The Journal of biological chemistry	2013	30
23218009	Adenosine triphosphate	Thadani R	Condensin, chromatin crossbarring and chromosome condensation.	Current biology 	2012	37
23239881	Adenosine triphosphate	Tan B	Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.	The Journal of biological chemistry	2013	44
23251084	Adenosine triphosphate	Naujokat C	Salinomycin as a drug for targeting human cancer stem cells.	Journal of biomedicine & biotechnology	2012	64
23263184	Adenosine triphosphate	Zhou H	ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase.	Nature	2013	29
23287468	Adenosine triphosphate	Vazquez-Martin A	The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells.	Cell cycle	2013	29
23287563	Adenosine triphosphate	Lin J	Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.	Clinical cancer research 	2013	38
23333938	Adenosine triphosphate	Atkins C	Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity.	Cancer research	2013	91
23355908	Adenosine triphosphate	Shain AH	The spectrum of SWI/SNF mutations, ubiquitous in human cancers.	PloS one	2013	101
23364915	Adenosine triphosphate	Hodge JW	Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.	International journal of cancer	2013	50
23376776	Adenosine triphosphate	Wu CA	Nutrient deprivation induces the Warburg effect through ROS/AMPK-dependent activation of pyruvate dehydrogenase kinase.	Biochimica et biophysica acta	2013	27
23403946	Adenosine triphosphate	Balasubramanian MN	Asparagine synthetase: regulation by cell stress and involvement in tumor biology.	American journal of physiology. Endocrinology and metabolism	2013	45
23432475	Adenosine triphosphate	Cheng Z	Mitochondria and metabolic homeostasis.	Antioxidants & redox signaling	2013	34
23436801	Adenosine triphosphate	Liu Q	Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.	Cancer research	2013	33
23449803	Adenosine triphosphate	Shirasaki T	MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells.	Journal of virology	2013	55
23453623	Adenosine triphosphate	Dong C	Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer.	Cancer cell	2013	149
23460667	Adenosine triphosphate	Golebiewska A	Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells.	Brain 	2013	28
23493349	Adenosine triphosphate	Xie L	FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.	Clinical cancer research 	2013	55
23498975	Adenosine triphosphate	Bartolome F	Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels.	Neuron	2013	38
23502424	Adenosine triphosphate	Polier S	ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system.	Nature chemical biology	2013	39
23532890	Adenosine triphosphate	Basilico C	Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.	Clinical cancer research 	2013	43
23562078	Adenosine triphosphate	Sene A	Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration.	Cell metabolism	2013	56
23564345	Adenosine triphosphate	Yoshida S	Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis.	Proceedings of the National Academy of Sciences of the United States of America	2013	47
23589839	Adenosine triphosphate	Nieminen AI	Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis.	Proceedings of the National Academy of Sciences of the United States of America	2013	32
23602572	Adenosine triphosphate	Pchelintsev NA	Placing the HIRA histone chaperone complex in the chromatin landscape.	Cell reports	2013	41
23603840	Adenosine triphosphate	Hall A	Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene.	Oncotarget	2013	43
23636326	Adenosine triphosphate	Yang H	mTOR kinase structure, mechanism and regulation.	Nature	2013	155
23639289	Adenosine triphosphate	Jangamreddy JR	Salinomycin induces activation of autophagy, mitophagy and affects mitochondrial polarity: differences between primary and cancer cells.	Biochimica et biophysica acta	2013	28
23647843	Adenosine triphosphate	Gao P	Cyclic G(2',5')pA(3',5')p is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase.	Cell	2013	147
23651857	Adenosine triphosphate	Hubert CG	Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A.	Genes & development	2013	36
23680146	Adenosine triphosphate	Holderfield M	RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.	Cancer cell	2013	32
23685672	Adenosine triphosphate	Lavoie H	Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization.	Nature chemical biology	2013	26
23688078	Adenosine triphosphate	Choi YH	ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.	Current pharmaceutical design	2014	42
23690617	Adenosine triphosphate	Marcoux J	Mass spectrometry reveals synergistic effects of nucleotides, lipids, and drugs binding to a multidrug resistance efflux pump.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
23698369	Adenosine triphosphate	Dykhuizen EC	BAF complexes facilitate decatenation of DNA by topoisomerase IIŒ±.	Nature	2013	63
23699655	Adenosine triphosphate	Guertin AD	Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.	Molecular cancer therapeutics	2013	43
23764003	Adenosine triphosphate	Roesch A	Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.	Cancer cell	2013	124
23764021	Adenosine triphosphate	Cheng G	Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death.	BMC cancer	2013	26
23792284	Adenosine triphosphate	Ji RR	Glia and pain: is chronic pain a gliopathy?	Pain	2013	154
23800749	Adenosine triphosphate	Garg AD	ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death.	Autophagy	2013	46
23806880	Adenosine triphosphate	Li J	Structure, function and regulation of the hsp90 machinery.	Biomedical journal	2013	83
23832118	Adenosine triphosphate	Inoue H	Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments.	Cell death and differentiation	2014	52
23844554	Adenosine triphosphate	Fox EM	Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.	Breast cancer research 	2013	27
23850489	Adenosine triphosphate	Foulds CE	Proteomic analysis of coregulators bound to ERŒ± on DNA and nucleosomes reveals coregulator dynamics.	Molecular cell	2013	38
23852373	Adenosine triphosphate	Martins I	Molecular mechanisms of ATP secretion during immunogenic cell death.	Cell death and differentiation	2014	71
23852728	Adenosine triphosphate	Betz C	Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology.	Proceedings of the National Academy of Sciences of the United States of America	2013	77
23883585	Adenosine triphosphate	Bey EA	Catalase abrogates Œ≤-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.	Molecular cancer therapeutics	2013	27
23886165	Adenosine triphosphate	Jin J	miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9.	Asian Pacific journal of cancer prevention 	2013	27
23886445	Adenosine triphosphate	Tao R	Regulation of MnSOD enzymatic activity by Sirt3 connects the mitochondrial acetylome signaling networks to aging and carcinogenesis.	Antioxidants & redox signaling	2014	34
23911327	Adenosine triphosphate	De Bock K	Role of PFKFB3-driven glycolysis in vessel sprouting.	Cell	2013	149
23932781	Adenosine triphosphate	Lin R	Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth.	Molecular cell	2013	47
23954449	Adenosine triphosphate	Stanley FK	CHD chromatin remodelling enzymes and the DNA damage response.	Mutation research	2013	29
23967283	Adenosine triphosphate	Yang Y	Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma.	PloS one	2013	27
23969692	Adenosine triphosphate	Parks SK	Disrupting proton dynamics and energy metabolism for cancer therapy.	Nature reviews. Cancer	2013	115
23991830	Adenosine triphosphate	Szabo C	Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms.	British journal of pharmacology	2014	58
24021215	Adenosine triphosphate	Stacy AE	Molecular pharmacology of ABCG2 and its role in chemoresistance.	Molecular pharmacology	2013	42
24025713	Adenosine triphosphate	Chini CC	Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.	Clinical cancer research 	2014	24
24037090	Adenosine triphosphate	Ko A	Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling.	Cell death and differentiation	2014	54
24050699	Adenosine triphosphate	Cole SP	Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future.	Annual review of pharmacology and toxicology	2014	30
24082052	Adenosine triphosphate	Williams TA	Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas.	Hypertension	2014	24
24096870	Adenosine triphosphate	Liu PP	Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway.	Cell death and differentiation	2014	48
24117156	Adenosine triphosphate	Bubici C	JNK signalling in cancer: in need of new, smarter therapeutic targets.	British journal of pharmacology	2014	32
24120954	Adenosine triphosphate	Kunjachan S	Multidrug resistance: Physiological principles and nanomedical solutions.	Advanced drug delivery reviews	2013	40
24122795	Adenosine triphosphate	Wang X	Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer--mechanisms and potential therapeutic insights.	Clinical cancer research 	2014	22
24186203	Adenosine triphosphate	Amelio I	p73 regulates serine biosynthesis in cancer.	Oncogene	2014	34
24186207	Adenosine triphosphate	Tennakoon JB	Androgens regulate prostate cancer cell growth via an AMPK-PGC-1Œ±-mediated metabolic switch.	Oncogene	2014	45
24206664	Adenosine triphosphate	Morita M	mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation.	Cell metabolism	2013	119
24211491	Adenosine triphosphate	Tahara T	Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators.	Gastroenterology	2014	23
24236104	Adenosine triphosphate	Bhattacharyya S	Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.	PloS one	2013	37
24253024	Adenosine triphosphate	Buontempo F	Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.	Leukemia	2014	23
24265069	Adenosine triphosphate	Burnstock G	Purinergic signalling in the urinary tract in health and disease.	Purinergic signalling	2014	29
24270265	Adenosine triphosphate	Goncharov DA	Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.	Circulation	2014	38
24277820	Adenosine triphosphate	Jansen RS	ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release.	Proceedings of the National Academy of Sciences of the United States of America	2013	37
24285728	Adenosine triphosphate	Doherty JR	Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.	Cancer research	2014	60
24311721	Adenosine triphosphate	Laszlo GS	Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.	Blood	2014	27
24332968	Adenosine triphosphate	Tornovsky-Babeay S	Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in Œ≤ cells.	Cell metabolism	2014	32
24337769	Adenosine triphosphate	Kang YK	A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.	Investigational new drugs	2014	29
24338270	Adenosine triphosphate	Singh P	Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.	Medical oncology	2014	45
24353160	Adenosine triphosphate	Yasuda H	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.	Science translational medicine	2013	60
24363178	Adenosine triphosphate	Gray LR	Regulation of pyruvate metabolism and human disease.	Cellular and molecular life sciences 	2014	42
24363449	Adenosine triphosphate	Cope CL	Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.	Journal of cell science	2014	26
24403227	Adenosine triphosphate	Ellinghaus P	BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I.	Cancer medicine	2013	27
24451478	Adenosine triphosphate	Klarer AC	Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism.	Cancer & metabolism	2014	21
24452853	Adenosine triphosphate	Langer F	Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation.	Thrombosis and haemostasis	2014	21
24459177	Adenosine triphosphate	Keppler D	The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia.	Drug metabolism and disposition	2014	23
24462205	Adenosine triphosphate	Mollapour M	Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.	Molecular cell	2014	31
24474669	Adenosine triphosphate	Garcia PD	Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.	Clinical cancer research 	2014	27
24480782	Adenosine triphosphate	Gameiro SR	Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.	Oncotarget	2014	68
24492893	Adenosine triphosphate	Callaghan R	Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?	Drug metabolism and disposition	2014	29
24500981	Adenosine triphosphate	Fucikova J	High hydrostatic pressure induces immunogenic cell death in human tumor cells.	International journal of cancer	2014	24
24508027	Adenosine triphosphate	Wong N	PKM2 contributes to cancer metabolism.	Cancer letters	2015	42
24513530	Adenosine triphosphate	Moreno-S√°nchez R	Who controls the ATP supply in cancer cells? Biochemistry lessons to understand cancer energy metabolism.	The international journal of biochemistry & cell biology	2014	31
24523596	Adenosine triphosphate	Noguchi K	Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.	Pharmacogenomics and personalized medicine	2014	31
24550282	Adenosine triphosphate	Faubert B	Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1Œ±.	Proceedings of the National Academy of Sciences of the United States of America	2014	49
24583800	Adenosine triphosphate	Meyer SC	Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.	Clinical cancer research 	2014	28
24585446	Adenosine triphosphate	Zhu B	Genetic variants in the SWI/SNF complex and smoking collaborate to modify the risk of pancreatic cancer in a Chinese population.	Molecular carcinogenesis	2015	18
24606795	Adenosine triphosphate	Valero T	Mitochondrial biogenesis: pharmacological approaches.	Current pharmaceutical design	2014	29
24656405	Adenosine triphosphate	Kitambi SS	RETRACTED: Vulnerability of glioblastoma cells to catastrophic vacuolization and death induced by a small molecule.	Cell	2014	45
24677093	Adenosine triphosphate	Rehman G	Role of AMP-activated protein kinase in cancer therapy.	Archiv der Pharmazie	2014	24
24705351	Adenosine triphosphate	Zhai B	Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.	Molecular cancer therapeutics	2014	45
24713656	Adenosine triphosphate	Amato KR	Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.	The Journal of clinical investigation	2014	21
24727893	Adenosine triphosphate	Bonora M	Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition.	Oncogene	2015	39
24732580	Adenosine triphosphate	Cosentino K	Mitochondrial alterations in apoptosis.	Chemistry and physics of lipids	2014	37
24736023	Adenosine triphosphate	Arend RC	Inhibition of Wnt/Œ≤-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.	Gynecologic oncology	2014	38
24746669	Adenosine triphosphate	Wang Z	Cyclin B1/Cdk1 coordinates mitochondrial respiration for cell-cycle G2/M progression.	Developmental cell	2014	37
24748656	Adenosine triphosphate	Dienstmann R	Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.	Molecular cancer therapeutics	2014	66
24749746	Adenosine triphosphate	Schuler PJ	Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.	Clinical and experimental immunology	2014	35
24768297	Adenosine triphosphate	Liang H	PTENŒ±, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism.	Cell metabolism	2014	45
24777293	Adenosine triphosphate	Shi L	miR-145 inhibits migration and invasion of glioma stem cells by targeting ABCG2.	Neuromolecular medicine	2014	24
24781191	Adenosine triphosphate	Arif T	Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo.	Molecular therapy. Nucleic acids	2014	23
24787293	Adenosine triphosphate	Martinez-Outschoorn U	Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function.	Seminars in oncology	2014	40
24788099	Adenosine triphosphate	Watanabe R	SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.	Cancer research	2014	33
24805240	Adenosine triphosphate	Fan J	Quantitative flux analysis reveals folate-dependent NADPH production.	Nature	2014	182
24837364	Adenosine triphosphate	Zhou JZ	Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis.	Oncogene	2015	15
24840079	Adenosine triphosphate	Zhao Y	The clinical development of MEK inhibitors.	Nature reviews. Clinical oncology	2014	65
24867695	Adenosine triphosphate	Cheng G	Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.	British journal of cancer	2014	23
24874432	Adenosine triphosphate	Takahashi K	Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy.	Molecular cancer research 	2014	29
24875192	Adenosine triphosphate	Pearce D	Collecting duct principal cell transport processes and their regulation.	Clinical journal of the American Society of Nephrology 	2015	36
24878061	Adenosine triphosphate	Chou TF	Specific inhibition of p97/VCP ATPase and kinetic analysis demonstrate interaction between D1 and D2 ATPase domains.	Journal of molecular biology	2014	30
24879823	Adenosine triphosphate	Hato SV	Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics.	Clinical cancer research 	2014	27
24938562	Adenosine triphosphate	Carvajal RD	Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.	JAMA	2014	69
24958102	Adenosine triphosphate	Wang Y	Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines.	Molecular and cellular biology	2014	29
24969777	Adenosine triphosphate	Jansen RS	ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report.	Arteriosclerosis, thrombosis, and vascular biology	2014	37
24995977	Adenosine triphosphate	Lo JC	Adipsin is an adipokine that improves Œ≤ cell function in diabetes.	Cell	2014	33
24998913	Adenosine triphosphate	Lee JV	Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation.	Cell metabolism	2014	82
25015789	Adenosine triphosphate	Isayev O	Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.	Oncotarget	2014	22
25017063	Adenosine triphosphate	Quir√≥s PM	ATP-dependent Lon protease controls tumor bioenergetics by reprogramming mitochondrial activity.	Cell reports	2014	31
25026296	Adenosine triphosphate	Wang Z	MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin.	Oncotarget	2014	61
25043301	Adenosine triphosphate	Lin L	MACC1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect.	Oncogene	2015	21
25043816	Adenosine triphosphate	Petruzzelli M	A switch from white to brown fat increases energy expenditure in cancer-associated cachexia.	Cell metabolism	2014	83
25057888	Adenosine triphosphate	Babon JJ	The molecular regulation of Janus kinase (JAK) activation.	The Biochemical journal	2014	27
25092294	Adenosine triphosphate	Eytan E	Disassembly of mitotic checkpoint complexes by the joint action of the AAA-ATPase TRIP13 and p31(comet).	Proceedings of the National Academy of Sciences of the United States of America	2014	33
25119037	Adenosine triphosphate	Van Nostrand JL	Inappropriate p53 activation during development induces features of CHARGE syndrome.	Nature	2014	33
25152236	Adenosine triphosphate	Ozden O	SIRT3 deacetylates and increases pyruvate dehydrogenase activity in cancer cells.	Free radical biology & medicine	2014	32
25156912	Adenosine triphosphate	Zhang X	GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR-YB1 pathway in vitro.	Molecular carcinogenesis	2015	16
25220464	Adenosine triphosphate	Fouquerel E	ARTD1/PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent of NAD+ depletion.	Cell reports	2014	32
25236865	Adenosine triphosphate	Mao Q	Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.	The AAPS journal	2015	45
25241037	Adenosine triphosphate	LeBleu VS	PGC-1Œ± mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote¬†metastasis.	Nature cell biology	2014	167
25259783	Adenosine triphosphate	Hardie DG	AMPK: positive and negative regulation, and its role in whole-body energy homeostasis.	Current opinion in cell biology	2015	80
25262208	Adenosine triphosphate	Miranda-Lorenzo I	Intracellular autofluorescence: a biomarker for epithelial cancer stem cells.	Nature methods	2014	36
25263561	Adenosine triphosphate	Bensaad K	Fatty acid uptake and lipid storage induced by HIF-1Œ± contribute to cell growth and survival after hypoxia-reoxygenation.	Cell reports	2014	45
25277190	Adenosine triphosphate	Bonuccelli G	Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells.	Oncotarget	2014	23
25281745	Adenosine triphosphate	Cole SP	Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter.	The Journal of biological chemistry	2014	24
25326666	Adenosine triphosphate	Ronan B	A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy.	Nature chemical biology	2014	56
25415869	Adenosine triphosphate	Rudolph J	Inhibitors of p21-activated kinases (PAKs).	Journal of medicinal chemistry	2015	18
25435018	Adenosine triphosphate	Silva R	Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy.	Pharmacology & therapeutics	2015	27
25437566	Adenosine triphosphate	Brehme M	A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease.	Cell reports	2014	69
25482473	Adenosine triphosphate	Parihar P	Mitochondrial sirtuins: emerging roles in metabolic regulations, energy homeostasis and diseases.	Experimental gerontology	2015	16
25519700	Adenosine triphosphate	Slotkin EK	MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.	Molecular cancer therapeutics	2015	18
25556000	Adenosine triphosphate	Bakthisaran R	Small heat shock proteins: Role in cellular functions and pathology.	Biochimica et biophysica acta	2015	44
25590809	Adenosine triphosphate	Moore Z	NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by Œ≤-lapachone.	Cell death & disease	2015	18
25607458	Adenosine triphosphate	Blagih J	The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo.	Immunity	2015	77
25639242	Adenosine triphosphate	Davie E	Nitrogen regulates AMPK to control TORC1 signaling.	Current biology 	2015	15
25662515	Adenosine triphosphate	Roskoski R Jr	Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.	Pharmacological research	2015	44
25670221	Adenosine triphosphate	Yang Q	Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.	Clinical cancer research 	2015	32
25673690	Adenosine triphosphate	Tsai YL	Characterization and mechanism of stress-induced translocation of 78-kilodalton glucose-regulated protein (GRP78) to the cell surface.	The Journal of biological chemistry	2015	22
25709099	Adenosine triphosphate	Sampath D	Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.	Pharmacology & therapeutics	2015	26
25715710	Adenosine triphosphate	Kaushik N	Responses of solid tumor cells in DMEM to reactive oxygen species generated by non-thermal plasma and chemically induced ROS systems.	Scientific reports	2015	17
25733882	Adenosine triphosphate	Zou HY	PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.	Proceedings of the National Academy of Sciences of the United States of America	2015	28
25751139	Adenosine triphosphate	Wang W	AMPK modulates Hippo pathway activity to regulate energy homeostasis.	Nature cell biology	2015	73
25785725	Adenosine triphosphate	Lee C	Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1.	Journal of the American Chemical Society	2015	19
25795921	Adenosine triphosphate	Daver N	Secondary mutations as mediators of resistance to targeted therapy in leukemia.	Blood	2015	21
25796366	Adenosine triphosphate	Torchy MP	Structure and function insights into the NuRD chromatin remodeling complex.	Cellular and molecular life sciences 	2015	26
25801706	Adenosine triphosphate	Israelson A	Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1.	Neuron	2015	19
25807077	Adenosine triphosphate	Lu CL	Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect.	PloS one	2015	23
25821004	Adenosine triphosphate	Hassanein M	Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer.	International journal of cancer	2015	22
25840885	Adenosine triphosphate	Zhang YK	Multidrug Resistance Proteins (MRPs) and Cancer Therapy.	The AAPS journal	2015	24
25840982	Adenosine triphosphate	Sadok A	Rho kinase inhibitors block melanoma cell migration and inhibit metastasis.	Cancer research	2015	19
25864878	Adenosine triphosphate	Nowicki S	Oncometabolites: tailoring our genes.	The FEBS journal	2015	21
25867026	Adenosine triphosphate	Sesen J	Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.	PloS one	2015	25
25867072	Adenosine triphosphate	He K	mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.	Oncogene	2016	20
25873900	Adenosine triphosphate	Chon HJ	The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.	Frontiers in pharmacology	2015	17
25890351	Adenosine triphosphate	Yang Z	T-cell metabolism in autoimmune disease.	Arthritis research & therapy	2015	22
25915845	Adenosine triphosphate	Helmke C	The role of Plk3 in oncogenesis.	Oncogene	2016	10
25941621	Adenosine triphosphate	Kepp O	Consensus guidelines for the detection of immunogenic cell death.	Oncoimmunology	2014	114
25975984	Adenosine triphosphate	Dinkova-Kostova AT	The emerging role of Nrf2 in mitochondrial function.	Free radical biology & medicine	2015	55
25982279	Adenosine triphosphate	Buchert M	Targeting JAK kinase in solid tumors: emerging opportunities and challenges.	Oncogene	2016	32
26002551	Adenosine triphosphate	Loubi√®re C	Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells.	Oncotarget	2015	15
26054020	Adenosine triphosphate	Guo W	MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer.	Hepatology	2015	25
26062441	Adenosine triphosphate	Wang J	Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer.	Oncotarget	2015	24
26097841	Adenosine triphosphate	Finka A	Multi-layered molecular mechanisms of polypeptide holding, unfolding and disaggregation by HSP70/HSP110 chaperones.	Frontiers in molecular biosciences	2015	21
26098574	Adenosine triphosphate	Furlow PW	Mechanosensitive pannexin-1 channels mediate microvascular metastatic cell survival.	Nature cell biology	2015	18
26100653	Adenosine triphosphate	Ween MP	The role of ABC transporters in ovarian cancer progression and chemoresistance.	Critical reviews in oncology/hematology	2015	16
26119936	Adenosine triphosphate	Whang YM	LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.	Oncogene	2016	12
26159692	Adenosine triphosphate	Dibble CC	Regulation of mTORC1 by PI3K signaling.	Trends in cell biology	2015	103
26170311	Adenosine triphosphate	Heredia A	Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice.	Proceedings of the National Academy of Sciences of the United States of America	2015	19
26177051	Adenosine triphosphate	Leontieva OV	Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).	Oncotarget	2015	25
26190651	Adenosine triphosphate	Fu X	2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.	Cell metabolism	2015	21
26207888	Adenosine triphosphate	Roskoski R Jr	A historical overview of protein kinases and their targeted small molecule inhibitors.	Pharmacological research	2015	42
26214738	Adenosine triphosphate	Senyilmaz D	Regulation of mitochondrial morphology and function by stearoylation of TFR1.	Nature	2015	20
26232225	Adenosine triphosphate	Sullivan LB	Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells.	Cell	2015	105
26300264	Adenosine triphosphate	Gao X	Human Hsp70 Disaggregase Reverses Parkinson's-Linked Œ±-Synuclein Amyloid Fibrils.	Molecular cell	2015	43
26311743	Adenosine triphosphate	Heerma van Voss MR	Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer.	Oncotarget	2015	18
26322680	Adenosine triphosphate	Dom√©nech E	AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest.	Nature cell biology	2015	29
26327810	Adenosine triphosphate	Zhang W	Insights into Chemoresistance of Prostate Cancer.	International journal of biological sciences	2015	16
26358751	Adenosine triphosphate	Guichard SM	AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.	Molecular cancer therapeutics	2015	15
26382145	Adenosine triphosphate	Stine ZE	MYC, Metabolism, and Cancer.	Cancer discovery	2015	84
26400757	Adenosine triphosphate	Ratajczak MZ	Emerging Strategies to Enhance Homing and Engraftment of Hematopoietic Stem Cells.	Stem cell reviews	2016	11
26433470	Adenosine triphosphate	Azimi I	Altered purinergic receptor-Ca¬≤‚Å∫ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells.	Molecular oncology	2016	13
26436840	Adenosine triphosphate	Poepsel S	Determinants of amyloid fibril degradation by the PDZ protease HTRA1.	Nature chemical biology	2015	19
26437365	Adenosine triphosphate	Goedeke L	MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels.	Nature medicine	2015	28
26466569	Adenosine triphosphate	Zhang C	RAF inhibitors that evade paradoxical MAPK pathway activation.	Nature	2015	44
26499806	Adenosine triphosphate	Chen Z	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.	Cancer letters	2016	53
26501192	Adenosine triphosphate	Wagschal A	Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis.	Nature medicine	2015	36
26519060	Adenosine triphosphate	Zhai L	Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.	Clinical cancer research 	2015	24
26579470	Adenosine triphosphate	Huang L	Mechanisms of resistance to EGFR tyrosine kinase inhibitors.	Acta pharmaceutica Sinica. B	2015	42
26607222	Adenosine triphosphate	Giannuzzo A	The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells.	Molecular cancer	2015	16
26616193	Adenosine triphosphate	Hardie DG	AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs.	Trends in cell biology	2016	73
26649310	Adenosine triphosphate	Moitra K	Overcoming Multidrug Resistance in Cancer Stem Cells.	BioMed research international	2015	16
26654173	Adenosine triphosphate	Zuccolo E	Constitutive Store-Operated Ca(2+) Entry Leads to Enhanced Nitric Oxide Production and Proliferation in Infantile Hemangioma-Derived Endothelial Colony-Forming Cells.	Stem cells and development	2016	11
26669263	Adenosine triphosphate	Pradhan SK	EP400 Deposits H3.3 into Promoters and Enhancers during Gene Activation.	Molecular cell	2016	12
26691987	Adenosine triphosphate	Okosun J	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.	Nature genetics	2016	16
26744319	Adenosine triphosphate	Wang MD	HBx regulates fatty acid oxidation to promote hepatocellular carcinoma survival during metabolic stress.	Oncotarget	2016	11
26791262	Adenosine triphosphate	Li C	Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer.	World journal of surgical oncology	2016	10
26804906	Adenosine triphosphate	Franco J	Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities.	Cell reports	2016	11
26818443	Adenosine triphosphate	Tang WK	Role of the D1-D2 Linker of Human VCP/p97 in the Asymmetry and ATPase Activity of the D1-domain.	Scientific reports	2016	12
26818947	Adenosine triphosphate	Imamura M	Genome-wide association studies in the Japanese population identify seven novel loci for type 2 diabetes.	Nature communications	2016	13
26830313	Adenosine triphosphate	Zhitomirsky B	Lysosomes as mediators of drug resistance in cancer.	Drug resistance updates 	2016	16
26836503	Adenosine triphosphate	Kadoch C	PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease.	Biochemistry	2016	10
26876430	Adenosine triphosphate	Garc√≠a-Berm√∫dez J	The ATPase Inhibitory Factor 1 (IF1): A master regulator of energy metabolism and of cell survival.	Biochimica et biophysica acta	2016	12
26887051	Adenosine triphosphate	Booth L	Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function.	Oncotarget	2016	16
26888060	Adenosine triphosphate	Abid Ali F	Cryo-EM structures of the eukaryotic replicative helicase bound to a translocation substrate.	Nature communications	2016	36
26895424	Adenosine triphosphate	Luijsterburg MS	PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining.	Molecular cell	2016	31
26902888	Adenosine triphosphate	Park D	Resveratrol induces autophagy by directly inhibiting mTOR through ATP competition.	Scientific reports	2016	21
26916001	Adenosine triphosphate	Garg G	Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.	Advances in cancer research	2016	11
26923594	Adenosine triphosphate	Park JH	Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer.	Cell reports	2016	18
26947070	Adenosine triphosphate	C√°rdenas C	Selective Vulnerability of Cancer Cells by Inhibition of Ca(2+) Transfer from Endoplasmic Reticulum to Mitochondria.	Cell reports	2016	22
27038735	Adenosine triphosphate	Zhang Y	Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca(2+)-XO-ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways.	Free radical biology & medicine	2016	15
27141887	Adenosine triphosphate	Martinez-Outschoorn UE	Cancer metabolism: a therapeutic perspective.	Nature reviews. Clinical oncology	2017	62
27180306	Adenosine triphosphate	Fletcher JI	ABC transporters as mediators of drug resistance and contributors to cancer cell biology.	Drug resistance updates 	2016	13
27250110	Adenosine triphosphate	Gao M	Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.	Journal of liposome research	2017	6
27309803	Adenosine triphosphate	Iwasaki S	Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor.	Nature	2016	22
27335445	Adenosine triphosphate	Stransky L	The Function of V-ATPases in Cancer.	Physiological reviews	2016	12
27344270	Adenosine triphosphate	Fiorillo M	Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs).	Aging	2016	13
27385336	Adenosine triphosphate	Cunniff B	AMPK activity regulates trafficking of mitochondria to the leading edge during cell migration and matrix invasion.	Molecular biology of the cell	2016	11
27413115	Adenosine triphosphate	Hodges C	The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer.	Cold Spring Harbor perspectives in medicine	2016	16
27502484	Adenosine triphosphate	Raturi A	TMX1 determines cancer cell metabolism as a thiol-based modulator of ER-mitochondria Ca2+ flux.	The Journal of cell biology	2016	12
27606689	Adenosine triphosphate	Madreiter-Sokolowski CT	Resveratrol Specifically Kills Cancer Cells by a Devastating Increase in the Ca2+ Coupling Between the Greatly Tethered Endoplasmic Reticulum and Mitochondria.	Cellular physiology and biochemistry 	2016	11
27748766	Adenosine triphosphate	Yang C	Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.	Oncogene	2017	8
27872130	Adenosine triphosphate	Saura C	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.	Cancer discovery	2017	9
27941796	Adenosine triphosphate	Kadoch C	Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states.	Nature genetics	2017	16
28060726	Adenosine triphosphate	Ogawa M	Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity.	Oncotarget	2017	11
28157507	Adenosine triphosphate	Alekseev S	Transcription without XPB Establishes a Unified Helicase-Independent Mechanism of Promoter Opening in Eukaryotic Gene Expression.	Molecular cell	2017	6
28192788	Adenosine triphosphate	Chan LN	Metabolic gatekeeper function of B-lymphoid transcription factors.	Nature	2017	10
28228254	Adenosine triphosphate	Faccenda D	Control of Mitochondrial Remodeling by the ATPase Inhibitory Factor 1¬†Unveils a Pro-survival Relay via OPA1.	Cell reports	2017	9
28230866	Adenosine triphosphate	Yao Z	Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells.	Cell death & disease	2017	7
28234357	Adenosine triphosphate	Garg AD	Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing.	Cell death and differentiation	2017	11
28239646	Adenosine triphosphate	Wang YY	Mammary adipocytes stimulate breast cancer invasion through metabolic remodeling of tumor cells.	JCI insight	2017	12
28512218	Adenosine triphosphate	Blythe EE	Ubiquitin- and ATP-dependent unfoldase activity of P97/VCP‚Ä¢NPLOC4‚Ä¢UFD1L is enhanced by a mutation that causes multisystem proteinopathy.	Proceedings of the National Academy of Sciences of the United States of America	2017	8
28723547	Adenosine triphosphate	Di Virgilio F	The P2X7 Receptor in Infection and Inflammation.	Immunity	2017	17
1907934	Guanosine triphosphate	Taylor MW	Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism.	FASEB journal 	1991	216
2549426	Guanosine triphosphate	Landis CA	GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.	Nature	1989	177
2551506	Guanosine triphosphate	van Corven EJ	Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins.	Cell	1989	158
8146159	Guanosine triphosphate	Bischoff FR	RanGAP1 induces GTPase activity of nuclear Ras-related Ran.	Proceedings of the National Academy of Sciences of the United States of America	1994	177
8402898	Guanosine triphosphate	Gout I	The GTPase dynamin binds to and is activated by a subset of SH3 domains.	Cell	1993	150
8717515	Guanosine triphosphate	Cantrell D	T cell antigen receptor signal transduction pathways.	Annual review of immunology	1996	125
9113989	Guanosine triphosphate	Vanhaesebroeck B	P110delta, a novel phosphoinositide 3-kinase in leukocytes.	Proceedings of the National Academy of Sciences of the United States of America	1997	112
10639096	Guanosine triphosphate	Somlyo AP	Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II.	The Journal of physiology	2000	222
10871853	Guanosine triphosphate	Schnelzer A	Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b.	Oncogene	2000	120
12486108	Guanosine triphosphate	Danen EH	The fibronectin-binding integrins alpha5beta1 and alphavbeta3 differentially modulate RhoA-GTP loading, organization of cell matrix adhesions, and fibronectin fibrillogenesis.	The Journal of cell biology	2002	87
12618308	Guanosine triphosphate	Bernards A	GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila.	Biochimica et biophysica acta	2003	110
15020670	Guanosine triphosphate	Wennerberg K	Rho-family GTPases: it's not only Rac and Rho (and I like it).	Journal of cell science	2004	163
15328152	Guanosine triphosphate	Wysoczynski M	Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient.	Blood	2005	68
15340059	Guanosine triphosphate	Li Y	Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity.	Molecular and cellular biology	2004	77
15657390	Guanosine triphosphate	Tsai RY	A multistep, GTP-driven mechanism controlling the dynamic cycling of nucleostemin.	The Journal of cell biology	2005	67
16236794	Guanosine triphosphate	Kamijo K	Dissecting the role of Rho-mediated signaling in contractile ring formation.	Molecular biology of the cell	2006	81
16475973	Guanosine triphosphate	Fritz G	Rho GTPases: promising cellular targets for novel anticancer drugs.	Current cancer drug targets	2006	64
16754960	Guanosine triphosphate	Pellinen T	Small GTPase Rab21 regulates cell adhesion and controls endosomal traffic of beta1-integrins.	The Journal of cell biology	2006	104
16980962	Guanosine triphosphate	Smith WW	Kinase activity of mutant LRRK2 mediates neuronal toxicity.	Nature neuroscience	2006	227
17079465	Guanosine triphosphate	Kurayoshi M	Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion.	Cancer research	2006	134
17126549	Guanosine triphosphate	Garc√≠a-Mata R	Catching a GEF by its tail.	Trends in cell biology	2007	70
17234759	Guanosine triphosphate	Morrison H	Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac.	Cancer research	2007	58
17263520	Guanosine triphosphate	Gorfe AA	Structure and dynamics of the full-length lipid-modified H-Ras protein in a 1,2-dimyristoylglycero-3-phosphocholine bilayer.	Journal of medicinal chemistry	2007	63
17360675	Guanosine triphosphate	Urano J	Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells.	Proceedings of the National Academy of Sciences of the United States of America	2007	67
17409395	Guanosine triphosphate	Wang H	PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition.	Cancer research	2007	78
17517660	Guanosine triphosphate	Oliveira JB	NRAS mutation causes a human autoimmune lymphoproliferative syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2007	57
17686471	Guanosine triphosphate	Garrett TA	VEGF-induced Rac1 activation in endothelial cells is regulated by the guanine nucleotide exchange factor Vav2.	Experimental cell research	2007	64
17981133	Guanosine triphosphate	Bi X	Insights into COPII coat nucleation from the structure of Sec23.Sar1 complexed with the active fragment of Sec31.	Developmental cell	2007	80
18344980	Guanosine triphosphate	Lim KH	Tumour maintenance is mediated by eNOS.	Nature	2008	104
18519636	Guanosine triphosphate	Xue W	DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma.	Genes & development	2008	75
18604198	Guanosine triphosphate	Kim E	Regulation of TORC1 by Rag GTPases in nutrient response.	Nature cell biology	2008	402
19252414	Guanosine triphosphate	Koorstra JB	The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target.	Cancer biology & therapy	2009	55
19299511	Guanosine triphosphate	Sato T	Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein.	The Journal of biological chemistry	2009	72
19595305	Guanosine triphosphate	Young A	Ras signaling and therapies.	Advances in cancer research	2009	86
19856314	Guanosine triphosphate	Pandey M	Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells.	International journal of cancer	2010	49
20484105	Guanosine triphosphate	Hendrix A	Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis.	Journal of the National Cancer Institute	2010	59
20570890	Guanosine triphosphate	Janakiraman M	Genomic and biological characterization of exon 4 KRAS mutations in human cancer.	Cancer research	2010	98
20937701	Guanosine triphosphate	Yoshimura S	Family-wide characterization of the DENN domain Rab GDP-GTP exchange factors.	The Journal of cell biology	2010	87
20951941	Guanosine triphosphate	Melo SA	A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells.	Cancer cell	2010	101
21491416	Guanosine triphosphate	Chen MY	Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.	Cancer	2011	38
21515363	Guanosine triphosphate	Stengel K	Cdc42 in oncogenic transformation, invasion, and tumorigenesis.	Cellular signalling	2011	53
21536732	Guanosine triphosphate	Finch AJ	Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome.	Genes & development	2011	66
21563770	Guanosine triphosphate	Meng H	Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism.	ACS nano	2011	44
21622195	Guanosine triphosphate	Rathinam R	Role of Rho GTPases and their regulators in cancer progression.	Frontiers in bioscience	2011	45
22114073	Guanosine triphosphate	Thakur VS	Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases.	Carcinogenesis	2012	31
22220215	Guanosine triphosphate	Carcamo WC	Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells.	PloS one	2011	37
22286105	Guanosine triphosphate	Smrcka AV	Role of phospholipase CŒµ in physiological phosphoinositide signaling networks.	Cellular signalling	2012	37
22494971	Guanosine triphosphate	Jeong WJ	Ras stabilization through aberrant activation of Wnt/Œ≤-catenin signaling promotes intestinal tumorigenesis.	Science signaling	2012	34
22749528	Guanosine triphosphate	Dur√°n RV	Glutaminolysis activates Rag-mTORC1 signaling.	Molecular cell	2012	160
23246410	Guanosine triphosphate	Lampson BL	Rare codons regulate KRas oncogenesis.	Current biology 	2013	29
23382236	Guanosine triphosphate	Kawazu M	Transforming mutations of RAC guanosine triphosphatases in human cancers.	Proceedings of the National Academy of Sciences of the United States of America	2013	26
23622247	Guanosine triphosphate	Riou P	14-3-3 proteins interact with a hybrid prenyl-phosphorylation motif to inhibit G proteins.	Cell	2013	37
23716719	Guanosine triphosphate	Panchaud N	Amino acid deprivation inhibits TORC1 through a GTPase-activating protein complex for the Rag family GTPase Gtr1.	Science signaling	2013	76
23737504	Guanosine triphosphate	Hocker HJ	Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function.	Proceedings of the National Academy of Sciences of the United States of America	2013	25
24037532	Guanosine triphosphate	Cook DR	Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease.	Oncogene	2014	69
24095279	Guanosine triphosphate	Tsun ZY	The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1.	Molecular cell	2013	120
24256730	Guanosine triphosphate	Ostrem JM	K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.	Nature	2013	221
24413737	Guanosine triphosphate	Sakata-Yanagimoto M	Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.	Nature genetics	2014	88
24431073	Guanosine triphosphate	Cheng Y	XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.	Molecular cancer therapeutics	2014	31
24481780	Guanosine triphosphate	Deb G	Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells.	Molecular carcinogenesis	2015	16
24814062	Guanosine triphosphate	Maertens O	An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer.	Advances in biological regulation	2014	27
25006165	Guanosine triphosphate	Basilico F	The pseudo GTPase CENP-M drives human kinetochore assembly.	eLife	2014	35
25446900	Guanosine triphosphate	Thomas JD	Rab1A is an mTORC1 activator and a colorectal oncogene.	Cancer cell	2014	56
25658205	Guanosine triphosphate	Kashatus JA	Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth.	Molecular cell	2015	63
25684575	Guanosine triphosphate	Fetics SK	Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD.	Structure	2015	31
25855816	Guanosine triphosphate	Sherpa C	The HIV-1 Rev response element (RRE) adopts alternative conformations that promote different rates of virus replication.	Nucleic acids research	2015	19
26051179	Guanosine triphosphate	Jin G	Skp2-Mediated RagA Ubiquitination Elicits a Negative Feedback to Prevent Amino-Acid-Dependent mTORC1 Hyperactivation by Recruiting GATOR1.	Molecular cell	2015	20
26051715	Guanosine triphosphate	Muratcioglu S	GTP-Dependent K-Ras Dimerization.	Structure	2015	28
26067754	Guanosine triphosphate	Kollareddy M	Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities.	Nature communications	2015	20
26080442	Guanosine triphosphate	Nan X	Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway.	Proceedings of the National Academy of Sciences of the United States of America	2015	36
26085527	Guanosine triphosphate	Nussinov R	The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas.	Molecular cancer research 	2015	18
26150526	Guanosine triphosphate	Phuchareon J	EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.	Proceedings of the National Academy of Sciences of the United States of America	2015	19
26483953	Guanosine triphosphate	Ichihara M	Beneficial biological effects and the underlying mechanisms of molecular hydrogen - comprehensive review of 321 original articles.	Medical gas research	2015	26
26595770	Guanosine triphosphate	Siprashvili Z	The noncoding RNAs SNORD50A and SNORD50B bind K-Ras and are recurrently deleted in human cancer.	Nature genetics	2016	20
26873344	Guanosine triphosphate	Nussinov R	K-Ras4B/calmodulin/PI3KŒ±: A promising new adenocarcinoma-specific drug target?	Expert opinion on therapeutic targets	2016	11
26985062	Guanosine triphosphate	Hobbs GA	RAS isoforms and mutations in cancer at a glance.	Journal of cell science	2016	30
27087647	Guanosine triphosphate	Bla≈æevit≈° O	Galectin-1 dimers can scaffold Raf-effectors to increase H-ras nanoclustering.	Scientific reports	2016	13
27181209	Guanosine triphosphate	Bianchi-Smiraglia A	Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.	Oncogene	2017	6
27396271	Guanosine triphosphate	Lu S	Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.	Chemical Society reviews	2016	13
27617292	Guanosine triphosphate	Yang M	A C9ORF72/SMCR8-containing complex regulates ULK1 and plays a dual role in autophagy.	Science advances	2016	22
27820802	Guanosine triphosphate	Spencer-Smith R	Inhibition of RAS function through targeting an allosteric regulatory site.	Nature chemical biology	2017	16
28108655	Guanosine triphosphate	Malecki J	The novel lysine specific methyltransferase METTL21B affects mRNA translation through inducible and dynamic methylation of Lys-165 in human eukaryotic elongation factor 1 alpha (eEF1A).	Nucleic acids research	2017	6
28114303	Guanosine triphosphate	Cao YL	MFN1 structures reveal nucleotide-triggered dimerization critical for mitochondrial fusion.	Nature	2017	17
28263956	Guanosine triphosphate	Lilja J	SHANK proteins limit integrin activation by directly interacting with Rap1 and¬†R-Ras.	Nature cell biology	2017	7
11981013	Carmustine	Gerson SL	Clinical relevance of MGMT in the treatment of cancer.	Journal of clinical oncology 	2002	99
15380096	Carmustine	Drabl√∏s F	Alkylation damage in DNA and RNA--repair mechanisms and medical significance.	DNA repair	2004	137
18625886	Carmustine	Geisler CH	Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.	Blood	2008	91
19204207	Carmustine	van den Bent MJ	Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.	Journal of clinical oncology 	2009	123
20035051	Carmustine	Li J	Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-kappaB Pathway.	The American journal of pathology	2010	45
20511192	Carmustine	Kunwar S	Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.	Neuro-oncology	2010	91
25105369	Carmustine	Adair JE	Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.	The Journal of clinical investigation	2014	20
25546364	Carmustine	Nash RA	High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.	JAMA neurology	2015	21
16966688	Dacarbazine	Bedikian AY	Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.	Journal of clinical oncology 	2006	126
18281670	Dacarbazine	Testori A	Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.	Journal of clinical oncology 	2008	71
18809613	Dacarbazine	Dudley ME	Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.	Journal of clinical oncology 	2008	417
19001327	Dacarbazine	Atkins MB	Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.	Journal of clinical oncology 	2008	63
19704068	Dacarbazine	Engert A	Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.	Journal of clinical oncology 	2009	49
19884534	Dacarbazine	Senzer NN	Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.	Journal of clinical oncology 	2009	162
21639808	Dacarbazine	Chapman PB	Improved survival with vemurafenib in melanoma with BRAF V600E mutation.	The New England journal of medicine	2011	1658
21670084	Dacarbazine	Montero JC	Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.	Clinical cancer research 	2011	73
21802280	Dacarbazine	Eggermont AM	New drugs in melanoma: it's a whole new world.	European journal of cancer	2011	47
22554099	Dacarbazine	Ascierto PA	The role of BRAF V600 mutation in melanoma.	Journal of translational medicine	2012	70
22663011	Dacarbazine	Flaherty KT	Improved survival with MEK inhibition in BRAF-mutated melanoma.	The New England journal of medicine	2012	423
22675422	Dacarbazine	Chartrain M	Melanoma chemotherapy leads to the selection of ABCB5-expressing cells.	PloS one	2012	35
22735384	Dacarbazine	Hauschild A	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.	Lancet	2012	561
22778320	Dacarbazine	Chan JA	Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.	Journal of clinical oncology 	2012	37
22972589	Dacarbazine	Patel SP	Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.	Cancer	2013	29
23087058	Dacarbazine	Aarntzen EH	Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.	Cancer research	2013	46
23735514	Dacarbazine	Robert C	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.	The Lancet. Oncology	2013	38
23833299	Dacarbazine	Nathanson KL	Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).	Clinical cancer research 	2013	40
24077405	Dacarbazine	Phan GQ	Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.	Cancer control 	2013	25
24239220	Dacarbazine	Younes A	Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.	The Lancet. Oncology	2013	35
24508103	Dacarbazine	McArthur GA	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.	The Lancet. Oncology	2014	161
24581497	Dacarbazine	Pencheva N	Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation.	Cell	2014	27
24582505	Dacarbazine	Larkin J	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.	The Lancet. Oncology	2014	33
25096067	Dacarbazine	Kim G	FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.	Clinical cancer research 	2014	21
25399552	Dacarbazine	Robert C	Nivolumab in previously untreated melanoma without BRAF mutation.	The New England journal of medicine	2015	648
25542447	Dacarbazine	Paraiso KH	Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.	Cancer discovery	2015	20
25795410	Dacarbazine	Weber JS	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.	The Lancet. Oncology	2015	332
25798726	Dacarbazine	Brahmer JR	Nivolumab: targeting PD-1 to bolster antitumor immunity.	Future oncology	2015	29
25823918	Dacarbazine	Mahoney KM	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.	Clinical therapeutics	2015	83
26115796	Dacarbazine	Ribas A	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.	The Lancet. Oncology	2015	208
26819277	Dacarbazine	Suzuki S	Current status of immunotherapy.	Japanese journal of clinical oncology	2016	12
27069074	Dacarbazine	Press OW	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.	Journal of clinical oncology 	2016	16
28284557	Dacarbazine	Dummer R	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.	The Lancet. Oncology	2017	17
6300903	Iron	Dautry-Varsat A	pH and the recycling of transferrin during receptor-mediated endocytosis.	Proceedings of the National Academy of Sciences of the United States of America	1983	262
8127021	Iron	Ryan MJ	HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney.	Kidney international	1994	161
8260699	Iron	Wang GL	Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction.	Blood	1993	137
9380735	Iron	Poss KD	Heme oxygenase 1 is required for mammalian iron reutilization.	Proceedings of the National Academy of Sciences of the United States of America	1997	217
11563810	Iron	Whitfield JB	Gamma glutamyl transferase.	Critical reviews in clinical laboratory sciences	2001	138
12105842	Iron	Bugianesi E	Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.	Gastroenterology	2002	260
12393428	Iron	Weinstein DA	Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease.	Blood	2002	109
12453412	Iron	Goetz DH	The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition.	Molecular cell	2002	315
12697826	Iron	Mihaylova VT	Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells.	Molecular and cellular biology	2003	80
12702559	Iron	Knowles HJ	Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells.	Cancer research	2003	78
14744237	Iron	Caro AA	Oxidative stress, toxicology, and pharmacology of CYP2E1.	Annual review of pharmacology and toxicology	2004	93
14871914	Iron	Jiang R	Body iron stores in relation to risk of type 2 diabetes in apparently healthy women.	JAMA	2004	102
15031665	Iron	Lee JW	Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions.	Experimental & molecular medicine	2004	147
15100158	Iron	Arbab AS	Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI.	Blood	2004	137
15369676	Iron	Gerald D	JunD reduces tumor angiogenesis by protecting cells from oxidative stress.	Cell	2004	148
15537542	Iron	Pham CG	Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species.	Cell	2004	148
16075059	Iron	Huang FW	A mouse model of juvenile hemochromatosis.	The Journal of clinical investigation	2005	119
16223732	Iron	Lu H	Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1.	The Journal of biological chemistry	2005	98
16430879	Iron	Valko M	Free radicals, metals and antioxidants in oxidative stress-induced cancer.	Chemico-biological interactions	2006	656
16452303	Iron	Park MH	The post-translational synthesis of a polyamine-derived amino acid, hypusine, in the eukaryotic translation initiation factor 5A (eIF5A).	Journal of biochemistry	2006	83
16508012	Iron	O'Donnell KA	Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.	Molecular and cellular biology	2006	65
16554418	Iron	Haase VH	Hypoxia-inducible factors in the kidney.	American journal of physiology. Renal physiology	2006	90
16732293	Iron	Cloos PA	The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.	Nature	2006	213
16887934	Iron	Ke Q	Hypoxia-inducible factor-1 (HIF-1).	Molecular pharmacology	2006	289
16920030	Iron	Daniels TR	The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells.	Clinical immunology	2006	96
16946298	Iron	Verga Falzacappa MV	STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation.	Blood	2007	144
17101781	Iron	Pan Y	Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro.	Molecular and cellular biology	2007	101
17822372	Iron	Jozkowicz A	Heme oxygenase-1 in tumors: is it a false friend?	Antioxidants & redox signaling	2007	83
18324353	Iron	Hatcher H	Curcumin: from ancient medicine to current clinical trials.	Cellular and molecular life sciences 	2008	250
18326817	Iron	Xia Y	Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin.	Blood	2008	81
18326822	Iron	Pinto JP	Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha.	Blood	2008	64
18355723	Iron	Yang WS	Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells.	Chemistry & biology	2008	78
18510925	Iron	Liu H	Structure of the DNA repair helicase XPD.	Cell	2008	88
18576916	Iron	Loboda A	Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities.	Antioxidants & redox signaling	2008	66
18621099	Iron	Lillig CH	Glutaredoxin systems.	Biochimica et biophysica acta	2008	153
18671304	Iron	Miura K	Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity.	Hepatology	2008	68
18689548	Iron	Ganz T	Immunoassay for human serum hepcidin.	Blood	2008	160
19304273	Iron	Kamp DW	Asbestos-induced lung diseases: an update.	Translational research 	2009	51
19540040	Iron	Bolignano D	Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene.	Cancer letters	2010	47
19788600	Iron	Fock KM	Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection.	Journal of gastroenterology and hepatology	2009	162
20010695	Iron	Chang NC	Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulum requires NAF-1.	The EMBO journal	2010	78
20062075	Iron	Yamaguchi K	Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.	Oncogene	2010	42
20137776	Iron	van der Lelij P	Warsaw breakage syndrome, a cohesinopathy associated with mutations in the XPD helicase family member DDX11/ChlR1.	American journal of human genetics	2010	54
20436681	Iron	Favaro E	MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU.	PloS one	2010	100
20448661	Iron	Linehan WM	The genetic basis of kidney cancer: a metabolic disease.	Nature reviews. Urology	2010	180
20498629	Iron	Chen Z	Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression.	Oncogene	2010	101
20550936	Iron	Devireddy LR	A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production.	Cell	2010	85
20580464	Iron	Sierra-Filardi E	Heme Oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release.	Immunobiology	2010	54
20686179	Iron	Pinnix ZK	Ferroportin and iron regulation in breast cancer progression and prognosis.	Science translational medicine	2010	83
20698697	Iron	Wang J	The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies.	Journal of the American Chemical Society	2010	57
20704546	Iron	Was H	Heme oxygenase-1 in tumor biology and therapy.	Current drug targets	2010	65
20728697	Iron	Sawyer DB	Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?	Progress in cardiovascular diseases	2010	44
20887198	Iron	Ganz T	Hepcidin and disorders of iron metabolism.	Annual review of medicine	2011	121
21149439	Iron	Hamacher-Brady A	Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production.	The Journal of biological chemistry	2011	42
21178486	Iron	Wiesner J	Antimicrobial peptides: the ancient arm of the human immune system.	Virulence	2010	137
21363917	Iron	Torti SV	Ironing out cancer.	Cancer research	2011	37
21427356	Iron	Josson S	Œ≤2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells.	Cancer research	2011	44
21801864	Iron	Lee DC	miR-210 targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines: siderosis of interstitial trophoblasts as a novel pathology of preterm preeclampsia and small-for-gestational-age pregnancies.	The American journal of pathology	2011	35
21851850	Iron	Daniels TR	The transferrin receptor and the targeted delivery of therapeutic agents against cancer.	Biochimica et biophysica acta	2012	85
21855608	Iron	Brissot P	Non-transferrin bound iron: a key role in iron overload and iron toxicity.	Biochimica et biophysica acta	2012	82
21875943	Iron	Miller LD	An iron regulatory gene signature predicts outcome in breast cancer.	Cancer research	2011	49
21904647	Iron	Lipinski B	Hydroxyl radical and its scavengers in health and disease.	Oxidative medicine and cellular longevity	2011	38
21907923	Iron	Tong WH	The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.	Cancer cell	2011	56
22032835	Iron	Munksgaard PS	The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations.	Gynecologic oncology	2012	35
22266943	Iron	DeVore NM	Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.	Nature	2012	61
22286106	Iron	Ray PD	Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling.	Cellular signalling	2012	451
22290531	Iron	Sun CC	Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.	American journal of hematology	2012	42
22424293	Iron	Merlot AM	Novel chelators for cancer treatment: where are we now?	Antioxidants & redox signaling	2013	31
22440905	Iron	Zager RA	Plasma and urinary heme oxygenase-1 in AKI.	Journal of the American Society of Nephrology 	2012	33
22453918	Iron	Chen Z	The iron chelators Dp44mT and DFO inhibit TGF-Œ≤-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1).	The Journal of biological chemistry	2012	49
22462691	Iron	Kovacevic Z	The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways.	Antioxidants & redox signaling	2013	38
22513004	Iron	Chakraborty S	The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.	Biochimica et biophysica acta	2012	99
22706697	Iron	Fan K	Magnetoferritin nanoparticles for targeting and visualizing tumour tissues.	Nature nanotechnology	2012	40
22728873	Iron	D'Alessio F	The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation.	Journal of hepatology	2012	43
22826563	Iron	Visconte V	SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.	Blood	2012	55
22931260	Iron	Zhuang Z	Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.	The New England journal of medicine	2012	68
23074173	Iron	Lui GY	The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.	Molecular pharmacology	2013	28
23302230	Iron	Alkins R	Focused ultrasound delivers targeted immune cells to metastatic brain tumors.	Cancer research	2013	37
23633457	Iron	Linehan WM	Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer.	Clinical cancer research 	2013	30
23873756	Iron	Murphy DR	Electronic health record-based triggers to detect potential delays in cancer diagnosis.	BMJ quality & safety	2014	29
23959881	Iron	Sohn YS	NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
24180257	Iron	Wegiel B	Heme oxygenase-1: a metabolic nike.	Antioxidants & redox signaling	2014	27
24269900	Iron	Fang BA	Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy.	Biochimica et biophysica acta	2014	27
24532803	Iron	Sahni S	The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells.	The Journal of biological chemistry	2014	21
24695223	Iron	Mancias JD	Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy.	Nature	2014	98
24814345	Iron	Chowdhury R	Ribosomal oxygenases are structurally conserved from prokaryotes to humans.	Nature	2014	27
25267626	Iron	Guo P	ICAM-1 as a molecular target for triple negative breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	27
25428262	Iron	Dolatshad H	Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.	Leukemia	2015	20
25728673	Iron	Sun X	HSPB1 as a novel regulator of ferroptotic cancer cell death.	Oncogene	2015	25
25734736	Iron	Chey WD	Irritable bowel syndrome: a clinical review.	JAMA	2015	86
25762074	Iron	Bai F	The Fe-S cluster-containing NEET proteins mitoNEET and NAF-1 as chemotherapeutic targets in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2015	17
25825391	Iron	White K	Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension.	EMBO molecular medicine	2015	22
25858146	Iron	Tesfay L	Hepcidin regulation in prostate and its disruption in prostate cancer.	Cancer research	2015	20
25885228	Iron	Chau LY	Heme oxygenase-1: emerging target of cancer therapy.	Journal of biomedical science	2015	23
25895646	Iron	Rochette L	Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms.	Trends in pharmacological sciences	2015	15
25938661	Iron	Healey EG	Repulsive guidance molecule is a structural bridge between neogenin and bone morphogenetic protein.	Nature structural & molecular biology	2015	18
26125440	Iron	Lui GY	Targeting cancer by binding iron: Dissecting cellular signaling pathways.	Oncotarget	2015	18
26166707	Iron	Gao M	Glutaminolysis and Transferrin Regulate Ferroptosis.	Molecular cell	2015	52
26291319	Iron	Michels K	Hepcidin and Host Defense against Infectious Diseases.	PLoS pathogens	2015	19
26403645	Iron	Sun X	Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.	Hepatology	2016	34
26405158	Iron	Kwon MY	Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death.	Oncotarget	2015	21
26675351	Iron	Vinchi F	Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease.	Blood	2016	27
26700815	Iron	Flavahan WA	Insulator dysfunction and oncogene activation in IDH mutant gliomas.	Nature	2016	130
26794443	Iron	Xie Y	Ferroptosis: process and function.	Cell death and differentiation	2016	40
26988023	Iron	Kabe Y	Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance.	Nature communications	2016	16
27100828	Iron	Loboda A	Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism.	Cellular and molecular life sciences 	2016	54
27245739	Iron	Hou W	Autophagy promotes ferroptosis by degradation of ferritin.	Autophagy	2016	19
27650732	Iron	Pergola PE	Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.	Kidney international	2016	13
27887750	Iron	Webster AC	Chronic Kidney Disease.	Lancet	2017	16
28060743	Iron	Gonz√°lez N	2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications.	Oncotarget	2017	5
28185035	Iron	McGowan JV	Anthracycline Chemotherapy and Cardiotoxicity.	Cardiovascular drugs and therapy	2017	12
28319068	Iron	Basuli D	Iron addiction: a novel therapeutic target in ovarian cancer.	Oncogene	2017	5
16258089	Gonadotropin releasing hormone	Smith MR	Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.	Journal of clinical oncology 	2005	79
18708085	Gonadotropin releasing hormone	Naor Z	Signaling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor.	Frontiers in neuroendocrinology	2009	66
22971343	Gonadotropin releasing hormone	Mitsiades N	Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.	Cancer research	2012	57
23648833	Gonadotropin releasing hormone	Taratula O	Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA.	Journal of controlled release 	2013	35
24036854	Gonadotropin releasing hormone	Shah V	Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.	Clinical cancer research 	2013	33
24056171	Gonadotropin releasing hormone	Thompson IR	GnRH pulse frequency-dependent differential regulation of LH and FSH gene expression.	Molecular and cellular endocrinology	2014	20
26753790	Gonadotropin releasing hormone	Cimino I	Novel role for anti-M√ºllerian hormone in the regulation of GnRH neuron excitability and hormone secretion.	Nature communications	2016	12
8387282	Cyclic AMP	Kitamura K	Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma.	Biochemical and biophysical research communications	1993	185
9660876	Cyclic AMP	Van Brocklyn JR	Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival.	The Journal of cell biology	1998	106
9839771	Cyclic AMP	Kiang JG	Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology.	Pharmacology & therapeutics	1998	139
10973256	Cyclic AMP	Kirschner LS	Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.	Nature genetics	2000	214
11035810	Cyclic AMP	Fang X	Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A.	Proceedings of the National Academy of Sciences of the United States of America	2000	195
11773440	Cyclic AMP	Filardo EJ	Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.	Molecular endocrinology	2002	228
11897506	Cyclic AMP	Filardo EJ	Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer.	The Journal of steroid biochemistry and molecular biology	2002	94
12149219	Cyclic AMP	Luft T	Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets.	Blood	2002	83
12566441	Cyclic AMP	Fujino H	Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases.	The Journal of biological chemistry	2003	77
12588810	Cyclic AMP	Puigserver P	Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator.	Endocrine reviews	2003	480
12955148	Cyclic AMP	Ludwig MG	Proton-sensing G-protein-coupled receptors.	Nature	2003	131
14607241	Cyclic AMP	Regan JW	EP2 and EP4 prostanoid receptor signaling.	Life sciences	2003	121
14623515	Cyclic AMP	Simpson ER	Sources of estrogen and their importance.	The Journal of steroid biochemistry and molecular biology	2003	126
15231873	Cyclic AMP	Razandi M	Plasma membrane estrogen receptors exist and functions as dimers.	Molecular endocrinology	2004	88
15246685	Cyclic AMP	Howe AK	Regulation of actin-based cell migration by cAMP/PKA.	Biochimica et biophysica acta	2004	96
15550931	Cyclic AMP	Ponsioen B	Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator.	EMBO reports	2004	142
15899904	Cyclic AMP	Shao J	Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer.	The Journal of biological chemistry	2005	69
15930299	Cyclic AMP	Liby K	The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling.	Cancer research	2005	104
16008550	Cyclic AMP	Dumaz N	Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft f√ºr Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels.	The FEBS journal	2005	76
16102838	Cyclic AMP	Lugnier C	Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.	Pharmacology & therapeutics	2006	170
16563471	Cyclic AMP	Lips P	Vitamin D physiology.	Progress in biophysics and molecular biology	2006	173
16645038	Cyclic AMP	Pedram A	Nature of functional estrogen receptors at the plasma membrane.	Molecular endocrinology	2006	156
16740699	Cyclic AMP	Ho SM	Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4.	Cancer research	2006	235
17018604	Cyclic AMP	Dumaz N	In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.	Cancer research	2006	97
17070667	Cyclic AMP	Pace TW	Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression.	Brain, behavior, and immunity	2007	142
17081989	Cyclic AMP	Gold MG	Molecular basis of AKAP specificity for PKA regulatory subunits.	Molecular cell	2006	111
17353197	Cyclic AMP	Sastry KS	Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation.	The Journal of biological chemistry	2007	55
17379646	Cyclic AMP	Filardo E	Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane.	Endocrinology	2007	131
17466566	Cyclic AMP	Ameri K	Activating transcription factor 4.	The international journal of biochemistry & cell biology	2008	111
17612487	Cyclic AMP	Dohi T	Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection.	Molecular cell	2007	56
17952119	Cyclic AMP	Yin X	A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development.	Oncogene	2008	71
18316612	Cyclic AMP	Sarkar D	Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1.	Cancer research	2008	87
18571301	Cyclic AMP	Pandi-Perumal SR	Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways.	Progress in neurobiology	2008	84
18604457	Cyclic AMP	Cheng X	Epac and PKA: a tale of two intracellular cAMP receptors.	Acta biochimica et biophysica Sinica	2008	97
18689544	Cyclic AMP	Arnold J	Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation.	Blood	2008	80
19037882	Cyclic AMP	Boggaram V	Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung.	Clinical science	2009	47
19190754	Cyclic AMP	Slominski AT	Sequential metabolism of 7-dehydrocholesterol to steroidal 5,7-dienes in adrenal glands and its biological implication in the skin.	PloS one	2009	47
19293268	Cyclic AMP	Bertherat J	Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes.	The Journal of clinical endocrinology and metabolism	2009	78
19351775	Cyclic AMP	Sakamoto KM	CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy.	Clinical cancer research 	2009	67
19386608	Cyclic AMP	Yanagida K	Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6.	The Journal of biological chemistry	2009	61
19654912	Cyclic AMP	Bouskine A	Low doses of bisphenol A promote human seminoma cell proliferation by activating PKA and PKG via a membrane G-protein-coupled estrogen receptor.	Environmental health perspectives	2009	47
20234090	Cyclic AMP	Kang S	p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells.	The Journal of clinical investigation	2010	48
20358582	Cyclic AMP	Horvath A	Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update.	Human mutation	2010	44
20424515	Cyclic AMP	Zhang D	Œ≤2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFŒ∫B and AP-1.	Cancer biology & therapy	2010	45
20495567	Cyclic AMP	Sheng Z	A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.	Nature medicine	2010	53
20514020	Cyclic AMP	Rzymski T	Regulation of autophagy by ATF4 in response to severe hypoxia.	Oncogene	2010	89
20624818	Cyclic AMP	Laneve P	A minicircuitry involving REST and CREB controls miR-9-2 expression during human neuronal differentiation.	Nucleic acids research	2010	51
21118894	Cyclic AMP	Alvarez-Saavedra M	miRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock.	Human molecular genetics	2011	68
21130867	Cyclic AMP	Mosenden R	Cyclic AMP-mediated immune regulation--overview of mechanisms of action in T cells.	Cellular signalling	2011	58
21145500	Cyclic AMP	Liu L	mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion.	Developmental cell	2010	78
21149639	Cyclic AMP	Sand√©n C	G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments.	Molecular pharmacology	2011	41
21220306	Cyclic AMP	Franco AT	Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.	Proceedings of the National Academy of Sciences of the United States of America	2011	52
21291858	Cyclic AMP	Grassie ME	The myosin phosphatase targeting protein (MYPT) family: a regulated mechanism for achieving substrate specificity of the catalytic subunit of protein phosphatase type 1Œ¥.	Archives of biochemistry and biophysics	2011	73
21354433	Cyclic AMP	Cheng SB	Retrograde transport of the transmembrane estrogen receptor, G-protein-coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the nucleus.	Steroids	2011	40
21385900	Cyclic AMP	Gu T	CREB is a novel nuclear target of PTEN phosphatase.	Cancer research	2011	35
21464287	Cyclic AMP	Gold MG	Architecture and dynamics of an A-kinase anchoring protein 79 (AKAP79) signaling complex.	Proceedings of the National Academy of Sciences of the United States of America	2011	39
21536868	Cyclic AMP	Mortensen RD	Posttranscriptional activation of gene expression in Xenopus laevis oocytes by microRNA-protein complexes (microRNPs).	Proceedings of the National Academy of Sciences of the United States of America	2011	42
21555366	Cyclic AMP	Polytarchou C	Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation.	Cancer research	2011	49
21559477	Cyclic AMP	Klarenbeek JB	A mTurquoise-based cAMP sensor for both FLIM and ratiometric read-out has improved dynamic range.	PloS one	2011	52
21655990	Cyclic AMP	Hadad S	Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.	Breast cancer research and treatment	2011	71
22049059	Cyclic AMP	Hsieh TH	Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway.	FASEB journal 	2012	37
22285928	Cyclic AMP	Yang C	Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells.	Gene	2012	60
22325466	Cyclic AMP	Kong WQ	MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma.	The FEBS journal	2012	33
22403610	Cyclic AMP	Zhang S	ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.	PloS one	2012	75
22553202	Cyclic AMP	Nin V	Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase.	The Journal of biological chemistry	2012	40
22576212	Cyclic AMP	Subbaramaiah K	Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women.	Cancer discovery	2012	72
22685290	Cyclic AMP	Du Y	Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18.	The Journal of biological chemistry	2012	112
22697792	Cyclic AMP	Knutson TP	Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.	Breast cancer research 	2012	39
22710715	Cyclic AMP	Park MH	p21-Activated kinase 4 promotes prostate cancer progression through CREB.	Oncogene	2013	29
22778400	Cyclic AMP	Narasimamurthy R	Circadian clock protein cryptochrome regulates the expression of proinflammatory cytokines.	Proceedings of the National Academy of Sciences of the United States of America	2012	75
22796012	Cyclic AMP	Wu J	Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human.	Cell	2012	614
22885100	Cyclic AMP	Chung JH	Resveratrol as a calorie restriction mimetic: therapeutic implications.	Trends in cell biology	2012	44
23019365	Cyclic AMP	Tan X	cAMP response element-binding protein promotes gliomagenesis by modulating the expression of oncogenic microRNA-23a.	Proceedings of the National Academy of Sciences of the United States of America	2012	33
23066090	Cyclic AMP	Almahariq M	A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion.	Molecular pharmacology	2013	66
23159879	Cyclic AMP	Lee G	Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression.	Nature biotechnology	2012	66
23558954	Cyclic AMP	Dominguez CL	Diacylglycerol kinase Œ± is a critical signaling node and novel therapeutic target in glioblastoma and other cancers.	Cancer discovery	2013	27
23663782	Cyclic AMP	Csibi A	The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4.	Cell	2013	122
23796953	Cyclic AMP	Jiang J	Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection.	Trends in pharmacological sciences	2013	32
23979134	Cyclic AMP	Yang Z	MicroRNA-433 inhibits liver cancer cell migration by repressing the protein expression and function of cAMP response element-binding protein.	The Journal of biological chemistry	2013	29
24101509	Cyclic AMP	Zhang X	Regulation of estrogen receptor Œ± by histone methyltransferase SMYD2-mediated protein methylation.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
24149987	Cyclic AMP	Rehmann H	Epac-inhibitors: facts and artefacts.	Scientific reports	2013	27
24185007	Cyclic AMP	Johannessen CM	A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.	Nature	2013	116
24316969	Cyclic AMP	Onodera Y	Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways.	The Journal of clinical investigation	2014	39
24366668	Cyclic AMP	van der Westhuizen ET	Quantification of ligand bias for clinically relevant Œ≤2-adrenergic receptor ligands: implications for drug taxonomy.	Molecular pharmacology	2014	42
24375753	Cyclic AMP	Diggs-Andrews KA	Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.	Annals of neurology	2014	23
24393785	Cyclic AMP	Pernicova I	Metformin--mode of action and clinical implications for diabetes and cancer.	Nature reviews. Endocrinology	2014	151
24571724	Cyclic AMP	Beuschlein F	Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome.	The New England journal of medicine	2014	64
24618891	Cyclic AMP	M√ºhleisen TW	Genome-wide association study reveals two new risk loci for bipolar disorder.	Nature communications	2014	70
24703167	Cyclic AMP	Bower JE	Yoga reduces inflammatory signaling in fatigued breast cancer survivors: a randomized controlled trial.	Psychoneuroendocrinology	2014	36
24771768	Cyclic AMP	Nwachukwu JC	Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network.	eLife	2014	29
24855271	Cyclic AMP	Sato Y	Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome.	Science	2014	37
24882690	Cyclic AMP	Schafer PH	Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.	Cellular signalling	2014	24
24950377	Cyclic AMP	Jarrett SG	PKA-mediated phosphorylation of ATR promotes recruitment of XPA to UV-induced DNA damage.	Molecular cell	2014	24
24995979	Cyclic AMP	Kong X	IRF4 is a key thermogenic transcriptional partner of PGC-1Œ±.	Cell	2014	48
25122662	Cyclic AMP	Xu L	Genomic analysis of fibrolamellar hepatocellular carcinoma.	Human molecular genetics	2015	16
25150496	Cyclic AMP	He X	The G protein Œ± subunit GŒ±s is a tumor suppressor in Sonic hedgehog-driven medulloblastoma.	Nature medicine	2014	32
25320361	Cyclic AMP	Weed DT	Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.	Clinical cancer research 	2015	35
25472719	Cyclic AMP	Henriksson E	SIK2 regulates CRTCs, HDAC4 and glucose uptake in adipocytes.	Journal of cell science	2015	15
25513961	Cyclic AMP	Ma√überg D	Monoterpene (-)-citronellal affects hepatocarcinoma cell signaling via an olfactory receptor.	Archives of biochemistry and biophysics	2015	17
25565142	Cyclic AMP	Modali SD	Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors.	Molecular endocrinology	2015	25
25788518	Cyclic AMP	Anastasaki C	Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning.	Human molecular genetics	2015	18
25875503	Cyclic AMP	Klarenbeek J	Fourth-generation epac-based FRET sensors for cAMP feature exceptional brightness, photostability and dynamic range: characterization of dedicated sensors for FLIM, for ratiometry and with high affinity.	PloS one	2015	29
25917098	Cyclic AMP	Sokolowska M	Prostaglandin E2 Inhibits NLRP3 Inflammasome Activation through EP4 Receptor and Intracellular Cyclic AMP in Human Macrophages.	Journal of immunology	2015	25
26099526	Cyclic AMP	Xu MJ	Fat-Specific Protein 27/CIDEC Promotes Development of Alcoholic Steatohepatitis in Mice and Humans.	Gastroenterology	2015	23
26168232	Cyclic AMP	Jarrett SG	Defining the Contribution of MC1R Physiological Ligands to ATR Phosphorylation at Ser435, a Predictor of DNA Repair in Melanocytes.	The Journal of investigative dermatology	2015	16
26632666	Cyclic AMP	Duan S	PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype.	Nature communications	2015	18
26706021	Cyclic AMP	Diaz-Gerevini GT	Beneficial action of resveratrol: How and why?	Nutrition	2016	22
27140397	Cyclic AMP	Chen Z	cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.	The Journal of clinical investigation	2016	16
27144433	Cyclic AMP	Cheng HL	Nobiletin inhibits human osteosarcoma cells metastasis by blocking ERK and JNK-mediated MMPs expression.	Oncotarget	2016	12
27551494	Cyclic AMP	Manteniotis S	Functional characterization of the ectopically expressed olfactory receptor 2AT4 in human myelogenous leukemia.	Cell death discovery	2016	11
27648837	Cyclic AMP	Hong Z	MicroRNA-138 and MicroRNA-25 Down-regulate Mitochondrial Calcium Uniporter, Causing the Pulmonary Arterial Hypertension Cancer Phenotype.	American journal of respiratory and critical care medicine	2017	10
27721408	Cyclic AMP	Yu T	Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance.	Oncogene	2017	5
7641194	Prostaglandin E2	Sano H	Expression of cyclooxygenase-1 and -2 in human colorectal cancer.	Cancer research	1995	183
9892207	Prostaglandin E2	Zimmermann KC	Cyclooxygenase-2 expression in human esophageal carcinoma.	Cancer research	1999	100
10869354	Prostaglandin E2	Murakami M	Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2.	The Journal of biological chemistry	2000	163
12589164	Prostaglandin E2	Tse WT	Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation.	Transplantation	2003	290
12958148	Prostaglandin E2	Jung YJ	IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis.	FASEB journal 	2003	155
15342370	Prostaglandin E2	Mailliard RB	alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.	Cancer research	2004	142
15476283	Prostaglandin E2	Li L	Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis.	Cancer	2004	76
16099998	Prostaglandin E2	Sotiropoulou PA	Interactions between human mesenchymal stem cells and natural killer cells.	Stem cells	2006	188
16319132	Prostaglandin E2	Kawamori T	Sphingosine kinase 1 is up-regulated in colon carcinogenesis.	FASEB journal 	2006	75
17606437	Prostaglandin E2	Prevosto C	Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction.	Haematologica	2007	86
17640394	Prostaglandin E2	Howe LR	Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer.	Breast cancer research 	2007	83
19037088	Prostaglandin E2	Suh Y	A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB-signaling pathways.	Carcinogenesis	2009	55
19493674	Prostaglandin E2	Spencer L	The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential.	European journal of cancer	2009	50
19887554	Prostaglandin E2	Qamri Z	Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.	Molecular cancer therapeutics	2009	48
20169190	Prostaglandin E2	Sharma-Walia N	Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion.	PLoS pathogens	2010	58
20234320	Prostaglandin E2	Shimizu K	Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.	Journal of thoracic oncology 	2010	49
21143185	Prostaglandin E2	Hei TK	Radiation induced non-targeted response: mechanism and potential clinical implications.	Current molecular pharmacology	2011	53
21474107	Prostaglandin E2	Goessling W	Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models.	Cell stem cell	2011	88
21946257	Prostaglandin E2	Baryawno N	Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target.	The Journal of clinical investigation	2011	64
22182446	Prostaglandin E2	Li T	Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO.	Cancer letters	2012	37
22465232	Prostaglandin E2	Whiteside TL	What are regulatory T cells (Treg) regulating in cancer and why?	Seminars in cancer biology	2012	55
22641101	Prostaglandin E2	Xin X	Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model.	Laboratory investigation; a journal of technical methods and pathology	2012	34
23515290	Prostaglandin E2	Vo BT	TGF-Œ≤ effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway.	Endocrinology	2013	40
24213679	Prostaglandin E2	Whiteside TL	Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression?	Cancer immunology, immunotherapy 	2014	43
24793239	Prostaglandin E2	Motz GT	Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.	Nature medicine	2014	80
25134454	Prostaglandin E2	Kaulmann A	Carotenoids, inflammation, and oxidative stress--implications of cellular signaling pathways and relation to chronic disease prevention.	Nutrition research	2014	31
25304688	Prostaglandin E2	Madrigal M	A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods.	Journal of translational medicine	2014	53
25954974	Prostaglandin E2	Liu X	Berberine Inhibits Invasion and Metastasis of Colorectal Cancer Cells via COX-2/PGE2 Mediated JAK2/STAT3 Signaling Pathway.	PloS one	2015	21
26573797	Prostaglandin E2	Wang X	p53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis.	Cancer research	2015	25
26801617	Prostaglandin E2	Martinez-Useros J	Obesity and colorectal cancer: molecular features of adipose tissue.	Journal of translational medicine	2016	24
26811607	Prostaglandin E2	Nosho K	Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer.	World journal of gastroenterology	2016	18
27045023	Prostaglandin E2	Newick K	Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization.	Cancer immunology research	2016	15
27074574	Prostaglandin E2	Guillem-Llobat P	Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells.	Oncotarget	2016	18
27215396	Prostaglandin E2	Reinartz S	A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome.	Genome biology	2016	11
10880336	Adenosine monophosphate	Pyne S	Sphingosine 1-phosphate signalling in mammalian cells.	The Biochemical journal	2000	135
11554766	Adenosine monophosphate	Imamura K	Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line.	Biochemical and biophysical research communications	2001	110
12847291	Adenosine monophosphate	Hong SP	Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases.	Proceedings of the National Academy of Sciences of the United States of America	2003	180
14511394	Adenosine monophosphate	Hawley SA	Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade.	Journal of biology	2003	485
14614828	Adenosine monophosphate	Woods A	LKB1 is the upstream kinase in the AMP-activated protein kinase cascade.	Current biology 	2003	431
14729328	Adenosine monophosphate	Carling D	The AMP-activated protein kinase cascade--a unifying system for energy control.	Trends in biochemical sciences	2004	232
15231735	Adenosine monophosphate	Corradetti MN	Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome.	Genes & development	2004	161
15358229	Adenosine monophosphate	Xiang X	AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms.	Biochemical and biophysical research communications	2004	75
15681023	Adenosine monophosphate	Luo Z	AMPK, the metabolic syndrome and cancer.	Trends in pharmacological sciences	2005	114
15866171	Adenosine monophosphate	Jones RG	AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.	Molecular cell	2005	497
16397245	Adenosine monophosphate	Han S	Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.	Cancer research	2006	63
16678125	Adenosine monophosphate	Dieudonne MN	Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells.	Biochemical and biophysical research communications	2006	70
16756488	Adenosine monophosphate	Alessi DR	LKB1-dependent signaling pathways.	Annual review of biochemistry	2006	242
16885382	Adenosine monophosphate	Xu Y	Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.	Cancer research	2006	104
17046224	Adenosine monophosphate	Shaw RJ	Glucose metabolism and cancer.	Current opinion in cell biology	2006	153
17192291	Adenosine monophosphate	K√∂rner A	Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies.	The Journal of clinical endocrinology and metabolism	2007	60
17237771	Adenosine monophosphate	Liang J	The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis.	Nature cell biology	2007	294
17560826	Adenosine monophosphate	Burns KA	Modulation of PPAR activity via phosphorylation.	Biochimica et biophysica acta	2007	112
17638885	Adenosine monophosphate	Buzzai M	Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth.	Cancer research	2007	307
18006825	Adenosine monophosphate	Dowling RJ	Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.	Cancer research	2007	269
18056705	Adenosine monophosphate	Okoshi R	Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress.	The Journal of biological chemistry	2008	88
18167336	Adenosine monophosphate	Hallstrom TC	An E2F1-dependent gene expression program that determines the balance between proliferation and cell death.	Cancer cell	2008	93
18212742	Adenosine monophosphate	Ben Sahra I	The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.	Oncogene	2008	260
18227155	Adenosine monophosphate	Hezel AF	Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms.	Molecular and cellular biology	2008	66
18256928	Adenosine monophosphate	Phoenix KN	Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model.	Breast cancer research and treatment	2009	47
18343152	Adenosine monophosphate	Hadad SM	Targeting AMPK: a new therapeutic opportunity in breast cancer.	Critical reviews in oncology/hematology	2008	52
18387000	Adenosine monophosphate	Huang X	Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice.	The Biochemical journal	2008	133
18403135	Adenosine monophosphate	Hasumi H	Identification and characterization of a novel folliculin-interacting protein FNIP2.	Gene	2008	63
18551130	Adenosine monophosphate	Papandreou I	Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L.	Cell death and differentiation	2008	97
18555664	Adenosine monophosphate	Jin T	Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin.	Cellular signalling	2008	74
19106626	Adenosine monophosphate	Vazquez-Martin A	The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.	Cell cycle	2009	74
19138981	Adenosine monophosphate	Zakikhani M	The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase.	Cancer prevention research	2008	80
19176385	Adenosine monophosphate	Beevers CS	Curcumin disrupts the Mammalian target of rapamycin-raptor complex.	Cancer research	2009	54
19197243	Adenosine monophosphate	Herrero-Mart√≠n G	TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells.	The EMBO journal	2009	112
19273282	Adenosine monophosphate	Viollet B	Targeting the AMPK pathway for the treatment of Type 2 diabetes.	Frontiers in bioscience	2009	52
19372545	Adenosine monophosphate	Park HU	AMP-activated protein kinase promotes human prostate cancer cell growth and survival.	Molecular cancer therapeutics	2009	56
19483724	Adenosine monophosphate	Taliaferro-Smith L	LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells.	Oncogene	2009	47
19549896	Adenosine monophosphate	Racanelli AC	Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.	Cancer research	2009	59
19584320	Adenosine monophosphate	Steinberg GR	AMPK in Health and Disease.	Physiological reviews	2009	389
19679549	Adenosine monophosphate	Kisfalvi K	Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth.	Cancer research	2009	109
19710915	Adenosine monophosphate	Scaglia N	Inhibition of stearoylCoA desaturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in cancer cells: role of AMPK.	PloS one	2009	49
19723334	Adenosine monophosphate	Hadad SM	Histological evaluation of AMPK signalling in primary breast cancer.	BMC cancer	2009	48
19892943	Adenosine monophosphate	Zeqiraj E	Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.	Science	2009	83
19966861	Adenosine monophosphate	Pradelli LA	Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation.	Oncogene	2010	52
20196784	Adenosine monophosphate	Harhaji-Trajkovic L	AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells.	Journal of cellular and molecular medicine	2009	58
20388847	Adenosine monophosphate	Rozengurt E	Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.	Clinical cancer research 	2010	80
20442309	Adenosine monophosphate	Ben Sahra I	Metformin in cancer therapy: a new perspective for an old antidiabetic drug?	Molecular cancer therapeutics	2010	145
20444885	Adenosine monophosphate	Kim AY	Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation.	Molecular endocrinology	2010	52
20530718	Adenosine monophosphate	Fritz V	Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.	Molecular cancer therapeutics	2010	45
20615625	Adenosine monophosphate	Sanli T	Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells.	International journal of radiation oncology, biology, physics	2010	57
20637208	Adenosine monophosphate	Saxena NK	Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma.	Gastroenterology	2010	45
20656475	Adenosine monophosphate	Jalving M	Metformin: taking away the candy for cancer?	European journal of cancer	2010	99
20712410	Adenosine monophosphate	Budanov AV	Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling.	Antioxidants & redox signaling	2011	35
20810185	Adenosine monophosphate	Rautou PE	Autophagy in liver diseases.	Journal of hepatology	2010	99
20810672	Adenosine monophosphate	Memmott RM	Metformin prevents tobacco carcinogen--induced lung tumorigenesis.	Cancer prevention research	2010	142
20824063	Adenosine monophosphate	Pereira ER	Transcriptional and post-transcriptional regulation of proangiogenic factors by the unfolded protein response.	PloS one	2010	48
20876807	Adenosine monophosphate	Yang PM	Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies.	Cancer research	2010	44
20878915	Adenosine monophosphate	Budanov AV	Stressin' Sestrins take an aging fight.	EMBO molecular medicine	2010	58
20880848	Adenosine monophosphate	Zhang WB	Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.	The Journal of biological chemistry	2010	43
20972457	Adenosine monophosphate	El Mjiyad N	Sugar-free approaches to cancer cell killing.	Oncogene	2011	58
20980833	Adenosine monophosphate	Vucicevic L	Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway.	Autophagy	2011	44
21074987	Adenosine monophosphate	Brahimi-Horn MC	Hypoxia and energetic tumour metabolism.	Current opinion in genetics & development	2011	68
21098087	Adenosine monophosphate	Frigo DE	CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells.	Cancer research	2011	39
21147110	Adenosine monophosphate	Calvisi DF	Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.	Gastroenterology	2011	98
21205641	Adenosine monophosphate	Egan DF	Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy.	Science	2011	612
21258367	Adenosine monophosphate	Kim J	AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1.	Nature cell biology	2011	1128
21475304	Adenosine monophosphate	Vara D	Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy.	Cell death and differentiation	2011	49
21540236	Adenosine monophosphate	Ben Sahra I	Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.	Cancer research	2011	162
21676631	Adenosine monophosphate	Liu J	Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft.	Urologic oncology	2013	28
21811093	Adenosine monophosphate	Jing K	Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53.	Autophagy	2011	38
21840335	Adenosine monophosphate	Speakman JR	Caloric restriction.	Molecular aspects of medicine	2011	152
22017684	Adenosine monophosphate	Inoki K	AMPK and mTOR in cellular energy homeostasis and drug targets.	Annual review of pharmacology and toxicology	2012	149
22048125	Adenosine monophosphate	Son SM	AŒ≤-induced formation of autophagosomes is mediated by RAGE-CaMKKŒ≤-AMPK signaling.	Neurobiology of aging	2012	32
22049153	Adenosine monophosphate	Young LE	The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2.	Molecular cancer research 	2012	61
22079189	Adenosine monophosphate	Ditch S	The ATM protein kinase and cellular redox signaling: beyond the DNA damage response.	Trends in biochemical sciences	2012	93
22120676	Adenosine monophosphate	Kim HS	Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression.	Biochemical pharmacology	2012	34
22137581	Adenosine monophosphate	Banko MR	Chemical genetic screen for AMPKŒ±2 substrates uncovers a network of proteins involved in mitosis.	Molecular cell	2011	78
22341444	Adenosine monophosphate	Raimundo N	Mitochondrial stress engages E2F1 apoptotic signaling to cause deafness.	Cell	2012	58
22363791	Adenosine monophosphate	Sanli T	Sestrin2 modulates AMPK subunit expression and its response to ionizing radiation in breast cancer cells.	PloS one	2012	38
22378068	Adenosine monophosphate	Shi WY	Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.	Cell death & disease	2012	56
22387548	Adenosine monophosphate	Zheng QY	Ursolic acid-induced AMP-activated protein kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder cancer T24 cells.	Biochemical and biophysical research communications	2012	32
22406476	Adenosine monophosphate	Din FV	Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells.	Gastroenterology	2012	91
22576211	Adenosine monophosphate	Martin MJ	Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.	Cancer discovery	2012	36
22619229	Adenosine monophosphate	Cardaci S	Redox implications of AMPK-mediated signal transduction beyond energetic clues.	Journal of cell science	2012	51
22643892	Adenosine monophosphate	Blandino G	Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.	Nature communications	2012	52
22722266	Adenosine monophosphate	Salem AF	Two-compartment tumor metabolism: autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells.	Cell cycle	2012	43
22728651	Adenosine monophosphate	Lee CW	AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells.	Cancer research	2012	54
22773548	Adenosine monophosphate	Chen HP	Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.	Gut	2013	68
22778263	Adenosine monophosphate	Racioppi L	Calcium/calmodulin-dependent protein kinase kinase 2: roles in signaling and pathophysiology.	The Journal of biological chemistry	2012	46
22809961	Adenosine monophosphate	Menendez JA	Metformin is synthetically lethal with glucose withdrawal in cancer cells.	Cell cycle	2012	46
22975376	Adenosine monophosphate	Chae YC	Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s.	Cancer cell	2012	30
22977732	Adenosine monophosphate	Nookala RK	Crystal structure of folliculin reveals a hidDENN function in genetically inherited renal cancer.	Open biology	2012	35
23104101	Adenosine monophosphate	Morris BJ	Seven sirtuins for seven deadly diseases of aging.	Free radical biology & medicine	2013	72
23160380	Adenosine monophosphate	Avivar-Valderas A	Regulation of autophagy during ECM detachment is linked to a selective inhibition of mTORC1 by PERK.	Oncogene	2013	30
23197693	Adenosine monophosphate	Sato A	Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK.	Stem cells translational medicine	2012	40
23278683	Adenosine monophosphate	Tacar O	Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems.	The Journal of pharmacy and pharmacology	2013	184
23325217	Adenosine monophosphate	O'Neill LA	Metabolism of inflammation limited by AMPK and pseudo-starvation.	Nature	2013	255
23370326	Adenosine monophosphate	R√≠os M	AMPK activation by oncogenesis is required to maintain cancer cell proliferation in astrocytic tumors.	Cancer research	2013	30
23587167	Adenosine monophosphate	Hardie DG	LKB1 and AMPK and the cancer-metabolism link - ten years after.	BMC biology	2013	81
23632475	Adenosine monophosphate	Storozhuk Y	Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.	British journal of cancer	2013	58
23644529	Adenosine monophosphate	Liang J	AMPK: a contextual oncogene or tumor suppressor?	Cancer research	2013	82
23663483	Adenosine monophosphate	Karnevi E	Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells.	BMC cancer	2013	31
23678003	Adenosine monophosphate	Saze Z	Adenosine production by human B cells and B cell-mediated suppression of activated T cells.	Blood	2013	26
23688501	Adenosine monophosphate	Sid B	Role of AMPK activation in oxidative cell damage: Implications for alcohol-induced liver disease.	Biochemical pharmacology	2013	31
23706743	Adenosine monophosphate	Leprivier G	The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation.	Cell	2013	88
23712032	Adenosine monophosphate	Chen MB	Activation of AMP-activated protein kinase (AMPK) mediates plumbagin-induced apoptosis and growth inhibition in cultured human colon cancer cells.	Cellular signalling	2013	28
23801715	Adenosine monophosphate	Hardie DG	AMPK: a target for drugs and natural products with effects on both diabetes and cancer.	Diabetes	2013	77
23863160	Adenosine monophosphate	Dunlop EA	The kinase triad, AMPK, mTORC1 and ULK1, maintains energy and nutrient homoeostasis.	Biochemical Society transactions	2013	26
23899558	Adenosine monophosphate	Chen MB	MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.	Cellular signalling	2014	35
23942093	Adenosine monophosphate	Zheng L	Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.	Clinical cancer research 	2013	43
24026768	Adenosine monophosphate	Matsuda M	Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases.	Reviews in endocrine & metabolic disorders	2014	20
24055102	Adenosine monophosphate	Lee JH	Sestrins orchestrate cellular metabolism to attenuate aging.	Cell metabolism	2013	61
24095280	Adenosine monophosphate	Shen CH	Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.	Molecular cell	2013	29
24096736	Adenosine monophosphate	Qu C	Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells.	Molecular and cellular biochemistry	2014	29
24100703	Adenosine monophosphate	Sanli T	AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway.	Cancer biology & therapy	2014	45
24119841	Adenosine monophosphate	Konno H	Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling.	Cell	2013	113
24338509	Adenosine monophosphate	Hadad SM	Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle.	Clinical & translational oncology 	2014	23
24359220	Adenosine monophosphate	Kaminskyy VO	Free radicals in cross talk between autophagy and apoptosis.	Antioxidants & redox signaling	2014	40
24419061	Adenosine monophosphate	Liu X	The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent.	Molecular cancer therapeutics	2014	43
24419232	Adenosine monophosphate	Dallaglio K	Paradoxic effects of metformin on endothelial cells and angiogenesis.	Carcinogenesis	2014	26
24486219	Adenosine monophosphate	Faubert B	The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator.	Cancer letters	2015	55
24520038	Adenosine monophosphate	Yue W	Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment.	Cancer prevention research	2014	32
24583766	Adenosine monophosphate	Hardie DG	AMPK: regulating energy balance at the cellular and whole body levels.	Physiology	2014	43
24662833	Adenosine monophosphate	Nguyen HG	Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model.	Oncogene	2014	34
24726383	Adenosine monophosphate	Burkewitz K	AMPK at the nexus of energetics and aging.	Cell metabolism	2014	48
24857548	Adenosine monophosphate	Zhou G	Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.	Molecular cell	2014	50
25126561	Adenosine monophosphate	Gao ZW	The roles of CD73 in cancer.	BioMed research international	2014	23
25241895	Adenosine monophosphate	Vincent EE	Differential effects of AMPK agonists on cell growth and metabolism.	Oncogene	2015	36
25373897	Adenosine monophosphate	DeRan M	Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein.	Cell reports	2014	49
25417601	Adenosine monophosphate	Schuler KM	Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.	Cancer medicine	2015	24
25448702	Adenosine monophosphate	Hardie DG	AMPK--sensing energy while talking to other signaling pathways.	Cell metabolism	2014	81
25470744	Adenosine monophosphate	Lande R	The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis.	Nature communications	2014	39
25576381	Adenosine monophosphate	Yang L	C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study.	Experimental cell research	2015	18
25609923	Adenosine monophosphate	Yuan CX	Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.	Drug design, development and therapy	2015	16
25632225	Adenosine monophosphate	Wang F	Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.	Drug design, development and therapy	2015	15
25679763	Adenosine monophosphate	Pineda CT	Degradation of AMPK by a cancer-specific ubiquitin ligase.	Cell	2015	51
25730670	Adenosine monophosphate	Xie Q	Mitochondrial control by DRP1 in brain tumor initiating cells.	Nature neuroscience	2015	49
25792811	Adenosine monophosphate	Niu NK	Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.	Drug design, development and therapy	2015	19
25834399	Adenosine monophosphate	Zhou ZW	Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells.	Drug design, development and therapy	2015	21
25849721	Adenosine monophosphate	Dowling RJ	Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.	Breast cancer research 	2015	17
25862373	Adenosine monophosphate	Kato H	Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor.	Biochemical and biophysical research communications	2015	17
25940306	Adenosine monophosphate	O'Brien AJ	Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis.	The Biochemical journal	2015	17
26116623	Adenosine monophosphate	Chen MB	C6 ceramide dramatically increases vincristine sensitivity both in vivo and in vitro, involving AMP-activated protein kinase-p53 signaling.	Carcinogenesis	2015	19
26160430	Adenosine monophosphate	Bupathi M	Hepatocellular carcinoma: Where there is unmet need.	Molecular oncology	2015	17
26160707	Adenosine monophosphate	Qi D	AMPK: energy sensor and survival mechanism in the ischemic heart.	Trends in endocrinology and metabolism	2015	24
26223300	Adenosine monophosphate	Cai H	Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice.	Science translational medicine	2015	23
26271666	Adenosine monophosphate	Hu X	Compound 13, an Œ±1-selective small molecule activator of AMPK, potently inhibits melanoma cell proliferation.	Tumour biology 	2016	10
26431379	Adenosine monophosphate	Yu Z	Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.	Oncotarget	2015	22
26440282	Adenosine monophosphate	Saito Y	AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow.	Cell stem cell	2015	25
26551713	Adenosine monophosphate	O'Connell MA	The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic.	Biochemical Society transactions	2015	20
26565381	Adenosine monophosphate	Farago AF	Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.	Journal of thoracic oncology 	2015	19
26625127	Adenosine monophosphate	Griss T	Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis.	PLoS biology	2015	32
26655904	Adenosine monophosphate	Joshi S	The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis.	Cell reports	2015	17
26678338	Adenosine monophosphate	von Eyss B	A MYC-Driven Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary Epithelial Cells and Breast Cancer.	Cancer cell	2015	23
26711141	Adenosine monophosphate	Dasgupta B	Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer.	Trends in pharmacological sciences	2016	20
26784987	Adenosine monophosphate	Sullivan K	Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection.	PloS one	2016	11
26811496	Adenosine monophosphate	Law BY	Hernandezine, a novel AMPK activator induces autophagic cell death in drug-resistant cancers.	Oncotarget	2016	17
26999735	Adenosine monophosphate	Liu X	LncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress.	Nature cell biology	2016	33
27034026	Adenosine monophosphate	Kim J	AMPK activators: mechanisms of action and physiological activities.	Experimental & molecular medicine	2016	16
27057473	Adenosine monophosphate	Figueir√≥ F	Phenotypic and functional characteristics of CD39high human regulatory B cells (Breg).	Oncoimmunology	2016	11
27294526	Adenosine monophosphate	Xu Y	Glycolysis determines dichotomous regulation of T cell subsets in hypoxia.	The Journal of clinical investigation	2016	12
27362768	Adenosine monophosphate	So≈õnicki S	Molecular targets of metformin antitumor action.	Pharmacological reports 	2016	12
27378194	Adenosine monophosphate	Gadducci A	Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.	Critical reviews in oncology/hematology	2016	11
27416781	Adenosine monophosphate	Jeon SM	Regulation and function of AMPK in physiology and diseases.	Experimental & molecular medicine	2016	30
28089566	Adenosine monophosphate	Howell JJ	Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex.	Cell metabolism	2017	14
28099841	Adenosine monophosphate	Momcilovic M	Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.	Cell reports	2017	10
28103582	Adenosine monophosphate	Zhou C	AMPK-autophagy inhibition sensitizes icaritin-induced anti-colorectal cancer cell activity.	Oncotarget	2017	6
28106780	Adenosine monophosphate	Ata R	Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer.	International journal of molecular sciences	2017	7
28197628	Adenosine monophosphate	Chang CH	Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling.	International journal of oncology	2017	6
28408430	Adenosine monophosphate	Carroll B	The lysosome: a crucial hub for AMPK and mTORC1 signalling.	The Biochemical journal	2017	7
28552616	Adenosine monophosphate	Li X	Nucleus-Translocated ACSS2 Promotes Gene Transcription for Lysosomal Biogenesis and Autophagy.	Molecular cell	2017	6
11274184	NAD	He CH	Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacting protein. Implication for heme oxygenase-1 gene regulation.	The Journal of biological chemistry	2001	114
11672522	NAD	Luo J	Negative control of p53 by Sir2alpha promotes cell survival under stress.	Cell	2001	654
12006491	NAD	Langley E	Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence.	The EMBO journal	2002	237
12697818	NAD	Dryden SC	Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle.	Molecular and cellular biology	2003	114
15542609	NAD	Backlund MG	15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.	The Journal of biological chemistry	2005	91
15632193	NAD	Bouras T	SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1.	The Journal of biological chemistry	2005	117
15684044	NAD	Kuzmichev A	Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation.	Proceedings of the National Academy of Sciences of the United States of America	2005	139
16166628	NAD	Zhao X	Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications.	Molecular and cellular biology	2005	93
16288037	NAD	Ford J	Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival.	Cancer research	2005	105
16618762	NAD	Heltweg B	Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.	Cancer research	2006	120
16892051	NAD	Wang C	Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage.	Nature cell biology	2006	131
16923962	NAD	Fu M	Hormonal control of androgen receptor function through SIRT1.	Molecular and cellular biology	2006	81
17015834	NAD	Clements CM	DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2.	Proceedings of the National Academy of Sciences of the United States of America	2006	199
17347138	NAD	Cornblatt BS	Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast.	Carcinogenesis	2007	82
17559965	NAD	Fraga MF	Epigenetics and aging: the targets and the marks.	Trends in genetics 	2007	150
17694090	NAD	Vaquero A	NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs.	Oncogene	2007	93
17694093	NAD	Xu WS	Histone deacetylase inhibitors: molecular mechanisms of action.	Oncogene	2007	384
17718403	NAD	Zakhari S	Overview: how is alcohol metabolized by the body?	Alcohol research & health 	2006	116
17957139	NAD	Allison SJ	SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathways.	Cell cycle	2007	61
18184747	NAD	Narala SR	SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity.	Molecular biology of the cell	2008	50
18203716	NAD	Li K	Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation.	The Journal of biological chemistry	2008	54
18235501	NAD	Kim JE	DBC1 is a negative regulator of SIRT1.	Nature	2008	213
18235502	NAD	Zhao W	Negative regulation of the deacetylase SIRT1 by DBC1.	Nature	2008	191
18364004	NAD	Katz JB	Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.	Immunological reviews	2008	106
18414679	NAD	Firestein R	The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth.	PloS one	2008	200
19060927	NAD	Lara E	Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect.	Oncogene	2009	69
19433578	NAD	Kabra N	SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.	The Journal of biological chemistry	2009	46
19478080	NAD	Zhang T	Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters.	The Journal of biological chemistry	2009	74
19604589	NAD	Feron O	Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells.	Radiotherapy and oncology 	2009	102
20127344	NAD	Bleeker FE	The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.	Acta neuropathologica	2010	77
20361926	NAD	Dinkova-Kostova AT	NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector.	Archives of biochemistry and biophysics	2010	110
20409078	NAD	Donmez G	Aging and disease: connections to sirtuins.	Aging cell	2010	119
20418485	NAD	Ahn J	Genome-wide association study of circulating vitamin D levels.	Human molecular genetics	2010	195
20471503	NAD	Yi J	SIRT1 and p53, effect on cancer, senescence and beyond.	Biochimica et biophysica acta	2010	52
21300765	NAD	V√©gran F	Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-Œ∫B/IL-8 pathway that drives tumor angiogenesis.	Cancer research	2011	120
21397863	NAD	Finley LW	SIRT3 opposes reprogramming of cancer cell metabolism through HIF1Œ± destabilization.	Cancer cell	2011	221
21472714	NAD	Alhazzazi TY	Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer.	Cancer	2011	53
21504832	NAD	Bosch-Presegu√© L	Stabilization of Suv39H1 by SirT1 is part of oxidative stress response and ensures genome protection.	Molecular cell	2011	49
21638050	NAD	Yang M	MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism.	Breast cancer research and treatment	2011	45
21920899	NAD	Elangovan S	SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor Œ± in breast cancer.	Cancer research	2011	37
22146883	NAD	Chen HC	SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.	Annals of surgical oncology	2012	41
22340598	NAD	Li L	Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.	Cancer cell	2012	121
22479251	NAD	Yamakuchi M	MicroRNA Regulation of SIRT1.	Frontiers in physiology	2012	42
22589701	NAD	Lu W	Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy.	PLoS biology	2012	33
22863012	NAD	Qiang L	Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of PparŒ≥.	Cell	2012	148
22941645	NAD	Krietsch J	PARP activation regulates the RNA-binding protein NONO in the DNA damage response to DNA double-strand breaks.	Nucleic acids research	2012	47
23056490	NAD	Latifi A	Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.	PloS one	2012	51
23417962	NAD	Donmez G	SIRT1 and SIRT2: emerging targets in neurodegeneration.	EMBO molecular medicine	2013	58
23526469	NAD	Marquardt JU	Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients.	Hepatology	2013	30
24439680	NAD	Hubbard BP	Small molecule SIRT1 activators for the treatment of aging and age-related diseases.	Trends in pharmacological sciences	2014	89
24650937	NAD	Murai J	Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.	The Journal of pharmacology and experimental therapeutics	2014	37
25280219	NAD	Li L	SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.	Cell stem cell	2014	30
25340584	NAD	Stiebler AC	Ribosomal readthrough at a short UGA stop codon context triggers dual localization of metabolic enzymes in Fungi and animals.	PLoS genetics	2014	23
26959057	NAD	Buhrmann C	Sirt1 Is Required for Resveratrol-Mediated Chemopreventive Effects in Colorectal Cancer Cells.	Nutrients	2016	13
27821631	NAD	Ma L	APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction.	Journal of the American Society of Nephrology 	2017	10
28143522	NAD	Drew DA	ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial.	Trials	2017	6
28223550	NAD	Bonuccelli G	NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting "stemness".	Oncotarget	2017	8
28380384	NAD	Krishnaiah SY	Clock Regulation of Metabolites Reveals Coupling between Transcription and Metabolism.	Cell metabolism	2017	9
1933891	Cytarabine	Kastan MB	Participation of p53 protein in the cellular response to DNA damage.	Cancer research	1991	637
7680764	Cytarabine	Fisher RI	Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.	The New England journal of medicine	1993	176
8358726	Cytarabine	Kaufmann SH	Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis.	Cancer research	1993	281
10653870	Cytarabine	Kantarjian HM	Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.	Journal of clinical oncology 	2000	103
10815900	Cytarabine	Tamm I	Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.	Clinical cancer research 	2000	129
12200686	Cytarabine	Konopleva M	Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.	Leukemia	2002	102
12393388	Cytarabine	Fr√∂hling S	Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.	Blood	2002	139
12702506	Cytarabine	Xu Q	Survival of acute myeloid leukemia cells requires PI3 kinase activation.	Blood	2003	111
14534335	Cytarabine	Hughes TP	Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.	The New England journal of medicine	2003	177
15687234	Cytarabine	Guzman ML	The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.	Blood	2005	163
15870183	Cytarabine	Tallman MS	Drug therapy for acute myeloid leukemia.	Blood	2005	146
16051734	Cytarabine	D√∂hner K	Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.	Blood	2005	147
16288046	Cytarabine	Guo F	Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.	Cancer research	2005	69
16502413	Cytarabine	Thomas DA	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.	Cancer	2006	84
16807468	Cytarabine	Mini E	Cellular pharmacology of gemcitabine.	Annals of oncology 	2006	117
16921041	Cytarabine	Paschka P	Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.	Journal of clinical oncology 	2006	111
17138821	Cytarabine	Cairo MS	Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.	Blood	2007	58
17151364	Cytarabine	Druker BJ	Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.	The New England journal of medicine	2006	759
17658395	Cytarabine	Pieters R	A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.	Lancet	2007	89
18000167	Cytarabine	Lange BJ	Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.	Blood	2008	77
18200035	Cytarabine	Zhang W	Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.	Leukemia	2008	61
18299451	Cytarabine	Wang ZY	Acute promyelocytic leukemia: from highly fatal to highly curable.	Blood	2008	218
18757419	Cytarabine	Li L	Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.	Cancer research	2008	82
18931345	Cytarabine	Qin T	Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.	Blood	2009	53
19047294	Cytarabine	B√ºchner T	Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.	Journal of clinical oncology 	2009	53
19194470	Cytarabine	Flotho C	The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.	Leukemia	2009	67
19898621	Cytarabine	Li L	Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers.	PloS one	2009	47
20016527	Cytarabine	Salzer WL	Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.	Leukemia	2010	48
20212254	Cytarabine	Ravandi F	Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.	Journal of clinical oncology 	2010	100
20215516	Cytarabine	Jin Y	Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.	Cancer research	2010	92
20451454	Cytarabine	Rubnitz JE	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.	The Lancet. Oncology	2010	94
20528872	Cytarabine	Romaguera JE	Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.	British journal of haematology	2010	46
20644121	Cytarabine	Lo-Coco F	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.	Blood	2010	60
20660832	Cytarabine	Gisselbrecht C	Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.	Journal of clinical oncology 	2010	159
20841507	Cytarabine	Schwind S	BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.	Blood	2010	41
20876803	Cytarabine	Chiarini F	Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.	Cancer research	2010	56
21131036	Cytarabine	Krug U	Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.	Lancet	2010	50
21172891	Cytarabine	Burnett AK	Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.	Journal of clinical oncology 	2011	114
21175313	Cytarabine	Preudhomme C	Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.	The New England journal of medicine	2010	61
21220605	Cytarabine	Burnett A	Therapeutic advances in acute myeloid leukemia.	Journal of clinical oncology 	2011	142
21233840	Cytarabine	Crist√≥bal I	PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.	Leukemia	2011	46
21239698	Cytarabine	Karp JE	Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.	Blood	2011	35
21680954	Cytarabine	Altman JK	Targeting mTOR for the treatment of AML. New agents and new directions.	Oncotarget	2011	47
21768474	Cytarabine	Inaba H	Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.	Journal of clinical oncology 	2011	45
21937694	Cytarabine	Wey S	Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling.	Blood	2012	31
21947824	Cytarabine	Thieblemont C	The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.	Journal of clinical oncology 	2011	44
22180162	Cytarabine	Estey EH	Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.	American journal of hematology	2012	42
22203733	Cytarabine	Montano R	Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.	Molecular cancer therapeutics	2012	53
22308295	Cytarabine	Uy GL	A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.	Blood	2012	96
22585696	Cytarabine	Garcia-Manero G	Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.	Journal of clinical oncology 	2012	39
22627678	Cytarabine	Stone RM	Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.	Leukemia	2012	59
22718839	Cytarabine	Delarue R	CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.	Blood	2013	41
22753902	Cytarabine	Mendler JH	RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.	Journal of clinical oncology 	2012	51
23129738	Cytarabine	Attar EC	Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.	Journal of clinical oncology 	2013	30
23249862	Cytarabine	Herrmann H	Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.	Oncotarget	2012	45
23321257	Cytarabine	Jourdan E	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.	Blood	2013	39
23526416	Cytarabine	Estey EH	Acute myeloid leukemia: 2013 update on risk-stratification and management.	American journal of hematology	2013	70
23569323	Cytarabine	Rubenstein JL	Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).	Journal of clinical oncology 	2013	49
23676502	Cytarabine	Chen Y	CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.	The Journal of clinical investigation	2013	49
23897964	Cytarabine	Serve H	Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.	Journal of clinical oncology 	2013	56
24307721	Cytarabine	Rushworth SA	Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.	Blood	2014	26
24708856	Cytarabine	Palma CA	MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia.	Molecular cancer	2014	27
24856239	Cytarabine	Pommier Y	Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2).	DNA repair	2014	49
24872388	Cytarabine	Weng H	Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S.	Cancer research	2014	23
24943107	Cytarabine	Oki Y	Double hit lymphoma: the MD Anderson Cancer Center clinical experience.	British journal of haematology	2014	31
25027517	Cytarabine	Gjertsen BT	Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.	Leukemia	2015	39
25710880	Cytarabine	Mussai F	Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.	Blood	2015	17
25833957	Cytarabine	Burnett AK	A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.	Blood	2015	21
26738796	Cytarabine	Singh N	Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.	Science translational medicine	2016	18
26968357	Cytarabine	Garcia-Manero G	Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.	The Lancet. Oncology	2016	12
27103402	Cytarabine	Niu X	Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.	Clinical cancer research 	2016	11
27367478	Cytarabine	De Kouchkovsky I	'Acute myeloid leukemia: a comprehensive review and 2016 update'.	Blood cancer journal	2016	24
27941792	Cytarabine	G√∂llner S	Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.	Nature medicine	2017	11
28109402	Cytarabine	Tamamyan G	Frontline treatment of acute myeloid leukemia in adults.	Critical reviews in oncology/hematology	2017	5
28416471	Cytarabine	Farge T	Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.	Cancer discovery	2017	7
28644114	Cytarabine	Stone RM	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.	The New England journal of medicine	2017	25
10836148	Uridine 5'-diphosphate	Tukey RH	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.	Annual review of pharmacology and toxicology	2000	208
11156391	Uridine 5'-diphosphate	Ando Y	Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.	Cancer research	2000	93
15007088	Uridine 5'-diphosphate	Innocenti F	Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.	Journal of clinical oncology 	2004	162
15914268	Uridine 5'-diphosphate	Lee JS	Nrf2 as a novel molecular target for chemoprevention.	Cancer letters	2005	85
16266320	Uridine 5'-diphosphate	Galili U	The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy.	Immunology and cell biology	2005	80
16289744	Uridine 5'-diphosphate	Moon YJ	Dietary flavonoids: effects on xenobiotic and carcinogen metabolism.	Toxicology in vitro 	2006	118
17244352	Uridine 5'-diphosphate	Wegman P	Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.	Breast cancer research 	2007	65
17710231	Uridine 5'-diphosphate	Ichikawa S	A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.	The Journal of clinical investigation	2007	104
18701722	Uridine 5'-diphosphate	Lau KS	N-Glycans in cancer progression.	Glycobiology	2008	109
19228077	Uridine 5'-diphosphate	Keating GM	Sorafenib: a review of its use in advanced hepatocellular carcinoma.	Drugs	2009	80
19285976	Uridine 5'-diphosphate	Kultti A	4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3.	Experimental cell research	2009	65
19647043	Uridine 5'-diphosphate	Hanover JA	The hexosamine signaling pathway: O-GlcNAc cycling in feast or famine.	Biochimica et biophysica acta	2010	110
20716633	Uridine 5'-diphosphate	Chow HH	Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study.	Cancer prevention research	2010	46
22395643	Uridine 5'-diphosphate	Rae JM	CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.	Journal of the National Cancer Institute	2012	63
22399294	Uridine 5'-diphosphate	Peng RQ	MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-Œ±-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7.	The Journal of biological chemistry	2012	48
23132334	Uridine 5'-diphosphate	Reese MJ	In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.	Drug metabolism and disposition	2013	38
23592772	Uridine 5'-diphosphate	Ma Z	Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-Œ∫B activity in pancreatic cancer cells.	The Journal of biological chemistry	2013	54
24870236	Uridine 5'-diphosphate	Zahreddine HA	The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.	Nature	2014	43
24931394	Uridine 5'-diphosphate	Stray-Pedersen A	PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia.	American journal of human genetics	2014	21
25233931	Uridine 5'-diphosphate	Murphy SE	Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups.	Carcinogenesis	2014	36
25422324	Uridine 5'-diphosphate	Wu Q	Decreased expression of hepatocyte nuclear factor 4Œ± (Hnf4Œ±)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity.	The Journal of biological chemistry	2015	15
25657018	Uridine 5'-diphosphate	Wikoff WR	Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma.	Cancer prevention research	2015	16
26092931	Uridine 5'-diphosphate	Nabi IR	The galectin lattice at a glance.	Journal of cell science	2015	37
26417955	Uridine 5'-diphosphate	Gammal RS	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.	Clinical pharmacology and therapeutics	2016	20
26503631	Uridine 5'-diphosphate	Roy HK	Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin.	Gut	2017	8
27530469	Uridine 5'-diphosphate	Talavera Pons S	Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.	British journal of clinical pharmacology	2017	7
11499871	4,4'-Methylenedianiline	Yoneda T	A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.	Journal of bone and mineral research 	2001	129
11805321	4,4'-Methylenedianiline	Kang DC	mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties.	Proceedings of the National Academy of Sciences of the United States of America	2002	166
12359858	4,4'-Methylenedianiline	Wang F	Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts.	Journal of the National Cancer Institute	2002	112
14518029	4,4'-Methylenedianiline	van Bokhoven A	Molecular characterization of human prostate carcinoma cell lines.	The Prostate	2003	146
14527951	4,4'-Methylenedianiline	Sunters A	FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.	The Journal of biological chemistry	2003	148
15090545	4,4'-Methylenedianiline	Bourguignon LY	CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion.	The Journal of biological chemistry	2004	101
15313925	4,4'-Methylenedianiline	Osta WA	EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy.	Cancer research	2004	98
15523088	4,4'-Methylenedianiline	Studeny M	Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.	Journal of the National Cancer Institute	2004	237
15599396	4,4'-Methylenedianiline	Boucharaba A	Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.	The Journal of clinical investigation	2004	103
17018625	4,4'-Methylenedianiline	Cai W	In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.	Cancer research	2006	70
17145894	4,4'-Methylenedianiline	Wang Y	Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice.	Cancer research	2006	69
17179479	4,4'-Methylenedianiline	Phillips TM	The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation.	Journal of the National Cancer Institute	2006	416
17267501	4,4'-Methylenedianiline	Barral PM	MDA-5 is cleaved in poliovirus-infected cells.	Journal of virology	2007	70
17332325	4,4'-Methylenedianiline	Cheng GZ	Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel.	Cancer research	2007	170
17332756	4,4'-Methylenedianiline	Bravo-Cordero JJ	MT1-MMP proinvasive activity is regulated by a novel Rab8-dependent exocytic pathway.	The EMBO journal	2007	86
17339367	4,4'-Methylenedianiline	Pledgie-Tracy A	Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines.	Molecular cancer therapeutics	2007	72
17483326	4,4'-Methylenedianiline	Hiraga T	Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.	Cancer research	2007	70
17671502	4,4'-Methylenedianiline	Tomlins SA	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.	Nature	2007	285
17785729	4,4'-Methylenedianiline	Sampath L	Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.	Journal of nuclear medicine 	2007	73
17947497	4,4'-Methylenedianiline	Shen F	Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells.	The Journal of pharmacology and experimental therapeutics	2008	56
18089802	4,4'-Methylenedianiline	Olmeda D	SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells.	Cancer research	2007	61
18182989	4,4'-Methylenedianiline	Grossmann ME	Effects of adiponectin on breast cancer cell growth and signaling.	British journal of cancer	2008	55
18353781	4,4'-Methylenedianiline	Cheng GZ	Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function.	The Journal of biological chemistry	2008	83
18504431	4,4'-Methylenedianiline	Bhaumik D	Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells.	Oncogene	2008	192
18681906	4,4'-Methylenedianiline	Croker AK	High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.	Journal of cellular and molecular medicine	2009	139
18794155	4,4'-Methylenedianiline	Stan SD	Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo.	Cancer research	2008	68
18829534	4,4'-Methylenedianiline	Pratap J	Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells.	Cancer research	2008	65
19011242	4,4'-Methylenedianiline	Chen M	Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin.	The Journal of biological chemistry	2009	56
19067525	4,4'-Methylenedianiline	Wang L	Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers.	Molecular pharmaceutics	2009	47
19190326	4,4'-Methylenedianiline	Hurst DR	Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis.	Cancer research	2009	146
19238171	4,4'-Methylenedianiline	Wu H	Suppression of cell growth and invasion by miR-205 in breast cancer.	Cell research	2009	117
19243594	4,4'-Methylenedianiline	Eiseler T	Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion.	Breast cancer research 	2009	58
19276163	4,4'-Methylenedianiline	McGovern UB	Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.	Molecular cancer therapeutics	2009	49
19372543	4,4'-Methylenedianiline	Lorenzi PL	DNA fingerprinting of the NCI-60 cell line panel.	Molecular cancer therapeutics	2009	69
19435893	4,4'-Methylenedianiline	Miller TW	Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.	Cancer research	2009	57
19509223	4,4'-Methylenedianiline	Zhang H	Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.	Cancer research	2009	45
19546228	4,4'-Methylenedianiline	Jo M	Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling.	The Journal of biological chemistry	2009	55
19620789	4,4'-Methylenedianiline	Besch R	Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.	The Journal of clinical investigation	2009	100
19720836	4,4'-Methylenedianiline	Lu X	Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone.	The Journal of biological chemistry	2009	67
19767768	4,4'-Methylenedianiline	Shao R	YKL-40, a secreted glycoprotein, promotes tumor angiogenesis.	Oncogene	2009	81
20145128	4,4'-Methylenedianiline	Ward CS	Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.	Cancer research	2010	66
20179208	4,4'-Methylenedianiline	Zhong Z	Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells.	Cancer research	2010	47
20356845	4,4'-Methylenedianiline	Yori JL	Kruppel-like factor 4 inhibits epithelial-to-mesenchymal transition through regulation of E-cadherin gene expression.	The Journal of biological chemistry	2010	70
20406981	4,4'-Methylenedianiline	Bhutia SK	Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24.	Cancer research	2010	53
20460522	4,4'-Methylenedianiline	Nimmagadda S	Molecular imaging of CXCR4 receptor expression in human cancer xenografts with 64CuAMD3100 positron emission tomography.	Cancer research	2010	45
20551059	4,4'-Methylenedianiline	Boni A	Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.	Cancer research	2010	200
20843787	4,4'-Methylenedianiline	Bourguignon LY	Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion.	The Journal of biological chemistry	2010	57
20876278	4,4'-Methylenedianiline	Scott RW	LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells.	The Journal of cell biology	2010	70
21189326	4,4'-Methylenedianiline	Johnson RW	TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling.	Cancer research	2011	57
21242971	4,4'-Methylenedianiline	Yu F	Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion.	Oncogene	2011	120
21301071	4,4'-Methylenedianiline	Kraning-Rush CM	The role of the cytoskeleton in cellular force generation in 2D and 3D environments.	Physical biology	2011	44
21321970	4,4'-Methylenedianiline	Jomova K	Arsenic: toxicity, oxidative stress and human disease.	Journal of applied toxicology 	2011	92
21389093	4,4'-Methylenedianiline	Ahmad A	Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells.	Cancer research	2011	52
21701558	4,4'-Methylenedianiline	Robinson JL	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1.	The EMBO journal	2011	73
23805171	4,4'-Methylenedianiline	Gupta V	ApoStream(‚Ñ¢), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood.	Biomicrofluidics	2012	68
24444438	4,4'-Methylenedianiline	Guo C	Hydrogen sulfide protected gastric epithelial cell from ischemia/reperfusion injury by Keap1 s-sulfhydration, MAPK dependent anti-apoptosis and NF-Œ∫B dependent anti-inflammation pathway.	European journal of pharmacology	2014	25
24887205	4,4'-Methylenedianiline	Kumar S	Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.	Journal of experimental & clinical cancer research 	2014	27
27034163	4,4'-Methylenedianiline	Ranoa DR	Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.	Oncotarget	2016	14
28178330	4,4'-Methylenedianiline	Rasool M	Comparative study of extrapolative factors linked with oxidative injury and anti-inflammatory status in chronic kidney disease patients experiencing cardiovascular distress.	PloS one	2017	5
7691276	Calcium	Linstedt AD	Giantin, a novel conserved Golgi membrane protein containing a cytoplasmic domain of at least 350 kDa.	Molecular biology of the cell	1993	149
8033105	Calcium	Becker KF	E-cadherin gene mutations provide clues to diffuse type gastric carcinomas.	Cancer research	1994	140
8397339	Calcium	Jain J	The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun.	Nature	1993	182
8805703	Calcium	Ono M	Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB.	Nature	1996	132
8996247	Calcium	Aiuti A	The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood.	The Journal of experimental medicine	1997	243
9334377	Calcium	Wu L	Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.	The Journal of experimental medicine	1997	111
9486651	Calcium	Gunn MD	A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1.	Nature	1998	163
9537325	Calcium	Guilford P	E-cadherin germline mutations in familial gastric cancer.	Nature	1998	255
10545506	Calcium	Nieman MT	N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression.	The Journal of cell biology	1999	187
10564536	Calcium	Mizejewski GJ	Role of integrins in cancer: survey of expression patterns.	Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine	1999	107
10572077	Calcium	Burger JA	Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.	Blood	1999	113
10617614	Calcium	Webb Y	Inhibition of protein palmitoylation, raft localization, and T cell signaling by 2-bromopalmitate and polyunsaturated fatty acids.	The Journal of biological chemistry	2000	129
10684258	Calcium	Hazan RB	Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis.	The Journal of cell biology	2000	195
10742151	Calcium	Asea A	HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine.	Nature medicine	2000	336
10866666	Calcium	Li M	ATF6 as a transcription activator of the endoplasmic reticulum stress element: thapsigargin stress-induced changes and synergistic interactions with NF-Y and YY1.	Molecular and cellular biology	2000	97
10884684	Calcium	Chin D	Calmodulin: a prototypical calcium sensor.	Trends in cell biology	2000	257
10931854	Calcium	Kozak KR	Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2.	The Journal of biological chemistry	2000	106
10931868	Calcium	Noren NK	p120 catenin regulates the actin cytoskeleton via Rho family GTPases.	The Journal of cell biology	2000	171
10934088	Calcium	Schulz R	Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy.	American journal of respiratory and critical care medicine	2000	99
11181568	Calcium	Lawrance IC	Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes.	Human molecular genetics	2001	89
11290340	Calcium	Bunnell SC	Dynamic actin polymerization drives T cell receptor-induced spreading: a role for the signal transduction adaptor LAT.	Immunity	2001	143
11325849	Calcium	Tsavaler L	Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins.	Cancer research	2001	121
11481452	Calcium	Gong G	Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B.	Proceedings of the National Academy of Sciences of the United States of America	2001	159
12093242	Calcium	Kirpichnikov D	Metformin: an update.	Annals of internal medicine	2002	188
12107827	Calcium	Nickoloff BJ	Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma.	Cell death and differentiation	2002	88
12134161	Calcium	Avizienyte E	Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling.	Nature cell biology	2002	104
12351684	Calcium	Heinlein CA	The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions.	Molecular endocrinology	2002	97
12356870	Calcium	Bunnell SC	T cell receptor ligation induces the formation of dynamically regulated signaling assemblies.	The Journal of cell biology	2002	214
12482879	Calcium	Fransson A	Atypical Rho GTPases have roles in mitochondrial homeostasis and apoptosis.	The Journal of biological chemistry	2003	99
12490194	Calcium	Wharton KA Jr	Runnin' with the Dvl: proteins that associate with Dsh/Dvl and their significance to Wnt signal transduction.	Developmental biology	2003	92
12528874	Calcium	Kyle RA	Review of 1027 patients with newly diagnosed multiple myeloma.	Mayo Clinic proceedings	2003	283
12626353	Calcium	Phillips RJ	The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases.	American journal of respiratory and critical care medicine	2003	111
12686516	Calcium	Brar SS	NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells.	American journal of physiology. Cell physiology	2003	76
12708612	Calcium	Weber LW	Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model.	Critical reviews in toxicology	2003	208
12780789	Calcium	International Myeloma Working Group.	Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.	British journal of haematology	2003	389
12836676	Calcium	Yap KL	Calmodulin target database.	Journal of structural and functional genomics	2000	156
14652238	Calcium	Grau MV	Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial.	Journal of the National Cancer Institute	2003	80
14667502	Calcium	Liang H	Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue.	Cancer cell	2003	92
15010700	Calcium	Bassik MC	Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis.	The EMBO journal	2004	86
15070697	Calcium	Moreaux J	BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.	Blood	2004	115
15124026	Calcium	Karai L	Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control.	The Journal of clinical investigation	2004	91
15191538	Calcium	Eckert RL	S100 proteins in the epidermis.	The Journal of investigative dermatology	2004	94
15284207	Calcium	Bai X	Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders.	Endocrinology	2004	74
15364929	Calcium	Jenkins CM	Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities.	The Journal of biological chemistry	2004	219
15604267	Calcium	Shen J	Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry.	Cancer research	2004	74
15735754	Calcium	Kremenevskaja N	Wnt-5a has tumor suppressor activity in thyroid carcinoma.	Oncogene	2005	78
15764707	Calcium	Zhang N	A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1.	Proceedings of the National Academy of Sciences of the United States of America	2005	70
15798098	Calcium	Nagpal S	Noncalcemic actions of vitamin D receptor ligands.	Endocrine reviews	2005	154
15827134	Calcium	Moreaux J	The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.	Blood	2005	67
16179951	Calcium	White C	The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the InsP3R.	Nature cell biology	2005	145
16211229	Calcium	Li S	Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression.	International journal of oncology	2005	73
16229685	Calcium	Stoeck A	A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44.	The Biochemical journal	2006	66
16288122	Calcium	Wei EK	Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study.	Journal of the National Cancer Institute	2005	125
16297907	Calcium	Hermani A	S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells.	Experimental cell research	2006	77
16332727	Calcium	Abdelrahim M	3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5.	Carcinogenesis	2006	63
16630562	Calcium	Fransson S	The atypical Rho GTPases Miro-1 and Miro-2 have essential roles in mitochondrial trafficking.	Biochemical and biophysical research communications	2006	113
16631011	Calcium	Caira FC	Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation.	Journal of the American College of Cardiology	2006	96
16735691	Calcium	Cao W	Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production.	The Journal of experimental medicine	2006	88
16846592	Calcium	Gebhardt C	S100A8 and S100A9 in inflammation and cancer.	Biochemical pharmacology	2006	180
16885372	Calcium	Walser TC	Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer.	Cancer research	2006	64
16946007	Calcium	Norman AW	Minireview: vitamin D receptor: new assignments for an already busy receptor.	Endocrinology	2006	109
16951173	Calcium	Litvinov IV	Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells.	Cancer research	2006	64
17062705	Calcium	Roelofs AJ	Molecular mechanisms of action of bisphosphonates: current status.	Clinical cancer research 	2006	84
17215481	Calcium	Lim LH	Annexin 1: the new face of an old molecule.	FASEB journal 	2007	86
17409416	Calcium	Kang HG	E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase.	Cancer research	2007	62
17585332	Calcium	Monteith GR	Calcium and cancer: targeting Ca2+ transport.	Nature reviews. Cancer	2007	148
17671655	Calcium	Groenestege WM	Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia.	The Journal of clinical investigation	2007	63
17680735	Calcium	Rong Y	Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis.	Annual review of physiology	2008	104
17700640	Calcium	Keller S	CD24 is a marker of exosomes secreted into urine and amniotic fluid.	Kidney international	2007	78
17715357	Calcium	Danzer KM	Different species of alpha-synuclein oligomers induce calcium influx and seeding.	The Journal of neuroscience 	2007	182
17724466	Calcium	Wendt MK	Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells.	Oncogene	2008	54
17726019	Calcium	Leclerc E	S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains.	The Journal of biological chemistry	2007	56
17953510	Calcium	Spolski R	Interleukin-21: basic biology and implications for cancer and autoimmunity.	Annual review of immunology	2008	207
18088161	Calcium	Cranney A	Effectiveness and safety of vitamin D in relation to bone health.	Evidence report/technology assessment	2007	113
18226465	Calcium	Duenas-Gonzalez A	Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.	Cancer treatment reviews	2008	70
18272392	Calcium	G√≥mez-Ramos A	Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells.	Molecular and cellular neurosciences	2008	58
18316581	Calcium	Czuczman MS	Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.	Clinical cancer research 	2008	51
18332219	Calcium	Cortesio CL	Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion.	The Journal of cell biology	2008	69
18339795	Calcium	Ralhan R	Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry.	Molecular & cellular proteomics 	2008	61
18450475	Calcium	Bourguignon LY	Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression.	Seminars in cancer biology	2008	84
18515009	Calcium	Reid DM	Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.	Cancer treatment reviews	2008	51
18579197	Calcium	Buell JS	Vitamin D and neurocognitive dysfunction: preventing "D"ecline?	Molecular aspects of medicine	2008	59
18694980	Calcium	Bouillon R	Vitamin D and human health: lessons from vitamin D receptor null mice.	Endocrine reviews	2008	262
18715144	Calcium	Bhakat KK	Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein.	Antioxidants & redox signaling	2009	80
18726070	Calcium	van Roy F	The cell-cell adhesion molecule E-cadherin.	Cellular and molecular life sciences 	2008	224
18795164	Calcium	Ahn KC	In vitro biologic activities of the antimicrobials triclocarban, its analogs, and triclosan in bioassay screens: receptor-based bioassay screens.	Environmental health perspectives	2008	70
18799424	Calcium	Veldkamp CT	Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12.	Science signaling	2008	109
18844224	Calcium	Dasgupta P	Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines.	International journal of cancer	2009	104
18854159	Calcium	Stathopulos PB	Structural and mechanistic insights into STIM1-mediated initiation of store-operated calcium entry.	Cell	2008	148
18949548	Calcium	Stafforini DM	Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2).	Cardiovascular drugs and therapy	2009	54
19015192	Calcium	Hartzell HC	Anoctamin/TMEM16 family members are Ca2+-activated Cl- channels.	The Journal of physiology	2009	96
19019825	Calcium	Stathopulos PB	Stromal interaction molecule (STIM) 1 and STIM2 calcium sensing regions exhibit distinct unfolding and oligomerization kinetics.	The Journal of biological chemistry	2009	58
19150949	Calcium	Izzedine H	Management of hypertension in angiogenesis inhibitor-treated patients.	Annals of oncology 	2009	62
19151922	Calcium	Dudek J	Functions and pathologies of BiP and its interaction partners.	Cellular and molecular life sciences 	2009	46
19166511	Calcium	Marongiu R	Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux.	Journal of neurochemistry	2009	48
19185847	Calcium	Yang S	Orai1 and STIM1 are critical for breast tumor cell migration and metastasis.	Cancer cell	2009	165
19234463	Calcium	Svensson L	Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation.	Nature medicine	2009	102
19276362	Calcium	Pelicano H	Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism.	Cancer research	2009	48
19290921	Calcium	Mohamed AJ	Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.	Immunological reviews	2009	88
19342367	Calcium	Maru DM	MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.	The American journal of pathology	2009	51
19379710	Calcium	Baranwal S	Molecular mechanisms controlling E-cadherin expression in breast cancer.	Biochemical and biophysical research communications	2009	52
19464786	Calcium	Prossnitz ER	Mechanisms of estrogen signaling and gene expression via GPR30.	Molecular and cellular endocrinology	2009	81
19491390	Calcium	Quiroga MP	B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.	Blood	2009	79
19560418	Calcium	Dougherty MK	KSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signals.	Molecular cell	2009	48
19563700	Calcium	Kumar P	Molecular mechanisms of endothelial hyperpermeability: implications in inflammation.	Expert reviews in molecular medicine	2009	97
19667145	Calcium	K√∂stner K	The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature.	Anticancer research	2009	77
19826129	Calcium	Heng DY	Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.	Journal of clinical oncology 	2009	268
19938015	Calcium	Garraway IP	Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo.	The Prostate	2010	63
20019188	Calcium	Boye K	S100A4 and metastasis: a small actor playing many roles.	The American journal of pathology	2010	122
20048153	Calcium	Busillo JM	Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling.	The Journal of biological chemistry	2010	89
20086172	Calcium	Ariazi EA	The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.	Cancer research	2010	54
20227497	Calcium	Haussler MR	The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the "Fountain of Youth" to mediate healthful aging.	The Journal of steroid biochemistry and molecular biology	2010	50
20335171	Calcium	Li C	Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.	The Journal of biological chemistry	2010	41
20354226	Calcium	Vandenabeele P	The role of the kinases RIP1 and RIP3 in TNF-induced necrosis.	Science signaling	2010	148
20484021	Calcium	Teicher BA	CXCL12 (SDF-1)/CXCR4 pathway in cancer.	Clinical cancer research 	2010	331
20484626	Calcium	Emmanouilidou E	Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival.	The Journal of neuroscience 	2010	262
20554944	Calcium	Ding X	Essential role of TRPC6 channels in G2/M phase transition and development of human glioma.	Journal of the National Cancer Institute	2010	46
20613726	Calcium	Yan J	LRRC26 auxiliary protein allows BK channel activation at resting voltage without calcium.	Nature	2010	90
20657034	Calcium	Patil S	Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.	Annals of oncology 	2011	40
20668910	Calcium	Nunes KP	RhoA/Rho-kinase and vascular diseases: what is the link?	Cellular and molecular life sciences 	2010	41
20702634	Calcium	McKenna DJ	MicroRNA 203 expression in keratinocytes is dependent on regulation of p53 levels by E6.	Journal of virology	2010	41
20736230	Calcium	Ramagopalan SV	A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution.	Genome research	2010	222
20843485	Calcium	Gonzalez CA	Diet and cancer prevention: Contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study.	European journal of cancer	2010	57
20947496	Calcium	Pi M	GPRC6A mediates the non-genomic effects of steroids.	The Journal of biological chemistry	2010	45
20978119	Calcium	He BC	Tetrandrine inhibits Wnt/Œ≤-catenin signaling and suppresses tumor growth of human colorectal cancer.	Molecular pharmacology	2011	44
21074201	Calcium	Choueiri TK	The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.	The Journal of urology	2011	55
21145844	Calcium	Malhi H	Endoplasmic reticulum stress in liver disease.	Journal of hepatology	2011	244
21160030	Calcium	Slominski AT	20-Hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells.	American journal of physiology. Cell physiology	2011	57
21192095	Calcium	de Groot J	Glutamate and the biology of gliomas.	Glia	2011	55
21197695	Calcium	Bikle DD	Vitamin D: an ancient hormone.	Experimental dermatology	2011	50
21203423	Calcium	Hovanessian AG	Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization.	PloS one	2010	45
21215707	Calcium	Arozarena I	Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.	Cancer cell	2011	67
21217057	Calcium	Zheng L	Auto-inhibitory role of the EF-SAM domain of STIM proteins in store-operated calcium entry.	Proceedings of the National Academy of Sciences of the United States of America	2011	36
21224390	Calcium	McAndrew D	ORAI1-mediated calcium influx in lactation and in breast cancer.	Molecular cancer therapeutics	2011	41
21266974	Calcium	Proctor MJ	An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study.	British journal of cancer	2011	71
21311022	Calcium	Choi M	K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension.	Science	2011	173
21353695	Calcium	Fizazi K	Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.	Lancet	2011	308
21364678	Calcium	Flourakis M	Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells.	Cell death & disease	2010	47
21407177	Calcium	Zhang K	The unfolded protein response transducer IRE1Œ± prevents ER stress-induced hepatic steatosis.	The EMBO journal	2011	88
21408177	Calcium	Wang SF	Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors.	PloS one	2011	36
21420431	Calcium	Holzer P	Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system.	Pharmacology & therapeutics	2011	38
21444679	Calcium	Jamieson NB	Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.	Clinical cancer research 	2011	36
21481794	Calcium	Chen J	CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3.	Cancer cell	2011	114
21544514	Calcium	Tseng CH	Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan.	Diabetologia	2011	38
21572519	Calcium	Zheng L	Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer.	PloS one	2011	62
21592394	Calcium	Wang WL	Effects of 1Œ±,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells.	Molecular cancer	2011	42
21602788	Calcium	Massie CE	The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis.	The EMBO journal	2011	156
21610146	Calcium	Moon EK	Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.	Clinical cancer research 	2011	82
21622563	Calcium	Zhou H	Novel mechanism of anti-apoptotic function of 78-kDa glucose-regulated protein (GRP78): endocrine resistance factor in breast cancer, through release of B-cell lymphoma 2 (BCL-2) from BCL-2-interacting killer (BIK).	The Journal of biological chemistry	2011	39
21685359	Calcium	Sack U	Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.	Journal of the National Cancer Institute	2011	50
21697531	Calcium	Sutendra G	The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension.	Science translational medicine	2011	56
21796119	Calcium	Morin RD	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.	Nature	2011	387
21799901	Calcium	Li X	Comparative mRNA and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specific molecular events.	PloS one	2011	37
21872797	Calcium	Haussler MR	Vitamin D receptor (VDR)-mediated actions of 1Œ±,25(OH)‚ÇÇvitamin D‚ÇÉ: genomic and non-genomic mechanisms.	Best practice & research. Clinical endocrinology & metabolism	2011	91
21876174	Calcium	Chen YF	Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2011	85
21903638	Calcium	De A	Wnt/Ca2+ signaling pathway: a brief overview.	Acta biochimica et biophysica Sinica	2011	63
22017435	Calcium	Rickert RC	Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.	Immunological reviews	2011	78
22078863	Calcium	Hines LE	Potentially harmful drug-drug interactions in the elderly: a review.	The American journal of geriatric pharmacotherapy	2011	35
22109080	Calcium	Mishra SK	S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence.	Cancer metastasis reviews	2012	36
22115958	Calcium	Yeung BH	Evolution and roles of stanniocalcin.	Molecular and cellular endocrinology	2012	36
22246129	Calcium	Kingeter LM	C-type lectin receptor-induced NF-Œ∫B activation in innate immune and inflammatory responses.	Cellular & molecular immunology	2012	34
22278364	Calcium	Fedirko V	Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European ppulations.	Cancer epidemiology, biomarkers & prevention 	2012	33
22315453	Calcium	Oki K	Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis.	Endocrinology	2012	37
22349828	Calcium	Trerotola M	Upregulation of Trop-2 quantitatively stimulates human cancer growth.	Oncogene	2013	26
22364157	Calcium	Rosanoff A	Suboptimal magnesium status in the United States: are the health consequences underestimated?	Nutrition reviews	2012	31
22367214	Calcium	Hutter CM	Characterization of gene-environment interactions for colorectal cancer susceptibility loci.	Cancer research	2012	51
22446186	Calcium	Selvaraj S	Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling.	The Journal of clinical investigation	2012	42
22543469	Calcium	Lacey DL	Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.	Nature reviews. Drug discovery	2012	91
22564524	Calcium	Duvvuri U	TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression.	Cancer research	2012	80
22575682	Calcium	Raturi A	Where the endoplasmic reticulum and the mitochondrion tie the knot: the mitochondria-associated membrane (MAM).	Biochimica et biophysica acta	2013	105
22647055	Calcium	Zhao H	Protective role of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice.	BMC gastroenterology	2012	41
22782502	Calcium	Haussler MR	Molecular mechanisms of vitamin D action.	Calcified tissue international	2013	118
22858544	Calcium	Lee SH	Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm.	Cell death and differentiation	2013	26
22885925	Calcium	Shi Y	Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome.	Nature genetics	2012	77
22911669	Calcium	Brennen WN	Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug.	Journal of the National Cancer Institute	2012	43
22915123	Calcium	Oul√®s B	Ryanodine receptor blockade reduces amyloid-Œ≤ load and memory impairments in Tg2576 mouse model of Alzheimer disease.	The Journal of neuroscience 	2012	45
22959412	Calcium	Raghavan M	Calreticulin in the immune system: ins and outs.	Trends in immunology	2013	31
23082778	Calcium	Chen CL	Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients.	Journal of proteome research	2012	34
23123827	Calcium	Markowitz J	Review of S100A9 biology and its role in cancer.	Biochimica et biophysica acta	2013	36
23143396	Calcium	Gibbings D	Selective autophagy degrades DICER and AGO2 and regulates miRNA activity.	Nature cell biology	2012	64
23168410	Calcium	Sun Y	Increase in serum Ca2+/Mg2+ ratio promotes proliferation of prostate cancer cells by activating TRPM7 channels.	The Journal of biological chemistry	2013	29
23213054	Calcium	Kuhne MR	BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.	Clinical cancer research 	2013	55
23246404	Calcium	Marchi S	Downregulation of the mitochondrial calcium uniporter by cancer-related miR-25.	Current biology 	2013	48
23328481	Calcium	Ryu S	Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration.	Cancer cell	2013	34
23362240	Calcium	Beck D	Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.	Science signaling	2013	30
23378584	Calcium	Hardwick JM	Multiple functions of BCL-2 family proteins.	Cold Spring Harbor perspectives in biology	2013	67
23416519	Calcium	Beuschlein F	Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension.	Nature genetics	2013	90
23430059	Calcium	Logue SE	New directions in ER stress-induced cell death.	Apoptosis 	2013	55
23431153	Calcium	Britschgi A	Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling.	Proceedings of the National Academy of Sciences of the United States of America	2013	69
23434461	Calcium	Roti G	Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer.	Cancer cell	2013	30
23486470	Calcium	Wu CJ	Epithelial cell adhesion molecule (EpCAM) regulates claudin dynamics and tight junctions.	The Journal of biological chemistry	2013	28
23511024	Calcium	Bergmeier W	Emerging roles of store-operated Ca¬≤‚Å∫ entry through STIM and ORAI proteins in immunity, hemostasis and cancer.	Channels	2013	26
23536011	Calcium	Harding TC	Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.	Science translational medicine	2013	25
23594099	Calcium	Chen YF	Remodeling of calcium signaling in tumor progression.	Journal of biomedical science	2013	47
23597567	Calcium	Zhao W	1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel Œ±2Œ¥1 subunit.	Cancer cell	2013	27
23686305	Calcium	Davis FM	Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent.	Oncogene	2014	54
23728943	Calcium	Cleary SP	Identification of driver genes in hepatocellular carcinoma by exome sequencing.	Hepatology	2013	63
23860259	Calcium	Wang S	Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis.	Biochimica et biophysica acta	2013	41
23890118	Calcium	Hoth M	The neglected CRAC proteins: Orai2, Orai3, and STIM2.	Current topics in membranes	2013	30
23913001	Calcium	Scholl UI	Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism.	Nature genetics	2013	93
23922354	Calcium	Bouillon R	Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine.	The Journal of clinical endocrinology and metabolism	2013	42
23994495	Calcium	Lawlor KE	Ambiguities in NLRP3 inflammasome regulation: is there a role for mitochondria?	Biochimica et biophysica acta	2014	29
24002662	Calcium	Sovolyova N	Stressed to death - mechanisms of ER stress-induced cell death.	Biological chemistry	2014	34
24054868	Calcium	Chen R	Cav1.3 channel Œ±1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers.	Urologic oncology	2014	22
24155668	Calcium	Willard SS	Glutamate, glutamate receptors, and downstream signaling pathways.	International journal of biological sciences	2013	34
24351972	Calcium	Stathopulos PB	STIM1/Orai1 coiled-coil interplay in the regulation of store-operated calcium entry.	Nature communications	2013	52
24472175	Calcium	Stanisz H	Inverse regulation of melanoma growth and migration by Orai1/STIM2-dependent calcium entry.	Pigment cell & melanoma research	2014	22
24552833	Calcium	Jeltsch M	CCBE1 enhances lymphangiogenesis via A disintegrin and metalloprotease with thrombospondin motifs-3-mediated vascular endothelial growth factor-C activation.	Circulation	2014	25
24599954	Calcium	Bill A	Small molecule-facilitated degradation of ANO1 protein: a new targeting approach for anticancer therapeutics.	The Journal of biological chemistry	2014	21
24660101	Calcium	Chen H	S100 protein family in human cancer.	American journal of cancer research	2014	30
24690483	Calcium	Lee YS	Genomic profile analysis of diffuse-type gastric cancers.	Genome biology	2014	22
24733928	Calcium	Heinecke JL	Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.	Proceedings of the National Academy of Sciences of the United States of America	2014	34
24766647	Calcium	Ekstr√∂m EJ	WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells.	Molecular cancer	2014	37
24768714	Calcium	Akl H	A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.	Biochimica et biophysica acta	2014	28
24781336	Calcium	Zhai X	Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC.	Medical oncology	2014	29
24786491	Calcium	Murata T	Regulation of Epstein-Barr virus reactivation from latency.	Microbiology and immunology	2014	22
24806074	Calcium	Jaiswal JK	S100A11 is required for efficient plasma membrane repair and survival of invasive cancer cells.	Nature communications	2014	26
24842883	Calcium	Lee JM	Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.	Journal of the National Cancer Institute	2014	45
24853390	Calcium	Kenney JW	Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles.	Advances in biological regulation	2014	29
25163766	Calcium	Sauter DRP	ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC).	Pflugers Archiv 	2015	16
25192047	Calcium	Herrmann DN	Synaptotagmin 2 mutations cause an autosomal-dominant form of lambert-eaton myasthenic syndrome and nonprogressive motor neuropathy.	American journal of human genetics	2014	21
25287686	Calcium	Chatterjee S	The intricate role of CXCR4 in cancer.	Advances in cancer research	2014	53
25311085	Calcium	Li JT	Nuclear factor of activated T cells 5 maintained by Hotair suppression of miR-568 upregulates S100 calcium binding protein A4 to promote breast cancer metastasis.	Breast cancer research 	2014	23
25328135	Calcium	Bai XL	Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/Œ≤-catenin signaling.	Oncogene	2015	19
25422446	Calcium	Lu S	A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2014	23
25448035	Calcium	Tamir S	Structure-function analysis of NEET proteins uncovers their role as key regulators of iron and ROS homeostasis in health and disease.	Biochimica et biophysica acta	2015	23
25468996	Calcium	Guo Z	E-cadherin interactome complexity and robustness resolved by quantitative proteomics.	Science signaling	2014	22
25480783	Calcium	Asuthkar S	The TRPM8 protein is a testosterone receptor: I. Biochemical evidence for direct TRPM8-testosterone interactions.	The Journal of biological chemistry	2015	15
25541060	Calcium	Wang W	Mitofusin-2 triggers mitochondria Ca2+ influx from the endoplasmic reticulum to induce apoptosis in hepatocellular carcinoma cells.	Cancer letters	2015	17
25565209	Calcium	Paupe V	CCDC90A (MCUR1) is a cytochrome c oxidase assembly factor and not a regulator of the mitochondrial calcium uniporter.	Cell metabolism	2015	22
25587051	Calcium	Weisenberger DJ	Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history.	Cancer epidemiology, biomarkers & prevention 	2015	18
25624484	Calcium	Giorgi C	p53 at the endoplasmic reticulum regulates apoptosis in a Ca2+-dependent manner.	Proceedings of the National Academy of Sciences of the United States of America	2015	46
25682935	Calcium	Saccone D	Regulation of the vitamin D receptor gene by environment, genetics and epigenetics.	Gene	2015	23
25707820	Calcium	Akbulut Y	(-)-Englerin‚ÄÖA is a potent and selective activator of TRPC4 and TRPC5 calcium channels.	Angewandte Chemie	2015	27
25758716	Calcium	Kumari S	Actin foci facilitate activation of the phospholipase C-Œ≥ in primary T lymphocytes via the WASP pathway.	eLife	2015	34
25772239	Calcium	Vassallo I	WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1.	Oncogene	2016	23
25842288	Calcium	Mathieu AL	PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator-dependent autoimmunity.	The Journal of allergy and clinical immunology	2015	15
25917875	Calcium	Selvaraj S	Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathway.	Molecular carcinogenesis	2016	19
26072287	Calcium	D√©liot N	Plasma membrane calcium channels in cancer: Alterations and consequences for cell proliferation and migration.	Biochimica et biophysica acta	2015	20
26098886	Calcium	Carson C	Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation.	PloS one	2015	16
26178670	Calcium	Fetahu IS	miR-135b- and miR-146b-dependent silencing of calcium-sensing receptor expression in colorectal tumors.	International journal of cancer	2016	11
26240369	Calcium	Nishimoto K	Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands.	Proceedings of the National Academy of Sciences of the United States of America	2015	32
26335399	Calcium	Vannini F	The dual role of iNOS in cancer.	Redox biology	2015	29
26386726	Calcium	Samuel P	Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.	Tumour biology 	2016	14
26404261	Calcium	Temraz S	Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.	International journal of molecular sciences	2015	16
26449662	Calcium	Pietra D	Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.	Leukemia	2016	21
26457758	Calcium	Waning DL	Excess TGF-Œ≤ mediates muscle weakness associated with bone metastases in mice.	Nature medicine	2015	41
26482279	Calcium	Motzer RJ	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.	The Lancet. Oncology	2015	72
26538029	Calcium	Morciano G	Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death.	Molecular biology of the cell	2016	16
26772784	Calcium	Bittremieux M	ER functions of oncogenes and tumor suppressors: Modulators of intracellular Ca(2+) signaling.	Biochimica et biophysica acta	2016	20
26862948	Calcium	Mvunta DH	Overexpression of SIRT1 is Associated With Poor Outcomes in Patients With Ovarian Carcinoma.	Applied immunohistochemistry & molecular morphology 	2017	7
26899994	Calcium	Li X	miR-155 acts as an anti-inflammatory factor in atherosclerosis-associated foam cell formation by repressing calcium-regulated heat stable protein 1.	Scientific reports	2016	14
26964645	Calcium	Yang C	Integrative analysis of microRNA and mRNA expression profiles in non-small-cell lung cancer.	Cancer gene therapy	2016	11
26973249	Calcium	Vervliet T	Bcl-2 proteins and calcium signaling: complexity beneath the surface.	Oncogene	2016	19
27055244	Calcium	Wen Y	Pathway Network Analyses for Autism Reveal Multisystem Involvement, Major Overlaps with Other Diseases and Convergence upon MAPK and Calcium Signaling.	PloS one	2016	14
27055401	Calcium	Sakallƒ± √áetin E	Selenium potentiates the anticancer effect of cisplatin against oxidative stress and calcium ion signaling-induced intracellular toxicity in MCF-7 breast cancer cells: involvement of the TRPV1 channel.	Journal of receptor and signal transduction research	2017	5
27138568	Calcium	Tosatto A	The mitochondrial calcium uniporter regulates breast cancer progression via HIF-1Œ±.	EMBO molecular medicine	2016	18
27211800	Calcium	Rozpedek W	The Role of the PERK/eIF2Œ±/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress.	Current molecular medicine	2016	13
27252279	Calcium	White JP	TRPV4: Molecular Conductor of a Diverse Orchestra.	Physiological reviews	2016	21
27402544	Calcium	Doghman-Bouguerra M	FATE1 antagonizes calcium- and drug-induced apoptosis by uncoupling ER and mitochondria.	EMBO reports	2016	14
27662816	Calcium	Wimalawansa SJ	Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome.	The Journal of steroid biochemistry and molecular biology	2018	5
27864307	Calcium	Dahan T	Pancreatic Œ≤-Cells Express the Fetal Islet Hormone Gastrin in Rodent and Human Diabetes.	Diabetes	2017	5
28199303	Calcium	Gudipaty SA	Mechanical stretch triggers rapid epithelial cell division through Piezo1.	Nature	2017	25
28614305	Calcium	Bononi A	BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation.	Nature	2017	13
9776413	Lomustine	Cairncross JG	Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.	Journal of the National Cancer Institute	1998	190
10653879	Lomustine	Smith JS	Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.	Journal of clinical oncology 	2000	110
17827463	Lomustine	Stupp R	Chemoradiotherapy in malignant glioma: standard of care and future directions.	Journal of clinical oncology 	2007	118
20980335	Lomustine	Bogdahn U	Targeted therapy for high-grade glioma with the TGF-Œ≤2 inhibitor trabedersen: results of a randomized and controlled phase IIb study.	Neuro-oncology	2011	80
23071237	Lomustine	van den Bent MJ	Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.	Journal of clinical oncology 	2013	157
23095825	Lomustine	Weller M	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.	Neuro-oncology	2012	31
23269986	Lomustine	Erdem-Eraslan L	Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.	Journal of clinical oncology 	2013	26
24516018	Lomustine	Cairncross JG	Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.	Journal of clinical oncology 	2014	65
25529192	Lomustine	Rod√≥n J	Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-Œ≤ receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.	Investigational new drugs	2015	21
26354927	Lomustine	Dubbink HJ	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.	Neuro-oncology	2016	19
27370396	Lomustine	Wick W	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.	Neuro-oncology	2016	11
11506818	Epigallocatechin gallate	Surh YJ	Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation.	Mutation research	2001	191
15814656	Epigallocatechin gallate	Shimizu M	(-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.	Clinical cancer research 	2005	69
17341611	Epigallocatechin gallate	Aggarwal BB	Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution.	Annals of the New York Academy of Sciences	2006	107
17998943	Epigallocatechin gallate	Siddiqui IA	Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.	Oncogene	2008	56
19147572	Epigallocatechin gallate	Choi KC	Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation.	Cancer research	2009	73
19190249	Epigallocatechin gallate	Golden EB	Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.	Blood	2009	49
19269153	Epigallocatechin gallate	Tsang WP	Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells.	The Journal of nutritional biochemistry	2010	81
19542190	Epigallocatechin gallate	McLarty J	Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro.	Cancer prevention research	2009	67
20015867	Epigallocatechin gallate	Balasubramanian S	The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.	Carcinogenesis	2010	42
20423306	Epigallocatechin gallate	Li Y	Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components.	Current medicinal chemistry	2010	52
20718984	Epigallocatechin gallate	Tang SN	The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition.	Journal of molecular signaling	2010	42
20946668	Epigallocatechin gallate	Li Y	Synergistic epigenetic reactivation of estrogen receptor-Œ± (ERŒ±) by combined green tea polyphenol and histone deacetylase inhibitor in ERŒ±-negative breast cancer cells.	Molecular cancer	2010	42
21177307	Epigallocatechin gallate	Siddiqui IA	Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer.	FASEB journal 	2011	40
21209038	Epigallocatechin gallate	Nandakumar V	(-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells.	Carcinogenesis	2011	69
21796625	Epigallocatechin gallate	Tang SN	Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics.	International journal of cancer	2012	50
21798853	Epigallocatechin gallate	Choudhury SR	(-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells.	Carcinogenesis	2011	41
21827739	Epigallocatechin gallate	Singh BN	Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications.	Biochemical pharmacology	2011	171
21965273	Epigallocatechin gallate	Wang H	Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1Œ±.	Carcinogenesis	2011	45
23201840	Epigallocatechin gallate	Du GJ	Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea.	Nutrients	2012	33
23593078	Epigallocatechin gallate	Mirza S	Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins.	Journal of breast cancer	2013	29
24518414	Epigallocatechin gallate	Saldanha SN	Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate.	Experimental cell research	2014	22
24946050	Epigallocatechin gallate	Gupta SC	Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols.	Archives of biochemistry and biophysics	2014	30
25017900	Epigallocatechin gallate	Appari M	Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition.	International journal of oncology	2014	20
25550533	Epigallocatechin gallate	Chung SS	Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFŒ∫B signaling.	Anticancer research	2015	24
25865775	Epigallocatechin gallate	Casey SC	Cancer prevention and therapy through the modulation of the tumor microenvironment.	Seminars in cancer biology	2015	27
26184171	Epigallocatechin gallate	Scarpa ES	Phytochemicals as Innovative Therapeutic Tools against Cancer Stem Cells.	International journal of molecular sciences	2015	16
26930714	Epigallocatechin gallate	Toden S	Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer.	Oncotarget	2016	14
26933999	Epigallocatechin gallate	Yu CC	Suppression of miR-204 enables oral squamous cell carcinomas to promote cancer stemness, EMT traits, and lymph node metastasis.	Oncotarget	2016	15
27200496	Epigallocatechin gallate	Yuan CH	Epigallocatechin gallate sensitizes cisplatin-resistant oral cancer CAR cell apoptosis and autophagy through stimulating AKT/STAT3 pathway and suppressing multidrug resistance 1 signaling.	Environmental toxicology	2017	10
1348364	Glutathione	Godwin AK	High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.	Proceedings of the National Academy of Sciences of the United States of America	1992	151
1825028	Glutathione	Kaelin WG Jr	Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product.	Cell	1991	183
8635688	Glutathione	Sen CK	Antioxidant and redox regulation of gene transcription.	FASEB journal 	1996	194
9092542	Glutathione	Ali-Osman F	Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins.	The Journal of biological chemistry	1997	115
9143691	Glutathione	MacMicking J	Nitric oxide and macrophage function.	Annual review of immunology	1997	695
9245797	Glutathione	Dawson DW	CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.	The Journal of cell biology	1997	172
9636171	Glutathione	Taagepera S	Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase.	Proceedings of the National Academy of Sciences of the United States of America	1998	103
10377395	Glutathione	Jakobsson PJ	Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target.	Proceedings of the National Academy of Sciences of the United States of America	1999	171
10485474	Glutathione	McMenamin ME	Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.	Cancer research	1999	141
10657232	Glutathione	Mustacich D	Thioredoxin reductase.	The Biochemical journal	2000	150
10944550	Glutathione	Borst P	A family of drug transporters: the multidrug resistance-associated proteins.	Journal of the National Cancer Institute	2000	219
11535245	Glutathione	Strange RC	Glutathione-S-transferase family of enzymes.	Mutation research	2001	119
11724789	Glutathione	Frankel A	The novel human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying unique substrate specificity.	The Journal of biological chemistry	2002	98
11773443	Glutathione	Song RX	Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation.	Molecular endocrinology	2002	87
12177198	Glutathione	Sherer TB	An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.	The Journal of neuroscience 	2002	123
12750453	Glutathione	Gao N	The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes.	Molecular endocrinology	2003	77
14534679	Glutathione	Boulikas T	Cisplatin and platinum drugs at the molecular level. (Review).	Oncology reports	2003	95
14576844	Glutathione	Townsend DM	The role of glutathione-S-transferase in anti-cancer drug resistance.	Oncogene	2003	166
15054096	Glutathione	Wang S	Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways.	The Journal of biological chemistry	2004	97
15059885	Glutathione	Hussain SP	p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis.	Cancer research	2004	83
15313918	Glutathione	Myzak MC	A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.	Cancer research	2004	138
15764812	Glutathione	Singh SV	Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species.	The Journal of biological chemistry	2005	94
15822171	Glutathione	Hayes JD	Glutathione transferases.	Annual review of pharmacology and toxicology	2005	555
16103712	Glutathione	Luqmani YA	Mechanisms of drug resistance in cancer chemotherapy.	Medical principles and practice 	2005	72
16219905	Glutathione	Aggarwal S	Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation.	Molecular pharmacology	2006	104
16332662	Glutathione	Gasper AV	Glutathione S-transferase M1 polymorphism and metabolism of sulforaphane from standard and high-glucosinolate broccoli.	The American journal of clinical nutrition	2005	67
16550164	Glutathione	McIlwain CC	Glutathione S-transferase polymorphisms: cancer incidence and therapy.	Oncogene	2006	83
16573358	Glutathione	Finaud J	Oxidative stress : relationship with exercise and training.	Sports medicine	2006	60
16678271	Glutathione	K√ºhn H	Inflammation and immune regulation by 12/15-lipoxygenases.	Progress in lipid research	2006	122
16818657	Glutathione	Findlay VJ	A novel role for human sulfiredoxin in the reversal of glutathionylation.	Cancer research	2006	70
16959615	Glutathione	Trachootham D	Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.	Cancer cell	2006	294
17081103	Glutathione	Brigelius-Floh√© R	Glutathione peroxidases and redox-regulated transcription factors.	Biological chemistry	2006	63
17182830	Glutathione	Fang M	Dietary polyphenols may affect DNA methylation.	The Journal of nutrition	2007	92
17360173	Glutathione	Seifried HE	A review of the interaction among dietary antioxidants and reactive oxygen species.	The Journal of nutritional biochemistry	2007	79
17409182	Glutathione	Monteiller C	The pro-inflammatory effects of low-toxicity low-solubility particles, nanoparticles and fine particles, on epithelial cells in vitro: the role of surface area.	Occupational and environmental medicine	2007	72
17468103	Glutathione	Qanungo S	Glutathione supplementation potentiates hypoxic apoptosis by S-glutathionylation of p65-NFkappaB.	The Journal of biological chemistry	2007	57
17508906	Glutathione	Papp LV	From selenium to selenoproteins: synthesis, identity, and their role in human health.	Antioxidants & redox signaling	2007	170
17640917	Glutathione	Lu J	Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.	Proceedings of the National Academy of Sciences of the United States of America	2007	94
17804715	Glutathione	Yu YP	Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis.	Cancer research	2007	60
17878511	Glutathione	Samuelsson B	Membrane prostaglandin E synthase-1: a novel therapeutic target.	Pharmacological reviews	2007	117
17934516	Glutathione	Achour M	The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression.	Oncogene	2008	56
18158646	Glutathione	Franco R	The central role of glutathione in the pathophysiology of human diseases.	Archives of physiology and biochemistry	2007	86
18171934	Glutathione	Langley B	Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection.	The Journal of neuroscience 	2008	67
18367735	Glutathione	Levine S	Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans.	The New England journal of medicine	2008	201
18372916	Glutathione	Frohlich DA	The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis.	Oncogene	2008	58
18572023	Glutathione	Pi J	Arsenic-induced malignant transformation of human keratinocytes: involvement of Nrf2.	Free radical biology & medicine	2008	53
18574029	Glutathione	Trachootham D	Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.	Blood	2008	57
18626009	Glutathione	van der Brug MP	RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways.	Proceedings of the National Academy of Sciences of the United States of America	2008	82
18664505	Glutathione	Peng DF	DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma.	Gut	2009	54
18757362	Glutathione	Lu J	Selenoproteins.	The Journal of biological chemistry	2009	94
18829555	Glutathione	Singh A	RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.	Cancer research	2008	98
18937164	Glutathione	Surh YJ	Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals.	Planta medica	2008	136
18992769	Glutathione	Ganapathy V	Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond.	Pharmacology & therapeutics	2009	143
19029908	Glutathione	Vaughn AE	Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c.	Nature cell biology	2008	104
19236887	Glutathione	Liu J	Role of oxidative stress in cadmium toxicity and carcinogenesis.	Toxicology and applied pharmacology	2009	71
19246244	Glutathione	Hogstrand C	Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation.	Trends in molecular medicine	2009	55
19268692	Glutathione	Steinbrenner H	Protection against reactive oxygen species by selenoproteins.	Biochimica et biophysica acta	2009	54
19327385	Glutathione	Rayman MP	Selenoproteins and human health: insights from epidemiological data.	Biochimica et biophysica acta	2009	54
19417020	Glutathione	Homma S	Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.	Clinical cancer research 	2009	96
19508889	Glutathione	Kim S	Oxidative stress-dependent toxicity of silver nanoparticles in human hepatoma cells.	Toxicology in vitro 	2009	87
19519952	Glutathione	Lewis-Wambi JS	Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?	Breast cancer research 	2009	62
19608619	Glutathione	MacLeod AK	Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds.	Carcinogenesis	2009	70
19654295	Glutathione	Yodkeeree S	Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species.	Cancer research	2009	45
19788937	Glutathione	Shen J	Mitochondrial copy number and risk of breast cancer: a pilot study.	Mitochondrion	2010	44
20061377	Glutathione	Fourquet S	Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation.	The Journal of biological chemistry	2010	81
20124447	Glutathione	Zhang P	Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth.	Molecular cancer therapeutics	2010	112
20126446	Glutathione	Qin Z	Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress.	PLoS pathogens	2010	53
20596078	Glutathione	Laborde E	Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death.	Cell death and differentiation	2010	65
20855962	Glutathione	Martinez-Outschoorn UE	Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFŒ∫B activation in the tumor stromal microenvironment.	Cell cycle	2010	136
20924967	Glutathione	Goel A	Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs.	Nutrition and cancer	2010	83
20966874	Glutathione	Jung KA	The Nrf2 system as a potential target for the development of indirect antioxidants.	Molecules	2010	73
21071633	Glutathione	Indran IR	hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells.	Cancer research	2011	49
21087145	Glutathione	Lubos E	Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities.	Antioxidants & redox signaling	2011	86
21156786	Glutathione	Pathi SS	GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway.	Molecular cancer research 	2011	39
21194351	Glutathione	Brigelius-Floh√© R	Basic principles and emerging concepts in the redox control of transcription factors.	Antioxidants & redox signaling	2011	114
21216256	Glutathione	Kryston TB	Role of oxidative stress and DNA damage in human carcinogenesis.	Mutation research	2011	152
21289278	Glutathione	Reitman ZJ	Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.	Proceedings of the National Academy of Sciences of the United States of America	2011	164
21397861	Glutathione	Ishimoto T	CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth.	Cancer cell	2011	212
21402146	Glutathione	Tang X	Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs.	Free radical biology & medicine	2011	47
21445976	Glutathione	Cash HL	LINE-1 hypomethylation is associated with bladder cancer risk among nonsmoking Chinese.	International journal of cancer	2012	43
21632234	Glutathione	Chikkaveeraiah BV	Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum.	Biosensors & bioelectronics	2011	35
21750178	Glutathione	Lovejoy DB	Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes.	Cancer research	2011	44
21818590	Glutathione	Croker AK	Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44‚Å∫ human breast cancer cells.	Breast cancer research and treatment	2012	63
21964034	Glutathione	Morgan B	Measuring E(GSH) and H2O2 with roGFP2-based redox probes.	Free radical biology & medicine	2011	37
21985599	Glutathione	Marra M	Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview.	Journal of translational medicine	2011	46
22001757	Glutathione	Chambers JC	Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma.	Nature genetics	2011	141
22015945	Glutathione	Pope WB	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.	Journal of neuro-oncology	2012	62
22020111	Glutathione	Hybertson BM	Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation.	Molecular aspects of medicine	2011	120
22117045	Glutathione	Yin L	Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH.	Blood	2012	33
22138445	Glutathione	Backos DS	The role of glutathione in brain tumor drug resistance.	Biochemical pharmacology	2012	31
22293754	Glutathione	Tamada M	Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells.	Cancer research	2012	50
22448089	Glutathione	Ishii T	Novel roles of peroxiredoxins in inflammation, cancer and innate immunity.	Journal of clinical biochemistry and nutrition	2012	33
22525041	Glutathione	Crawford A	Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease.	Gene	2012	31
22667998	Glutathione	Lewerenz J	The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities.	Antioxidants & redox signaling	2013	100
22837425	Glutathione	Corominas-Faja B	Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.	Aging	2012	41
22854025	Glutathione	Galluzzi L	Prognostic impact of vitamin B6 metabolism in lung cancer.	Cell reports	2012	38
22887998	Glutathione	Wanka C	Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis.	The Journal of biological chemistry	2012	41
22934847	Glutathione	Mat√©s JM	Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer.	Current molecular medicine	2013	40
23123197	Glutathione	Wei PC	Loss of the oxidative stress sensor NPGPx compromises GRP78 chaperone activity and induces systemic disease.	Molecular cell	2012	33
23194063	Glutathione	Gandhy SU	Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs.	BMC cancer	2012	30
23201771	Glutathione	Brigelius-Floh√© R	Glutathione peroxidases.	Biochimica et biophysica acta	2013	137
23221387	Glutathione	Barrett CW	Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma.	Cancer research	2013	31
23242140	Glutathione	Maddocks OD	Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells.	Nature	2013	159
23322302	Glutathione	Nicolay BN	Loss of RBF1 changes glutamine catabolism.	Genes & development	2013	36
23334333	Glutathione	Nagano O	Redox regulation in stem-like cancer cells by CD44 variant isoforms.	Oncogene	2013	62
23535601	Glutathione	Son J	Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway.	Nature	2013	342
23747014	Glutathione	Sullivan LB	The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling.	Molecular cell	2013	66
23752353	Glutathione	Yang L	Fucoidan derived from Undaria pinnatifida induces apoptosis in human hepatocellular carcinoma SMMC-7721 cells via the ROS-mediated mitochondrial pathway.	Marine drugs	2013	25
23824744	Glutathione	Huang Q	Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics.	Cancer research	2013	60
24031087	Glutathione	Dey P	Insight into the mechanisms of action of estrogen receptor Œ≤ in the breast, prostate, colon, and CNS.	Journal of molecular endocrinology	2013	26
24089526	Glutathione	Pei S	Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells.	The Journal of biological chemistry	2013	40
24292713	Glutathione	Glasauer A	Targeting SOD1 reduces experimental non‚Äìsmall-cell lung cancer.	The Journal of clinical investigation	2014	31
24297161	Glutathione	Dunbar EM	Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.	Investigational new drugs	2014	31
24334253	Glutathione	Evans MK	Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death.	Free radical biology & medicine	2014	21
24516043	Glutathione	Drayton RM	Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.	Clinical cancer research 	2014	33
24523301	Glutathione	Gross MI	Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.	Molecular cancer therapeutics	2014	113
24633012	Glutathione	Yamamoto T	Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway.	Nature communications	2014	29
24637114	Glutathione	Pekovic-Vaughan V	The circadian clock regulates rhythmic activation of the NRF2/glutathione-mediated antioxidant defense pathway to modulate pulmonary fibrosis.	Genes & development	2014	44
24692350	Glutathione	Bhattacharyya A	Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases.	Physiological reviews	2014	99
24778250	Glutathione	Pader I	Thioredoxin-related protein of 14 kDa is an efficient L-cystine reductase and S-denitrosylase.	Proceedings of the National Academy of Sciences of the United States of America	2014	21
24913818	Glutathione	Egner PA	Rapid and sustainable detoxication of airborne pollutants by broccoli sprout beverage: results of a randomized clinical trial in China.	Cancer prevention research	2014	32
25002527	Glutathione	Ye P	Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition.	Molecular and cellular biology	2014	24
25006124	Glutathione	Tessoulin B	PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.	Blood	2014	26
25091696	Glutathione	Tang X	A joint analysis of metabolomics and genetics of breast cancer.	Breast cancer research 	2014	33
25159108	Glutathione	Yager JD	Mechanisms of estrogen carcinogenesis: The role of E2/E1-quinone metabolites suggests new approaches to preventive intervention--A review.	Steroids	2015	22
25229745	Glutathione	D'Alessandro A	Metabolic effect of TAp63Œ±: enhanced glycolysis and pentose phosphate pathway, resulting in increased antioxidant defense.	Oncotarget	2014	25
25283382	Glutathione	Shi J	Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.	Tumour biology 	2015	22
25364233	Glutathione	Wang YY	Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.	Drug design, development and therapy	2014	24
25524627	Glutathione	Li J	Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells.	Proceedings of the National Academy of Sciences of the United States of America	2015	17
25589789	Glutathione	Schmidt A	Non-thermal plasma activates human keratinocytes by stimulation of antioxidant and phase II pathways.	The Journal of biological chemistry	2015	17
25607840	Glutathione	Sellers K	Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation.	The Journal of clinical investigation	2015	84
25723170	Glutathione	Oshimori N	TGF-Œ≤ promotes heterogeneity and drug resistance in squamous cell carcinoma.	Cell	2015	58
25749517	Glutathione	Hambright HG	Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells.	Oncotarget	2015	15
25793315	Glutathione	Sun L	cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions.	Cell research	2015	20
25798841	Glutathione	Sleire L	Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion.	Oncogene	2015	17
25834400	Glutathione	Pan ST	Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells.	Drug design, development and therapy	2015	18
25912260	Glutathione	Zuo L	Biological and physiological role of reactive oxygen species--the good, the bad and the ugly.	Acta physiologica	2015	28
25937369	Glutathione	Dannenmann B	High glutathione and glutathione peroxidase-2 levels mediate cell-type-specific DNA damage protection in human induced pluripotent stem cells.	Stem cell reports	2015	17
25952651	Glutathione	Wettersten HI	Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.	Cancer research	2015	30
26019222	Glutathione	Robert SM	SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma.	Science translational medicine	2015	19
26122708	Glutathione	Tebay LE	Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.	Free radical biology & medicine	2015	58
26482881	Glutathione	DeNicola GM	NRF2 regulates serine biosynthesis in non-small cell lung cancer.	Nature genetics	2015	70
26491296	Glutathione	Gurunathan S	Reduced graphene oxide-silver nanoparticle nanocomposite: a potential anticancer nanotherapy.	International journal of nanomedicine	2015	17
26541605	Glutathione	Yun J	Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.	Science	2015	73
26669865	Glutathione	Emir UE	Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.	Cancer research	2016	19
26792059	Glutathione	Amir Aslani B	Studies on oxidants and antioxidants with a brief glance at their relevance to the immune system.	Life sciences	2016	13
26844296	Glutathione	D√≥ka √â	A novel persulfide detection method reveals protein persulfide- and polysulfide-reducing functions of thioredoxin and glutathione systems.	Science advances	2016	20
26890363	Glutathione	Manz DH	Iron and cancer: recent insights.	Annals of the New York Academy of Sciences	2016	11
27015352	Glutathione	Sun X	Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.	Hepatology	2016	14
27055559	Glutathione	Shitara K	Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205).	Gastric cancer 	2017	11
27072394	Glutathione	Ser HL	Streptomyces malaysiense sp. nov.: A novel Malaysian mangrove soil actinobacterium with antioxidative activity and cytotoxic potential against human cancer cell lines.	Scientific reports	2016	11
27113762	Glutathione	Zhou L	SIRT5 promotes IDH2 desuccinylation and G6PD deglutarylation to enhance cellular antioxidant defense.	EMBO reports	2016	12
27133165	Glutathione	Wang W	Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.	Cell	2016	23
27193186	Glutathione	Zheng ZG	The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer.	Scientific reports	2016	15
27245224	Glutathione	Peir√≥ C	Inflammation, glucose, and vascular cell damage: the role of the pentose phosphate pathway.	Cardiovascular diabetology	2016	11
27477511	Glutathione	Chio IIC	NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer.	Cell	2016	29
27628030	Glutathione	Mehmood T	Deoxyelephantopin induces apoptosis in HepG2 cells via oxidative stress, NF-Œ∫B inhibition and mitochondrial dysfunction.	BioFactors	2017	6
27878243	Glutathione	H√§ggblad Sahlberg S	Different functions of AKT1 and AKT2 in molecular pathways, cell migration and metabolism in colon cancer cells.	International journal of oncology	2017	6
28007895	Glutathione	Semenza GL	Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of¬†the breast cancer stem cell phenotype.	The EMBO journal	2017	12
28017891	Glutathione	Xie Y	Self-immolative nanoparticles for simultaneous delivery of microRNA and targeting of polyamine metabolism in combination cancer therapy.	Journal of controlled release 	2017	7
28551354	Glutathione	Poprac P	Targeting Free Radicals in Oxidative Stress-Related Human Diseases.	Trends in pharmacological sciences	2017	10
1279431	Oxygen	Shweiki D	Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.	Nature	1992	672
1846317	Oxygen	Szatrowski TP	Production of large amounts of hydrogen peroxide by human tumor cells.	Cancer research	1991	409
8770536	Oxygen	Hayes JD	The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance.	Critical reviews in biochemistry and molecular biology	1995	479
8790408	Oxygen	Lebovitz RM	Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice.	Proceedings of the National Academy of Sciences of the United States of America	1996	226
8811177	Oxygen	Wood RD	DNA repair in eukaryotes.	Annual review of biochemistry	1996	133
8855223	Oxygen	Iliopoulos O	Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.	Proceedings of the National Academy of Sciences of the United States of America	1996	170
9192621	Oxygen	Shim H	c-Myc transactivation of LDH-A: implications for tumor metabolism and growth.	Proceedings of the National Academy of Sciences of the United States of America	1997	249
9207108	Oxygen	Rosenquist TA	Cloning and characterization of a mammalian 8-oxoguanine DNA glycosylase.	Proceedings of the National Academy of Sciences of the United States of America	1997	105
9741580	Oxygen	Wink DA	Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide.	Free radical biology & medicine	1998	161
9840812	Oxygen	Gu YZ	Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha.	Gene expression	1998	111
10398599	Oxygen	Dawson DW	Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.	Science	1999	303
10517533	Oxygen	Hayes JD	Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress.	Free radical research	1999	217
10551817	Oxygen	Richard DE	p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1.	The Journal of biological chemistry	1999	155
10581086	Oxygen	Jones MK	Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.	Nature medicine	1999	105
10640274	Oxygen	Ravi R	Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.	Genes & development	2000	226
10657297	Oxygen	Baysal BE	Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma.	Science	2000	304
10699287	Oxygen	Maeda H	Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.	Journal of controlled release 	2000	796
10759556	Oxygen	Kuraoka I	Removal of oxygen free-radical-induced 5',8-purine cyclodeoxynucleosides from DNA by the nucleotide excision-repair pathway in human cells.	Proceedings of the National Academy of Sciences of the United States of America	2000	92
10775435	Oxygen	Boiteux S	The human OGG1 gene: structure, functions, and its implication in the process of carcinogenesis.	Archives of biochemistry and biophysics	2000	92
10823814	Oxygen	Osthus RC	Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc.	The Journal of biological chemistry	2000	200
10823831	Oxygen	Cockman ME	Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.	The Journal of biological chemistry	2000	216
10843709	Oxygen	Manna SK	Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation.	Journal of immunology	2000	133
10910033	Oxygen	Hussain SP	Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease.	Cancer research	2000	102
11015506	Oxygen	Costeloe K	The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability.	Pediatrics	2000	100
11034104	Oxygen	Lee CG	Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.	Cancer research	2000	118
11292862	Oxygen	Ivan M	HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.	Science	2001	1056
11306467	Oxygen	Aebersold DM	Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer.	Cancer research	2001	109
11331612	Oxygen	Hoffman MA	von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.	Human molecular genetics	2001	91
11376945	Oxygen	Cheng G	Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5.	Gene	2001	220
11507045	Oxygen	Fukumura D	Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo.	Cancer research	2001	91
11516994	Oxygen	Semenza GL	Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology.	Trends in molecular medicine	2001	162
11522632	Oxygen	Loncaster JA	Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix.	Cancer research	2001	103
11535817	Oxygen	Ruefli AA	The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.	Proceedings of the National Academy of Sciences of the United States of America	2001	113
11590433	Oxygen	Hwang PM	Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells.	Nature medicine	2001	91
11691837	Oxygen	Schipani E	Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival.	Genes & development	2001	189
11832451	Oxygen	Okuda M	Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein.	Gastroenterology	2002	204
11904416	Oxygen	Hazra TK	Identification and characterization of a human DNA glycosylase for repair of modified bases in oxidatively damaged DNA.	Proceedings of the National Academy of Sciences of the United States of America	2002	172
11927290	Oxygen	Semenza GL	HIF-1 and tumor progression: pathophysiology and therapeutics.	Trends in molecular medicine	2002	183
11943784	Oxygen	Lu H	Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis.	The Journal of biological chemistry	2002	157
12004076	Oxygen	Min JH	Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling.	Science	2002	172
12011461	Oxygen	J√∂gi A	Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype.	Proceedings of the National Academy of Sciences of the United States of America	2002	104
12020670	Oxygen	Farrow B	Inflammation and the development of pancreatic cancer.	Surgical oncology	2002	93
12086861	Oxygen	Maranchie JK	The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.	Cancer cell	2002	130
12154035	Oxygen	Rapisarda A	Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.	Cancer research	2002	102
12209156	Oxygen	Kaelin WG Jr	Molecular basis of the VHL hereditary cancer syndrome.	Nature reviews. Cancer	2002	193
12242281	Oxygen	Hudson CC	Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.	Molecular and cellular biology	2002	270
12351678	Oxygen	Ivan M	Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor.	Proceedings of the National Academy of Sciences of the United States of America	2002	142
12509294	Oxygen	Barzilai A	ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage.	DNA repair	2002	91
12519769	Oxygen	Hammond EM	ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation.	The Journal of biological chemistry	2003	75
12600231	Oxygen	Dent P	Stress and radiation-induced activation of multiple intracellular signaling pathways.	Radiation research	2003	109
12615973	Oxygen	Metzen E	Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing.	Journal of cell science	2003	94
12671019	Oxygen	Yeo EJ	YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.	Journal of the National Cancer Institute	2003	89
12711606	Oxygen	Takada Y	Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase.	The Journal of biological chemistry	2003	87
12748298	Oxygen	Okano S	Spatial and temporal cellular responses to single-strand breaks in human cells.	Molecular and cellular biology	2003	113
12821280	Oxygen	Ichihashi M	UV-induced skin damage.	Toxicology	2003	101
12821677	Oxygen	Ling YH	Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells.	The Journal of biological chemistry	2003	101
12839953	Oxygen	Rosato RR	The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.	Cancer research	2003	113
12912907	Oxygen	Berra E	HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia.	The EMBO journal	2003	333
12921773	Oxygen	Ohshima H	Chemical basis of inflammation-induced carcinogenesis.	Archives of biochemistry and biophysics	2003	90
14526383	Oxygen	Giaccia A	HIF-1 as a target for drug development.	Nature reviews. Drug discovery	2003	123
14580780	Oxygen	Waisberg M	Molecular and cellular mechanisms of cadmium carcinogenesis.	Toxicology	2003	138
14597738	Oxygen	Schioppa T	Regulation of the chemokine receptor CXCR4 by hypoxia.	The Journal of experimental medicine	2003	193
14610616	Oxygen	Hileman EO	Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity.	Cancer chemotherapy and pharmacology	2004	72
14645546	Oxygen	Hu CJ	Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation.	Molecular and cellular biology	2003	356
14691554	Oxygen	Kondo K	Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth.	PLoS biology	2003	197
14744246	Oxygen	Klaunig JE	The role of oxidative stress in carcinogenesis.	Annual review of pharmacology and toxicology	2004	257
14985465	Oxygen	Zimmer M	Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.	Molecular cancer research 	2004	82
15073169	Oxygen	Singh SV	Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C.	The Journal of biological chemistry	2004	71
15104534	Oxygen	Marxsen JH	Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.	The Biochemical journal	2004	80
15126346	Oxygen	Xie Y	Deficiencies in mouse Myh and Ogg1 result in tumor predisposition and G to T mutations in codon 12 of the K-ras oncogene in lung tumors.	Cancer research	2004	73
15150115	Oxygen	Mitsushita J	The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation.	Cancer research	2004	77
15155719	Oxygen	Vaquero EC	Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells.	The Journal of biological chemistry	2004	98
15173093	Oxygen	Pei XY	Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.	Clinical cancer research 	2004	102
15297389	Oxygen	De Larco JE	The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8.	Clinical cancer research 	2004	72
15315937	Oxygen	Higgins DF	Hypoxic induction of Ctgf is directly mediated by Hif-1.	American journal of physiology. Renal physiology	2004	83
15389790	Oxygen	Lim SD	Increased Nox1 and hydrogen peroxide in prostate cancer.	The Prostate	2005	85
15489221	Oxygen	Kurz EU	Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species.	The Journal of biological chemistry	2004	83
15509775	Oxygen	Fribley A	Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.	Molecular and cellular biology	2004	145
15544038	Oxygen	Ushio-Fukai M	Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase.	Molecular and cellular biochemistry	2004	106
15591418	Oxygen	Vaupel P	The role of hypoxia-induced factors in tumor progression.	The oncologist	2004	136
15611513	Oxygen	Kim WY	Role of VHL gene mutation in human cancer.	Journal of clinical oncology 	2004	224
15647368	Oxygen	Petros JA	mtDNA mutations increase tumorigenicity in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2005	249
15802268	Oxygen	Phillips RJ	Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha.	The Journal of biological chemistry	2005	95
15811878	Oxygen	Komarova EA	p53 is a suppressor of inflammatory response in mice.	FASEB journal 	2005	70
15879598	Oxygen	Fang J	Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity.	The Journal of biological chemistry	2005	70
15952883	Oxygen	Kaelin WG	Proline hydroxylation and gene expression.	Annual review of biochemistry	2005	118
15964800	Oxygen	Dai Y	Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.	Molecular and cellular biology	2005	70
15978720	Oxygen	Sarkar D	Molecular mechanisms of aging-associated inflammation.	Cancer letters	2006	79
15987702	Oxygen	Pollard PJ	Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.	Human molecular genetics	2005	207
15994012	Oxygen	B√°rdos JI	Negative and positive regulation of HIF-1: a complex network.	Biochimica et biophysica acta	2005	77
16002209	Oxygen	Zhou J	Tumor hypoxia and cancer progression.	Cancer letters	2006	70
16006525	Oxygen	Eggler AL	Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2.	Proceedings of the National Academy of Sciences of the United States of America	2005	121
16054088	Oxygen	Mansfield KD	Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation.	Cell metabolism	2005	191
16141358	Oxygen	Hunyady L	Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II.	Molecular endocrinology	2006	121
16153592	Oxygen	Kaelin WG Jr	The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing.	Biochemical and biophysical research communications	2005	67
16163384	Oxygen	Achanta G	Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma.	The EMBO journal	2005	99
16166325	Oxygen	Ramanathan B	Resistance to paclitaxel is proportional to cellular total antioxidant capacity.	Cancer research	2005	66
16290020	Oxygen	Kang SW	2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications.	Trends in molecular medicine	2005	77
16294028	Oxygen	Desouki MM	Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors.	Cancer biology & therapy	2005	66
16301830	Oxygen	Carmeliet P	VEGF as a key mediator of angiogenesis in cancer.	Oncology	2005	195
16301831	Oxygen	Ferrara N	VEGF as a therapeutic target in cancer.	Oncology	2005	112
16417408	Oxygen	Chi JT	Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers.	PLoS medicine	2006	195
16446448	Oxygen	Vartanian V	The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase.	Proceedings of the National Academy of Sciences of the United States of America	2006	80
16455479	Oxygen	Boffetta P	Alcohol and cancer.	The Lancet. Oncology	2006	150
16456579	Oxygen	Papa S	The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease.	Cell death and differentiation	2006	70
16473865	Oxygen	Yang SR	Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages.	American journal of physiology. Lung cellular and molecular physiology	2006	136
16495339	Oxygen	Pedram A	Functional estrogen receptors in the mitochondria of breast cancer cells.	Molecular biology of the cell	2006	80
16513837	Oxygen	Cairns R	Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment.	Molecular cancer research 	2006	74
16517406	Oxygen	Papandreou I	HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption.	Cell metabolism	2006	501
16517740	Oxygen	Gersuk GM	Dectin-1 and TLRs permit macrophages to distinguish between different Aspergillus fumigatus cellular states.	Journal of immunology	2006	110
16532036	Oxygen	Mochizuki T	Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells.	Oncogene	2006	75
16585181	Oxygen	Esteban MA	Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.	Cancer research	2006	85
16585195	Oxygen	Dayan F	The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha.	Cancer research	2006	67
16642001	Oxygen	Erler JT	Lysyl oxidase is essential for hypoxia-induced metastasis.	Nature	2006	431
16648488	Oxygen	Connolly E	Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells.	Molecular and cellular biology	2006	65
16707454	Oxygen	Chaj√®s V	Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival.	Cancer research	2006	78
16716598	Oxygen	Hirota K	Regulation of angiogenesis by hypoxia-inducible factor 1.	Critical reviews in oncology/hematology	2006	122
16724053	Oxygen	Shaw RJ	Ras, PI(3)K and mTOR signalling controls tumour cell growth.	Nature	2006	571
16724055	Oxygen	Pouyss√©gur J	Hypoxia signalling in cancer and approaches to enforce tumour regression.	Nature	2006	405
16728594	Oxygen	Matoba S	p53 regulates mitochondrial respiration.	Science	2006	485
16740701	Oxygen	Aprelikova O	Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection.	Cancer research	2006	66
16754882	Oxygen	Basile JR	Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2006	75
16839880	Oxygen	Bensaad K	TIGAR, a p53-inducible regulator of glycolysis and apoptosis.	Cell	2006	533
16847054	Oxygen	Peng XH	Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression.	The Journal of biological chemistry	2006	72
16850162	Oxygen	Hail N Jr	Mechanisms of fenretinide-induced apoptosis.	Apoptosis 	2006	61
16857678	Oxygen	Djavaheri-Mergny M	NF-kappaB activation represses tumor necrosis factor-alpha-induced autophagy.	The Journal of biological chemistry	2006	139
16861899	Oxygen	Fels DR	The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth.	Cancer biology & therapy	2006	91
16899602	Oxygen	Generali D	Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.	Clinical cancer research 	2006	78
16970222	Oxygen	Alvarez RH	Biology of platelet-derived growth factor and its involvement in disease.	Mayo Clinic proceedings	2006	70
17072325	Oxygen	Bubici C	Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance.	Oncogene	2006	113
17084552	Oxygen	Blazek ER	Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia.	International journal of radiation oncology, biology, physics	2007	60
17160708	Oxygen	Wu WS	The signaling mechanism of ROS in tumor progression.	Cancer metastasis reviews	2006	175
17182618	Oxygen	Koivunen P	Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF.	The Journal of biological chemistry	2007	124
17208433	Oxygen	Gordan JD	Hypoxia-inducible factors: central regulators of the tumor phenotype.	Current opinion in genetics & development	2007	157
17220275	Oxygen	Yan Q	The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo.	Molecular and cellular biology	2007	62
17222355	Oxygen	Hebert C	High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma.	Molecular cancer	2007	122
17234762	Oxygen	Kim YJ	Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology.	Cancer research	2007	65
17255293	Oxygen	Kaelin WG Jr	The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.	Clinical cancer research 	2007	88
17279683	Oxygen	Cho SJ	Long-term exposure to CdTe quantum dots causes functional impairments in live cells.	Langmuir 	2007	67
17284606	Oxygen	Gruber M	Acute postnatal ablation of Hif-2alpha results in anemia.	Proceedings of the National Academy of Sciences of the United States of America	2007	157
17289868	Oxygen	Fruehauf JP	Reactive oxygen species: a breath of life or death?	Clinical cancer research 	2007	207
17292829	Oxygen	Dolado I	p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis.	Cancer cell	2007	115
17303406	Oxygen	Bengoechea-Alonso MT	SREBP in signal transduction: cholesterol metabolism and beyond.	Current opinion in cell biology	2007	61
17363476	Oxygen	Valerie K	Radiation-induced cell signaling: inside-out and outside-in.	Molecular cancer therapeutics	2007	115
17401425	Oxygen	Hussain SP	TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.	Oncogene	2007	116
17404109	Oxygen	Puri N	c-Met is a potentially new therapeutic target for treatment of human melanoma.	Clinical cancer research 	2007	63
17440056	Oxygen	Alexandre J	Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species.	Cancer research	2007	82
17482542	Oxygen	Keith B	Hypoxia-inducible factors, stem cells, and cancer.	Cell	2007	333
17494630	Oxygen	Schoner W	Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth.	American journal of physiology. Cell physiology	2007	123
17513612	Oxygen	Han W	Shikonin circumvents cancer drug resistance by induction of a necroptotic death.	Molecular cancer therapeutics	2007	78
17545622	Oxygen	De Milito A	Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species.	Cancer research	2007	67
17551816	Oxygen	Semenza GL	HIF-1 mediates the Warburg effect in clear cell renal carcinoma.	Journal of bioenergetics and biomembranes	2007	80
17595539	Oxygen	Airley RE	Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics.	Chemotherapy	2007	66
17603752	Oxygen	Liao D	Hypoxia: a key regulator of angiogenesis in cancer.	Cancer metastasis reviews	2007	177
17643088	Oxygen	Jain RK	Angiogenesis in brain tumours.	Nature reviews. Neuroscience	2007	335
17704323	Oxygen	Zhao W	Oxidative damage pathways in relation to normal tissue injury.	The British journal of radiology	2007	56
17785204	Oxygen	Gao P	HIF-dependent antitumorigenic effect of antioxidants in vivo.	Cancer cell	2007	173
17786216	Oxygen	Matouk IJ	The H19 non-coding RNA is essential for human tumor growth.	PloS one	2007	185
17873906	Oxygen	Gort EH	The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha.	Oncogene	2008	51
17875751	Oxygen	Talmadge JE	Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy.	Clinical cancer research 	2007	82
17893868	Oxygen	Federico A	Chronic inflammation and oxidative stress in human carcinogenesis.	International journal of cancer	2007	165
17916722	Oxygen	Semenza GL	Life with oxygen.	Science	2007	169
17917680	Oxygen	Chen Y	Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells.	Cell death and differentiation	2008	131
17967865	Oxygen	Guzy RD	Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis.	Molecular and cellular biology	2008	113
17996713	Oxygen	Braunstein S	A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer.	Molecular cell	2007	91
17998060	Oxygen	Brown JM	Tumor hypoxia in cancer therapy.	Methods in enzymology	2007	69
18006827	Oxygen	Xia C	Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor.	Cancer research	2007	122
18032788	Oxygen	Chen Y	Mitochondrial electron-transport-chain inhibitors of complexes I and II induce autophagic cell death mediated by reactive oxygen species.	Journal of cell science	2007	130
18059169	Oxygen	Azad MB	Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3.	Autophagy	2008	93
18157161	Oxygen	Shrivastav M	Regulation of DNA double-strand break repair pathway choice.	Cell research	2008	339
18192505	Oxygen	Sallmyr A	Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML.	Blood	2008	79
18193093	Oxygen	Courtois-Cox S	Many roads lead to oncogene-induced senescence.	Oncogene	2008	115
18199558	Oxygen	Chan N	Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance.	Cancer research	2008	72
18259201	Oxygen	Weidemann A	Biology of HIF-1alpha.	Cell death and differentiation	2008	173
18264786	Oxygen	Legg JA	Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration.	Angiogenesis	2008	54
18281474	Oxygen	Furuta E	Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1.	Cancer research	2008	91
18295553	Oxygen	Akbari M	Mitochondrial base excision repair of uracil and AP sites takes place by single-nucleotide insertion and long-patch DNA synthesis.	DNA repair	2008	58
18339858	Oxygen	Kumar B	Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype.	Cancer research	2008	157
18394557	Oxygen	Duran A	The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis.	Cancer cell	2008	181
18406051	Oxygen	Ushio-Fukai M	Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy.	Cancer letters	2008	133
18413749	Oxygen	Derdak Z	The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells.	Cancer research	2008	56
18452647	Oxygen	Shibuya M	Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.	BMB reports	2008	53
18463161	Oxygen	Gianni D	The involvement of the tyrosine kinase c-Src in the regulation of reactive oxygen species generation mediated by NADPH oxidase-1.	Molecular biology of the cell	2008	53
18485806	Oxygen	Kundu JK	Inflammation: gearing the journey to cancer.	Mutation research	2008	150
18500244	Oxygen	Dewhirst MW	Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response.	Nature reviews. Cancer	2008	212
18511948	Oxygen	Fagerholm R	NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.	Nature genetics	2008	78
18524993	Oxygen	Sallmyr A	Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks.	Blood	2008	57
18535813	Oxygen	Bidlingmaier S	The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.	Journal of molecular medicine	2008	83
18541534	Oxygen	McFate T	Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells.	The Journal of biological chemistry	2008	96
18596824	Oxygen	Ellis LM	VEGF-targeted therapy: mechanisms of anti-tumour activity.	Nature reviews. Cancer	2008	387
18616529	Oxygen	Fujii S	Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome.	Cancer science	2008	65
18635960	Oxygen	Yang MH	TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development.	Cell cycle	2008	80
18682599	Oxygen	Mantegazza AR	NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells.	Blood	2008	78
18709470	Oxygen	Yang H	Mesothelioma epidemiology, carcinogenesis, and pathogenesis.	Current treatment options in oncology	2008	58
18791199	Oxygen	Cannito S	Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells.	Carcinogenesis	2008	91
18795165	Oxygen	Pacurari M	Raw single-wall carbon nanotubes induce oxidative stress and activate MAPKs, AP-1, NF-kappaB, and Akt in normal and malignant human mesothelial cells.	Environmental health perspectives	2008	57
18801366	Oxygen	Lim SO	Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter.	Gastroenterology	2008	80
18809331	Oxygen	Yee Koh M	HIF-1 regulation: not so easy come, easy go.	Trends in biochemical sciences	2008	99
18838554	Oxygen	Degtyarev M	Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents.	The Journal of cell biology	2008	157
18922898	Oxygen	Sun Y	The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents.	Cancer research	2008	55
18924608	Oxygen	Bedogni B	Notch1 is an effector of Akt and hypoxia in melanoma development.	The Journal of clinical investigation	2008	72
18941752	Oxygen	Owen MR	Angiogenesis and vascular remodelling in normal and cancerous tissues.	Journal of mathematical biology	2009	49
18955971	Oxygen	Boya P	Lysosomal membrane permeabilization in cell death.	Oncogene	2008	259
18979503	Oxygen	Tonissen KF	Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.	Molecular nutrition & food research	2009	48
18981219	Oxygen	Bencokova Z	ATM activation and signaling under hypoxic conditions.	Molecular and cellular biology	2009	57
19018762	Oxygen	Toyokuni S	Role of iron in carcinogenesis: cancer as a ferrotoxic disease.	Cancer science	2009	75
19033663	Oxygen	Sonveaux P	Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice.	The Journal of clinical investigation	2008	332
19047340	Oxygen	Hori M	Oxidative stress and left ventricular remodelling after myocardial infarction.	Cardiovascular research	2009	95
19088044	Oxygen	Kusmartsev S	Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.	Clinical cancer research 	2008	87
19098000	Oxygen	Harada H	The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors.	The Journal of biological chemistry	2009	48
19112107	Oxygen	Martin D	CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex.	The Journal of biological chemistry	2009	94
19114105	Oxygen	Semenza GL	Regulation of cancer cell metabolism by hypoxia-inducible factor 1.	Seminars in cancer biology	2009	132
19118006	Oxygen	Cano CE	Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function.	Cancer research	2009	46
19118902	Oxygen	Wiesen JL	Dicer is regulated by cellular stresses and interferons.	Molecular immunology	2009	66
19139406	Oxygen	Gruhne B	The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species.	Proceedings of the National Academy of Sciences of the United States of America	2009	73
19190247	Oxygen	Lucas DM	The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.	Blood	2009	55
19252501	Oxygen	Wang Y	Regulation of endocytosis via the oxygen-sensing pathway.	Nature medicine	2009	74
19255431	Oxygen	Xia X	Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis.	Proceedings of the National Academy of Sciences of the United States of America	2009	124
19265193	Oxygen	Yamaguchi H	p53 acetylation is crucial for its transcription-independent proapoptotic functions.	The Journal of biological chemistry	2009	50
19273217	Oxygen	Wittchen ES	Endothelial signaling in paracellular and transcellular leukocyte transmigration.	Frontiers in bioscience	2009	48
19276355	Oxygen	Yamaura M	NADPH oxidase 4 contributes to transformation phenotype of melanoma cells by regulating G2-M cell cycle progression.	Cancer research	2009	58
19281826	Oxygen	Roberts CK	Oxidative stress and metabolic syndrome.	Life sciences	2009	114
19359588	Oxygen	Zhao S	Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.	Science	2009	301
19362020	Oxygen	Allen IC	The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA.	Immunity	2009	310
19372578	Oxygen	McCord AM	Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.	Molecular cancer research 	2009	70
19383922	Oxygen	Kopetz S	Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.	Cancer research	2009	48
19413947	Oxygen	Lebedeva MA	Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis.	Biochimica et biophysica acta	2009	62
19459851	Oxygen	Kizaka-Kondoh S	Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia.	Cancer science	2009	46
19470762	Oxygen	Sudarshan S	Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species.	Molecular and cellular biology	2009	78
19479945	Oxygen	Ruan K	Role of hypoxia in the hallmarks of human cancer.	Journal of cellular biochemistry	2009	96
19493276	Oxygen	Kamata T	Roles of Nox1 and other Nox isoforms in cancer development.	Cancer science	2009	49
19505186	Oxygen	Sarsour EH	Redox control of the cell cycle in health and disease.	Antioxidants & redox signaling	2009	79
19524509	Oxygen	Mathew R	Autophagy suppresses tumorigenesis through elimination of p62.	Cell	2009	502
19633358	Oxygen	Monaghan-Benson E	The regulation of vascular endothelial growth factor-induced microvascular permeability requires Rac and reactive oxygen species.	The Journal of biological chemistry	2009	69
19648934	Oxygen	Dansen TB	Redox-sensitive cysteines bridge p300/CBP-mediated acetylation and FoxO4 activity.	Nature chemical biology	2009	61
19652553	Oxygen	Zhang Z	MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.	Cell cycle	2009	101
19674190	Oxygen	Onnis B	Development of HIF-1 inhibitors for cancer therapy.	Journal of cellular and molecular medicine	2009	79
19686841	Oxygen	Kahle PJ	DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders.	Free radical biology & medicine	2009	79
19689405	Oxygen	Mar√≠n-Hern√°ndez A	HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms.	Mini reviews in medicinal chemistry	2009	80
19696738	Oxygen	Park HJ	FoxM1, a critical regulator of oxidative stress during oncogenesis.	The EMBO journal	2009	72
19706526	Oxygen	Bertout JA	HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses.	Proceedings of the National Academy of Sciences of the United States of America	2009	59
19713938	Oxygen	Bensaad K	Modulation of intracellular ROS levels by TIGAR controls autophagy.	The EMBO journal	2009	101
19718046	Oxygen	Soeda A	Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.	Oncogene	2009	169
19718051	Oxygen	Gruhne B	Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints.	Oncogene	2009	49
19732782	Oxygen	Kwak MK	Targeting NRF2 signaling for cancer chemoprevention.	Toxicology and applied pharmacology	2010	89
19755709	Oxygen	Diaz B	Tks5-dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formation.	Science signaling	2009	80
19756672	Oxygen	Muthusamy V	The UV response of the skin: a review of the MAPK, NFkappaB and TNFalpha signal transduction pathways.	Archives of dermatological research	2010	41
19770585	Oxygen	Heddleston JM	The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.	Cell cycle	2009	220
19786027	Oxygen	Xue J	Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity.	Gastroenterology	2010	42
19844232	Oxygen	Lundgren K	Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer.	British journal of cancer	2009	47
19845620	Oxygen	Taylor CT	The role of NF-kappaB in hypoxia-induced gene expression.	Annals of the New York Academy of Sciences	2009	46
19858293	Oxygen	Krieg AJ	Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth.	Molecular and cellular biology	2010	110
19861459	Oxygen	Dang CV	MYC-induced cancer cell energy metabolism and therapeutic opportunities.	Clinical cancer research 	2009	222
19889935	Oxygen	Burdette D	Activation of transcription factor Nrf2 by hepatitis C virus induces the cell-survival pathway.	The Journal of general virology	2010	46
19893619	Oxygen	Lei Z	Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration.	PloS one	2009	72
19920251	Oxygen	Hitosugi T	Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.	Science signaling	2009	221
19929412	Oxygen	Dewhirst MW	Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress.	Radiation research	2009	69
19955394	Oxygen	Schetter AJ	Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways.	Carcinogenesis	2010	169
19955413	Oxygen	Franovic A	Human cancers converge at the HIF-2alpha oncogenic axis.	Proceedings of the National Academy of Sciences of the United States of America	2009	49
19956681	Oxygen	Aghajanian A	Direct activation of RhoA by reactive oxygen species requires a redox-sensitive motif.	PloS one	2009	68
20010808	Oxygen	David CJ	HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer.	Nature	2010	284
20010815	Oxygen	Campaner S	Cdk2 suppresses cellular senescence induced by the c-myc oncogene.	Nature cell biology	2010	83
20015196	Oxygen	Chiche J	Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer.	Journal of cellular and molecular medicine	2010	115
20018866	Oxygen	Fan Y	Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition.	The Journal of biological chemistry	2010	43
20019356	Oxygen	Klaunig JE	Oxidative stress and oxidative damage in carcinogenesis.	Toxicologic pathology	2010	171
20022734	Oxygen	Mazure NM	Hypoxia-induced autophagy: cell death or cell survival?	Current opinion in cell biology	2010	131
20023628	Oxygen	Sibanda BL	Crystal structure of DNA-PKcs reveals a large open-ring cradle comprised of HEAT repeats.	Nature	2010	82
20038740	Oxygen	De Angelis A	Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function.	Circulation	2010	70
20103649	Oxygen	Pires IM	Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability.	Cancer research	2010	44
20164116	Oxygen	Rey S	Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling.	Cardiovascular research	2010	107
20169192	Oxygen	Copp√© JP	A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen.	PloS one	2010	118
20176937	Oxygen	Horak P	Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2010	45
20197461	Oxygen	Xu Y	CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma.	Cancer research	2010	59
20203261	Oxygen	Swords RT	Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.	Blood	2010	75
20221698	Oxygen	Garg AD	Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity.	Apoptosis 	2010	40
20227042	Oxygen	He G	Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.	Cancer cell	2010	113
20309962	Oxygen	Pistollato F	Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.	Stem cells	2010	66
20345372	Oxygen	Willems SH	Thiol isomerases negatively regulate the cellular shedding activity of ADAM17.	The Biochemical journal	2010	52
20357180	Oxygen	Gottlieb RA	Autophagy in health and disease. 5. Mitophagy as a way of life.	American journal of physiology. Cell physiology	2010	77
20428844	Oxygen	Foldbjerg R	Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549.	Archives of toxicology	2011	71
20452943	Oxygen	Gottlieb E	p53 regulation of metabolic pathways.	Cold Spring Harbor perspectives in biology	2010	65
20453876	Oxygen	Bobrovnikova-Marjon E	PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage.	Oncogene	2010	78
20460382	Oxygen	Chen Y	Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.	The Journal of biological chemistry	2010	43
20463368	Oxygen	Michelakis ED	Metabolic modulation of glioblastoma with dichloroacetate.	Science translational medicine	2010	201
20478436	Oxygen	Reiter RJ	Melatonin: a multitasking molecule.	Progress in brain research	2010	69
20513808	Oxygen	Reitman ZJ	Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.	Journal of the National Cancer Institute	2010	110
20517715	Oxygen	Imtiyaz HZ	Hypoxia-inducible factors as essential regulators of inflammation.	Current topics in microbiology and immunology	2010	75
20520707	Oxygen	Sendoel A	HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase.	Nature	2010	57
20523116	Oxygen	Graham KA	NADPH oxidase 4 is an oncoprotein localized to mitochondria.	Cancer biology & therapy	2010	64
20530669	Oxygen	Jiang T	High levels of Nrf2 determine chemoresistance in type II endometrial cancer.	Cancer research	2010	80
20532218	Oxygen	Soucy-Faulkner A	Requirement of NOX2 and reactive oxygen species for efficient RIG-I-mediated antiviral response through regulation of MAVS expression.	PLoS pathogens	2010	43
20535745	Oxygen	Toullec A	Oxidative stress promotes myofibroblast differentiation and tumour spreading.	EMBO molecular medicine	2010	74
20555359	Oxygen	Pyne NJ	Sphingosine 1-phosphate and cancer.	Nature reviews. Cancer	2010	257
20574517	Oxygen	Venkataraman S	MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence.	PloS one	2010	55
20581868	Oxygen	Bartkova J	Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas.	Oncogene	2010	56
20609355	Oxygen	Jeanne M	PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.	Cancer cell	2010	68
20618067	Oxygen	Storz P	Forkhead homeobox type O transcription factors in the responses to oxidative stress.	Antioxidants & redox signaling	2011	74
20660313	Oxygen	Mazumdar J	HIF-2alpha deletion promotes Kras-driven lung tumor development.	Proceedings of the National Academy of Sciences of the United States of America	2010	52
20665378	Oxygen	Rosmorduc O	Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease.	Seminars in liver disease	2010	52
20671264	Oxygen	Bar EE	Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres.	The American journal of pathology	2010	93
20697088	Oxygen	Hursting SD	Energy balance, host-related factors, and cancer progression.	Journal of clinical oncology 	2010	80
20711182	Oxygen	Luciani A	Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition.	Nature cell biology	2010	129
20715845	Oxygen	Gianni D	A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells.	ACS chemical biology	2010	51
20716925	Oxygen	Acharya A	Redox regulation in cancer: a double-edged sword with therapeutic potential.	Oxidative medicine and cellular longevity	2010	104
20812780	Oxygen	Wilson MA	The role of cysteine oxidation in DJ-1 function and dysfunction.	Antioxidants & redox signaling	2011	65
20819950	Oxygen	de Cavanagh EM	Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?	Cardiovascular research	2011	37
20861671	Oxygen	Lisanti MP	Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment.	Cancer biology & therapy	2010	66
20889127	Oxygen	Eichner LJ	miR-378(‚àó) mediates metabolic shift in breast cancer cells via the PGC-1Œ≤/ERRŒ≥ transcriptional pathway.	Cell metabolism	2010	80
20890298	Oxygen	Swietach P	New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation.	Oncogene	2010	60
20923773	Oxygen	Luanpitpong S	Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1.	The Journal of biological chemistry	2010	41
20948290	Oxygen	Dang CV	Glutaminolysis: supplying carbon or nitrogen or both for cancer cells?	Cell cycle	2010	76
20962028	Oxygen	Lu X	Hypoxia and hypoxia-inducible factors: master regulators of metastasis.	Clinical cancer research 	2010	161
20965423	Oxygen	Majmundar AJ	Hypoxia-inducible factors and the response to hypoxic stress.	Molecular cell	2010	441
20965425	Oxygen	Wellen KE	Cellular metabolic stress: considering how cells respond to nutrient excess.	Molecular cell	2010	99
20965426	Oxygen	Haigis MC	The aging stress response.	Molecular cell	2010	133
20969928	Oxygen	Ferbeyre G	The role of Stat5 transcription factors as tumor suppressors or oncogenes.	Biochimica et biophysica acta	2011	40
21072054	Oxygen	Lee JJ	PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation.	Cell death and differentiation	2011	41
21085745	Oxygen	Cuenca AG	A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma.	Molecular medicine	2011	101
21095582	Oxygen	Cam H	mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1Œ±.	Molecular cell	2010	64
21106363	Oxygen	De Bock K	Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.	Current opinion in genetics & development	2011	42
21127501	Oxygen	Hjelmeland AB	Acidic stress promotes a glioma stem cell phenotype.	Cell death and differentiation	2011	92
21139141	Oxygen	Bensimon A	ATM-dependent and -independent dynamics of the nuclear phosphoproteome after DNA damage.	Science signaling	2010	91
21148070	Oxygen	Bodily JM	Human papillomavirus E7 enhances hypoxia-inducible factor 1-mediated transcription by inhibiting binding of histone deacetylases.	Cancer research	2011	40
21157431	Oxygen	Cosentino C	ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair.	The EMBO journal	2011	108
21195017	Oxygen	Hur W	Small molecule modulators of antioxidant response pathway.	Current opinion in chemical biology	2011	53
21228261	Oxygen	Jiang F	NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair.	Pharmacological reviews	2011	146
21235356	Oxygen	Giannoni E	Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness.	Antioxidants & redox signaling	2011	50
21245941	Oxygen	Seth P	On-target inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvate.	Neoplasia	2011	41
21296189	Oxygen	H√ºttemann M	The multiple functions of cytochrome c and their regulation in life and death decisions of the mammalian cell: From respiration to apoptosis.	Mitochondrion	2011	58
21298084	Oxygen	van Uden P	Evolutionary conserved regulation of HIF-1Œ≤ by NF-Œ∫B.	PLoS genetics	2011	38
21300795	Oxygen	Kim MJ	Involvement of autophagy in oncogenic K-Ras-induced malignant cell transformation.	The Journal of biological chemistry	2011	76
21307646	Oxygen	Chong ZZ	Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.	Oxidative medicine and cellular longevity	2010	56
21365312	Oxygen	Baird L	The cytoprotective role of the Keap1-Nrf2 pathway.	Archives of toxicology	2011	165
21368860	Oxygen	Marino ML	Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells.	Cell death & disease	2010	43
21369578	Oxygen	Celardo I	Pharmacological potential of cerium oxide nanoparticles.	Nanoscale	2011	41
21386137	Oxygen	Ozden O	Acetylation of MnSOD directs enzymatic activity responding to cellular nutrient status or oxidative stress.	Aging	2011	55
21386818	Oxygen	Zhu AX	HCC and angiogenesis: possible targets and future directions.	Nature reviews. Clinical oncology	2011	94
21421804	Oxygen	Raina D	Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.	Molecular cancer therapeutics	2011	62
21466972	Oxygen	Rohwer N	Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.	Drug resistance updates 	2011	95
21486948	Oxygen	Papa L	Estrogen receptor mediates a distinct mitochondrial unfolded protein response.	Journal of cell science	2011	42
21497090	Oxygen	Bosch M	Caveolin-1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility.	Current biology 	2011	52
21512133	Oxygen	Koh MY	The hypoxia-associated factor switches cells from HIF-1Œ±- to HIF-2Œ±-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion.	Cancer research	2011	65
21525939	Oxygen	Donadelli M	Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.	Cell death & disease	2011	45
21530747	Oxygen	Ullman TA	Intestinal inflammation and cancer.	Gastroenterology	2011	212
21555452	Oxygen	Kelly TJ	A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like.	Molecular and cellular biology	2011	48
21555567	Oxygen	Shaw AT	Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress.	Proceedings of the National Academy of Sciences of the United States of America	2011	56
21566064	Oxygen	Shrivastava A	Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy.	Molecular cancer therapeutics	2011	51
21567162	Oxygen	Shao L	Reactive oxygen species and hematopoietic stem cell senescence.	International journal of hematology	2011	39
21593862	Oxygen	Carmeliet P	Molecular mechanisms and clinical applications of angiogenesis.	Nature	2011	923
21606348	Oxygen	Billia F	PTEN-inducible kinase 1 (PINK1)/Park6 is indispensable for normal heart function.	Proceedings of the National Academy of Sciences of the United States of America	2011	78
21616142	Oxygen	Batinic-Haberle I	Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics.	Free radical biology & medicine	2011	50
21637285	Oxygen	Martin SK	The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.	Leukemia	2011	44
21664268	Oxygen	Traber MG	Vitamins C and E: beneficial effects from a mechanistic perspective.	Free radical biology & medicine	2011	96
21664270	Oxygen	Wagner BA	The rate of oxygen utilization by cells.	Free radical biology & medicine	2011	50
21692241	Oxygen	Pike LS	Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells.	Biochimica et biophysica acta	2011	80
21700219	Oxygen	Lv L	Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth.	Molecular cell	2011	134
21708191	Oxygen	Tzivion G	FoxO transcription factors; Regulation by AKT and 14-3-3 proteins.	Biochimica et biophysica acta	2011	154
21709315	Oxygen	Luo W	Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells.	Oncotarget	2011	54
21712406	Oxygen	Raychaudhuri P	FoxM1: a master regulator of tumor metastasis.	Cancer research	2011	78
21712410	Oxygen	Mathieu J	HIF induces human embryonic stem cell markers in cancer cells.	Cancer research	2011	146
21734239	Oxygen	Zhou J	The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.	Blood	2011	64
21742796	Oxygen	Goel S	Normalization of the vasculature for treatment of cancer and other diseases.	Physiological reviews	2011	317
21763418	Oxygen	Xie CM	Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation.	Free radical biology & medicine	2011	48
21782234	Oxygen	Szot CS	3D in¬†vitro bioengineered tumors based on collagen I hydrogels.	Biomaterials	2011	47
21785006	Oxygen	Semenza GL	Regulation of metabolism by hypoxia-inducible factor 1.	Cold Spring Harbor symposia on quantitative biology	2011	91
21825039	Oxygen	Ding ZB	Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation.	Clinical cancer research 	2011	38
21834525	Oxygen	Lippert AR	Boronate oxidation as a bioorthogonal reaction approach for studying the chemistry of hydrogen peroxide in living systems.	Accounts of chemical research	2011	70
21836617	Oxygen	Heddleston JM	Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential.	Cell death and differentiation	2012	41
21853114	Oxygen	Hahm ER	Withaferin A-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species.	PloS one	2011	52
21856739	Oxygen	Ostman A	Regulation of protein tyrosine phosphatases by reversible oxidation.	Journal of biochemistry	2011	70
21871443	Oxygen	Kim KY	Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization.	Biochemical and biophysical research communications	2011	41
21876558	Oxygen	Hu Y	K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis.	Cell research	2012	66
21878644	Oxygen	Achuthan S	Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species.	The Journal of biological chemistry	2011	47
21884940	Oxygen	Karisch R	Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome".	Cell	2011	49
21931870	Oxygen	Ivanov AV	Hepatitis C virus proteins activate NRF2/ARE pathway by distinct ROS-dependent and independent mechanisms in HUH7 cells.	PloS one	2011	42
21945098	Oxygen	Schneider L	Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress.	Free radical biology & medicine	2011	36
21951851	Oxygen	Li ZY	Mitochondrial ROS generation for regulation of autophagic pathways in cancer.	Biochemical and biophysical research communications	2011	58
21962515	Oxygen	Haque A	Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity.	Cell	2011	42
21969601	Oxygen	Wu C	Hypoxia potentiates microRNA-mediated gene silencing through posttranslational modification of Argonaute2.	Molecular and cellular biology	2011	46
21984483	Oxygen	Jing Y	Cadmium increases HIF-1 and VEGF expression through ROS, ERK, and AKT signaling pathways and induces malignant transformation of human bronchial epithelial cells.	Toxicological sciences 	2012	42
21994322	Oxygen	Burdette D	Hepatitis C virus activates interleukin-1Œ≤ via caspase-1-inflammasome complex.	The Journal of general virology	2012	36
22011623	Oxygen	Gong K	Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma.	Free radical biology & medicine	2011	36
22019631	Oxygen	Vurusaner B	Tumor suppressor genes and ROS: complex networks of interactions.	Free radical biology & medicine	2012	56
22052977	Oxygen	Anastasiou D	Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses.	Science	2011	261
22057568	Oxygen	Suski JM	Relation between mitochondrial membrane potential and ROS formation.	Methods in molecular biology	2012	38
22064655	Oxygen	Huang WC	Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells.	Molecular cancer research 	2012	51
22065079	Oxygen	Carbone M	Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.	Clinical cancer research 	2012	50
22079466	Oxygen	Piao LS	CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma.	Cancer letters	2012	53
22084445	Oxygen	Hirschhaeuser F	Lactate: a metabolic key player in cancer.	Cancer research	2011	158
22089927	Oxygen	Kaelin WG Jr	Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases.	Cold Spring Harbor symposia on quantitative biology	2011	59
22090360	Oxygen	Skinner HD	TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.	Clinical cancer research 	2012	70
22094256	Oxygen	Anders L	A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.	Cancer cell	2011	109
22094260	Oxygen	Skrtiƒá M	Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.	Cancer cell	2011	91
22117613	Oxygen	Maillet A	Redox regulation of p53, redox effectors regulated by p53: a subtle balance.	Antioxidants & redox signaling	2012	38
22123926	Oxygen	Contractor T	p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2.	Cancer research	2012	43
22135092	Oxygen	Tang X	Functional interaction between responses to lactic acidosis and hypoxia regulates genomic transcriptional outputs.	Cancer research	2012	36
22139133	Oxygen	Ferber EC	FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression.	Cell death and differentiation	2012	65
22147748	Oxygen	Meng F	Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.	Molecular cancer therapeutics	2012	51
22193987	Oxygen	Garg AD	Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin.	Cancer immunology, immunotherapy 	2012	48
22205687	Oxygen	Palaz√≥n A	Molecular pathways: hypoxia response in immune cells fighting or promoting cancer.	Clinical cancer research 	2012	50
22225988	Oxygen	Schwab LP	Hypoxia-inducible factor 1Œ± promotes primary tumor growth and tumor-initiating cell activity in breast cancer.	Breast cancer research 	2012	48
22281437	Oxygen	Lozy F	Autophagy and cancer cell metabolism.	Seminars in cell & developmental biology	2012	54
22284662	Oxygen	L√≥pez J	Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance.	BMC cancer	2012	44
22294757	Oxygen	Fong DY	Physical activity for cancer survivors: meta-analysis of randomised controlled trials.	BMJ	2012	125
22331464	Oxygen	Ma J	PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function.	Molecular and cellular biology	2012	37
22333951	Oxygen	Raju D	Vacuolating cytotoxin and variants in Atg16L1 that disrupt autophagy promote Helicobacter pylori infection in humans.	Gastroenterology	2012	40
22349704	Oxygen	Hagenbuchner J	FOXO3-induced reactive oxygen species are regulated by BCL2L11 (Bim) and SESN3.	Journal of cell science	2012	44
22393286	Oxygen	Akhtar MJ	Zinc oxide nanoparticles selectively induce apoptosis in human cancer cells through reactive oxygen species.	International journal of nanomedicine	2012	51
22411871	Oxygen	Nieborowska-Skorska M	Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.	Blood	2012	32
22421439	Oxygen	Zhao J	Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis.	Proceedings of the National Academy of Sciences of the United States of America	2012	162
22423966	Oxygen	Yang CS	Autophagy protein Rubicon mediates phagocytic NADPH oxidase activation in response to microbial infection or TLR stimulation.	Cell host & microbe	2012	34
22428047	Oxygen	Sonveaux P	Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis.	PloS one	2012	74
22458843	Oxygen	Zhu P	Angiopoietin-like 4: a decade of research.	Bioscience reports	2012	43
22460322	Oxygen	Boren J	Apoptosis-induced mitochondrial dysfunction causes cytoplasmic lipid droplet formation.	Cell death and differentiation	2012	37
22461640	Oxygen	Munson JM	Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma.	Science translational medicine	2012	37
22522114	Oxygen	Kotsakis A	Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.	Journal of immunological methods	2012	51
22525300	Oxygen	Shay JE	Hypoxia-inducible factors: crosstalk between inflammation and metabolism.	Seminars in cell & developmental biology	2012	32
22525710	Oxygen	Rapisarda A	Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.	Nature reviews. Clinical oncology	2012	48
22533670	Oxygen	Giralt A	SIRT3, a pivotal actor in mitochondrial functions: metabolism, cell death and aging.	The Biochemical journal	2012	50
22562464	Oxygen	Luo Z	The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.	Cancer research	2012	68
22595400	Oxygen	Scoditti E	Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer.	Archives of biochemistry and biophysics	2012	49
22614980	Oxygen	Jones LW	Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.	Journal of clinical oncology 	2012	49
22632748	Oxygen	Vendramini-Costa DB	Molecular link mechanisms between inflammation and cancer.	Current pharmaceutical design	2012	101
22642602	Oxygen	Liang D	The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells.	BMC cancer	2012	36
22687819	Oxygen	Jansson T	The emerging role of mTORC1 signaling in placental nutrient-sensing.	Placenta	2012	33
22701472	Oxygen	Arcidiacono B	Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms.	Experimental diabetes research	2012	74
22705852	Oxygen	Verfaillie T	PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress.	Cell death and differentiation	2012	115
22713662	Oxygen	Pires IM	Targeting radiation-resistant hypoxic tumour cells through ATR inhibition.	British journal of cancer	2012	38
22728268	Oxygen	Boudreau HE	Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells.	Free radical biology & medicine	2012	49
22750268	Oxygen	Chen JQ	Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells.	Biochimica et biophysica acta	2012	64
22770242	Oxygen	Anguera MC	Molecular signatures of human induced pluripotent stem cells highlight sex differences and cancer genes.	Cell stem cell	2012	41
22796521	Oxygen	Chiba T	Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation.	Gastroenterology	2012	79
22801492	Oxygen	Montagner M	SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors.	Nature	2012	65
22818162	Oxygen	Koh MY	Passing the baton: the HIF switch.	Trends in biochemical sciences	2012	65
22836756	Oxygen	Zhang X	MicroRNA-21 modulates the levels of reactive oxygen species by targeting SOD3 and TNFŒ±.	Cancer research	2012	42
22871044	Oxygen	Vernon PJ	Eat-me: autophagy, phagocytosis, and reactive oxygen species signaling.	Antioxidants & redox signaling	2013	33
22897481	Oxygen	Sheng SL	Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma.	The FEBS journal	2012	42
22899010	Oxygen	Janiszewska M	Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells.	Genes & development	2012	68
22917578	Oxygen	Frank M	Mitophagy is triggered by mild oxidative stress in a mitochondrial fission dependent manner.	Biochimica et biophysica acta	2012	90
22922758	Oxygen	Sentelle RD	Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy.	Nature chemical biology	2012	86
22927446	Oxygen	Gong K	Autophagy-related gene 7 (ATG7) and reactive oxygen species/extracellular signal-regulated kinase regulate tetrandrine-induced autophagy in human hepatocellular carcinoma.	The Journal of biological chemistry	2012	33
22959024	Oxygen	Bailey KM	Targeting the metabolic microenvironment of tumors.	Advances in pharmacology	2012	35
22962263	Oxygen	Noman MZ	Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells.	Cancer research	2012	38
22978471	Oxygen	Wu CC	Regulation of the intrinsic apoptosis pathway by reactive oxygen species.	Antioxidants & redox signaling	2013	47
22986741	Oxygen	Jerby L	Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer.	Cancer research	2012	31
23000343	Oxygen	Li L	Starvation-induced autophagy is regulated by mitochondrial reactive oxygen species leading to AMPK activation.	Cellular signalling	2013	59
23027923	Oxygen	Croci DO	Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma.	The Journal of experimental medicine	2012	36
23041058	Oxygen	Lee JH	Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression.	Pharmacology & therapeutics	2013	34
23063463	Oxygen	Samarakoon R	TGF-Œ≤ signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities.	Cellular signalling	2013	80
23071357	Oxygen	Tamada M	Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells.	Clinical cancer research 	2012	47
23079083	Oxygen	Selimovic D	Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells.	Cellular signalling	2013	35
23103253	Oxygen	Elorza A	HIF2Œ± acts as an mTORC1 activator through the amino acid carrier SLC7A5.	Molecular cell	2012	33
23108410	Oxygen	Higgs MR	Hepatitis C virus-induced activation of Œ≤-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events.	Oncogene	2013	27
23115158	Oxygen	Li S	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.	Neuro-oncology	2013	38
23146905	Oxygen	Hagenbuchner J	BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery.	Oncogene	2013	36
23174192	Oxygen	Hasselbalch HC	Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?	Leukemia research	2013	40
23174333	Oxygen	Hoekstra AS	The role of complex II in disease.	Biochimica et biophysica acta	2013	25
23177934	Oxygen	Favaro E	Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells.	Cell metabolism	2012	64
23181220	Oxygen	Kongara S	The interplay between autophagy and ROS in tumorigenesis.	Frontiers in oncology	2012	40
23185017	Oxygen	Cheung EC	Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death.	Proceedings of the National Academy of Sciences of the United States of America	2012	48
23216817	Oxygen	Polet F	Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force.	Journal of internal medicine	2013	32
23220211	Oxygen	Wu M	The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems.	Journal of theoretical biology	2013	39
23272301	Oxygen	Mitsuishi Y	The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism.	Frontiers in oncology	2012	81
23277535	Oxygen	Austin S	PGC1Œ± and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders.	Journal of cell science	2012	99
23297826	Oxygen	Agani F	Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer.	Current cancer drug targets	2013	40
23301832	Oxygen	Mimeault M	Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells.	Journal of cellular and molecular medicine	2013	60
23303309	Oxygen	Watson J	Oxidants, antioxidants and the current incurability of metastatic cancers.	Open biology	2013	86
23318445	Oxygen	Kumari U	Evidence of mitochondrial dysfunction and impaired ROS detoxifying machinery in Fanconi anemia cells.	Oncogene	2014	26
23321518	Oxygen	Fujiwara S	PDK1 inhibition is a novel therapeutic target in multiple myeloma.	British journal of cancer	2013	31
23326372	Oxygen	Singhapol C	Mitochondrial telomerase protects cancer cells from nuclear DNA damage and apoptosis.	PloS one	2013	30
23333149	Oxygen	Lagadinou ED	BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.	Cell stem cell	2013	142
23347351	Oxygen	Liu G	Molecular basis of asbestos-induced lung disease.	Annual review of pathology	2013	32
23373897	Oxygen	Janko C	Redox modulation of HMGB1-related signaling.	Antioxidants & redox signaling	2014	23
23378588	Oxygen	Gasparre G	Relevance of mitochondrial genetics and metabolism in cancer development.	Cold Spring Harbor perspectives in biology	2013	30
23391506	Oxygen	Li H	Stress response of glioblastoma cells mediated by miR-17-5p targeting PTEN and the passenger strand miR-17-3p targeting MDM2.	Oncotarget	2012	42
23392169	Oxygen	Luo H	PTEN-regulated AKT/FoxO3a/Bim signaling contributes to reactive oxygen species-mediated apoptosis in selenite-treated colorectal cancer cells.	Cell death & disease	2013	35
23416000	Oxygen	Vazquez F	PGC1Œ± expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress.	Cancer cell	2013	133
23475579	Oxygen	Das TP	Induction of reactive oxygen species generation inhibits epithelial-mesenchymal transition and promotes growth arrest in prostate cancer cells.	Molecular carcinogenesis	2014	23
23480168	Oxygen	Kim GH	The role of redox signaling in epigenetics and cardiovascular disease.	Antioxidants & redox signaling	2013	34
23524583	Oxygen	Zhang S	Generation of cancer stem-like cells through the formation of polyploid giant cancer cells.	Oncogene	2014	58
23533664	Oxygen	Luo H	Resveratrol induces premature senescence in lung cancer cells via ROS-mediated DNA damage.	PloS one	2013	33
23546867	Oxygen	Kwon JE	Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1.	Apoptosis 	2013	29
23589885	Oxygen	Kucharzewska P	Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development.	Proceedings of the National Academy of Sciences of the United States of America	2013	148
23633453	Oxygen	Nawrocki ST	Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.	Clinical cancer research 	2013	32
23637463	Oxygen	Volonte D	Inhibition of nuclear factor-erythroid 2-related factor (Nrf2) by caveolin-1 promotes stress-induced premature senescence.	Molecular biology of the cell	2013	26
23642249	Oxygen	Infanger DW	Engineered culture models for studies of tumor-microenvironment interactions.	Annual review of biomedical engineering	2013	28
23649437	Oxygen	Brunelli A	Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.	Chest	2013	41
23671091	Oxygen	Kamphorst JJ	Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids.	Proceedings of the National Academy of Sciences of the United States of America	2013	126
23685237	Oxygen	Deng X	PM2.5-induced oxidative stress triggers autophagy in human lung epithelial A549 cells.	Toxicology in vitro 	2013	25
23699409	Oxygen	Young RM	Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress.	Genes & development	2013	54
23703322	Oxygen	Montero J	p53 regulates a non-apoptotic death induced by ROS.	Cell death and differentiation	2013	38
23705969	Oxygen	Domenech M	Lysosomal membrane permeabilization by targeted magnetic nanoparticles in alternating magnetic fields.	ACS nano	2013	27
23736373	Oxygen	Lee P	Functional thermogenic beige adipogenesis is inducible in human neck fat.	International journal of obesity	2014	47
23740244	Oxygen	Arora S	An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor Œ∫B- and hypoxia-inducible factor 1Œ±-mediated up-regulation of CXCR4.	The Journal of biological chemistry	2013	44
23760662	Oxygen	Huang A	Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.	Cancer immunology, immunotherapy 	2013	40
23770291	Oxygen	Kauppinen A	Antagonistic crosstalk between NF-Œ∫B and SIRT1 in the regulation of inflammation and metabolic disorders.	Cellular signalling	2013	88
23792563	Oxygen	Cancer Genome Atlas Research Network.	Comprehensive molecular characterization of clear cell renal cell carcinoma.	Nature	2013	637
23811687	Oxygen	Du W	TAp73 enhances the pentose phosphate pathway and supports cell proliferation.	Nature cell biology	2013	64
23820265	Oxygen	Ga√±√°n-G√≥mez I	Oncogenic functions of the transcription factor Nrf2.	Free radical biology & medicine	2013	47
23828498	Oxygen	Markowitz J	Myeloid-derived suppressor cells in breast cancer.	Breast cancer research and treatment	2013	32
23841076	Oxygen	Shin S	The omega-3 polyunsaturated fatty acid DHA induces simultaneous apoptosis and autophagy via mitochondrial ROS-mediated Akt-mTOR signaling in prostate cancer cells expressing mutant p53.	BioMed research international	2013	29
23880293	Oxygen	Cheng X	Regulation of the Nrf2 antioxidant pathway by microRNAs: New players in micromanaging redox homeostasis.	Free radical biology & medicine	2013	43
23907464	Oxygen	Kim AD	A ginseng metabolite, compound K, induces autophagy and apoptosis via generation of reactive oxygen species and activation of JNK in human colon cancer cells.	Cell death & disease	2013	34
23915189	Oxygen	Hoesel B	The complexity of NF-Œ∫B signaling in inflammation and cancer.	Molecular cancer	2013	366
23932902	Oxygen	Moser SC	PHD1 links cell-cycle progression to oxygen sensing through hydroxylation of the centrosomal protein Cep192.	Developmental cell	2013	25
23936814	Oxygen	Gurunathan S	Cytotoxicity of biologically synthesized silver nanoparticles in MDA-MB-231 human breast cancer cells.	BioMed research international	2013	30
23941831	Oxygen	Rogler G	Chronic ulcerative colitis and colorectal cancer.	Cancer letters	2014	39
23947803	Oxygen	De Francesco EM	HIF-1Œ±/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs).	Breast cancer research 	2013	35
23955302	Oxygen	Zhang J	A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS.	Nature cell biology	2013	58
23999440	Oxygen	Semenza GL	HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations.	The Journal of clinical investigation	2013	246
24045183	Oxygen	Mujcic H	Hypoxic activation of the PERK/eIF2Œ± arm of the unfolded protein response promotes metastasis through induction of LAMP3.	Clinical cancer research 	2013	27
24076634	Oxygen	Doedens AL	Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen.	Nature immunology	2013	105
24080946	Oxygen	Stankov MV	Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy.	Leukemia	2014	21
24084631	Oxygen	Chauhan VP	Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels.	Nature communications	2013	116
24091667	Oxygen	Wang Y	Piperlongumine induces autophagy by targeting p38 signaling.	Cell death & disease	2013	30
24095676	Oxygen	Rouault-Pierre K	HIF-2Œ± protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress.	Cell stem cell	2013	32
24097820	Oxygen	Zhang Y	Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance.	Cancer research	2013	43
24106207	Oxygen	Golay J	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.	Blood	2013	41
24115572	Oxygen	Pereira L	Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK.	EMBO molecular medicine	2013	28
24121277	Oxygen	Venere M	Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.	Cell death and differentiation	2014	37
24123012	Oxygen	Hiraga R	Nox4-derived ROS signaling contributes to TGF-Œ≤-induced epithelial-mesenchymal transition in pancreatic cancer cells.	Anticancer research	2013	26
24159565	Oxygen	Young L	Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.	The Lancet. Respiratory medicine	2013	26
24166504	Oxygen	De Saedeleer CJ	Glucose deprivation increases monocarboxylate transporter 1 (MCT1) expression and MCT1-dependent tumor cell migration.	Oncogene	2014	24
24185179	Oxygen	Sato A	Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells.	Stem cell research	2014	26
24204632	Oxygen	Lonardo E	Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells.	PloS one	2013	47
24240701	Oxygen	Shin DH	SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin.	Cancer research	2014	20
24265551	Oxygen	Gurunathan S	Green synthesis of silver nanoparticles using Ganoderma neo-japonicum Imazeki: a potential cytotoxic agent against breast cancer cells.	International journal of nanomedicine	2013	27
24280005	Oxygen	Griffiths B	Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth.	Cancer & metabolism	2013	47
24280585	Oxygen	Li YC	Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells.	Cancer letters	2014	36
24293652	Oxygen	Lan L	Novel method for site-specific induction of oxidative DNA damage reveals differences in recruitment of repair proteins to heterochromatin and euchromatin.	Nucleic acids research	2014	25
24324009	Oxygen	Papa L	SirT3 regulates the mitochondrial unfolded protein response.	Molecular and cellular biology	2014	42
24333723	Oxygen	Ji RC	Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis.	Cancer letters	2014	22
24381719	Oxygen	Popa-Wagner A	ROS and brain diseases: the good, the bad, and the ugly.	Oxidative medicine and cellular longevity	2013	29
24382987	Oxygen	Ohnishi S	DNA damage in inflammation-related carcinogenesis and cancer stem cells.	Oxidative medicine and cellular longevity	2013	29
24413150	Oxygen	Shi Y	ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis.	Cell death and differentiation	2014	39
24418575	Oxygen	Mehla K	MUC1: a novel metabolic master regulator.	Biochimica et biophysica acta	2014	21
24435707	Oxygen	Cho KH	A ROS/STAT3/HIF-1Œ± signaling cascade mediates EGF-induced TWIST1 expression and prostate cancer cell invasion.	The Prostate	2014	21
24465942	Oxygen	Ahn HJ	Targeting cancer cells with reactive oxygen and nitrogen species generated by atmospheric-pressure air plasma.	PloS one	2014	36
24466275	Oxygen	Liu AM	miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.	PloS one	2014	26
24469051	Oxygen	Yin M	Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-Œ∫B p65 to evoke reactive oxygen species generation and p53 activation.	Oncogene	2015	20
24477002	Oxygen	Sayin VI	Antioxidants accelerate lung cancer progression in mice.	Science translational medicine	2014	136
24509161	Oxygen	Crosas-Molist E	The NADPH oxidase NOX4 inhibits hepatocyte proliferation and liver cancer progression.	Free radical biology & medicine	2014	20
24515801	Oxygen	Lee SO	The orphan nuclear receptor NR4A1 (Nur77) regulates oxidative and endoplasmic reticulum stress in pancreatic cancer cells.	Molecular cancer research 	2014	21
24517586	Oxygen	Camps C	Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia.	Molecular cancer	2014	29
24550462	Oxygen	Loenarz C	Hydroxylation of the eukaryotic ribosomal decoding center affects translational accuracy.	Proceedings of the National Academy of Sciences of the United States of America	2014	40
24554772	Oxygen	Samstad EO	Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release.	Journal of immunology	2014	42
24569087	Oxygen	Brocato J	Molecular responses to hypoxia-inducible factor 1Œ± and beyond.	Molecular pharmacology	2014	23
24574456	Oxygen	Ishaq M	Atmospheric gas plasma-induced ROS production activates TNF-ASK1 pathway for the induction of melanoma cancer cell apoptosis.	Molecular biology of the cell	2014	30
24574503	Oxygen	McNeill A	Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.	Brain 	2014	39
24583460	Oxygen	Duan D	Shikonin targets cytosolic thioredoxin reductase to induce ROS-mediated apoptosis in human promyelocytic leukemia HL-60 cells.	Free radical biology & medicine	2014	20
24583638	Oxygen	Ogrunc M	Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation.	Cell death and differentiation	2014	46
24610033	Oxygen	Ramakrishnan S	Vascular endothelial growth factor signaling in hypoxia and inflammation.	Journal of neuroimmune pharmacology 	2014	22
24616478	Oxygen	Caro-Maldonado A	Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells.	Journal of immunology	2014	64
24647101	Oxygen	Tsang CK	Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance.	Nature communications	2014	32
24692674	Oxygen	Bauer G	Targeting extracellular ROS signaling of tumor cells.	Anticancer research	2014	20
24695224	Oxygen	Gad H	MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.	Nature	2014	83
24732804	Oxygen	Jutooru I	Mechanism of action of phenethylisothiocyanate and other reactive oxygen species-inducing anticancer agents.	Molecular and cellular biology	2014	25
24732809	Oxygen	Lu J	The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism.	Cancer letters	2015	49
24743516	Oxygen	Sousa CM	The complex landscape of pancreatic cancer metabolism.	Carcinogenesis	2014	22
24759730	Oxygen	Ma Y	Non-thermal atmospheric pressure plasma preferentially induces apoptosis in p53-mutated cancer cells by activating ROS stress-response pathways.	PloS one	2014	33
24776803	Oxygen	van Galen P	The unfolded protein response governs integrity of the haematopoietic stem-cell pool during stress.	Nature	2014	58
24786789	Oxygen	Xu Y	Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase.	Cancer research	2014	23
24791940	Oxygen	Cortez MA	Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.	Molecular therapy 	2014	38
24825347	Oxygen	Pate KT	Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer.	The EMBO journal	2014	76
24832602	Oxygen	Park EJ	Œ≤-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells.	Cell death & disease	2014	26
24835990	Oxygen	Mariani CJ	TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma.	Cell reports	2014	34
24836575	Oxygen	Schwab L	Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage.	Nature medicine	2014	30
24875536	Oxygen	Zhang L	Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways.	Toxicology letters	2014	28
24885398	Oxygen	Renganathan A	GAS5 long non-coding RNA in malignant pleural mesothelioma.	Molecular cancer	2014	21
24901008	Oxygen	Landskron G	Chronic inflammation and cytokines in the tumor microenvironment.	Journal of immunology research	2014	178
24913980	Oxygen	Soriani A	Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1.	Journal of immunology	2014	23
24939850	Oxygen	Guo H	HIV-1 infection induces interleukin-1Œ≤ production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes.	The Journal of biological chemistry	2014	29
24942866	Oxygen	Cooks T	Caught in the cross fire: p53 in inflammation.	Carcinogenesis	2014	25
24946087	Oxygen	Amann A	The human volatilome: volatile organic compounds (VOCs) in exhaled breath, skin emanations, urine, feces and saliva.	Journal of breath research	2014	25
24953182	Oxygen	Paul MK	Dynamic changes in intracellular ROS levels regulate airway basal stem cell homeostasis through Nrf2-dependent Notch signaling.	Cell stem cell	2014	52
24969860	Oxygen	Gupta RK	Oxidative stress and antioxidants in disease and cancer: a review.	Asian Pacific journal of cancer prevention 	2014	32
24986882	Oxygen	Grusch M	Spatio-temporally precise activation of engineered receptor tyrosine kinases by light.	The EMBO journal	2014	35
25023700	Oxygen	Patel A	MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.	Oncogene	2015	20
25029543	Oxygen	Nakabeppu Y	Cellular levels of 8-oxoguanine in either DNA or the nucleotide pool play pivotal roles in carcinogenesis and survival of cancer cells.	International journal of molecular sciences	2014	26
25111660	Oxygen	Saw CL	The berry constituents quercetin, kaempferol, and pterostilbene synergistically attenuate reactive oxygen species: involvement of the Nrf2-ARE signaling pathway.	Food and chemical toxicology 	2014	29
25117006	Oxygen	Pastorek J	Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use.	Seminars in cancer biology	2015	28
25129147	Oxygen	Lorenzo FR	A genetic mechanism for Tibetan high-altitude adaptation.	Nature genetics	2014	64
25168343	Oxygen	Santen RJ	Estrogen metabolites and breast cancer.	Steroids	2015	25
25186948	Oxygen	Ye J	Serine catabolism regulates mitochondrial redox control during hypoxia.	Cancer discovery	2014	58
25196648	Oxygen	Kumar V	Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment.	Immunology	2014	38
25200065	Oxygen	Zhang D	Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.	Molecular cancer	2014	25
25201986	Oxygen	Duque-Correa MA	Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas.	Proceedings of the National Academy of Sciences of the United States of America	2014	29
25238263	Oxygen	Chen MF	IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus.	Oncotarget	2014	23
25242319	Oxygen	Huang	HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression.	Cell reports	2014	39
25255025	Oxygen	Shepardson KM	Myeloid derived hypoxia inducible factor 1-alpha is required for protection against pulmonary Aspergillus fumigatus infection.	PLoS pathogens	2014	23
25257172	Oxygen	Filomeni G	Oxidative stress and autophagy: the clash between damage and metabolic needs.	Cell death and differentiation	2015	150
25263450	Oxygen	Lincet H	How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions?	Oncogene	2015	26
25294812	Oxygen	Zhou H	Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway.	Oncotarget	2014	22
25301052	Oxygen	Ma X	Lin28/let-7 axis regulates aerobic glycolysis and cancer progression via PDK1.	Nature communications	2014	26
25341036	Oxygen	Huang H	Mcl-1 promotes lung cancer cell migration by directly interacting with VDAC to increase mitochondrial Ca2+ uptake and reactive oxygen species generation.	Cell death & disease	2014	23
25351418	Oxygen	van den Beucken T	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.	Nature communications	2014	43
25355928	Oxygen	Javeed N	Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic Œ≤-cell Dysfunction.	Clinical cancer research 	2015	16
25409149	Oxygen	Venkatanarayan A	IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo.	Nature	2015	29
25433364	Oxygen	Adachi T	Plasma-activated medium induces A549 cell injury via a spiral apoptotic cascade involving the mitochondrial-nuclear network.	Free radical biology & medicine	2015	32
25435281	Oxygen	Maya-Mendoza A	Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress.	Molecular oncology	2015	24
25438054	Oxygen	Ma B	Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase.	Nature cell biology	2015	41
25440060	Oxygen	Walter KM	Hif-2Œ± promotes degradation of mammalian peroxisomes by selective autophagy.	Cell metabolism	2014	20
25444956	Oxygen	Ranasinghe WK	HIF1Œ± expression under normoxia in prostate cancer--which pathways to target?	The Journal of urology	2015	16
25474014	Oxygen	Phang JM	Proline metabolism and cancer: emerging links to glutamine and collagen.	Current opinion in clinical nutrition and metabolic care	2015	23
25497091	Oxygen	Baek G	MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies.	Cell reports	2014	25
25521078	Oxygen	Olagnier D	Cellular oxidative stress response controls the antiviral and apoptotic programs in dengue virus-infected dendritic cells.	PLoS pathogens	2014	36
25526894	Oxygen	Sanders YY	Epigenetic mechanisms regulate NADPH oxidase-4 expression in cellular senescence.	Free radical biology & medicine	2015	21
25533676	Oxygen	Gossage L	VHL, the story of a tumour suppressor gene.	Nature reviews. Cancer	2015	75
25535359	Oxygen	Amelio I	TAp73 opposes tumor angiogenesis by promoting hypoxia-inducible factor 1Œ± degradation.	Proceedings of the National Academy of Sciences of the United States of America	2015	26
25541259	Oxygen	Mizuno T	Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species.	Gynecologic oncology	2015	24
25542180	Oxygen	Obre E	Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy.	The international journal of biochemistry & cell biology	2015	27
25546605	Oxygen	Movafagh S	Regulation of hypoxia-inducible factor-1a by reactive oxygen species: new developments in an old debate.	Journal of cellular biochemistry	2015	38
25559363	Oxygen	H√∂ll M	ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells.	Molecular carcinogenesis	2016	13
25583481	Oxygen	Bartesaghi S	Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2015	15
25584894	Oxygen	Schug ZT	Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress.	Cancer cell	2015	82
25585126	Oxygen	Wu Q	ROS-mediated DNA methylation pattern alterations in carcinogenesis.	Current drug targets	2015	29
25590811	Oxygen	Singer E	Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma.	Cell death & disease	2015	18
25592377	Oxygen	Liu X	NADPH oxidase 1-dependent ROS is crucial for TLR4 signaling to promote tumor metastasis of non-small cell lung cancer.	Tumour biology 	2015	16
25617478	Oxygen	Cashman CR	Mechanisms of distal axonal degeneration in peripheral neuropathies.	Neuroscience letters	2015	28
25622857	Oxygen	Wang F	Activation of the NF-Œ∫B pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinoma.	Molecular cancer	2015	16
25670081	Oxygen	Jin L	Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth.	Cancer cell	2015	37
25689954	Oxygen	Courtnay R	Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K.	Molecular biology reports	2015	36
25693838	Oxygen	Wang Q	Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.	The Journal of pathology	2015	44
25704383	Oxygen	Span PN	Biology of hypoxia.	Seminars in nuclear medicine	2015	16
25714022	Oxygen	Zou P	ROS generation mediates the anti-cancer effects of WZ35 via activating JNK and ER stress apoptotic pathways in gastric cancer.	Oncotarget	2015	20
25762540	Oxygen	Dudek-Periƒá AM	Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin.	Cancer research	2015	20
25779952	Oxygen	Vellinga TT	SIRT1/PGC1Œ±-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer.	Clinical cancer research 	2015	20
25791797	Oxygen	van Tellingen O	Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.	Drug resistance updates 	2015	44
25799988	Oxygen	Jiang L	Ferroptosis as a p53-mediated activity during tumour suppression.	Nature	2015	117
25809609	Oxygen	Dang K	The role of hypoxia-induced miR-210 in cancer progression.	International journal of molecular sciences	2015	18
25814684	Oxygen	Eelen G	Endothelial cell metabolism in normal and diseased vasculature.	Circulation research	2015	52
25818486	Oxygen	Roy K	NADPH oxidases and cancer.	Clinical science	2015	28
25829424	Oxygen	Qiu B	HIF2Œ±-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma.	Cancer discovery	2015	32
25855294	Oxygen	Kim D	SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance.	Nature	2015	54
25912479	Oxygen	Sch√§fer M	Nrf2--A regulator of keratinocyte redox signaling.	Free radical biology & medicine	2015	19
25945836	Oxygen	Lucarelli G	Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma.	Oncotarget	2015	23
25950484	Oxygen	Roca-Alonso L	Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in Œ≤-adrenergic signaling and enhances apoptosis.	Cell death & disease	2015	21
25980682	Oxygen	Kim B	Curcumin induces ER stress-mediated apoptosis through selective generation of reactive oxygen species in cervical cancer cells.	Molecular carcinogenesis	2016	13
25981581	Oxygen	Hao W	Licochalcone A-induced human gastric cancer BGC-823 cells apoptosis by regulating ROS-mediated MAPKs and PI3K/AKT signaling pathways.	Scientific reports	2015	16
25982278	Oxygen	Hubackova S	IFNŒ≥ induces oxidative stress, DNA damage and tumor cell senescence via TGFŒ≤/SMAD signaling-dependent induction of Nox4 and suppression of ANT2.	Oncogene	2016	12
26024660	Oxygen	Qin LS	ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis.	Journal of experimental & clinical cancer research 	2015	24
26028023	Oxygen	Chen CC	The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation.	Oncogene	2016	14
26078812	Oxygen	Krstiƒá J	Transforming Growth Factor-Beta and Oxidative Stress Interplay: Implications in Tumorigenesis and Cancer Progression.	Oxidative medicine and cellular longevity	2015	22
26080835	Oxygen	Cottini F	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.	Cancer discovery	2015	22
26096935	Oxygen	Latina A	ŒîNp63 targets cytoglobin to inhibit oxidative stress-induced apoptosis in keratinocytes and lung cancer.	Oncogene	2016	12
26119783	Oxygen	Murakami S	Roles of Nrf2 in cell proliferation and differentiation.	Free radical biology & medicine	2015	26
26122615	Oxygen	Kruiswijk F	p53 in survival, death and metabolic health: a lifeguard with a licence to kill.	Nature reviews. Molecular cell biology	2015	126
26146622	Oxygen	Zimna A	Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies.	BioMed research international	2015	18
26184557	Oxygen	Klotz LO	Redox regulation of FoxO transcription factors.	Redox biology	2015	45
26186941	Oxygen	Ding N	Mismatch repair proteins recruit DNA methyltransferase 1 to sites of oxidative DNA damage.	Journal of molecular cell biology	2016	12
26212717	Oxygen	Intlekofer AM	Hypoxia Induces Production of L-2-Hydroxyglutarate.	Cell metabolism	2015	53
26216294	Oxygen	Doebele RC	An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.	Cancer discovery	2015	26
26219228	Oxygen	Zhang X	Isoliensinine induces apoptosis in triple-negative human breast cancer cells through ROS generation and p38 MAPK/JNK activation.	Scientific reports	2015	16
26245371	Oxygen	Wu D	Structural integration in hypoxia-inducible factors.	Nature	2015	34
26257063	Oxygen	Yang WH	Imipramine blue halts head and neck cancer invasion through promoting F-box and leucine-rich repeat protein 14-mediated Twist1 degradation.	Oncogene	2016	10
26314709	Oxygen	V√°raljai R	Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells.	Genes & development	2015	16
26317471	Oxygen	Arpaia N	A Distinct Function of Regulatory T Cells in Tissue Protection.	Cell	2015	81
26319899	Oxygen	Xu X	Aldehyde dehydrogenases and cancer stem cells.	Cancer letters	2015	19
26341399	Oxygen	Bronner DN	Endoplasmic Reticulum Stress Activates the Inflammasome via NLRP3- and Caspase-2-Driven Mitochondrial Damage.	Immunity	2015	36
26344566	Oxygen	Zhang J	ATM functions at the peroxisome to induce pexophagy in response to ROS.	Nature cell biology	2015	45
26373319	Oxygen	Li HJ	Long non-coding RNA UCA1 promotes glutamine metabolism by targeting miR-16 in human bladder cancer.	Japanese journal of clinical oncology	2015	18
26387536	Oxygen	Blanco FF	The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.	Oncogene	2016	19
26414765	Oxygen	Geng J	Kinases Mst1 and Mst2 positively regulate phagocytic induction of reactive oxygen species and bactericidal activity.	Nature immunology	2015	21
26420419	Oxygen	Reich M	TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro.	Gut	2016	16
26454217	Oxygen	Yeh PS	Honokiol induces autophagy of neuroblastoma cells through activating the PI3K/Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration.	Cancer letters	2016	14
26475962	Oxygen	Che M	Expanding roles of superoxide dismutases in cell regulation and cancer.	Drug discovery today	2016	13
26501191	Oxygen	Huang L	Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.	Nature medicine	2015	39
26516076	Oxygen	Broekgaarden M	Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies.	Cancer metastasis reviews	2015	18
26543237	Oxygen	De Preter G	Inhibition of the pentose phosphate pathway by dichloroacetate unravels a missing link between aerobic glycolysis and cancer cell proliferation.	Oncotarget	2016	12
26568842	Oxygen	Watson AS	Autophagy limits proliferation and glycolytic metabolism in acute myeloid leukemia.	Cell death discovery	2015	22
26598532	Oxygen	Erapaneedi R	A novel family of fluorescent hypoxia sensors reveal strong heterogeneity in tumor hypoxia at the cellular level.	The EMBO journal	2016	13
26621844	Oxygen	Um HD	Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species.	Oncotarget	2016	22
26631723	Oxygen	Yu W	Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies.	The Journal of biological chemistry	2016	12
26672603	Oxygen	Sankpal UT	Combination of tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species.	Oncotarget	2016	10
26682001	Oxygen	Ryoo IG	Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance.	Oxidative medicine and cellular longevity	2016	12
26703470	Oxygen	Laukka T	Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes.	The Journal of biological chemistry	2016	22
26719345	Oxygen	Santoro V	Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.	Journal of the National Cancer Institute	2016	11
26734996	Oxygen	Capello M	Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest.	Oncotarget	2016	11
26735018	Oxygen	Lee SB	An ID2-dependent mechanism for VHL inactivation in cancer.	Nature	2016	18
26772155	Oxygen	Gu S	ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction underlie apoptosis induced by resveratrol and arsenic trioxide in A549 cells.	Chemico-biological interactions	2016	15
26787841	Oxygen	Mazar J	MicroRNA 211 Functions as a Metabolic Switch in Human Melanoma Cells.	Molecular and cellular biology	2016	14
26791157	Oxygen	Blaser H	TNF and ROS Crosstalk in Inflammation.	Trends in cell biology	2016	32
26801746	Oxygen	Ai Z	Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.	Cancer letters	2016	11
26804739	Oxygen	Subramani R	Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition.	Scientific reports	2016	17
26878598	Oxygen	Greenshields AL	Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate.	Molecular carcinogenesis	2017	9
26894974	Oxygen	Syu JP	Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia.	Oncotarget	2016	11
26907999	Oxygen	Dingjan I	Lipid peroxidation causes endosomal antigen release for cross-presentation.	Scientific reports	2016	11
26918353	Oxygen	Yu L	The sweet trap in tumors: aerobic glycolysis and potential targets for therapy.	Oncotarget	2016	15
26934227	Oxygen	Ma C	NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.	Nature	2016	37
26940009	Oxygen	Dai W	Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma.	Scientific reports	2016	11
26942675	Oxygen	Li X	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.	Molecular cell	2016	19
26947075	Oxygen	Liou GY	Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions.	Cell reports	2016	17
26976705	Oxygen	N√≥brega-Pereira S	G6PD protects from oxidative damage and improves healthspan in mice.	Nature communications	2016	12
27001847	Oxygen	Zhang C	Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m‚Å∂A-demethylation of NANOG mRNA.	Proceedings of the National Academy of Sciences of the United States of America	2016	42
27003603	Oxygen	W√∂rmann SM	Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and¬†Gemcitabine Resistance in Mice and Is Associated With¬†Patient Survival.	Gastroenterology	2016	17
27027295	Oxygen	Chouchani ET	Mitochondrial ROS regulate thermogenic energy expenditure and sulfenylation of UCP1.	Nature	2016	36
27042933	Oxygen	Kaur A	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.	Nature	2016	34
27049945	Oxygen	Jiang L	Reductive carboxylation supports redox homeostasis during anchorage-independent growth.	Nature	2016	56
27136895	Oxygen	Fiorillo M	Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells.	Oncotarget	2016	17
27139518	Oxygen	Wigerup C	Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer.	Pharmacology & therapeutics	2016	23
27154978	Oxygen	Diebold L	Mitochondrial ROS regulation of proliferating cells.	Free radical biology & medicine	2016	20
27197257	Oxygen	Tan Z	The Role of PGC1Œ± in Cancer Metabolism and its Therapeutic Implications.	Molecular cancer therapeutics	2016	12
27270434	Oxygen	Ratnikov BI	Metabolic rewiring in melanoma.	Oncogene	2017	9
27368101	Oxygen	Briggs KJ	Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine.	Cell	2016	20
27426517	Oxygen	Fiorese CJ	The Transcription Factor ATF5 Mediates a Mammalian Mitochondrial UPR.	Current biology 	2016	28
27484637	Oxygen	Prieto-Dom√≠nguez N	Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.	Journal of pineal research	2016	11
27523917	Oxygen	Qin S	Multiple regulations of Keap1/Nrf2 system by dietary phytochemicals.	Molecular nutrition & food research	2016	12
27588494	Oxygen	Diedrich JD	Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1Œ± activation.	Oncotarget	2016	11
27686535	Oxygen	Ansari A	Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease.	Aging cell	2017	11
27698118	Oxygen	Ou Y	Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses.	Proceedings of the National Academy of Sciences of the United States of America	2016	15
27732568	Oxygen	Akamata K	SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis.	Oncotarget	2016	13
27892954	Oxygen	Plovier H	A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice.	Nature medicine	2017	36
28063379	Oxygen	Maciejczyk M	Oxidative stress, mitochondrial abnormalities and antioxidant defense in Ataxia-telangiectasia, Bloom syndrome and Nijmegen breakage syndrome.	Redox biology	2017	8
28099844	Oxygen	Bulusu V	Acetate Recapturing by Nuclear Acetyl-CoA Synthetase 2 Prevents Loss of Histone Acetylation during Oxygen and Serum Limitation.	Cell reports	2017	6
28137309	Oxygen	Lee SY	Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation.	Molecular cancer	2017	11
28145866	Oxygen	Krall EB	KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.	eLife	2017	7
28152544	Oxygen	Patel GK	Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.	British journal of cancer	2017	8
28165481	Oxygen	Fisicaro P	Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B.	Nature medicine	2017	9
28263965	Oxygen	Intlekofer AM	L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH.	Nature chemical biology	2017	12
28279976	Oxygen	Yang SJ	Regulation of hypoxia responses by flavin adenine dinucleotide-dependent modulation of HIF-1Œ± protein stability.	The EMBO journal	2017	6
28291391	Oxygen	Willmann JK	Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results.	Journal of clinical oncology 	2017	9
28306514	Oxygen	Gupta A	PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation.	Molecular cell	2017	7
28396419	Oxygen	Rand AA	Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids.	Proceedings of the National Academy of Sciences of the United States of America	2017	6
28524116	Oxygen	Kim KY	Inhibition of Autophagy Promotes Salinomycin-Induced Apoptosis via Reactive Oxygen Species-Mediated PI3K/AKT/mTOR and ERK/p38 MAPK-Dependent Signaling in Human Prostate Cancer Cells.	International journal of molecular sciences	2017	10
7560060	Dexamethasone	Schinkel AH	Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.	The Journal of clinical investigation	1995	122
7569975	Dexamethasone	Scheinman RI	Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids.	Science	1995	204
10085290	Dexamethasone	Griffiths GJ	Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis.	The Journal of cell biology	1999	109
11049970	Dexamethasone	Hideshima T	Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.	Blood	2000	133
11306489	Dexamethasone	Hideshima T	The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.	Cancer research	2001	315
11572983	Dexamethasone	Han J	Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals.	Proceedings of the National Academy of Sciences of the United States of America	2001	114
11753617	Dexamethasone	Gupta D	Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.	Leukemia	2001	98
12000743	Dexamethasone	Wang Z	Deciphering the phosphorylation "code" of the glucocorticoid receptor in vivo.	The Journal of biological chemistry	2002	83
12036884	Dexamethasone	Mitsiades N	Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.	Blood	2002	103
12070027	Dexamethasone	Derenne S	Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.	Blood	2002	97
12173037	Dexamethasone	Mitsiades CS	Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.	Oncogene	2002	110
12614096	Dexamethasone	Grumbach MM	Management of the clinically inapparent adrenal mass ("incidentaloma").	Annals of internal medicine	2003	90
14500688	Dexamethasone	Bharti AC	Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells.	Journal of immunology	2003	119
14638850	Dexamethasone	Rich JN	Phase II trial of gefitinib in recurrent glioblastoma.	Journal of clinical oncology 	2004	134
14695887	Dexamethasone	Mitsiades CS	Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.	Proceedings of the National Academy of Sciences of the United States of America	2004	153
14996737	Dexamethasone	Wu W	Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells.	Cancer research	2004	87
15070700	Dexamethasone	Bharti AC	Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis.	Blood	2004	82
15251979	Dexamethasone	Pui CH	Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.	Blood	2004	107
15470214	Dexamethasone	Petrylak DP	Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.	The New England journal of medicine	2004	692
15914534	Dexamethasone	Ilias I	Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health.	The Journal of clinical endocrinology and metabolism	2005	86
16239257	Dexamethasone	Chen W	MED14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor.	Molecular endocrinology	2006	65
16405512	Dexamethasone	Hermisson M	O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.	Journal of neurochemistry	2006	70
16728695	Dexamethasone	Catley L	Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.	Blood	2006	92
16740717	Dexamethasone	Maiso P	The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.	Cancer research	2006	61
16885367	Dexamethasone	Baughn LB	A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.	Cancer research	2006	64
16924108	Dexamethasone	Ito T	OX40 ligand shuts down IL-10-producing regulatory T cells.	Proceedings of the National Academy of Sciences of the United States of America	2006	62
17016430	Dexamethasone	Chauhan D	A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.	Oncogene	2007	60
17236958	Dexamethasone	Gonzalez J	Effect of bevacizumab on radiation necrosis of the brain.	International journal of radiation oncology, biology, physics	2007	67
17332241	Dexamethasone	Trudel S	Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.	Blood	2007	67
17591945	Dexamethasone	Kuhn DJ	Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.	Blood	2007	166
17593024	Dexamethasone	Barlogie B	Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.	British journal of haematology	2007	82
17690257	Dexamethasone	Richardson PG	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.	Blood	2007	102
18172311	Dexamethasone	Matsui W	Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.	Cancer research	2008	174
18305219	Dexamethasone	Chen Q	Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.	Blood	2008	77
19009291	Dexamethasone	Galustian C	The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.	Cancer immunology, immunotherapy 	2009	89
19139079	Dexamethasone	Azab AK	CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.	Blood	2009	144
19139565	Dexamethasone	Urry Z	Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function.	The Journal of clinical investigation	2009	52
19181644	Dexamethasone	Lust JA	Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.	Mayo Clinic proceedings	2009	61
19225538	Dexamethasone	Reeder CB	Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.	Leukemia	2009	51
19349600	Dexamethasone	Nghiemphu PL	Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.	Neurology	2009	69
19470933	Dexamethasone	Attard G	Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.	Journal of clinical oncology 	2009	152
19509164	Dexamethasone	Ikeda H	The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.	Clinical cancer research 	2009	52
19584292	Dexamethasone	McMillin DW	Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.	Cancer research	2009	46
19626046	Dexamethasone	Dimopoulos MA	Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.	Leukemia	2009	61
19762485	Dexamethasone	Kurtova AV	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.	Blood	2009	89
19826119	Dexamethasone	Lin TS	Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.	Journal of clinical oncology 	2009	78
19902470	Dexamethasone	Vuk-Pavloviƒá S	Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.	The Prostate	2010	80
19906234	Dexamethasone	Pace TW	Cytokines and glucocorticoid receptor signaling. Relevance to major depression.	Annals of the New York Academy of Sciences	2009	58
20124509	Dexamethasone	Nair B	Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.	Blood	2010	68
20179016	Dexamethasone	Gustafson MP	Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.	Neuro-oncology	2010	50
20200450	Dexamethasone	Bonapace L	Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.	The Journal of clinical investigation	2010	100
20382844	Dexamethasone	G√∂rg√ºn G	A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.	Blood	2010	94
20445578	Dexamethasone	Kuiper RP	IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.	Leukemia	2010	60
20647567	Dexamethasone	Bachmann PS	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.	Blood	2010	44
20660823	Dexamethasone	Thomas DA	Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.	Journal of clinical oncology 	2010	53
21098398	Dexamethasone	Chen SS	Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.	Blood	2011	35
21123825	Dexamethasone	Jaccard A	Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.	Blood	2011	48
21148812	Dexamethasone	Kawedia JD	Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.	Blood	2011	54
21257720	Dexamethasone	Ritchie JP	SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.	Clinical cancer research 	2011	60
21628408	Dexamethasone	Shaughnessy JD Jr	Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.	Blood	2011	39
21803855	Dexamethasone	Hoellenriegel J	The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.	Blood	2011	151
21860026	Dexamethasone	Zhu YX	Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.	Blood	2011	126
21962393	Dexamethasone	Krishnan A	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.	The Lancet. Oncology	2011	52
21990393	Dexamethasone	Yamaguchi M	Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.	Journal of clinical oncology 	2011	68
22170708	Dexamethasone	Attard G	Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.	The Journal of clinical endocrinology and metabolism	2012	65
22422823	Dexamethasone	Kumar S	Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.	Blood	2012	57
22498745	Dexamethasone	Cavo M	Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.	Blood	2012	54
22919026	Dexamethasone	Kwong YL	SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.	Blood	2012	54
22975377	Dexamethasone	Chauhan D	A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.	Cancer cell	2012	100
22996336	Dexamethasone	Zheng Y	PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.	Leukemia	2013	30
23243282	Dexamethasone	Richardson PG	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.	Blood	2013	44
23289374	Dexamethasone	Zou J	Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells.	Journal of hematology & oncology	2013	27
23432640	Dexamethasone	Voorhees PM	A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.	British journal of haematology	2013	39
23565715	Dexamethasone	Heintel D	High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.	British journal of haematology	2013	29
23658244	Dexamethasone	Aboody KS	Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies.	Science translational medicine	2013	60
23897961	Dexamethasone	Sonneveld P	Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.	Journal of clinical oncology 	2013	47
24030633	Dexamethasone	Saha MN	PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.	Molecular cancer therapeutics	2013	26
24253022	Dexamethasone	Ocio EM	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).	Leukemia	2014	58
24315100	Dexamethasone	Arora VK	Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.	Cell	2013	164
24319254	Dexamethasone	Tian Z	A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.	Blood	2014	65
24335104	Dexamethasone	Mulligan G	Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.	Blood	2014	23
24603643	Dexamethasone	Aapro M	A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.	Annals of oncology 	2014	44
24615402	Dexamethasone	Isikbay M	Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.	Hormones & cancer	2014	36
24631949	Dexamethasone	Gralla RJ	A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.	Annals of oncology 	2014	32
24888813	Dexamethasone	Pollack IF	Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.	Journal of clinical oncology 	2014	39
24914135	Dexamethasone	Zhu YX	Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.	Blood	2014	29
25064128	Dexamethasone	Gibbs J	An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action.	Nature medicine	2014	55
25232177	Dexamethasone	Carreira S	Tumor clone dynamics in lethal prostate cancer.	Science translational medicine	2014	82
25294016	Dexamethasone	Orlowski RZ	A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.	American journal of hematology	2015	25
25301704	Dexamethasone	Peirs S	ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.	Blood	2014	31
25336632	Dexamethasone	Jing D	Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.	Blood	2015	26
25415285	Dexamethasone	Szmania S	Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.	Journal of immunotherapy	2015	31
25573908	Dexamethasone	Kopp JB	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.	Journal of the American Society of Nephrology 	2015	26
25888260	Dexamethasone	Surace L	Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response.	Immunity	2015	24
25999435	Dexamethasone	Benson DM Jr	A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.	Clinical cancer research 	2015	30
26195701	Dexamethasone	Gribben JG	Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.	Journal of clinical oncology 	2015	21
26272769	Dexamethasone	Rapoport BL	Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.	The Lancet. Oncology	2015	17
26423795	Dexamethasone	Sarantopoulos J	Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.	Clinical cancer research 	2016	20
26509855	Dexamethasone	Goodman NF	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.	Endocrine practice 	2015	18
26527784	Dexamethasone	Hesketh PJ	Antiemetics: American Society of Clinical Oncology Focused Guideline Update.	Journal of clinical oncology 	2016	36
26565896	Dexamethasone	Rajkumar SV	Myeloma today: Disease definitions and treatment advances.	American journal of hematology	2016	14
26631114	Dexamethasone	van de Donk NW	Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.	Blood	2016	30
26686406	Dexamethasone	Richardson PG	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.	The Lancet. Haematology	2015	27
26755709	Dexamethasone	Viardot A	Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.	Blood	2016	16
26842680	Dexamethasone	Muller L	Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets.	Scientific reports	2016	27
27646843	Dexamethasone	Yee AJ	Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.	The Lancet. Oncology	2016	14
28053023	Dexamethasone	Vogl DT	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.	Clinical cancer research 	2017	6
28076695	Dexamethasone	Laubach JP	Deacetylase inhibitors: an advance in myeloma therapy?	Expert review of hematology	2017	6
28196531	Dexamethasone	Kiessling S	Enhancing circadian clock function in cancer cells inhibits tumor growth.	BMC biology	2017	8
28461396	Dexamethasone	Badros A	Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.	Blood	2017	12
1596899	Folic acid	Weitman SD	Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues.	Cancer research	1992	138
9815541	Folic acid	Silver DA	Prostate-specific membrane antigen expression in normal and malignant human tissues.	Clinical cancer research 	1997	179
10699311	Folic acid	Sudimack J	Targeted drug delivery via the folate receptor.	Advanced drug delivery reviews	2000	130
11156248	Folic acid	Sirotnak FM	Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.	Clinical cancer research 	2000	98
12810640	Folic acid	van Engeland M	Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer.	Cancer research	2003	79
12860938	Folic acid	Vogelzang NJ	Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.	Journal of clinical oncology 	2003	413
14755683	Folic acid	Ghosh A	Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.	Journal of cellular biochemistry	2004	113
14977639	Folic acid	Sharp L	Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review.	American journal of epidemiology	2004	73
16421170	Folic acid	Waterland RA	Post-weaning diet affects genomic imprinting at the insulin-like growth factor 2 (Igf2) locus.	Human molecular genetics	2006	83
17062687	Folic acid	Kershaw MH	A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.	Clinical cancer research 	2006	275
17096326	Folic acid	Slattery ML	Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer.	International journal of cancer	2007	87
17254956	Folic acid	Hong S	The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform.	Chemistry & biology	2007	129
18078840	Folic acid	Lukusa T	Human chromosome fragility.	Biochimica et biophysica acta	2008	53
18222534	Folic acid	Kalli KR	Folate receptor alpha as a tumor target in epithelial ovarian cancer.	Gynecologic oncology	2008	72
19078924	Folic acid	Bansal N	The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.	Cancer control 	2009	72
19951991	Folic acid	Puig-Kr√∂ger A	Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages.	Cancer research	2009	75
20223594	Folic acid	Eden T	Aetiology of childhood leukaemia.	Cancer treatment reviews	2010	48
20446114	Folic acid	Ueland PM	Choline and betaine in health and disease.	Journal of inherited metabolic disease	2011	60
20571015	Folic acid	Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group.	Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.	JAMA	2010	60
20594533	Folic acid	Cooper K	Chemoprevention of colorectal cancer: systematic review and economic evaluation.	Health technology assessment	2010	44
20686660	Folic acid	Christensen BC	Breast cancer DNA methylation profiles are associated with tumor size and alcohol and folate intake.	PLoS genetics	2010	59
20802351	Folic acid	Hainsworth JD	A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.	Journal of thoracic oncology 	2010	48
21158707	Folic acid	Huang J	Cancer chemoprevention by targeting the epigenome.	Current drug targets	2011	45
21546571	Folic acid	Song DG	In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).	Cancer research	2011	59
21622715	Folic acid	Bareford MD	Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.	Cancer research	2011	40
21926976	Folic acid	van Dam GM	Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-Œ± targeting: first in-human results.	Nature medicine	2011	352
22281794	Folic acid	Zafarana G	Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy.	Cancer	2012	31
22547449	Folic acid	O'Shannessy DJ	Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance.	Oncotarget	2012	57
22949852	Folic acid	Singh S	Epigenetic effects of environmental chemicals bisphenol A and phthalates.	International journal of molecular sciences	2012	52
22954694	Folic acid	Desmoulin SK	The human proton-coupled folate transporter: Biology and therapeutic applications to cancer.	Cancer biology & therapy	2012	42
22955508	Folic acid	Gerhauser C	Cancer chemoprevention and nutriepigenetics: state of the art and future challenges.	Topics in current chemistry	2013	38
23307860	Folic acid	Banerjee S	New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential.	Clinical cancer research 	2013	64
23474348	Folic acid	Armstrong DK	Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.	Gynecologic oncology	2013	36
23794259	Folic acid	Franchina T	Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer.	Journal of cellular physiology	2014	26
24028341	Folic acid	Zhang Z	Folate receptor Œ± associated with triple-negative breast cancer and poor prognosis.	Archives of pathology & laboratory medicine	2014	21
24451681	Folic acid	Nilsson R	Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer.	Nature communications	2014	73
24798476	Folic acid	Zhong Y	Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.	Biomacromolecules	2014	25
25146845	Folic acid	He J	Association of MTHFR C677T and A1298C polymorphisms with non-Hodgkin lymphoma susceptibility: evidence from a meta-analysis.	Scientific reports	2014	34
25579803	Folic acid	Gustavsson B	A review of the evolution of systemic chemotherapy in the management of colorectal cancer.	Clinical colorectal cancer	2015	40
25816016	Folic acid	Necela BM	Folate receptor-Œ± (FOLR1) expression and function in triple negative tumors.	PloS one	2015	15
26595060	Folic acid	Kurosaki A	Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.	International journal of cancer	2016	11
26795251	Folic acid	Gherardin NA	Diversity of T Cells Restricted by the MHC Class I-Related Molecule MR1 Facilitates Differential Antigen Recognition.	Immunity	2016	20
26921342	Folic acid	Huang YH	Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth.	Cancer research	2016	13
27015562	Folic acid	Booth L	Pemetrexed + Sorafenib lethality is increased by inhibition of ERBB1/2/3-PI3K-NFŒ∫B compensatory survival signaling.	Oncotarget	2016	10
27248175	Folic acid	Cheung A	Targeting folate receptor alpha for cancer treatment.	Oncotarget	2016	12
27280394	Folic acid	Samanta D	PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis.	Cancer research	2016	12
27306792	Folic acid	Hoogstins CE	A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer.	Clinical cancer research 	2016	18
27919747	Folic acid	Wu KF	H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/Œ≤-catenin pathway.	Experimental cell research	2017	9
28236692	Folic acid	Gawde KA	Synthesis and characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin difluorinated analogue.	Journal of colloid and interface science	2017	7
28245646	Folic acid	Luong D	Polyvalent Folate-Dendrimer-Coated Iron Oxide Theranostic Nanoparticles for Simultaneous Magnetic Resonance Imaging and Precise Cancer Cell Targeting.	Biomacromolecules	2017	8
9841917	Mitomycin	M√ºller M	p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs.	The Journal of experimental medicine	1998	123
12065746	Mitomycin	Howlett NG	Biallelic inactivation of BRCA2 in Fanconi anemia.	Science	2002	290
12086603	Mitomycin	Taniguchi T	Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways.	Cell	2002	129
12973351	Mitomycin	Meetei AR	A novel ubiquitin ligase is deficient in Fanconi anemia.	Nature genetics	2003	184
15314022	Mitomycin	Andreassen PR	ATR couples FANCD2 monoubiquitination to the DNA-damage response.	Genes & development	2004	143
15661754	Mitomycin	Howlett NG	The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability.	Human molecular genetics	2005	95
16153896	Mitomycin	Litman R	BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ.	Cancer cell	2005	152
17103105	Mitomycin	Marelli L	Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.	Cardiovascular and interventional radiology	2007	137
20347429	Mitomycin	Singh TR	MHF1-MHF2, a histone-fold-containing protein complex, participates in the Fanconi anemia pathway via FANCM.	Molecular cell	2010	94
21325298	Mitomycin	Brand RE	Serum biomarker panels for the detection of pancreatic cancer.	Clinical cancer research 	2011	72
23103770	Mitomycin	Subramaniam A	Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma.	Biochimica et biophysica acta	2013	42
23388460	Mitomycin	Fu D	Recruitment of DNA polymerase eta by FANCD2 in the early response to DNA damage.	Cell cycle	2013	27
24787015	Mitomycin	Rossi M	High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy.	Cell death & disease	2014	25
25893307	Mitomycin	Chen X	A novel role for non-ubiquitinated FANCD2 in response to hydroxyurea-induced DNA damage.	Oncogene	2016	16
27050274	Mitomycin	Xu T	MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin Œ±5.	Oncotarget	2016	10
27208205	Mitomycin	Park JY	Complementation of hypersensitivity to DNA interstrand crosslinking agents demonstrates that XRCC2 is a Fanconi anaemia gene.	Journal of medical genetics	2016	25
11731512	5-Thymidylic acid	Shirota Y	ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.	Journal of clinical oncology 	2001	112
14752076	5-Thymidylic acid	Popat S	Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.	Journal of clinical oncology 	2004	82
20647341	5-Thymidylic acid	Boni V	miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation.	Molecular cancer therapeutics	2010	48
24732946	5-Thymidylic acid	Wilson PM	Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.	Nature reviews. Clinical oncology	2014	45
10954755	Vorinostat	Richon VM	Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.	Proceedings of the National Academy of Sciences of the United States of America	2000	251
11016644	Vorinostat	Butler LM	Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.	Cancer research	2000	143
12189205	Vorinostat	Butler LM	The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.	Proceedings of the National Academy of Sciences of the United States of America	2002	128
14734806	Vorinostat	Gui CY	Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.	Proceedings of the National Academy of Sciences of the United States of America	2004	159
15596714	Vorinostat	Shao Y	Apoptotic and autophagic cell death induced by histone deacetylase inhibitors.	Proceedings of the National Academy of Sciences of the United States of America	2004	169
15738394	Vorinostat	Peart MJ	Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.	Proceedings of the National Academy of Sciences of the United States of America	2005	151
16186112	Vorinostat	Chen CS	Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes.	The Journal of biological chemistry	2005	77
17363733	Vorinostat	Carew JS	Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.	Blood	2007	183
17545612	Vorinostat	Chen CS	Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.	Cancer research	2007	70
17962618	Vorinostat	Mann BS	FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.	The oncologist	2007	260
18347167	Vorinostat	Weichert W	Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.	Clinical cancer research 	2008	98
18413790	Vorinostat	Fournel M	MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.	Molecular cancer therapeutics	2008	75
19671864	Vorinostat	Badros A	Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.	Clinical cancer research 	2009	69
19738609	Vorinostat	Munster PN	Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.	British journal of cancer	2009	46
20427703	Vorinostat	Leshchenko VV	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.	Blood	2010	51
20460513	Vorinostat	Conti C	Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage.	Cancer research	2010	58
20631069	Vorinostat	Park MA	Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.	Cancer research	2010	41
21084276	Vorinostat	Lopez G	Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.	Cancer research	2011	35
21559012	Vorinostat	Munster PN	A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.	British journal of cancer	2011	81
21637290	Vorinostat	Li D	SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.	Cell death and differentiation	2011	77
21653597	Vorinostat	Singh MM	Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.	Neuro-oncology	2011	38
21660961	Vorinostat	Bruzzese F	HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.	Journal of cellular physiology	2011	43
21909380	Vorinostat	Nalls D	Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.	PloS one	2011	67
21926171	Vorinostat	Eades G	miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells.	The Journal of biological chemistry	2011	62
22002311	Vorinostat	Zhang X	Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.	Oncogene	2012	46
22038994	Vorinostat	Landreville S	Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.	Clinical cancer research 	2012	66
22308110	Vorinostat	Humphreys KJ	Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.	Molecular carcinogenesis	2013	26
22461695	Vorinostat	Yang D	Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.	Journal of immunology	2012	30
23382048	Vorinostat	Nakagawa T	EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.	Cancer research	2013	44
23408854	Vorinostat	Pandiyan K	Functional DNA demethylation is accompanied by chromatin accessibility.	Nucleic acids research	2013	26
23449455	Vorinostat	Bolden JE	HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses.	Cell death & disease	2013	49
24371063	Vorinostat	Shulak L	Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-Œ∫B-dependent autophagy.	Journal of virology	2014	21
24620025	Vorinostat	Archin NM	HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.	The Journal of infectious diseases	2014	89
24991835	Vorinostat	Mahalingam D	Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.	Autophagy	2014	68
25142817	Vorinostat	Montalban-Bravo G	Novel drugs for older patients with acute myeloid leukemia.	Leukemia	2015	20
25393367	Vorinostat	Yang H	Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.	British journal of cancer	2015	26
26136424	Vorinostat	Paschall AV	H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance.	Journal of immunology	2015	17
27239721	Vorinostat	Manal M	Inhibitors of histone deacetylase as antitumor agents: A critical review.	Bioorganic chemistry	2016	14
27363832	Vorinostat	Naymagon L	Novel agents in the treatment of multiple myeloma: a review about the future.	Journal of hematology & oncology	2016	13
27582487	Vorinostat	Min HY	Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.	Clinical cancer research 	2017	5
28486043	Vorinostat	Sekeres MA	Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.	Journal of clinical oncology 	2017	11
16434701	Vitamin D3	Saram√§ki A	Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor.	Nucleic acids research	2006	80
17122772	Vitamin D3	O'Brien CA	A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.	Nature	2007	1111
17363299	Vitamin D3	Santiago C	Structures of T Cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the TIM receptor family.	Immunity	2007	59
17999359	Vitamin D3	Antoniou AC	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.	American journal of human genetics	2007	104
19538496	Vitamin D3	Robinson DS	Regulatory T cells and asthma.	Clinical and experimental allergy 	2009	47
20227041	Vitamin D3	Stambolsky P	Modulation of the vitamin D3 response by cancer-associated mutant p53.	Cancer cell	2010	81
21792899	Vitamin D3	Slattery ML	Toll-like receptor genes and their association with colon and rectal cancer development and prognosis.	International journal of cancer	2012	31
22095230	Vitamin D3	Janjetovic Z	High basal NF-Œ∫B activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives.	British journal of cancer	2011	43
22446628	Vitamin D3	Everitt AR	IFITM3 restricts the morbidity and mortality associated with influenza.	Nature	2012	208
23869782	Vitamin D3	Slominski AT	Cytochromes p450 and skin cancer: role of local endocrine pathways.	Anti-cancer agents in medicinal chemistry	2014	37
24529992	Vitamin D3	Bikle DD	Vitamin D metabolism, mechanism of action, and clinical applications.	Chemistry & biology	2014	75
24808867	Vitamin D3	Carlberg C	Genome-wide (over)view on the actions of vitamin D.	Frontiers in physiology	2014	22
25451058	Vitamin D3	Lu G	Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity.	Antimicrobial agents and chemotherapy	2015	20
25617667	Vitamin D3	Slominski AT	Novel non-calcemic secosteroids that are produced by human epidermal keratinocytes protect against solar radiation.	The Journal of steroid biochemistry and molecular biology	2015	20
25776849	Vitamin D3	Hollm√©n M	Characterization of macrophage--cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer.	Scientific reports	2015	16
11181660	Methotrexate	Ravdin PM	Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.	Journal of clinical oncology 	2001	169
12689936	Methotrexate	Giebel S	Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.	Blood	2003	101
12944571	Methotrexate	Grossman HB	Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.	The New England journal of medicine	2003	277
16034041	Methotrexate	von der Maase H	Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.	Journal of clinical oncology 	2005	228
16230674	Methotrexate	Fisher RI	New treatment options have changed the survival of patients with follicular lymphoma.	Journal of clinical oncology 	2005	69
16707747	Methotrexate	Pritchard KI	HER2 and responsiveness of breast cancer to adjuvant chemotherapy.	The New England journal of medicine	2006	103
17132719	Methotrexate	Patte C	Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.	Blood	2007	64
17469100	Methotrexate	Wolfe F	The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.	Arthritis and rheumatism	2007	59
17686970	Methotrexate	Mishra PJ	A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance.	Proceedings of the National Academy of Sciences of the United States of America	2007	140
18370855	Methotrexate	Polgar O	ABCG2: structure, function and role in drug response.	Expert opinion on drug metabolism & toxicology	2008	50
18411419	Methotrexate	Khouri IF	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.	Blood	2008	92
18754698	Methotrexate	Chou AJ	Therapy for osteosarcoma: where do we go from here?	Paediatric drugs	2008	67
19088023	Methotrexate	Song B	miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit.	Clinical cancer research 	2008	61
19289630	Methotrexate	Stewart JS	Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck corrected.	Journal of clinical oncology 	2009	60
19684603	Methotrexate	Trevi√±o LR	Germline genomic variants associated with childhood acute lymphoblastic leukemia.	Nature genetics	2009	132
19734943	Methotrexate	Song B	Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells.	Oncogene	2009	125
20008645	Methotrexate	Byrski T	Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.	Journal of clinical oncology 	2010	116
20010625	Methotrexate	M√∂ricke A	Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.	Leukemia	2010	87
20113825	Methotrexate	Gianni L	Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.	Lancet	2010	184
20224986	Methotrexate	Liu T	Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.	Molecular and cellular biochemistry	2010	43
20433742	Methotrexate	Song B	Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells.	Molecular cancer	2010	73
20943624	Methotrexate	Vermorken JB	Optimal treatment for recurrent/metastatic head and neck cancer.	Annals of oncology 	2010	58
21190991	Methotrexate	Lamy T	How I treat LGL leukemia.	Blood	2011	46
21385856	Methotrexate	Avvisati G	AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance.	Blood	2011	38
21501481	Methotrexate	Kao KJ	Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.	BMC cancer	2011	81
21917518	Methotrexate	Di Leo A	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.	The Lancet. Oncology	2011	36
22045784	Methotrexate	Chan CC	Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.	The oncologist	2011	47
22102692	Methotrexate	Huang J	HMGB1 promotes drug resistance in osteosarcoma.	Cancer research	2012	84
22151962	Methotrexate	West NR	Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.	Breast cancer research 	2011	92
22301993	Methotrexate	Huang J	Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma.	Autophagy	2012	33
22351696	Methotrexate	Cheang MC	Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.	Clinical cancer research 	2012	37
22665540	Methotrexate	Ebb D	Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.	Journal of clinical oncology 	2012	46
22715121	Methotrexate	Iland HJ	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).	Blood	2012	42
22845486	Methotrexate	Barrett D	Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.	Paediatric drugs	2012	35
22869883	Methotrexate	Koreth J	Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.	Journal of clinical oncology 	2012	39
23032984	Methotrexate	Deepak P	T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-Œ±) inhibitors: results of the REFURBISH study.	The American journal of gastroenterology	2013	29
23291185	Methotrexate	Ma Y	Inhibition of the Wnt-Œ≤-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy.	Biochemical and biophysical research communications	2013	28
23341518	Methotrexate	Loi S	Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.	Journal of clinical oncology 	2013	227
23462296	Methotrexate	Januchowski R	Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2013	27
23490655	Methotrexate	Harbeck N	Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.	European journal of cancer	2013	28
23792190	Methotrexate	S√°ez-Ayala M	Directed phenotype switching as an effective antimelanoma strategy.	Cancer cell	2013	30
24443618	Methotrexate	Prat A	Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.	Clinical cancer research 	2014	33
24525232	Methotrexate	Choi W	Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.	Cancer cell	2014	181
24821881	Methotrexate	Plimack ER	Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.	Journal of clinical oncology 	2014	23
24821883	Methotrexate	Choueiri TK	Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.	Journal of clinical oncology 	2014	21
24958183	Methotrexate	Choi SW	Current and emerging strategies for the prevention of graft-versus-host disease.	Nature reviews. Clinical oncology	2014	29
25456364	Methotrexate	Kennedy GA	Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.	The Lancet. Oncology	2014	35
25498218	Methotrexate	Sternberg CN	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.	The Lancet. Oncology	2015	32
25498219	Methotrexate	Grignani G	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.	The Lancet. Oncology	2015	34
25892145	Methotrexate	Machiels JP	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2015	46
26130705	Methotrexate	Ciurea SO	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.	Blood	2015	62
26247164	Methotrexate	Axelrad J	Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.	Clinical gastroenterology and hepatology 	2016	11
27211551	Methotrexate	Pasquier E	Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study.	EBioMedicine	2016	12
27307501	Methotrexate	Cappelli LC	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.	Annals of the rheumatic diseases	2017	17
27324280	Methotrexate	Piperno-Neumann S	Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.	The Lancet. Oncology	2016	12
27827824	Methotrexate	Abu Zaid M	Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.	Blood	2017	7
28061797	Methotrexate	Angulo P	Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy.	Journal of hematology & oncology	2017	7
28270698	Methotrexate	Alexander JL	Gut microbiota modulation of chemotherapy efficacy and toxicity.	Nature reviews. Gastroenterology & hepatology	2017	9
1673147	L-Methionine	Wolf SF	Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells.	Journal of immunology	1991	163
9067278	L-Methionine	Ma J	Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer.	Cancer research	1997	112
11001804	L-Methionine	Lucock M	Folic acid: nutritional biochemistry, molecular biology, and role in disease processes.	Molecular genetics and metabolism	2000	107
12163691	L-Methionine	Giovannucci E	Epidemiologic studies of folate and colorectal neoplasia: a review.	The Journal of nutrition	2002	96
12730865	L-Methionine	Pufulete M	Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study.	Gastroenterology	2003	76
14532004	L-Methionine	Bloom J	Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation.	Cell	2003	85
15298442	L-Methionine	Stover PJ	Physiology of folate and vitamin B12 in health and disease.	Nutrition reviews	2004	91
15728811	L-Methionine	Kobayashi S	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2005	914
15737014	L-Methionine	Pao W	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.	PLoS medicine	2005	933
15837811	L-Methionine	Chen JL	Structural and kinetic basis for heightened immunogenicity of T cell vaccines.	The Journal of experimental medicine	2005	80
16912157	L-Methionine	Inukai M	Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.	Cancer research	2006	117
16924677	L-Methionine	Kutay H	Downregulation of miR-122 in the rodent and human hepatocellular carcinomas.	Journal of cellular biochemistry	2006	181
17020982	L-Methionine	Kosaka T	Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.	Clinical cancer research 	2006	143
17085664	L-Methionine	Balak MN	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.	Clinical cancer research 	2006	213
17160901	L-Methionine	Upadhyaya M	An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation.	American journal of human genetics	2007	64
17607709	L-Methionine	Benvenuti S	The MET receptor tyrosine kinase in invasion and metastasis.	Journal of cellular physiology	2007	81
18077431	L-Methionine	Beroukhim R	Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.	Proceedings of the National Academy of Sciences of the United States of America	2007	422
18093943	L-Methionine	Bean J	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.	Proceedings of the National Academy of Sciences of the United States of America	2007	476
18376396	L-Methionine	Gregory PA	The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.	Nature cell biology	2008	1244
18379349	L-Methionine	Beau-Faller M	MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor na√Øve cohort.	Journal of thoracic oncology 	2008	64
18413375	L-Methionine	Terakawa Y	Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy.	Journal of nuclear medicine 	2008	57
18600305	L-Methionine	Wells A	E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas.	Clinical & experimental metastasis	2008	85
18709663	L-Methionine	Ma PC	Expression and mutational analysis of MET in human solid cancers.	Genes, chromosomes & cancer	2008	79
18728283	L-Methionine	Ricketts C	Germline SDHB mutations and familial renal cell carcinoma.	Journal of the National Cancer Institute	2008	85
18981003	L-Methionine	Costa DB	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.	Clinical cancer research 	2008	54
19359275	L-Methionine	Snider L	RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy.	Human molecular genetics	2009	87
19632948	L-Methionine	Nguyen KS	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.	Clinical lung cancer	2009	116
19723643	L-Methionine	Krishnaswamy S	Ethnic differences and functional analysis of MET mutations in lung cancer.	Clinical cancer research 	2009	61
20068183	L-Methionine	Schiffman JD	Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.	Cancer research	2010	91
20124471	L-Methionine	McDermott U	Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.	Cancer research	2010	55
20129249	L-Methionine	Turke AB	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.	Cancer cell	2010	311
20145172	L-Methionine	Corney DC	Frequent downregulation of miR-34 family in human ovarian cancers.	Clinical cancer research 	2010	89
20215504	L-Methionine	Schoeberl B	An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.	Cancer research	2010	94
20805998	L-Methionine	Kong D	Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells.	PloS one	2010	132
20852131	L-Methionine	Ashworth TD	Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1.	Blood	2010	42
21266357	L-Methionine	Qi J	Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.	Cancer research	2011	50
21336307	L-Methionine	Chang CJ	p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs.	Nature cell biology	2011	221
21343371	L-Methionine	Anglesio MS	IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.	Clinical cancer research 	2011	61
21521745	L-Methionine	Tworkoski K	Phosphoproteomic screen identifies potential therapeutic targets in melanoma.	Molecular cancer research 	2011	37
21665936	L-Methionine	Armstrong AJ	Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.	Molecular cancer research 	2011	172
21840990	L-Methionine	Iozzo RV	Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling.	The Journal of biological chemistry	2011	52
21878621	L-Methionine	Teng YW	Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas.	The Journal of biological chemistry	2011	51
22389872	L-Methionine	Catenacci DV	Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.	Cancer discovery	2011	39
22580601	L-Methionine	Muller PA	Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion.	Oncogene	2013	57
22678362	L-Methionine	Stehling O	MMS19 assembles iron-sulfur proteins required for DNA metabolism and genomic integrity.	Science	2012	67
22763439	L-Methionine	Straussman R	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.	Nature	2012	461
23073625	L-Methionine	Lu SC	S-adenosylmethionine in liver health, injury, and cancer.	Physiological reviews	2012	76
23241961	L-Methionine	Yang H	MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma.	The Journal of clinical investigation	2013	35
23431330	L-Methionine	Pavon-Eternod M	Overexpression of initiator methionine tRNA leads to global reprogramming of tRNA expression and increased proliferation in human epithelial cells.	RNA	2013	31
23455543	L-Methionine	Ulanovskaya OA	NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink.	Nature chemical biology	2013	62
23539183	L-Methionine	Lewis PW	Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.	Science	2013	226
23603901	L-Methionine	Chan KM	The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.	Genes & development	2013	133
23721103	L-Methionine	Sakai K	Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.	Cancer science	2013	28
23916847	L-Methionine	Murphy SK	Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.	Gastroenterology	2013	52
24037894	L-Methionine	Fiorentino DF	Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1Œ≥.	Arthritis and rheumatism	2013	37
24222941	L-Methionine	Dongiovanni P	PNPLA3 I148M polymorphism and progressive liver disease.	World journal of gastroenterology	2013	32
25521095	L-Methionine	Steuer CE	The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer.	Cancer	2015	20
25525250	L-Methionine	Funato K	Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation.	Science	2014	60
25526088	L-Methionine	Pietrocola F	Spermidine induces autophagy by inhibiting the acetyltransferase EP300.	Cell death and differentiation	2015	22
25671304	L-Methionine	Lamb R	Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction.	Oncotarget	2015	19
25736301	L-Methionine	Tanaka N	Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet.	Biochimica et biophysica acta	2015	20
25900080	L-Methionine	O'Leary VB	PARTICLE, a Triplex-Forming Long ncRNA, Regulates Locus-Specific Methylation in Response to Low-Dose Irradiation.	Cell reports	2015	29
26711467	L-Methionine	Vartanian S	Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis.	Molecular & cellular proteomics 	2016	11
26912361	L-Methionine	Mavrakis KJ	Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.	Science	2016	33
27229140	L-Methionine	Fang D	The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas.	Science	2016	20
27523608	L-Methionine	Damgaard RB	The Deubiquitinase OTULIN Is an Essential Negative Regulator of Inflammation and Autoimmunity.	Cell	2016	25
27868107	L-Methionine	Horowitz A	Class I HLA haplotypes form two schools that educate NK cells in different ways.	Science immunology	2016	12
28263307	L-Methionine	Piunti A	Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.	Nature medicine	2017	16
28263309	L-Methionine	Mohammad F	EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.	Nature medicine	2017	17
15572759	Deoxyuridine triphosphate	Liu X	Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.	Journal of the National Cancer Institute	2004	71
19509158	Deoxyuridine triphosphate	Li J	MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor.	Clinical cancer research 	2009	102
20145154	Deoxyuridine triphosphate	Kaneda H	FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth.	Cancer research	2010	53
20179157	Deoxyuridine triphosphate	Beljanski V	A novel sphingosine kinase inhibitor induces autophagy in tumor cells.	The Journal of pharmacology and experimental therapeutics	2010	45
20844036	Deoxyuridine triphosphate	Abend JR	Regulation of tumor necrosis factor-like weak inducer of apoptosis receptor protein (TWEAKR) expression by Kaposi's sarcoma-associated herpesvirus microRNA prevents TWEAK-induced apoptosis and inflammatory cytokine expression.	Journal of virology	2010	66
20956938	Deoxyuridine triphosphate	Dunn EF	Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.	Oncogene	2011	40
21325072	Deoxyuridine triphosphate	Song L	Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-Œ∫B pathway in human non-small cell lung cancer.	Clinical cancer research 	2011	50
21884573	Deoxyuridine triphosphate	Huang C	Œ≤1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.	Breast cancer research 	2011	58
22264502	Deoxyuridine triphosphate	Cui Z	The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor.	Urologic oncology	2013	48
22933030	Deoxyuridine triphosphate	Niraula S	Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.	Breast cancer research and treatment	2012	66
2328727	Progesterone	Kastner P	Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B.	The EMBO journal	1990	265
2644532	Progesterone	Fisher B	A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.	The New England journal of medicine	1989	154
3458212	Progesterone	Berthois Y	Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture.	Proceedings of the National Academy of Sciences of the United States of America	1986	165
7723794	Progesterone	Taplin ME	Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.	The New England journal of medicine	1995	200
8405201	Progesterone	Pike MC	Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.	Epidemiologic reviews	1993	171
8504731	Progesterone	Krishnan AV	Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving.	Endocrinology	1993	140
8643607	Progesterone	Yeh S	Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells.	Proceedings of the National Academy of Sciences of the United States of America	1996	121
9030781	Progesterone	Meijer L	Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.	European journal of biochemistry	1997	319
9371488	Progesterone	Clarke RB	Dissociation between steroid receptor expression and cell proliferation in the human breast.	Cancer research	1997	160
9504686	Progesterone	Allred DC	Prognostic and predictive factors in breast cancer by immunohistochemical analysis.	Modern pathology 	1998	420
9524123	Progesterone	Migliaccio A	Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor.	The EMBO journal	1998	125
9839517	Progesterone	Risch HA	Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone.	Journal of the National Cancer Institute	1998	141
10655479	Progesterone	Lange CA	Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome.	Proceedings of the National Academy of Sciences of the United States of America	2000	137
11043579	Progesterone	Filardo EJ	Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.	Molecular endocrinology	2000	343
11140706	Progesterone	Camp RL	Validation of tissue microarray technology in breast carcinoma.	Laboratory investigation; a journal of technical methods and pathology	2000	121
11171938	Progesterone	Clarke R	Cellular and molecular pharmacology of antiestrogen action and resistance.	Pharmacological reviews	2001	93
11545730	Progesterone	Boonyaratanakornkit V	Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases.	Molecular cell	2001	140
11559718	Progesterone	Ellis MJ	Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.	Journal of clinical oncology 	2001	104
11585728	Progesterone	Yang X	Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.	Cancer research	2001	107
11717311	Progesterone	Richer JK	Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells.	The Journal of biological chemistry	2002	167
11719442	Progesterone	Hayward SW	Malignant transformation in a nontumorigenic human prostatic epithelial cell line.	Cancer research	2001	105
11733374	Progesterone	Torhorst J	Tissue microarrays for rapid linking of molecular changes to clinical endpoints.	The American journal of pathology	2001	88
11745677	Progesterone	Piek JM	Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.	The Journal of pathology	2001	142
11792709	Progesterone	Yang F	Linking beta-catenin to androgen-signaling pathway.	The Journal of biological chemistry	2002	101
11981002	Progesterone	Lakhani SR	The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.	Journal of clinical oncology 	2002	177
12160086	Progesterone	Neville MC	Hormonal regulation of mammary differentiation and milk secretion.	Journal of mammary gland biology and neoplasia	2002	95
12373602	Progesterone	Boyd NF	The association of breast mitogens with mammographic densities.	British journal of cancer	2002	85
12529347	Progesterone	Konecny G	Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.	Journal of the National Cancer Institute	2003	91
12618500	Progesterone	Osborne CK	Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.	Journal of the National Cancer Institute	2003	187
12627523	Progesterone	Bos R	Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.	Cancer	2003	141
12743151	Progesterone	Bardou VJ	Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.	Journal of clinical oncology 	2003	122
12824206	Progesterone	Li CI	Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.	JAMA	2003	77
12858169	Progesterone	Johnson MD	Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland.	Nature medicine	2003	89
14578209	Progesterone	Lin EY	Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.	The American journal of pathology	2003	356
14695316	Progesterone	Cronin M	Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay.	The American journal of pathology	2004	134
14759989	Progesterone	Colditz GA	Risk factors for breast cancer according to estrogen and progesterone receptor status.	Journal of the National Cancer Institute	2004	152
15084238	Progesterone	Arpino G	Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.	Breast cancer research 	2004	115
15169792	Progesterone	Nevalainen MT	Signal transducer and activator of transcription-5 activation and breast cancer prognosis.	Journal of clinical oncology 	2004	71
15172987	Progesterone	Widschwendter M	Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen.	Cancer research	2004	96
15221988	Progesterone	Giordano SH	Breast carcinoma in men: a population-based study.	Cancer	2004	114
15455388	Progesterone	Lengyel E	C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.	International journal of cancer	2005	88
15466970	Progesterone	Althuis MD	Etiology of hormone receptor-defined breast cancer: a systematic review of the literature.	Cancer epidemiology, biomarkers & prevention 	2004	190
15475452	Progesterone	Colleoni M	Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.	Clinical cancer research 	2004	73
15539556	Progesterone	Thomas P	Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells.	Endocrinology	2005	359
15545664	Progesterone	Winer EP	American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.	Journal of clinical oncology 	2005	146
15574759	Progesterone	Al-Kuraya K	Prognostic relevance of gene amplifications and coamplifications in breast cancer.	Cancer research	2004	82
15601642	Progesterone	Missmer SA	Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.	Journal of the National Cancer Institute	2004	142
15617686	Progesterone	Clarke RB	A putative human breast stem cell population is enriched for steroid receptor-positive cells.	Developmental biology	2005	89
15641021	Progesterone	Simpson PT	Molecular evolution of breast cancer.	The Journal of pathology	2005	99
15668482	Progesterone	Lukanova A	Endogenous hormones and ovarian cancer: epidemiology and current hypotheses.	Cancer epidemiology, biomarkers & prevention 	2005	74
15685451	Progesterone	Lim YC	Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.	Cancer chemotherapy and pharmacology	2005	74
15746036	Progesterone	Takahashi Y	Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.	Clinical cancer research 	2005	89
15753463	Progesterone	Gutierrez MC	Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.	Journal of clinical oncology 	2005	129
15762276	Progesterone	Nadji M	Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers.	American journal of clinical pathology	2005	70
15805248	Progesterone	Saal LH	PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.	Cancer research	2005	258
15897552	Progesterone	Mamounas EP	Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.	Journal of clinical oncology 	2005	110
15900045	Progesterone	Kaaks R	Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).	Journal of the National Cancer Institute	2005	91
16000569	Progesterone	De Laurentiis M	A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.	Clinical cancer research 	2005	76
16019138	Progesterone	Chen DC	Serum adiponectin and leptin levels in Taiwanese breast cancer patients.	Cancer letters	2006	86
16103053	Progesterone	Iorio MV	MicroRNA gene expression deregulation in human breast cancer.	Cancer research	2005	1201
16126938	Progesterone	Mulholland DJ	Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?	Endocrine reviews	2005	129
16145046	Progesterone	Arpino G	Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.	Journal of the National Cancer Institute	2005	104
16175185	Progesterone	Li CI	Clinical characteristics of different histologic types of breast cancer.	British journal of cancer	2005	73
16234531	Progesterone	Cui X	Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.	Journal of clinical oncology 	2005	118
16299229	Progesterone	Willipinski-Stapelfeldt B	Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells.	Clinical cancer research 	2005	81
16339279	Progesterone	Condon JC	Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-kappaB may contribute to the onset of labor through inhibition of PR function.	Molecular endocrinology	2006	85
16357129	Progesterone	Mehra R	Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.	Cancer research	2005	84
16397211	Progesterone	Fiegl H	Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer.	Cancer research	2006	65
16489055	Progesterone	Tworoger SS	Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women.	Cancer research	2006	80
16489069	Progesterone	Olivier M	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.	Clinical cancer research 	2006	126
16491124	Progesterone	Doane AS	An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.	Oncogene	2006	154
16505416	Progesterone	Oh DS	Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.	Journal of clinical oncology 	2006	119
16515478	Progesterone	Ariazi EA	Estrogen receptors as therapeutic targets in breast cancer.	Current topics in medicinal chemistry	2006	63
16585219	Progesterone	Creighton CJ	Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.	Cancer research	2006	86
16611412	Progesterone	Ghebeh H	The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.	Neoplasia	2006	142
16648502	Progesterone	Wapnir IL	Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.	Journal of clinical oncology 	2006	71
16678549	Progesterone	Benowitz NL	Female sex and oral contraceptive use accelerate nicotine metabolism.	Clinical pharmacology and therapeutics	2006	111
16702379	Progesterone	Missmer SA	Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period.	Cancer epidemiology, biomarkers & prevention 	2006	69
16757721	Progesterone	Carey LA	Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.	JAMA	2006	1027
16772530	Progesterone	Hardy DB	Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-kappaB activation of cyclooxygenase 2 expression.	Molecular endocrinology	2006	69
16849684	Progesterone	Asselin-Labat ML	Steroid hormone receptor status of mouse mammary stem cells.	Journal of the National Cancer Institute	2006	98
16951137	Progesterone	Amend K	Breast cancer in African-American women: differences in tumor biology from European-American women.	Cancer research	2006	67
17074804	Progesterone	Faivre EJ	Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells.	Molecular and cellular biology	2007	85
17085646	Progesterone	Filardo EJ	Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.	Clinical cancer research 	2006	101
17113977	Progesterone	Russo J	The role of estrogen in the initiation of breast cancer.	The Journal of steroid biochemistry and molecular biology	2006	82
17116942	Progesterone	Haffty BG	Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.	Journal of clinical oncology 	2006	226
17138644	Progesterone	Boonyaratanakornkit V	The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle.	Molecular endocrinology	2007	72
17146782	Progesterone	Rakha EA	Prognostic markers in triple-negative breast cancer.	Cancer	2007	285
17239243	Progesterone	Dunnwald LK	Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.	Breast cancer research 	2007	158
17245340	Progesterone	Forget MA	The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types.	British journal of cancer	2007	57
17259978	Progesterone	Janowski BA	Activating gene expression in mammalian cells with promoter-targeted duplex RNAs.	Nature chemical biology	2007	168
17261184	Progesterone	Chavey C	Oestrogen receptor negative breast cancers exhibit high cytokine content.	Breast cancer research 	2007	86
17308128	Progesterone	Albanito L	G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.	Cancer research	2007	140
17312270	Progesterone	Adams BD	The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines.	Molecular endocrinology	2007	152
17329194	Progesterone	Cleator S	Triple-negative breast cancer: therapeutic options.	The Lancet. Oncology	2007	211
17332353	Progesterone	Huang F	Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.	Cancer research	2007	105
17334350	Progesterone	Rodriguez-Pinilla SM	Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer.	Modern pathology 	2007	64
17372238	Progesterone	Yang XR	Differences in risk factors for breast cancer molecular subtypes in a population-based study.	Cancer epidemiology, biomarkers & prevention 	2007	161
17387718	Progesterone	Bauer KR	Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.	Cancer	2007	481
17403429	Progesterone	Smith HO	GPR30: a novel indicator of poor survival for endometrial carcinoma.	American journal of obstetrics and gynecology	2007	77
17409397	Progesterone	Pick E	High HSP90 expression is associated with decreased survival in breast cancer.	Cancer research	2007	78
17446929	Progesterone	Leong CO	The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.	The Journal of clinical investigation	2007	101
17462639	Progesterone	Engmann L	The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.	Fertility and sterility	2008	62
17510236	Progesterone	Burney RO	Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis.	Endocrinology	2007	162
17512856	Progesterone	LHRH-agonists in Early Breast Cancer Overview group.	Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.	Lancet	2007	61
17652280	Progesterone	Glass AG	Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.	Journal of the National Cancer Institute	2007	99
17671124	Progesterone	Badve S	FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.	Clinical cancer research 	2007	69
17671126	Progesterone	Dent R	Triple-negative breast cancer: clinical features and patterns of recurrence.	Clinical cancer research 	2007	767
17679725	Progesterone	Viale G	Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.	Journal of clinical oncology 	2007	80
17679728	Progesterone	Smith IE	A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.	Journal of clinical oncology 	2007	58
17910759	Progesterone	Kreike B	Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.	Breast cancer research 	2007	171
17954709	Progesterone	Harris L	American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.	Journal of clinical oncology 	2007	496
18037158	Progesterone	Tomsov√° M	Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.	Gynecologic oncology	2008	64
18048329	Progesterone	Gupta GP	ID genes mediate tumor reinitiation during breast cancer lung metastasis.	Proceedings of the National Academy of Sciences of the United States of America	2007	91
18089790	Progesterone	Sempere LF	Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer.	Cancer research	2007	212
18171422	Progesterone	Reis-Filho JS	Triple negative tumours: a critical review.	Histopathology	2008	228
18202149	Progesterone	Faivre EJ	Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors.	Molecular endocrinology	2008	61
18216219	Progesterone	Arpino G	Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.	Endocrine reviews	2008	143
18227529	Progesterone	Dowsett M	Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.	Journal of clinical oncology 	2008	84
18245484	Progesterone	Massarweh S	Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.	Cancer research	2008	154
18250347	Progesterone	Liedtke C	Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.	Journal of clinical oncology 	2008	473
18285604	Progesterone	Kyndi M	Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.	Journal of clinical oncology 	2008	89
18316557	Progesterone	Cheang MC	Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.	Clinical cancer research 	2008	318
18324472	Progesterone	Lund MJ	Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.	Breast cancer research and treatment	2009	114
18381931	Progesterone	Wu JM	Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases.	Clinical cancer research 	2008	68
18386815	Progesterone	Davies MP	Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.	International journal of cancer	2008	53
18391223	Progesterone	Horwitz KB	Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.	Proceedings of the National Academy of Sciences of the United States of America	2008	62
18413639	Progesterone	Nguyen PL	Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.	Journal of clinical oncology 	2008	162
18451146	Progesterone	Yang XH	CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization.	Cancer research	2008	63
18487567	Progesterone	Badve SS	Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.	Journal of clinical oncology 	2008	60
18543098	Progesterone	Dent R	Pattern of metastatic spread in triple-negative breast cancer.	Breast cancer research and treatment	2009	88
18559090	Progesterone	Honeth G	The CD44+/CD24- phenotype is enriched in basal-like breast tumors.	Breast cancer research 	2008	186
18612148	Progesterone	Anders CK	Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.	Journal of clinical oncology 	2008	159
18669459	Progesterone	Honma N	Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.	Journal of clinical oncology 	2008	58
18679793	Progesterone	Tewes M	Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.	Breast cancer research and treatment	2009	52
18681955	Progesterone	Tamimi RM	Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.	Breast cancer research 	2008	90
18698041	Progesterone	Shaaban AM	Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.	Clinical cancer research 	2008	63
18726992	Progesterone	Phipps AI	Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer.	Cancer	2008	54
18779615	Progesterone	Atchley DP	Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.	Journal of clinical oncology 	2008	113
18980022	Progesterone	Anders C	Understanding and treating triple-negative breast cancer.	Oncology	2008	67
18981013	Progesterone	Luu TH	A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.	Clinical cancer research 	2008	64
18988226	Progesterone	Suzuki R	Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis.	International journal of cancer	2009	72
19028704	Progesterone	Rebbeck TR	Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.	Carcinogenesis	2009	46
19042984	Progesterone	Sturgeon CM	National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.	Clinical chemistry	2008	97
19088018	Progesterone	Dowsett M	Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.	Clinical cancer research 	2008	64
19188147	Progesterone	Beck AH	The macrophage colony-stimulating factor 1 response signature in breast carcinoma.	Clinical cancer research 	2009	59
19204205	Progesterone	Hugh J	Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.	Journal of clinical oncology 	2009	111
19276248	Progesterone	Gonzalez-Angulo AM	Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.	Clinical cancer research 	2009	72
19298662	Progesterone	Young SR	The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.	BMC cancer	2009	55
19299408	Progesterone	Simmons C	Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?	Annals of oncology 	2009	62
19317994	Progesterone	Gnerlich JL	Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease.	Journal of the American College of Surgeons	2009	69
19318481	Progesterone	Rakha EA	Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.	Clinical cancer research 	2009	132
19318616	Progesterone	Setiawan VW	Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study.	American journal of epidemiology	2009	76
19320967	Progesterone	Stead LA	Triple-negative breast cancers are increased in black women regardless of age or body mass index.	Breast cancer research 	2009	81
19336554	Progesterone	Dolle JM	Risk factors for triple-negative breast cancer in women under the age of 45 years.	Cancer epidemiology, biomarkers & prevention 	2009	76
19342456	Progesterone	Graham JD	DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast.	Endocrinology	2009	50
19343511	Progesterone	Trivers KF	The epidemiology of triple-negative breast cancer, including race.	Cancer causes & control 	2009	82
19351835	Progesterone	Alli E	Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.	Cancer research	2009	52
19372580	Progesterone	Hu X	Genetic alterations and oncogenic pathways associated with breast cancer subtypes.	Molecular cancer research 	2009	80
19380449	Progesterone	Baselga J	Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2009	148
19380452	Progesterone	Penault-Llorca F	Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2009	50
19385968	Progesterone	Morimoto K	Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.	Cancer science	2009	59
19411448	Progesterone	Witkiewicz AK	An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.	The American journal of pathology	2009	116
19416831	Progesterone	Caldas-Lopes E	Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.	Proceedings of the National Academy of Sciences of the United States of America	2009	97
19432961	Progesterone	Lowery AJ	MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.	Breast cancer research 	2009	129
19436038	Progesterone	Cheang MC	Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.	Journal of the National Cancer Institute	2009	447
19440038	Progesterone	Liu B	Metformin induces unique biological and molecular responses in triple negative breast cancer cells.	Cell cycle	2009	123
19454029	Progesterone	Zhu W	Circulating microRNAs in breast cancer and healthy subjects.	BMC research notes	2009	114
19463150	Progesterone	Kwan ML	Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors.	Breast cancer research 	2009	95
19567422	Progesterone	Milne RL	Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.	Journal of the National Cancer Institute	2009	52
19574486	Progesterone	Onitilo AA	Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.	Clinical medicine & research	2009	165
19596646	Progesterone	Anders CK	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.	Clinical breast cancer	2009	118
19596702	Progesterone	Liedtke C	Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.	Annals of oncology 	2009	71
19638585	Progesterone	Peters AA	Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.	Cancer research	2009	79
19664291	Progesterone	Fehm T	Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.	Breast cancer research 	2009	61
19687332	Progesterone	Ellard SL	Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.	Journal of clinical oncology 	2009	60
19704069	Progesterone	Huo D	Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.	Journal of clinical oncology 	2009	109
19720911	Progesterone	Millar EK	Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.	Journal of clinical oncology 	2009	69
19764994	Progesterone	Parise CA	Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.	The breast journal	2009	73
19775602	Progesterone	Dawson SJ	Triple negative breast cancers: clinical and prognostic implications.	European journal of cancer	2009	61
19826037	Progesterone	Maillot G	Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth.	Cancer research	2009	92
19858088	Progesterone	Aitken SJ	Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.	Annals of oncology 	2010	43
19887463	Progesterone	Park S	Expression of androgen receptors in primary breast cancer.	Annals of oncology 	2010	71
19898421	Progesterone	Niemeier LA	Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.	Modern pathology 	2010	81
19901010	Progesterone	Gluz O	Triple-negative breast cancer--current status and future directions.	Annals of oncology 	2009	125
19949017	Progesterone	Dowsett M	Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.	Journal of clinical oncology 	2010	178
19994911	Progesterone	Giske√∏deg√•rd GF	Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics.	Journal of proteome research	2010	43
20060649	Progesterone	Bosch A	Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.	Cancer treatment reviews	2010	62
20082448	Progesterone	Rimawi MF	Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes.	Cancer	2010	52
20100965	Progesterone	Silver DP	Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.	Journal of clinical oncology 	2010	231
20124474	Progesterone	Hoffman AE	CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses.	Cancer research	2010	49
20179196	Progesterone	Turner N	FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.	Cancer research	2010	139
20194857	Progesterone	Voduc KD	Breast cancer subtypes and the risk of local and regional relapse.	Journal of clinical oncology 	2010	247
20332136	Progesterone	Cancello G	Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.	Annals of oncology 	2010	41
20404251	Progesterone	Hammond ME	American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.	Journal of clinical oncology 	2010	560
20427430	Progesterone	Kerlikowske K	Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.	Journal of the National Cancer Institute	2010	84
20524868	Progesterone	Hammond ME	American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.	Archives of pathology & laboratory medicine	2010	84
20537966	Progesterone	Podo F	Triple-negative breast cancer: present challenges and new perspectives.	Molecular oncology	2010	70
20547990	Progesterone	Sestak I	Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.	Journal of clinical oncology 	2010	59
20569503	Progesterone	Creighton CJ	Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.	Breast cancer research 	2010	78
20586616	Progesterone	Hammond ME	American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).	Archives of pathology & laboratory medicine	2010	150
20629078	Progesterone	Stark A	African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study.	Cancer	2010	54
20647302	Progesterone	Weigel MT	Current and emerging biomarkers in breast cancer: prognosis and prediction.	Endocrine-related cancer	2010	99
20663194	Progesterone	Tuominen VJ	ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67.	Breast cancer research 	2010	142
20664514	Progesterone	Ismail-Khan R	A review of triple-negative breast cancer.	Cancer control 	2010	42
20664598	Progesterone	Dawson SJ	BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.	British journal of cancer	2010	58
20665103	Progesterone	Kabos P	Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.	Breast cancer research and treatment	2011	45
20679727	Progesterone	Jiang Z	Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.	The Journal of clinical investigation	2010	58
20735820	Progesterone	Cole LA	Biological functions of hCG and hCG-related molecules.	Reproductive biology and endocrinology 	2010	43
20798217	Progesterone	Hastak K	Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.	Cancer research	2010	47
20813970	Progesterone	Esteva FJ	PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.	The American journal of pathology	2010	100
20837693	Progesterone	Nielsen TO	A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.	Clinical cancer research 	2010	187
20861225	Progesterone	Toft DJ	Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.	Molecular endocrinology	2011	40
20863372	Progesterone	Hoefnagel LD	Receptor conversion in distant breast cancer metastases.	Breast cancer research 	2010	52
20880178	Progesterone	Pu XX	Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression.	Journal of gastroenterology and hepatology	2010	97
20881962	Progesterone	Schramek D	Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.	Nature	2010	138
20920193	Progesterone	Pinhel IF	Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.	Breast cancer research 	2010	42
20946665	Progesterone	Yau C	A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.	Breast cancer research 	2010	52
21057787	Progesterone	Groheux D	Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.	European journal of nuclear medicine and molecular imaging	2011	41
21059212	Progesterone	Thompson AM	Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).	Breast cancer research 	2010	63
21067385	Progesterone	Foulkes WD	Triple-negative breast cancer.	The New England journal of medicine	2010	625
21092082	Progesterone	Kurian AW	Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups.	Breast cancer research 	2010	45
21161370	Progesterone	Pal SK	Triple negative breast cancer: unmet medical needs.	Breast cancer research and treatment	2011	82
21191117	Progesterone	Yang XR	Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.	Journal of the National Cancer Institute	2011	223
21278435	Progesterone	Hudis CA	Triple-negative breast cancer: an unmet medical need.	The oncologist	2011	171
21324165	Progesterone	Soini Y	Transcription factors zeb1, twist and snai1 in breast carcinoma.	BMC cancer	2011	37
21346227	Progesterone	Phipps AI	Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.	Journal of the National Cancer Institute	2011	70
21356373	Progesterone	Conklin MW	Aligned collagen is a prognostic signature for survival in human breast carcinoma.	The American journal of pathology	2011	217
21363912	Progesterone	Hill VK	Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity.	Cancer research	2011	47
21369698	Progesterone	Catchpole S	PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells.	International journal of oncology	2011	45
21387260	Progesterone	Lara-Medina F	Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.	Cancer	2011	47
21414337	Progesterone	Africander D	Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception.	Steroids	2011	40
21435948	Progesterone	Paranjape T	A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.	The Lancet. Oncology	2011	44
21472708	Progesterone	Anders CK	The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.	Cancer	2011	35
21483002	Progesterone	Mahmoud SM	Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.	Journal of clinical oncology 	2011	287
21490305	Progesterone	Gonzalez-Angulo AM	PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.	Molecular cancer therapeutics	2011	76
21502402	Progesterone	Hong J	Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness.	Cancer research	2011	62
21552212	Progesterone	Collins LC	Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.	Modern pathology 	2011	49
21605893	Progesterone	Aktas B	Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.	Gynecologic oncology	2011	37
21667121	Progesterone	Gaudet MM	Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger.	Breast cancer research and treatment	2011	56
21670451	Progesterone	Abdulkarim BS	Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.	Journal of clinical oncology 	2011	57
21677874	Progesterone	Davison Z	Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.	Neoplasia	2011	50
21779467	Progesterone	Ossovskaya V	Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.	Genes & cancer	2010	49
21795664	Progesterone	Yaghjyan L	Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics.	Journal of the National Cancer Institute	2011	50
21802721	Progesterone	Early Breast Cancer Trialists' Collaborative Group (EBCTCG).	Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.	Lancet	2011	412
21825015	Progesterone	Fackler MJ	Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.	Cancer research	2011	72
21830014	Progesterone	Tamimi RM	Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer.	Breast cancer research and treatment	2012	59
21844186	Progesterone	Stevens KN	Common breast cancer susceptibility loci are associated with triple-negative breast cancer.	Cancer research	2011	53
21846820	Progesterone	Palmer JR	Parity and lactation in relation to estrogen receptor negative breast cancer in African American women.	Cancer epidemiology, biomarkers & prevention 	2011	57
21852249	Progesterone	Figueroa JD	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium.	Human molecular genetics	2011	41
21859480	Progesterone	Li J	A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China.	BMC cancer	2011	50
21870331	Progesterone	Pinheiro C	GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression.	Histology and histopathology	2011	52
21900114	Progesterone	Arvold ND	Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy.	Journal of clinical oncology 	2011	67
21914172	Progesterone	Sihto H	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.	Breast cancer research 	2011	50
21969591	Progesterone	Haughian JM	Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch.	Proceedings of the National Academy of Sciences of the United States of America	2012	42
21990413	Progesterone	Cuzick J	Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.	Journal of clinical oncology 	2011	129
22028449	Progesterone	Hammes SR	Minireview: Recent advances in extranuclear steroid receptor actions.	Endocrinology	2011	50
22031096	Progesterone	Dougall WC	Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.	Clinical cancer research 	2012	48
22037553	Progesterone	Haiman CA	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.	Nature genetics	2011	145
22081974	Progesterone	Fasching PA	Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.	BMC cancer	2011	62
22112968	Progesterone	He X	Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.	Annals of oncology 	2012	54
22115959	Progesterone	Wetendorf M	The progesterone receptor regulates implantation, decidualization, and glandular development via a complex paracrine signaling network.	Molecular and cellular endocrinology	2012	48
22124102	Progesterone	Amir E	Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.	Journal of clinical oncology 	2012	88
22144499	Progesterone	Mavaddat N	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).	Cancer epidemiology, biomarkers & prevention 	2012	80
22147079	Progesterone	Lowery AJ	Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype.	Breast cancer research and treatment	2012	61
22178456	Progesterone	Amir E	Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.	Cancer treatment reviews	2012	35
22189713	Progesterone	Deng XS	Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers.	Cell cycle	2012	51
22264274	Progesterone	Chan SR	STAT1-deficient mice spontaneously develop estrogen receptor Œ±-positive luminal mammary carcinomas.	Breast cancer research 	2012	56
22270867	Progesterone	Krzeslak A	Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers.	Pathology oncology research 	2012	39
22330809	Progesterone	Cizkova M	PIK3CA mutation impact on survival in breast cancer patients and in ERŒ±, PR and ERBB2-based subgroups.	Breast cancer research 	2012	44
22331459	Progesterone	Stevens KN	19p13.1 is a triple-negative-specific breast cancer susceptibility locus.	Cancer research	2012	50
22367781	Progesterone	Rao R	Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.	Molecular cancer therapeutics	2012	40
22370325	Progesterone	Bergh J	FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.	Journal of clinical oncology 	2012	40
22430491	Progesterone	Horiuchi D	MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.	The Journal of experimental medicine	2012	79
22446188	Progesterone	Ma CX	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.	The Journal of clinical investigation	2012	63
22452927	Progesterone	Keegan TH	Occurrence of breast cancer subtypes in adolescent and young adult women.	Breast cancer research 	2012	34
22495674	Progesterone	Filardo EJ	Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology.	Endocrinology	2012	73
22496457	Progesterone	Palafox M	RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.	Cancer research	2012	44
22517820	Progesterone	Gelmon K	Targeting triple-negative breast cancer: optimising therapeutic outcomes.	Annals of oncology 	2012	45
22544643	Progesterone	Lin NU	Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.	Cancer	2012	64
22545144	Progesterone	Clarke CL	Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes.	PloS one	2012	30
22551559	Progesterone	Griffiths CL	Triple negative breast cancer: a brief review of its characteristics and treatment options.	Journal of pharmacy practice	2012	31
22562122	Progesterone	Niraula S	Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis.	Breast cancer research and treatment	2012	36
22583394	Progesterone	Ritte R	Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.	Breast cancer research 	2012	33
22583478	Progesterone	Rivas MA	Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.	Breast cancer research 	2012	37
22613095	Progesterone	Tate CR	Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.	Breast cancer research 	2012	55
22614657	Progesterone	Hartman AR	Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.	Cancer	2012	40
22677156	Progesterone	Lucci A	Circulating tumour cells in non-metastatic breast cancer: a prospective study.	The Lancet. Oncology	2012	103
22689798	Progesterone	Chlebowski RT	Diabetes, metformin, and breast cancer in postmenopausal women.	Journal of clinical oncology 	2012	49
22698676	Progesterone	Mercier I	Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug.	The American journal of pathology	2012	68
22704583	Progesterone	Paterson AH	Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.	The Lancet. Oncology	2012	37
22711706	Progesterone	Chia SK	A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.	Clinical cancer research 	2012	55
22711854	Progesterone	Lindstr√∂m LS	Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.	Journal of clinical oncology 	2012	89
22751119	Progesterone	Cittelly DM	Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.	Oncogene	2013	41
22773826	Progesterone	Clarke CA	Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.	Journal of the National Cancer Institute	2012	61
22817698	Progesterone	Byrski T	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.	Breast cancer research 	2012	41
22821401	Progesterone	Kabos P	Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.	Breast cancer research and treatment	2012	40
22824040	Progesterone	Medrek C	The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients.	BMC cancer	2012	113
22844349	Progesterone	Macias H	Mammary gland development.	Wiley interdisciplinary reviews. Developmental biology	2012	77
22847191	Progesterone	Liu Y	MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis.	Medical science monitor 	2012	35
22878371	Progesterone	Mohammed ZM	The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer.	British journal of cancer	2012	33
22956860	Progesterone	Creighton CJ	The molecular profile of luminal B breast cancer.	Biologics 	2012	54
23012306	Progesterone	Boyle P	Triple-negative breast cancer: epidemiological considerations and recommendations.	Annals of oncology 	2012	118
23035882	Progesterone	Bastien RR	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.	BMC medical genomics	2012	75
23088337	Progesterone	Franken B	Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer.	Breast cancer research 	2012	36
23088371	Progesterone	Shehata M	Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland.	Breast cancer research 	2012	88
23136140	Progesterone	Palmer JR	Genetic susceptibility loci for subtypes of breast cancer in an African American population.	Cancer epidemiology, biomarkers & prevention 	2013	29
23139210	Progesterone	McCleland ML	An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer.	Cancer research	2012	33
23171949	Progesterone	Craig DW	Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.	Molecular cancer therapeutics	2013	56
23177737	Progesterone	Ballar√© C	Nucleosome-driven transcription factor binding and gene regulation.	Molecular cell	2013	50
23233704	Progesterone	Prat A	Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.	Journal of clinical oncology 	2013	98
23242585	Progesterone	Ma CX	A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.	Breast cancer research and treatment	2013	29
23251644	Progesterone	Budczies J	Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization.	PloS one	2012	159
23274845	Progesterone	Wu Y	Physical activity and risk of breast cancer: a meta-analysis of prospective studies.	Breast cancer research and treatment	2013	68
23303565	Progesterone	Kim JJ	Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.	Endocrine reviews	2013	86
23319610	Progesterone	Ferraro DA	Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
23321033	Progesterone	Turner N	Targeting triple negative breast cancer: is p53 the answer?	Cancer treatment reviews	2013	39
23358903	Progesterone	Bayraktar S	Molecularly targeted therapies for metastatic triple-negative breast cancer.	Breast cancer research and treatment	2013	35
23412770	Progesterone	Karihtala P	Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.	Breast cancer research and treatment	2013	27
23436342	Progesterone	De Los Santos JF	Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.	Cancer	2013	27
23436929	Progesterone	O'Toole SA	Therapeutic targets in triple negative breast cancer.	Journal of clinical pathology	2013	42
23451089	Progesterone	Taher C	High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes.	PloS one	2013	30
23536562	Progesterone	Stevens KN	Genetic susceptibility to triple-negative breast cancer.	Cancer research	2013	45
23629941	Progesterone	Pellatt AJ	Telomere length, telomere-related genes, and breast cancer risk: the breast cancer health disparities study.	Genes, chromosomes & cancer	2013	33
23634195	Progesterone	Stagg J	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects.	Therapeutic advances in medical oncology	2013	30
23636398	Progesterone	Cancer Genome Atlas Research Network.	Integrated genomic characterization of endometrial carcinoma.	Nature	2013	664
23645624	Progesterone	Rosner B	Breast cancer risk prediction with heterogeneous risk profiles according to breast cancer tumor markers.	American journal of epidemiology	2013	33
23666971	Progesterone	Sang Q	Identification of microRNAs in human follicular fluid: characterization of microRNAs that govern steroidogenesis in vitro and are associated with polycystic ovary syndrome in vivo.	The Journal of clinical endocrinology and metabolism	2013	31
23737486	Progesterone	Zhang X	A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.	Cancer research	2013	94
23748853	Progesterone	Eichelser C	Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.	Clinical chemistry	2013	41
23816962	Progesterone	Dowsett M	Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.	Journal of clinical oncology 	2013	103
23845225	Progesterone	Sieh W	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.	The Lancet. Oncology	2013	66
23890780	Progesterone	Endogenous Hormones and Breast Cancer Collaborative Group.	Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies.	The Lancet. Oncology	2013	58
23902874	Progesterone	Johnston SR	Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.	The Lancet. Oncology	2013	34
23920327	Progesterone	Engebraaten O	Triple-negative breast cancer and the need for new therapeutic targets.	The American journal of pathology	2013	34
23929266	Progesterone	Thike AA	Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.	Modern pathology 	2014	22
23939688	Progesterone	Piva R	From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (Review).	International journal of oncology	2013	31
23965901	Progesterone	Gucalp A	Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.	Clinical cancer research 	2013	104
23988612	Progesterone	Mohamed A	Targeted therapy for breast cancer.	The American journal of pathology	2013	28
23993780	Progesterone	Rivenbark AG	Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine.	The American journal of pathology	2013	31
24069582	Progesterone	den Hollander P	Targeted therapy for breast cancer prevention.	Frontiers in oncology	2013	33
24140203	Progesterone	Widschwendter M	The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.	The Lancet. Oncology	2013	26
24188089	Progesterone	Bertrand KA	Mammographic density and risk of breast cancer by age and tumor characteristics.	Breast cancer research 	2013	34
24188694	Progesterone	Bilir B	Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.	Journal of translational medicine	2013	29
24265601	Progesterone	Jones A	Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development.	PLoS medicine	2013	27
24269135	Progesterone	Aurilio G	A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.	European journal of cancer	2014	30
24322788	Progesterone	Cadoo KA	Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.	The quarterly journal of nuclear medicine and molecular imaging 	2013	28
24353241	Progesterone	Park SH	Correlations between apparent diffusion coefficient values of invasive ductal carcinoma and pathologic factors on diffusion-weighted MRI at 3.0 Tesla.	Journal of magnetic resonance imaging 	2015	17
24375928	Progesterone	Munsell MF	Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.	Epidemiologic reviews	2014	40
24424068	Progesterone	Thomas P	Enhancement of cell surface expression and receptor functions of membrane progestin receptor Œ± (mPRŒ±) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors.	Endocrinology	2014	21
24439313	Progesterone	Aebi S	Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.	The Lancet. Oncology	2014	23
24463450	Progesterone	Santagata S	Taxonomy of breast cancer based on normal cell phenotype predicts outcome.	The Journal of clinical investigation	2014	60
24469035	Progesterone	Daniel AR	Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.	Oncogene	2015	32
24477977	Progesterone	Anderson KN	Reproductive risk factors and breast cancer subtypes: a review of the literature.	Breast cancer research and treatment	2014	57
24521995	Progesterone	Sweeney C	Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.	Cancer epidemiology, biomarkers & prevention 	2014	30
24552158	Progesterone	Hagan CR	Molecular determinants of context-dependent progesterone receptor action in breast cancer.	BMC medicine	2014	23
24569463	Progesterone	Yoshida T	Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.	British journal of cancer	2014	48
24606718	Progesterone	Chen L	Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells.	Molecular cancer	2014	28
24670641	Progesterone	Chen X	XBP1 promotes triple-negative breast cancer by controlling the HIF1Œ± pathway.	Nature	2014	137
24721646	Progesterone	Chittaranjan S	Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.	Clinical cancer research 	2014	24
24722644	Progesterone	Soussan M	Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer.	PloS one	2014	33
24777111	Progesterone	Howlader N	US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.	Journal of the National Cancer Institute	2014	107
24799465	Progesterone	Giordano SH	Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.	Journal of clinical oncology 	2014	52
24951027	Progesterone	Maisonneuve P	Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.	Breast cancer research 	2014	25
24967588	Progesterone	Ferrari N	Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer.	PloS one	2014	23
25173780	Progesterone	van Waarde A	Potential applications for sigma receptor ligands in cancer diagnosis and therapy.	Biochimica et biophysica acta	2015	16
25206307	Progesterone	Hosford SR	Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.	Pharmacogenomics and personalized medicine	2014	27
25236687	Progesterone	Villarreal-Garza C	Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.	Cancer	2015	17
25277734	Progesterone	Sabatier R	Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.	Molecular cancer	2014	20
25320358	Progesterone	Chen EJ	Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.	Clinical cancer research 	2015	45
25333260	Progesterone	Eichelser C	Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.	Oncotarget	2014	40
25403582	Progesterone	Gnant M	Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.	Annals of oncology 	2015	25
25453096	Progesterone	Samanta D	Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2014	69
25495193	Progesterone	Cao MD	Metabolic characterization of triple negative breast cancer.	BMC cancer	2014	26
25584414	Progesterone	Vasquez YM	FOXO1 is required for binding of PR on IRF4, novel transcriptional regulator of endometrial stromal decidualization.	Molecular endocrinology	2015	18
25663687	Progesterone	Nyante SJ	Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.	Journal of the National Cancer Institute	2015	16
25682074	Progesterone	Wong-Brown MW	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.	Breast cancer research and treatment	2015	18
25726524	Progesterone	Rinc√≥n R	PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.	Oncotarget	2015	18
25740979	Progesterone	Goodwin PJ	Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.	Journal of the National Cancer Institute	2015	17
25759599	Progesterone	Graveel CR	Critical analysis of the potential for microRNA biomarkers in breast cancer management.	Breast cancer	2015	17
25762479	Progesterone	Abduljabbar R	Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer.	Breast cancer research and treatment	2015	19
25847929	Progesterone	Telli ML	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.	Journal of clinical oncology 	2015	35
25888956	Progesterone	Chang YY	Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.	Molecular cancer	2015	26
25895611	Progesterone	Zardavas D	Clinical management of breast cancer heterogeneity.	Nature reviews. Clinical oncology	2015	44
25902832	Progesterone	Toss A	Molecular characterization and targeted therapeutic approaches in breast cancer.	Breast cancer research 	2015	23
25922306	Progesterone	Yang Q	The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.	Reproductive sciences	2016	15
25969506	Progesterone	Tao L	Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study.	Cancer epidemiology, biomarkers & prevention 	2015	15
26040322	Progesterone	Huo CW	High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium.	Breast cancer research 	2015	24
26040571	Progesterone	Jamdade VS	Therapeutic targets of triple-negative breast cancer: a review.	British journal of pharmacology	2015	21
26045046	Progesterone	Goodwin CM	Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.	Cell death and differentiation	2015	25
26053034	Progesterone	Hait NC	The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERŒ± expression and enhances hormonal therapy for breast cancer.	Oncogenesis	2015	23
26153859	Progesterone	Mohammed H	Progesterone receptor modulates ERŒ± action in breast cancer.	Nature	2015	78
26181262	Progesterone	Santa-Maria CA	Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.	JAMA oncology	2015	17
26182172	Progesterone	Neuhouser ML	Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.	JAMA oncology	2015	32
26195705	Progesterone	Van Poznak C	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.	Journal of clinical oncology 	2015	37
26201402	Progesterone	Barton VN	Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.	Hormones & cancer	2015	17
26211827	Progesterone	Early Breast Cancer Trialists' Collaborative Group (EBCTCG).	Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.	Lancet	2015	65
26266985	Progesterone	Van Keymeulen A	Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.	Nature	2015	51
26341644	Progesterone	Kumar P	An overview of triple-negative breast cancer.	Archives of gynecology and obstetrics	2016	19
26387133	Progesterone	Palma G	Triple negative breast cancer: looking for the missing link between biology and treatments.	Oncotarget	2015	29
26455641	Progesterone	Clarke R	Endocrine resistance in breast cancer--An overview and update.	Molecular and cellular endocrinology	2015	22
26563128	Progesterone	Ma CX	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.	Clinical cancer research 	2016	17
26617202	Progesterone	Takashima T	Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.	The Lancet. Oncology	2016	11
26677438	Progesterone	Yadav BS	Biomarkers in triple negative breast cancer: A review.	World journal of clinical oncology	2015	15
26683709	Progesterone	Jiang T	Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis.	Oncotarget	2016	14
26694831	Progesterone	Hurvitz S	Triple-negative breast cancer: advancements in characterization and treatment approach.	Current opinion in obstetrics & gynecology	2016	13
26765445	Progesterone	Dai ZJ	Association Between Single Nucleotide Polymorphisms in DNA Polymerase Kappa Gene and Breast Cancer Risk in Chinese Han Population: A STROBE-Compliant Observational Study.	Medicine	2016	11
26769139	Progesterone	Thompson E	The immune microenvironment of breast ductal carcinoma in situ.	Modern pathology 	2016	13
26822398	Progesterone	Harbeck N	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.	The Lancet. Oncology	2016	12
26855592	Progesterone	Xu H	Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis.	OncoTargets and therapy	2016	15
26858339	Progesterone	Harris LN	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.	Journal of clinical oncology 	2016	73
26868521	Progesterone	Kasimir-Bauer S	Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.	Breast cancer research 	2016	16
26874901	Progesterone	Chan A	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.	The Lancet. Oncology	2016	26
26909695	Progesterone	Rostami R	Brain metastasis in breast cancer: a comprehensive literature review.	Journal of neuro-oncology	2016	13
26926676	Progesterone	Gluz O	West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.	Journal of clinical oncology 	2016	21
27052658	Progesterone	Bonnefoi H	A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).	Annals of oncology 	2016	12
27144536	Progesterone	Li H	MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.	Radiology	2016	20
27171498	Progesterone	Chen X	Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.	The Journal of pathology	2016	12
27179402	Progesterone	Gianni L	5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.	The Lancet. Oncology	2016	21
27191888	Progesterone	Huang NS	Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer.	Oncotarget	2016	17
27322743	Progesterone	Nolan E	RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.	Nature medicine	2016	23
27325862	Progesterone	Colleoni M	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.	Journal of clinical oncology 	2016	13
27386569	Progesterone	Singhal H	Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.	Science advances	2016	11
27388585	Progesterone	Millis SZ	Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19‚ÄØ784 Diverse Solid Tumors.	JAMA oncology	2016	15
27390604	Progesterone	Dai X	Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.	Journal of Cancer	2016	15
27407093	Progesterone	Friedenreich CM	Physical Activity and Cancer Outcomes: A Precision Medicine Approach.	Clinical cancer research 	2016	16
27540977	Progesterone	Zhang K	Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.	Cancer biomarkers 	2016	15
27725895	Progesterone	Hon JD	Breast cancer molecular subtypes: from TNBC to QNBC.	American journal of cancer research	2016	11
27765921	Progesterone	Yao H	Triple-negative breast cancer: is there a treatment on the horizon?	Oncotarget	2017	8
27775705	Progesterone	Horiuchi D	PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.	Nature medicine	2016	12
27885264	Progesterone	Carroll JS	Deciphering the divergent roles of progestogens in breast cancer.	Nature reviews. Cancer	2017	11
27908454	Progesterone	Robertson JFR	Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.	Lancet	2016	16
27935867	Progesterone	V√°zquez R	The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.	Oncotarget	2017	5
27974799	Progesterone	Hosseini H	Early dissemination seeds metastasis in breast cancer.	Nature	2016	34
28030809	Progesterone	McDaniel JM	Genomic regulation of invasion by STAT3 in triple negative breast cancer.	Oncotarget	2017	6
28041951	Progesterone	Chuffa LG	The role of sex hormones and steroid receptors on female reproductive cancers.	Steroids	2017	11
28052940	Progesterone	Busch EL	Endometrial Cancer Risk Factors, Hormone Receptors, and Mortality Prediction.	Cancer epidemiology, biomarkers & prevention 	2017	6
28108260	Progesterone	Maiti A	Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.	Cellular signalling	2017	11
28108967	Progesterone	Inoue M	Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.	Breast cancer	2017	5
28259011	Progesterone	Duffy MJ	Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).	European journal of cancer	2017	12
28356971	Progesterone	Luo Y	Elevated microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer patients.	Oncology letters	2017	5
28412963	Progesterone	Knutson TP	Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs.	Journal of hematology & oncology	2017	6
14504078	Trimethylamine	Hans CP	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.	Blood	2004	543
19001334	Trimethylamine	Chia S	Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.	Journal of clinical oncology 	2008	57
19750230	Trimethylamine	Mokarram P	Distinct high-profile methylated genes in colorectal cancer.	PloS one	2009	46
20413299	Trimethylamine	Tol J	Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.	European journal of cancer	2010	61
22611154	Trimethylamine	Fuchs TA	Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies.	Blood	2012	35
22919003	Trimethylamine	Davies KD	Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.	Clinical cancer research 	2012	77
23018874	Trimethylamine	Yoshimoto M	PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.	Modern pathology 	2013	25
24217091	Trimethylamine	Velcheti V	Programmed death ligand-1 expression in non-small cell lung cancer.	Laboratory investigation; a journal of technical methods and pathology	2014	175
7634330	Ceramide (d18:1/12:0)	Bose R	Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals.	Cell	1995	133
8617770	Ceramide (d18:1/12:0)	Chinnaiyan AM	FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis.	The Journal of biological chemistry	1996	112
8706124	Ceramide (d18:1/12:0)	Santana P	Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis.	Cell	1996	121
8968075	Ceramide (d18:1/12:0)	Hakomori S	Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism.	Cancer research	1996	174
11595837	Ceramide (d18:1/12:0)	Mandlekar S	Mechanisms of tamoxifen-induced apoptosis.	Apoptosis 	2001	89
11801602	Ceramide (d18:1/12:0)	Chalfant CE	De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1.	The Journal of biological chemistry	2002	92
12531554	Ceramide (d18:1/12:0)	Maceyka M	Sphingosine kinase, sphingosine-1-phosphate, and apoptosis.	Biochimica et biophysica acta	2002	115
12947396	Ceramide (d18:1/12:0)	Kolesnick R	Radiation and ceramide-induced apoptosis.	Oncogene	2003	105
14557812	Ceramide (d18:1/12:0)	Gulbins E	Raft ceramide in molecular medicine.	Oncogene	2003	101
15013522	Ceramide (d18:1/12:0)	Reynolds CP	Ceramide synthesis and metabolism as a target for cancer therapy.	Cancer letters	2004	84
15205343	Ceramide (d18:1/12:0)	Daido S	Pivotal role of the cell death factor BNIP3 in ceramide-induced autophagic cell death in malignant glioma cells.	Cancer research	2004	112
15867097	Ceramide (d18:1/12:0)	Chang DH	Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.	The Journal of experimental medicine	2005	124
16043028	Ceramide (d18:1/12:0)	Signorelli P	Resveratrol as an anticancer nutrient: molecular basis, open questions and promises.	The Journal of nutritional biochemistry	2005	75
16219683	Ceramide (d18:1/12:0)	Chalfant CE	Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling.	Journal of cell science	2005	93
16415355	Ceramide (d18:1/12:0)	Lavieu G	Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation.	The Journal of biological chemistry	2006	82
16616335	Ceramide (d18:1/12:0)	Carracedo A	The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells.	Cancer cell	2006	75
16818650	Ceramide (d18:1/12:0)	Carracedo A	Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes.	Cancer research	2006	64
17090686	Ceramide (d18:1/12:0)	Oskouian B	Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer.	Proceedings of the National Academy of Sciences of the United States of America	2006	76
17303574	Ceramide (d18:1/12:0)	Baran Y	Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells.	The Journal of biological chemistry	2007	58
17308067	Ceramide (d18:1/12:0)	Senkal CE	Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas.	Molecular cancer therapeutics	2007	59
17339025	Ceramide (d18:1/12:0)	Holland WL	Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.	Cell metabolism	2007	330
17560332	Ceramide (d18:1/12:0)	Swanton C	Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.	Cancer cell	2007	116
17979847	Ceramide (d18:1/12:0)	Fujii S	Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.	Immunological reviews	2007	55
18058224	Ceramide (d18:1/12:0)	Ruckh√§berle E	Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.	Breast cancer research and treatment	2008	95
18166162	Ceramide (d18:1/12:0)	Patra SK	Dissecting lipid raft facilitated cell signaling pathways in cancer.	Biochimica et biophysica acta	2008	89
18245173	Ceramide (d18:1/12:0)	Liu YY	A role for ceramide in driving cancer cell resistance to doxorubicin.	FASEB journal 	2008	56
18270325	Ceramide (d18:1/12:0)	Chen CL	Ceramide induces p38 MAPK and JNK activation through a mechanism involving a thioredoxin-interacting protein-mediated pathway.	Blood	2008	54
18426979	Ceramide (d18:1/12:0)	Zeidan YH	Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway.	The Journal of cell biology	2008	52
18511810	Ceramide (d18:1/12:0)	Paugh SW	A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.	Blood	2008	87
18567738	Ceramide (d18:1/12:0)	Smith EL	The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases.	FASEB journal 	2008	67
18691013	Ceramide (d18:1/12:0)	Shida D	Targeting SphK1 as a new strategy against cancer.	Current drug targets	2008	92
18787411	Ceramide (d18:1/12:0)	Park MA	Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.	Cancer biology & therapy	2008	77
19028839	Ceramide (d18:1/12:0)	Mukhopadhyay A	Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling.	FASEB journal 	2009	70
19029119	Ceramide (d18:1/12:0)	Pattingre S	Role of JNK1-dependent Bcl-2 phosphorylation in ceramide-induced macroautophagy.	The Journal of biological chemistry	2009	89
19060920	Ceramide (d18:1/12:0)	Li DD	The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells.	Oncogene	2009	82
19425170	Ceramide (d18:1/12:0)	Salazar M	Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells.	The Journal of clinical investigation	2009	173
19608407	Ceramide (d18:1/12:0)	Lopez PH	Gangliosides in cell recognition and membrane protein regulation.	Current opinion in structural biology	2009	62
19723703	Ceramide (d18:1/12:0)	Senkal CE	Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways.	FASEB journal 	2010	88
20053954	Ceramide (d18:1/12:0)	Hayashi T	Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction.	Molecular pharmacology	2010	64
20061445	Ceramide (d18:1/12:0)	French KJ	Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.	The Journal of pharmacology and experimental therapeutics	2010	94
20178791	Ceramide (d18:1/12:0)	Stancevic B	Ceramide-rich platforms in transmembrane signaling.	FEBS letters	2010	66
20353945	Ceramide (d18:1/12:0)	Kosaka N	Secretory mechanisms and intercellular transfer of microRNAs in living cells.	The Journal of biological chemistry	2010	452
20406683	Ceramide (d18:1/12:0)	Mesicek J	Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells.	Cellular signalling	2010	60
20502000	Ceramide (d18:1/12:0)	Kornhuber J	Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications.	Cellular physiology and biochemistry 	2010	42
20540746	Ceramide (d18:1/12:0)	Liu YY	Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.	Molecular cancer	2010	40
20552297	Ceramide (d18:1/12:0)	Wu BX	Mammalian neutral sphingomyelinases: regulation and roles in cell signaling responses.	Neuromolecular medicine	2010	42
20926375	Ceramide (d18:1/12:0)	Loveridge C	The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells.	The Journal of biological chemistry	2010	40
21057646	Ceramide (d18:1/12:0)	Iguchi H	Secretory microRNAs as a versatile communication tool.	Communicative & integrative biology	2010	53
21695182	Ceramide (d18:1/12:0)	Lee H	Mitochondrial ceramide-rich macrodomains functionalize Bax upon irradiation.	PloS one	2011	52
22248339	Ceramide (d18:1/12:0)	Mullen TD	Ceramide synthases at the centre of sphingolipid metabolism and biology.	The Biochemical journal	2012	92
22619219	Ceramide (d18:1/12:0)	Takahashi T	Role of sulfatide in normal and pathological cells and tissues.	Journal of lipid research	2012	37
22778441	Ceramide (d18:1/12:0)	Czarnota GJ	Tumor radiation response enhancement by acoustical stimulation of the vasculature.	Proceedings of the National Academy of Sciences of the United States of America	2012	33
23166225	Ceramide (d18:1/12:0)	Rosa R	Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.	Clinical cancer research 	2013	27
23180565	Ceramide (d18:1/12:0)	Saddoughi SA	Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.	EMBO molecular medicine	2013	75
23290776	Ceramide (d18:1/12:0)	Saddoughi SA	Diverse functions of ceramide in cancer cell death and proliferation.	Advances in cancer research	2013	32
23290781	Ceramide (d18:1/12:0)	Heffernan-Stroud LA	Sphingosine kinase 1 in cancer.	Advances in cancer research	2013	29
23293083	Ceramide (d18:1/12:0)	Borrego F	The CD300 molecules: an emerging family of regulators of the immune system.	Blood	2013	34
23615526	Ceramide (d18:1/12:0)	Schneider G	Bioactive lipids S1P and C1P are prometastatic factors in human rhabdomyosarcoma, and their tissue levels increase in response to radio/chemotherapy.	Molecular cancer research 	2013	25
23638983	Ceramide (d18:1/12:0)	Neubauer HA	Roles, regulation and inhibitors of sphingosine kinase 2.	The FEBS journal	2013	40
23863933	Ceramide (d18:1/12:0)	Simanshu DK	Non-vesicular trafficking by a ceramide-1-phosphate transfer protein regulates eicosanoids.	Nature	2013	42
23926298	Ceramide (d18:1/12:0)	Oaks JJ	Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.	Blood	2013	31
24091326	Ceramide (d18:1/12:0)	Cheng JC	Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.	The Journal of clinical investigation	2013	29
24587339	Ceramide (d18:1/12:0)	Zhang Y	Sphingosine kinase 1 and cancer: a systematic review and meta-analysis.	PloS one	2014	26
24632610	Ceramide (d18:1/12:0)	Edmond V	Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility.	Oncogene	2015	16
25303541	Ceramide (d18:1/12:0)	Booth L	PDE5 inhibitors enhance celecoxib killing in multiple tumor types.	Journal of cellular physiology	2015	17
25428807	Ceramide (d18:1/12:0)	Singh R	Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer.	Molecular cancer	2014	51
26071354	Ceramide (d18:1/12:0)	Chen MB	MicroRNA-101 down-regulates sphingosine kinase 1 in colorectal cancer cells.	Biochemical and biophysical research communications	2015	28
26625315	Ceramide (d18:1/12:0)	Ramos-Torres √Å	The pepper's natural ingredient capsaicin induces autophagy blockage in prostate cancer cells.	Oncotarget	2016	11
26670557	Ceramide (d18:1/12:0)	Jiang C	Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction.	Nature communications	2015	37
27771292	Ceramide (d18:1/12:0)	Coant N	Ceramidases, roles in sphingolipid metabolism and in health and disease.	Advances in biological regulation	2017	6
8757191	Dihydrotestosterone	Gann PH	Prospective study of sex hormone levels and risk of prostate cancer.	Journal of the National Cancer Institute	1996	118
11306464	Dihydrotestosterone	Gregory CW	Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.	Cancer research	2001	146
11389051	Dihydrotestosterone	Gregory CW	A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.	Cancer research	2001	158
12788802	Dihydrotestosterone	Liu PY	Androgens and cardiovascular disease.	Endocrine reviews	2003	120
14760063	Dihydrotestosterone	Mohler JL	The androgen axis in recurrent prostate cancer.	Clinical cancer research 	2004	217
15001675	Dihydrotestosterone	Larson SM	Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.	Journal of nuclear medicine 	2004	70
15126525	Dihydrotestosterone	Wang C	Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.	The Journal of clinical endocrinology and metabolism	2004	86
15369448	Dihydrotestosterone	Scher HI	Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.	Endocrine-related cancer	2004	72
15833816	Dihydrotestosterone	Bohl CE	Structural basis for antagonism and resistance of bicalutamide in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2005	76
16510604	Dihydrotestosterone	Stanbrough M	Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.	Cancer research	2006	325
18230794	Dihydrotestosterone	Endogenous Hormones and Prostate Cancer Collaborative Group.	Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.	Journal of the National Cancer Institute	2008	149
18319300	Dihydrotestosterone	Cutress ML	Structural basis for the nuclear import of the human androgen receptor.	Journal of cell science	2008	53
18676866	Dihydrotestosterone	Locke JA	Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.	Cancer research	2008	226
19111796	Dihydrotestosterone	Yuan X	Mechanisms mediating androgen receptor reactivation after castration.	Urologic oncology	2009	87
19289629	Dihydrotestosterone	Mendiratta P	Genomic strategy for targeting therapy in castration-resistant prostate cancer.	Journal of clinical oncology 	2009	44
19351832	Dihydrotestosterone	Sun T	The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.	Cancer research	2009	77
19752089	Dihydrotestosterone	Cao Q	A role for the clock gene per1 in prostate cancer.	Cancer research	2009	49
19808968	Dihydrotestosterone	Waltering KK	Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.	Cancer research	2009	70
19901020	Dihydrotestosterone	Zhu ML	Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells.	FASEB journal 	2010	64
20086173	Dihydrotestosterone	Hofland J	Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.	Cancer research	2010	58
20945501	Dihydrotestosterone	Waltering KK	Androgen regulation of micro-RNAs in prostate cancer.	The Prostate	2011	47
21092758	Dihydrotestosterone	Vasaitis TS	CYP17 inhibitors for prostate cancer therapy.	The Journal of steroid biochemistry and molecular biology	2011	44
21303972	Dihydrotestosterone	Mohler JL	Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.	Cancer research	2011	47
21436259	Dihydrotestosterone	Lamont KR	Minireview: Alternative activation pathways for the androgen receptor in prostate cancer.	Molecular endocrinology	2011	52
21712345	Dihydrotestosterone	Cai C	Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.	Endocrine-related cancer	2011	40
21795608	Dihydrotestosterone	Chang KH	Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2011	84
23704919	Dihydrotestosterone	Gao L	Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.	PloS one	2013	35
23993097	Dihydrotestosterone	Chang KH	A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.	Cell	2013	80
24451109	Dihydrotestosterone	Cochrane DR	Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.	Breast cancer research 	2014	60
25311217	Dihydrotestosterone	Taplin ME	Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.	Journal of clinical oncology 	2014	32
25512207	Dihydrotestosterone	Azad AA	Targeting heat shock proteins in metastatic castration-resistant prostate cancer.	Nature reviews. Urology	2015	17
25619691	Dihydrotestosterone	Puc J	Ligand-dependent enhancer activation regulated by topoisomerase-I activity.	Cell	2015	28
26030522	Dihydrotestosterone	Li Z	Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.	Nature	2015	44
26342199	Dihydrotestosterone	Kawahara T	ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.	Oncotarget	2015	18
27893717	Dihydrotestosterone	Feng J	Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.	Oncogene	2017	6
9603331	Mevalonic acid	Blanchard TJ	Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine.	The Journal of general virology	1998	100
12538656	Mevalonic acid	Gober HJ	Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells.	The Journal of experimental medicine	2003	163
16613876	Mevalonic acid	Motoshima H	AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer.	The Journal of physiology	2006	129
20696928	Mevalonic acid	Clendening JW	Dysregulation of the mevalonate pathway promotes transformation.	Proceedings of the National Academy of Sciences of the United States of America	2010	85
21262914	Mevalonic acid	Cao Z	MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase.	Cancer research	2011	50
22265415	Mevalonic acid	Freed-Pastor WA	Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.	Cell	2012	198
22310279	Mevalonic acid	Clendening JW	Targeting tumor cell metabolism with statins.	Oncogene	2012	50
22529099	Mevalonic acid	Thurnher M	Novel aspects of mevalonate pathway inhibitors as antitumor agents.	Clinical cancer research 	2012	47
24367099	Mevalonic acid	Wang Z	Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.	Proceedings of the National Academy of Sciences of the United States of America	2014	67
26750334	Mevalonic acid	Santinon G	Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways.	Trends in cell biology	2016	21
27044891	Mevalonic acid	Hashimoto A	P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance.	The Journal of cell biology	2016	11
27270400	Mevalonic acid	Akula MK	Control of the innate immune response by the mevalonate pathway.	Nature immunology	2016	16
27775703	Mevalonic acid	Parrales A	DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.	Nature cell biology	2016	15
2006410	L-Leucine	Blackwood EM	Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.	Science	1991	452
2114220	L-Leucine	Cawthon RM	A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations.	Cell	1990	175
2171780	L-Leucine	Poli V	IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP.	Cell	1990	162
7937919	L-Leucine	Moi P	Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region.	Proceedings of the National Academy of Sciences of the United States of America	1994	301
7958932	L-Leucine	Hemesath TJ	microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family.	Genes & development	1994	139
8321203	L-Leucine	Stein B	Functional and physical associations between NF-kappa B and C/EBP family members: a Rel domain-bZIP interaction.	Molecular and cellular biology	1993	132
8425220	L-Leucine	Amati B	Oncogenic activity of the c-Myc protein requires dimerization with Max.	Cell	1993	139
8510758	L-Leucine	Crozat A	Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma.	Nature	1993	190
8599946	L-Leucine	Hohjoh H	Cytoplasmic ribonucleoprotein complexes containing human LINE-1 protein and RNA.	The EMBO journal	1996	132
8674125	L-Leucine	Ho IC	The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4.	Cell	1996	142
9192902	L-Leucine	Heery DM	A signature motif in transcriptional co-activators mediates binding to nuclear receptors.	Nature	1997	499
9326658	L-Leucine	Kiyono T	Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein.	Proceedings of the National Academy of Sciences of the United States of America	1997	156
9533877	L-Leucine	Kajava AV	Structural diversity of leucine-rich repeat proteins.	Journal of molecular biology	1998	109
9843217	L-Leucine	Khanna KK	ATM associates with and phosphorylates p53: mapping the region of interaction.	Nature genetics	1998	125
9930862	L-Leucine	Walczak H	Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.	Nature medicine	1999	463
10075936	L-Leucine	Stommel JM	A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking.	The EMBO journal	1999	191
10329646	L-Leucine	Inohara N	Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB.	The Journal of biological chemistry	1999	149
10531035	L-Leucine	Cenciarelli C	Identification of a family of human F-box proteins.	Current biology 	1999	112
10880512	L-Leucine	Inohara N	An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways.	The Journal of biological chemistry	2000	134
10980695	L-Leucine	Boyd SD	An intact HDM2 RING-finger domain is required for nuclear exclusion of p53.	Nature cell biology	2000	98
11058605	L-Leucine	Inohara N	Human Nod1 confers responsiveness to bacterial lipopolysaccharides.	The Journal of biological chemistry	2001	92
11087742	L-Leucine	Ogura Y	Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB.	The Journal of biological chemistry	2001	294
11390368	L-Leucine	Poyet JL	Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1.	The Journal of biological chemistry	2001	99
11687797	L-Leucine	Hoffman HM	Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome.	Nature genetics	2001	291
11864996	L-Leucine	Brunet A	14-3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport.	The Journal of cell biology	2002	137
12101249	L-Leucine	Peng T	The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation.	Molecular and cellular biology	2002	119
12766759	L-Leucine	Inohara N	NODs: intracellular proteins involved in inflammation and apoptosis.	Nature reviews. Immunology	2003	203
12789278	L-Leucine	Widlund HR	Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival.	Oncogene	2003	79
12873764	L-Leucine	Gallo SA	The HIV Env-mediated fusion reaction.	Biochimica et biophysica acta	2003	151
15044951	L-Leucine	Tanabe T	Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition.	The EMBO journal	2004	95
15345710	L-Leucine	Laederich MB	The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.	The Journal of biological chemistry	2004	79
15771576	L-Leucine	Ting JP	CATERPILLER: a novel gene family important in immunity, cell death, and diseases.	Annual review of immunology	2005	104
15808505	L-Leucine	Gao T	PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.	Molecular cell	2005	280
15952891	L-Leucine	Inohara	NOD-LRR proteins: role in host-microbial interactions and inflammatory disease.	Annual review of biochemistry	2005	253
16209941	L-Leucine	Hao B	Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase.	Molecular cell	2005	102
16407133	L-Leucine	Satou Y	HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells.	Proceedings of the National Academy of Sciences of the United States of America	2006	191
16487042	L-Leucine	Jeong WS	Nrf2: a potential molecular target for cancer chemoprevention by natural compounds.	Antioxidants & redox signaling	2006	86
16498449	L-Leucine	Ting JP	CATERPILLERs, pyrin and hereditary immunological disorders.	Nature reviews. Immunology	2006	100
16510280	L-Leucine	Strieter RM	Cancer CXC chemokine networks and tumour angiogenesis.	European journal of cancer	2006	104
16705038	L-Leucine	Politi K	Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.	Genes & development	2006	130
16877544	L-Leucine	Jensen KB	Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence.	Proceedings of the National Academy of Sciences of the United States of America	2006	98
17280616	L-Leucine	Lin ML	Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.	Breast cancer research 	2007	55
17363510	L-Leucine	Sarkaria JN	Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.	Molecular cancer therapeutics	2007	101
17658261	L-Leucine	Nerlov C	The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control.	Trends in cell biology	2007	111
17722061	L-Leucine	Nakano I	Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells.	Journal of neuroscience research	2008	64
18162466	L-Leucine	Gao T	The phosphatase PHLPP controls the cellular levels of protein kinase C.	The Journal of biological chemistry	2008	74
18362948	L-Leucine	Ting JP	NLRs at the intersection of cell death and immunity.	Nature reviews. Immunology	2008	140
18483179	L-Leucine	Chen W	Glucocorticoid receptor phosphorylation differentially affects target gene expression.	Molecular endocrinology	2008	85
18511290	L-Leucine	Brognard J	PHLiPPing the switch on Akt and protein kinase C signaling.	Trends in endocrinology and metabolism	2008	72
18688028	L-Leucine	Goldoni S	An antimetastatic role for decorin in breast cancer.	The American journal of pathology	2008	52
18701920	L-Leucine	Imai Y	Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila.	The EMBO journal	2008	165
18798267	L-Leucine	Goldoni S	Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs.	International journal of cancer	2008	69
19228429	L-Leucine	Saito M	In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP).	Retrovirology	2009	61
19351437	L-Leucine	Zahnow CA	CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases.	Expert reviews in molecular medicine	2009	50
19433454	L-Leucine	Goldoni S	Decorin is a novel antagonistic ligand of the Met receptor.	The Journal of cell biology	2009	86
20052801	L-Leucine	Qin Z	Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes.	Journal of leukocyte biology	2010	64
20080798	L-Leucine	Lu T	Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65.	Proceedings of the National Academy of Sciences of the United States of America	2010	84
20127796	L-Leucine	Hou W	MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins.	Hepatology	2010	59
20182580	L-Leucine	Liao Y	Physiological regulation of Akt activity and stability.	American journal of translational research	2010	103
20420952	L-Leucine	Todaro M	Colon cancer stem cells: promise of targeted therapy.	Gastroenterology	2010	110
20974860	L-Leucine	Buraschi S	Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels.	The Journal of biological chemistry	2010	53
21061913	L-Leucine	Hai T	ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component?	Gene expression	2010	59
21125339	L-Leucine	Takahashi H	Significance of Lgr5(+ve) cancer stem cells in the colon and rectum.	Annals of surgical oncology	2011	41
21191067	L-Leucine	Davis BK	Cutting edge: NLRC5-dependent activation of the inflammasome.	Journal of immunology	2011	61
21252346	L-Leucine	Gregory SM	Discovery of a viral NLR homolog that inhibits the inflammasome.	Science	2011	69
21257317	L-Leucine	Tsukada J	The CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated system for gene regulation.	Cytokine	2011	69
21378983	L-Leucine	Deng X	Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.	Nature chemical biology	2011	121
21563202	L-Leucine	Kawaguchi T	Branched-chain amino acids as pharmacological nutrients in chronic liver disease.	Hepatology	2011	51
21703540	L-Leucine	Allen IC	NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-Œ∫B signaling pathways.	Immunity	2011	103
21750348	L-Leucine	Beezhold K	miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis.	Toxicological sciences 	2011	40
21804599	L-Leucine	Molina JR	PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma.	Oncogene	2012	53
21811631	L-Leucine	Jeong YS	Integrated expression profiling and genome-wide analysis of ChREBP targets reveals the dual role for ChREBP in glucose-regulated gene expression.	PloS one	2011	41
21829496	L-Leucine	Walker F	LGR5 is a negative regulator of tumourigenicity, antagonizes Wnt signalling and regulates cell adhesion in colorectal cancer cell lines.	PloS one	2011	39
22194599	L-Leucine	Neill T	Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1Œ±, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3.	The Journal of biological chemistry	2012	49
22209898	L-Leucine	Turner JG	Nuclear export of proteins and drug resistance in cancer.	Biochemical pharmacology	2012	96
22260996	L-Leucine	Baghy K	Decorin-TGFŒ≤ axis in hepatic fibrosis and cirrhosis.	The journal of histochemistry and cytochemistry 	2012	33
22340730	L-Leucine	O'Neill AK	Suppression of survival signalling pathways by the phosphatase PHLPP.	The FEBS journal	2013	29
22354780	L-Leucine	Dodd KM	Leucine and mTORC1: a complex relationship.	American journal of physiology. Endocrinology and metabolism	2012	46
22382496	L-Leucine	Lynch J	MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-Œ≤ signalling pathway.	Carcinogenesis	2012	42
22385964	L-Leucine	Wang J	A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage.	Cell	2012	110
22391563	L-Leucine	Li X	The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer.	Oncogene	2013	26
22439850	L-Leucine	de Lau WB	The R-spondin protein family.	Genome biology	2012	73
22490869	L-Leucine	Meissner TB	NLRC5 cooperates with the RFX transcription factor complex to induce MHC class I gene expression.	Journal of immunology	2012	33
22734070	L-Leucine	Payne EM	L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.	Blood	2012	45
22735579	L-Leucine	Neill T	Decorin: a guardian from the matrix.	The American journal of pathology	2012	76
22749352	L-Leucine	Lei Y	The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy.	Immunity	2012	72
22761315	L-Leucine	Manka SW	Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1.	Proceedings of the National Academy of Sciences of the United States of America	2012	53
22945237	L-Leucine	Kuner R	The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer.	Journal of molecular medicine	2013	35
22948661	L-Leucine	Wang W	PTPN14 is required for the density-dependent control of YAP1.	Genes & development	2012	49
23029096	L-Leucine	Buraschi S	Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model.	PloS one	2012	37
23058688	L-Leucine	Sofeu Feugaing DD	More than matrix: the multifaceted role of decorin in cancer.	European journal of cell biology	2013	27
23283305	L-Leucine	Chung S	Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.	Oncotarget	2012	40
23349017	L-Leucine	Al-Kharusi MR	LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs.	Carcinogenesis	2013	26
23564911	L-Leucine	Kojima K	Prognostic impact and targeting of CRM1 in acute myeloid leukemia.	Blood	2013	59
23592611	L-Leucine	Di Virgilio F	The therapeutic potential of modifying inflammasomes and NOD-like receptors.	Pharmacological reviews	2013	29
23644456	L-Leucine	Styrkarsdottir U	Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits.	Nature	2013	64
23846336	L-Leucine	Liao WT	microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2.	Clinical cancer research 	2013	37
23916833	L-Leucine	Manzoni C	Inhibition of LRRK2 kinase activity stimulates macroautophagy.	Biochimica et biophysica acta	2013	30
23975430	L-Leucine	Roy SS	Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.	Oncogene	2014	29
24014241	L-Leucine	Willems L	Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.	Blood	2013	56
24052624	L-Leucine	Wang Q	Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.	Journal of the National Cancer Institute	2013	31
24282287	L-Leucine	Hirsch D	LGR5 positivity defines stem-like cells in colorectal cancer.	Carcinogenesis	2014	44
24338587	L-Leucine	Garc√≠a-Rodr√≠guez JL	SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling.	Hepatology	2014	21
24392697	L-Leucine	Newton AC	Turning off AKT: PHLPP as a drug target.	Annual review of pharmacology and toxicology	2014	31
24410877	L-Leucine	Ihle MA	Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.	BMC cancer	2014	52
24441039	L-Leucine	Satoyoshi R	Asporin activates coordinated invasion of scirrhous gastric cancer and cancer-associated fibroblasts.	Oncogene	2015	18
24477476	L-Leucine	Martina JA	Novel roles for the MiTF/TFE family of transcription factors in organelle biogenesis, nutrient sensing, and energy homeostasis.	Cellular and molecular life sciences 	2014	28
24480070	L-Leucine	Moreth K	Biglycan-triggered TLR-2- and TLR-4-signaling exacerbates the pathophysiology of ischemic acute kidney injury.	Matrix biology 	2014	24
24531984	L-Leucine	Wang Q	Targeting glutamine transport to suppress melanoma cell growth.	International journal of cancer	2014	45
24550486	L-Leucine	Heuberger J	Shp2/MAPK signaling controls goblet/paneth cell fate decisions in the intestine.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
24560620	L-Leucine	Zhang L	NLRC3, a member of the NLR family of proteins, is a negative regulator of innate immune signaling induced by the DNA sensor STING.	Immunity	2014	56
24639526	L-Leucine	Carmon KS	RSPO-LGR4 functions via IQGAP1 to potentiate Wnt signaling.	Proceedings of the National Academy of Sciences of the United States of America	2014	22
24681892	L-Leucine	Hu L	Biglycan enhances gastric cancer invasion by activating FAK signaling pathway.	Oncotarget	2014	23
24703948	L-Leucine	Wang P	Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt.	Molecular cell	2014	21
24885567	L-Leucine	Du T	Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway.	Molecular cancer	2014	21
25013376	L-Leucine	Xu WH	Long non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma.	International journal of biological sciences	2014	27
25231743	L-Leucine	Mets E	MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia.	Leukemia	2015	22
25323695	L-Leucine	Baud MGJ	Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes.	Science	2014	27
25458917	L-Leucine	Moon EJ	Dual roles of NRF2 in tumor prevention and progression: possible implications in cancer treatment.	Free radical biology & medicine	2015	25
25624468	L-Leucine	Seifert M	Functional capacities of human IgM memory B cells in early inflammatory responses and secondary germinal center reactions.	Proceedings of the National Academy of Sciences of the United States of America	2015	24
25661523	L-Leucine	J√§rvel√§inen H	Pivotal role for decorin in angiogenesis.	Matrix biology 	2015	25
25753223	L-Leucine	Friedman AD	C/EBPŒ± in normal and malignant myelopoiesis.	International journal of hematology	2015	17
25852826	L-Leucine	Ganguly R	MELK-a conserved kinase: functions, signaling, cancer, and controversy.	Clinical and translational medicine	2015	20
25879280	L-Leucine	Man SM	Regulation of inflammasome activation.	Immunological reviews	2015	68
26449471	L-Leucine	Wolfson RL	Sestrin2 is a leucine sensor for the mTORC1 pathway.	Science	2016	119
26522384	L-Leucine	Neill T	Decorin as a multivalent therapeutic agent against cancer.	Advanced drug delivery reviews	2016	12
26586190	L-Leucine	Saxton RA	Structural basis for leucine sensing by the Sestrin2-mTORC1 pathway.	Science	2016	54
26611634	L-Leucine	Hansen CG	The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.	Cell research	2015	21
26719542	L-Leucine	Li Y	HBXIP and LSD1 Scaffolded by lncRNA Hotair Mediate Transcriptional Activation by c-Myc.	Cancer research	2016	10
26739710	L-Leucine	Pedersen SF	Biophysics and Physiology of the Volume-Regulated Anion Channel (VRAC)/Volume-Sensitive Outwardly Rectifying Anion Channel (VSOR).	Pflugers Archiv 	2016	14
26856989	L-Leucine	Zhang J	LRG1 modulates epithelial-mesenchymal transition and angiogenesis in colorectal cancer via HIF-1Œ± activation.	Journal of experimental & clinical cancer research 	2016	23
27064449	L-Leucine	Luo J	LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption.	Nature medicine	2016	25
27082996	L-Leucine	Ji W	OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases.	PloS one	2016	12
27295191	L-Leucine	Maishi N	Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan.	Scientific reports	2016	11
27302165	L-Leucine	Cormerais Y	Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth.	Cancer research	2016	13
27455510	L-Leucine	Moon JS	NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages.	Nature medicine	2016	21
27477328	L-Leucine	Chen HH	Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T¬†cells.	The Journal of allergy and clinical immunology	2017	7
27590293	L-Leucine	van Sonderen A	Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up.	Neurology	2016	16
27669650	L-Leucine	He Y	Mechanism and Regulation of NLRP3 Inflammasome Activation.	Trends in biochemical sciences	2016	50
27693454	L-Leucine	Gubbiotti MA	Decorin interacting network: A comprehensive analysis of decorin-binding partners and their versatile functions.	Matrix biology 	2016	13
27893017	L-Leucine	Finke C	Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies.	JAMA neurology	2017	11
27898682	L-Leucine	Lotta LA	Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis.	PLoS medicine	2016	13
28093447	L-Leucine	Karki R	Inflammasomes and Cancer.	Cancer immunology research	2017	12
28214016	L-Leucine	Kohler RS	MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.	Gynecologic oncology	2017	6
28358093	L-Leucine	de Sousa e Melo F	A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer.	Nature	2017	30
28380376	L-Leucine	Anderson KA	SIRT4 Is a Lysine Deacylase that Controls Leucine Metabolism and Insulin Secretion.	Cell metabolism	2017	18
28436964	L-Leucine	Zhang Y	SWELL1 is a regulator of adipocyte size, insulin signalling and glucose homeostasis.	Nature cell biology	2017	6
16106218	Sphing-4-enine-1-phosphate	Van Brocklyn JR	Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines.	Journal of neuropathology and experimental neurology	2005	108
16194537	Sphing-4-enine-1-phosphate	Sarkar S	Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells.	FEBS letters	2005	73
16397235	Sphing-4-enine-1-phosphate	LaMontagne K	Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.	Cancer research	2006	76
16636149	Sphing-4-enine-1-phosphate	Sukocheva O	Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1.	The Journal of cell biology	2006	63
17078925	Sphing-4-enine-1-phosphate	Meyer zu Heringdorf D	Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism.	Biochimica et biophysica acta	2007	87
17974990	Sphing-4-enine-1-phosphate	Sankala HM	Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin.	Cancer research	2007	60
18245172	Sphing-4-enine-1-phosphate	Tan W	An essential role for Rac1 in endothelial cell function and vascular development.	FASEB journal 	2008	77
18362204	Sphing-4-enine-1-phosphate	Gude DR	Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal.	FASEB journal 	2008	77
18713968	Sphing-4-enine-1-phosphate	Fabre S	FOXO1 regulates L-Selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase.	Journal of immunology	2008	84
18824518	Sphing-4-enine-1-phosphate	Kawamori T	Role for sphingosine kinase 1 in colon carcinogenesis.	FASEB journal 	2009	86
19723667	Sphing-4-enine-1-phosphate	Kapitonov D	Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts.	Cancer research	2009	63
19729656	Sphing-4-enine-1-phosphate	Hait NC	Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.	Science	2009	283
20570726	Sphing-4-enine-1-phosphate	Tonelli F	FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.	Cellular signalling	2010	58
21062159	Sphing-4-enine-1-phosphate	Ponnusamy S	Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.	Future oncology	2010	62
21546914	Sphing-4-enine-1-phosphate	Spiegel S	The outs and the ins of sphingosine-1-phosphate in immunity.	Nature reviews. Immunology	2011	192
22001186	Sphing-4-enine-1-phosphate	Maceyka M	Sphingosine-1-phosphate signaling and its role in disease.	Trends in cell biology	2012	208
22098666	Sphing-4-enine-1-phosphate	Bao M	Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma.	Liver international 	2012	32
22298596	Sphing-4-enine-1-phosphate	Nagahashi M	Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis.	Cancer research	2012	90
22397330	Sphing-4-enine-1-phosphate	Schnute ME	Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1.	The Biochemical journal	2012	65
23143305	Sphing-4-enine-1-phosphate	√áuburu N	Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.	The Journal of clinical investigation	2012	44
23618389	Sphing-4-enine-1-phosphate	Cai H	The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells.	Cell communication and signaling 	2013	32
23861887	Sphing-4-enine-1-phosphate	Rex K	Sphingosine kinase activity is not required for tumor cell viability.	PloS one	2013	26
24140934	Sphing-4-enine-1-phosphate	Qin Z	Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.	Molecular cancer therapeutics	2014	22
24210073	Sphing-4-enine-1-phosphate	Nagahashi M	Sphingosine-1-phosphate in chronic intestinal inflammation and cancer.	Advances in biological regulation	2014	23
24464131	Sphing-4-enine-1-phosphate	Harikumar KB	K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5.	Nature immunology	2014	35
25347472	Sphing-4-enine-1-phosphate	Degagn√© E	Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs.	The Journal of clinical investigation	2014	34
25499971	Sphing-4-enine-1-phosphate	Kihara Y	Lysophospholipid receptors in drug discovery.	Experimental cell research	2015	28
26126854	Sphing-4-enine-1-phosphate	Kleinfelter LM	Haploid Genetic Screen Reveals a Profound and Direct Dependence on Cholesterol for Hantavirus Membrane Fusion.	mBio	2015	15
26429117	Sphing-4-enine-1-phosphate	Pyne NJ	Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation.	Advances in biological regulation	2016	23
26540633	Sphing-4-enine-1-phosphate	Lu Z	Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1).	Oncotarget	2016	30
26857281	Sphing-4-enine-1-phosphate	Li J	Overexpression of SphK1 enhances cell proliferation and invasion in triple-negative breast cancer via the PI3K/AKT signaling pathway.	Tumour biology 	2016	12
26970273	Sphing-4-enine-1-phosphate	Pyne S	Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances.	Progress in lipid research	2016	15
27956387	Sphing-4-enine-1-phosphate	Powell JA	Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.	Blood	2017	5
28052056	Sphing-4-enine-1-phosphate	van der Weyden L	Genome-wide in vivo screen identifies novel host regulators of metastatic colonization.	Nature	2017	19
28420720	Sphing-4-enine-1-phosphate	Britten CD	A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.	Clinical cancer research 	2017	8
7729684	L-Alanine	Matsuoka S	p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.	Genes & development	1995	194
10323868	L-Alanine	Montagnoli A	Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation.	Genes & development	1999	151
10567572	L-Alanine	Yamamoto K	BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M.	Molecular and cellular biology	1999	194
10581258	L-Alanine	Bulavin DV	Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation.	The EMBO journal	1999	142
10962009	L-Alanine	Lee SL	Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.	The Journal of biological chemistry	2000	100
11579100	L-Alanine	Turkson J	Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation.	The Journal of biological chemistry	2001	118
12029639	L-Alanine	Hsu YS	Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.	Hepatology	2002	105
14966274	L-Alanine	Vassin VM	Replication protein A (RPA) phosphorylation prevents RPA association with replication centers.	Molecular and cellular biology	2004	75
15361502	L-Alanine	Chan HL	Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.	Gut	2004	105
15781667	L-Alanine	Li H	Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer.	Cancer research	2005	65
15871997	L-Alanine	Yuen MF	Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications.	Gut	2005	77
16139227	L-Alanine	Enomoto A	Akt/PKB regulates actin organization and cell motility via Girdin/APE.	Developmental cell	2005	128
16391218	L-Alanine	Chen CJ	Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.	JAMA	2006	487
16446383	L-Alanine	Radomska HS	Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.	The Journal of experimental medicine	2006	64
16685733	L-Alanine	Swanson MG	Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy.	Magnetic resonance in medicine	2006	66
16785532	L-Alanine	Teeling JL	The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.	Journal of immunology	2006	127
16914578	L-Alanine	Wen PY	Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.	Clinical cancer research 	2006	100
17077998	L-Alanine	Flaig TW	A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.	Investigational new drugs	2007	58
17087951	L-Alanine	Hadziyannis SJ	Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.	Gastroenterology	2006	150
17918180	L-Alanine	Fraser M	Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.	International journal of cancer	2008	51
18302293	L-Alanine	Hsu C	A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.	Hepatology	2008	53
18676862	L-Alanine	Waldhauer I	Tumor-associated MICA is shed by ADAM proteases.	Cancer research	2008	70
19075018	L-Alanine	Kaneko O	A binding domain on mesothelin for CA125/MUC16.	The Journal of biological chemistry	2009	52
19100265	L-Alanine	Ruhl CE	Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population.	Gastroenterology	2009	66
19267406	L-Alanine	Wong VW	High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B.	International journal of cancer	2009	62
19276368	L-Alanine	Chen RQ	CDC25B mediates rapamycin-induced oncogenic responses in cancer cells.	Cancer research	2009	46
19302335	L-Alanine	Nguyen VT	Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden.	Journal of viral hepatitis	2009	74
19302977	L-Alanine	Li T	MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells.	Biochemical and biophysical research communications	2009	95
19560417	L-Alanine	Red Brewer M	The juxtamembrane region of the EGF receptor functions as an activation domain.	Molecular cell	2009	121
19816404	L-Alanine	Cheng Q	ATM activates p53 by regulating MDM2 oligomerization and E3 processivity.	The EMBO journal	2009	64
20036194	L-Alanine	Olmos D	Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.	The Lancet. Oncology	2010	106
20696886	L-Alanine	Kim T	Aspartate-glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells.	Proceedings of the National Academy of Sciences of the United States of America	2010	93
20815808	L-Alanine	Gui J	Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies.	Clinical science	2011	71
20959817	L-Alanine	Yin J	Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma.	The American journal of gastroenterology	2011	39
21123452	L-Alanine	Dijkgraaf GJ	Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.	Cancer research	2011	106
21149604	L-Alanine	Chinnasamy N	A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.	Journal of immunology	2011	48
21208101	L-Alanine	O'Shaughnessy J	Iniparib plus chemotherapy in metastatic triple-negative breast cancer.	The New England journal of medicine	2011	196
21321221	L-Alanine	Keunen O	Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2011	185
21323729	L-Alanine	Chen CJ	Natural history of chronic hepatitis B REVEALed.	Journal of gastroenterology and hepatology	2011	46
21497551	L-Alanine	Yang HI	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.	The Lancet. Oncology	2011	77
21538343	L-Alanine	Zhu AX	Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.	Cancer	2011	55
21688282	L-Alanine	Bhala N	The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.	Hepatology	2011	88
21783417	L-Alanine	Zhou C	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.	The Lancet. Oncology	2011	839
21880764	L-Alanine	Zhu Z	Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies.	Journal of virology	2011	43
21937277	L-Alanine	Sch√∂ffski P	Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.	The Lancet. Oncology	2011	44
22066022	L-Alanine	Bihrer V	Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma.	PloS one	2011	48
22162641	L-Alanine	Ou SH	Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.	Drug design, development and therapy	2011	38
22362824	L-Alanine	van der Lely AJ	Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.	The Journal of clinical endocrinology and metabolism	2012	35
22426755	L-Alanine	Montonen J	Consumption of red meat and whole-grain bread in relation to biomarkers of obesity, inflammation, glucose metabolism and oxidative stress.	European journal of nutrition	2013	29
22700995	L-Alanine	Kindler HL	A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.	Annals of oncology 	2012	55
22894884	L-Alanine	Di Giacomo AM	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.	The Lancet. Oncology	2012	53
22954507	L-Alanine	Camidge DR	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.	The Lancet. Oncology	2012	288
22962440	L-Alanine	Widemann BC	A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.	Clinical cancer research 	2012	34
23073627	L-Alanine	Gagnon KB	Molecular physiology of SPAK and OSR1: two Ste20-related protein kinases regulating ion transport.	Physiological reviews	2012	35
23213206	L-Alanine	Mazor R	Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.	Proceedings of the National Academy of Sciences of the United States of America	2012	34
23355498	L-Alanine	Loomba R	Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study.	American journal of epidemiology	2013	28
23444397	L-Alanine	HPS2-THRIVE Collaborative Group.	HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.	European heart journal	2013	104
23463346	L-Alanine	Beyoƒülu D	Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification.	Hepatology	2013	46
23564522	L-Alanine	Asahina Y	Œ±-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.	Hepatology	2013	40
23575478	L-Alanine	Jimeno A	Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors.	Clinical cancer research 	2013	40
23633921	L-Alanine	Khan AP	The role of sarcosine metabolism in prostate cancer progression.	Neoplasia	2013	34
24069390	L-Alanine	Kennedy KM	Catabolism of exogenous lactate reveals it as a legitimate metabolic substrate in breast cancer.	PloS one	2013	36
24102757	L-Alanine	Saab S	Impact of coffee on liver diseases: a systematic review.	Liver international 	2014	22
24107395	L-Alanine	Gordon SC	Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.	Clinical gastroenterology and hepatology 	2014	29
24123097	L-Alanine	Wong GL	On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir.	Hepatology	2014	26
24163103	L-Alanine	Mitra M	Structural determinants of human APOBEC3A enzymatic and nucleic acid binding properties.	Nucleic acids research	2014	27
24249672	L-Alanine	Bagatell R	Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.	Pediatric blood & cancer	2014	26
24352239	L-Alanine	Tessarz P	Glutamine methylation in histone H2A is an RNA-polymerase-I-dedicated modification.	Nature	2014	40
24411639	L-Alanine	Reck M	Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.	The Lancet. Oncology	2014	129
24448638	L-Alanine	Sausville E	Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.	Cancer chemotherapy and pharmacology	2014	31
24462733	L-Alanine	El-Serag HB	A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.	Gastroenterology	2014	34
24583798	L-Alanine	Papadopoulos KP	Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.	Clinical cancer research 	2014	22
24615778	L-Alanine	Kahl BS	A phase 1 study of the PI3KŒ¥ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).	Blood	2014	36
24919570	L-Alanine	Shiwarski DJ	To "grow" or "go": TMEM16A expression as a switch between tumor growth and metastasis in SCCHN.	Clinical cancer research 	2014	24
24928858	L-Alanine	Loughery J	Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters.	Nucleic acids research	2014	33
24947364	L-Alanine	Scott RA	Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity.	Diabetes	2014	32
25042054	L-Alanine	Yamasaki K	Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients.	Hepatology	2014	24
25212606	L-Alanine	Puzanov I	A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.	Clinical cancer research 	2015	25
25267294	L-Alanine	Barton O	Polo-like kinase 3 regulates CtIP during DNA double-strand break repair in G1.	The Journal of cell biology	2014	20
25449138	L-Alanine	Liew SC	Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases.	European journal of medical genetics	2015	20
25468160	L-Alanine	Neuschwander-Tetri BA	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.	Lancet	2015	205
25500057	L-Alanine	Bedard PL	A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.	Clinical cancer research 	2015	48
25601341	L-Alanine	Ryan CJ	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.	The Lancet. Oncology	2015	109
25695221	L-Alanine	Ichihara E	Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.	Journal of thoracic oncology 	2015	20
25696919	L-Alanine	Sharman J	An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.	Blood	2015	29
25721064	L-Alanine	Papadopoulos KP	Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody¬Æ targeting the DR5 receptor.	Cancer chemotherapy and pharmacology	2015	19
25754348	L-Alanine	Khozin S	FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.	Clinical cancer research 	2015	24
25882986	L-Alanine	Pignata S	Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.	The Lancet. Oncology	2015	17
25981818	L-Alanine	Li J	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.	The Lancet. Oncology	2015	57
26311725	L-Alanine	Schlumberger M	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.	Clinical cancer research 	2016	15
26352813	L-Alanine	Burton BK	A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency.	The New England journal of medicine	2015	19
26409216	L-Alanine	Liang HW	Hepatitis B virus-human chimeric transcript HBx-LINE1 promotes hepatic injury via sequestering cellular microRNA-122.	Journal of hepatology	2016	13
26439863	L-Alanine	Matheson NJ	Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef.	Cell host & microbe	2015	30
26455325	L-Alanine	van Geldermalsen M	ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.	Oncogene	2016	46
26472751	L-Alanine	O'Brien SM	A phase 2 study of idelalisib plus rituximab in treatment-na√Øve older patients with chronic lymphocytic leukemia.	Blood	2015	30
26708155	L-Alanine	Shaw AT	Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.	The Lancet. Oncology	2016	95
26714945	L-Alanine	Sun JJ	Postoperative Adjuvant¬†Transcatheter Arterial Chemoembolization After R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion.	Annals of surgical oncology	2016	15
26858122	L-Alanine	Antonia S	Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.	The Lancet. Oncology	2016	75
26952546	L-Alanine	Rosenberg JE	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.	Lancet	2016	295
26973324	L-Alanine	Kim DW	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.	The Lancet. Oncology	2016	70
26980062	L-Alanine	Kazandjian D	FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.	Clinical cancer research 	2016	16
27022112	L-Alanine	Urata Y	Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.	Journal of clinical oncology 	2016	13
27075625	L-Alanine	Wang H	NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.	Science translational medicine	2016	21
27081703	L-Alanine	Yang Z	MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis.	Oncotarget	2016	11
27247226	L-Alanine	Seiwert TY	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.	The Lancet. Oncology	2016	106
27265347	L-Alanine	Uesaka K	Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).	Lancet	2016	23
27480103	L-Alanine	Ascierto PA	Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.	The Lancet. Oncology	2016	27
27622997	L-Alanine	Hodi FS	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.	The Lancet. Oncology	2016	71
27670892	L-Alanine	Masuishi T	Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.	Clinical colorectal cancer	2017	9
27751847	L-Alanine	Goss G	Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.	The Lancet. Oncology	2016	30
27825636	L-Alanine	Drilon A	Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.	The Lancet. Oncology	2016	31
27836716	L-Alanine	Gettinger SN	Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.	The Lancet. Oncology	2016	28
27887660	L-Alanine	Cai B	Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.	Journal of hematology & oncology	2016	12
27908594	L-Alanine	Swisher EM	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2017	48
28264872	L-Alanine	Kristeleit R	A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.	Clinical cancer research 	2017	8
28359784	L-Alanine	Ascierto PA	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.	The Lancet. Oncology	2017	16
28576675	L-Alanine	Baselga J	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.	The Lancet. Oncology	2017	10
28602779	L-Alanine	Shaw AT	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.	The Lancet. Oncology	2017	18
28645776	L-Alanine	Perl AE	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.	The Lancet. Oncology	2017	10
28958502	L-Alanine	Wu YL	Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2017	10
10092233	APC	Seeling JM	Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A.	Science	1999	112
10548110	APC	Lukas C	Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex.	Nature	1999	97
11533658	APC	Ryo A	Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC.	Nature cell biology	2001	132
12000790	APC	Amit S	Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway.	Genes & development	2002	189
14743218	APC	Song MS	The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex.	Nature cell biology	2004	77
17681132	APC	Strnad P	Regulated HsSAS-6 levels ensure formation of a single procentriole per centriole during the centrosome duplication cycle.	Developmental cell	2007	125
17942902	APC	Hinoi T	Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation.	Cancer research	2007	108
19336570	APC	Huang EH	Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis.	Cancer research	2009	338
19450512	APC	Phelps RA	A two-step model for colon adenoma initiation and progression caused by APC loss.	Cell	2009	111
20460455	APC	Bottomly D	Identification of {beta}-catenin binding regions in colon cancer cells using ChIP-Seq.	Nucleic acids research	2010	70
9558396	Fludarabine	Kitada S	Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.	Blood	1998	118
9780338	Fludarabine	Aversa F	Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.	The New England journal of medicine	1998	127
10477712	Fludarabine	Damle RN	Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.	Blood	1999	382
12000866	Fludarabine	Dudley ME	A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.	Journal of immunotherapy	2002	91
12662126	Fludarabine	Plosker GL	Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.	Drugs	2003	78
12791654	Fludarabine	Maris MB	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.	Blood	2003	79
15632206	Fludarabine	Miller JS	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.	Blood	2005	373
15753458	Fludarabine	Aversa F	Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.	Journal of clinical oncology 	2005	123
15800326	Fludarabine	Dudley ME	Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.	Journal of clinical oncology 	2005	465
15905192	Fludarabine	Burger M	Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.	Blood	2005	76
15914560	Fludarabine	Beyer M	Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.	Blood	2005	108
16543464	Fludarabine	Kojima K	Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.	Blood	2006	71
17283363	Fludarabine	Grever MR	Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.	Journal of clinical oncology 	2007	76
17296974	Fludarabine	O'Brien S	Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.	Journal of clinical oncology 	2007	56
18334676	Fludarabine	Ferrajoli A	Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.	Blood	2008	111
18411418	Fludarabine	Tam CS	Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.	Blood	2008	162
18599795	Fludarabine	Pepper C	Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.	Blood	2008	71
18628480	Fludarabine	Wu L	lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.	Clinical cancer research 	2008	102
18836097	Fludarabine	Balakrishnan K	AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.	Blood	2009	60
18941118	Fludarabine	Zenz T	miR-34a as part of the resistance network in chronic lymphocytic leukemia.	Blood	2009	63
18950462	Fludarabine	Shi J	Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.	British journal of haematology	2008	52
19549911	Fludarabine	Buchner M	Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.	Cancer research	2009	62
19643983	Fludarabine	Zenz T	Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.	Blood	2009	62
19706886	Fludarabine	Verneris MR	Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.	Blood	2009	77
20085940	Fludarabine	Rubnitz JE	NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.	Journal of clinical oncology 	2010	129
20194844	Fludarabine	Robak T	Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.	Journal of clinical oncology 	2010	75
20194866	Fludarabine	Wierda WG	Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.	Journal of clinical oncology 	2010	129
20335218	Fludarabine	Buchner M	Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.	Blood	2010	62
20439626	Fludarabine	Gyurkocza B	Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.	Journal of clinical oncology 	2010	46
20680271	Fludarabine	Bachanova V	Allogeneic natural killer cells for refractory lymphoma.	Cancer immunology, immunotherapy 	2010	54
20697090	Fludarabine	Zenz T	TP53 mutation and survival in chronic lymphocytic leukemia.	Journal of clinical oncology 	2010	99
20697368	Fludarabine	Cutler C	Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.	Bone marrow transplantation	2011	39
20719934	Fludarabine	Hong JJ	Successful treatment of melanoma brain metastases with adoptive cell therapy.	Clinical cancer research 	2010	47
20849361	Fludarabine	Geller MA	A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.	Cytotherapy	2011	94
20888994	Fludarabine	Hallek M	Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.	Lancet	2010	353
21402714	Fludarabine	Amrein PC	Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.	Clinical cancer research 	2011	41
21791425	Fludarabine	Curti A	Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.	Blood	2011	81
21844497	Fludarabine	Fischer K	Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.	Journal of clinical oncology 	2011	75
21856867	Fludarabine	Wierda WG	Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.	Blood	2011	40
22039264	Fludarabine	Rossi D	Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.	Blood	2011	85
22045765	Fludarabine	Sorror ML	Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.	JAMA	2011	48
22128299	Fludarabine	Tromp JM	Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.	Clinical cancer research 	2012	35
22184378	Fludarabine	Roberts AW	Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.	Journal of clinical oncology 	2012	199
22308293	Fludarabine	Rossi D	Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.	Blood	2012	64
22493413	Fludarabine	Pettitt AR	Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.	Journal of clinical oncology 	2012	32
22610076	Fludarabine	Zhu DX	miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.	Carcinogenesis	2012	52
22740450	Fludarabine	Mahoney E	ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.	Blood	2012	32
22796535	Fludarabine	Ciurea SO	Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.	Biology of blood and marrow transplantation 	2012	36
22873532	Fludarabine	Kluin-Nelemans HC	Treatment of older patients with mantle-cell lymphoma.	The New England journal of medicine	2012	58
23086750	Fludarabine	Oscier DG	The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.	Blood	2013	52
23091097	Fludarabine	Skowronska A	Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.	Journal of clinical oncology 	2012	33
23530110	Fludarabine	Federico M	R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.	Journal of clinical oncology 	2013	31
23720127	Fludarabine	Hallek M	Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.	American journal of hematology	2013	38
24005245	Fludarabine	Ruggeri A	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT.	Leukemia	2014	20
24277076	Fludarabine	Hoellenriegel J	The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.	Blood	2014	31
24652989	Fludarabine	Stilgenbauer S	Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.	Blood	2014	60
24719405	Fludarabine	Bachanova V	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.	Blood	2014	71
24912431	Fludarabine	Cao Y	The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.	Leukemia	2015	21
25049322	Fludarabine	Byrd JC	Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.	Journal of clinical oncology 	2014	39
25154820	Fludarabine	Kochenderfer JN	Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.	Journal of clinical oncology 	2015	237
25319501	Fludarabine	Lee DW	T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.	Lancet	2015	367
25908509	Fludarabine	Hallek M	Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.	American journal of hematology	2015	50
25940712	Fludarabine	Ninomiya S	Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.	Blood	2015	32
26002963	Fludarabine	Treon SP	How I treat Waldenstr√∂m macroglobulinemia.	Blood	2015	15
26039205	Fludarabine	Bacigalupo A	Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update.	Bone marrow transplantation	2015	17
26053664	Fludarabine	Bleakley M	Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.	The Journal of clinical investigation	2015	38
26486789	Fludarabine	Fischer K	Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.	Blood	2016	38
26492934	Fludarabine	Thompson PA	Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.	Blood	2016	29
26639348	Fludarabine	Roberts AW	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.	The New England journal of medicine	2016	143
26675346	Fludarabine	Ljungstr√∂m V	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.	Blood	2016	17
26762740	Fludarabine	Ikeda S	PD-L1 Is Upregulated by Simultaneous Amplification of¬†the PD-L1 and JAK2 Genes in Non-Small Cell Lung¬†Cancer.	Journal of thoracic oncology 	2016	16
26764356	Fludarabine	Mielcarek M	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.	Blood	2016	11
27111235	Fludarabine	Turtle CJ	CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.	The Journal of clinical investigation	2016	120
27605551	Fludarabine	Turtle CJ	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.	Science translational medicine	2016	48
28291388	Fludarabine	Kochenderfer JN	Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.	Journal of clinical oncology 	2017	13
28395880	Fludarabine	Chandran SS	Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.	The Lancet. Oncology	2017	8
28408462	Fludarabine	Gardner RA	Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.	Blood	2017	11
28715249	Fludarabine	Turtle CJ	Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.	Journal of clinical oncology 	2017	10
7641693	17a-Ethynylestradiol	Cavaill√®s V	Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.	The EMBO journal	1995	168
8168078	17a-Ethynylestradiol	Ottaviano YL	Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.	Cancer research	1994	122
9039267	17a-Ethynylestradiol	Zwijsen RM	CDK-independent activation of estrogen receptor by cyclin D1.	Cell	1997	170
9041202	17a-Ethynylestradiol	Relf M	Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.	Cancer research	1997	130
9199297	17a-Ethynylestradiol	Nakshatri H	Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.	Molecular and cellular biology	1997	186
9252329	17a-Ethynylestradiol	Anzick SL	AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.	Science	1997	373
9278514	17a-Ethynylestradiol	Paech K	Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.	Science	1997	315
9338076	17a-Ethynylestradiol	Baylin SB	Alterations in DNA methylation: a fundamental aspect of neoplasia.	Advances in cancer research	1998	332
9362426	17a-Ethynylestradiol	Coleman RE	Skeletal complications of malignancy.	Cancer	1997	219
9367686	17a-Ethynylestradiol	Carmeci C	Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer.	Genomics	1997	125
9391166	17a-Ethynylestradiol	Gehm BD	Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor.	Proceedings of the National Academy of Sciences of the United States of America	1997	105
9501191	17a-Ethynylestradiol	Lavinsky RM	Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.	Proceedings of the National Academy of Sciences of the United States of America	1998	112
9662379	17a-Ethynylestradiol	Kononen J	Tissue microarrays for high-throughput molecular profiling of tumor specimens.	Nature medicine	1998	777
9747868	17a-Ethynylestradiol	Fisher B	Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.	Journal of the National Cancer Institute	1998	717
10080586	17a-Ethynylestradiol	Kuerer HM	Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.	Journal of clinical oncology 	1999	225
10334533	17a-Ethynylestradiol	Harvey JM	Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.	Journal of clinical oncology 	1999	417
10334989	17a-Ethynylestradiol	Fan S	BRCA1 inhibition of estrogen receptor signaling in transfected cells.	Science	1999	103
10411913	17a-Ethynylestradiol	Vasioukhin V	The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin.	Proceedings of the National Academy of Sciences of the United States of America	1999	237
10454584	17a-Ethynylestradiol	Vigo E	CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase.	Molecular and cellular biology	1999	98
10606235	17a-Ethynylestradiol	Kyo S	Estrogen activates telomerase.	Cancer research	1999	100
10688862	17a-Ethynylestradiol	Henderson BE	Hormonal carcinogenesis.	Carcinogenesis	2000	177
10696569	17a-Ethynylestradiol	Liehr JG	Is estradiol a genotoxic mutagenic carcinogen?	Endocrine reviews	2000	97
10713699	17a-Ethynylestradiol	Cogswell PC	Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.	Oncogene	2000	126
11016622	17a-Ethynylestradiol	Eads CA	Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.	Cancer research	2000	102
11136970	17a-Ethynylestradiol	Shang Y	Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription.	Cell	2000	515
11181778	17a-Ethynylestradiol	Bos R	Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.	Journal of the National Cancer Institute	2001	143
11257103	17a-Ethynylestradiol	Welcsh PL	BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.	Human molecular genetics	2001	122
11289127	17a-Ethynylestradiol	Roger P	Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.	Cancer research	2001	92
11438457	17a-Ethynylestradiol	Leav I	Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.	The American journal of pathology	2001	97
11473106	17a-Ethynylestradiol	Wijayaratne AL	The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators.	The Journal of biological chemistry	2001	107
11504747	17a-Ethynylestradiol	Chia SK	Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.	Journal of clinical oncology 	2001	94
11507038	17a-Ethynylestradiol	Gruvberger S	Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.	Cancer research	2001	168
11517191	17a-Ethynylestradiol	Lazennec G	ER beta inhibits proliferation and invasion of breast cancer cells.	Endocrinology	2001	101
11553815	17a-Ethynylestradiol	S√∏rlie T	Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.	Proceedings of the National Academy of Sciences of the United States of America	2001	2677
11710890	17a-Ethynylestradiol	King MC	Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.	JAMA	2001	93
11751417	17a-Ethynylestradiol	Xie D	Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features.	Cancer research	2001	90
11929836	17a-Ethynylestradiol	Stabile LP	Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen.	Cancer research	2002	104
11940574	17a-Ethynylestradiol	Leung JY	Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling.	The Journal of biological chemistry	2002	125
12060624	17a-Ethynylestradiol	Schindl M	Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.	Clinical cancer research 	2002	102
12400004	17a-Ethynylestradiol	Real PJ	Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells.	Oncogene	2002	88
12408373	17a-Ethynylestradiol	Anderson WF	Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.	Breast cancer research and treatment	2002	107
12415108	17a-Ethynylestradiol	Wong CW	Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade.	Proceedings of the National Academy of Sciences of the United States of America	2002	84
12479367	17a-Ethynylestradiol	Clark AS	Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.	Molecular cancer therapeutics	2002	139
12498683	17a-Ethynylestradiol	Daujat S	Crosstalk between CARM1 methylation and CBP acetylation on histone H3.	Current biology 	2002	85
12657462	17a-Ethynylestradiol	Wu C	The function of the protein tyrosine phosphatase SHP-1 in cancer.	Gene	2003	76
12705869	17a-Ethynylestradiol	Fujita N	MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer.	Cell	2003	149
12796359	17a-Ethynylestradiol	Jensen EV	The estrogen receptor: a model for molecular medicine.	Clinical cancer research 	2003	83
12917485	17a-Ethynylestradiol	Sotiriou C	Breast cancer classification and prognosis based on gene expression profiles from a population-based study.	Proceedings of the National Academy of Sciences of the United States of America	2003	486
12928347	17a-Ethynylestradiol	Key TJ	Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women.	Journal of the National Cancer Institute	2003	246
12959972	17a-Ethynylestradiol	Frasor J	Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype.	Endocrinology	2003	248
12960427	17a-Ethynylestradiol	Schaner ME	Gene expression patterns in ovarian carcinomas.	Molecular biology of the cell	2003	80
14729654	17a-Ethynylestradiol	Paruthiyil S	Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest.	Cancer research	2004	147
14734488	17a-Ethynylestradiol	Schiff R	Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.	Clinical cancer research 	2004	87
14736707	17a-Ethynylestradiol	Chen JQ	Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells.	American journal of physiology. Endocrinology and metabolism	2004	74
14745018	17a-Ethynylestradiol	Str√∂m A	Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D.	Proceedings of the National Academy of Sciences of the United States of America	2004	132
14764897	17a-Ethynylestradiol	Song RX	The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane.	Proceedings of the National Academy of Sciences of the United States of America	2004	88
14871808	17a-Ethynylestradiol	Foulkes WD	The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.	Cancer research	2004	73
15001666	17a-Ethynylestradiol	Bourdeau V	Genome-wide identification of high-affinity estrogen response elements in human and mouse.	Molecular endocrinology	2004	102
15014181	17a-Ethynylestradiol	Coombes RC	A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.	The New England journal of medicine	2004	271
15033914	17a-Ethynylestradiol	Stossi F	Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors.	Endocrinology	2004	72
15041722	17a-Ethynylestradiol	Foulkes WD	Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.	Clinical cancer research 	2004	77
15090535	17a-Ethynylestradiol	Maggiolini M	The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells.	The Journal of biological chemistry	2004	126
15111773	17a-Ethynylestradiol	Johnson MD	Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.	Breast cancer research and treatment	2004	114
15169882	17a-Ethynylestradiol	Louie MC	ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance.	Molecular and cellular biology	2004	103
15193262	17a-Ethynylestradiol	Michalides R	Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.	Cancer cell	2004	73
15193263	17a-Ethynylestradiol	Ma XJ	A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.	Cancer cell	2004	241
15199112	17a-Ethynylestradiol	Shou J	Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.	Journal of the National Cancer Institute	2004	288
15220474	17a-Ethynylestradiol	Biswas DK	NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis.	Proceedings of the National Academy of Sciences of the United States of America	2004	115
15223047	17a-Ethynylestradiol	Dontu G	Breast cancer, stem/progenitor cells and the estrogen receptor.	Trends in endocrinology and metabolism	2004	95
15310774	17a-Ethynylestradiol	Fink AK	Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.	Journal of clinical oncology 	2004	78
15328174	17a-Ethynylestradiol	Nielsen TO	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.	Clinical cancer research 	2004	631
15342389	17a-Ethynylestradiol	Kubo M	Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer.	Cancer research	2004	110
15342805	17a-Ethynylestradiol	Hughes KS	Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.	The New England journal of medicine	2004	106
15345050	17a-Ethynylestradiol	Lin CY	Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells.	Genome biology	2004	103
15369453	17a-Ethynylestradiol	Bardin A	Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.	Endocrine-related cancer	2004	80
15380517	17a-Ethynylestradiol	Torres-Arzayus MI	High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene.	Cancer cell	2004	148
15496458	17a-Ethynylestradiol	Acconcia F	Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol.	Molecular biology of the cell	2005	129
15520168	17a-Ethynylestradiol	Campbell IG	Mutation of the PIK3CA gene in ovarian and breast cancer.	Cancer research	2004	226
15534099	17a-Ethynylestradiol	Camp RL	X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.	Clinical cancer research 	2004	337
15572757	17a-Ethynylestradiol	Martino S	Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.	Journal of the National Cancer Institute	2004	94
15574760	17a-Ethynylestradiol	Loo LW	Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes.	Cancer research	2004	70
15583021	17a-Ethynylestradiol	Herynk MH	Estrogen receptor mutations in human disease.	Endocrine reviews	2004	83
15585641	17a-Ethynylestradiol	deGraffenried LA	Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.	Clinical cancer research 	2004	82
15591335	17a-Ethynylestradiol	Paik S	A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.	The New England journal of medicine	2004	1319
15602573	17a-Ethynylestradiol	Proikas-Cezanne T	WIPI-1alpha (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy.	Oncogene	2004	100
15671525	17a-Ethynylestradiol	Lam LT	Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.	Clinical cancer research 	2005	107
15701879	17a-Ethynylestradiol	Osborne CK	Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.	Clinical cancer research 	2005	93
15734144	17a-Ethynylestradiol	Kalaitzidis D	Transcription factor cross-talk: the estrogen receptor and NF-kappaB.	Trends in endocrinology and metabolism	2005	84
15735034	17a-Ethynylestradiol	Stabile LP	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.	Cancer research	2005	86
15755967	17a-Ethynylestradiol	Osborne CK	Estrogen-receptor biology: continuing progress and therapeutic implications.	Journal of clinical oncology 	2005	81
15808510	17a-Ethynylestradiol	Park KJ	Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation.	Molecular cell	2005	65
15857973	17a-Ethynylestradiol	Koehler KF	Reflections on the discovery and significance of estrogen receptor beta.	Endocrine reviews	2005	68
15899795	17a-Ethynylestradiol	Dai H	A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.	Cancer research	2005	91
15961505	17a-Ethynylestradiol	Sentis S	Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity.	Molecular endocrinology	2005	68
15986123	17a-Ethynylestradiol	Rae JM	GREB 1 is a critical regulator of hormone dependent breast cancer growth.	Breast cancer research and treatment	2005	85
15998903	17a-Ethynylestradiol	Smith IE	Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.	Journal of clinical oncology 	2005	92
16012726	17a-Ethynylestradiol	Tsutsui S	Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density.	Oncology reports	2005	92
16033833	17a-Ethynylestradiol	Lakhani SR	Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.	Clinical cancer research 	2005	155
16082211	17a-Ethynylestradiol	Aggarwal BB	Molecular targets and anticancer potential of indole-3-carbinol and its derivatives.	Cell cycle	2005	103
16087863	17a-Ethynylestradiol	Lagani√®re J	From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response.	Proceedings of the National Academy of Sciences of the United States of America	2005	133
16115903	17a-Ethynylestradiol	Rouzier R	Breast cancer molecular subtypes respond differently to preoperative chemotherapy.	Clinical cancer research 	2005	370
16137620	17a-Ethynylestradiol	Wang Q	Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking.	Molecular cell	2005	188
16165085	17a-Ethynylestradiol	Wang Z	Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66.	Biochemical and biophysical research communications	2005	103
16172792	17a-Ethynylestradiol	Zhang Z	Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.	Breast cancer research and treatment	2005	71
16234364	17a-Ethynylestradiol	Mitsiades CS	Antimyeloma activity of heat shock protein-90 inhibition.	Blood	2006	80
16239258	17a-Ethynylestradiol	Vivacqua A	The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.	Molecular endocrinology	2006	104
16288118	17a-Ethynylestradiol	Fisher B	Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.	Journal of the National Cancer Institute	2005	240
16317585	17a-Ethynylestradiol	Li SY	PIK3CA mutations in breast cancer are associated with poor outcome.	Breast cancer research and treatment	2006	60
16322319	17a-Ethynylestradiol	Normanno N	Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.	Endocrine-related cancer	2005	75
16333030	17a-Ethynylestradiol	Lewis JS	Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation.	Journal of the National Cancer Institute	2005	78
16341146	17a-Ethynylestradiol	Livasy CA	Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.	Modern pathology 	2006	250
16368942	17a-Ethynylestradiol	McCabe A	Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis.	Journal of the National Cancer Institute	2005	81
16394250	17a-Ethynylestradiol	Hall JM	Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting.	Molecular interventions	2005	75
16396959	17a-Ethynylestradiol	Carroll JS	Estrogen receptor target gene: an evolving concept.	Molecular endocrinology	2006	90
16397019	17a-Ethynylestradiol	Diaz N	Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.	Clinical cancer research 	2006	81
16427018	17a-Ethynylestradiol	Wei X	MUC1 oncoprotein stabilizes and activates estrogen receptor alpha.	Molecular cell	2006	76
16469706	17a-Ethynylestradiol	Zhu P	Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway.	Cell	2006	94
16478745	17a-Ethynylestradiol	Sotiriou C	Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.	Journal of the National Cancer Institute	2006	549
16511588	17a-Ethynylestradiol	Deroo BJ	Estrogen receptors and human disease.	The Journal of clinical investigation	2006	283
16533778	17a-Ethynylestradiol	Rodr√≠guez-Pinilla SM	Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas.	Clinical cancer research 	2006	73
16603601	17a-Ethynylestradiol	Pestalozzi BC	Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).	Annals of oncology 	2006	76
16609087	17a-Ethynylestradiol	Berry DA	Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.	JAMA	2006	145
16626501	17a-Ethynylestradiol	Perreard L	Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay.	Breast cancer research 	2006	62
16651450	17a-Ethynylestradiol	Dreijerink KM	Menin links estrogen receptor activation to histone H3K4 trimethylation.	Cancer research	2006	67
16682622	17a-Ethynylestradiol	Xia W	A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2006	113
16682724	17a-Ethynylestradiol	Linden HM	Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.	Journal of clinical oncology 	2006	67
16705121	17a-Ethynylestradiol	Holm C	Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.	Journal of the National Cancer Institute	2006	68
16707433	17a-Ethynylestradiol	Bond GL	MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.	Cancer research	2006	111
16729877	17a-Ethynylestradiol	S√∏rlie T	Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.	BMC genomics	2006	110
16737553	17a-Ethynylestradiol	Habel LA	A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.	Breast cancer research 	2006	115
16754886	17a-Ethynylestradiol	Wang Z	A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling.	Proceedings of the National Academy of Sciences of the United States of America	2006	101
16809442	17a-Ethynylestradiol	Chang EC	Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells.	Endocrinology	2006	123
16835357	17a-Ethynylestradiol	Vivacqua A	17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30.	Molecular pharmacology	2006	78
16846527	17a-Ethynylestradiol	Birgisdottir V	Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer.	Breast cancer research 	2006	75
16849584	17a-Ethynylestradiol	Frasor J	Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome.	Cancer research	2006	73
16854453	17a-Ethynylestradiol	McCubrey JA	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.	Advances in enzyme regulation	2006	168
16885386	17a-Ethynylestradiol	Wolf I	15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.	Cancer research	2006	63
16897746	17a-Ethynylestradiol	Bergamaschi A	Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.	Genes, chromosomes & cancer	2006	162
16899776	17a-Ethynylestradiol	Fan C	Concordance among gene-expression-based predictors for breast cancer.	The New England journal of medicine	2006	352
16901744	17a-Ethynylestradiol	Ilan N	Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.	The international journal of biochemistry & cell biology	2006	159
16904320	17a-Ethynylestradiol	Singh PK	Cell surface-associated mucins in signal transduction.	Trends in cell biology	2006	122
16931954	17a-Ethynylestradiol	Hicks DG	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.	The American journal of surgical pathology	2006	71
16938528	17a-Ethynylestradiol	Kim MJ	Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.	Human pathology	2006	84
16940181	17a-Ethynylestradiol	Hossain A	Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA.	Molecular and cellular biology	2006	171
16954471	17a-Ethynylestradiol	Buyse M	Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.	Journal of the National Cancer Institute	2006	257
16980581	17a-Ethynylestradiol	Eeckhoute J	A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer.	Genes & development	2006	104
17028294	17a-Ethynylestradiol	Hecht JL	Molecular and pathologic aspects of endometrial carcinogenesis.	Journal of clinical oncology 	2006	94
17030978	17a-Ethynylestradiol	McTiernan A	Relation of BMI and physical activity to sex hormones in postmenopausal women.	Obesity	2006	66
17115111	17a-Ethynylestradiol	Goetz MP	The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.	Breast cancer research and treatment	2007	115
17135638	17a-Ethynylestradiol	Bates GJ	Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.	Journal of clinical oncology 	2006	234
17169390	17a-Ethynylestradiol	Jordan VC	Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.	Steroids	2007	78
17178894	17a-Ethynylestradiol	Fan M	Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.	Cancer research	2006	93
17213279	17a-Ethynylestradiol	Tworoger SS	Plasma adiponectin concentrations and risk of incident breast cancer.	The Journal of clinical endocrinology and metabolism	2007	81
17234468	17a-Ethynylestradiol	Livasy CA	Identification of a basal-like subtype of breast ductal carcinoma in situ.	Human pathology	2007	60
17235397	17a-Ethynylestradiol	Amaravadi RK	Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma.	The Journal of clinical investigation	2007	390
17276470	17a-Ethynylestradiol	M√°rquez-Garb√°n DC	Estrogen receptor signaling pathways in human non-small cell lung cancer.	Steroids	2007	63
17312304	17a-Ethynylestradiol	Cuzick J	Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.	Journal of the National Cancer Institute	2007	96
17312305	17a-Ethynylestradiol	Powles TJ	Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.	Journal of the National Cancer Institute	2007	83
17317830	17a-Ethynylestradiol	Harris LN	Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.	Clinical cancer research 	2007	59
17334996	17a-Ethynylestradiol	J√∂nsson G	High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.	Genes, chromosomes & cancer	2007	66
17360330	17a-Ethynylestradiol	Kwon YS	Sensitive ChIP-DSL technology reveals an extensive estrogen receptor alpha-binding program on human gene promoters.	Proceedings of the National Academy of Sciences of the United States of America	2007	59
17372279	17a-Ethynylestradiol	Tworoger SS	A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.	Journal of clinical oncology 	2007	68
17401012	17a-Ethynylestradiol	Loi S	Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.	Journal of clinical oncology 	2007	271
17407600	17a-Ethynylestradiol	Zhou Y	Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.	BMC cancer	2007	58
17438091	17a-Ethynylestradiol	Carey LA	The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.	Clinical cancer research 	2007	472
17440086	17a-Ethynylestradiol	Fu Y	GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis.	Cancer research	2007	92
17456570	17a-Ethynylestradiol	Rohrmann S	Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans.	The Journal of clinical endocrinology and metabolism	2007	57
17470737	17a-Ethynylestradiol	Arpino G	Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.	Journal of the National Cancer Institute	2007	62
17475399	17a-Ethynylestradiol	Riggins RB	Pathways to tamoxifen resistance.	Cancer letters	2007	79
17502350	17a-Ethynylestradiol	Shi B	Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.	Molecular and cellular biology	2007	107
17529974	17a-Ethynylestradiol	Stacey SN	Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer.	Nature genetics	2007	320
17542648	17a-Ethynylestradiol	Lin CY	Whole-genome cartography of estrogen receptor alpha binding sites.	PLoS genetics	2007	202
17554627	17a-Ethynylestradiol	Bauer M	Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer.	Breast cancer research and treatment	2008	58
17575221	17a-Ethynylestradiol	P√©rez-Tenorio G	PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.	Clinical cancer research 	2007	96
17578664	17a-Ethynylestradiol	Millikan RC	Epidemiology of basal-like breast cancer.	Breast cancer research and treatment	2008	306
17586727	17a-Ethynylestradiol	Sasser AK	Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer.	FASEB journal 	2007	70
17592774	17a-Ethynylestradiol	Levin ER	Estrogen receptors outside the nucleus in breast cancer.	Breast cancer research and treatment	2008	50
17616709	17a-Ethynylestradiol	Eeckhoute J	Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer.	Cancer research	2007	125
17620276	17a-Ethynylestradiol	Morris GJ	Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database.	Cancer	2007	144
17626182	17a-Ethynylestradiol	Liu X	Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	115
17639037	17a-Ethynylestradiol	Vona-Davis L	Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression.	Endocrine-related cancer	2007	137
17660348	17a-Ethynylestradiol	Gomez BP	Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines.	FASEB journal 	2007	67
17663798	17a-Ethynylestradiol	Hoadley KA	EGFR associated expression profiles vary with breast tumor subtype.	BMC genomics	2007	104
17673939	17a-Ethynylestradiol	Taylor KM	The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer.	Molecular medicine	2007	60
17679729	17a-Ethynylestradiol	Blum W	Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.	Journal of clinical oncology 	2007	93
17683518	17a-Ethynylestradiol	Teschendorff AE	An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.	Genome biology	2007	176
17700529	17a-Ethynylestradiol	Williams C	A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells.	Oncogene	2008	70
17761946	17a-Ethynylestradiol	Dhasarathy A	The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha.	Molecular endocrinology	2007	79
17785421	17a-Ethynylestradiol	Tiwari-Woodruff S	Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment.	Proceedings of the National Academy of Sciences of the United States of America	2007	74
17872378	17a-Ethynylestradiol	DuSell CD	27-hydroxycholesterol is an endogenous selective estrogen receptor modulator.	Molecular endocrinology	2008	73
17897439	17a-Ethynylestradiol	Schlange T	Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.	Breast cancer research 	2007	75
17925008	17a-Ethynylestradiol	Chin SF	High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.	Genome biology	2007	116
17928597	17a-Ethynylestradiol	Hayes DF	HER2 and response to paclitaxel in node-positive breast cancer.	The New England journal of medicine	2007	139
17981890	17a-Ethynylestradiol	Rose DP	Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women.	Endocrine reviews	2007	71
18000219	17a-Ethynylestradiol	Hosey AM	Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.	Journal of the National Cancer Institute	2007	61
18006846	17a-Ethynylestradiol	Mertens-Talcott SU	The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells.	Cancer research	2007	152
18071188	17a-Ethynylestradiol	Owusu C	Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.	Journal of clinical oncology 	2008	77
18165639	17a-Ethynylestradiol	De Laurentiis M	Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.	Journal of clinical oncology 	2008	82
18172323	17a-Ethynylestradiol	Frietze S	CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1.	Cancer research	2008	64
18172760	17a-Ethynylestradiol	Qadir MA	Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization.	Breast cancer research and treatment	2008	70
18230721	17a-Ethynylestradiol	Liu S	BRCA1 regulates human mammary stem/progenitor cell fate.	Proceedings of the National Academy of Sciences of the United States of America	2008	157
18240539	17a-Ethynylestradiol	Mundy GR	Osteoporosis and inflammation.	Nutrition reviews	2007	102
18242510	17a-Ethynylestradiol	Iorns E	Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.	Cancer cell	2008	53
18258689	17a-Ethynylestradiol	Chang EC	Estrogen Receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding.	Molecular endocrinology	2008	66
18258979	17a-Ethynylestradiol	Sparano JA	Development of the 21-gene assay and its application in clinical practice and clinical trials.	Journal of clinical oncology 	2008	127
18294387	17a-Ethynylestradiol	Ghebeh H	FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.	BMC cancer	2008	52
18297396	17a-Ethynylestradiol	Lu X	Predicting features of breast cancer with gene expression patterns.	Breast cancer research and treatment	2008	90
18317227	17a-Ethynylestradiol	Soslow RA	Histologic subtypes of ovarian carcinoma: an overview.	International journal of gynecological pathology 	2008	63
18339859	17a-Ethynylestradiol	Cheng AS	Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome.	Cancer research	2008	54
18347134	17a-Ethynylestradiol	Sun M	Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells.	Molecular cancer therapeutics	2008	110
18375767	17a-Ethynylestradiol	Tan-Wong SM	Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene.	Proceedings of the National Academy of Sciences of the United States of America	2008	62
18398032	17a-Ethynylestradiol	Gunter MJ	A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer.	Cancer epidemiology, biomarkers & prevention 	2008	66
18414489	17a-Ethynylestradiol	Hua S	Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression.	Molecular systems biology	2008	66
18437174	17a-Ethynylestradiol	Gown AM	Current issues in ER and HER2 testing by IHC in breast cancer.	Modern pathology 	2008	66
18438407	17a-Ethynylestradiol	Stacey SN	Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer.	Nature genetics	2008	219
18443585	17a-Ethynylestradiol	Ben-Porath I	An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.	Nature genetics	2008	811
18451221	17a-Ethynylestradiol	Ignatiadis M	Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.	Clinical cancer research 	2008	52
18451222	17a-Ethynylestradiol	Ma XJ	A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.	Clinical cancer research 	2008	66
18458044	17a-Ethynylestradiol	Pestalozzi BC	Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.	Journal of clinical oncology 	2008	54
18498629	17a-Ethynylestradiol	Loi S	Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.	BMC genomics	2008	136
18506688	17a-Ethynylestradiol	Shabo I	Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival.	International journal of cancer	2008	52
18509175	17a-Ethynylestradiol	Azim AA	Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.	Journal of clinical oncology 	2008	79
18515733	17a-Ethynylestradiol	Ross JS	Commercialized multigene predictors of clinical outcome for breast cancer.	The oncologist	2008	55
18550773	17a-Ethynylestradiol	Park SH	Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha.	Molecular endocrinology	2008	55
18593897	17a-Ethynylestradiol	Kondo N	miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.	Cancer research	2008	106
18593923	17a-Ethynylestradiol	Rizzo P	Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches.	Cancer research	2008	106
18657504	17a-Ethynylestradiol	Le Romancer M	Regulation of estrogen rapid signaling through arginine methylation by PRMT1.	Molecular cell	2008	76
18662380	17a-Ethynylestradiol	Wirapati P	Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.	Breast cancer research 	2008	249
18687985	17a-Ethynylestradiol	Pinzone JJ	The role of Dickkopf-1 in bone development, homeostasis, and disease.	Blood	2009	85
18698033	17a-Ethynylestradiol	Desmedt C	Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.	Clinical cancer research 	2008	235
18708351	17a-Ethynylestradiol	Miller TE	MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1.	The Journal of biological chemistry	2008	258
18714348	17a-Ethynylestradiol	Martin KJ	Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.	PloS one	2008	90
18722177	17a-Ethynylestradiol	Kim JH	CCAR1, a key regulator of mediator complex recruitment to nuclear receptor transcription complexes.	Molecular cell	2008	55
18755890	17a-Ethynylestradiol	Foekens JA	Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2008	132
18757322	17a-Ethynylestradiol	Creighton CJ	Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.	Journal of clinical oncology 	2008	102
18765548	17a-Ethynylestradiol	Helleman J	Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.	Clinical cancer research 	2008	58
18787018	17a-Ethynylestradiol	Adams BD	Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells.	Endocrinology	2009	55
18790736	17a-Ethynylestradiol	Zhao JJ	MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.	The Journal of biological chemistry	2008	195
18794137	17a-Ethynylestradiol	Creighton CJ	Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.	Cancer research	2008	50
18806226	17a-Ethynylestradiol	Dumont N	Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers.	Proceedings of the National Academy of Sciences of the United States of America	2008	81
18821585	17a-Ethynylestradiol	Cirillo D	Leptin signaling in breast cancer: an overview.	Journal of cellular biochemistry	2008	65
18841463	17a-Ethynylestradiol	Tan AR	Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?	Breast cancer research and treatment	2009	48
18974155	17a-Ethynylestradiol	Studebaker AW	Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner.	Cancer research	2008	70
18996136	17a-Ethynylestradiol	Fox EM	Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways.	Steroids	2009	47
19003523	17a-Ethynylestradiol	Fagan DH	Crosstalk between IGF1R and estrogen receptor signaling in breast cancer.	Journal of mammary gland biology and neoplasia	2008	57
19027010	17a-Ethynylestradiol	Liu WH	MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells.	Gastroenterology	2009	65
19052240	17a-Ethynylestradiol	Hu Q	Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules.	Proceedings of the National Academy of Sciences of the United States of America	2008	111
19074586	17a-Ethynylestradiol	Vandenberg LN	Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption.	Endocrine reviews	2009	218
19079346	17a-Ethynylestradiol	Gonzalez ME	Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.	Oncogene	2009	75
19112174	17a-Ethynylestradiol	Yamnik RL	S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation.	The Journal of biological chemistry	2009	62
19116382	17a-Ethynylestradiol	Gunter MJ	Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women.	Journal of the National Cancer Institute	2009	135
19116762	17a-Ethynylestradiol	Toh Y	The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications.	Clinical & experimental metastasis	2009	67
19147748	17a-Ethynylestradiol	Andre F	Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.	Clinical cancer research 	2009	97
19198621	17a-Ethynylestradiol	Harris WP	Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.	Nature clinical practice. Urology	2009	142
19204204	17a-Ethynylestradiol	Parker JS	Supervised risk predictor of breast cancer based on intrinsic subtypes.	Journal of clinical oncology 	2009	954
19219042	17a-Ethynylestradiol	Zheng W	Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1.	Nature genetics	2009	252
19221464	17a-Ethynylestradiol	Schoenlein PV	Autophagy facilitates the progression of ERalpha-positive breast cancer cells to antiestrogen resistance.	Autophagy	2009	54
19221498	17a-Ethynylestradiol	Alimova IN	Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro.	Cell cycle	2009	136
19234134	17a-Ethynylestradiol	Sotgia F	Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts.	The American journal of pathology	2009	52
19237579	17a-Ethynylestradiol	Yang J	Lipocalin 2 promotes breast cancer progression.	Proceedings of the National Academy of Sciences of the United States of America	2009	85
19244106	17a-Ethynylestradiol	Wu X	The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.	Cancer research	2009	51
19264808	17a-Ethynylestradiol	Wickramasinghe NS	Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells.	Nucleic acids research	2009	109
19272155	17a-Ethynylestradiol	Rody A	T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.	Breast cancer research 	2009	94
19330030	17a-Ethynylestradiol	Thomas G	A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).	Nature genetics	2009	273
19349544	17a-Ethynylestradiol	Anderson SJ	Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.	Journal of clinical oncology 	2009	63
19366795	17a-Ethynylestradiol	Crowder RJ	PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.	Cancer research	2009	52
19389994	17a-Ethynylestradiol	Santen RJ	History of aromatase: saga of an important biological mediator and therapeutic target.	Endocrine reviews	2009	89
19421758	17a-Ethynylestradiol	Fang YJ	Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer.	International journal of colorectal disease	2009	47
19451693	17a-Ethynylestradiol	Bierie B	Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer.	The Journal of clinical investigation	2009	46
19458043	17a-Ethynylestradiol	Swanton C	Chromosomal instability determines taxane response.	Proceedings of the National Academy of Sciences of the United States of America	2009	80
19470930	17a-Ethynylestradiol	Visvanathan K	American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.	Journal of clinical oncology 	2009	73
19473525	17a-Ethynylestradiol	Luo W	GAGE: generally applicable gene set enrichment for pathway analysis.	BMC bioinformatics	2009	219
19483720	17a-Ethynylestradiol	Walter M	Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells.	Oncogene	2009	70
19487384	17a-Ethynylestradiol	Shi L	Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.	Journal of clinical oncology 	2009	52
19498003	17a-Ethynylestradiol	Paulsson J	Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer.	The American journal of pathology	2009	59
19501895	17a-Ethynylestradiol	Smith HO	GPR30 predicts poor survival for ovarian cancer.	Gynecologic oncology	2009	65
19509232	17a-Ethynylestradiol	Attard G	Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.	Cancer research	2009	59
19514831	17a-Ethynylestradiol	Vona-Davis L	The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review.	Journal of women's health	2009	69
19528081	17a-Ethynylestradiol	Bhat-Nakshatri P	Estradiol-regulated microRNAs control estradiol response in breast cancer cells.	Nucleic acids research	2009	109
19531256	17a-Ethynylestradiol	Rene Gonzalez R	Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer.	Breast cancer research 	2009	56
19535820	17a-Ethynylestradiol	Goldhirsch A	Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.	Annals of oncology 	2009	262
19563758	17a-Ethynylestradiol	Hua S	Genomic antagonism between retinoic acid and estrogen signaling in breast cancer.	Cell	2009	112
19581928	17a-Ethynylestradiol	Sullivan NJ	Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells.	Oncogene	2009	186
19582160	17a-Ethynylestradiol	Kao J	Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.	PloS one	2009	264
19584327	17a-Ethynylestradiol	Menashe I	Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis.	Journal of the National Cancer Institute	2009	54
19602591	17a-Ethynylestradiol	Hartman J	Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells.	Cancer research	2009	52
19622763	17a-Ethynylestradiol	Deblois G	Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity.	Cancer research	2009	58
19628648	17a-Ethynylestradiol	Welboren WJ	Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated?	Endocrine-related cancer	2009	46
19653045	17a-Ethynylestradiol	Arrington AK	Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer.	Annals of surgical oncology	2009	49
19671800	17a-Ethynylestradiol	Liu L	Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.	Cancer research	2009	128
19684618	17a-Ethynylestradiol	Leivonen SK	Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines.	Oncogene	2009	75
19706389	17a-Ethynylestradiol	Castellano L	The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response.	Proceedings of the National Academy of Sciences of the United States of America	2009	120
19730444	17a-Ethynylestradiol	Spizzo R	miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells.	Cell death and differentiation	2010	85
19738052	17a-Ethynylestradiol	Saetrom P	A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis.	Cancer research	2009	52
19767412	17a-Ethynylestradiol	Maggiolini M	The unfolding stories of GPR30, a new membrane-bound estrogen receptor.	The Journal of endocrinology	2010	95
19836388	17a-Ethynylestradiol	Kristensen LS	Epigenetics and cancer treatment.	European journal of pharmacology	2009	57
19838210	17a-Ethynylestradiol	Hao L	Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.	Oncogene	2010	43
19874578	17a-Ethynylestradiol	Finn RS	PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.	Breast cancer research 	2009	228
19887647	17a-Ethynylestradiol	Ma Y	BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha.	Molecular endocrinology	2010	55
19897598	17a-Ethynylestradiol	Charn TH	Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection.	Molecular endocrinology	2010	47
19911270	17a-Ethynylestradiol	Resetkova E	Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.	Breast cancer research and treatment	2010	60
19920189	17a-Ethynylestradiol	Frasor J	Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer.	Cancer research	2009	45
19925796	17a-Ethynylestradiol	Yamnik RL	mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation.	FEBS letters	2010	43
20020197	17a-Ethynylestradiol	Gy√∂rffy B	An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.	Breast cancer research and treatment	2010	524
20042638	17a-Ethynylestradiol	Lim S	Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.	Carcinogenesis	2010	129
20065188	17a-Ethynylestradiol	Mamounas EP	Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.	Journal of clinical oncology 	2010	78
20080637	17a-Ethynylestradiol	Lov√©n J	MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2010	48
20080953	17a-Ethynylestradiol	Ross-Innes CS	Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer.	Genes & development	2010	87
20101232	17a-Ethynylestradiol	Ye Y	ERalpha signaling through slug regulates E-cadherin and EMT.	Oncogene	2010	44
20110355	17a-Ethynylestradiol	Takabe K	Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2.	The Journal of biological chemistry	2010	85
20127405	17a-Ethynylestradiol	Castellano I	Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.	Breast cancer research and treatment	2010	49
20133657	17a-Ethynylestradiol	McPherson SJ	Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated.	Proceedings of the National Academy of Sciences of the United States of America	2010	51
20134314	17a-Ethynylestradiol	Heneghan HM	Circulating microRNAs as novel minimally invasive biomarkers for breast cancer.	Annals of surgery	2010	189
20144946	17a-Ethynylestradiol	Reverter A	Regulatory impact factors: unraveling the transcriptional regulation of complex traits from expression data.	Bioinformatics	2010	42
20180843	17a-Ethynylestradiol	Xiong J	An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples.	The FEBS journal	2010	48
20181970	17a-Ethynylestradiol	Cummings SR	Lasofoxifene in postmenopausal women with osteoporosis.	The New England journal of medicine	2010	60
20197310	17a-Ethynylestradiol	Kang L	Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling.	Molecular endocrinology	2010	82
20203690	17a-Ethynylestradiol	Chan QK	Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest.	Cell death and differentiation	2010	54
20208560	17a-Ethynylestradiol	Millour J	FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.	Oncogene	2010	44
20219941	17a-Ethynylestradiol	Schmidt D	A CTCF-independent role for cohesin in tissue-specific transcription.	Genome research	2010	159
20231686	17a-Ethynylestradiol	Staaf J	Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.	Journal of clinical oncology 	2010	58
20332324	17a-Ethynylestradiol	Johnston SR	New strategies in estrogen receptor-positive breast cancer.	Clinical cancer research 	2010	66
20351197	17a-Ethynylestradiol	Bredfeldt TG	Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT.	Molecular endocrinology	2010	61
20385358	17a-Ethynylestradiol	Mak P	ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading.	Cancer cell	2010	130
20388878	17a-Ethynylestradiol	Di Leva G	MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer.	Journal of the National Cancer Institute	2010	101
20395295	17a-Ethynylestradiol	Motiani RK	A novel native store-operated calcium channel encoded by Orai3: selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen receptor-negative breast cancer cells.	The Journal of biological chemistry	2010	75
20411366	17a-Ethynylestradiol	Ibrahim EM	Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies.	Medical oncology	2011	94
20427689	17a-Ethynylestradiol	Barone I	Estrogen receptor mutations and changes in downstream gene expression and signaling.	Clinical cancer research 	2010	44
20442245	17a-Ethynylestradiol	Hsu PY	Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping.	Genome research	2010	41
20459607	17a-Ethynylestradiol	Staaf J	High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.	Breast cancer research 	2010	52
20479250	17a-Ethynylestradiol	Loi S	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	114
20490652	17a-Ethynylestradiol	Rodr√≠guez-Gonz√°lez FG	MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer.	Breast cancer research and treatment	2011	38
20501593	17a-Ethynylestradiol	Bernardo GM	FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.	Development	2010	71
20501637	17a-Ethynylestradiol	Leung YK	Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion.	Endocrine-related cancer	2010	43
20509143	17a-Ethynylestradiol	Storci G	TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype.	Journal of cellular physiology	2010	41
20519679	17a-Ethynylestradiol	Swain SM	Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.	The New England journal of medicine	2010	59
20530877	17a-Ethynylestradiol	Miller TW	Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.	The Journal of clinical investigation	2010	120
20535543	17a-Ethynylestradiol	Zhao Y	Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer.	Breast cancer research and treatment	2011	41
20547749	17a-Ethynylestradiol	Stender JD	Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation.	Molecular and cellular biology	2010	67
20551055	17a-Ethynylestradiol	Madeo A	Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts.	Cancer research	2010	50
20634194	17a-Ethynylestradiol	Mayer EL	Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.	Clinical cancer research 	2010	53
20661439	17a-Ethynylestradiol	Stacey SN	Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus.	PLoS genetics	2010	45
20664043	17a-Ethynylestradiol	Reeves GK	Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci.	JAMA	2010	51
20682797	17a-Ethynylestradiol	Yang J	The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.	Cancer research	2010	50
20697068	17a-Ethynylestradiol	Symmans WF	Genomic index of sensitivity to endocrine therapy for breast cancer.	Journal of clinical oncology 	2010	88
20699374	17a-Ethynylestradiol	Long J	Evaluation of breast cancer susceptibility loci in Chinese women.	Cancer epidemiology, biomarkers & prevention 	2010	46
20711231	17a-Ethynylestradiol	Arias-Romero LE	A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells.	Oncogene	2010	52
20805453	17a-Ethynylestradiol	Bianchini G	Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.	Journal of clinical oncology 	2010	64
20821253	17a-Ethynylestradiol	Grossmann ME	Obesity and breast cancer: status of leptin and adiponectin in pathological processes.	Cancer metastasis reviews	2010	52
20852631	17a-Ethynylestradiol	Antoniou AC	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.	Nature genetics	2010	160
20858276	17a-Ethynylestradiol	Lowery AJ	Dysregulated miR-183 inhibits migration in breast cancer cells.	BMC cancer	2010	45
20864510	17a-Ethynylestradiol	Kalashnikova EV	ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.	Cancer research	2010	42
20876186	17a-Ethynylestradiol	Suzuki HI	Emerging complexity of microRNA generation cascades.	Journal of biochemistry	2011	38
20876285	17a-Ethynylestradiol	Cittelly DM	Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.	Carcinogenesis	2010	57
20876420	17a-Ethynylestradiol	Ingle JN	Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.	Journal of clinical oncology 	2010	75
20887199	17a-Ethynylestradiol	Osborne CK	Mechanisms of endocrine resistance in breast cancer.	Annual review of medicine	2011	237
20889718	17a-Ethynylestradiol	Lupien M	Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.	Genes & development	2010	59
20932292	17a-Ethynylestradiol	Sircoulomb F	Genome profiling of ERBB2-amplified breast cancers.	BMC cancer	2010	54
20935677	17a-Ethynylestradiol	Zhang XT	A positive feedback loop of ER-Œ±36/EGFR promotes malignant growth of ER-negative breast cancer cells.	Oncogene	2011	41
20936945	17a-Ethynylestradiol	Krishnan AV	Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D.	Annual review of pharmacology and toxicology	2011	90
20956553	17a-Ethynylestradiol	Madak-Erdogan Z	Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs.	Molecular and cellular biology	2011	48
20956939	17a-Ethynylestradiol	Sachdeva M	MicroRNA-101-mediated Akt activation and estrogen-independent growth.	Oncogene	2011	37
20975711	17a-Ethynylestradiol	Li J	Identification of high-quality cancer prognostic markers and metastasis network modules.	Nature communications	2010	136
20978187	17a-Ethynylestradiol	de Souza Rocha Simonini P	Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells.	Cancer research	2010	78
20978357	17a-Ethynylestradiol	Glynn SA	Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.	The Journal of clinical investigation	2010	63
21057537	17a-Ethynylestradiol	Rao X	MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.	Oncogene	2011	109
21057539	17a-Ethynylestradiol	Patel JB	Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22.	Oncogene	2011	39
21084273	17a-Ethynylestradiol	Wynendaele J	An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.	Cancer research	2010	51
21123450	17a-Ethynylestradiol	Rhodes LV	Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.	Cancer research	2011	59
21127264	17a-Ethynylestradiol	Fedele CG	Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.	Proceedings of the National Academy of Sciences of the United States of America	2010	77
21149515	17a-Ethynylestradiol	Murphy LC	Clinical significance of estrogen receptor phosphorylation.	Endocrine-related cancer	2011	47
21151129	17a-Ethynylestradiol	Hurtado A	FOXA1 is a key determinant of estrogen receptor function and endocrine response.	Nature genetics	2011	242
21169259	17a-Ethynylestradiol	O'Brien KM	Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.	Clinical cancer research 	2010	103
21172025	17a-Ethynylestradiol	Cittelly DM	Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.	Molecular cancer	2010	69
21172665	17a-Ethynylestradiol	Yang Y	TDRD3 is an effector molecule for arginine-methylated histone marks.	Molecular cell	2010	71
21191116	17a-Ethynylestradiol	Iwamoto T	Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.	Journal of the National Cancer Institute	2011	69
21212030	17a-Ethynylestradiol	R√∏nneberg JA	Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer.	Molecular oncology	2011	52
21220480	17a-Ethynylestradiol	Osborne CK	Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.	Clinical cancer research 	2011	53
21220595	17a-Ethynylestradiol	Loo CE	Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.	Journal of clinical oncology 	2011	42
21235772	17a-Ethynylestradiol	Grober OM	Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation.	BMC genomics	2011	49
21263130	17a-Ethynylestradiol	Fletcher O	Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study.	Journal of the National Cancer Institute	2011	120
21289245	17a-Ethynylestradiol	Halder SK	1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells.	The Journal of clinical endocrinology and metabolism	2011	38
21292829	17a-Ethynylestradiol	Becker MA	The IGF pathway regulates ERŒ± through a S6K1-dependent mechanism in breast cancer cells.	Molecular endocrinology	2011	41
21310761	17a-Ethynylestradiol	Park S	Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.	Annals of oncology 	2011	43
21325075	17a-Ethynylestradiol	Hu R	Androgen receptor expression and breast cancer survival in postmenopausal women.	Clinical cancer research 	2011	87
21364029	17a-Ethynylestradiol	Phipps AI	Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer.	Cancer epidemiology, biomarkers & prevention 	2011	58
21367843	17a-Ethynylestradiol	Thangavel C	Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.	Endocrine-related cancer	2011	56
21372033	17a-Ethynylestradiol	Subbaramaiah K	Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland.	Cancer prevention research	2011	124
21372223	17a-Ethynylestradiol	Attard G	New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.	Clinical cancer research 	2011	49
21375733	17a-Ethynylestradiol	Hannafon BN	Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer.	Breast cancer research 	2011	57
21422418	17a-Ethynylestradiol	Desmedt C	Multifactorial approach to predicting resistance to anthracyclines.	Journal of clinical oncology 	2011	46
21425139	17a-Ethynylestradiol	Baba Y	Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers.	Cancer	2011	36
21430657	17a-Ethynylestradiol	Madlensky L	Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.	Clinical pharmacology and therapeutics	2011	57
21445275	17a-Ethynylestradiol	Kawazu M	Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development.	PloS one	2011	56
21451508	17a-Ethynylestradiol	M√ºrdter TE	Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.	Clinical pharmacology and therapeutics	2011	67
21482677	17a-Ethynylestradiol	Meyer DS	Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.	Cancer research	2011	43
21482760	17a-Ethynylestradiol	Nicolau M	Topology based data analysis identifies a subgroup of breast cancers with a unique mutational profile and excellent survival.	Proceedings of the National Academy of Sciences of the United States of America	2011	38
21482774	17a-Ethynylestradiol	Mendes-Pereira AM	Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen.	Proceedings of the National Academy of Sciences of the United States of America	2012	48
21502505	17a-Ethynylestradiol	Shi L	Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2011	71
21505063	17a-Ethynylestradiol	Sieuwerts AM	mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.	Clinical cancer research 	2011	65
21553120	17a-Ethynylestradiol	Guttilla IK	Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs.	Breast cancer research and treatment	2012	38
21555689	17a-Ethynylestradiol	Ellis MJ	Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.	Journal of clinical oncology 	2011	96
21558518	17a-Ethynylestradiol	Hatzis C	A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.	JAMA	2011	168
21572428	17a-Ethynylestradiol	Pan X	Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer.	Nature medicine	2011	39
21595894	17a-Ethynylestradiol	Zhang Y	Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.	Breast cancer research 	2011	47
21666713	17a-Ethynylestradiol	Bergamaschi A	Tamoxifen downregulation of miR-451 increases 14-3-3Œ∂ and promotes breast cancer cell survival and endocrine resistance.	Oncogene	2012	62
21689398	17a-Ethynylestradiol	Patnaik JL	Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study.	Breast cancer research 	2011	87
21690342	17a-Ethynylestradiol	Jin K	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.	Proceedings of the National Academy of Sciences of the United States of America	2012	31
21713035	17a-Ethynylestradiol	Al Saleh S	Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells.	PloS one	2011	39
21737487	17a-Ethynylestradiol	Buffa FM	microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer.	Cancer research	2011	115
21738599	17a-Ethynylestradiol	Roth√© F	Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer.	PloS one	2011	71
21741601	17a-Ethynylestradiol	Ni M	Targeting androgen receptor in estrogen receptor-negative breast cancer.	Cancer cell	2011	100
21753181	17a-Ethynylestradiol	Anderson WF	Incidence of breast cancer in the United States: current and future trends.	Journal of the National Cancer Institute	2011	52
21796367	17a-Ethynylestradiol	van Nes JG	Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.	Breast cancer research and treatment	2012	30
21807638	17a-Ethynylestradiol	Filipits M	A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.	Clinical cancer research 	2011	96
21868756	17a-Ethynylestradiol	Pan D	Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.	Cancer research	2011	49
21868760	17a-Ethynylestradiol	Qian P	Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis.	Cancer research	2011	51
21878914	17a-Ethynylestradiol	Kong SL	Cellular reprogramming by the conjoint action of ERŒ±, FOXA1, and GATA3 to a ligand-inducible growth state.	Molecular systems biology	2011	57
21893191	17a-Ethynylestradiol	Wertheimer E	Rac signaling in breast cancer: a tale of GEFs and GAPs.	Cellular signalling	2012	66
21908496	17a-Ethynylestradiol	Rojo F	Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.	Annals of oncology 	2012	42
21916582	17a-Ethynylestradiol	Cook KL	Autophagy and endocrine resistance in breast cancer.	Expert review of anticancer therapy	2011	38
21935603	17a-Ethynylestradiol	Pontiggia O	The tumor microenvironment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through Œ≤1 integrin.	Breast cancer research and treatment	2012	34
21940501	17a-Ethynylestradiol	Keller PJ	Defining the cellular precursors to human breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2012	84
21983130	17a-Ethynylestradiol	Chen X	Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERŒ±-positive endometrioid adenocarcinoma.	Cancer letters	2012	31
21984977	17a-Ethynylestradiol	Brough R	Functional viability profiles of breast cancer.	Cancer discovery	2011	49
21996731	17a-Ethynylestradiol	Fanale D	Breast cancer genome-wide association studies: there is strength in numbers.	Oncogene	2012	34
22010023	17a-Ethynylestradiol	Miller TW	Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.	Journal of clinical oncology 	2011	91
22011582	17a-Ethynylestradiol	Ariazi EA	Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time.	Proceedings of the National Academy of Sciences of the United States of America	2011	46
22014575	17a-Ethynylestradiol	Chang CY	The metabolic regulator ERRŒ±, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer.	Cancer cell	2011	41
22041887	17a-Ethynylestradiol	Martinez-Outschoorn UE	Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.	Cancer biology & therapy	2011	49
22042860	17a-Ethynylestradiol	Santagata S	High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2011	89
22049316	17a-Ethynylestradiol	Miller TW	ERŒ±-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.	Cancer discovery	2011	71
22056872	17a-Ethynylestradiol	Vesuna F	Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-Œ±.	Oncogene	2012	49
22083089	17a-Ethynylestradiol	And√≤ S	The multifactorial role of leptin in driving the breast cancer microenvironment.	Nature reviews. Endocrinology	2011	40
22108298	17a-Ethynylestradiol	Piotrowska H	Biological activity of piceatannol: leaving the shadow of resveratrol.	Mutation research	2012	48
22114931	17a-Ethynylestradiol	Miller TW	Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.	Breast cancer research 	2011	97
22121102	17a-Ethynylestradiol	Slattery ML	JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.	Molecular carcinogenesis	2013	34
22123186	17a-Ethynylestradiol	Wang YC	Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.	Breast cancer research 	2011	62
22125492	17a-Ethynylestradiol	Magnani L	PBX1 genomic pioneer function drives ERŒ± signaling underlying progression in breast cancer.	PLoS genetics	2011	50
22138582	17a-Ethynylestradiol	Gerhardt J	FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.	The American journal of pathology	2012	32
22151997	17a-Ethynylestradiol	Chimge NO	Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2.	Breast cancer research 	2011	38
22158050	17a-Ethynylestradiol	Keklikoglou I	MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-Œ∫B and TGF-Œ≤ signaling pathways.	Oncogene	2012	70
22158945	17a-Ethynylestradiol	Nasser MW	S100A7 enhances mammary tumorigenesis through upregulation of inflammatory pathways.	Cancer research	2012	38
22177311	17a-Ethynylestradiol	Dittrich R	Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation.	Fertility and sterility	2012	37
22178455	17a-Ethynylestradiol	Eroles P	Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.	Cancer treatment reviews	2012	103
22217398	17a-Ethynylestradiol	Tran B	Luminal-B breast cancer and novel therapeutic targets.	Breast cancer research 	2011	50
22223266	17a-Ethynylestradiol	Markowski DN	MED12 mutations in uterine fibroids--their relationship to cytogenetic subgroups.	International journal of cancer	2012	38
22231041	17a-Ethynylestradiol	Munster PN	Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.	Journal of clinical oncology 	2012	33
22231848	17a-Ethynylestradiol	Visser JA	Anti-M√ºllerian hormone: an ovarian reserve marker in primary ovarian insufficiency.	Nature reviews. Endocrinology	2012	39
22240241	17a-Ethynylestradiol	Jamieson S	Molecular pathogenesis of granulosa cell tumors of the ovary.	Endocrine reviews	2012	31
22244658	17a-Ethynylestradiol	Cramer DW	The epidemiology of endometrial and ovarian cancer.	Hematology/oncology clinics of North America	2012	40
22252842	17a-Ethynylestradiol	Sharma A	HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.	Cancer	2012	33
22257677	17a-Ethynylestradiol	Guttilla IK	ERŒ±, microRNAs, and the epithelial-mesenchymal transition in breast cancer.	Trends in endocrinology and metabolism	2012	31
22261811	17a-Ethynylestradiol	Azim HA Jr	Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling.	Clinical cancer research 	2012	57
22262870	17a-Ethynylestradiol	Haibe-Kains B	A three-gene model to robustly identify breast cancer molecular subtypes.	Journal of the National Cancer Institute	2012	86
22267197	17a-Ethynylestradiol	Ghoussaini M	Genome-wide association analysis identifies three new breast cancer susceptibility loci.	Nature genetics	2012	114
22282662	17a-Ethynylestradiol	Barone I	Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells.	Cancer research	2012	30
22291085	17a-Ethynylestradiol	Iwamoto T	Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.	Journal of clinical oncology 	2012	38
22301780	17a-Ethynylestradiol	Baumgarten SC	Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers.	Molecular endocrinology	2012	46
22348646	17a-Ethynylestradiol	Antoniou AC	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.	Breast cancer research 	2012	33
22391567	17a-Ethynylestradiol	Bernardo GM	FOXA1 represses the molecular phenotype of basal breast cancer cells.	Oncogene	2013	41
22408746	17a-Ethynylestradiol	Novitskiy SV	TGF-Œ≤ receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms.	Cancer discovery	2011	38
22417809	17a-Ethynylestradiol	Zhou C	Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration.	Breast cancer research 	2012	31
22420471	17a-Ethynylestradiol	Liu S	CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.	Breast cancer research 	2012	82
22422990	17a-Ethynylestradiol	Julin B	Dietary cadmium exposure and risk of postmenopausal breast cancer: a population-based prospective cohort study.	Cancer research	2012	42
22430211	17a-Ethynylestradiol	Yeramian A	Endometrial carcinoma: molecular alterations involved in tumor development and progression.	Oncogene	2013	26
22430216	17a-Ethynylestradiol	De Marco P	Insulin-like growth factor-I regulates GPER expression and function in cancer cells.	Oncogene	2013	29
22431524	17a-Ethynylestradiol	Kamarajugadda S	Glucose oxidation modulates anoikis and tumor metastasis.	Molecular and cellular biology	2012	43
22438791	17a-Ethynylestradiol	Anbalagan M	Post-translational modifications of nuclear receptors and human disease.	Nuclear receptor signaling	2012	51
22496456	17a-Ethynylestradiol	Asmann YW	Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer.	Cancer research	2012	38
22503553	17a-Ethynylestradiol	Klinge CM	miRNAs and estrogen action.	Trends in endocrinology and metabolism	2012	49
22508765	17a-Ethynylestradiol	He HH	Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics.	Genome research	2012	84
22508827	17a-Ethynylestradiol	Ignatiadis M	Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.	Journal of clinical oncology 	2012	62
22511581	17a-Ethynylestradiol	Ho GY	Adipokines linking obesity with colorectal cancer risk in postmenopausal women.	Cancer research	2012	41
22532573	17a-Ethynylestradiol	Fasching PA	The role of genetic breast cancer susceptibility variants as prognostic factors.	Human molecular genetics	2012	40
22532584	17a-Ethynylestradiol	Prat A	Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.	Annals of oncology 	2012	32
22537901	17a-Ethynylestradiol	Tseng LM	CIP2A is a target of bortezomib in human triple negative breast cancer cells.	Breast cancer research 	2012	33
22538770	17a-Ethynylestradiol	Santarpia L	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.	Breast cancer research and treatment	2012	37
22547799	17a-Ethynylestradiol	Lee H	Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation.	Proceedings of the National Academy of Sciences of the United States of America	2012	54
22566377	17a-Ethynylestradiol	Mohan HM	Molecular pathways: the role of NR4A orphan nuclear receptors in cancer.	Clinical cancer research 	2012	42
22573715	17a-Ethynylestradiol	Fagan DH	Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.	Cancer research	2012	45
22589709	17a-Ethynylestradiol	Cheng F	Prediction of drug-target interactions and drug repositioning via network-based inference.	PLoS computational biology	2012	114
22632819	17a-Ethynylestradiol	Zhi X	YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor.	The American journal of pathology	2012	33
22662208	17a-Ethynylestradiol	Meeran SM	Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications.	PloS one	2012	30
22692575	17a-Ethynylestradiol	Leth-Larsen R	Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.	Molecular medicine	2012	36
22723937	17a-Ethynylestradiol	Zhao Y	MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells.	PloS one	2012	32
22745190	17a-Ethynylestradiol	Hickey TE	Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?	Molecular endocrinology	2012	46
22752300	17a-Ethynylestradiol	Cook KL	Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness.	Cancer research	2012	48
22770227	17a-Ethynylestradiol	Kim J	Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer.	Breast cancer research 	2012	31
22829776	17a-Ethynylestradiol	Coviello AD	A genome-wide association meta-analysis of circulating sex hormone-binding globulin reveals multiple Loci implicated in sex steroid hormone regulation.	PLoS genetics	2012	35
22853014	17a-Ethynylestradiol	Mehta RS	Combination anastrozole and fulvestrant in metastatic breast cancer.	The New England journal of medicine	2012	63
22875023	17a-Ethynylestradiol	Ramaswamy B	Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.	Cancer research	2012	60
22878588	17a-Ethynylestradiol	Switzer CH	S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer.	Molecular cancer research 	2012	31
22933934	17a-Ethynylestradiol	Ovcaricek T	Triple negative breast cancer - prognostic factors and survival.	Radiology and oncology	2011	40
22993197	17a-Ethynylestradiol	Motiani RK	Orai3 is an estrogen receptor Œ±-regulated Ca¬≤‚Å∫ channel that promotes tumorigenesis.	FASEB journal 	2013	45
23035151	17a-Ethynylestradiol	Dubsky P	EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.	Annals of oncology 	2013	35
23060440	17a-Ethynylestradiol	Zhang Y	Estrogen receptor Œ± signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2.	The Journal of biological chemistry	2012	34
23103568	17a-Ethynylestradiol	Renoir JM	Estrogen receptor signaling as a target for novel breast cancer therapeutics.	Biochemical pharmacology	2013	41
23112837	17a-Ethynylestradiol	Castilla M√Å	MicroRNA-200 family modulation in distinct breast cancer phenotypes.	PloS one	2012	34
23128390	17a-Ethynylestradiol	Rao X	CpG island shore methylation regulates caveolin-1 expression in breast cancer.	Oncogene	2013	33
23136233	17a-Ethynylestradiol	Eiermann W	The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.	Annals of oncology 	2013	36
23164950	17a-Ethynylestradiol	Volden PA	The influence of glucocorticoid signaling on tumor progression.	Brain, behavior, and immunity	2013	25
23169515	17a-Ethynylestradiol	Azim HA Jr	Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.	Journal of clinical oncology 	2013	29
23178278	17a-Ethynylestradiol	Yue W	Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis.	Steroids	2013	45
23181381	17a-Ethynylestradiol	Zan H	Regulation of Aicda expression and AID activity.	Autoimmunity	2013	28
23208510	17a-Ethynylestradiol	Deblois G	The PGC-1/ERR signaling axis in cancer.	Oncogene	2013	30
23213055	17a-Ethynylestradiol	Goetz MP	CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.	Clinical cancer research 	2013	31
23224237	17a-Ethynylestradiol	Li CI	Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age.	Breast cancer research and treatment	2013	38
23246967	17a-Ethynylestradiol	Sarkar S	Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells.	Oncogene	2014	22
23272133	17a-Ethynylestradiol	Sheth S	Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway.	PloS one	2012	53
23283524	17a-Ethynylestradiol	Zhang X	Postmenopausal plasma sex hormone levels and breast cancer risk over 20¬†years of follow-up.	Breast cancer research and treatment	2013	43
23319822	17a-Ethynylestradiol	Wik E	Lack of estrogen receptor-Œ± is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.	Clinical cancer research 	2013	38
23334326	17a-Ethynylestradiol	D'Assoro AB	The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERŒ±(+) breast cancer cells.	Oncogene	2014	38
23344024	17a-Ethynylestradiol	Garc√≠a-Becerra R	Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.	International journal of molecular sciences	2012	59
23347430	17a-Ethynylestradiol	Sanders DA	Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells.	Genome biology	2013	46
23371292	17a-Ethynylestradiol	Zhu AZ	The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.	Cancer epidemiology, biomarkers & prevention 	2013	28
23375982	17a-Ethynylestradiol	Bhan A	Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol.	Journal of molecular biology	2013	61
23379261	17a-Ethynylestradiol	Li Y	Epigenetic reactivation of estrogen receptor-Œ± (ERŒ±) by genistein enhances hormonal therapy sensitivity in ERŒ±-negative breast cancer.	Molecular cancer	2013	37
23403292	17a-Ethynylestradiol	Mohammed H	Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.	Cell reports	2013	78
23425944	17a-Ethynylestradiol	Ruddy KJ	Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship.	Annals of oncology 	2013	29
23442322	17a-Ethynylestradiol	Ithimakin S	HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.	Cancer research	2013	62
23492819	17a-Ethynylestradiol	Singh B	MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis.	Carcinogenesis	2013	34
23532539	17a-Ethynylestradiol	Dethlefsen C	The role of intratumoral and systemic IL-6 in breast cancer.	Breast cancer research and treatment	2013	67
23535731	17a-Ethynylestradiol	Bojesen SE	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.	Nature genetics	2013	199
23535733	17a-Ethynylestradiol	Garcia-Closas M	Genome-wide association studies identify four ER negative-specific breast cancer risk loci.	Nature genetics	2013	173
23535825	17a-Ethynylestradiol	Zheng W	Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls.	Human molecular genetics	2013	35
23536434	17a-Ethynylestradiol	Wardell SE	Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.	Clinical cancer research 	2013	28
23540573	17a-Ethynylestradiol	French JD	Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers.	American journal of human genetics	2013	76
23550157	17a-Ethynylestradiol	Redfern AD	RNA-induced silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators.	Proceedings of the National Academy of Sciences of the United States of America	2013	26
23569315	17a-Ethynylestradiol	Rimawi MF	Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.	Journal of clinical oncology 	2013	45
23626803	17a-Ethynylestradiol	Manavalan TT	Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.	PloS one	2013	27
23636943	17a-Ethynylestradiol	Hah N	Enhancer transcripts mark active estrogen receptor binding sites.	Genome research	2013	141
23644528	17a-Ethynylestradiol	Berry WL	KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells.	Cancer research	2013	74
23690420	17a-Ethynylestradiol	Hughes KS	Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.	Journal of clinical oncology 	2013	77
23696246	17a-Ethynylestradiol	Katoh M	FGF receptors: cancer biology and therapeutics.	Medicinal research reviews	2014	76
23711559	17a-Ethynylestradiol	Feng S	Role of aryl hydrocarbon receptor in cancer.	Biochimica et biophysica acta	2013	35
23715497	17a-Ethynylestradiol	Xuan D	APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry.	Carcinogenesis	2013	32
23739063	17a-Ethynylestradiol	Loi S	Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.	Journal of the National Cancer Institute	2013	37
23752191	17a-Ethynylestradiol	Li Q	Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer.	Oncogene	2014	53
23774759	17a-Ethynylestradiol	Madak-Erdogan Z	Integrative genomics of gene and metabolic regulation by estrogen receptors Œ± and Œ≤, and their coregulators.	Molecular systems biology	2013	27
23791814	17a-Ethynylestradiol	Jiang X	The immune system and inflammation in breast cancer.	Molecular and cellular endocrinology	2014	28
23818604	17a-Ethynylestradiol	Gerdes MJ	Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue.	Proceedings of the National Academy of Sciences of the United States of America	2013	73
23835710	17a-Ethynylestradiol	Visvanathan K	Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.	Journal of clinical oncology 	2013	81
23836010	17a-Ethynylestradiol	Mih√°ly Z	A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer.	Breast cancer research and treatment	2013	53
23845444	17a-Ethynylestradiol	Vaillant F	Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.	Cancer cell	2013	72
23861811	17a-Ethynylestradiol	Lamb R	Wnt pathway activity in breast cancer sub-types and stem-like cells.	PloS one	2013	41
23917289	17a-Ethynylestradiol	Silber JH	Characteristics associated with differences in survival among black and white women with breast cancer.	JAMA	2013	68
23918944	17a-Ethynylestradiol	Phillips KA	Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2013	28
23948299	17a-Ethynylestradiol	Hsu PY	Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer.	Cancer cell	2013	26
23954741	17a-Ethynylestradiol	Haldos√©n LA	Estrogen receptor beta in breast cancer.	Molecular and cellular endocrinology	2014	26
23958744	17a-Ethynylestradiol	Howe LR	Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer.	Clinical cancer research 	2013	78
23971832	17a-Ethynylestradiol	Borges S	Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis.	Breast cancer research 	2013	28
24013225	17a-Ethynylestradiol	Zhou ZN	Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo.	Oncogene	2014	26
24029245	17a-Ethynylestradiol	Sestak I	Factors predicting late recurrence for estrogen receptor-positive breast cancer.	Journal of the National Cancer Institute	2013	41
24055055	17a-Ethynylestradiol	Li S	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.	Cell reports	2013	146
24058649	17a-Ethynylestradiol	Babayan A	Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients.	PloS one	2013	29
24060820	17a-Ethynylestradiol	Province MA	CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.	Clinical pharmacology and therapeutics	2014	37
24077289	17a-Ethynylestradiol	Dey P	Estrogen receptor Œ≤ upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer.	Oncogene	2014	29
24114568	17a-Ethynylestradiol	DeSantis C	Breast cancer statistics, 2013.	CA	2014	417
24176761	17a-Ethynylestradiol	Tella SH	Prevention and treatment of postmenopausal osteoporosis.	The Journal of steroid biochemistry and molecular biology	2014	33
24185512	17a-Ethynylestradiol	Toy W	ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.	Nature genetics	2013	185
24210818	17a-Ethynylestradiol	Wu Q	27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth.	Cell reports	2013	58
24217577	17a-Ethynylestradiol	Merenbakh-Lamin K	D538G mutation in estrogen receptor-Œ±: A novel mechanism for acquired endocrine resistance in breast cancer.	Cancer research	2013	70
24258260	17a-Ethynylestradiol	S√∏rensen KP	Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer.	Breast cancer research and treatment	2013	66
24273215	17a-Ethynylestradiol	Vera-Badillo FE	Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.	Journal of the National Cancer Institute	2014	56
24283290	17a-Ethynylestradiol	Liao XH	Estrogen receptor Œ± mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway.	The FEBS journal	2014	22
24288332	17a-Ethynylestradiol	Nelson ER	27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology.	Science	2013	122
24290378	17a-Ethynylestradiol	Meyer KB	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.	American journal of human genetics	2013	42
24298069	17a-Ethynylestradiol	Zhang XH	Metastasis dormancy in estrogen receptor-positive breast cancer.	Clinical cancer research 	2013	32
24337597	17a-Ethynylestradiol	Auvinen P	Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival.	Breast cancer research and treatment	2014	24
24343304	17a-Ethynylestradiol	Palmer JR	A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium.	Cancer causes & control 	2014	33
24347518	17a-Ethynylestradiol	Gnant M	Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.	Annals of oncology 	2014	43
24366116	17a-Ethynylestradiol	Vercellini P	Endometriosis: pathogenesis and treatment.	Nature reviews. Endocrinology	2014	57
24369047	17a-Ethynylestradiol	Rocca A	Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.	Expert opinion on pharmacotherapy	2014	23
24393852	17a-Ethynylestradiol	Mita MM	Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.	Clinical breast cancer	2014	23
24398047	17a-Ethynylestradiol	Jeselsohn R	Emergence of constitutively active estrogen receptor-Œ± mutations in pretreated advanced estrogen receptor-positive breast cancer.	Clinical cancer research 	2014	102
24412361	17a-Ethynylestradiol	Klein BJ	The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.	Cell reports	2014	30
24449868	17a-Ethynylestradiol	Huang B	Differential expression of estrogen receptor Œ±, Œ≤1, and Œ≤2 in lobular and ductal breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
24462521	17a-Ethynylestradiol	Gy≈ërffy B	TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers.	Molecular oncology	2014	20
24469049	17a-Ethynylestradiol	Cyr AR	TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis.	Oncogene	2015	22
24525122	17a-Ethynylestradiol	Zhao Z	17Œ≤-Estradiol treatment inhibits breast cell proliferation, migration and invasion by decreasing MALAT-1 RNA level.	Biochemical and biophysical research communications	2014	26
24620909	17a-Ethynylestradiol	Agner SC	Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility study.	Radiology	2014	25
24647569	17a-Ethynylestradiol	Schalper KA	In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.	Clinical cancer research 	2014	116
24663045	17a-Ethynylestradiol	Mayer IA	Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2014	49
24718936	17a-Ethynylestradiol	Scaling AL	GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast.	Hormones & cancer	2014	22
24774538	17a-Ethynylestradiol	Ciruelos Gil EM	Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.	Cancer treatment reviews	2014	41
24803582	17a-Ethynylestradiol	Silwal-Pandit L	TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.	Clinical cancer research 	2014	41
24831732	17a-Ethynylestradiol	Li X	Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation.	Phytotherapy research 	2014	30
24858917	17a-Ethynylestradiol	Ohba K	In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis via APOBEC3B induction.	PloS one	2014	26
24874954	17a-Ethynylestradiol	Feng Q	An epigenomic approach to therapy for tamoxifen-resistant breast cancer.	Cell research	2014	45
24876105	17a-Ethynylestradiol	Dinami R	miR-155 drives telomere fragility in human breast cancer by targeting TRF1.	Cancer research	2014	23
24881463	17a-Ethynylestradiol	Pagani O	Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.	The New England journal of medicine	2014	93
24895374	17a-Ethynylestradiol	Rohan TE	Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.	Journal of the National Cancer Institute	2014	40
24915873	17a-Ethynylestradiol	Ali HR	Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.	Annals of oncology 	2014	60
24924200	17a-Ethynylestradiol	Gan R	Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3.	Cancer gene therapy	2014	25
24929677	17a-Ethynylestradiol	Varley KE	Recurrent read-through fusion transcripts in breast cancer.	Breast cancer research and treatment	2014	32
24935269	17a-Ethynylestradiol	Chung L	Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer.	Breast cancer research 	2014	21
24957076	17a-Ethynylestradiol	Fuentes-Mattei E	Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.	Journal of the National Cancer Institute	2014	32
24971815	17a-Ethynylestradiol	Paterni I	Estrogen receptors alpha (ERŒ±) and beta (ERŒ≤): subtype-selective ligands and clinical potential.	Steroids	2014	34
24975878	17a-Ethynylestradiol	Li CL	Elevated p53 promotes the processing of miR-18a to decrease estrogen receptor-Œ± in female hepatocellular carcinoma.	International journal of cancer	2015	15
25006803	17a-Ethynylestradiol	Askarian-Amiri ME	Emerging role of long non-coding RNA SOX2OT in SOX2 regulation in breast cancer.	PloS one	2014	31
25009010	17a-Ethynylestradiol	De Mattos-Arruda L	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.	Annals of oncology 	2014	63
25011475	17a-Ethynylestradiol	Jin UH	The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis.	BMC cancer	2014	22
25013076	17a-Ethynylestradiol	Yu M	Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.	Science	2014	167
25038752	17a-Ethynylestradiol	Lim WK	Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma.	Nature genetics	2014	37
25071141	17a-Ethynylestradiol	Sabine VS	Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.	Journal of clinical oncology 	2014	23
25085789	17a-Ethynylestradiol	Gaykema SB	89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.	Clinical cancer research 	2014	23
25091503	17a-Ethynylestradiol	Saladores P	Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.	The pharmacogenomics journal	2015	20
25123150	17a-Ethynylestradiol	Sieuwerts AM	Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.	Hormones & cancer	2014	30
25185096	17a-Ethynylestradiol	Partridge AH	Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.	Journal of clinical oncology 	2014	43
25193543	17a-Ethynylestradiol	Liu S	Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.	Breast cancer research 	2014	25
25208879	17a-Ethynylestradiol	Burstein MD	Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.	Clinical cancer research 	2015	92
25213081	17a-Ethynylestradiol	Bergamaschi A	The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.	Breast cancer research 	2014	22
25224496	17a-Ethynylestradiol	Palmer JR	Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium.	Journal of the National Cancer Institute	2014	43
25241899	17a-Ethynylestradiol	Finlay-Schultz J	Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a.	Oncogene	2015	16
25284585	17a-Ethynylestradiol	Dillon LM	P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.	Oncogene	2015	19
25296969	17a-Ethynylestradiol	Su X	Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes.	Oncotarget	2014	52
25307233	17a-Ethynylestradiol	Zhao W	Comprehensive characterization of cancer subtype associated long non-coding RNAs and their clinical implications.	Scientific reports	2014	26
25313140	17a-Ethynylestradiol	Hashim A	RNA sequencing identifies specific PIWI-interacting small non-coding RNA expression patterns in breast cancer.	Oncotarget	2014	28
25327703	17a-Ethynylestradiol	Fejerman L	Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25.	Nature communications	2014	31
25332247	17a-Ethynylestradiol	Baselga J	Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.	Journal of clinical oncology 	2014	56
25339261	17a-Ethynylestradiol	Jordan VC	The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.	Endocrine-related cancer	2015	23
25347744	17a-Ethynylestradiol	Mahajan K	ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.	Oncogene	2015	21
25361613	17a-Ethynylestradiol	Ibrahim EM	The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.	Breast cancer research and treatment	2014	33
25361981	17a-Ethynylestradiol	Tobin NP	Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.	Annals of oncology 	2015	17
25380844	17a-Ethynylestradiol	van Kruchten M	Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.	Cancer discovery	2015	18
25381136	17a-Ethynylestradiol	Twelves C	Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.	Breast cancer research and treatment	2014	29
25381338	17a-Ethynylestradiol	Paoletti C	Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.	Clinical cancer research 	2015	20
25388283	17a-Ethynylestradiol	Bailey ST	Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer.	Cancer research	2015	17
25406186	17a-Ethynylestradiol	Patel B	Role of nuclear progesterone receptor isoforms in uterine pathophysiology.	Human reproduction update	2015	16
25488809	17a-Ethynylestradiol	Wade MA	The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer.	Nucleic acids research	2015	18
25489079	17a-Ethynylestradiol	Whitesell L	HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.	Proceedings of the National Academy of Sciences of the United States of America	2014	23
25495490	17a-Ethynylestradiol	Francis PA	Adjuvant ovarian suppression in premenopausal breast cancer.	The New England journal of medicine	2015	79
25501357	17a-Ethynylestradiol	Mao Y	The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.	PloS one	2014	24
25529635	17a-Ethynylestradiol	Glubb DM	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.	American journal of human genetics	2015	23
25537515	17a-Ethynylestradiol	Bihani T	Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.	Oncotarget	2015	18
25538079	17a-Ethynylestradiol	Martz CA	Systematic identification of signaling pathways with potential to confer anticancer drug resistance.	Science signaling	2014	47
25587053	17a-Ethynylestradiol	Diep CH	Progesterone action in breast, uterine, and ovarian cancers.	Journal of molecular endocrinology	2015	24
25592968	17a-Ethynylestradiol	Fang D	17Œ≤-estradiol regulates cell proliferation, colony formation, migration, invasion and promotes apoptosis by upregulating miR-9 and thus degrades MALAT-1 in osteosarcoma cell MG-63 in an estrogen receptor-independent manner.	Biochemical and biophysical research communications	2015	17
25597633	17a-Ethynylestradiol	Anbalagan M	Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer.	Molecular and cellular endocrinology	2015	17
25616260	17a-Ethynylestradiol	Albanito L	Effects of atrazine on estrogen receptor Œ±- and G protein-coupled receptor 30-mediated signaling and proliferation in cancer cells and cancer-associated fibroblasts.	Environmental health perspectives	2015	15
25633049	17a-Ethynylestradiol	Vilquin P	MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.	Breast cancer research 	2015	17
25713166	17a-Ethynylestradiol	Ng CK	Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.	Journal of the National Cancer Institute	2015	21
25720324	17a-Ethynylestradiol	Nawaz S	Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer.	Modern pathology 	2015	16
25728767	17a-Ethynylestradiol	Yi P	Structure of a biologically active estrogen receptor-coactivator complex on DNA.	Molecular cell	2015	23
25752574	17a-Ethynylestradiol	Franco HL	TNFŒ± signaling exposes latent estrogen receptor binding sites to alter the breast cancer cell transcriptome.	Molecular cell	2015	24
25792301	17a-Ethynylestradiol	Dhillon S	Palbociclib: first global approval.	Drugs	2015	18
25825707	17a-Ethynylestradiol	Tang H	Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis.	EBioMedicine	2015	22
25848861	17a-Ethynylestradiol	Gy≈ërffy B	Multigene prognostic tests in breast cancer: past, present, future.	Breast cancer research 	2015	37
25855707	17a-Ethynylestradiol	Mavaddat N	Prediction of breast cancer risk based on profiling with common genetic variants.	Journal of the National Cancer Institute	2015	85
25868410	17a-Ethynylestradiol	Killelea BK	Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database.	Journal of the American College of Surgeons	2015	15
25876649	17a-Ethynylestradiol	Hill SM	Melatonin: an inhibitor of breast cancer.	Endocrine-related cancer	2015	32
25877889	17a-Ethynylestradiol	Bosch A	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.	Science translational medicine	2015	36
25879485	17a-Ethynylestradiol	Lai A	Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.	Journal of medicinal chemistry	2015	29
25892662	17a-Ethynylestradiol	Feitelson MA	Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.	Seminars in cancer biology	2015	24
25893606	17a-Ethynylestradiol	Zhou X	Estrogen regulates Hippo signaling via GPER in breast cancer.	The Journal of clinical investigation	2015	29
25964252	17a-Ethynylestradiol	Warner ET	Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.	Journal of clinical oncology 	2015	25
25979954	17a-Ethynylestradiol	Guttery DS	Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.	Clinical chemistry	2015	27
25990368	17a-Ethynylestradiol	Yuan J	Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and Œ≤1-integrin signaling pathway in tumor cells.	Breast cancer research 	2015	16
25991817	17a-Ethynylestradiol	Wardell SE	Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.	Clinical cancer research 	2015	19
25995301	17a-Ethynylestradiol	Dieci MV	Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.	Annals of oncology 	2015	23
26033453	17a-Ethynylestradiol	St√ºckrath I	Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.	Oncotarget	2015	16
26056290	17a-Ethynylestradiol	den Boon JA	Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling.	Proceedings of the National Academy of Sciences of the United States of America	2015	30
26059247	17a-Ethynylestradiol	Yamamoto-Ibusuki M	Targeted therapies for ER+/HER2- metastatic breast cancer.	BMC medicine	2015	15
26085483	17a-Ethynylestradiol	Ambrosone CB	Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women.	Journal of the National Cancer Institute	2015	20
26124144	17a-Ethynylestradiol	Honda S	Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers.	Proceedings of the National Academy of Sciences of the United States of America	2015	33
26166704	17a-Ethynylestradiol	Li W	Condensin I and II Complexes License Full Estrogen Receptor Œ±-Dependent Enhancer Activation.	Molecular cell	2015	18
26185195	17a-Ethynylestradiol	Gunter MJ	Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk.	Journal of the National Cancer Institute	2015	20
26243145	17a-Ethynylestradiol	Sousa S	Human breast cancer cells educate macrophages toward the M2 activation status.	Breast cancer research 	2015	30
26251289	17a-Ethynylestradiol	Johnston SR	Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.	Journal of the National Cancer Institute	2015	20
26257067	17a-Ethynylestradiol	Merino D	Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.	Oncogene	2016	14
26261103	17a-Ethynylestradiol	Chu D	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.	Clinical cancer research 	2016	32
26286584	17a-Ethynylestradiol	Strong AL	Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers.	Breast cancer research 	2015	20
26303083	17a-Ethynylestradiol	Jia M	Estrogen receptor alpha and beta in health and disease.	Best practice & research. Clinical endocrinology & metabolism	2015	31
26324739	17a-Ethynylestradiol	Beaver JA	FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.	Clinical cancer research 	2015	33
26364613	17a-Ethynylestradiol	Xue X	LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer.	Oncogene	2016	40
26476745	17a-Ethynylestradiol	Tsuboi M	APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers.	Breast cancer	2016	10
26541326	17a-Ethynylestradiol	Baptista MZ	Prognostic significance of PD-L1 and PD-L2 in breast cancer.	Human pathology	2016	27
26560360	17a-Ethynylestradiol	Schiavon G	Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.	Science translational medicine	2015	63
26586665	17a-Ethynylestradiol	Meeks HD	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.	Journal of the National Cancer Institute	2016	14
26598746	17a-Ethynylestradiol	Levine MN	Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.	Journal of clinical oncology 	2016	17
26618344	17a-Ethynylestradiol	Castro MA	Regulators of genetic risk of breast cancer identified by integrative network analysis.	Nature genetics	2016	12
26732355	17a-Ethynylestradiol	Cox TR	Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis.	Cancer research	2016	16
26777690	17a-Ethynylestradiol	Wei W	Ligand Activation of ERRŒ± by Cholesterol Mediates Statin and Bisphosphonate Effects.	Cell metabolism	2016	13
26786933	17a-Ethynylestradiol	Colleoni M	Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.	Journal of clinical oncology 	2016	13
26836308	17a-Ethynylestradiol	Fanning SW	Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.	eLife	2016	29
26867935	17a-Ethynylestradiol	Pusztai L	New Strategies in Breast Cancer: Immunotherapy.	Clinical cancer research 	2016	16
26877254	17a-Ethynylestradiol	Roberg-Larsen H	Mass spectrometric detection of 27-hydroxycholesterol in breast cancer exosomes.	The Journal of steroid biochemistry and molecular biology	2017	6
26884586	17a-Ethynylestradiol	Burstein HJ	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.	Journal of clinical oncology 	2016	17
26899533	17a-Ethynylestradiol	Masuda T	Clinical and biological significance of circulating tumor cells in cancer.	Molecular oncology	2016	14
26921331	17a-Ethynylestradiol	den Hollander P	Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival.	Cancer research	2016	13
26923330	17a-Ethynylestradiol	Johnson J	Targeting the RB-E2F pathway in breast cancer.	Oncogene	2016	16
26928228	17a-Ethynylestradiol	Dunning AM	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.	Nature genetics	2016	18
26947176	17a-Ethynylestradiol	Sflomos G	A Preclinical Model for ERŒ±-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response.	Cancer cell	2016	22
26960396	17a-Ethynylestradiol	Piscuoglio S	The Genomic Landscape of Male Breast Cancers.	Clinical cancer research 	2016	16
26987290	17a-Ethynylestradiol	Sun X	Let-7c blocks estrogen-activated Wnt signaling in induction of self-renewal of breast cancer stem cells.	Cancer gene therapy	2016	10
26995633	17a-Ethynylestradiol	Yang SX	New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.	Cancer treatment reviews	2016	25
27020857	17a-Ethynylestradiol	Herrera-Abreu MT	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.	Cancer research	2016	23
27020862	17a-Ethynylestradiol	Weir HM	AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.	Cancer research	2016	17
27029038	17a-Ethynylestradiol	Micucci C	Current perspectives between metabolic syndrome and cancer.	Oncotarget	2016	13
27059645	17a-Ethynylestradiol	Steelman LS	The therapeutic potential of mTOR inhibitors in breast cancer.	British journal of clinical pharmacology	2016	13
27062924	17a-Ethynylestradiol	Swinstead EE	Steroid Receptors Reprogram FoxA1 Occupancy through Dynamic Chromatin Transitions.	Cell	2016	29
27073890	17a-Ethynylestradiol	Mao Y	The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis.	PloS one	2016	16
27160528	17a-Ethynylestradiol	Mamtani A	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.	Annals of surgical oncology	2016	13
27225691	17a-Ethynylestradiol	Speers C	Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer.	Clinical cancer research 	2016	13
27226503	17a-Ethynylestradiol	Gradishar W	NCCN Guidelines Update: Breast Cancer.	Journal of the National Comprehensive Cancer Network 	2016	10
27233379	17a-Ethynylestradiol	De Marchi T	Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer.	Drug discovery today	2016	10
27269946	17a-Ethynylestradiol	Fribbens C	Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.	Journal of clinical oncology 	2016	45
27277684	17a-Ethynylestradiol	Singh R	Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis.	Cell death & disease	2016	12
27348297	17a-Ethynylestradiol	Gibson WJ	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.	Nature genetics	2016	23
27349747	17a-Ethynylestradiol	Finn RS	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.	Breast cancer research 	2016	15
27400969	17a-Ethynylestradiol	Buus R	Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.	Journal of the National Cancer Institute	2016	14
27474173	17a-Ethynylestradiol	Massihnia D	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.	Oncotarget	2016	11
27513155	17a-Ethynylestradiol	Giuliano AE	Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.	Annals of surgery	2016	30
27532364	17a-Ethynylestradiol	Chandarlapaty S	Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.	JAMA oncology	2016	30
27548161	17a-Ethynylestradiol	Rond√≥n-Lagos M	Tamoxifen Resistance: Emerging Molecular Targets.	International journal of molecular sciences	2016	10
27557300	17a-Ethynylestradiol	Cardoso F	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.	The New England journal of medicine	2016	91
27694385	17a-Ethynylestradiol	Svoronos N	Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells.	Cancer discovery	2017	12
27748765	17a-Ethynylestradiol	Harrod A	Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer.	Oncogene	2017	8
27879270	17a-Ethynylestradiol	Shibata T	Breast Cancer Resistance to Antiestrogens Is Enhanced by Increased ER Degradation and ERBB2 Expression.	Cancer research	2017	5
27886589	17a-Ethynylestradiol	Angus L	ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.	Cancer treatment reviews	2017	5
27902959	17a-Ethynylestradiol	Lee GA	Kaempferol, a phytoestrogen, suppressed triclosan-induced epithelial-mesenchymal transition and metastatic-related behaviors of MCF-7 breast cancer cells.	Environmental toxicology and pharmacology	2017	5
27903149	17a-Ethynylestradiol	Jiralerspong S	Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities.	Journal of clinical oncology 	2016	14
27914795	17a-Ethynylestradiol	Wintrob ZA	Insulin use, adipokine profiles and breast cancer prognosis.	Cytokine	2017	11
27926948	17a-Ethynylestradiol	Priedigkeit N	Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.	JAMA oncology	2017	9
27939373	17a-Ethynylestradiol	Nault JC	Molecular Classification of Hepatocellular Adenoma Associates¬†With Risk Factors, Bleeding, and Malignant Transformation.	Gastroenterology	2017	7
27940449	17a-Ethynylestradiol	Page K	Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer.	Clinical chemistry	2017	6
27959613	17a-Ethynylestradiol	Finn RS	Palbociclib and Letrozole in Advanced Breast Cancer.	The New England journal of medicine	2016	71
28045625	17a-Ethynylestradiol	Ellis MJ	Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).	Journal of clinical oncology 	2017	11
28057046	17a-Ethynylestradiol	Ethier JL	Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis.	Breast cancer research 	2017	9
28147342	17a-Ethynylestradiol	McDermott MS	Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.	Oncotarget	2017	5
28216025	17a-Ethynylestradiol	Dey N	PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.	Pharmacology & therapeutics	2017	13
28239379	17a-Ethynylestradiol	Laffont S	Estrogen Receptor-Dependent Regulation of Dendritic Cell Development and Function.	Frontiers in immunology	2017	10
28249905	17a-Ethynylestradiol	Cejalvo JM	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.	Cancer research	2017	9
28249908	17a-Ethynylestradiol	Jansen VM	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.	Cancer research	2017	8
28270386	17a-Ethynylestradiol	Iyengar NM	Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index.	Cancer prevention research	2017	8
28270497	17a-Ethynylestradiol	Ma CX	NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.	Clinical cancer research 	2017	10
28274582	17a-Ethynylestradiol	Jameera Begam A	Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review.	Bioorganic chemistry	2017	6
28585217	17a-Ethynylestradiol	Engin A	Obesity-associated Breast Cancer: Analysis of risk factors.	Advances in experimental medicine and biology	2017	7
3029430	Guanine	Baker CC	Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines.	Journal of virology	1987	217
8342602	Guanine	Hruban RH	K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.	The American journal of pathology	1993	140
8978692	Guanine	Kubota Y	Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein.	The EMBO journal	1996	191
9586664	Guanine	Andreyev HJ	Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.	Journal of the National Cancer Institute	1998	160
9850057	Guanine	Rutter JL	A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription.	Cancer research	1998	107
10029064	Guanine	Esteller M	Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.	Cancer research	1999	225
10767620	Guanine	Pegg AE	Repair of O(6)-alkylguanine by alkyltransferases.	Mutation research	2000	125
10811111	Guanine	Esteller M	Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.	Cancer research	2000	98
10946227	Guanine	Pearl LH	Structure and function in the uracil-DNA glycosylase superfamily.	Mutation research	2000	91
11282020	Guanine	Cantrell DA	Phosphoinositide 3-kinase signalling pathways.	Journal of cell science	2001	121
11433031	Guanine	Mohaghegh P	The Bloom's and Werner's syndrome proteins are DNA structure-specific helicases.	Nucleic acids research	2001	211
15072585	Guanine	Sugimura T	Heterocyclic amines: Mutagens/carcinogens produced during cooking of meat and fish.	Cancer science	2004	114
15250723	Guanine	Phan AT	Propeller-type parallel-stranded G-quadruplexes in the human c-myc promoter.	Journal of the American Chemical Society	2004	133
15685439	Guanine	Ohgaki H	Epidemiology and etiology of gliomas.	Acta neuropathologica	2005	228
16293724	Guanine	Castellone MD	Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis.	Science	2005	282
16408022	Guanine	Phan AT	Small-molecule interaction with a five-guanine-tract G-quadruplex structure from the human MYC promoter.	Nature chemical biology	2005	79
16482161	Guanine	Yu B	Crystal structures of catalytic complexes of the oxidative DNA/RNA repair enzyme AlkB.	Nature	2006	70
17362008	Guanine	Phan AT	Structure of an unprecedented G-quadruplex scaffold in the human c-kit promoter.	Journal of the American Chemical Society	2007	98
17581577	Guanine	David SS	Base-excision repair of oxidative DNA damage.	Nature	2007	312
17913750	Guanine	Patel DJ	Human telomere, oncogenic promoter and 5'-UTR G-quadruplexes: diverse higher order DNA and RNA targets for cancer therapeutics.	Nucleic acids research	2007	185
18471961	Guanine	Teodoridis JM	CpG island methylator phenotype (CIMP) in cancer: causes and implications.	Cancer letters	2008	51
18556592	Guanine	Sanders YY	Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis.	American journal of respiratory cell and molecular biology	2008	63
18587051	Guanine	Maiti A	Crystal structure of human thymine DNA glycosylase bound to DNA elucidates sequence-specific mismatch recognition.	Proceedings of the National Academy of Sciences of the United States of America	2008	50
18842585	Guanine	Creacy SD	G4 resolvase 1 binds both DNA and RNA tetramolecular quadruplex with high affinity and is the major source of tetramolecular quadruplex G4-DNA and G4-RNA resolving activity in HeLa cell lysates.	The Journal of biological chemistry	2008	51
19099189	Guanine	Wu Y	Welcome the family of FANCJ-like helicases to the block of genome stability maintenance proteins.	Cellular and molecular life sciences 	2009	49
19454272	Guanine	Bates PJ	Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.	Experimental and molecular pathology	2009	131
19581307	Guanine	Gonz√°lez V	Identification and characterization of nucleolin as a c-myc G-quadruplex-binding protein.	The Journal of biological chemistry	2009	75
19951354	Guanine	Neidle S	Human telomeric G-quadruplex: the current status of telomeric G-quadruplexes as therapeutic targets in human cancer.	The FEBS journal	2010	67
20399712	Guanine	van Loon B	Oxygen as a friend and enemy: How to combat the mutational potential of 8-oxo-guanine.	DNA repair	2010	77
21642970	Guanine	Phan AT	Structure-function studies of FMRP RGG peptide recognition of an RNA duplex-quadruplex junction.	Nature structural & molecular biology	2011	51
22122467	Guanine	Zhang J	Temozolomide: mechanisms of action, repair and resistance.	Current molecular pharmacology	2012	84
22306580	Guanine	Rodriguez R	Small-molecule-induced DNA damage identifies alternative DNA structures in human genes.	Nature chemical biology	2012	102
22311030	Guanine	Xiang Y	Association of the microRNA-499 variants with susceptibility to hepatocellular carcinoma in a Chinese population.	Molecular biology reports	2012	36
22570426	Guanine	Zhang W	miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.	Neuro-oncology	2012	44
23609544	Guanine	Beaudoin JD	Exploring mRNA 3'-UTR G-quadruplexes: evidence of roles in both alternative polyadenylation and mRNA shortening.	Nucleic acids research	2013	26
23770846	Guanine	Quan H	Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition.	Oncogene	2014	25
24163102	Guanine	Henderson A	Detection of G-quadruplex DNA in mammalian cells.	Nucleic acids research	2014	86
24413734	Guanine	Palomero T	Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.	Nature genetics	2014	99
24476918	Guanine	Mill√°n-Ari√±o L	Mapping of six somatic linker histone H1 variants in human breast cancer cells uncovers specific features of H1.2.	Nucleic acids research	2014	24
24842956	Guanine	Ostrom QT	The epidemiology of glioma in adults: a "state of the science" review.	Neuro-oncology	2014	127
25079319	Guanine	Wolfe AL	RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer.	Nature	2014	99
25409153	Guanine	Freudenthal BD	Uncovering the polymerase-induced cytotoxicity of an oxidized nucleotide.	Nature	2015	27
25481712	Guanine	Eshleman JR	KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound.	Clinical gastroenterology and hepatology 	2015	15
26192317	Guanine	Chambers VS	High-throughput sequencing of DNA G-quadruplex structures in the human genome.	Nature biotechnology	2015	71
26374839	Guanine	Vasilyev N	Crystal structure reveals specific recognition of a G-quadruplex RNA by a Œ≤-turn in the RGG motif of FMRP.	Proceedings of the National Academy of Sciences of the United States of America	2015	26
26731791	Guanine	Panni T	Genome-Wide Analysis of DNA Methylation and Fine Particulate Matter Air Pollution in Three Study Populations: KORA F3, KORA F4, and the Normative Aging Study.	Environmental health perspectives	2016	19
26857264	Guanine	Hu N	Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer.	Cancer research	2016	11
26942677	Guanine	Aregger M	CDK1-Cyclin B1 Activates RNMT, Coordinating mRNA Cap Methylation with G1 Phase Transcription.	Molecular cell	2016	10
27820808	Guanine	Fouquerel E	Oxidative guanine base damage regulates human telomerase activity.	Nature structural & molecular biology	2016	11
28062691	Guanine	Abate F	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.	Proceedings of the National Academy of Sciences of the United States of America	2017	7
8090225	Platinum	O'Donovan A	XPG endonuclease makes the 3' incision in human DNA nucleotide excision repair.	Nature	1994	128
8895738	Platinum	Fink D	The role of DNA mismatch repair in platinum drug resistance.	Cancer research	1996	115
11870167	Platinum	Bristow RE	Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.	Journal of clinical oncology 	2002	270
12409326	Platinum	Scagliotti GV	Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2002	123
12529460	Platinum	Zhang L	Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.	The New England journal of medicine	2003	704
12712470	Platinum	Cass I	Improved survival in women with BRCA-associated ovarian carcinoma.	Cancer	2003	117
12748309	Platinum	Abrams TJ	SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.	Molecular cancer therapeutics	2003	147
15173214	Platinum	Gurubhagavatula S	XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.	Journal of clinical oncology 	2004	76
15310767	Platinum	P√©rez-Soler R	Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.	Journal of clinical oncology 	2004	157
15547181	Platinum	Vasey PA	Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.	Journal of the National Cancer Institute	2004	89
15607931	Platinum	Chaney SG	Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.	Critical reviews in oncology/hematology	2005	69
16014882	Platinum	Shepherd FA	Erlotinib in previously treated non-small-cell lung cancer.	The New England journal of medicine	2005	1077
16914580	Platinum	Halder J	Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.	Clinical cancer research 	2006	90
16951202	Platinum	Zhang S	Organic cation transporters are determinants of oxaliplatin cytotoxicity.	Cancer research	2006	77
16966686	Platinum	Bepler G	RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.	Journal of clinical oncology 	2006	81
17229776	Platinum	Bellmunt J	Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.	Annals of oncology 	2007	69
17259930	Platinum	Seiwert TY	The concurrent chemoradiation paradigm--general principles.	Nature clinical practice. Oncology	2007	64
17290060	Platinum	Dressman HK	An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.	Journal of clinical oncology 	2007	95
17538161	Platinum	Vermorken JB	Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.	Journal of clinical oncology 	2007	169
17878479	Platinum	Heymach JV	Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.	Journal of clinical oncology 	2007	65
17909199	Platinum	Herbst RS	Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.	Journal of clinical oncology 	2007	94
18024863	Platinum	Burger RA	Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.	Journal of clinical oncology 	2007	198
18094425	Platinum	Quinn JE	BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy.	Clinical cancer research 	2007	57
18165641	Platinum	Ramalingam SS	Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.	Journal of clinical oncology 	2008	61
18165643	Platinum	Garcia AA	Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.	Journal of clinical oncology 	2008	135
18235126	Platinum	Socinski MA	Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.	Journal of clinical oncology 	2008	84
18263769	Platinum	Ramalingam S	Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.	The oncologist	2008	80
18264087	Platinum	Sakai W	Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.	Nature	2008	241
18316546	Platinum	Martin LP	Platinum resistance: the role of DNA repair pathways.	Clinical cancer research 	2008	161
18413725	Platinum	Swisher EM	Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.	Cancer research	2008	117
18649131	Platinum	Byrski T	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2009	76
18686947	Platinum	Rieter WJ	Nanoscale coordination polymers for platinum-based anticancer drug delivery.	Journal of the American Chemical Society	2008	58
18836486	Platinum	Baba T	Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.	Oncogene	2009	126
18955455	Platinum	Tan DS	"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.	Journal of clinical oncology 	2008	106
19027483	Platinum	Kim ES	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.	Lancet	2008	278
19074899	Platinum	Yang N	MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.	Cancer research	2008	113
19188680	Platinum	Reck M	Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.	Journal of clinical oncology 	2009	322
19193619	Platinum	Etemadmoghadam D	Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.	Clinical cancer research 	2009	74
19318572	Platinum	Eckstein N	Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells.	Cancer research	2009	50
19332730	Platinum	Natale RB	Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.	Journal of clinical oncology 	2009	55
19349352	Platinum	Kuo KT	Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.	The American journal of pathology	2009	98
19380441	Platinum	Yuan X	Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy.	Journal of clinical oncology 	2009	59
19410716	Platinum	Pirker R	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.	Lancet	2009	310
19414683	Platinum	Bai H	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	96
19549709	Platinum	Soria JC	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.	Annals of oncology 	2009	45
19652055	Platinum	Blumenschein GR Jr	Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.	Journal of clinical oncology 	2009	51
19654294	Platinum	Sakai W	Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.	Cancer research	2009	75
19667264	Platinum	Shaw AT	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	Journal of clinical oncology 	2009	422
19805294	Platinum	Bertolini G	Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.	Proceedings of the National Academy of Sciences of the United States of America	2009	248
19901115	Platinum	Makhija S	Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.	Journal of clinical oncology 	2010	46
19914732	Platinum	Dempke WC	Targeted therapies for non-small cell lung cancer.	Lung cancer	2010	49
19917871	Platinum	Azzoli CG	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	145
19943199	Platinum	Livesey KM	Autophagy inhibition in combination cancer treatment.	Current opinion in investigational drugs	2009	55
19957335	Platinum	Su HY	Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway.	International journal of cancer	2010	45
20022809	Platinum	Mitsudomi T	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.	The Lancet. Oncology	2010	870
20047843	Platinum	Stewart DJ	Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.	Critical reviews in oncology/hematology	2010	65
20068568	Platinum	Lordick F	Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).	British journal of cancer	2010	41
20103634	Platinum	Galanis E	Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.	Cancer research	2010	101
20104527	Platinum	Delage B	Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.	International journal of cancer	2010	65
20150572	Platinum	Reck M	Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).	Annals of oncology 	2010	138
20164691	Platinum	Isakoff SJ	Triple-negative breast cancer: role of specific chemotherapy agents.	Cancer journal	2010	55
20336784	Platinum	Nakayama N	Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.	Cancer	2010	48
20406929	Platinum	Fong PC	Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.	Journal of clinical oncology 	2010	223
20493771	Platinum	Cappuzzo F	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.	The Lancet. Oncology	2010	301
20534738	Platinum	Solis LM	Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.	Clinical cancer research 	2010	105
20547991	Platinum	Konstantinopoulos PA	Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.	Journal of clinical oncology 	2010	112
20551945	Platinum	Janku F	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?	Nature reviews. Clinical oncology	2010	63
20564122	Platinum	Fang F	A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.	Cancer	2010	46
20581869	Platinum	Cooke SL	Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.	Oncogene	2010	52
20584542	Platinum	Friedlander M	A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.	Gynecologic oncology	2010	45
20888993	Platinum	Rustin GJ	Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.	Lancet	2010	77
20889728	Platinum	Landen CN Jr	Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.	Molecular cancer therapeutics	2010	114
21041624	Platinum	Su F	Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	56
21048039	Platinum	Licitra L	Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.	Annals of oncology 	2011	58
21098323	Platinum	Matei D	Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.	Journal of clinical oncology 	2011	41
21114420	Platinum	Page BD	Signal transducer and activator of transcription 3 inhibitors: a patent review.	Expert opinion on therapeutic patents	2011	37
21215996	Platinum	Burger RA	Overview of anti-angiogenic agents in development for ovarian cancer.	Gynecologic oncology	2011	35
21216927	Platinum	Rizzo S	Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.	Molecular cancer therapeutics	2011	65
21299897	Platinum	Wilken R	Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.	Molecular cancer	2011	111
21336183	Platinum	Camidge DR	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.	Journal of thoracic oncology 	2011	66
21377930	Platinum	Machiels JP	Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.	The Lancet. Oncology	2011	39
21468130	Platinum	Forster MD	Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.	Nature reviews. Clinical oncology	2011	42
21472713	Platinum	Fu S	Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.	Cancer	2011	44
21521830	Platinum	Jelovac D	Recent progress in the diagnosis and treatment of ovarian cancer.	CA	2011	119
21571862	Platinum	Stronach EA	HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.	Cancer research	2011	45
21618587	Platinum	Latifi A	Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.	Journal of cellular biochemistry	2011	70
21627863	Platinum	Wei J	Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer.	Chinese journal of cancer	2011	50
21676886	Platinum	Konstantinopoulos PA	Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.	Cancer research	2011	61
21709188	Platinum	Norquist B	Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.	Journal of clinical oncology 	2011	102
21765211	Platinum	Lesterhuis WJ	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.	The Journal of clinical investigation	2011	41
21775533	Platinum	Tan XL	Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.	Clinical cancer research 	2011	43
21795409	Platinum	Coward J	Interleukin-6 as a therapeutic target in human ovarian cancer.	Clinical cancer research 	2011	103
21841826	Platinum	de la Cruz-Morcillo MA	P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance.	Oncogene	2012	32
21907927	Platinum	Roodhart JM	Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids.	Cancer cell	2011	64
21934105	Platinum	Lowery MA	An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.	The oncologist	2011	43
21969500	Platinum	Brugger W	Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	71
21990299	Platinum	Yang D	Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.	JAMA	2011	113
22101352	Platinum	Katagiri A	Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.	Modern pathology 	2012	42
22119437	Platinum	Soria JC	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.	Cancer treatment reviews	2012	37
22131882	Platinum	Stronach EA	DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.	Neoplasia	2011	41
22142828	Platinum	Steg AD	Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.	Clinical cancer research 	2012	92
22203755	Platinum	Kaye SB	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.	Journal of clinical oncology 	2012	106
22237007	Platinum	Gao W	MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer.	Cancer biology & therapy	2012	33
22278287	Platinum	Ajabnoor GM	Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells.	Cell death & disease	2012	33
22330607	Platinum	Kim A	Therapeutic strategies in epithelial ovarian cancer.	Journal of experimental & clinical cancer research 	2012	67
22330686	Platinum	Postel-Vinay S	The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.	Nature reviews. Clinical oncology	2012	31
22416079	Platinum	Romero I	Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.	Endocrinology	2012	76
22452356	Platinum	Ledermann J	Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.	The New England journal of medicine	2012	239
22473592	Platinum	Seront E	Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.	Annals of oncology 	2012	33
22549947	Platinum	Matei D	Epigenetic resensitization to platinum in ovarian cancer.	Cancer research	2012	89
22564989	Platinum	Scagliotti GV	Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.	Journal of clinical oncology 	2012	55
22576213	Platinum	Birkbak NJ	Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.	Cancer discovery	2012	50
22593197	Platinum	Berns EM	The changing view of high-grade serous ovarian cancer.	Cancer research	2012	43
22696230	Platinum	Chung LY	Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2.	Clinical cancer research 	2012	37
22721387	Platinum	Tang Z	The role of mesothelin in tumor progression and targeted therapy.	Anti-cancer agents in medicinal chemistry	2013	27
22897840	Platinum	Marchini S	Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.	European journal of cancer	2013	43
22941649	Platinum	McNeil EM	DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.	Nucleic acids research	2012	35
22965962	Platinum	Ramlau R	Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.	Journal of clinical oncology 	2012	38
22986452	Platinum	Yao Y	Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.	Cancer immunology, immunotherapy 	2013	47
22996961	Platinum	Castellarin M	Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease.	The Journal of pathology	2013	27
23002282	Platinum	Kaye SB	A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer.	Annals of oncology 	2013	26
23012302	Platinum	Andr√© F	Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.	Annals of oncology 	2012	66
23017820	Platinum	Obermayr E	Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium.	Gynecologic oncology	2013	26
23019585	Platinum	McAuliffe SM	Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.	Proceedings of the National Academy of Sciences of the United States of America	2012	87
23045278	Platinum	van Jaarsveld MT	miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.	Oncogene	2013	59
23047548	Platinum	Abkevich V	Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.	British journal of cancer	2012	64
23129122	Platinum	Wu YL	Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).	Annals of oncology 	2013	46
23135908	Platinum	Liu YP	Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling.	Cancer research	2013	44
23257362	Platinum	Verhaak RG	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.	The Journal of clinical investigation	2013	126
23349823	Platinum	Barr MP	Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature.	PloS one	2013	52
23401448	Platinum	Mok T	Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?	Journal of clinical oncology 	2013	30
23436796	Platinum	Dijkgraaf EM	Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment.	Cancer research	2013	40
23514287	Platinum	Friboulet L	ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.	The New England journal of medicine	2013	89
23649446	Platinum	Socinski MA	Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.	Chest	2013	28
23649448	Platinum	Jett JR	Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.	Chest	2013	45
23724913	Platinum	Shaw AT	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.	The New England journal of medicine	2013	697
23782814	Platinum	Wu YL	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.	The Lancet. Oncology	2013	75
23810788	Platinum	Sandhu SK	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.	The Lancet. Oncology	2013	101
23833300	Platinum	Cardarella S	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.	Clinical cancer research 	2013	46
23881923	Platinum	Shen Y	BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.	Clinical cancer research 	2013	74
23883922	Platinum	Garassino MC	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.	The Lancet. Oncology	2013	127
23948351	Platinum	Shi Y	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.	The Lancet. Oncology	2013	82
23950211	Platinum	Zhang L	miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.	Cancer research	2013	39
24035405	Platinum	Calabr√≤ L	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.	The Lancet. Oncology	2013	48
24085845	Platinum	Johnson N	Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.	Proceedings of the National Academy of Sciences of the United States of America	2013	36
24094768	Platinum	Fuchs CS	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.	Lancet	2014	314
24168967	Platinum	Sun C	miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.	Journal of the National Cancer Institute	2013	30
24216225	Platinum	Cohen RB	Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).	Cancer treatment reviews	2014	24
24218601	Platinum	Etemadmoghadam D	Synthetic lethality between CCNE1 amplification and loss of BRCA1.	Proceedings of the National Academy of Sciences of the United States of America	2013	34
24240112	Platinum	Pennington KP	Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.	Clinical cancer research 	2014	94
24281000	Platinum	Granata A	Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.	British journal of cancer	2014	21
24366758	Platinum	Koizumi W	Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).	Journal of cancer research and clinical oncology	2014	27
24366937	Platinum	Vergote IB	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.	Journal of clinical oncology 	2014	26
24439931	Platinum	Rajan A	Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2014	25
24531034	Platinum	Wu C	Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer.	The Tohoku journal of experimental medicine	2014	28
24531842	Platinum	Liang Q	A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses.	Nature chemical biology	2014	42
24552320	Platinum	Tewari KS	Improved survival with bevacizumab in advanced cervical cancer.	The New England journal of medicine	2014	164
24560445	Platinum	Topp MD	Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts.	Molecular oncology	2014	30
24573551	Platinum	Malik SM	U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.	Clinical cancer research 	2014	28
24607283	Platinum	Liu JF	PARP inhibitors in ovarian cancer: current status and future promise.	Gynecologic oncology	2014	23
24637564	Platinum	Adhireksan Z	Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity.	Nature communications	2014	23
24727321	Platinum	Beltran H	Aggressive variants of castration-resistant prostate cancer.	Clinical cancer research 	2014	59
24794243	Platinum	von Minckwitz G	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.	The Lancet. Oncology	2014	100
24858042	Platinum	Miow QH	Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer.	Oncogene	2015	26
24868098	Platinum	Khozin S	U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.	The oncologist	2014	26
24882434	Platinum	Ledermann J	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.	The Lancet. Oncology	2014	192
24886434	Platinum	Abubaker K	Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.	BMC cancer	2014	23
24928832	Platinum	Seiwert TY	A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.	Annals of oncology 	2014	27
24929208	Platinum	Thayanithy V	Tumor-stromal cross talk: direct cell-to-cell transfer of oncogenic microRNAs via tunneling nanotubes.	Translational research 	2014	30
24933332	Platinum	Garon EB	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.	Lancet	2014	158
24950985	Platinum	Monk BJ	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.	The Lancet. Oncology	2014	57
24952704	Platinum	Qian W	Novel combination of mitochondrial division inhibitor 1 (mdivi-1) and platinum agents produces synergistic pro-apoptotic effect in drug resistant tumor cells.	Oncotarget	2014	23
24958820	Platinum	Fakhry C	Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.	Journal of clinical oncology 	2014	44
25010037	Platinum	Hall AB	Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.	Oncotarget	2014	27
25015375	Platinum	Kuhlmann JD	ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.	Clinical chemistry	2014	20
25035395	Platinum	Wang Y	Epigenetic targeting of ovarian cancer stem cells.	Cancer research	2014	31
25069034	Platinum	Sullivan I	Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.	Cancer letters	2014	22
25072261	Platinum	Golan T	Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.	British journal of cancer	2014	31
25091798	Platinum	Masterson L	De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials.	European journal of cancer	2014	39
25093514	Platinum	Watkins JA	Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.	Breast cancer research 	2014	32
25129345	Platinum	Byrski T	Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.	Breast cancer research and treatment	2014	39
25154822	Platinum	Ang KK	Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.	Journal of clinical oncology 	2014	120
25157892	Platinum	Kankotia S	Dichloroacetate and cancer: new home for an orphan drug?	Biochimica et biophysica acta	2014	40
25165721	Platinum	Ozkok A	Pathophysiology of cisplatin-induced acute kidney injury.	BioMed research international	2014	54
25170012	Platinum	Kazandjian D	FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.	The oncologist	2014	28
25216266	Platinum	Meng E	ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.	PloS one	2014	28
25218906	Platinum	Liu JF	Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.	The Lancet. Oncology	2014	73
25225436	Platinum	du Bois A	Incorporation of pazopanib in maintenance therapy of ovarian cancer.	Journal of clinical oncology 	2014	46
25349291	Platinum	Iyengar P	Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.	Journal of clinical oncology 	2014	35
25359574	Platinum	Lo Iacono M	ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway.	International journal of cancer	2015	15
25366685	Platinum	Kaufman B	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.	Journal of clinical oncology 	2015	192
25370471	Platinum	Sarker D	First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.	Clinical cancer research 	2015	54
25377507	Platinum	Doebele RC	Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.	Cancer	2015	17
25395283	Platinum	Scagliotti GV	Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.	Annals of oncology 	2015	17
25398436	Platinum	Galanis E	Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.	Cancer research	2015	44
25470694	Platinum	Solomon BJ	First-line crizotinib versus chemotherapy in ALK-positive lung cancer.	The New England journal of medicine	2014	413
25481791	Platinum	Oza AM	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.	The Lancet. Oncology	2015	87
25537514	Platinum	Gu Y	The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.	Oncotarget	2015	17
25552556	Platinum	Jenkins PM	Giant ankyrin-G: a critical innovation in vertebrate evolution of fast and integrated neuronal signaling.	Proceedings of the National Academy of Sciences of the United States of America	2015	25
25579119	Platinum	Pink RC	The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.	Gynecologic oncology	2015	29
25597412	Platinum	Fujita Y	The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer.	Molecular therapy 	2015	28
25636205	Platinum	Groenendijk FH	ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.	European urology	2016	19
25646366	Platinum	Caplin ME	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.	Annals of oncology 	2015	35
25667280	Platinum	Mazi√®res J	Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.	Journal of clinical oncology 	2015	40
25707631	Platinum	Nick AM	A framework for a personalized surgical approach to ovarian cancer.	Nature reviews. Clinical oncology	2015	28
25708226	Platinum	Tangutoori S	PARP inhibitors: A new era of targeted therapy.	Maturitas	2015	29
25710373	Platinum	Schwarz RF	Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.	PLoS medicine	2015	61
25722381	Platinum	Blumenschein GR Jr	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)‚Ä†.	Annals of oncology 	2015	34
25770156	Platinum	Watkins J	Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.	Cancer discovery	2015	17
25779564	Platinum	Scott CL	Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.	Journal of clinical oncology 	2015	58
25818403	Platinum	Coleman RL	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.	Gynecologic oncology	2015	47
25819643	Platinum	Calabr√≤ L	Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.	The Lancet. Respiratory medicine	2015	19
25823737	Platinum	Stevanoviƒá S	Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.	Journal of clinical oncology 	2015	61
25829397	Platinum	Mok T	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.	Clinical cancer research 	2015	66
25847936	Platinum	Isakoff SJ	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.	Journal of clinical oncology 	2015	54
25890361	Platinum	Koneru M	A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.	Journal of translational medicine	2015	31
25979846	Platinum	Panou V	The established and future biomarkers of malignant pleural mesothelioma.	Cancer treatment reviews	2015	17
26014294	Platinum	Zhou C	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	37
26017449	Platinum	Patch AM	Whole-genome characterization of chemoresistant ovarian cancer.	Nature	2015	158
26036632	Platinum	Garc√≠a-Cano J	Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance.	Oncotarget	2015	19
26119935	Platinum	Ciamporcero E	YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage.	Oncogene	2016	19
26125441	Platinum	Nagaraj AB	Critical role of Wnt/Œ≤-catenin signaling in driving epithelial ovarian cancer platinum resistance.	Oncotarget	2015	30
26159065	Platinum	Soria JC	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.	The Lancet. Oncology	2015	69
26169611	Platinum	Scagliotti G	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	52
26181256	Platinum	Beltran H	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.	JAMA oncology	2015	52
26279307	Platinum	He J	Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.	Scientific reports	2015	48
26317305	Platinum	Phillips T	Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.	Applied immunohistochemistry & molecular morphology 	2015	32
26324367	Platinum	Masters GA	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.	Journal of clinical oncology 	2015	74
26351341	Platinum	Sacco AG	Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.	Journal of clinical oncology 	2015	33
26410730	Platinum	Oing C	Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.	The Journal of urology	2016	10
26412456	Platinum	Borghaei H	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.	The New England journal of medicine	2015	776
26463832	Platinum	Konstantinopoulos PA	Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.	Cancer discovery	2015	39
26511885	Platinum	Alexandrov LB	A mutational signature in gastric cancer suggests therapeutic strategies.	Nature communications	2015	20
26530471	Platinum	Planells-Cases R	Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs.	The EMBO journal	2015	19
26625211	Platinum	Nogales V	Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.	Oncotarget	2016	13
26716514	Platinum	Cheng H	Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells.	Oncotarget	2016	17
26723501	Platinum	Domchek SM	Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.	Gynecologic oncology	2016	22
26724258	Platinum	Cheng HH	Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.	European urology	2016	11
26729200	Platinum	Gong WJ	Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response.	Tumour biology 	2016	24
26745875	Platinum	Mafficini A	BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.	Oncotarget	2016	11
26823294	Platinum	Schuler M	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.	Journal of thoracic oncology 	2016	17
26898616	Platinum	Tan CS	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.	Lung cancer	2016	23
26957554	Platinum	Telli ML	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.	Clinical cancer research 	2016	33
26970723	Platinum	Fehrenbacher L	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.	Lancet	2016	231
26984449	Platinum	Kazandjian D	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.	The oncologist	2016	36
27002934	Platinum	Drew Y	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.	British journal of cancer	2016	19
27026676	Platinum	Sul J	FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.	The oncologist	2016	24
27041570	Platinum	√ñze≈ü AR	NF-Œ∫B-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.	Oncogene	2016	19
27074572	Platinum	Zhou M	Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer.	Oncotarget	2016	49
27265743	Platinum	Planchard D	A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.	Clinical lung cancer	2016	21
27283860	Platinum	Planchard D	Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.	The Lancet. Oncology	2016	43
27432917	Platinum	Crin√≤ L	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.	Journal of clinical oncology 	2016	38
27502726	Platinum	Olaussen KA	Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.	Annals of oncology 	2016	12
27590317	Platinum	Mateo J	DNA Repair in Prostate Cancer: Biology and Clinical Implications.	European urology	2017	7
27617661	Platinum	Ledermann JA	Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.	The Lancet. Oncology	2016	27
27717299	Platinum	Mirza MR	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.	The New England journal of medicine	2016	85
27718847	Platinum	Reck M	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.	The New England journal of medicine	2016	369
27733243	Platinum	Sharma P	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.	The Lancet. Oncology	2016	42
27736844	Platinum	Konecny GE	PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.	British journal of cancer	2016	21
27745820	Platinum	Langer CJ	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.	The Lancet. Oncology	2016	97
27803005	Platinum	Lee SH	Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.	Annals of oncology 	2017	9
27803064	Platinum	Ramalingam SS	Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.	Clinical cancer research 	2017	5
27903674	Platinum	Inman BA	Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.	Clinical cancer research 	2017	8
27932068	Platinum	Rudin CM	Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.	The Lancet. Oncology	2017	23
27937096	Platinum	Spigel DR	Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.	Journal of clinical oncology 	2017	13
27979383	Platinum	Rittmeyer A	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.	Lancet	2017	162
28104537	Platinum	Rangachari D	Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ‚â•50% Expression in Lung Adenocarcinoma.	Journal of thoracic oncology 	2017	10
28131785	Platinum	Sharma P	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.	The Lancet. Oncology	2017	58
28212060	Platinum	Bellmunt J	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.	The New England journal of medicine	2017	70
28221868	Platinum	Lheureux S	Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.	Journal of clinical oncology 	2017	8
28291584	Platinum	Alley EW	Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.	The Lancet. Oncology	2017	22
28328302	Platinum	Bauml J	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.	Journal of clinical oncology 	2017	19
28373005	Platinum	Gulley JL	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.	The Lancet. Oncology	2017	23
28375787	Platinum	Apolo AB	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.	Journal of clinical oncology 	2017	31
28407528	Platinum	Giroux Leprieur E	Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.	European journal of cancer	2017	7
28424325	Platinum	Ning YM	FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.	The oncologist	2017	11
28438473	Platinum	Coleman RL	Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.	The Lancet. Oncology	2017	9
28490518	Platinum	Sen T	CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.	Cancer research	2017	9
28754483	Platinum	Pujade-Lauraine E	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.	The Lancet. Oncology	2017	14
2144057	Thymidine	Baker SJ	Suppression of human colorectal carcinoma cell growth by wild-type p53.	Science	1990	400
7133135	Thymidine	Reddy EP	A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene.	Nature	1982	265
7684692	Thymidine	Graham CH	Establishment and characterization of first trimester human trophoblast cells with extended lifespan.	Experimental cell research	1993	198
8523568	Thymidine	Moore PS	Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae.	Journal of virology	1996	145
8962164	Thymidine	Venugopal R	Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene.	Proceedings of the National Academy of Sciences of the United States of America	1996	246
9426049	Thymidine	Grignani F	High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein.	Cancer research	1998	106
9809561	Thymidine	Shields AF	Imaging proliferation in vivo with F-18FLT and positron emission tomography.	Nature medicine	1998	219
10720158	Thymidine	Choi SW	Folate and carcinogenesis: an integrated scheme.	The Journal of nutrition	2000	161
10778957	Thymidine	Salonga D	Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.	Clinical cancer research 	2000	124
10955814	Thymidine	Ueno T	Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.	Clinical cancer research 	2000	166
12215561	Thymidine	Rasey JS	Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells.	Journal of nuclear medicine 	2002	81
14747554	Thymidine	Feng WH	Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.	Journal of virology	2004	84
15763604	Thymidine	Walko CM	Capecitabine: a review.	Clinical therapeutics	2005	77
16103070	Thymidine	Ali S	Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.	Cancer research	2005	71
16282341	Thymidine	Berger C	Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.	Blood	2006	93
16905462	Thymidine	Kim JH	Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.	Molecular therapy 	2006	86
17060676	Thymidine	Locker GY	ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.	Journal of clinical oncology 	2006	290
17227781	Thymidine	Ripka S	WNT5A--target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer.	Carcinogenesis	2007	61
17495131	Thymidine	Yang J	AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.	Blood	2007	67
17965776	Thymidine	Thorne SH	Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.	The Journal of clinical investigation	2007	68
18162040	Thymidine	Kirn DH	Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.	PLoS medicine	2007	83
18369324	Thymidine	Aboody KS	Stem and progenitor cell-mediated tumor selective gene therapy.	Gene therapy	2008	88
18455396	Thymidine	Stuart-Harris R	Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients.	Breast	2008	85
18523066	Thymidine	Bading JR	Imaging of cell proliferation: status and prospects.	Journal of nuclear medicine 	2008	63
19119139	Thymidine	Casteel DE	A DNA polymerase-{alpha}{middle dot}primase cofactor with homology to replication protein A-32 regulates DNA replication in mammalian cells.	The Journal of biological chemistry	2009	64
19244169	Thymidine	Vlashi E	In vivo imaging, tracking, and targeting of cancer stem cells.	Journal of the National Cancer Institute	2009	85
19345145	Thymidine	Ciceri F	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.	The Lancet. Oncology	2009	131
20053681	Thymidine	Gagou ME	Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1.	Molecular biology of the cell	2010	41
20080668	Thymidine	Pine SR	Microenvironmental modulation of asymmetric cell division in human lung cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2010	56
20510733	Thymidine	Maul RW	AID and somatic hypermutation.	Advances in immunology	2010	57
20522802	Thymidine	Kajstura J	Cardiomyogenesis in the adult human heart.	Circulation research	2010	105
20530679	Thymidine	Coffelt SB	Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions.	Cancer research	2010	76
20682912	Thymidine	Slinger E	HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis.	Science signaling	2010	69
21912681	Thymidine	Skalsky RL	Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene.	PloS one	2011	51
22186794	Thymidine	Parato KA	The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.	Molecular therapy 	2012	54
22269649	Thymidine	Cheng F	Protecting against wayward human induced pluripotent stem cells with a suicide gene.	Biomaterials	2012	31
23850491	Thymidine	Westphal M	Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2013	33
24275137	Thymidine	Deng J	Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro.	Biochemical and biophysical research communications	2014	26
24797299	Thymidine	Pflug N	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.	Blood	2014	22
24917306	Thymidine	Mitsuhashi A	Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.	Cancer	2014	24
25482511	Thymidine	Lunt SY	Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation.	Molecular cell	2015	42
27110680	Thymidine	Pacold ME	A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.	Nature chemical biology	2016	31
1279432	L-Tyrosine	Plate KH	Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.	Nature	1992	346
1350381	L-Tyrosine	Holmes WE	Identification of heregulin, a specific activator of p185erbB2.	Science	1992	161
1359541	L-Tyrosine	Guy CT	Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.	Proceedings of the National Academy of Sciences of the United States of America	1992	334
1656220	L-Tyrosine	O'Bryan JP	axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.	Molecular and cellular biology	1991	157
1846706	L-Tyrosine	Bottaro DP	Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.	Science	1991	382
1849459	L-Tyrosine	Klein R	The trk proto-oncogene encodes a receptor for nerve growth factor.	Cell	1991	188
1850549	L-Tyrosine	Kaplan DR	The trk proto-oncogene product: a signal transducing receptor for nerve growth factor.	Science	1991	178
1922387	L-Tyrosine	Pulverer BJ	Phosphorylation of c-jun mediated by MAP kinases.	Nature	1991	298
2032290	L-Tyrosine	Boulton TG	ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF.	Cell	1991	361
2156626	L-Tyrosine	Kaplan DR	PDGF beta-receptor stimulates tyrosine phosphorylation of GAP and association of GAP with a signaling complex.	Cell	1990	151
2408149	L-Tyrosine	Lugo TG	Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.	Science	1990	215
2448137	L-Tyrosine	Yarden Y	Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.	The EMBO journal	1987	250
2455897	L-Tyrosine	Rudd CE	The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes.	Proceedings of the National Academy of Sciences of the United States of America	1988	190
2784195	L-Tyrosine	Veillette A	Signal transduction through the CD4 receptor involves the activation of the internal membrane tyrosine-protein kinase p56lck.	Nature	1989	163
6157683	L-Tyrosine	Ushiro H	Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.	The Journal of biological chemistry	1980	191
7513258	L-Tyrosine	Ponzetto C	A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family.	Cell	1994	208
7538656	L-Tyrosine	Alimandi M	Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.	Oncogene	1995	141
7542586	L-Tyrosine	Marais R	Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation.	The EMBO journal	1995	143
7559628	L-Tyrosine	Singh S	Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) corrected.	The Journal of biological chemistry	1995	214
7724599	L-Tyrosine	Kaipainen A	Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.	Proceedings of the National Academy of Sciences of the United States of America	1995	260
7796399	L-Tyrosine	Owens LV	Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors.	Cancer research	1995	137
7892601	L-Tyrosine	Levitzki A	Tyrosine kinase inhibition: an approach to drug development.	Science	1995	215
7926300	L-Tyrosine	Hotamisligil GS	Tumor necrosis factor alpha: a key component of the obesity-diabetes link.	Diabetes	1994	161
7929439	L-Tyrosine	Waltenberger J	Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.	The Journal of biological chemistry	1994	264
8052651	L-Tyrosine	Nishikawa R	A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.	Proceedings of the National Academy of Sciences of the United States of America	1994	242
8099202	L-Tyrosine	Mulligan LM	Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.	Nature	1993	188
8103403	L-Tyrosine	Donis-Keller H	Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.	Human molecular genetics	1993	133
8122112	L-Tyrosine	Morris SW	Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.	Science	1994	403
8168137	L-Tyrosine	Golub TR	Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.	Cell	1994	146
8380905	L-Tyrosine	Vetrie D	The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.	Nature	1993	208
8596638	L-Tyrosine	Holgado-Madruga M	A Grb2-associated docking protein in EGF- and insulin-receptor signalling.	Nature	1996	155
8616716	L-Tyrosine	Druker BJ	Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.	Nature medicine	1996	536
8617204	L-Tyrosine	Joukov V	A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.	The EMBO journal	1996	212
8628398	L-Tyrosine	Meydan N	Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor.	Nature	1996	153
8635462	L-Tyrosine	Migliaccio A	Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.	The EMBO journal	1996	149
8946930	L-Tyrosine	Nakao M	Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.	Leukemia	1996	202
9006938	L-Tyrosine	Huang HS	The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.	The Journal of biological chemistry	1997	173
9140397	L-Tyrosine	Schmidt L	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.	Nature genetics	1997	282
9168116	L-Tyrosine	Baskaran R	Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation.	Nature	1997	112
9217161	L-Tyrosine	Irmler M	Inhibition of death receptor signals by cellular FLIP.	Nature	1997	435
9247128	L-Tyrosine	Alroy I	The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions.	FEBS letters	1997	121
9360930	L-Tyrosine	Lacronique V	A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.	Science	1997	170
9403702	L-Tyrosine	Petit AM	Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.	The American journal of pathology	1997	120
9435229	L-Tyrosine	Achen MG	Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).	Proceedings of the National Academy of Sciences of the United States of America	1998	194
9438854	L-Tyrosine	Hirota S	Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.	Science	1998	720
9472046	L-Tyrosine	Klemke RL	CAS/Crk coupling serves as a "molecular switch" for induction of cell migration.	The Journal of cell biology	1998	177
9566874	L-Tyrosine	Turkson J	Stat3 activation by Src induces specific gene regulation and is required for cell transformation.	Molecular and cellular biology	1998	157
9744771	L-Tyrosine	Schulte TW	The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.	Cancer chemotherapy and pharmacology	1998	106
9763511	L-Tyrosine	Lee G	Tau interacts with src-family non-receptor tyrosine kinases.	Journal of cell science	1998	108
9815926	L-Tyrosine	Goldstein NI	Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.	Clinical cancer research 	1995	123
9831867	L-Tyrosine	Ross JS	The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.	Stem cells	1998	110
9856951	L-Tyrosine	Lee KM	Molecular basis of T cell inactivation by CTLA-4.	Science	1998	125
9865697	L-Tyrosine	Cheng AM	Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation.	Cell	1998	101
9892193	L-Tyrosine	Fong TA	SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.	Cancer research	1999	147
9988270	L-Tyrosine	Irby RB	Activating SRC mutation in a subset of advanced human colon cancers.	Nature genetics	1999	111
10075741	L-Tyrosine	Biscardi JS	c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function.	The Journal of biological chemistry	1999	182
10086382	L-Tyrosine	Craft N	A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.	Nature medicine	1999	181
10205169	L-Tyrosine	Siegel PM	Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer.	The EMBO journal	1999	146
10223227	L-Tyrosine	Nakajima M	The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.	Cancer	1999	119
10224280	L-Tyrosine	Li S	The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.	The Journal of experimental medicine	1999	131
10371505	L-Tyrosine	Sethi T	Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo.	Nature medicine	1999	134
10395191	L-Tyrosine	Hotamisligil GS	The role of TNFalpha and TNF receptors in obesity and insulin resistance.	Journal of internal medicine	1999	97
10404636	L-Tyrosine	Wells A	EGF receptor.	The international journal of biochemistry & cell biology	1999	192
10482195	L-Tyrosine	Sliwkowski MX	Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).	Seminars in oncology	1999	120
10520995	L-Tyrosine	Tamagnone L	Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates.	Cell	1999	236
10611246	L-Tyrosine	Lee RJ	Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.	Molecular and cellular biology	2000	96
10699960	L-Tyrosine	Grimberg A	Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis.	Journal of cellular physiology	2000	91
10815932	L-Tyrosine	Ciardiello F	Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.	Clinical cancer research 	2000	110
10835628	L-Tyrosine	Karkkainen MJ	Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema.	Nature genetics	2000	113
10851045	L-Tyrosine	Bromberg J	The role of STATs in transcriptional control and their impact on cellular function.	Oncogene	2000	273
10873094	L-Tyrosine	Cance WG	Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes.	Clinical cancer research 	2000	119
10888890	L-Tyrosine	Paloneva J	Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts.	Nature genetics	2000	110
10961344	L-Tyrosine	Adams TE	Structure and function of the type 1 insulin-like growth factor receptor.	Cellular and molecular life sciences 	2000	117
10966114	L-Tyrosine	Zheng N	Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases.	Cell	2000	291
11090077	L-Tyrosine	Mizuki M	Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.	Blood	2000	106
11146556	L-Tyrosine	Ogawa K	The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.	Oncogene	2000	96
11156523	L-Tyrosine	Harari D	Molecular mechanisms underlying ErbB2/HER2 action in breast cancer.	Oncogene	2000	122
11160159	L-Tyrosine	Epling-Burnette PK	Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression.	The Journal of clinical investigation	2001	159
11181169	L-Tyrosine	Robinson CJ	The splice variants of vascular endothelial growth factor (VEGF) and their receptors.	Journal of cell science	2001	171
11213830	L-Tyrosine	Miettinen M	Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.	Virchows Archiv 	2001	258
11278868	L-Tyrosine	Schroeder JA	Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland.	The Journal of biological chemistry	2001	94
11280802	L-Tyrosine	Zelinski DP	EphA2 overexpression causes tumorigenesis of mammary epithelial cells.	Cancer research	2001	129
11282421	L-Tyrosine	Cross MJ	FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition.	Trends in pharmacological sciences	2001	163
11287972	L-Tyrosine	Druker BJ	Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.	The New England journal of medicine	2001	756
11287973	L-Tyrosine	Druker BJ	Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.	The New England journal of medicine	2001	398
11290608	L-Tyrosine	Yamamoto Y	Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.	Blood	2001	203
11297536	L-Tyrosine	Mahadev K	Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin action cascade.	The Journal of biological chemistry	2001	119
11331884	L-Tyrosine	Miao H	Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway.	Nature cell biology	2001	92
11345501	L-Tyrosine	Shibuya M	Structure and function of VEGF/VEGF-receptor system involved in angiogenesis.	Cell structure and function	2001	88
11350724	L-Tyrosine	Prenzel N	The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.	Endocrine-related cancer	2001	122
11350918	L-Tyrosine	Ciardiello F	Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.	Clinical cancer research 	2001	85
11359907	L-Tyrosine	Laughner E	HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.	Molecular and cellular biology	2001	265
11369781	L-Tyrosine	Yin BW	Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.	The Journal of biological chemistry	2001	129
11386265	L-Tyrosine	Gao X	Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.	The New England journal of medicine	2001	144
11406546	L-Tyrosine	Molina MA	Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.	Cancer research	2001	172
11416160	L-Tyrosine	Hendrix MJ	Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry.	Proceedings of the National Academy of Sciences of the United States of America	2001	101
11420660	L-Tyrosine	Garcia R	Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.	Oncogene	2001	173
11423618	L-Tyrosine	Gorre ME	Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.	Science	2001	641
11426640	L-Tyrosine	Mendelsohn J	The EGF receptor family as targets for cancer therapy.	Oncogene	2000	210
11459867	L-Tyrosine	Adjei AA	Blocking oncogenic Ras signaling for cancer therapy.	Journal of the National Cancer Institute	2001	160
11483589	L-Tyrosine	Li Y	The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin.	The Journal of biological chemistry	2001	89
11493665	L-Tyrosine	Raiborg C	FYVE and coiled-coil domains determine the specific localisation of Hrs to early endosomes.	Journal of cell science	2001	90
11526490	L-Tyrosine	Tuveson DA	STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.	Oncogene	2001	105
11585753	L-Tyrosine	Moasser MM	The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.	Cancer research	2001	91
11585760	L-Tyrosine	Whitman SP	Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.	Cancer research	2001	119
11595683	L-Tyrosine	Ciardiello F	A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.	Clinical cancer research 	2001	140
11597398	L-Tyrosine	Yarden Y	The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.	European journal of cancer	2001	314
11597399	L-Tyrosine	Nicholson RI	EGFR and cancer prognosis.	European journal of cancer	2001	393
11598267	L-Tyrosine	Saha S	A phosphatase associated with metastasis of colorectal cancer.	Science	2001	149
11607845	L-Tyrosine	Schaller MD	Paxillin: a focal adhesion-associated adaptor protein.	Oncogene	2001	144
11719439	L-Tyrosine	Rubin BP	KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.	Cancer research	2001	155
11743208	L-Tyrosine	Bouchard MJ	Calcium signaling by HBx protein in hepatitis B virus DNA replication.	Science	2001	102
11756186	L-Tyrosine	Kelly LM	FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.	Blood	2002	101
11756187	L-Tyrosine	Graham SM	Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.	Blood	2002	276
11782378	L-Tyrosine	Chakravarti A	Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.	Cancer research	2002	114
11861607	L-Tyrosine	Samelson LE	Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins.	Annual review of immunology	2002	171
11870534	L-Tyrosine	P√©rez-Tenorio G	Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients.	British journal of cancer	2002	92
11896121	L-Tyrosine	Heinrich MC	Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.	Journal of clinical oncology 	2002	86
11948098	L-Tyrosine	Buettner R	Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.	Clinical cancer research 	2002	273
11960372	L-Tyrosine	Niu G	Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.	Oncogene	2002	308
11984589	L-Tyrosine	Crone SA	ErbB2 is essential in the prevention of dilated cardiomyopathy.	Nature medicine	2002	178
12010785	L-Tyrosine	Levis M	A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.	Blood	2002	90
12036858	L-Tyrosine	Thiede C	Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.	Blood	2002	293
12094370	L-Tyrosine	Fletcher CD	Diagnosis of gastrointestinal stromal tumors: A consensus approach.	Human pathology	2002	519
12094371	L-Tyrosine	Dematteo RP	Clinical management of gastrointestinal stromal tumors: before and after STI-571.	Human pathology	2002	86
12124177	L-Tyrosine	Sattler M	Critical role for Gab2 in transformation by BCR/ABL.	Cancer cell	2002	93
12124352	L-Tyrosine	Yakes FM	Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.	Cancer research	2002	165
12130516	L-Tyrosine	Roche-Lestienne C	Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.	Blood	2002	99
12176867	L-Tyrosine	Gilliland DG	The roles of FLT3 in hematopoiesis and leukemia.	Blood	2002	239
12181401	L-Tyrosine	Demetri GD	Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.	The New England journal of medicine	2002	692
12194988	L-Tyrosine	Kelly LM	Genetics of myeloid leukemias.	Annual review of genomics and human genetics	2002	102
12202786	L-Tyrosine	Arteaga CL	Epidermal growth factor receptor dependence in human tumors: more than just expression?	The oncologist	2002	89
12204104	L-Tyrosine	Muramatsu T	Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis.	Journal of biochemistry	2002	85
12204532	L-Tyrosine	Shah NP	Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.	Cancer cell	2002	391
12204533	L-Tyrosine	Agus DB	Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.	Cancer cell	2002	203
12213723	L-Tyrosine	Schoppmann SF	Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis.	The American journal of pathology	2002	183
12214266	L-Tyrosine	Xia W	Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.	Oncogene	2002	162
12370822	L-Tyrosine	Niu G	Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.	Oncogene	2002	99
12384534	L-Tyrosine	Wakeling AE	ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.	Cancer research	2002	135
12398893	L-Tyrosine	Hiratsuka S	MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis.	Cancer cell	2002	185
12399961	L-Tyrosine	Hochhaus A	Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.	Leukemia	2002	131
12409327	L-Tyrosine	Baselga J	Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.	Journal of clinical oncology 	2002	108
12424067	L-Tyrosine	Joensuu H	Management of malignant gastrointestinal stromal tumours.	The Lancet. Oncology	2002	85
12446738	L-Tyrosine	Tsutsumi R	Attenuation of Helicobacter pylori CagA x SHP-2 signaling by interaction between CagA and C-terminal Src kinase.	The Journal of biological chemistry	2003	90
12464636	L-Tyrosine	Orian-Rousseau V	CD44 is required for two consecutive steps in HGF/c-Met signaling.	Genes & development	2002	143
12467226	L-Tyrosine	Rusnak DW	The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.	Molecular cancer therapeutics	2001	141
12499271	L-Tyrosine	Carlomagno F	ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.	Cancer research	2002	115
12502502	L-Tyrosine	Buteau J	Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor.	Diabetes	2003	97
12509383	L-Tyrosine	Donato NJ	BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.	Blood	2003	153
12522257	L-Tyrosine	Heinrich MC	PDGFRA activating mutations in gastrointestinal stromal tumors.	Science	2003	401
12526739	L-Tyrosine	Arnaud L	Fyn tyrosine kinase is a critical regulator of disabled-1 during brain development.	Current biology 	2003	90
12538684	L-Tyrosine	Brown JA	Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.	Journal of immunology	2003	212
12576334	L-Tyrosine	Bhatia R	Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.	Blood	2003	121
12598680	L-Tyrosine	Segal RA	Selectivity in neurotrophin signaling: theme and variations.	Annual review of neuroscience	2003	112
12610629	L-Tyrosine	Cho HS	Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.	Nature	2003	345
12628344	L-Tyrosine	Gu H	The "Gab" in signal transduction.	Trends in cell biology	2003	108
12648469	L-Tyrosine	Holbro T	The ErbB receptors and their role in cancer progression.	Experimental cell research	2003	156
12648667	L-Tyrosine	Dikic I	Negative receptor signalling.	Current opinion in cell biology	2003	83
12654250	L-Tyrosine	Hantschel O	A myristoyl/phosphotyrosine switch regulates c-Abl.	Cell	2003	105
12663862	L-Tyrosine	Mareel M	Clinical, cellular, and molecular aspects of cancer invasion.	Physiological reviews	2003	94
12670889	L-Tyrosine	Kimura ET	High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.	Cancer research	2003	274
12680238	L-Tyrosine	Aggarwal BB	Anticancer potential of curcumin: preclinical and clinical studies.	Anticancer research	2003	283
12686563	L-Tyrosine	Lai J	Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer.	The Journal of biological chemistry	2003	90
12743152	L-Tyrosine	Cohen EE	Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.	Journal of clinical oncology 	2003	99
12773095	L-Tyrosine	Heinrich PC	Principles of interleukin (IL)-6-type cytokine signalling and its regulation.	The Biochemical journal	2003	627
12782602	L-Tyrosine	Sriuranpong V	Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system.	Cancer research	2003	88
12802020	L-Tyrosine	Lu Q	TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation.	Proceedings of the National Academy of Sciences of the United States of America	2003	91
12824187	L-Tyrosine	Buchanan FG	Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor.	The Journal of biological chemistry	2003	106
12826400	L-Tyrosine	Neel BG	The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.	Trends in biochemical sciences	2003	318
12833138	L-Tyrosine	Song L	Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.	Oncogene	2003	95
12841864	L-Tyrosine	Hirohashi S	Cell adhesion system and human cancer morphogenesis.	Cancer science	2003	84
12845624	L-Tyrosine	Witton CJ	Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.	The Journal of pathology	2003	134
12853564	L-Tyrosine	Holbro T	The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.	Proceedings of the National Academy of Sciences of the United States of America	2003	299
12860957	L-Tyrosine	Mendelsohn J	Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.	Journal of clinical oncology 	2003	193
12884908	L-Tyrosine	Ma PC	c-Met: structure, functions and potential for therapeutic inhibition.	Cancer metastasis reviews	2003	120
12884910	L-Tyrosine	Summy JM	Src family kinases in tumor progression and metastasis.	Cancer metastasis reviews	2003	243
12887919	L-Tyrosine	Seo DW	TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism.	Cell	2003	127
12897328	L-Tyrosine	Ross JS	The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.	The oncologist	2003	96
12949711	L-Tyrosine	Hirota S	Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.	Gastroenterology	2003	112
12951584	L-Tyrosine	Stirewalt DL	The role of FLT3 in haematopoietic malignancies.	Nature reviews. Cancer	2003	155
12970773	L-Tyrosine	Levis M	FLT3: ITDoes matter in leukemia.	Leukemia	2003	114
14502555	L-Tyrosine	Cal√≤ V	STAT proteins: from normal control of cellular events to tumorigenesis.	Journal of cellular physiology	2003	140
14517187	L-Tyrosine	Morgan B	Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.	Journal of clinical oncology 	2003	105
14527402	L-Tyrosine	Burgess AW	An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.	Molecular cell	2003	225
14559814	L-Tyrosine	Ma PC	c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.	Cancer research	2003	131
14644997	L-Tyrosine	Loh ML	Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.	Blood	2004	94
14701768	L-Tyrosine	Soulieres D	Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.	Journal of clinical oncology 	2004	152
14708008	L-Tyrosine	Hantschel O	Regulation of the c-Abl and Bcr-Abl tyrosine kinases.	Nature reviews. Molecular cell biology	2004	125
14712221	L-Tyrosine	Fernandis AZ	Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells.	Oncogene	2004	70
14726163	L-Tyrosine	Orchard JA	ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.	Lancet	2004	71
14726387	L-Tyrosine	Smith BD	Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.	Blood	2004	137
14739340	L-Tyrosine	Seton-Rogers SE	Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2004	92
14755679	L-Tyrosine	Taplin ME	Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.	Journal of cellular biochemistry	2004	96
14765127	L-Tyrosine	Zaidi SK	Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription.	The EMBO journal	2004	92
14967450	L-Tyrosine	Marmor MD	Signal transduction and oncogenesis by ErbB/HER receptors.	International journal of radiation oncology, biology, physics	2004	84
15004560	L-Tyrosine	Bottini N	A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes.	Nature genetics	2004	314
15021893	L-Tyrosine	Marmor MD	Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases.	Oncogene	2004	136
15032571	L-Tyrosine	Wong S	The BCR-ABL story: bench to bedside and back.	Annual review of immunology	2004	100
15050914	L-Tyrosine	Mitsiades CS	Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.	Cancer cell	2004	124
15054042	L-Tyrosine	Rombouts EJ	Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia.	Blood	2004	72
15057284	L-Tyrosine	Qian X	E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.	The EMBO journal	2004	111
15118125	L-Tyrosine	Paez JG	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.	Science	2004	2101
15126356	L-Tyrosine	Hutchinson JN	Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion.	Cancer research	2004	81
15155950	L-Tyrosine	Wang Z	Mutational analysis of the tyrosine phosphatome in colorectal cancers.	Science	2004	159
15166220	L-Tyrosine	Dumoutier L	Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling.	The Journal of biological chemistry	2004	86
15186216	L-Tyrosine	Daly RJ	Cortactin signalling and dynamic actin networks.	The Biochemical journal	2004	80
15207811	L-Tyrosine	Fredriksson L	The PDGF family: four gene products form five dimeric isoforms.	Cytokine & growth factor reviews	2004	143
15240681	L-Tyrosine	Chemnitz JM	SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.	Journal of immunology	2004	240
15249664	L-Tyrosine	Dechow TN	Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C.	Proceedings of the National Academy of Sciences of the United States of America	2004	73
15284455	L-Tyrosine	Sordella R	Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.	Science	2004	355
15289342	L-Tyrosine	Huang S	Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.	Cancer research	2004	74
15329413	L-Tyrosine	Pao W	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.	Proceedings of the National Academy of Sciences of the United States of America	2004	1046
15329723	L-Tyrosine	Douma S	Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB.	Nature	2004	163
15349821	L-Tyrosine	Derycke LD	N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling.	The International journal of developmental biology	2004	85
15361874	L-Tyrosine	Graux C	Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.	Nature genetics	2004	81
15365079	L-Tyrosine	Corless CL	Biology of gastrointestinal stromal tumors.	Journal of clinical oncology 	2004	179
15374980	L-Tyrosine	Wood ER	A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.	Cancer research	2004	215
15380511	L-Tyrosine	Ishizawar R	c-Src and cooperating partners in human cancer.	Cancer cell	2004	186
15380516	L-Tyrosine	Wang SC	Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2.	Cancer cell	2004	101
15385631	L-Tyrosine	Austin CD	Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.	Molecular biology of the cell	2004	120
15457249	L-Tyrosine	Stephens P	Lung cancer: intragenic ERBB2 kinase mutations in tumours.	Nature	2004	175
15466206	L-Tyrosine	Wilhelm SM	BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.	Cancer research	2004	844
15469392	L-Tyrosine	Turkson J	STAT proteins as novel targets for cancer drug discovery.	Expert opinion on therapeutic targets	2004	83
15489908	L-Tyrosine	Parsons SJ	Src family kinases, key regulators of signal transduction.	Oncogene	2004	211
15489910	L-Tyrosine	Boggon TJ	Structure and regulation of Src family kinases.	Oncogene	2004	182
15489911	L-Tyrosine	Playford MP	The interplay between Src and integrins in normal and tumor biology.	Oncogene	2004	165
15489919	L-Tyrosine	Silva CM	Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis.	Oncogene	2004	113
15492241	L-Tyrosine	Tracy S	Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.	Cancer research	2004	90
15494733	L-Tyrosine	Ren XR	Focal adhesion kinase in netrin-1 signaling.	Nature neuroscience	2004	77
15498859	L-Tyrosine	Kim KT	Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival.	Blood	2005	73
15534001	L-Tyrosine	Williams CC	The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone.	The Journal of cell biology	2004	102
15542430	L-Tyrosine	Li YM	Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.	Cancer cell	2004	150
15542435	L-Tyrosine	Mellinghoff IK	HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.	Cancer cell	2004	117
15558067	L-Tyrosine	Barda-Saad M	Dynamic molecular interactions linking the T cell antigen receptor to the actin cytoskeleton.	Nature immunology	2005	120
15602010	L-Tyrosine	Hoeben A	Vascular endothelial growth factor and angiogenesis.	Pharmacological reviews	2004	337
15604238	L-Tyrosine	Bentires-Alj M	Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.	Cancer research	2004	130
15604253	L-Tyrosine	Kosaka T	Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.	Cancer research	2004	253
15649887	L-Tyrosine	Wang R	Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation.	The Journal of biological chemistry	2005	69
15653507	L-Tyrosine	Yuan ZL	Stat3 dimerization regulated by reversible acetylation of a single lysine residue.	Science	2005	241
15665299	L-Tyrosine	Amann J	Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.	Cancer research	2005	103
15681531	L-Tyrosine	Marchetti A	EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.	Journal of clinical oncology 	2005	158
15684082	L-Tyrosine	Friedman LM	Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.	Proceedings of the National Academy of Sciences of the United States of America	2005	72
15684311	L-Tyrosine	Spector NL	Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.	Journal of clinical oncology 	2005	87
15690056	L-Tyrosine	Reed CC	Decorin prevents metastatic spreading of breast cancer.	Oncogene	2005	68
15695389	L-Tyrosine	Nagy P	Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.	Cancer research	2005	112
15705894	L-Tyrosine	Yang J	Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation.	Cancer research	2005	135
15710947	L-Tyrosine	Han SW	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.	Journal of clinical oncology 	2005	141
15719031	L-Tyrosine	Ren R	Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.	Nature reviews. Cancer	2005	186
15720813	L-Tyrosine	Hoelzinger DB	Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets.	Neoplasia	2005	99
15735648	L-Tyrosine	Salvador JM	Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases.	Nature immunology	2005	85
15741570	L-Tyrosine	Shigematsu H	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.	Journal of the National Cancer Institute	2005	483
15749926	L-Tyrosine	Xu C	Basic fibroblast growth factor supports undifferentiated human embryonic stem cell growth without conditioned medium.	Stem cells	2005	76
15753357	L-Tyrosine	Shigematsu H	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.	Cancer research	2005	151
15753462	L-Tyrosine	Herbst RS	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.	Journal of clinical oncology 	2005	88
15767641	L-Tyrosine	Pao W	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.	Journal of clinical oncology 	2005	104
15768830	L-Tyrosine	Williams TM	The Caveolin genes: from cell biology to medicine.	Annals of medicine	2004	121
15769183	L-Tyrosine	Cerchia L	Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase.	PLoS biology	2005	68
15776112	L-Tyrosine	Zhuang L	Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts.	The Journal of clinical investigation	2005	130
15800629	L-Tyrosine	Ma JB	Structural basis for 5'-end-specific recognition of guide RNA by the A. fulgidus Piwi protein.	Nature	2005	197
15830281	L-Tyrosine	Llovet JM	Updated treatment approach to hepatocellular carcinoma.	Journal of gastroenterology	2005	129
15831234	L-Tyrosine	Giannini C	Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.	Neuro-oncology	2005	169
15833866	L-Tyrosine	Chinnaiyan P	Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).	Cancer research	2005	89
15837627	L-Tyrosine	Levine RL	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.	Cancer cell	2005	637
15863030	L-Tyrosine	Eswarakumar VP	Cellular signaling by fibroblast growth factor receptors.	Cytokine & growth factor reviews	2005	501
15864276	L-Tyrosine	Hynes NE	ERBB receptors and cancer: the complexity of targeted inhibitors.	Nature reviews. Cancer	2005	874
15870198	L-Tyrosine	Zhang Q	STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes.	Proceedings of the National Academy of Sciences of the United States of America	2005	76
15870435	L-Tyrosine	Cappuzzo F	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.	Journal of the National Cancer Institute	2005	322
15895073	L-Tyrosine	Chiarle R	Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.	Nature medicine	2005	134
15897464	L-Tyrosine	Kwak EL	Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.	Proceedings of the National Academy of Sciences of the United States of America	2005	220
15918149	L-Tyrosine	Roberts LR	Hepatocellular carcinoma: molecular pathways and new therapeutic targets.	Seminars in liver disease	2005	67
15920544	L-Tyrosine	Bhargava R	EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.	Modern pathology 	2005	81
15922853	L-Tyrosine	Christensen JG	c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.	Cancer letters	2005	120
15930355	L-Tyrosine	Antonescu CR	Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.	Clinical cancer research 	2005	163
15955300	L-Tyrosine	Solan JL	Connexin phosphorylation as a regulatory event linked to gap junction channel assembly.	Biochimica et biophysica acta	2005	101
15955900	L-Tyrosine	Burris HA 3rd	Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.	Journal of clinical oncology 	2005	128
15967113	L-Tyrosine	Hu X	mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.	Neoplasia	2005	65
15982921	L-Tyrosine	Arighi E	RET tyrosine kinase signaling in development and cancer.	Cytokine & growth factor reviews	2005	75
15987685	L-Tyrosine	Keilhack H	Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.	The Journal of biological chemistry	2005	100
15994331	L-Tyrosine	Clayton AH	Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis.	The Journal of biological chemistry	2005	87
15994928	L-Tyrosine	Zhao X	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.	Cancer research	2005	120
16012181	L-Tyrosine	Segaert S	Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.	Annals of oncology 	2005	66
16027153	L-Tyrosine	Potter MD	Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state.	The Journal of biological chemistry	2005	123
16027439	L-Tyrosine	Rugo HS	Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.	Journal of clinical oncology 	2005	87
16037387	L-Tyrosine	Jelinek J	JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.	Blood	2005	74
16039586	L-Tyrosine	Ding Q	Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.	Molecular cell	2005	184
16043829	L-Tyrosine	Herbst RS	TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2005	284
16049312	L-Tyrosine	Pan Q	Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.	The Journal of molecular diagnostics 	2005	76
16061658	L-Tyrosine	Aqeilan RI	WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function.	Cancer research	2005	73
16076867	L-Tyrosine	Schnittger S	Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.	Blood	2005	111
16080193	L-Tyrosine	Hiscox S	Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation.	International journal of cancer	2006	77
16081687	L-Tyrosine	Levine RL	The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.	Blood	2005	79
16082245	L-Tyrosine	Miettinen M	KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation.	Applied immunohistochemistry & molecular morphology 	2005	90
16095999	L-Tyrosine	Bellacosa A	Activation of AKT kinases in cancer: implications for therapeutic targeting.	Advances in cancer research	2005	215
16098464	L-Tyrosine	Macrae M	A conditional feedback loop regulates Ras activity through EphA2.	Cancer cell	2005	82
16099634	L-Tyrosine	Avizienyte E	Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition.	Current opinion in cell biology	2005	75
16104843	L-Tyrosine	Takahashi H	The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions.	Clinical science	2005	150
16105816	L-Tyrosine	Nagai Y	Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.	Cancer research	2005	102
16105881	L-Tyrosine	Moustakas A	Non-Smad TGF-beta signals.	Journal of cell science	2005	325
16106023	L-Tyrosine	Mukohara T	Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.	Journal of the National Cancer Institute	2005	90
16109776	L-Tyrosine	Verhaak RG	Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.	Blood	2005	103
16110317	L-Tyrosine	Wu XR	Urothelial tumorigenesis: a tale of divergent pathways.	Nature reviews. Cancer	2005	190
16113104	L-Tyrosine	Gee JM	Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.	Endocrine-related cancer	2005	66
16170173	L-Tyrosine	Philip PA	Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.	Journal of clinical oncology 	2005	95
16170353	L-Tyrosine	Ota H	Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.	Oncogene	2006	121
16203990	L-Tyrosine	Borrello MG	Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene.	Proceedings of the National Academy of Sciences of the United States of America	2005	71
16212809	L-Tyrosine	Abounader R	Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis.	Neuro-oncology	2005	80
16230383	L-Tyrosine	Baird K	Gene expression profiling of human sarcomas: insights into sarcoma biology.	Cancer research	2005	89
16231326	L-Tyrosine	Shigematsu H	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.	International journal of cancer	2006	145
16258541	L-Tyrosine	Bell DW	Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.	Nature genetics	2005	123
16260764	L-Tyrosine	Seeliger MA	High yield bacterial expression of active c-Abl and c-Src tyrosine kinases.	Protein science 	2005	79
16264989	L-Tyrosine	Haura EB	Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer.	Nature clinical practice. Oncology	2005	109
16278491	L-Tyrosine	Basso AD	Lipid posttranslational modifications. Farnesyl transferase inhibitors.	Journal of lipid research	2006	77
16288224	L-Tyrosine	Natarajan M	HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells.	Oncogene	2006	69
16288292	L-Tyrosine	Altomare DA	Perturbations of the AKT signaling pathway in human cancer.	Oncogene	2005	342
16288295	L-Tyrosine	Cheng JQ	The Akt/PKB pathway: molecular target for cancer drug discovery.	Oncogene	2005	127
16299810	L-Tyrosine	Hanada N	Co-regulation of B-Myb expression by E2F1 and EGF receptor.	Molecular carcinogenesis	2006	62
16314522	L-Tyrosine	Giri DK	Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor.	Molecular and cellular biology	2005	80
16336962	L-Tyrosine	Shibuya M	Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis.	Experimental cell research	2006	233
16377102	L-Tyrosine	Normanno N	Epidermal growth factor receptor (EGFR) signaling in cancer.	Gene	2006	383
16407877	L-Tyrosine	Jain RK	Lessons from phase III clinical trials on anti-VEGF therapy for cancer.	Nature clinical practice. Oncology	2006	267
16413489	L-Tyrosine	Foo SS	Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly.	Cell	2006	145
16434982	L-Tyrosine	Lo HW	Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival.	British journal of cancer	2006	94
16452206	L-Tyrosine	O'Reilly KE	mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.	Cancer research	2006	806
16452222	L-Tyrosine	Konecny GE	Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.	Cancer research	2006	223
16452232	L-Tyrosine	Burgess T	Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.	Cancer research	2006	67
16467097	L-Tyrosine	Riely GJ	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2006	181
16467847	L-Tyrosine	Husebye H	Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity.	The EMBO journal	2006	128
16489012	L-Tyrosine	Sato M	Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.	Cancer research	2006	124
16493428	L-Tyrosine	Koretzky GA	SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond.	Nature reviews. Immunology	2006	81
16503733	L-Tyrosine	Leeman RJ	STAT3 as a therapeutic target in head and neck cancer.	Expert opinion on biological therapy	2006	77
16507829	L-Tyrosine	Carlomagno F	BAY 43-9006 inhibition of oncogenic RET mutants.	Journal of the National Cancer Institute	2006	94
16507911	L-Tyrosine	Trevino JG	Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.	The American journal of pathology	2006	71
16522812	L-Tyrosine	Hughes T	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.	Blood	2006	187
16540667	L-Tyrosine	Alvarez JV	Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.	Cancer research	2006	66
16540671	L-Tyrosine	Pore N	EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.	Cancer research	2006	67
16551858	L-Tyrosine	Wardelmann E	Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.	Clinical cancer research 	2006	62
16552725	L-Tyrosine	Lo HW	Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1.	Journal of cellular biochemistry	2006	93
16557282	L-Tyrosine	Ostman A	Protein-tyrosine phosphatases and cancer.	Nature reviews. Cancer	2006	173
16585185	L-Tyrosine	Orth JD	A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization.	Cancer research	2006	85
16585512	L-Tyrosine	Vajkoczy P	Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.	Proceedings of the National Academy of Sciences of the United States of America	2006	76
16618748	L-Tyrosine	Nakamura K	Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells.	Cancer research	2006	67
16631753	L-Tyrosine	Roy H	Biology of vascular endothelial growth factors.	FEBS letters	2006	89
16648858	L-Tyrosine	Ferby I	Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.	Nature medicine	2006	95
16651418	L-Tyrosine	Cabodi S	p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.	Cancer research	2006	65
16682498	L-Tyrosine	Meresse B	Reprogramming of CTLs into natural killer-like cells in celiac disease.	The Journal of experimental medicine	2006	68
16682621	L-Tyrosine	Xin L	Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor.	Proceedings of the National Academy of Sciences of the United States of America	2006	60
16683005	L-Tyrosine	Nahta R	Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.	Nature clinical practice. Oncology	2006	233
16731741	L-Tyrosine	Ellis LM	The role of neuropilins in cancer.	Molecular cancer therapeutics	2006	73
16737840	L-Tyrosine	Hafizi S	Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases.	Cytokine & growth factor reviews	2006	83
16738850	L-Tyrosine	Roovers RC	Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.	Cancer immunology, immunotherapy 	2007	58
16740687	L-Tyrosine	Song L	Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.	Cancer research	2006	79
16740702	L-Tyrosine	Srinivasan D	Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells.	Cancer research	2006	86
16740718	L-Tyrosine	Tokarski JS	The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.	Cancer research	2006	102
16775234	L-Tyrosine	Talpaz M	Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.	The New England journal of medicine	2006	367
16778093	L-Tyrosine	Peruzzi B	Targeting the c-Met signaling pathway in cancer.	Clinical cancer research 	2006	108
16778220	L-Tyrosine	Naresh A	The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.	Cancer research	2006	76
16835231	L-Tyrosine	Seidler DG	Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation.	The Journal of biological chemistry	2006	67
16843263	L-Tyrosine	Wang SE	HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.	Cancer cell	2006	140
16857985	L-Tyrosine	Knapper S	A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.	Blood	2006	103
16859511	L-Tyrosine	Galliher AJ	Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells.	Breast cancer research 	2006	104
16890796	L-Tyrosine	Faivre S	New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.	Seminars in oncology	2006	61
16908937	L-Tyrosine	Abou-Alfa GK	Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.	Journal of clinical oncology 	2006	269
16959784	L-Tyrosine	Misra S	Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells.	The Journal of biological chemistry	2006	60
17043651	L-Tyrosine	Iwamaru A	A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.	Oncogene	2007	101
17045208	L-Tyrosine	Guo Z	Regulation of androgen receptor activity by tyrosine phosphorylation.	Cancer cell	2006	149
17047074	L-Tyrosine	Morgillo F	Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.	Cancer research	2006	104
17053061	L-Tyrosine	Chan RJ	PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.	Blood	2007	85
17057753	L-Tyrosine	Tonks NK	Protein tyrosine phosphatases: from genes, to function, to disease.	Nature reviews. Molecular cell biology	2006	464
17060635	L-Tyrosine	Zhao JJ	The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation.	Proceedings of the National Academy of Sciences of the United States of America	2006	80
17084981	L-Tyrosine	Hehlgans S	Signalling via integrins: implications for cell survival and anticancer strategies.	Biochimica et biophysica acta	2007	105
17085050	L-Tyrosine	Linggi B	ErbB receptors: new insights on mechanisms and biology.	Trends in cell biology	2006	116
17090188	L-Tyrosine	Miettinen M	Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.	Archives of pathology & laboratory medicine	2006	282
17090670	L-Tyrosine	Horvath S	Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target.	Proceedings of the National Academy of Sciences of the United States of America	2006	215
17096862	L-Tyrosine	Nahta R	HER2 therapy: molecular mechanisms of trastuzumab resistance.	Breast cancer research 	2006	127
17098419	L-Tyrosine	Eskens FA	The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.	European journal of cancer	2006	74
17114005	L-Tyrosine	Schust J	Stattic: a small-molecule inhibitor of STAT3 activation and dimerization.	Chemistry & biology	2006	241
17115032	L-Tyrosine	Wang SC	Tyrosine phosphorylation controls PCNA function through protein stability.	Nature cell biology	2006	110
17124058	L-Tyrosine	Small D	FLT3 mutations: biology and treatment.	Hematology. American Society of Hematology. Education Program	2006	64
17175059	L-Tyrosine	Luppi F	Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.	Lung cancer	2007	62
17177598	L-Tyrosine	Lee JC	Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.	PLoS medicine	2006	96
17178882	L-Tyrosine	Liu L	Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.	Cancer research	2006	298
17183644	L-Tyrosine	Zaleskas VM	Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.	PloS one	2006	76
17189395	L-Tyrosine	Ono M	Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.	Clinical cancer research 	2006	81
17192538	L-Tyrosine	Geyer CE	Lapatinib plus capecitabine for HER2-positive advanced breast cancer.	The New England journal of medicine	2006	629
17219439	L-Tyrosine	Shi Q	A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.	Molecular carcinogenesis	2007	61
17227708	L-Tyrosine	Mohi MG	The role of Shp2 (PTPN11) in cancer.	Current opinion in genetics & development	2007	72
17229773	L-Tyrosine	Valabrega G	Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.	Annals of oncology 	2007	120
17254967	L-Tyrosine	Chu I	p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2.	Cell	2007	125
17259557	L-Tyrosine	Riedemann J	IGF1R signalling and its inhibition.	Endocrine-related cancer	2006	72
17290066	L-Tyrosine	Subramanian J	Lung cancer in never smokers: a review.	Journal of clinical oncology 	2007	153
17290067	L-Tyrosine	Sequist LV	Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.	Journal of clinical oncology 	2007	156
17295177	L-Tyrosine	Villanueva A	Genomics and signaling pathways in hepatocellular carcinoma.	Seminars in liver disease	2007	156
17304354	L-Tyrosine	Piccaluga PP	Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets.	The Journal of clinical investigation	2007	72
17308108	L-Tyrosine	Sawada K	c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.	Cancer research	2007	92
17314037	L-Tyrosine	Bublil EM	The EGF receptor family: spearheading a merger of signaling and therapeutics.	Current opinion in cell biology	2007	114
17317726	L-Tyrosine	Thamilselvan V	FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway.	FASEB journal 	2007	60
17318191	L-Tyrosine	Coluccia AM	Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.	The EMBO journal	2007	71
17322912	L-Tyrosine	Peschard P	From Tpr-Met to Met, tumorigenesis and tubes.	Oncogene	2007	61
17324579	L-Tyrosine	Roskoski R Jr	Vascular endothelial growth factor (VEGF) signaling in tumor progression.	Critical reviews in oncology/hematology	2007	119
17325667	L-Tyrosine	Mahadevan D	A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors.	Oncogene	2007	77
17332337	L-Tyrosine	Lutterbach B	Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.	Cancer research	2007	95
17355866	L-Tyrosine	Seeliger MA	c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.	Structure	2007	62
17360477	L-Tyrosine	Zhang X	Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T.	Proceedings of the National Academy of Sciences of the United States of America	2007	61
17363602	L-Tyrosine	Shor AC	Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.	Cancer research	2007	82
17376775	L-Tyrosine	Forrester MT	Assessment and application of the biotin switch technique for examining protein S-nitrosylation under conditions of pharmacologically induced oxidative stress.	The Journal of biological chemistry	2007	87
17426060	L-Tyrosine	Fizazi K	The role of Src in prostate cancer.	Annals of oncology 	2007	60
17431114	L-Tyrosine	Liu TJ	Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.	Molecular cancer therapeutics	2007	59
17435539	L-Tyrosine	DeMatteo RP	Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor.	Annals of surgery	2007	61
17440062	L-Tyrosine	Balakrishnan A	Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma.	Cancer research	2007	58
17440088	L-Tyrosine	Galliher AJ	Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.	Cancer research	2007	98
17440164	L-Tyrosine	Scaltriti M	Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.	Journal of the National Cancer Institute	2007	179
17446858	L-Tyrosine	Ursini-Siegel J	Insights from transgenic mouse models of ERBB2-induced breast cancer.	Nature reviews. Cancer	2007	97
17470685	L-Tyrosine	Strumberg D	Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.	The oncologist	2007	97
17473213	L-Tyrosine	Morgillo F	Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.	Clinical cancer research 	2007	82
17483331	L-Tyrosine	Ostrander JH	Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.	Cancer research	2007	62
17496911	L-Tyrosine	Goldsmith ZG	G protein regulation of MAPK networks.	Oncogene	2007	87
17517630	L-Tyrosine	Qian X	Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.	Proceedings of the National Academy of Sciences of the United States of America	2007	56
17519389	L-Tyrosine	Amin HM	Pathobiology of ALK+ anaplastic large-cell lymphoma.	Blood	2007	65
17529973	L-Tyrosine	Hunter DJ	A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer.	Nature genetics	2007	668
17530017	L-Tyrosine	Nahta R	Trastuzumab: triumphs and tribulations.	Oncogene	2007	82
17531096	L-Tyrosine	Berishaj M	Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer.	Breast cancer research 	2007	93
17541402	L-Tyrosine	Pardanani A	TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.	Leukemia	2007	71
17551144	L-Tyrosine	Taguchi F	Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.	Journal of the National Cancer Institute	2007	70
17558857	L-Tyrosine	Guarino M	The role of epithelial-mesenchymal transition in cancer pathology.	Pathology	2007	233
17574121	L-Tyrosine	Kuijper S	Regulation of angiogenesis by Eph-ephrin interactions.	Trends in cardiovascular medicine	2007	80
17606725	L-Tyrosine	Wacker B	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.	Clinical cancer research 	2007	88
17615536	L-Tyrosine	Rocha-Lima CM	EGFR targeting of solid tumors.	Cancer control 	2007	58
17620423	L-Tyrosine	Omuro AM	Lessons learned in the development of targeted therapy for malignant gliomas.	Molecular cancer therapeutics	2007	61
17623837	L-Tyrosine	Thomas MB	Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.	Cancer	2007	71
17625570	L-Tyrosine	Soda M	Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.	Nature	2007	1116
17644065	L-Tyrosine	Ling Y	Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells.	Biochemical and biophysical research communications	2007	58
17646646	L-Tyrosine	Huang PH	Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2007	149
17647198	L-Tyrosine	Chong ZZ	The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.	Histology and histopathology	2007	80
17667967	L-Tyrosine	Pasini B	Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.	European journal of human genetics 	2008	87
17681753	L-Tyrosine	Zandi R	Mechanisms for oncogenic activation of the epidermal growth factor receptor.	Cellular signalling	2007	63
17699871	L-Tyrosine	Ritter CA	Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.	Clinical cancer research 	2007	172
17715389	L-Tyrosine	Kantarjian HM	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.	Blood	2007	138
17721432	L-Tyrosine	Levine RL	Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.	Nature reviews. Cancer	2007	141
17785413	L-Tyrosine	Tward AD	Distinct pathways of genomic progression to benign and malignant tumors of the liver.	Proceedings of the National Academy of Sciences of the United States of America	2007	71
17785585	L-Tyrosine	Cortes J	Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.	Blood	2007	60
17827454	L-Tyrosine	Harari PM	Biology of interactions: antiepidermal growth factor receptor agents.	Journal of clinical oncology 	2007	58
17855663	L-Tyrosine	Pathak AK	Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells.	Molecular cancer research 	2007	56
17888036	L-Tyrosine	Mitsudomi T	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.	Cancer science	2007	129
17894407	L-Tyrosine	De Luca A	The role of the EGFR signaling in tumor microenvironment.	Journal of cellular physiology	2008	96
17906625	L-Tyrosine	Cortina C	EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells.	Nature genetics	2007	85
17909916	L-Tyrosine	Shah AN	Development and characterization of gemcitabine-resistant pancreatic tumor cells.	Annals of surgical oncology	2007	152
17918158	L-Tyrosine	Patel BB	Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R.	International journal of cancer	2008	51
17927446	L-Tyrosine	Gong Y	Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.	PLoS medicine	2007	118
17934481	L-Tyrosine	Baker SJ	Hematopoietic cytokine receptor signaling.	Oncogene	2007	70
17943726	L-Tyrosine	Matsui J	E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.	International journal of cancer	2008	54
17962511	L-Tyrosine	Schade AE	Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.	Blood	2008	54
17965322	L-Tyrosine	Bacher U	Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.	Blood	2008	50
17981673	L-Tyrosine	Bhola NE	Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer.	Frontiers in bioscience 	2008	54
17999740	L-Tyrosine	Sibilia M	The epidermal growth factor receptor: from development to tumorigenesis.	Differentiation; research in biological diversity	2007	90
18056992	L-Tyrosine	Sidera K	A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2.	The Journal of biological chemistry	2008	53
18060032	L-Tyrosine	Gao SP	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.	The Journal of clinical investigation	2007	209
18076015	L-Tyrosine	Dematteo RP	Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).	Cancer	2008	105
18079969	L-Tyrosine	Brantley-Sieders DM	The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.	The Journal of clinical investigation	2008	95
18083107	L-Tyrosine	Rikova K	Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.	Cell	2007	634
18089823	L-Tyrosine	Engelman JA	PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.	Cancer research	2007	177
18092308	L-Tyrosine	Xiao Z	Cell-specific internalization study of an aptamer from whole cell selection.	Chemistry	2008	66
18097461	L-Tyrosine	Chiarle R	The anaplastic lymphoma kinase in the pathogenesis of cancer.	Nature reviews. Cancer	2008	182
18172262	L-Tyrosine	Hutterer M	Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme.	Clinical cancer research 	2008	79
18180459	L-Tyrosine	Guo A	Signaling networks assembled by oncogenic EGFR and c-Met.	Proceedings of the National Academy of Sciences of the United States of America	2008	188
18192401	L-Tyrosine	Ohnishi N	Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse.	Proceedings of the National Academy of Sciences of the United States of America	2008	172
18198190	L-Tyrosine	Fang WB	Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism.	Journal of cell science	2008	55
18200041	L-Tyrosine	Pedersen-Bjergaard J	Genetics of therapy-related myelodysplasia and acute myeloid leukemia.	Leukemia	2008	55
18211286	L-Tyrosine	Vazquez-Martin A	Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.	Cell proliferation	2008	59
18219225	L-Tyrosine	Flaherty KT	Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.	Cancer biology & therapy	2008	50
18223214	L-Tyrosine	Baskar S	Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.	Clinical cancer research 	2008	67
18223323	L-Tyrosine	Espinosa I	A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors.	The American journal of surgical pathology	2008	86
18224294	L-Tyrosine	Bessette DC	PRL PTPs: mediators and markers of cancer progression.	Cancer metastasis reviews	2008	63
18228120	L-Tyrosine	Wagner KU	Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression.	Journal of mammary gland biology and neoplasia	2008	57
18230792	L-Tyrosine	Zhang W	Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.	Journal of the National Cancer Institute	2008	109
18236164	L-Tyrosine	Barr S	Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.	Clinical & experimental metastasis	2008	73
18270328	L-Tyrosine	Tomasson MH	Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.	Blood	2008	69
18271917	L-Tyrosine	Higashiyama S	Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands.	Cancer science	2008	64
18281274	L-Tyrosine	Zabolotny JM	Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo.	The Journal of biological chemistry	2008	91
18286234	L-Tyrosine	Chan G	The tyrosine phosphatase Shp2 (PTPN11) in cancer.	Cancer metastasis reviews	2008	118
18288131	L-Tyrosine	Renneville A	Cooperating gene mutations in acute myeloid leukemia: a review of the literature.	Leukemia	2008	62
18291115	L-Tyrosine	Lafky JM	Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.	Biochimica et biophysica acta	2008	78
18297114	L-Tyrosine	Wheeler DL	Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.	Oncogene	2008	168
18303429	L-Tyrosine	Marks JL	Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.	Journal of thoracic oncology 	2008	75
18308254	L-Tyrosine	Bussink J	Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer.	The Lancet. Oncology	2008	84
18312355	L-Tyrosine	Lasota J	Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.	Histopathology	2008	74
18316611	L-Tyrosine	Shattuck DL	Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.	Cancer research	2008	119
18337815	L-Tyrosine	Christofk HR	Pyruvate kinase M2 is a phosphotyrosine-binding protein.	Nature	2008	289
18339872	L-Tyrosine	Zhang YX	AXL is a potential target for therapeutic intervention in breast cancer progression.	Cancer research	2008	69
18347068	L-Tyrosine	Goetz JG	Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine-phosphorylated caveolin-1.	The Journal of cell biology	2008	56
18362333	L-Tyrosine	Diehn M	Identification of noninvasive imaging surrogates for brain tumor gene-expression modules.	Proceedings of the National Academy of Sciences of the United States of America	2008	102
18374420	L-Tyrosine	Nakahata N	Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology.	Pharmacology & therapeutics	2008	66
18395971	L-Tyrosine	Zeng ZS	c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases.	Cancer letters	2008	55
18404164	L-Tyrosine	Sithanandam G	The ERBB3 receptor in cancer and cancer gene therapy.	Cancer gene therapy	2008	64
18413800	L-Tyrosine	Godin-Heymann N	The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.	Molecular cancer therapeutics	2008	60
18425119	L-Tyrosine	Saharinen P	Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts.	Nature cell biology	2008	125
18430438	L-Tyrosine	Fuller SJ	ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.	Journal of molecular and cellular cardiology	2008	51
18431473	L-Tyrosine	Curtin JF	Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.	PloS one	2008	51
18437168	L-Tyrosine	Ladanyi M	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.	Modern pathology 	2008	80
18450602	L-Tyrosine	Schlenk RF	Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.	The New England journal of medicine	2008	334
18450603	L-Tyrosine	Marcucci G	MicroRNA expression in cytogenetically normal acute myeloid leukemia.	The New England journal of medicine	2008	149
18451159	L-Tyrosine	Park SI	Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.	Cancer research	2008	103
18451166	L-Tyrosine	McDermott U	Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.	Cancer research	2008	124
18454307	L-Tyrosine	Sundvall M	Role of ErbB4 in breast cancer.	Journal of mammary gland biology and neoplasia	2008	50
18465356	L-Tyrosine	Frasca F	The role of insulin receptors and IGF-I receptors in cancer and other diseases.	Archives of physiology and biochemistry	2008	89
18469855	L-Tyrosine	Osipo C	ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.	Oncogene	2008	62
18477770	L-Tyrosine	Porkka K	Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.	Blood	2008	64
18483213	L-Tyrosine	Abdulghani J	Stat3 promotes metastatic progression of prostate cancer.	The American journal of pathology	2008	75
18483355	L-Tyrosine	Engelman JA	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.	Clinical cancer research 	2008	204
18483389	L-Tyrosine	Agaram NP	Molecular characterization of pediatric gastrointestinal stromal tumors.	Clinical cancer research 	2008	58
18487549	L-Tyrosine	Finn RS	Targeting Src in breast cancer.	Annals of oncology 	2008	62
18492751	L-Tyrosine	Liu Z	Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.	The Journal of clinical endocrinology and metabolism	2008	109
18508251	L-Tyrosine	Curiel TJ	Regulatory T cells and treatment of cancer.	Current opinion in immunology	2008	68
18508592	L-Tyrosine	Buxade M	The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases).	Frontiers in bioscience 	2008	51
18519975	L-Tyrosine	Achen MG	Molecular control of lymphatic metastasis.	Annals of the New York Academy of Sciences	2008	55
18533085	L-Tyrosine	Perez EA	Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.	Mayo Clinic proceedings	2008	51
18541900	L-Tyrosine	Shah NP	Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.	Journal of clinical oncology 	2008	111
18546292	L-Tyrosine	Daneshmanesh AH	Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.	International journal of cancer	2008	55
18559524	L-Tyrosine	Hilberg F	BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.	Cancer research	2008	140
18559874	L-Tyrosine	Paschka P	Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.	Journal of clinical oncology 	2008	63
18562239	L-Tyrosine	Ramos JW	The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells.	The international journal of biochemistry & cell biology	2008	144
18568074	L-Tyrosine	Guix M	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.	The Journal of clinical investigation	2008	177
18593892	L-Tyrosine	Choi YL	Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.	Cancer research	2008	112
18599154	L-Tyrosine	Rho JK	Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.	Lung cancer	2009	64
18612155	L-Tyrosine	Kulke MH	Activity of sunitinib in patients with advanced neuroendocrine tumors.	Journal of clinical oncology 	2008	114
18620091	L-Tyrosine	Wagh PK	Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.	Advances in cancer research	2008	58
18676737	L-Tyrosine	Brantley EC	Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression.	Clinical cancer research 	2008	57
18676839	L-Tyrosine	Ambs S	Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer.	Cancer research	2008	256
18684881	L-Tyrosine	Metcalfe DD	Mast cells and mastocytosis.	Blood	2008	88
18696232	L-Tyrosine	Thomson S	Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.	Clinical & experimental metastasis	2008	73
18713470	L-Tyrosine	Stefanini MO	A compartment model of VEGF distribution in blood, healthy and diseased tissues.	BMC systems biology	2008	52
18718806	L-Tyrosine	Sabbah M	Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.	Drug resistance updates 	2008	99
18724359	L-Tyrosine	Moss√© YP	Identification of ALK as a major familial neuroblastoma predisposition gene.	Nature	2008	283
18772882	L-Tyrosine	Lehembre F	NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin.	The EMBO journal	2008	53
18779404	L-Tyrosine	Levine RL	Myeloproliferative disorders.	Blood	2008	97
18782861	L-Tyrosine	Tao RH	All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells.	Journal of cell science	2008	70
18794884	L-Tyrosine	Yuan TL	PI3K pathway alterations in cancer: variations on a theme.	Oncogene	2008	549
18800267	L-Tyrosine	Burgess AW	EGFR family: structure physiology signalling and therapeutic targets.	Growth factors	2008	73
18803986	L-Tyrosine	Medina PJ	Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.	Clinical therapeutics	2008	68
18804418	L-Tyrosine	Linardou H	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.	The Lancet. Oncology	2008	195
18818206	L-Tyrosine	Nasser MW	Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.	The Journal of biological chemistry	2008	137
18829493	L-Tyrosine	Huynh H	Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.	Clinical cancer research 	2008	59
18836087	L-Tyrosine	Cappuzzo F	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.	Annals of oncology 	2009	90
18840713	L-Tyrosine	Kornblau SM	Functional proteomic profiling of AML predicts response and survival.	Blood	2009	96
18851712	L-Tyrosine	Sirvent A	Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells.	Biology of the cell	2008	52
18852116	L-Tyrosine	Wilhelm SM	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.	Molecular cancer therapeutics	2008	297
18922892	L-Tyrosine	Joshi B	Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion.	Cancer research	2008	77
18922965	L-Tyrosine	Boutros T	Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer.	Pharmacological reviews	2008	142
18923523	L-Tyrosine	Janoueix-Lerosey I	Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.	Nature	2008	230
18927285	L-Tyrosine	Fichtner I	Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.	Clinical cancer research 	2008	93
18927303	L-Tyrosine	Takeuchi K	Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.	Clinical cancer research 	2008	121
18927310	L-Tyrosine	Finke JH	Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients.	Clinical cancer research 	2008	126
18955454	L-Tyrosine	Di Leo A	Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.	Journal of clinical oncology 	2008	92
18990089	L-Tyrosine	Car√©n H	High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.	The Biochemical journal	2008	66
19010843	L-Tyrosine	Hu-Lowe DD	Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.	Clinical cancer research 	2008	116
19010894	L-Tyrosine	Eichhorn PJ	Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.	Cancer research	2008	148
19010912	L-Tyrosine	Pratilas CA	Genetic predictors of MEK dependence in non-small cell lung cancer.	Cancer research	2008	89
19010923	L-Tyrosine	Yano S	Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.	Cancer research	2008	181
19011564	L-Tyrosine	Liegl B	Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes.	The American journal of surgical pathology	2009	46
19013279	L-Tyrosine	Xu C	Regulation of T cell receptor activation by dynamic membrane binding of the CD3epsilon cytoplasmic tyrosine-based motif.	Cell	2008	143
19032370	L-Tyrosine	Mano H	Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.	Cancer science	2008	54
19034632	L-Tyrosine	Jin Q	Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.	Journal of mammary gland biology and neoplasia	2008	51
19039322	L-Tyrosine	Remsing Rix LL	Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.	Leukemia	2009	63
19060928	L-Tyrosine	Scaltriti M	Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.	Oncogene	2009	116
19064915	L-Tyrosine	Soda M	A mouse model for EML4-ALK-positive lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2008	131
19074825	L-Tyrosine	Wykosky J	The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.	Molecular cancer research 	2008	98
19074879	L-Tyrosine	Migliore C	MicroRNAs impair MET-mediated invasive growth.	Cancer research	2008	63
19088172	L-Tyrosine	Gow CH	Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.	Annals of oncology 	2009	49
19098899	L-Tyrosine	Du J	Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.	Nature biotechnology	2009	87
19118495	L-Tyrosine	Sahin O	Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance.	BMC systems biology	2009	54
19135109	L-Tyrosine	Robey RW	ABCG2: a perspective.	Advanced drug delivery reviews	2009	86
19136975	L-Tyrosine	Scott SA	Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.	Nature chemical biology	2009	110
19157632	L-Tyrosine	Kim JE	Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.	Lung cancer	2009	48
19164557	L-Tyrosine	Gajiwala KS	KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.	Proceedings of the National Academy of Sciences of the United States of America	2009	75
19169797	L-Tyrosine	Zhao J	Signal transduction by focal adhesion kinase in cancer.	Cancer metastasis reviews	2009	187
19182515	L-Tyrosine	Acevedo VD	Paths of FGFR-driven tumorigenesis.	Cell cycle	2009	48
19208461	L-Tyrosine	Hynes NE	ErbB receptors and signaling pathways in cancer.	Current opinion in cell biology	2009	248
19217204	L-Tyrosine	Montagut C	Targeting the RAF-MEK-ERK pathway in cancer therapy.	Cancer letters	2009	114
19223473	L-Tyrosine	Yuan HT	Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium.	Molecular and cellular biology	2009	92
19234440	L-Tyrosine	Inamura K	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	Modern pathology 	2009	107
19238210	L-Tyrosine	Gandhi J	Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.	PloS one	2009	75
19238633	L-Tyrosine	Kalikaki A	Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.	British journal of cancer	2008	50
19276259	L-Tyrosine	Yung TK	Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.	Clinical cancer research 	2009	109
19276286	L-Tyrosine	Ko JS	Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.	Clinical cancer research 	2009	243
19276373	L-Tyrosine	Iorio MV	microRNA-205 regulates HER3 in human breast cancer.	Cancer research	2009	114
19276677	L-Tyrosine	Wheeler DL	Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.	Cancer biology & therapy	2009	57
19287384	L-Tyrosine	Kilpivaara O	A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.	Nature genetics	2009	92
19295545	L-Tyrosine	Mustjoki S	Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.	Leukemia	2009	64
19318484	L-Tyrosine	Wong KK	A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.	Clinical cancer research 	2009	56
19318488	L-Tyrosine	Eder JP	Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.	Clinical cancer research 	2009	143
19346236	L-Tyrosine	Song X	Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks.	Human molecular genetics	2009	57
19346299	L-Tyrosine	Ross JS	The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.	The oncologist	2009	218
19359243	L-Tyrosine	Masuyama N	HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin.	The Journal of biological chemistry	2009	80
19364815	L-Tyrosine	Pedersen K	A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis.	Molecular and cellular biology	2009	47
19383809	L-Tyrosine	Takeuchi K	KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.	Clinical cancer research 	2009	167
19389879	L-Tyrosine	Metzelder S	Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.	Blood	2009	67
19411631	L-Tyrosine	Salvucci O	EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures.	Blood	2009	47
19412429	L-Tyrosine	Pillay V	The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.	Neoplasia	2009	50
19426560	L-Tyrosine	Birge RB	Crk and CrkL adaptor proteins: networks for physiological and pathological signaling.	Cell communication and signaling 	2009	77
19435801	L-Tyrosine	Tomar A	A FAK-p120RasGAP-p190RhoGAP complex regulates polarity in migrating cells.	Journal of cell science	2009	54
19459784	L-Tyrosine	Palmer RH	Anaplastic lymphoma kinase: signalling in development and disease.	The Biochemical journal	2009	109
19470474	L-Tyrosine	Mullighan CG	JAK mutations in high-risk childhood acute lymphoblastic leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2009	161
19470923	L-Tyrosine	Zhu AX	Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.	Journal of clinical oncology 	2009	143
19478061	L-Tyrosine	Veeriah S	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.	Proceedings of the National Academy of Sciences of the United States of America	2009	83
19483681	L-Tyrosine	Rapley EA	A genome-wide association study of testicular germ cell tumor.	Nature genetics	2009	108
19483740	L-Tyrosine	Linardou H	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.	Nature reviews. Clinical oncology	2009	59
19522824	L-Tyrosine	Stratakis CA	The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications.	Journal of internal medicine	2009	57
19536107	L-Tyrosine	Baselga J	Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.	Nature reviews. Cancer	2009	333
19549778	L-Tyrosine	Meshinchi S	Structural and functional alterations of FLT3 in acute myeloid leukemia.	Clinical cancer research 	2009	55
19556245	L-Tyrosine	Patel A	On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex.	The Journal of biological chemistry	2009	61
19561643	L-Tyrosine	Enomoto M	Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling.	Oncogene	2009	50
19581523	L-Tyrosine	Wheeler DL	The role of Src in solid tumors.	The oncologist	2009	80
19584155	L-Tyrosine	Schmid K	EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.	Clinical cancer research 	2009	74
19595306	L-Tyrosine	Jiang BH	PI3K/PTEN signaling in angiogenesis and tumorigenesis.	Advances in cancer research	2009	123
19597153	L-Tyrosine	Seike M	MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers.	Proceedings of the National Academy of Sciences of the United States of America	2009	160
19602710	L-Tyrosine	Kayser S	Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.	Blood	2009	47
19617568	L-Tyrosine	Ponzo MG	Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2009	82
19620627	L-Tyrosine	Trageser D	Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function.	The Journal of experimental medicine	2009	50
19620785	L-Tyrosine	Taulli R	The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.	The Journal of clinical investigation	2009	103
19633047	L-Tyrosine	Kataoka Y	Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.	Annals of oncology 	2010	61
19638581	L-Tyrosine	Faratian D	Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.	Cancer research	2009	49
19648052	L-Tyrosine	Broxterman HJ	Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib.	Drug resistance updates 	2009	59
19648928	L-Tyrosine	Lim E	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.	Nature medicine	2009	480
19652056	L-Tyrosine	Hughes T	Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.	Journal of clinical oncology 	2009	72
19654296	L-Tyrosine	Carter H	Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations.	Cancer research	2009	152
19654408	L-Tyrosine	Zarrinkar PP	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Blood	2009	128
19671734	L-Tyrosine	Mitra D	An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.	Molecular cancer therapeutics	2009	50
19671843	L-Tyrosine	Jackman DM	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.	Clinical cancer research 	2009	116
19680294	L-Tyrosine	Hirsch FR	Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.	Oncogene	2009	59
19684613	L-Tyrosine	Li C	Nuclear EGFR contributes to acquired resistance to cetuximab.	Oncogene	2009	96
19692684	L-Tyrosine	Rosell R	Screening for epidermal growth factor receptor mutations in lung cancer.	The New England journal of medicine	2009	495
19718025	L-Tyrosine	Prickett TD	Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.	Nature genetics	2009	131
19723038	L-Tyrosine	Aggarwal BB	Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?.	Annals of the New York Academy of Sciences	2009	189
19737224	L-Tyrosine	Martinelli E	Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.	Clinical and experimental immunology	2009	48
19754359	L-Tyrosine	van der Veeken J	Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.	Current cancer drug targets	2009	61
19758803	L-Tyrosine	Lai AZ	Crosstalk in Met receptor oncogenesis.	Trends in cell biology	2009	68
19759520	L-Tyrosine	Regales L	Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.	The Journal of clinical investigation	2009	119
19768731	L-Tyrosine	Haller F	Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31.	The Journal of pathology	2010	50
19770381	L-Tyrosine	Martinelli G	IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.	Journal of clinical oncology 	2009	68
19773371	L-Tyrosine	Hoftijzer H	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.	European journal of endocrinology	2009	49
19785662	L-Tyrosine	Hegedus C	Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.	British journal of pharmacology	2009	48
19786658	L-Tyrosine	Johnston S	Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.	Journal of clinical oncology 	2009	201
19787002	L-Tyrosine	Kim LC	Src kinases as therapeutic targets for cancer.	Nature reviews. Clinical oncology	2009	232
19789626	L-Tyrosine	Dubreuil P	Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.	PloS one	2009	59
19798427	L-Tyrosine	Oldani A	Helicobacter pylori counteracts the apoptotic action of its VacA toxin by injecting the CagA protein into gastric epithelial cells.	PLoS pathogens	2009	52
19802008	L-Tyrosine	O'Connell MP	The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma.	Oncogene	2010	74
19805051	L-Tyrosine	Sos ML	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.	Proceedings of the National Academy of Sciences of the United States of America	2009	92
19808698	L-Tyrosine	Yoshimoto G	FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.	Blood	2009	46
19808973	L-Tyrosine	Qian F	Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.	Cancer research	2009	73
19809159	L-Tyrosine	Taylor JG 6th	Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.	The Journal of clinical investigation	2009	81
19826113	L-Tyrosine	Matulonis UA	Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.	Journal of clinical oncology 	2009	58
19828702	L-Tyrosine	Wang Y	Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.	Blood	2009	50
19843665	L-Tyrosine	Wang W	Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.	Clinical cancer research 	2009	69
19850869	L-Tyrosine	Faber AC	Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2009	137
19861462	L-Tyrosine	Wang SC	Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors.	Clinical cancer research 	2009	68
19884552	L-Tyrosine	Spector NL	Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2009	115
19887545	L-Tyrosine	Hirai H	Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.	Molecular cancer therapeutics	2009	103
19901108	L-Tyrosine	Makishima H	Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.	Journal of clinical oncology 	2009	61
19922469	L-Tyrosine	Mitsudomi T	Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.	The FEBS journal	2010	111
19934298	L-Tyrosine	Wells SA Jr	Targeting the RET pathway in thyroid cancer.	Clinical cancer research 	2009	47
19949011	L-Tyrosine	Jackman D	Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.	Journal of clinical oncology 	2010	178
19960228	L-Tyrosine	Peereboom DM	Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.	Journal of neuro-oncology	2010	59
19965662	L-Tyrosine	Friedberg JW	Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.	Blood	2010	203
20007921	L-Tyrosine	Albini A	Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.	Journal of the National Cancer Institute	2010	104
20008298	L-Tyrosine	Santos FP	Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.	Blood	2010	63
20018914	L-Tyrosine	Ghosh AK	Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression.	Blood	2010	64
20022659	L-Tyrosine	Mao C	KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.	Lung cancer	2010	81
20027191	L-Tyrosine	Esteva FJ	Molecular predictors of response to trastuzumab and lapatinib in breast cancer.	Nature reviews. Clinical oncology	2010	52
20027224	L-Tyrosine	Hinoue T	Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling.	PloS one	2009	54
20028749	L-Tyrosine	Dahabreh IJ	Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.	Clinical cancer research 	2010	46
20028874	L-Tyrosine	Zhuang G	Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy.	Cancer research	2010	63
20030624	L-Tyrosine	Lo HW	EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.	Current molecular pharmacology	2010	42
20031486	L-Tyrosine	Liu X	Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.	Trends in molecular medicine	2010	48
20038814	L-Tyrosine	Ma J	Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade.	The Journal of clinical investigation	2010	76
20049846	L-Tyrosine	Guarino M	Src signaling in cancer invasion.	Journal of cellular physiology	2010	131
20054396	L-Tyrosine	Davis RE	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.	Nature	2010	344
20064507	L-Tyrosine	Kruser TJ	Mechanisms of resistance to HER family targeting antibodies.	Experimental cell research	2010	51
20067773	L-Tyrosine	Zhang X	A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes.	Biochemical pharmacology	2010	52
20068094	L-Tyrosine	Manara MC	NVP-BEZ235 as a new therapeutic option for sarcomas.	Clinical cancer research 	2010	55
20068149	L-Tyrosine	Novosyadlyy R	Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.	Cancer research	2010	96
20072130	L-Tyrosine	Janes MR	Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.	Nature medicine	2010	137
20072652	L-Tyrosine	Lin L	A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.	Neoplasia	2010	54
20080645	L-Tyrosine	Gjerdrum C	Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival.	Proceedings of the National Academy of Sciences of the United States of America	2010	152
20081860	L-Tyrosine	Morin RD	Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.	Nature genetics	2010	394
20101214	L-Tyrosine	Gustafson WC	Myc proteins as therapeutic targets.	Oncogene	2010	59
20103629	L-Tyrosine	Huang D	Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.	Cancer research	2010	63
20108024	L-Tyrosine	Suda K	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.	Cancer metastasis reviews	2010	47
20110609	L-Tyrosine	Kim W	Interneuronal transfer of human tau between Lamprey central neurons in situ.	Journal of Alzheimer's disease 	2010	47
20125090	L-Tyrosine	Di Cosimo S	Management of breast cancer with targeted agents: importance of heterogeneity. corrected.	Nature reviews. Clinical oncology	2010	49
20130423	L-Tyrosine	Lurje G	EGFR signaling and drug discovery.	Oncology	2009	109
20130650	L-Tyrosine	Naka K	TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.	Nature	2010	152
20142587	L-Tyrosine	Burstein HJ	Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.	Journal of clinical oncology 	2010	98
20145116	L-Tyrosine	Lepp√§nen VM	Structural determinants of growth factor binding and specificity by VEGF receptor 2.	Proceedings of the National Academy of Sciences of the United States of America	2010	46
20145120	L-Tyrosine	Holland SJ	R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.	Cancer research	2010	121
20145208	L-Tyrosine	Sehat B	SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor.	Science signaling	2010	72
20146086	L-Tyrosine	Clarke JL	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.	Journal of neuro-oncology	2010	57
20149254	L-Tyrosine	Fr√©min C	From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.	Journal of hematology & oncology	2010	65
20152770	L-Tyrosine	Balamuth NJ	Ewing's sarcoma.	The Lancet. Oncology	2010	108
20154216	L-Tyrosine	Hazan-Halevy I	STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.	Blood	2010	67
20156581	L-Tyrosine	Mazurek S	Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.	The international journal of biochemistry & cell biology	2011	158
20159553	L-Tyrosine	Mollapour M	Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.	Molecular cell	2010	57
20164687	L-Tyrosine	Burness ML	Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?	Cancer journal	2010	42
20165865	L-Tyrosine	Liegl-Atzwanger B	Gastrointestinal stromal tumors.	Virchows Archiv 	2010	50
20179713	L-Tyrosine	Pasquale EB	Eph receptors and ephrins in cancer: bidirectional signalling and beyond.	Nature reviews. Cancer	2010	319
20197548	L-Tyrosine	Akada H	Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.	Blood	2010	86
20226597	L-Tyrosine	Araujo J	Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.	Cancer treatment reviews	2010	47
20303741	L-Tyrosine	Cecchi F	Targeting the HGF/Met signalling pathway in cancer.	European journal of cancer	2010	73
20303742	L-Tyrosine	Orian-Rousseau V	CD44, a therapeutic target for metastasising tumours.	European journal of cancer	2010	116
20308550	L-Tyrosine	Vivanco I	The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation.	Proceedings of the National Academy of Sciences of the United States of America	2010	40
20332118	L-Tyrosine	Schaller MD	Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions.	Journal of cell science	2010	173
20333297	L-Tyrosine	Mahajan K	Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation.	PloS one	2010	48
20368553	L-Tyrosine	Escudier B	Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.	Journal of clinical oncology 	2010	165
20371362	L-Tyrosine	Huynh H	Molecularly targeted therapy in hepatocellular carcinoma.	Biochemical pharmacology	2010	40
20371662	L-Tyrosine	Robinson BG	Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.	The Journal of clinical endocrinology and metabolism	2010	44
20385184	L-Tyrosine	Tai W	The role of HER2 in cancer therapy and targeted drug delivery.	Journal of controlled release 	2010	69
20399956	L-Tyrosine	Grossmann KS	The tyrosine phosphatase Shp2 in development and cancer.	Advances in cancer research	2010	60
20404132	L-Tyrosine	Oh ST	Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.	Blood	2010	103
20406969	L-Tyrosine	Ko JS	Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.	Cancer research	2010	85
20457905	L-Tyrosine	Ulanet DB	Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.	Proceedings of the National Academy of Sciences of the United States of America	2010	86
20458050	L-Tyrosine	Batchelor TT	Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.	Journal of clinical oncology 	2010	148
20460524	L-Tyrosine	Dey JH	Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.	Cancer research	2010	55
20479403	L-Tyrosine	Sequist LV	Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	103
20489150	L-Tyrosine	Benedettini E	Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis.	The American journal of pathology	2010	47
20497720	L-Tyrosine	Xie HR	SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease.	Chinese medical journal	2010	82
20501798	L-Tyrosine	O'Brien NA	Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.	Molecular cancer therapeutics	2010	88
20501804	L-Tyrosine	Hammers HJ	Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.	Molecular cancer therapeutics	2010	56
20505120	L-Tyrosine	Himanen JP	Architecture of Eph receptor clusters.	Proceedings of the National Academy of Sciences of the United States of America	2010	82
20512148	L-Tyrosine	Lauth M	DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS.	Nature structural & molecular biology	2010	49
20515495	L-Tyrosine	Krakstad C	Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.	Molecular cancer	2010	72
20537386	L-Tyrosine	An X	BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.	Leukemia research	2010	50
20554717	L-Tyrosine	Cook KM	Angiogenesis inhibitors: current strategies and future prospects.	CA	2010	87
20570559	L-Tyrosine	Herbst RS	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.	The Lancet. Oncology	2010	106
20571069	L-Tyrosine	Hirai H	MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.	Molecular cancer therapeutics	2010	292
20573926	L-Tyrosine	Maemondo M	Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.	The New England journal of medicine	2010	1115
20574050	L-Tyrosine	Broyl A	Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.	Blood	2010	65
20578891	L-Tyrosine	Xing M	Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.	Thyroid 	2010	73
20585556	L-Tyrosine	Harmon B	Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step.	PLoS pathogens	2010	42
20606083	L-Tyrosine	Monk BJ	Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.	Journal of clinical oncology 	2010	45
20615965	L-Tyrosine	Honigberg LA	The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.	Proceedings of the National Academy of Sciences of the United States of America	2010	276
20616959	L-Tyrosine	Bol√≥s V	The dual kinase complex FAK-Src as a promising therapeutic target in cancer.	OncoTargets and therapy	2010	44
20625116	L-Tyrosine	Boissel N	Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.	Journal of clinical oncology 	2010	46
20627894	L-Tyrosine	Eichler AF	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.	Neuro-oncology	2010	57
20644162	L-Tyrosine	Lechner MG	Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells.	Journal of immunology	2010	155
20664532	L-Tyrosine	Brooks AJ	The growth hormone receptor: mechanism of activation and clinical implications.	Nature reviews. Endocrinology	2010	59
20689754	L-Tyrosine	Aleshin A	SRC: a century of science brought to the clinic.	Neoplasia	2010	66
20700123	L-Tyrosine	Kikkawa N	miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC).	British journal of cancer	2010	50
20702778	L-Tyrosine	Hudecek M	The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.	Blood	2010	71
20705759	L-Tyrosine	Kindler T	FLT3 as a therapeutic target in AML: still challenging after all these years.	Blood	2010	96
20713723	L-Tyrosine	Yao Z	TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	110
20716591	L-Tyrosine	Sathornsumetee S	Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.	Neuro-oncology	2010	52
20716670	L-Tyrosine	Mimeault M	Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies.	Pharmacological reviews	2010	48
20720570	L-Tyrosine	Kolch W	Functional proteomics to dissect tyrosine kinase signalling pathways in cancer.	Nature reviews. Cancer	2010	55
20733134	L-Tyrosine	Fischer T	Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.	Journal of clinical oncology 	2010	102
20736484	L-Tyrosine	Moritz A	Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases.	Science signaling	2010	105
20799954	L-Tyrosine	Shen Q	Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion.	Molecular cancer	2010	55
20813200	L-Tyrosine	Foley J	EGFR signaling in breast cancer: bad to the bone.	Seminars in cell & developmental biology	2010	52
20824720	L-Tyrosine	da Cunha Santos G	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.	Cancer	2010	44
20840588	L-Tyrosine	Mishra S	The role of prohibitin in cell signaling.	The FEBS journal	2010	43
20841479	L-Tyrosine	Cepero V	MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.	Cancer research	2010	52
20858715	L-Tyrosine	Rankin EB	AXL is an essential factor and therapeutic target for metastatic ovarian cancer.	Cancer research	2010	53
20859283	L-Tyrosine	Seruga B	Drug resistance in metastatic castration-resistant prostate cancer.	Nature reviews. Clinical oncology	2011	74
20861192	L-Tyrosine	Hochgr√§fe F	Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.	Cancer research	2010	58
20871269	L-Tyrosine	Pirker R	Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.	Journal of thoracic oncology 	2010	61
20872043	L-Tyrosine	Neyns B	Phase II study of sunitinib malate in patients with recurrent high-grade glioma.	Journal of neuro-oncology	2011	44
20887192	L-Tyrosine	da Cunha Santos G	EGFR mutations and lung cancer.	Annual review of pathology	2011	72
20889717	L-Tyrosine	Ozawa T	PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.	Genes & development	2010	61
20922806	L-Tyrosine	Song X	Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma.	Cancer	2011	35
20924128	L-Tyrosine	Buck E	Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.	Molecular cancer therapeutics	2010	74
20940188	L-Tyrosine	Sequist LV	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.	Journal of clinical oncology 	2010	101
20952508	L-Tyrosine	Shojaei F	HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.	Cancer research	2010	83
20952518	L-Tyrosine	Borthakur G	Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.	Haematologica	2011	47
20965785	L-Tyrosine	Mahon FX	Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.	The Lancet. Oncology	2010	261
20966971	L-Tyrosine	Frame MC	The FERM domain: organizing the structure and function of FAK.	Nature reviews. Molecular cell biology	2010	98
20969586	L-Tyrosine	Watowich SS	Mechanisms regulating dendritic cell specification and development.	Immunological reviews	2010	46
20971703	L-Tyrosine	Oser M	Specific tyrosine phosphorylation sites on cortactin regulate Nck1-dependent actin polymerization in invadopodia.	Journal of cell science	2010	55
20979473	L-Tyrosine	Choi YL	EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.	The New England journal of medicine	2010	297
21037017	L-Tyrosine	Chang TH	Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.	American journal of respiratory and critical care medicine	2011	41
21042280	L-Tyrosine	Montero JC	P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer.	Oncogene	2011	38
21051724	L-Tyrosine	Chen X	Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma.	Investigative ophthalmology & visual science	2011	37
21057535	L-Tyrosine	Vuoriluoto K	Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer.	Oncogene	2011	153
21062933	L-Tyrosine	Suda K	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.	Clinical cancer research 	2010	55
21072204	L-Tyrosine	Kompier LC	FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.	PloS one	2010	66
21102609	L-Tyrosine	Trusolino L	MET signalling: principles and functions in development, organ regeneration and cancer.	Nature reviews. Molecular cell biology	2010	287
21142802	L-Tyrosine	Tandon M	Emerging strategies for EphA2 receptor targeting for cancer therapeutics.	Expert opinion on therapeutic targets	2011	66
21151131	L-Tyrosine	Griffiths DS	LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease.	Nature cell biology	2011	38
21152424	L-Tyrosine	Ware KE	Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.	PloS one	2010	54
21156283	L-Tyrosine	Rui L	Cooperative epigenetic modulation by cancer amplicon genes.	Cancer cell	2010	87
21163703	L-Tyrosine	De Roock W	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.	The Lancet. Oncology	2011	145
21165163	L-Tyrosine	Zhang Z	EGFR-mutated lung cancer: a paradigm of molecular oncology.	Oncotarget	2010	60
21168239	L-Tyrosine	Chung JH	Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.	Lung cancer	2011	45
21170960	L-Tyrosine	Wilhelm SM	Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.	International journal of cancer	2011	169
21199531	L-Tyrosine	Nakamura T	Hepatocyte growth factor twenty years on: Much more than a growth factor.	Journal of gastroenterology and hepatology	2011	90
21204711	L-Tyrosine	Gutierrez C	HER2: biology, detection, and clinical implications.	Archives of pathology & laboratory medicine	2011	57
21205925	L-Tyrosine	Chen KF	Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.	The Journal of pharmacology and experimental therapeutics	2011	69
21220474	L-Tyrosine	Donev IS	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.	Clinical cancer research 	2011	38
21220499	L-Tyrosine	Nagai T	Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.	Molecular cancer therapeutics	2011	39
21225626	L-Tyrosine	Sun S	Head neck squamous cell carcinoma c-Met‚Å∫ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis.	International journal of cancer	2011	37
21233313	L-Tyrosine	Nelson EA	The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.	Blood	2011	85
21233402	L-Tyrosine	Rosell R	Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.	Clinical cancer research 	2011	86
21237299	L-Tyrosine	Greten TF	Myeloid derived suppressor cells in human diseases.	International immunopharmacology	2011	112
21252289	L-Tyrosine	Minematsu T	Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.	Molecular cancer therapeutics	2011	37
21252716	L-Tyrosine	Travis WD	International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.	Journal of thoracic oncology 	2011	680
21253578	L-Tyrosine	Gu TL	Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma.	PloS one	2011	96
21258250	L-Tyrosine	Ludovini V	Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.	Journal of thoracic oncology 	2011	51
21270442	L-Tyrosine	Levis M	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.	Blood	2011	109
21278436	L-Tyrosine	Baselga J	Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.	The oncologist	2011	83
21278786	L-Tyrosine	Serra V	PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.	Oncogene	2011	174
21278796	L-Tyrosine	Garofalo C	Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.	Oncogene	2011	60
21288922	L-Tyrosine	Shaw AT	Targeting anaplastic lymphoma kinase in lung cancer.	Clinical cancer research 	2011	51
21293176	L-Tyrosine	Brand TM	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.	Cancer biology & therapy	2011	46
21299849	L-Tyrosine	Quentmeier H	BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.	Journal of hematology & oncology	2011	39
21303969	L-Tyrosine	Ramalingam SS	Lung cancer: New biological insights and recent therapeutic advances.	CA	2011	99
21307659	L-Tyrosine	Garrett JT	Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.	Cancer biology & therapy	2011	55
21316606	L-Tyrosine	Liu F	JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation.	Cancer cell	2011	77
21317449	L-Tyrosine	Markman B	Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.	Oncotarget	2010	121
21317930	L-Tyrosine	Mudduluru G	Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.	Oncogene	2011	75
21324877	L-Tyrosine	Choufani S	A novel approach identifies new differentially methylated regions (DMRs) associated with imprinted genes.	Genome research	2011	43
21324925	L-Tyrosine	Ghosh R	Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.	Cancer research	2011	55
21325052	L-Tyrosine	Sun Q	Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth.	Proceedings of the National Academy of Sciences of the United States of America	2011	150
21354226	L-Tyrosine	Tai WT	Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.	Journal of hepatology	2011	46
21358673	L-Tyrosine	Weigelt B	PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.	Oncogene	2011	69
21364581	L-Tyrosine	Sheng Q	The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.	British journal of cancer	2011	40
21368164	L-Tyrosine	Chakrabarty A	Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.	Proceedings of the National Academy of Sciences of the United States of America	2012	122
21376233	L-Tyrosine	Sun T	Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.	Cell	2011	88
21383697	L-Tyrosine	Oneyama C	MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.	Oncogene	2011	44
21385943	L-Tyrosine	Garrett JT	Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.	Proceedings of the National Academy of Sciences of the United States of America	2011	160
21399647	L-Tyrosine	Zhang S	Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.	Nature medicine	2011	155
21399664	L-Tyrosine	Gao XN	MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.	Oncogene	2011	54
21408136	L-Tyrosine	Gopal U	A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion.	PloS one	2011	42
21411864	L-Tyrosine	Chappell WH	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.	Oncotarget	2011	179
21412928	L-Tyrosine	Paulson V	High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis.	Genes, chromosomes & cancer	2011	36
21422473	L-Tyrosine	Herman SE	Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.	Blood	2011	188
21426149	L-Tyrosine	Barr AJ	Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development.	Future medicinal chemistry	2010	50
21430269	L-Tyrosine	Sequist LV	Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.	Science translational medicine	2011	712
21439312	L-Tyrosine	Larsen AK	Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis.	Pharmacology & therapeutics	2011	36
21443688	L-Tyrosine	Tian S	YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.	Cancer science	2011	53
21454604	L-Tyrosine	Eathiraj S	Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197.	The Journal of biological chemistry	2011	39
21465472	L-Tyrosine	Ciravolo V	Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.	Journal of cellular physiology	2012	64
21468131	L-Tyrosine	Okines A	Targeting the human EGFR family in esophagogastric cancer.	Nature reviews. Clinical oncology	2011	48
21471286	L-Tyrosine	Hegi ME	Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.	Molecular cancer therapeutics	2011	42
21482987	L-Tyrosine	D'Angelo SP	Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.	Journal of clinical oncology 	2011	64
21487037	L-Tyrosine	Gentile A	Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis.	Cancer research	2011	45
21501518	L-Tyrosine	Howe EN	Targets of miR-200c mediate suppression of cell motility and anoikis resistance.	Breast cancer research 	2011	75
21504625	L-Tyrosine	Yuan Y	Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.	Journal of hematology & oncology	2011	40
21519015	L-Tyrosine	O'Neil BH	Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.	Journal of clinical oncology 	2011	38
21527061	L-Tyrosine	Zhou W	East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.	Chinese journal of cancer	2011	39
21531810	L-Tyrosine	Wu JY	Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.	Clinical cancer research 	2011	96
21552268	L-Tyrosine	Delahaye NF	Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors.	Nature medicine	2011	95
21562040	L-Tyrosine	Soverini S	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.	Blood	2011	98
21565214	L-Tyrosine	Tugues S	Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.	Molecular aspects of medicine	2011	50
21573178	L-Tyrosine	Querings S	Benchmarking of mutation diagnostics in clinical lung cancer specimens.	PloS one	2011	37
21575866	L-Tyrosine	Sakamoto H	CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.	Cancer cell	2011	130
21576635	L-Tyrosine	Peck AR	Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.	Journal of clinical oncology 	2011	38
21606412	L-Tyrosine	Kurzrock R	Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.	Journal of clinical oncology 	2011	114
21613408	L-Tyrosine	Lovly CM	Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.	Cancer research	2011	51
21628563	L-Tyrosine	Li Y	c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype.	Proceedings of the National Academy of Sciences of the United States of America	2011	86
21642685	L-Tyrosine	Carvajal RD	KIT as a therapeutic target in metastatic melanoma.	JAMA	2011	120
21642981	L-Tyrosine	Joffre C	A direct role for Met endocytosis in tumorigenesis.	Nature cell biology	2011	63
21653320	L-Tyrosine	Wang X	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.	Blood	2011	111
21655094	L-Tyrosine	Han W	EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.	PloS one	2011	66
21665146	L-Tyrosine	Schmid MC	Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kŒ≥, a single convergent point promoting tumor inflammation and progression.	Cancer cell	2011	77
21676217	L-Tyrosine	Wang L	PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.	BMC cancer	2011	53
21690253	L-Tyrosine	Pilati C	Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.	The Journal of experimental medicine	2011	64
21690468	L-Tyrosine	Guo J	Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.	Journal of clinical oncology 	2011	97
21691275	L-Tyrosine	Hart S	SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.	Leukemia	2011	39
21711246	L-Tyrosine	Koch S	Signal transduction by vascular endothelial growth factor receptors.	The Biochemical journal	2011	203
21720997	L-Tyrosine	Kim HR	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.	Cancer	2012	37
21734175	L-Tyrosine	Chmielecki J	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.	Science translational medicine	2011	177
21743492	L-Tyrosine	Quintavalle C	miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPŒº.	Oncogene	2012	58
21751200	L-Tyrosine	von Mehren M	Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.	Cancer	2012	35
21752724	L-Tyrosine	Chu E	An update on the current and emerging targeted agents in metastatic colorectal cancer.	Clinical colorectal cancer	2012	39
21764376	L-Tyrosine	Yasuda H	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.	The Lancet. Oncology	2012	93
21768463	L-Tyrosine	Sequist LV	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.	Journal of clinical oncology 	2011	135
21776389	L-Tyrosine	Sen B	Regulation of SRC family kinases in human cancers.	Journal of signal transduction	2011	62
21788562	L-Tyrosine	Zhou Q	Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	64
21791426	L-Tyrosine	Chomel JC	Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.	Blood	2011	43
21791641	L-Tyrosine	Sasaki T	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.	Cancer research	2011	172
21831840	L-Tyrosine	Hwang CI	Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.	Proceedings of the National Academy of Sciences of the United States of America	2011	47
21841788	L-Tyrosine	Ungureanu D	The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.	Nature structural & molecular biology	2011	60
21849857	L-Tyrosine	Janku F	Novel therapeutic targets in non-small cell lung cancer.	Journal of thoracic oncology 	2011	38
21852385	L-Tyrosine	Wang M	EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks.	Cancer research	2011	37
21856766	L-Tyrosine	Chaft JE	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.	Clinical cancer research 	2011	102
21885862	L-Tyrosine	Taeger J	Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.	Molecular cancer therapeutics	2011	35
21898375	L-Tyrosine	Molina AM	Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.	Cancer	2012	35
21906675	L-Tyrosine	Wang H	Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway.	Cellular signalling	2012	37
21908557	L-Tyrosine	Fox EM	A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.	Cancer research	2011	58
21911423	L-Tyrosine	Hurtz C	BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.	The Journal of experimental medicine	2011	47
21915099	L-Tyrosine	Lefave CV	Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas.	The EMBO journal	2011	48
21925381	L-Tyrosine	Vorlov√° S	Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation.	Molecular cell	2011	44
21926191	L-Tyrosine	Yakes FM	Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.	Molecular cancer therapeutics	2011	173
21926387	L-Tyrosine	Travis WD	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.	Proceedings of the American Thoracic Society	2011	83
21931021	L-Tyrosine	Paugh BS	Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.	Journal of clinical oncology 	2011	75
21933749	L-Tyrosine	Shaw AT	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.	The Lancet. Oncology	2011	230
21933973	L-Tyrosine	Verma A	Targeting Axl and Mer kinases in cancer.	Molecular cancer therapeutics	2011	78
21936542	L-Tyrosine	Guagnano V	Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-4-(4-ethyl-piperazin-1-yl)-phenylamino-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.	Journal of medicinal chemistry	2011	63
21975932	L-Tyrosine	Jin X	EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction.	Cancer research	2011	45
21976538	L-Tyrosine	Taniguchi K	Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.	Clinical cancer research 	2011	85
21985784	L-Tyrosine	Ebi H	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.	The Journal of clinical investigation	2011	69
21996738	L-Tyrosine	Feng H	Dynamin 2 mediates PDGFRŒ±-SHP-2-promoted glioblastoma growth and invasion.	Oncogene	2012	33
22006329	L-Tyrosine	Zammarchi F	Antitumorigenic potential of STAT3 alternative splicing modulation.	Proceedings of the National Academy of Sciences of the United States of America	2011	48
22015057	L-Tyrosine	Garcia-Donas J	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.	The Lancet. Oncology	2011	64
22017446	L-Tyrosine	Joensuu H	The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy.	Annual review of medicine	2012	33
22052230	L-Tyrosine	Yano S	Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.	Journal of thoracic oncology 	2011	56
22057914	L-Tyrosine	Cheng Y	MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.	Molecular cancer therapeutics	2012	40
22059152	L-Tyrosine	Guo D	An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.	Cancer discovery	2011	70
22080864	L-Tyrosine	Feng H	Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRŒ±-stimulated glioma tumorigenesis in mice and humans.	The Journal of clinical investigation	2011	39
22084170	L-Tyrosine	Kreahling JM	MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.	Molecular cancer therapeutics	2012	42
22105169	L-Tyrosine	Fukuoka H	EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.	The Journal of clinical investigation	2011	37
22105349	L-Tyrosine	Magalhaes MA	Cortactin phosphorylation regulates cell invasion through a pH-dependent pathway.	The Journal of cell biology	2011	59
22116549	L-Tyrosine	Gupta M	Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy.	Leukemia	2012	32
22124364	L-Tyrosine	Arteaga CL	Treatment of HER2-positive breast cancer: current status and future perspectives.	Nature reviews. Clinical oncology	2011	215
22127113	L-Tyrosine	Brand TM	The nuclear epidermal growth factor receptor signaling network and its role in cancer.	Discovery medicine	2011	63
22128289	L-Tyrosine	Organ SL	An overview of the c-MET signaling pathway.	Therapeutic advances in medical oncology	2011	111
22130231	L-Tyrosine	Takahashi S	Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.	Biological & pharmaceutical bulletin	2011	48
22137795	L-Tyrosine	Snuderl M	Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.	Cancer cell	2011	200
22140546	L-Tyrosine	Li C	Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.	PloS one	2011	59
22140653	L-Tyrosine	Rodrik-Outmezguine VS	mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.	Cancer discovery	2011	152
22142822	L-Tyrosine	Beji A	Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer.	Clinical cancer research 	2012	32
22144665	L-Tyrosine	Ying W	Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.	Molecular cancer therapeutics	2012	64
22153719	L-Tyrosine	Zhang S	Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.	Trends in pharmacological sciences	2012	64
22156549	L-Tyrosine	Cilloni D	Molecular pathways: BCR-ABL.	Clinical cancer research 	2012	42
22157681	L-Tyrosine	Garofalo M	EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.	Nature medicine	2011	120
22160019	L-Tyrosine	Burger JA	Nurture versus nature: the microenvironment in chronic lymphocytic leukemia.	Hematology. American Society of Hematology. Education Program	2011	44
22161825	L-Tyrosine	Eccles SA	The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology.	The International journal of developmental biology	2011	41
22167270	L-Tyrosine	Sharma K	Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response.	Molecular & cellular proteomics 	2012	37
22167408	L-Tyrosine	Jamal-Hanjani M	Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.	Clinical cancer research 	2012	37
22170610	L-Tyrosine	Png KJ	A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells.	Nature	2011	151
22173954	L-Tyrosine	Xie M	Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.	Journal of cellular biochemistry	2012	45
22178589	L-Tyrosine	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	86
22179665	L-Tyrosine	Migliore C	MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer.	Clinical cancer research 	2012	33
22180308	L-Tyrosine	Tai WT	Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.	Molecular cancer therapeutics	2012	36
22180443	L-Tyrosine	Ponader S	The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.	Blood	2012	171
22184391	L-Tyrosine	van Gaal JC	Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.	Journal of clinical oncology 	2012	35
22187964	L-Tyrosine	Korshunov VA	Axl-dependent signalling: a clinical update.	Clinical science	2012	36
22194472	L-Tyrosine	Ju YS	A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.	Genome research	2012	130
22203239	L-Tyrosine	Mineo M	Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion.	Angiogenesis	2012	65
22207735	L-Tyrosine	Yuan H	Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.	Blood	2012	53
22213818	L-Tyrosine	Vanderhoek M	Impact of the definition of peak standardized uptake value on quantification of treatment response.	Journal of nuclear medicine 	2012	33
22215692	L-Tyrosine	Gao J	Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology.	Cancer research	2012	34
22215748	L-Tyrosine	Bergethon K	ROS1 rearrangements define a unique molecular class of lung cancers.	Journal of clinical oncology 	2012	295
22215752	L-Tyrosine	Su KY	Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.	Journal of clinical oncology 	2012	128
22215905	L-Tyrosine	Pollak M	The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology.	Clinical cancer research 	2012	37
22226241	L-Tyrosine	Heinemann V	Systemic treatment of advanced pancreatic cancer.	Cancer treatment reviews	2012	37
22228822	L-Tyrosine	Kim Y	The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.	Molecular cancer therapeutics	2012	36
22235099	L-Tyrosine	Doebele RC	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.	Clinical cancer research 	2012	242
22238366	L-Tyrosine	Gozgit JM	Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.	Molecular cancer therapeutics	2012	71
22238368	L-Tyrosine	Chen CT	MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.	Molecular cancer therapeutics	2012	49
22239438	L-Tyrosine	Seshacharyulu P	Targeting the EGFR signaling pathway in cancer therapy.	Expert opinion on therapeutic targets	2012	88
22248929	L-Tyrosine	Garrett JT	Will PI3K pathway inhibitors be effective as single agents in patients with cancer?	Oncotarget	2011	35
22249257	L-Tyrosine	Yamadori T	Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.	Oncogene	2012	41
22257651	L-Tyrosine	Ou SH	Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.	Critical reviews in oncology/hematology	2012	32
22257673	L-Tyrosine	Baselga J	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.	Lancet	2012	236
22261334	L-Tyrosine	Han W	Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.	Cancer letters	2012	70
22268382	L-Tyrosine	Taylor TE	Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.	Current cancer drug targets	2012	43
22279054	L-Tyrosine	de Rooij MF	The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.	Blood	2012	134
22282022	L-Tyrosine	Doebele RC	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.	Cancer	2012	55
22282308	L-Tyrosine	Cheng L	Molecular pathology of lung cancer: key to personalized medicine.	Modern pathology 	2012	45
22285168	L-Tyrosine	Rosell R	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.	The Lancet. Oncology	2012	1030
22286129	L-Tyrosine	Hantschel O	BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.	Nature chemical biology	2012	57
22289988	L-Tyrosine	Renneville A	Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.	Leukemia	2012	30
22307544	L-Tyrosine	Mahajan K	PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.	Journal of cellular physiology	2012	49
22311673	L-Tyrosine	Little SE	Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity.	Cancer research	2012	33
22315472	L-Tyrosine	Deng N	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.	Gut	2012	139
22317763	L-Tyrosine	Wang W	Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.	Clinical cancer research 	2012	32
22319590	L-Tyrosine	Looyenga BD	STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.	PloS one	2012	37
22322096	L-Tyrosine	Stokes MP	PTMScan direct: identification and quantification of peptides from critical signaling proteins by immunoaffinity enrichment coupled with LC-MS/MS.	Molecular & cellular proteomics 	2012	35
22323597	L-Tyrosine	Szerlip NJ	Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.	Proceedings of the National Academy of Sciences of the United States of America	2012	141
22323827	L-Tyrosine	Lovly CM	Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.	Science translational medicine	2012	36
22327623	L-Tyrosine	Takeuchi K	RET, ROS1 and ALK fusions in lung cancer.	Nature medicine	2012	277
22327624	L-Tyrosine	Kohno T	KIF5B-RET fusions in lung adenocarcinoma.	Nature medicine	2012	189
22328973	L-Tyrosine	Hammerman PS	Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.	Cancer discovery	2011	143
22337149	L-Tyrosine	Pollak M	The insulin and insulin-like growth factor receptor family in neoplasia: an update.	Nature reviews. Cancer	2012	276
22354171	L-Tyrosine	Malinge S	Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.	The Journal of clinical investigation	2012	35
22362000	L-Tyrosine	Hoellenriegel J	Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.	Leukemia	2012	46
22368270	L-Tyrosine	Man CH	Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.	Blood	2012	62
22369928	L-Tyrosine	Gavine PR	AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.	Cancer research	2012	105
22370318	L-Tyrosine	Lee JS	Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).	Journal of clinical oncology 	2012	74
22371878	L-Tyrosine	Khoury HJ	Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.	Blood	2012	61
22390767	L-Tyrosine	Prud'homme GJ	Cancer stem cells and novel targets for antitumor strategies.	Current pharmaceutical design	2012	36
22393126	L-Tyrosine	Hamerlik P	Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.	The Journal of experimental medicine	2012	105
22395361	L-Tyrosine	Yu Y	Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells.	Leukemia	2012	43
22407829	L-Tyrosine	Perez-Moreno P	Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.	Clinical cancer research 	2012	51
22410775	L-Tyrosine	Paccez JD	The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target.	Oncogene	2013	34
22410779	L-Tyrosine	Wang Z	SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells.	Oncogene	2013	32
22426421	L-Tyrosine	Ng KP	A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.	Nature medicine	2012	140
22436374	L-Tyrosine	Chen G	Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.	BMC medicine	2012	36
22439932	L-Tyrosine	Yamaguchi T	NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma.	Cancer cell	2012	64
22446502	L-Tyrosine	Hanfstein B	Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).	Leukemia	2012	78
22449073	L-Tyrosine	Buggy JJ	Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.	International reviews of immunology	2012	38
22451900	L-Tyrosine	Xue L	Sensitive kinase assay linked with phosphoproteomics for identifying direct kinase substrates.	Proceedings of the National Academy of Sciences of the United States of America	2012	42
22452895	L-Tyrosine	Yang JC	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.	The Lancet. Oncology	2012	84
22452896	L-Tyrosine	Miller VA	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.	The Lancet. Oncology	2012	235
22458527	L-Tyrosine	Troiani T	Targeting EGFR in pancreatic cancer treatment.	Current drug targets	2012	33
22461510	L-Tyrosine	Bai Y	Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.	Cancer research	2012	33
22461643	L-Tyrosine	Stern HM	Improving treatment of HER2-positive cancers: opportunities and challenges.	Science translational medicine	2012	44
22471661	L-Tyrosine	Rexer BN	Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.	Critical reviews in oncogenesis	2012	74
22489043	L-Tyrosine	Brecqueville M	Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.	Genes, chromosomes & cancer	2012	40
22504141	L-Tyrosine	Cross NC	Standardized definitions of molecular response in chronic myeloid leukemia.	Leukemia	2012	59
22508830	L-Tyrosine	Witta SE	Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.	Journal of clinical oncology 	2012	58
22520625	L-Tyrosine	Wang YN	Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family.	Cell & bioscience	2012	36
22525271	L-Tyrosine	Liu X	PTPN14 interacts with and negatively regulates the oncogenic function of YAP.	Oncogene	2013	43
22529104	L-Tyrosine	Pignatelli J	Hic-5 promotes invadopodia formation and invasion during TGF-Œ≤-induced epithelial-mesenchymal transition.	The Journal of cell biology	2012	59
22530990	L-Tyrosine	Cecchi F	Targeting the HGF/Met signaling pathway in cancer therapy.	Expert opinion on therapeutic targets	2012	54
22535374	L-Tyrosine	De Boeck A	Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling.	Gut	2013	37
22536154	L-Tyrosine	Schelhaas M	Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis.	PLoS pathogens	2012	100
22541616	L-Tyrosine	Saintigny P	Recent advances in non-small cell lung cancer biology and clinical management.	Discovery medicine	2012	35
22547605	L-Tyrosine	J√§nne PA	Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.	Journal of clinical oncology 	2012	82
22553343	L-Tyrosine	Yamada T	Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.	Clinical cancer research 	2012	41
22553347	L-Tyrosine	Sj√∂dahl G	A molecular taxonomy for urothelial carcinoma.	Clinical cancer research 	2012	92
22566605	L-Tyrosine	Blum W	Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.	Blood	2012	47
22573349	L-Tyrosine	Griffioen AW	Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.	Clinical cancer research 	2012	40
22579287	L-Tyrosine	Shan Y	Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.	Cell	2012	92
22580612	L-Tyrosine	Kufe DW	MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches.	Oncogene	2013	92
22585002	L-Tyrosine	Carpenter EL	Targeting ALK in neuroblastoma--preclinical and clinical advancements.	Nature reviews. Clinical oncology	2012	38
22585576	L-Tyrosine	Felcht M	Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling.	The Journal of clinical investigation	2012	101
22589274	L-Tyrosine	Kelber JA	KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.	Cancer research	2012	33
22589483	L-Tyrosine	Matthay KK	Promising therapeutic targets in neuroblastoma.	Clinical cancer research 	2012	44
22605650	L-Tyrosine	Wagner AJ	Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.	Cancer	2012	36
22608783	L-Tyrosine	Lambrechts D	VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.	The Lancet. Oncology	2012	46
22614177	L-Tyrosine	Swords R	Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.	Leukemia	2012	39
22614325	L-Tyrosine	Mano H	ALKoma: a cancer subtype with a shared target.	Cancer discovery	2012	36
22617245	L-Tyrosine	Yasuda H	Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.	Journal of thoracic oncology 	2012	34
22624718	L-Tyrosine	Lapalombella R	Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.	Cancer cell	2012	31
22635005	L-Tyrosine	Peinado H	Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.	Nature medicine	2012	678
22641068	L-Tyrosine	Buurman R	Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.	Gastroenterology	2012	52
22641215	L-Tyrosine	Tobin LA	Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.	Oncogene	2013	30
22649091	L-Tyrosine	Sen B	Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.	Science translational medicine	2012	37
22652764	L-Tyrosine	Nagathihalli NS	Src-mediated regulation of E-cadherin and EMT in pancreatic cancer.	Frontiers in bioscience	2012	30
22653972	L-Tyrosine	Hehlmann R	How I treat CML blast crisis.	Blood	2012	39
22658319	L-Tyrosine	Hurvitz SA	Current approaches and future directions in the treatment of HER2-positive breast cancer.	Cancer treatment reviews	2013	31
22661537	L-Tyrosine	Rimkunas VM	Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.	Clinical cancer research 	2012	60
22673630	L-Tyrosine	Chen ZY	EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.	The oncologist	2012	38
22677429	L-Tyrosine	Park SJ	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.	Lung cancer	2012	63
22683780	L-Tyrosine	Kentsis A	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.	Nature medicine	2012	53
22689061	L-Tyrosine	Huang JM	YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14.	Oncogene	2013	47
22689860	L-Tyrosine	Tai YT	Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.	Blood	2012	48
22705009	L-Tyrosine	Ma S	Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma.	Gastroenterology	2012	30
22711876	L-Tyrosine	Shaik S	SCF(Œ≤-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2.	The Journal of experimental medicine	2012	32
22713237	L-Tyrosine	Carrassa L	Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.	Cell cycle	2012	37
22726438	L-Tyrosine	Lin CC	Inhibition of basal FGF receptor signaling by dimeric Grb2.	Cell	2012	41
22733536	L-Tyrosine	Heon S	The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.	Clinical cancer research 	2012	36
22736441	L-Tyrosine	Suda K	Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.	Cancer metastasis reviews	2012	32
22738912	L-Tyrosine	Yaqoob U	Neuropilin-1 stimulates tumor growth by increasing fibronectin fibril assembly in the tumor microenvironment.	Cancer research	2012	36
22751098	L-Tyrosine	Zhang Z	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.	Nature genetics	2012	298
22761469	L-Tyrosine	Arcila ME	Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.	Clinical cancer research 	2012	62
22763448	L-Tyrosine	Wilson TR	Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.	Nature	2012	365
22773810	L-Tyrosine	Ohashi K	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.	Proceedings of the National Academy of Sciences of the United States of America	2012	143
22776705	L-Tyrosine	Goto K	An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting.	Annals of oncology 	2012	33
22785351	L-Tyrosine	Yarden Y	The ERBB network: at last, cancer therapy meets systems biology.	Nature reviews. Cancer	2012	161
22806307	L-Tyrosine	Togashi Y	Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.	Cancer chemotherapy and pharmacology	2012	42
22816879	L-Tyrosine	He R	Small molecule tools for functional interrogation of protein tyrosine phosphatases.	The FEBS journal	2013	32
22825000	L-Tyrosine	Thunnissen E	EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.	Virchows Archiv 	2012	42
22826274	L-Tyrosine	Bai H	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.	Journal of clinical oncology 	2012	65
22833179	L-Tyrosine	Toh HC	Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.	Cancer	2013	26
22837387	L-Tyrosine	Singh D	Transforming fusions of FGFR and TACC genes in human glioblastoma.	Science	2012	184
22843788	L-Tyrosine	Tanizaki J	Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.	Clinical cancer research 	2012	53
22844075	L-Tyrosine	Nakagawa T	Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.	Molecular cancer therapeutics	2012	31
22869151	L-Tyrosine	Vainchenker W	JAK/STAT signaling in hematological malignancies.	Oncogene	2013	88
22874768	L-Tyrosine	Harbinski F	Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth.	Cancer discovery	2012	34
22875912	L-Tyrosine	Wiestner A	Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.	Blood	2012	40
22878749	L-Tyrosine	Goldberg SB	A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.	Journal of thoracic oncology 	2012	32
22889873	L-Tyrosine	Aurisicchio L	The promise of anti-ErbB3 monoclonals as new cancer therapeutics.	Oncotarget	2012	36
22890323	L-Tyrosine	Linger RM	Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.	Oncogene	2013	44
22891040	L-Tyrosine	Kim SM	Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.	Molecular cancer therapeutics	2012	38
22891331	L-Tyrosine	Fenton TR	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.	Proceedings of the National Academy of Sciences of the United States of America	2012	33
22891351	L-Tyrosine	Couto JP	STAT3 negatively regulates thyroid tumorigenesis.	Proceedings of the National Academy of Sciences of the United States of America	2012	43
22895193	L-Tyrosine	Seshagiri S	Recurrent R-spondin fusions in colon cancer.	Nature	2012	250
22896000	L-Tyrosine	Cortes J	Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.	Blood	2012	43
22897846	L-Tyrosine	Tamagnone L	Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer.	Cancer cell	2012	41
22897847	L-Tyrosine	Roberts KG	Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.	Cancer cell	2012	159
22898678	L-Tyrosine	Leboulleux S	Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.	The Lancet. Oncology	2012	62
22899358	L-Tyrosine	Fujita Y	Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.	Journal of thoracic oncology 	2012	33
22906415	L-Tyrosine	Crews LA	Selective elimination of leukemia stem cells: hitting a moving target.	Cancer letters	2013	29
22908275	L-Tyrosine	Greulich H	Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.	Proceedings of the National Academy of Sciences of the United States of America	2012	73
22915637	L-Tyrosine	Radich JP	A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.	Blood	2012	33
22916011	L-Tyrosine	Neveu G	Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly.	PLoS pathogens	2012	32
22916121	L-Tyrosine	Petty A	A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo.	PloS one	2012	35
22922303	L-Tyrosine	Fagiani E	Angiopoietins in angiogenesis.	Cancer letters	2013	86
22935675	L-Tyrosine	Huang CP	ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors.	Cancer letters	2013	28
22941188	L-Tyrosine	Peifer M	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.	Nature genetics	2012	256
22942426	L-Tyrosine	Zizzo G	Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction.	Journal of immunology	2012	99
22949154	L-Tyrosine	Cortes JE	Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.	Journal of clinical oncology 	2012	69
22954454	L-Tyrosine	Brindley DN	Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy.	Biochimica et biophysica acta	2013	26
22961666	L-Tyrosine	Byers LA	Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.	Cancer discovery	2012	95
22965961	L-Tyrosine	Schmoll HJ	Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).	Journal of clinical oncology 	2012	49
22966038	L-Tyrosine	Liby KT	Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.	Pharmacological reviews	2012	75
22967996	L-Tyrosine	Awada A	Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.	Annals of oncology 	2013	27
22975686	L-Tyrosine	Rushworth SA	BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-Œ∫B.	Cellular signalling	2013	33
22975805	L-Tyrosine	Seo JS	The transcriptional landscape and mutational profile of lung adenocarcinoma.	Genome research	2012	146
22988851	L-Tyrosine	Yoon MK	Cell cycle regulation by the intrinsically disordered proteins p21 and p27.	Biochemical Society transactions	2012	56
22996586	L-Tyrosine	Yan Y	MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-mediated epithelial-mesenchymal transition and adhesion in hepatoma cells.	Hepatology	2013	42
23012300	L-Tyrosine	von Minckwitz G	Neoadjuvant treatments for triple-negative breast cancer (TNBC).	Annals of oncology 	2012	37
23012305	L-Tyrosine	Crown J	Emerging targeted therapies in triple-negative breast cancer.	Annals of oncology 	2012	55
23012449	L-Tyrosine	Schito L	Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2012	44
23027128	L-Tyrosine	Zheng Y	Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT.	Oncogene	2013	25
23041228	L-Tyrosine	Blanco-Aparicio C	Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.	Biochemical pharmacology	2013	29
23041612	L-Tyrosine	Zhang S	The onco-embryonic antigen ROR1 is expressed by a variety of human cancers.	The American journal of pathology	2012	36
23045285	L-Tyrosine	Gusenbauer S	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.	Oncogene	2013	37
23045577	L-Tyrosine	Advani RH	Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.	Journal of clinical oncology 	2013	210
23052255	L-Tyrosine	Suehara Y	Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.	Clinical cancer research 	2012	39
23073628	L-Tyrosine	Lennartsson J	Stem cell factor receptor/c-Kit: from basic science to clinical implications.	Physiological reviews	2012	108
23079155	L-Tyrosine	Yang JJ	Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.	Lung cancer	2013	42
23084121	L-Tyrosine	Nielsen DL	Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.	Breast	2013	29
23085373	L-Tyrosine	Mohapatra B	Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases.	Biochimica et biophysica acta	2013	55
23085539	L-Tyrosine	McCubrey JA	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.	Oncotarget	2012	105
23090888	L-Tyrosine	Jabbour E	Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.	American journal of hematology	2012	32
23103856	L-Tyrosine	Young A	Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.	Cancer discovery	2013	55
23104879	L-Tyrosine	Odiete O	Neuregulin in cardiovascular development and disease.	Circulation research	2012	46
23108136	L-Tyrosine	Terme M	VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.	Cancer research	2013	70
23113752	L-Tyrosine	Savvides P	Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.	Thyroid 	2013	35
23122493	L-Tyrosine	Karachaliou N	KRAS mutations in lung cancer.	Clinical lung cancer	2013	41
23127174	L-Tyrosine	Ashman LK	Therapeutic targeting of c-KIT in cancer.	Expert opinion on investigational drugs	2013	31
23136191	L-Tyrosine	Spoerke JM	Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.	Clinical cancer research 	2012	46
23149917	L-Tyrosine	Daly C	Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition.	Cancer research	2013	64
23150586	L-Tyrosine	Zhao W	Bioinspired multivalent DNA network for capture and release of cells.	Proceedings of the National Academy of Sciences of the United States of America	2012	36
23154552	L-Tyrosine	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	97
23159595	L-Tyrosine	Spencer DH	Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data.	The Journal of molecular diagnostics 	2013	34
23169517	L-Tyrosine	Smith DC	Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.	Journal of clinical oncology 	2013	120
23172303	L-Tyrosine	Shibuya M	Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.	Journal of biochemistry	2013	103
23172312	L-Tyrosine	Cortot AB	Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.	Cancer research	2013	56
23172555	L-Tyrosine	Ellison G	EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.	Journal of clinical pathology	2013	58
23190221	L-Tyrosine	Cortes JE	Ponatinib in refractory Philadelphia chromosome-positive leukemias.	The New England journal of medicine	2012	143
23196275	L-Tyrosine	Conklin CM	Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.	Journal of thoracic oncology 	2013	39
23201355	L-Tyrosine	Roskoski R Jr	Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.	Pharmacological research	2013	39
23209031	L-Tyrosine	Gerdes CA	GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.	Clinical cancer research 	2013	31
23209344	L-Tyrosine	Byeon SE	The role of Src kinase in macrophage-mediated inflammatory responses.	Mediators of inflammation	2012	48
23212523	L-Tyrosine	Loh ML	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.	Blood	2013	36
23213056	L-Tyrosine	Stabile LP	c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.	Clinical cancer research 	2013	29
23223358	L-Tyrosine	Khorashad JS	BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.	Blood	2013	47
23233609	L-Tyrosine	Mullighan CG	The molecular genetic makeup of acute lymphoblastic leukemia.	Hematology. American Society of Hematology. Education Program	2012	44
23238013	L-Tyrosine	Binda E	The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas.	Cancer cell	2012	45
23242437	L-Tyrosine	Kobayashi S	Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	26
23242808	L-Tyrosine	Girotti MR	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.	Cancer discovery	2013	106
23245941	L-Tyrosine	Rosenbluh J	Œ≤-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis.	Cell	2012	165
23246963	L-Tyrosine	Montero JC	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.	Oncogene	2014	29
23258844	L-Tyrosine	Kim KH	Wnt/Œ≤-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.	Neuro-oncology	2013	32
23264597	L-Tyrosine	Burger JA	Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling.	Blood	2013	32
23275034	L-Tyrosine	Ward KK	Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.	Clinical & experimental metastasis	2013	29
23281850	L-Tyrosine	Wade A	Proteoglycans and their roles in brain cancer.	The FEBS journal	2013	27
23297823	L-Tyrosine	Cheung M	Diverse mechanisms of AKT pathway activation in human malignancy.	Current cancer drug targets	2013	42
23299311	L-Tyrosine	Zhang B	Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-Œ≤-catenin signaling.	Blood	2013	70
23302890	L-Tyrosine	Scheffer KD	Tetraspanin CD151 mediates papillomavirus type 16 endocytosis.	Journal of virology	2013	41
23307858	L-Tyrosine	Jahangiri A	Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.	Clinical cancer research 	2013	54
23318419	L-Tyrosine	Brouxhon SM	Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling.	Oncogene	2014	22
23318457	L-Tyrosine	Sia D	Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.	Oncogene	2013	49
23319661	L-Tyrosine	Lin YL	Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
23322008	L-Tyrosine	Zhang X	A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation.	Cancer research	2013	30
23328547	L-Tyrosine	Oxnard GR	Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.	Journal of thoracic oncology 	2013	31
23332287	L-Tyrosine	Gadgeel SM	Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.	Clinical lung cancer	2013	31
23333150	L-Tyrosine	Goff DJ	A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.	Cell stem cell	2013	54
23334327	L-Tyrosine	Do TV	Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.	Oncogene	2014	35
23334668	L-Tyrosine	Holmfeldt L	The genomic landscape of hypodiploid acute lymphoblastic leukemia.	Nature genetics	2013	131
23344264	L-Tyrosine	Yeh P	DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.	Clinical cancer research 	2013	37
23362162	L-Tyrosine	Tuononen K	Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.	Genes, chromosomes & cancer	2013	35
23362324	L-Tyrosine	Zhu AX	Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.	Clinical cancer research 	2013	25
23365119	L-Tyrosine	Montero-Conde C	Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.	Cancer discovery	2013	101
23370315	L-Tyrosine	Hirsch FR	Epidermal growth factor receptor inhibition in lung cancer: status 2012.	Journal of thoracic oncology 	2013	28
23371856	L-Tyrosine	Arcila ME	EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.	Molecular cancer therapeutics	2013	48
23375101	L-Tyrosine	Rapraeger AC	Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-Œ±vŒ≤3 integrin complex in tumorigenesis and angiogenesis.	The FEBS journal	2013	26
23383079	L-Tyrosine	Liu HB	Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.	PloS one	2013	28
23388504	L-Tyrosine	Goyal L	Targeting the HGF/c-MET pathway in hepatocellular carcinoma.	Clinical cancer research 	2013	57
23400546	L-Tyrosine	Lee J	Identification of ROS1 rearrangement in gastric adenocarcinoma.	Cancer	2013	35
23400594	L-Tyrosine	Casetti L	Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.	Cancer research	2013	29
23401433	L-Tyrosine	Li T	Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.	Journal of clinical oncology 	2013	97
23401440	L-Tyrosine	Roberts PJ	KRAS mutation: should we test for it, and does it matter?	Journal of clinical oncology 	2013	58
23401451	L-Tyrosine	Ohashi K	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.	Journal of clinical oncology 	2013	113
23401452	L-Tyrosine	Laurie SA	Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer.	Journal of clinical oncology 	2013	31
23401458	L-Tyrosine	Sadiq AA	MET as a possible target for non-small-cell lung cancer.	Journal of clinical oncology 	2013	43
23407558	L-Tyrosine	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	57
23410976	L-Tyrosine	Day BW	EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.	Cancer cell	2013	44
23418360	L-Tyrosine	Du WW	MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling.	Journal of cell science	2013	44
23426935	L-Tyrosine	Kato H	Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma.	International journal of oncology	2013	26
23434765	L-Tyrosine	Niture SK	Regulation of Nrf2-an update.	Free radical biology & medicine	2014	105
23437362	L-Tyrosine	Soares HP	Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.	PloS one	2013	45
23441129	L-Tyrosine	Walters DM	Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib.	Neoplasia	2013	28
23445613	L-Tyrosine	Fiskus W	Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.	Molecular cancer therapeutics	2013	29
23453860	L-Tyrosine	Scagliotti GV	The emerging role of MET/HGF inhibitors in oncology.	Cancer treatment reviews	2013	52
23470965	L-Tyrosine	Yu HA	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.	Clinical cancer research 	2013	343
23471820	L-Tyrosine	Sanda T	TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.	Cancer discovery	2013	35
23484006	L-Tyrosine	Navis AC	Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2.	PloS one	2013	28
23502220	L-Tyrosine	Hochhaus A	Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.	Blood	2013	29
23509284	L-Tyrosine	Knight JF	Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	28
23516327	L-Tyrosine	Frisch SM	Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis.	Journal of cell science	2013	66
23529353	L-Tyrosine	English DP	HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.	Molecular diagnosis & therapy	2013	31
23532331	L-Tyrosine	Cance WG	Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.	Science signaling	2013	27
23532334	L-Tyrosine	Bean GR	PUMA and BIM are required for oncogene inactivation-induced apoptosis.	Science signaling	2013	36
23533263	L-Tyrosine	Akhavan D	De-repression of PDGFRŒ≤ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.	Cancer discovery	2013	28
23536707	L-Tyrosine	Terai H	Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.	Molecular cancer research 	2013	44
23542173	L-Tyrosine	Yamaguchi H	Signaling cross-talk in the resistance to HER family receptor targeted therapy.	Oncogene	2014	28
23542356	L-Tyrosine	Shien K	Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.	Cancer research	2013	72
23550148	L-Tyrosine	Killian JK	Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor.	Cancer discovery	2013	78
23551194	L-Tyrosine	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	Archives of pathology & laboratory medicine	2013	80
23552377	L-Tyrosine	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	Journal of thoracic oncology 	2013	147
23552693	L-Tyrosine	Beaty BT	Œ≤1 integrin regulates Arg to promote invadopodial maturation and matrix degradation.	Molecular biology of the cell	2013	47
23552883	L-Tyrosine	Mitamura T	Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET.	Oncogenesis	2013	34
23559152	L-Tyrosine	Lee JK	Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.	Annals of oncology 	2013	32
23562183	L-Tyrosine	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	The Journal of molecular diagnostics 	2013	80
23569237	L-Tyrosine	Wei Y	Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2013	50
23584089	L-Tyrosine	Sadanandam A	A colorectal cancer classification system that associates cellular phenotype and responses to therapy.	Nature medicine	2013	205
23585477	L-Tyrosine	Schlegel J	MERTK receptor tyrosine kinase is a therapeutic target in melanoma.	The Journal of clinical investigation	2013	46
23592754	L-Tyrosine	Rusakiewicz S	Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.	Cancer research	2013	57
23594426	L-Tyrosine	Lee CK	Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.	Journal of the National Cancer Institute	2013	116
23596048	L-Tyrosine	Rajala HL	Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia.	Blood	2013	59
23598276	L-Tyrosine	Katayama R	Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.	Cancer research	2013	59
23601239	L-Tyrosine	Chen HX	IGF-1R as an anti-cancer target--trials and tribulations.	Chinese journal of cancer	2013	44
23610448	L-Tyrosine	Guerin E	A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.	Cancer research	2013	25
23613268	L-Tyrosine	Grunwald MR	FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.	International journal of hematology	2013	42
23613521	L-Tyrosine	Ravandi F	Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.	Blood	2013	66
23619944	L-Tyrosine	Peled N	Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.	Cellular oncology	2013	27
23620405	L-Tyrosine	Hudecek M	Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.	Clinical cancer research 	2013	105
23620574	L-Tyrosine	Jain P	Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.	Blood	2013	28
23623056	L-Tyrosine	Joensuu H	Gastrointestinal stromal tumour.	Lancet	2013	73
23624919	L-Tyrosine	Vultur A	MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines.	Oncogene	2014	23
23625998	L-Tyrosine	Kadomatsu K	The heparin-binding growth factor midkine: the biological activities and candidate receptors.	Journal of biochemistry	2013	28
23630186	L-Tyrosine	Gassenmaier M	CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.	Stem cells	2013	27
23630281	L-Tyrosine	Mahlknecht G	Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth.	Proceedings of the National Academy of Sciences of the United States of America	2013	29
23631653	L-Tyrosine	Kayser S	FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations.	Leukemia & lymphoma	2014	29
23633458	L-Tyrosine	von Roemeling CA	Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.	Clinical cancer research 	2013	49
23637631	L-Tyrosine	Giacomini CP	Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.	PLoS genetics	2013	30
23639648	L-Tyrosine	Miettinen M	Gastrointestinal stromal tumors.	Gastroenterology clinics of North America	2013	36
23644467	L-Tyrosine	Zhang K	The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis.	Nature cell biology	2013	95
23649974	L-Tyrosine	Paccez JD	The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications.	International journal of cancer	2014	37
23650389	L-Tyrosine	Acunzo M	Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.	Proceedings of the National Academy of Sciences of the United States of America	2013	40
23651669	L-Tyrosine	Gerber JM	Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations.	Oncotarget	2013	27
23656643	L-Tyrosine	Maxson JE	Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.	The New England journal of medicine	2013	100
23661005	L-Tyrosine	Hage C	The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.	Cell death & disease	2013	39
23666471	L-Tyrosine	Yang J	New molecular insights into osteosarcoma targeted therapy.	Current opinion in oncology	2013	78
23677068	L-Tyrosine	Sekido Y	Molecular pathogenesis of malignant mesothelioma.	Carcinogenesis	2013	39
23678293	L-Tyrosine	Liang J	The C-kit receptor-mediated signal transduction and tumor-related diseases.	International journal of biological sciences	2013	31
23680147	L-Tyrosine	Jaiswal BS	Oncogenic ERBB3 mutations in human cancers.	Cancer cell	2013	82
23684459	L-Tyrosine	Kim E	Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.	Cancer cell	2013	152
23684620	L-Tyrosine	Han J	Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients.	Biochemical and biophysical research communications	2013	31
23690424	L-Tyrosine	Siu LL	Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.	Journal of clinical oncology 	2013	37
23695170	L-Tyrosine	Morgillo F	Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.	Clinical cancer research 	2013	32
23719267	L-Tyrosine	Davies KD	Molecular pathways: ROS1 fusion proteins in cancer.	Clinical cancer research 	2013	54
23720580	L-Tyrosine	Chintalgattu V	Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity.	Science translational medicine	2013	28
23728339	L-Tyrosine	Kao CJ	miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.	Oncogene	2014	38
23729403	L-Tyrosine	Kutluk Cenik B	BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.	Molecular cancer therapeutics	2013	26
23743928	L-Tyrosine	Selinger CI	Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.	Modern pathology 	2013	33
23754386	L-Tyrosine	Sutto L	Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase.	Proceedings of the National Academy of Sciences of the United States of America	2013	30
23764004	L-Tyrosine	Chen L	SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.	Cancer cell	2013	37
23768755	L-Tyrosine	Roengvoraphoj M	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.	Cancer treatment reviews	2013	28
23770288	L-Tyrosine	Kamato D	Transforming growth factor-Œ≤ signalling: role and consequences of Smad linker region phosphorylation.	Cellular signalling	2013	47
23771907	L-Tyrosine	Cui B	Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.	Cancer research	2013	33
23778141	L-Tyrosine	Stephens PJ	Whole exome sequencing of adenoid cystic carcinoma.	The Journal of clinical investigation	2013	64
23782157	L-Tyrosine	Wang ML	Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.	The New England journal of medicine	2013	240
23782158	L-Tyrosine	Byrd JC	Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.	The New England journal of medicine	2013	389
23786770	L-Tyrosine	Liao RG	Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.	Cancer research	2013	54
23792360	L-Tyrosine	Yao HP	MSP-RON signalling in cancer: pathogenesis and therapeutic potential.	Nature reviews. Cancer	2013	40
23798385	L-Tyrosine	Buraschi S	Decorin causes autophagy in endothelial cells via Peg3.	Proceedings of the National Academy of Sciences of the United States of America	2013	51
23805317	L-Tyrosine	Garofalo M	MiR-34a/c-Dependent PDGFR-Œ±/Œ≤ Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.	PloS one	2013	34
23820017	L-Tyrosine	Madden SF	BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome.	Breast cancer research 	2013	39
23829935	L-Tyrosine	Remon J	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.	Cancer treatment reviews	2014	25
23830194	L-Tyrosine	Brand TM	Nuclear EGFR as a molecular target in cancer.	Radiotherapy and oncology 	2013	45
23831709	L-Tyrosine	Spiess C	Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies.	Nature biotechnology	2013	50
23835704	L-Tyrosine	Weston BW	Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.	Journal of clinical oncology 	2013	42
23836557	L-Tyrosine	Yang G	A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr√∂m macroglobulinemia.	Blood	2013	42
23836561	L-Tyrosine	Ravandi F	Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.	Blood	2013	30
23842646	L-Tyrosine	Greuber EK	Role of ABL family kinases in cancer: from leukaemia to solid tumours.	Nature reviews. Cancer	2013	81
23856031	L-Tyrosine	Okamoto K	Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.	Cancer letters	2013	28
23872583	L-Tyrosine	Kanda R	Erlotinib resistance in lung cancer cells mediated by integrin Œ≤1/Src/Akt-driven bypass signaling.	Cancer research	2013	33
23880303	L-Tyrosine	Kelleher FC	Fibroblast growth factor receptors, developmental corruption and malignant disease.	Carcinogenesis	2013	27
23883968	L-Tyrosine	Rickert RC	New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.	Nature reviews. Immunology	2013	60
23890105	L-Tyrosine	Fattore L	Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies.	Journal of translational medicine	2013	28
23896275	L-Tyrosine	Garcia-Carbonero R	Inhibition of HSP90 molecular chaperones: moving into the clinic.	The Lancet. Oncology	2013	74
23896413	L-Tyrosine	Gotlib J	The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.	Blood	2013	38
23901039	L-Tyrosine	Corso S	Cell-autonomous and non-cell-autonomous mechanisms of HGF/MET-driven resistance to targeted therapies: from basic research to a clinical perspective.	Cancer discovery	2013	25
23908138	L-Tyrosine	Tai WT	Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.	Hepatology	2014	24
23912457	L-Tyrosine	Raina D	Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.	Oncogene	2014	25
23913134	L-Tyrosine	Minami J	Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.	Leukemia	2014	24
23916671	L-Tyrosine	Mantyh P	Bone cancer pain: causes, consequences, and therapeutic opportunities.	Pain	2013	36
23921085	L-Tyrosine	Meyer AS	The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.	Science signaling	2013	67
23926299	L-Tyrosine	Warsch W	JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia.	Blood	2013	26
23927790	L-Tyrosine	Kim HR	Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping.	Journal of experimental & clinical cancer research 	2013	28
23928062	L-Tyrosine	Burger JA	B cell receptor signaling in chronic lymphocytic leukemia.	Trends in immunology	2013	52
23931927	L-Tyrosine	Gridelli C	ALK inhibitors in the treatment of advanced NSCLC.	Cancer treatment reviews	2014	39
23933118	L-Tyrosine	Thakker RV	Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4).	Molecular and cellular endocrinology	2014	46
23940216	L-Tyrosine	Batchelor TT	Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.	Journal of clinical oncology 	2013	91
23940282	L-Tyrosine	Chang BY	Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.	Blood	2013	46
23949426	L-Tyrosine	Tebbutt N	Targeting the ERBB family in cancer: couples therapy.	Nature reviews. Cancer	2013	75
23951022	L-Tyrosine	Wu YC	Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.	PloS one	2013	26
23953842	L-Tyrosine	Yewale C	Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.	Biomaterials	2013	60
23958373	L-Tyrosine	Akinleye A	Ibrutinib and novel BTK inhibitors in clinical development.	Journal of hematology & oncology	2013	51
23965898	L-Tyrosine	Barone G	New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.	Clinical cancer research 	2013	29
23970380	L-Tyrosine	Walker CJ	Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.	Blood	2013	40
23972815	L-Tyrosine	Rosell R	Genetics and biomarkers in personalisation of lung cancer treatment.	Lancet	2013	66
23982172	L-Tyrosine	Ben-Batalla I	Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma.	Blood	2013	41
23982174	L-Tyrosine	Pidala J	Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality.	Blood	2013	26
23989717	L-Tyrosine	Ky B	Emerging paradigms in cardiomyopathies associated with cancer therapies.	Circulation research	2013	35
23991695	L-Tyrosine	Kohno T	RET fusion gene: translation to personalized lung cancer therapy.	Cancer science	2013	26
23999433	L-Tyrosine	Neviani P	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.	The Journal of clinical investigation	2013	61
24002496	L-Tyrosine	Cortes JE	Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.	Journal of clinical oncology 	2013	69
24002501	L-Tyrosine	Elisei R	Cabozantinib in progressive medullary thyroid cancer.	Journal of clinical oncology 	2013	143
24009080	L-Tyrosine	Siemens H	Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness.	Oncotarget	2013	51
24019492	L-Tyrosine	Red Brewer M	Mechanism for activation of mutated epidermal growth factor receptors in lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	27
24019536	L-Tyrosine	Jacquemet G	RCP-driven Œ±5Œ≤1 recycling suppresses Rac and promotes RhoA activity via the RacGAP1-IQGAP1 complex.	The Journal of cell biology	2013	33
24019545	L-Tyrosine	Motzer RJ	Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.	Journal of clinical oncology 	2013	59
24026012	L-Tyrosine	Giles KM	Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.	Molecular cancer therapeutics	2013	33
24034250	L-Tyrosine	Wei Y	EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance.	Cell	2013	125
24044505	L-Tyrosine	Xia W	An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.	Breast cancer research 	2013	34
24045150	L-Tyrosine	Giordano S	Met as a therapeutic target in HCC: facts and hopes.	Journal of hepatology	2014	29
24046014	L-Tyrosine	Zimmerman EI	Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.	Blood	2013	43
24053309	L-Tyrosine	Nguyen DP	Inflammation and prostate cancer: the role of interleukin 6 (IL-6).	BJU international	2014	39
24054705	L-Tyrosine	Goffin JR	Epidermal growth factor receptor: pathway, therapies, and pipeline.	Clinical therapeutics	2013	25
24060861	L-Tyrosine	Hallberg B	Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.	Nature reviews. Cancer	2013	101
24065147	L-Tyrosine	Niederst MJ	Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.	Science signaling	2013	61
24072220	L-Tyrosine	Goldberg SB	Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.	The oncologist	2013	42
24082147	L-Tyrosine	Wang Y	STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor.	Proceedings of the National Academy of Sciences of the United States of America	2013	38
24096486	L-Tyrosine	Ouyang H	microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-Œ≤ actions.	Oncogene	2014	36
24101047	L-Tyrosine	Gainor JF	Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.	Journal of clinical oncology 	2013	75
24104062	L-Tyrosine	O'Connell MP	Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.	Cancer discovery	2013	50
24105277	L-Tyrosine	Hata A	Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.	Cancer	2013	46
24122810	L-Tyrosine	Arai Y	Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.	Hepatology	2014	45
24132104	L-Tyrosine	Shaw AT	Tyrosine kinase gene rearrangements in epithelial malignancies.	Nature reviews. Cancer	2013	70
24135138	L-Tyrosine	Ricarte-Filho JC	Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers.	The Journal of clinical investigation	2013	31
24135488	L-Tyrosine	Buczek M	Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms.	Biochimica et biophysica acta	2014	27
24165158	L-Tyrosine	Rho JK	MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.	Cancer research	2014	30
24170546	L-Tyrosine	Dunne PD	AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.	Clinical cancer research 	2014	29
24180494	L-Tyrosine	Cortes JE	A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.	The New England journal of medicine	2013	140
24186067	L-Tyrosine	Lemke G	Biology of the TAM receptors.	Cold Spring Harbor perspectives in biology	2013	70
24186319	L-Tyrosine	Lengline E	Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.	Haematologica	2013	28
24190997	L-Tyrosine	Batchelor TT	Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.	Proceedings of the National Academy of Sciences of the United States of America	2013	94
24199193	L-Tyrosine	Kamran MZ	Role of STAT3 in cancer metastasis and translational advances.	BioMed research international	2013	49
24199682	L-Tyrosine	Yamaguchi N	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.	Lung cancer	2014	28
24199791	L-Tyrosine	Ahmad A	Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.	Journal of hematology & oncology	2013	36
24215724	L-Tyrosine	Gieseler F	Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact.	Cell communication and signaling 	2013	37
24216507	L-Tyrosine	Chen X	Induction of myelodysplasia by myeloid-derived suppressor cells.	The Journal of clinical investigation	2013	42
24227820	L-Tyrosine	Galanis A	Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.	Blood	2014	45
24233839	L-Tyrosine	Lee HJ	Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma.	Carcinogenesis	2014	21
24240237	L-Tyrosine	Choi SH	Œ±-Catenin interacts with APC to regulate Œ≤-catenin proteolysis and transcriptional repression of Wnt target genes.	Genes & development	2013	27
24242861	L-Tyrosine	Rosenberg JE	A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.	Investigational new drugs	2014	43
24248375	L-Tyrosine	Drake JM	Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.	Proceedings of the National Academy of Sciences of the United States of America	2013	31
24258346	L-Tyrosine	Kitamura K	MiR-134/487b/655 cluster regulates TGF-Œ≤-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.	Molecular cancer therapeutics	2014	40
24263190	L-Tyrosine	Goel HL	VEGF targets the tumour cell.	Nature reviews. Cancer	2013	182
24265152	L-Tyrosine	Shi H	A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.	Cancer discovery	2014	54
24269963	L-Tyrosine	Roskoski R Jr	The ErbB/HER family of protein-tyrosine kinases and cancer.	Pharmacological research	2014	150
24270740	L-Tyrosine	Cheng S	BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.	Leukemia	2014	45
24276851	L-Tyrosine	Girnita L	Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation.	Cellular and molecular life sciences 	2014	31
24285021	L-Tyrosine	Beau-Faller M	Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.	Annals of oncology 	2014	36
24291281	L-Tyrosine	Ky B	Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.	Journal of the American College of Cardiology	2014	52
24296170	L-Tyrosine	Mellman I	Endocytosis and cancer.	Cold Spring Harbor perspectives in biology	2013	62
24296758	L-Tyrosine	Aisner DL	ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.	Molecular cancer research 	2014	35
24302556	L-Tyrosine	Malchers F	Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.	Cancer discovery	2014	24
24310612	L-Tyrosine	Nathanson DA	Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.	Science	2014	86
24311722	L-Tyrosine	Woyach JA	Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).	Blood	2014	48
24311723	L-Tyrosine	Jabbour E	Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).	Blood	2014	63
24315443	L-Tyrosine	Miller JD	Human iPSC-based modeling of late-onset disease via progerin-induced aging.	Cell stem cell	2013	146
24316259	L-Tyrosine	Ho WE	Artemisinins: pharmacological actions beyond anti-malarial.	Pharmacology & therapeutics	2014	50
24319184	L-Tyrosine	Levis M	FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?	Hematology. American Society of Hematology. Education Program	2013	38
24320965	L-Tyrosine	Cui JJ	Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.	Journal of medicinal chemistry	2014	22
24323026	L-Tyrosine	Gandhi L	Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.	Journal of clinical oncology 	2014	42
24323036	L-Tyrosine	Rousselot P	Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.	Journal of clinical oncology 	2014	41
24323901	L-Tyrosine	Touil Y	Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.	Clinical cancer research 	2014	40
24331411	L-Tyrosine	Li B	MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.	Lung cancer	2014	38
24332241	L-Tyrosine	O'Brien S	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.	The Lancet. Oncology	2014	104
24332320	L-Tyrosine	Shi L	Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.	Lung cancer	2014	22
24334603	L-Tyrosine	Shi X	Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.	Clinical cancer research 	2014	31
24355409	L-Tyrosine	Gelsomino F	Targeting the MET gene for the treatment of non-small-cell lung cancer.	Critical reviews in oncology/hematology	2014	21
24357428	L-Tyrosine	Burger JA	Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.	Current hematologic malignancy reports	2014	21
24360619	L-Tyrosine	Figueroa-Magalh√£es MC	Treatment of HER2-positive breast cancer.	Breast	2014	29
24366361	L-Tyrosine	van der Veer A	IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.	Blood	2014	26
24368849	L-Tyrosine	Mathew LK	miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma.	Proceedings of the National Academy of Sciences of the United States of America	2014	26
24374310	L-Tyrosine	Chen C	Identification of a major determinant for serine-threonine kinase phosphoacceptor specificity.	Molecular cell	2014	22
24378644	L-Tyrosine	Siegelin MD	Epidermal growth factor receptor mutations in lung adenocarcinoma.	Laboratory investigation; a journal of technical methods and pathology	2014	47
24379361	L-Tyrosine	Widhopf GF 2nd	ROR1 can interact with TCL1 and enhance leukemogenesis in EŒº-TCL1 transgenic mice.	Proceedings of the National Academy of Sciences of the United States of America	2014	22
24379393	L-Tyrosine	Atay S	Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion.	Proceedings of the National Academy of Sciences of the United States of America	2014	40
24379439	L-Tyrosine	Steinkamp MP	erbB3 is an active tyrosine kinase capable of homo- and heterointeractions.	Molecular and cellular biology	2014	27
24384534	L-Tyrosine	Maroun CR	The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.	Pharmacology & therapeutics	2014	39
24384849	L-Tyrosine	Corless CL	Gastrointestinal stromal tumors: what do we know now?	Modern pathology 	2014	25
24388873	L-Tyrosine	Siveen KS	Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors.	Biochimica et biophysica acta	2014	100
24403067	L-Tyrosine	Neill T	Decorin induces mitophagy in breast carcinoma cells via peroxisome proliferator-activated receptor Œ≥ coactivator-1Œ± (PGC-1Œ±) and mitostatin.	The Journal of biological chemistry	2014	23
24415539	L-Tyrosine	Woyach JA	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.	Blood	2014	52
24416238	L-Tyrosine	Peng Z	Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis.	PloS one	2014	21
24419415	L-Tyrosine	Watanabe S	Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.	Journal of thoracic oncology 	2014	25
24421390	L-Tyrosine	Wang JY	The capable ABL: what is its biological function?	Molecular and cellular biology	2014	29
24435449	L-Tyrosine	Liu S	Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.	Molecular cancer therapeutics	2014	22
24436047	L-Tyrosine	Shern JF	Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.	Cancer discovery	2014	96
24436048	L-Tyrosine	Will M	Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.	Cancer discovery	2014	45
24440599	L-Tyrosine	Kats LM	Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.	Cell stem cell	2014	44
24440911	L-Tyrosine	Zhang Y	Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.	Cell death and differentiation	2014	21
24441398	L-Tyrosine	Esposito CL	Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.	Molecular therapy 	2014	34
24443522	L-Tyrosine	Yang JJ	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.	Clinical cancer research 	2014	32
24456475	L-Tyrosine	Warth A	ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases.	Histopathology	2014	20
24463227	L-Tyrosine	Berasain C	Amphiregulin.	Seminars in cell & developmental biology	2014	33
24463606	L-Tyrosine	Tsai FC	A polarized Ca2+, diacylglycerol and STIM1 signalling system regulates directed cell migration.	Nature cell biology	2014	50
24472739	L-Tyrosine	Goyal A	Decorin activates AMPK, an energy sensor kinase, to induce autophagy in endothelial cells.	Matrix biology 	2014	22
24478319	L-Tyrosine	Yu HA	Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.	Annals of oncology 	2014	30
24493829	L-Tyrosine	Costa C	The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.	Clinical cancer research 	2014	55
24501009	L-Tyrosine	Reckamp KL	A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.	Cancer	2014	25
24503127	L-Tyrosine	Gao Q	Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.	Gastroenterology	2014	26
24510746	L-Tyrosine	Scartozzi M	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.	International journal of cancer	2014	22
24520092	L-Tyrosine	Gala K	Molecular pathways: HER3 targeted therapy.	Clinical cancer research 	2014	39
24525236	L-Tyrosine	Puissant A	SYK is a critical regulator of FLT3 in acute myeloid leukemia.	Cancer cell	2014	36
24533047	L-Tyrosine	Liang W	Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.	PloS one	2014	25
24535670	L-Tyrosine	de Bruin EC	Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.	Cancer discovery	2014	42
24556040	L-Tyrosine	Motzer RJ	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	55
24561444	L-Tyrosine	Mulligan LM	RET revisited: expanding the oncogenic portfolio.	Nature reviews. Cancer	2014	68
24563076	L-Tyrosine	Ross JS	New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.	The oncologist	2014	61
24604288	L-Tyrosine	Hu X	Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.	International journal of cancer	2014	30
24609268	L-Tyrosine	Guilluy C	Isolated nuclei adapt to force and reveal a mechanotransduction pathway in the nucleus.	Nature cell biology	2014	92
24621885	L-Tyrosine	Zhang Y	MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.	PloS one	2014	24
24623852	L-Tyrosine	Smith CC	Crenolanib is a selective type I pan-FLT3 inhibitor.	Proceedings of the National Academy of Sciences of the United States of America	2014	35
24626858	L-Tyrosine	Nagatsuma AK	Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.	Gastric cancer 	2015	27
24632616	L-Tyrosine	Hardy S	The protein tyrosine phosphatase PRL-2 interacts with the magnesium transporter CNNM3 to promote oncogenesis.	Oncogene	2015	19
24633157	L-Tyrosine	Behjati S	Recurrent PTPRB and PLCG1 mutations in angiosarcoma.	Nature genetics	2014	38
24636848	L-Tyrosine	Reguart N	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.	Lung cancer	2014	21
24643470	L-Tyrosine	Modjtahedi H	A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.	Naunyn-Schmiedeberg's archives of pharmacology	2014	23
24644001	L-Tyrosine	Li L	Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.	Clinical cancer research 	2014	54
24654231	L-Tyrosine	Chen R	A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma.	Cancer research	2014	34
24657661	L-Tyrosine	Corrado C	Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8-dependent survival of leukemia cells.	Cancer letters	2014	40
24658140	L-Tyrosine	Petschnigg J	The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells.	Nature methods	2014	26
24658273	L-Tyrosine	Hendriks RW	Targeting Bruton's tyrosine kinase in B cell malignancies.	Nature reviews. Cancer	2014	56
24658326	L-Tyrosine	Knubel KH	MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme.	Oncotarget	2014	22
24659631	L-Tyrosine	Herman SE	Ibrutinib inhibits BCR and NF-Œ∫B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.	Blood	2014	46
24659719	L-Tyrosine	Burke RT	A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.	Oncotarget	2014	22
24662820	L-Tyrosine	Beristain AG	PKA signaling drives mammary tumorigenesis through Src.	Oncogene	2015	17
24664307	L-Tyrosine	Johnson GL	Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.	Clinical cancer research 	2014	20
24685132	L-Tyrosine	Sun C	Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.	Cell reports	2014	51
24691965	L-Tyrosine	Lemmon MA	The EGFR family: not so prototypical receptor tyrosine kinases.	Cold Spring Harbor perspectives in biology	2014	62
24705251	L-Tyrosine	Wu G	The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.	Nature genetics	2014	141
24715074	L-Tyrosine	Lee JK	Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.	JAMA	2014	33
24718867	L-Tyrosine	Patwardhan PP	Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs.	Clinical cancer research 	2014	20
24725424	L-Tyrosine	Leitinger B	Discoidin domain receptor functions in physiological and pathological conditions.	International review of cell and molecular biology	2014	41
24727677	L-Tyrosine	Spirin PV	Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling.	Leukemia	2014	21
24729196	L-Tyrosine	Jabbour E	Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.	American journal of hematology	2014	40
24737315	L-Tyrosine	Poluzzi C	Endorepellin evokes autophagy in endothelial cells.	The Journal of biological chemistry	2014	21
24737502	L-Tyrosine	Alvarado Y	Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.	Cancer	2014	21
24737648	L-Tyrosine	Zhao M	The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.	Cancer	2014	23
24743704	L-Tyrosine	Li S	Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.	British journal of cancer	2014	29
24747441	L-Tyrosine	Seguin L	An integrin Œ≤‚ÇÉ-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.	Nature cell biology	2014	77
24768581	L-Tyrosine	Kuiper JL	Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.	Lung cancer	2014	28
24771645	L-Tyrosine	Wynes MW	FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.	Clinical cancer research 	2014	46
24790650	L-Tyrosine	D'Antonio C	Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies.	Therapeutic advances in medical oncology	2014	26
24800946	L-Tyrosine	Takahashi N	Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer.	British journal of cancer	2014	22
24811343	L-Tyrosine	Sehgal L	FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.	Leukemia	2014	29
24813888	L-Tyrosine	Pirazzoli V	Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.	Cell reports	2014	23
24814346	L-Tyrosine	Shi Y	PTEN is a protein tyrosine phosphatase for IRS1.	Nature structural & molecular biology	2014	21
24815784	L-Tyrosine	Reiss KA	Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.	Immunotherapy	2014	20
24821329	L-Tyrosine	Di Ieva A	Aggressive pituitary adenomas--diagnosis and emerging treatments.	Nature reviews. Endocrinology	2014	24
24827131	L-Tyrosine	Choueiri TK	A phase I study of cabozantinib (XL184) in patients with renal cell cancer.	Annals of oncology 	2014	26
24829205	L-Tyrosine	Wodarz D	Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.	Blood	2014	23
24830724	L-Tyrosine	Izumchenko E	The TGFŒ≤-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.	Cancer research	2014	24
24831979	L-Tyrosine	Gregorc V	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.	The Lancet. Oncology	2014	44
24837095	L-Tyrosine	Graham RP	Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.	Human pathology	2014	28
24843152	L-Tyrosine	Lupardus PJ	Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.	Proceedings of the National Academy of Sciences of the United States of America	2014	29
24850843	L-Tyrosine	Wang R	FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.	Clinical cancer research 	2014	31
24856188	L-Tyrosine	Stenman G	Diagnostic and therapeutic implications of new molecular biomarkers in salivary gland cancers.	Oral oncology	2014	25
24857124	L-Tyrosine	Gerber DE	Management and future directions in non-small cell lung cancer with known activating mutations.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2014	24
24867380	L-Tyrosine	Liu S	Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.	Cancer treatment reviews	2014	32
24867389	L-Tyrosine	Simbolo M	Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.	Oncotarget	2014	33
24869598	L-Tyrosine	Woyach JA	Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.	The New England journal of medicine	2014	164
24874471	L-Tyrosine	Chen Y	Identification of druggable cancer driver genes amplified across TCGA datasets.	PloS one	2014	38
24881631	L-Tyrosine	Byrd JC	Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.	The New England journal of medicine	2014	203
24886126	L-Tyrosine	Ma J	Targeting of erbB3 receptor to overcome resistance in cancer treatment.	Molecular cancer	2014	31
24893891	L-Tyrosine	Cross DA	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.	Cancer discovery	2014	219
24897931	L-Tyrosine	Martini M	PI3K/AKT signaling pathway and cancer: an updated review.	Annals of medicine	2014	98
24911146	L-Tyrosine	Park KS	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.	The Journal of clinical investigation	2014	20
24913799	L-Tyrosine	Van Emburgh BO	Acquired resistance to EGFR-targeted therapies in¬†colorectal cancer.	Molecular oncology	2014	24
24918548	L-Tyrosine	Shan Y	Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase.	Nature structural & molecular biology	2014	22
24919575	L-Tyrosine	Yoshida T	Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.	Clinical cancer research 	2014	31
24928736	L-Tyrosine	Roskoski R Jr	ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.	Pharmacological research	2014	29
24939055	L-Tyrosine	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental & clinical cancer research 	2014	24
24950332	L-Tyrosine	Fu D	Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering.	Nature chemistry	2014	27
24957147	L-Tyrosine	Gallipoli P	JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.	Blood	2014	24
24973425	L-Tyrosine	Zhang Z	Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.	Clinical cancer research 	2014	24
24975478	L-Tyrosine	Geahlen RL	Getting Syk: spleen tyrosine kinase as a therapeutic target.	Trends in pharmacological sciences	2014	32
24981256	L-Tyrosine	Camidge DR	Acquired resistance to TKIs in solid tumours: learning from lung cancer.	Nature reviews. Clinical oncology	2014	138
25042202	L-Tyrosine	Younes A	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.	The Lancet. Oncology	2014	48
25043054	L-Tyrosine	Zhang B	Proteogenomic characterization of human colon and rectal cancer.	Nature	2014	220
25049327	L-Tyrosine	Roberts KG	Outcomes of children with BCR-ABL1‚Äìlike acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.	Journal of clinical oncology 	2014	41
25052473	L-Tyrosine	Derwahl M	Estrogen and its role in thyroid cancer.	Endocrine-related cancer	2014	23
25053825	L-Tyrosine	Fiskus W	BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.	Molecular cancer therapeutics	2014	40
25056203	L-Tyrosine	Zhang H	ROR1 expression correlated with poor clinical outcome in human ovarian cancer.	Scientific reports	2014	24
25066121	L-Tyrosine	Porporato PE	A mitochondrial switch promotes tumor metastasis.	Cell reports	2014	80
25071110	L-Tyrosine	Schleiermacher G	Emergence of new ALK mutations at relapse of neuroblastoma.	Journal of clinical oncology 	2014	32
25073158	L-Tyrosine	Chou RH	EGFR modulates DNA synthesis and repair through Tyr phosphorylation of histone H4.	Developmental cell	2014	23
25081536	L-Tyrosine	Grass GD	CD147: regulator of hyaluronan signaling in invasiveness and chemoresistance.	Advances in cancer research	2014	21
25082755	L-Tyrosine	Chiron D	Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.	Cancer discovery	2014	41
25086175	L-Tyrosine	Ferris RL	Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion.	Journal of immunology	2014	31
25092144	L-Tyrosine	Gerloff D	NF-Œ∫B/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.	Leukemia	2015	27
25098269	L-Tyrosine	Sulzmaier FJ	FAK in cancer: mechanistic findings and clinical applications.	Nature reviews. Cancer	2014	170
25100872	L-Tyrosine	Kaley TJ	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.	Neuro-oncology	2015	16
25103305	L-Tyrosine	Sorensen BS	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.	Cancer	2014	44
25125655	L-Tyrosine	Arasada RR	EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling.	Cancer research	2014	23
25125659	L-Tyrosine	Wilson C	AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs.	Cancer research	2014	28
25134459	L-Tyrosine	Eiring AM	Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.	Leukemia	2015	29
25136066	L-Tyrosine	Brand TM	AXL mediates resistance to cetuximab therapy.	Cancer research	2014	33
25138588	L-Tyrosine	Kamel S	Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.	Leukemia	2015	31
25150798	L-Tyrosine	Burger JA	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.	The Lancet. Oncology	2014	66
25173427	L-Tyrosine	Lovly CM	Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.	Nature medicine	2014	65
25175099	L-Tyrosine	Seto T	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.	The Lancet. Oncology	2014	95
25178641	L-Tyrosine	Millis SZ	Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.	Clinical genitourinary cancer	2015	15
25186177	L-Tyrosine	Wan X	Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.	Science translational medicine	2014	26
25187556	L-Tyrosine	Rankin EB	Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.	Proceedings of the National Academy of Sciences of the United States of America	2014	44
25189416	L-Tyrosine	Cheng S	Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.	Leukemia	2015	24
25193510	L-Tyrosine	Mazumdar T	A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.	Molecular cancer therapeutics	2014	21
25193862	L-Tyrosine	Wilson C	Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.	Oncotarget	2014	37
25193870	L-Tyrosine	Degryse S	JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.	Blood	2014	27
25193986	L-Tyrosine	Zhang JX	MiR-29c mediates epithelial-to-mesenchymal transition in human colorectal carcinoma metastasis via PTP4A and GNA13 regulation of Œ≤-catenin signaling.	Annals of oncology 	2014	22
25202833	L-Tyrosine	Hsueh AJ	Intraovarian control of early folliculogenesis.	Endocrine reviews	2015	25
25207766	L-Tyrosine	Roberts KG	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.	The New England journal of medicine	2014	178
25209362	L-Tyrosine	Nikiforov YE	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.	Cancer	2014	62
25209439	L-Tyrosine	Henry C	Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both Œ≤-catenin dependent and independent Wnt signalling.	Journal of cancer research and clinical oncology	2015	16
25220640	L-Tyrosine	He RJ	Protein tyrosine phosphatases as potential therapeutic targets.	Acta pharmacologica Sinica	2014	30
25222496	L-Tyrosine	Zhang Y	Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.	PloS one	2014	32
25225437	L-Tyrosine	Smith MR	Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.	Journal of clinical oncology 	2014	27
25228534	L-Tyrosine	Katayama R	Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.	Clinical cancer research 	2014	56
25231999	L-Tyrosine	Konig H	Targeting FLT3 to treat leukemia.	Expert opinion on therapeutic targets	2015	23
25239228	L-Tyrosine	Chen YB	Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.	Biology of blood and marrow transplantation 	2014	34
25240910	L-Tyrosine	Bauer TM	Targeting PI3 kinase in cancer.	Pharmacology & therapeutics	2015	23
25242553	L-Tyrosine	Kariolis MS	An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.	Nature chemical biology	2014	23
25247337	L-Tyrosine	Hoffknecht P	Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.	Journal of thoracic oncology 	2015	42
25249658	L-Tyrosine	Gonzalez DM	Signaling mechanisms of the epithelial-mesenchymal transition.	Science signaling	2014	170
25250573	L-Tyrosine	Stanford JC	Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution.	The Journal of clinical investigation	2014	24
25251599	L-Tyrosine	Reichl P	Axl activates autocrine transforming growth factor-Œ≤ signaling in hepatocellular carcinoma.	Hepatology	2015	26
25263564	L-Tyrosine	Toso A	Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.	Cell reports	2014	38
25264305	L-Tyrosine	Shaw AT	Crizotinib in ROS1-rearranged non-small-cell lung cancer.	The New England journal of medicine	2014	220
25270908	L-Tyrosine	Schlenk RF	Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.	Blood	2014	33
25276427	L-Tyrosine	Iqbal N	Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications.	Molecular biology international	2014	51
25303979	L-Tyrosine	Yu HA	Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.	Clinical cancer research 	2014	29
25305202	L-Tyrosine	Levade M	Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.	Blood	2014	34
25311215	L-Tyrosine	Leighl NB	Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.	Journal of clinical oncology 	2014	49
25316657	L-Tyrosine	Lee BY	FAK signaling in human cancer as a target for therapeutics.	Pharmacology & therapeutics	2015	31
25319834	L-Tyrosine	Lee JC	Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour.	The Journal of pathology	2015	15
25322323	L-Tyrosine	Awad MM	ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.	Clinical advances in hematology & oncology 	2014	48
25323681	L-Tyrosine	Rozengurt E	Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance.	Molecular cancer therapeutics	2014	34
25332238	L-Tyrosine	Abu-Thuraia A	Axl phosphorylates Elmo scaffold proteins to promote Rac activation and cell invasion.	Molecular and cellular biology	2015	21
25337673	L-Tyrosine	Wu X	AXL kinase as a novel target for cancer therapy.	Oncotarget	2014	44
25344523	L-Tyrosine	Da Roit F	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.	Haematologica	2015	32
25344858	L-Tyrosine	Axelrod H	Axl as a mediator of cellular growth and survival.	Oncotarget	2014	26
25351743	L-Tyrosine	Katayama R	Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.	Clinical cancer research 	2015	25
25353071	L-Tyrosine	Dadu R	Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.	The Journal of clinical endocrinology and metabolism	2015	21
25355068	L-Tyrosine	Berger C	Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.	Cancer immunology research	2015	26
25369307	L-Tyrosine	Rizvi S	Cholangiocarcinoma: molecular pathways and therapeutic opportunities.	Seminars in liver disease	2014	31
25374165	L-Tyrosine	Lei YY	Mitogen-activated protein kinase signal transduction in solid tumors.	Asian Pacific journal of cancer prevention 	2014	21
25376790	L-Tyrosine	Hu X	Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.	BMC cancer	2014	21
25381264	L-Tyrosine	Ciamporcero E	Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models.	Molecular cancer therapeutics	2015	19
25403583	L-Tyrosine	Won JK	Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.	Annals of oncology 	2015	19
25405368	L-Tyrosine	Chiyomaru T	Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer.	International journal of oncology	2015	25
25405807	L-Tyrosine	Wang Z	Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.	PloS one	2014	41
25411317	L-Tyrosine	Zhang S	Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.	Proceedings of the National Academy of Sciences of the United States of America	2014	38
25420417	L-Tyrosine	Geng R	Apatinib for the treatment of gastric cancer.	Expert opinion on pharmacotherapy	2015	17
25456362	L-Tyrosine	J√§nne PA	Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2014	20
25468140	L-Tyrosine	Kalia M	Biomarkers for personalized oncology: recent advances and future challenges.	Metabolism	2015	36
25468223	L-Tyrosine	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	30
25474320	L-Tyrosine	Roth GJ	Nintedanib: from discovery to the clinic.	Journal of medicinal chemistry	2015	16
25474488	L-Tyrosine	Su J	MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer.	PloS one	2014	23
25482516	L-Tyrosine	Cheng N	Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer.	Oncology reports	2015	22
25492965	L-Tyrosine	Haskins JW	Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.	Science signaling	2014	29
25500121	L-Tyrosine	Girotti MR	Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.	Cancer cell	2015	45
25501033	L-Tyrosine	Penna E	miR-214 as a key hub that controls cancer networks: small player, multiple functions.	The Journal of investigative dermatology	2015	28
25502142	L-Tyrosine	M√ºller J	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.	Nature communications	2014	69
25517749	L-Tyrosine	Bresler SC	ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.	Cancer cell	2014	58
25527197	L-Tyrosine	Vaishnavi A	TRKing down an old oncogene in a new era of targeted therapy.	Cancer discovery	2015	33
25542448	L-Tyrosine	Miao B	EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.	Cancer discovery	2015	17
25544636	L-Tyrosine	Schwartz S	Feedback suppression of PI3KŒ± signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3KŒ≤.	Cancer cell	2015	48
25563590	L-Tyrosine	Moody TW	EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer.	Current drug targets	2016	11
25568918	L-Tyrosine	Graham DK	The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.	Nature reviews. Cancer	2014	87
25572173	L-Tyrosine	Ran L	Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.	Cancer discovery	2015	22
25573003	L-Tyrosine	Burke JE	Synergy in activating class I PI3Ks.	Trends in biochemical sciences	2015	20
25573991	L-Tyrosine	Jain P	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.	Blood	2015	44
25583177	L-Tyrosine	Beuselinck B	Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.	Clinical cancer research 	2015	18
25594431	L-Tyrosine	Rothlin CV	TAM receptor signaling in immune homeostasis.	Annual review of immunology	2015	54
25605972	L-Tyrosine	Murray PB	Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK.	Science signaling	2015	24
25611025	L-Tyrosine	Liao BC	Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.	Current opinion in oncology	2015	16
25628918	L-Tyrosine	Huang J	MicroRNA regulation and therapeutic targeting of survivin in cancer.	American journal of cancer research	2015	15
25658601	L-Tyrosine	Bertaux-Skeirik N	CD44 plays a functional role in Helicobacter pylori-induced epithelial cell proliferation.	PLoS pathogens	2015	25
25662504	L-Tyrosine	Kondapalli KC	A leak pathway for luminal protons in endosomes drives oncogenic signalling in glioblastoma.	Nature communications	2015	16
25663685	L-Tyrosine	Eke I	Simultaneous Œ≤1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.	Journal of the National Cancer Institute	2015	22
25668120	L-Tyrosine	Chiu CH	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.	Journal of thoracic oncology 	2015	23
25670642	L-Tyrosine	Wang HB	Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells.	Nature communications	2015	21
25686603	L-Tyrosine	Pemovska T	Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.	Nature	2015	31
25712686	L-Tyrosine	DeMichele A	The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.	Clinical cancer research 	2015	18
25731159	L-Tyrosine	Taniguchi K	A gp130-Src-YAP module links inflammation to epithelial regeneration.	Nature	2015	84
25742700	L-Tyrosine	Alinari L	Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.	Blood	2015	20
25758528	L-Tyrosine	Niederst MJ	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.	Nature communications	2015	67
25759025	L-Tyrosine	Geng H	Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.	Cancer cell	2015	23
25760142	L-Tyrosine	Bae SY	Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.	Oncotarget	2015	16
25767293	L-Tyrosine	Brand TM	AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.	Clinical cancer research 	2015	18
25769900	L-Tyrosine	Zhu G	Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer.	The Journal of molecular diagnostics 	2015	32
25779941	L-Tyrosine	Rusan M	Genomic landscape of human papillomavirus-associated cancers.	Clinical cancer research 	2015	21
25792358	L-Tyrosine	Collins VP	Pilocytic astrocytoma: pathology, molecular mechanisms and markers.	Acta neuropathologica	2015	17
25794154	L-Tyrosine	Yang F	Protein domain-level landscape of cancer-type-specific somatic mutations.	PLoS computational biology	2015	17
25797245	L-Tyrosine	Chiron D	Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.	Oncotarget	2015	19
25799995	L-Tyrosine	Chen Z	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.	Nature	2015	30
25801750	L-Tyrosine	Lin C	Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.	Clinical lung cancer	2015	18
25805587	L-Tyrosine	Young RM	B-cell receptor signaling in diffuse large B-cell lymphoma.	Seminars in hematology	2015	30
25807554	L-Tyrosine	Tang MC	Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.	PloS one	2015	17
25814080	L-Tyrosine	Baccarani M	A review of the European LeukemiaNet recommendations for the management of CML.	Annals of hematology	2015	17
25814448	L-Tyrosine	Tsai CF	Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics.	Nature communications	2015	19
25814554	L-Tyrosine	Grossmann A	Phospho-tyrosine dependent protein-protein interaction network.	Molecular systems biology	2015	15
25829398	L-Tyrosine	Cervantes-Gomez F	Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.	Clinical cancer research 	2015	37
25838351	L-Tyrosine	Hing ZA	Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.	Blood	2015	16
25846096	L-Tyrosine	Oser MG	Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.	The Lancet. Oncology	2015	62
25846554	L-Tyrosine	Pailler E	High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.	Annals of oncology 	2015	28
25852056	L-Tyrosine	Thol F	How I treat refractory and early relapsed acute myeloid leukemia.	Blood	2015	22
25852057	L-Tyrosine	Flynn R	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.	Blood	2015	19
25853747	L-Tyrosine	Treon SP	Ibrutinib in previously treated Waldenstr√∂m's macroglobulinemia.	The New England journal of medicine	2015	88
25855404	L-Tyrosine	Furnari FB	Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma.	Nature reviews. Cancer	2015	51
25861727	L-Tyrosine	Costa PM	MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.	Journal of controlled release 	2015	22
25865556	L-Tyrosine	Han T	PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.	Journal of hepatology	2015	19
25865888	L-Tyrosine	Stuhlmiller TJ	Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.	Cell reports	2015	59
25866791	L-Tyrosine	Brahmkhatri VP	Insulin-like growth factor system in cancer: novel targeted therapies.	BioMed research international	2015	21
25870145	L-Tyrosine	Eberlein CA	Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.	Cancer research	2015	46
25870799	L-Tyrosine	Yip PY	Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.	Translational lung cancer research	2015	20
25873174	L-Tyrosine	Crescenzo R	Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.	Cancer cell	2015	54
25873175	L-Tyrosine	Elkabets M	AXL mediates resistance to PI3KŒ± inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.	Cancer cell	2015	42
25882375	L-Tyrosine	Ali SM	Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.	The oncologist	2015	18
25882755	L-Tyrosine	Watanabe M	Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.	Clinical cancer research 	2015	50
25887320	L-Tyrosine	Ho-Yen CM	The clinical and functional significance of c-Met in breast cancer: a review.	Breast cancer research 	2015	25
25888090	L-Tyrosine	Iragavarapu C	Novel ALK inhibitors in clinical use and development.	Journal of hematology & oncology	2015	36
25895031	L-Tyrosine	Tang Y	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.	Oncotarget	2015	45
25897154	L-Tyrosine	Lee CK	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.	Journal of clinical oncology 	2015	40
25899785	L-Tyrosine	Kris MG	Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.	Annals of oncology 	2015	27
25913680	L-Tyrosine	Cabanillas ME	A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.	Cancer	2015	15
25917266	L-Tyrosine	Malinowska-Ozdowy K	KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia.	Leukemia	2015	17
25918719	L-Tyrosine	Tai YL	Emerging roles of focal adhesion kinase in cancer.	BioMed research international	2015	28
25925741	L-Tyrosine	Dong S	The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.	Journal of hematology & oncology	2015	26
25928165	L-Tyrosine	Hirano T	Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression.	Molecular cancer	2015	18
25939061	L-Tyrosine	Thress KS	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.	Nature medicine	2015	164
25949902	L-Tyrosine	Draghiciu O	Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.	Oncoimmunology	2015	17
25961915	L-Tyrosine	Yonesaka K	Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.	Oncogene	2016	11
25971713	L-Tyrosine	Jabbour E	Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.	Clinical lymphoma, myeloma & leukemia	2015	17
25971889	L-Tyrosine	Cao HH	Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.	Molecular cancer	2015	20
25972157	L-Tyrosine	Liu TM	Hypermorphic mutation of phospholipase C, Œ≥2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.	Blood	2015	21
25979927	L-Tyrosine	Politi K	Lung cancer in the era of precision medicine.	Clinical cancer research 	2015	15
25998384	L-Tyrosine	Lin K	EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-Œ∫B.	Biochemical and biophysical research communications	2015	20
26015511	L-Tyrosine	G√∂ke F	FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers.	Clinical cancer research 	2015	16
26020382	L-Tyrosine	Mao C	Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.	Medicine	2015	16
26022942	L-Tyrosine	Steuer CE	Targeting EGFR in lung cancer: Lessons learned and future perspectives.	Molecular aspects of medicine	2015	17
26032687	L-Tyrosine	Liffers K	Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.	Targeted oncology	2016	11
26036643	L-Tyrosine	Tricker EM	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.	Cancer discovery	2015	41
26051236	L-Tyrosine	Yang JC	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.	The Lancet. Oncology	2015	57
26052929	L-Tyrosine	Lee Y	Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.	Molecular carcinogenesis	2016	15
26058079	L-Tyrosine	Stratikopoulos EE	Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.	Cancer cell	2015	32
26066081	L-Tyrosine	Tomas A	WASH and Tsg101/ALIX-dependent diversion of stress-internalized EGFR from the canonical endocytic pathway.	Nature communications	2015	16
26108694	L-Tyrosine	Smith CC	FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.	Leukemia	2015	16
26124204	L-Tyrosine	Della Corte CM	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.	Clinical cancer research 	2015	23
26141208	L-Tyrosine	Zhou C	Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).	Annals of oncology 	2015	50
26153496	L-Tyrosine	Yoshioka H	A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).	Annals of oncology 	2015	18
26160838	L-Tyrosine	Cheng N	Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.	Oncotarget	2015	28
26168295	L-Tyrosine	Burggraaf J	Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met.	Nature medicine	2015	31
26170206	L-Tyrosine	Rai KR	Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia.	Journal of hematology & oncology	2015	15
26172401	L-Tyrosine	Park IK	Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.	Leukemia	2015	18
26181354	L-Tyrosine	Yu HA	Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.	JAMA oncology	2015	32
26182302	L-Tyrosine	Ross JS	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.	JAMA oncology	2015	24
26182309	L-Tyrosine	Maddocks KJ	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.	JAMA oncology	2015	55
26186743	L-Tyrosine	Yeung AW	Role of indoleamine 2,3-dioxygenase in health and disease.	Clinical science	2015	20
26192967	L-Tyrosine	Toulany M	Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation.	Seminars in cancer biology	2015	19
26193078	L-Tyrosine	Ten Hacken E	Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.	Biochimica et biophysica acta	2016	26
26199389	L-Tyrosine	Scala S	Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.	Clinical cancer research 	2015	19
26201448	L-Tyrosine	Khella HWZ	miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.	Molecular therapy 	2015	15
26206560	L-Tyrosine	Kirane A	Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.	Cancer research	2015	17
26227959	L-Tyrosine	Sun W	Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer.	Journal of hematology & oncology	2015	30
26237430	L-Tyrosine	Lavall√©e VP	The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.	Nature genetics	2015	23
26243863	L-Tyrosine	Kavuri SM	HER2 activating mutations are targets for colorectal cancer treatment.	Cancer discovery	2015	26
26261265	L-Tyrosine	Qian BZ	FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis.	The Journal of experimental medicine	2015	21
26269204	L-Tyrosine	Planchard D	EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.	Annals of oncology 	2015	45
26282169	L-Tyrosine	Soucheray M	Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.	Cancer research	2015	19
26282175	L-Tyrosine	Guo G	Ligand-Independent EGFR Signaling.	Cancer research	2015	22
26283684	L-Tyrosine	Dunne PD	EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.	Clinical cancer research 	2016	13
26286024	L-Tyrosine	Ramsdale R	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.	Science signaling	2015	18
26286850	L-Tyrosine	Larrue C	Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.	Blood	2016	14
26295376	L-Tyrosine	Marchetti A	Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.	Journal of thoracic oncology 	2015	37
26297432	L-Tyrosine	Bora-Singhal N	Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.	Neoplasia	2015	19
26302406	L-Tyrosine	Kourtidis A	Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120¬†catenin activity.	Nature cell biology	2015	22
26305508	L-Tyrosine	Lu C	Over-expression of ROR2 and Wnt5a cooperatively correlates with unfavorable prognosis in patients with non-small cell lung cancer.	Oncotarget	2015	18
26308162	L-Tyrosine	Russo A	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.	Oncotarget	2015	38
26324363	L-Tyrosine	Tabernero J	Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.	Journal of clinical oncology 	2015	44
26324372	L-Tyrosine	Kelly K	Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.	Journal of clinical oncology 	2015	24
26331539	L-Tyrosine	Prost S	Erosion of the chronic myeloid leukaemia stem cell pool by PPARŒ≥ agonists.	Nature	2015	29
26334838	L-Tyrosine	Ishii H	Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.	Oncotarget	2015	19
26354436	L-Tyrosine	Narayana SK	The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry.	The Journal of biological chemistry	2015	21
26364599	L-Tyrosine	Zhou L	Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.	Oncogene	2016	39
26370354	L-Tyrosine	Tan CS	Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.	The Lancet. Oncology	2015	50
26387544	L-Tyrosine	Meads MB	Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.	Oncogene	2016	11
26399658	L-Tyrosine	Caunt CJ	MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.	Nature reviews. Cancer	2015	61
26406150	L-Tyrosine	Choueiri TK	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.	The New England journal of medicine	2015	118
26416732	L-Tyrosine	Bertotti A	The genomic landscape of response to EGFR blockade in colorectal cancer.	Nature	2015	65
26429980	L-Tyrosine	Iams WT	Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.	Clinical cancer research 	2015	20
26432786	L-Tyrosine	Sameni M	Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.	Clinical cancer research 	2016	12
26444240	L-Tyrosine	Wiesner T	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer.	Nature	2015	31
26444637	L-Tyrosine	Kroemer G	Natural and therapy-induced immunosurveillance in breast cancer.	Nature medicine	2015	40
26446944	L-Tyrosine	Sundaresan TK	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.	Clinical cancer research 	2016	67
26461059	L-Tyrosine	Kuan FC	Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis.	British journal of cancer	2015	19
26473186	L-Tyrosine	Kim J	Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise.	Clinical cancer research 	2015	21
26489445	L-Tyrosine	Kuboki Y	Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.	Annals of oncology 	2016	12
26496898	L-Tyrosine	Zhang N	HER3/ErbB3, an emerging cancer therapeutic target.	Acta biochimica et biophysica Sinica	2016	11
26536822	L-Tyrosine	Tarighat SS	The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.	Leukemia	2016	18
26538619	L-Tyrosine	Stafford JH	Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.	Neuro-oncology	2016	23
26545934	L-Tyrosine	Suzawa K	Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.	Cancer science	2016	15
26554308	L-Tyrosine	Zhou J	Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.	Oncotarget	2015	16
26555154	L-Tyrosine	Myers SH	AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.	Journal of medicinal chemistry	2016	21
26563355	L-Tyrosine	Sartore-Bianchi A	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.	Journal of the National Cancer Institute	2016	13
26573073	L-Tyrosine	Melosky B	Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.	Journal of clinical oncology 	2016	12
26575700	L-Tyrosine	Tan H	miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer.	International journal of oncology	2016	10
26576830	L-Tyrosine	Zhao C	Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism.	Trends in pharmacological sciences	2016	17
26577492	L-Tyrosine	Sueoka-Aragane N	Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.	Cancer science	2016	18
26584640	L-Tyrosine	Yin Y	mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR.	Cell research	2016	12
26589495	L-Tyrosine	Cang S	ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.	Journal of hematology & oncology	2015	41
26599344	L-Tyrosine	Shi Y	Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study.	PloS one	2015	18
26601866	L-Tyrosine	Wong DJ	Targeted Therapy for Melanoma.	Cancer treatment and research	2016	10
26616860	L-Tyrosine	Debruyne DN	ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.	Oncogene	2016	16
26619122	L-Tyrosine	Hedberg ML	Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.	The Journal of clinical investigation	2016	21
26620497	L-Tyrosine	Shea M	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.	Therapeutic advances in respiratory disease	2016	21
26627015	L-Tyrosine	Wong SQ	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.	Cancer research	2015	27
26627737	L-Tyrosine	Hart T	High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.	Cell	2015	127
26628631	L-Tyrosine	Wiestner A	The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.	Haematologica	2015	18
26641137	L-Tyrosine	Byrd JC	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.	The New England journal of medicine	2016	58
26655421	L-Tyrosine	Chanan-Khan A	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.	The Lancet. Oncology	2016	28
26655502	L-Tyrosine	Mat√† R	IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway.	Oncotarget	2016	11
26655835	L-Tyrosine	Guo X	Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.	Nature cell biology	2016	14
26678713	L-Tyrosine	Uchida J	Dynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment.	Cancer science	2016	11
26693896	L-Tyrosine	Mirzaei H	MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma.	European journal of cancer	2016	18
26698910	L-Tyrosine	Shaw AT	Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.	The New England journal of medicine	2016	62
26701983	L-Tyrosine	Zhou X	Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression.	Journal of the American Society of Nephrology 	2016	13
26716903	L-Tyrosine	Nanjo S	High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.	Oncotarget	2016	12
26719536	L-Tyrosine	Isozaki H	Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.	Cancer research	2016	15
26722841	L-Tyrosine	Heppner DE	Redox-dependent regulation of epidermal growth factor receptor signaling.	Redox biology	2016	12
26724471	L-Tyrosine	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	24
26729027	L-Tyrosine	Khatri A	Multifunctional Abl kinases in health and disease.	Journal of cell science	2016	11
26729184	L-Tyrosine	Greig SL	Osimertinib: First Global Approval.	Drugs	2016	21
26730496	L-Tyrosine	Furtek SL	Strategies and Approaches of Targeting STAT3 for Cancer Treatment.	ACS chemical biology	2016	38
26733183	L-Tyrosine	Geiger JL	The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.	Oral oncology	2016	16
26751586	L-Tyrosine	Fujita S	Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib.	Journal of thoracic oncology 	2016	14
26763248	L-Tyrosine	Scaltriti M	Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy.	Clinical cancer research 	2016	12
26768482	L-Tyrosine	Seki Y	Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.	The oncologist	2016	14
26771606	L-Tyrosine	Wang Z	Transactivation of Epidermal Growth Factor Receptor by G Protein-Coupled Receptors: Recent Progress, Challenges and Future Research.	International journal of molecular sciences	2016	14
26773212	L-Tyrosine	Donzelli S	MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer.	Seminars in cell & developmental biology	2016	11
26779812	L-Tyrosine	Du Y	Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.	Nature medicine	2016	22
26789630	L-Tyrosine	Yoshida T	ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.	PloS one	2016	17
26799287	L-Tyrosine	Del Re M	Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.	Oncotarget	2017	13
26799612	L-Tyrosine	Jabbour E	Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.	American journal of hematology	2016	13
26824988	L-Tyrosine	de Melo Gagliato D	Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.	Oncotarget	2016	25
26833433	L-Tyrosine	Carvalho S	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.	British journal of pharmacology	2016	11
26840022	L-Tyrosine	Pan W	KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.	Oncotarget	2016	12
26845114	L-Tyrosine	Zhou C	Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature.	Journal of thoracic oncology 	2016	13
26852079	L-Tyrosine	van der Wekken AJ	Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature.	Critical reviews in oncology/hematology	2016	18
26855149	L-Tyrosine	Ambrogio C	Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.	Nature medicine	2016	20
26855150	L-Tyrosine	Noll EM	CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.	Nature medicine	2016	15
26859458	L-Tyrosine	Iacobucci I	Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia.	Cancer cell	2016	22
26861455	L-Tyrosine	Incio J	PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity.	Clinical cancer research 	2016	18
26862733	L-Tyrosine	Wu SG	The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.	Oncotarget	2016	29
26872634	L-Tyrosine	Schwab C	EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.	Blood	2016	18
26873401	L-Tyrosine	Sawada G	Genomic Landscape of Esophageal Squamous Cell Carcinoma in¬†a Japanese Population.	Gastroenterology	2016	35
26880800	L-Tyrosine	Stiff A	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.	Cancer research	2016	16
26884585	L-Tyrosine	Li J	Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.	Journal of clinical oncology 	2016	79
26911335	L-Tyrosine	Kim C	Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPŒµ and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.	BMC nephrology	2016	11
26916631	L-Tyrosine	Marchetti A	ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.	Journal of thoracic oncology 	2016	16
26936507	L-Tyrosine	Turro E	A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.	Science translational medicine	2016	10
26943330	L-Tyrosine	Bai XY	Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.	PloS one	2016	11
26957112	L-Tyrosine	Wu J	Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.	Journal of hematology & oncology	2016	15
26969090	L-Tyrosine	Haas NB	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.	Lancet	2016	41
26973209	L-Tyrosine	Imamura F	Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.	Lung cancer	2016	14
26980726	L-Tyrosine	Duployez N	Comprehensive mutational profiling of core binding factor acute myeloid leukemia.	Blood	2016	12
26984351	L-Tyrosine	Miller MA	Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance.	Cancer discovery	2016	24
26989078	L-Tyrosine	Yang X	Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.	Oncotarget	2016	13
26998761	L-Tyrosine	Chang VT	Initiation of T cell signaling by CD45 segregation at 'close contacts'.	Nature immunology	2016	26
27002617	L-Tyrosine	Wang Y	Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma.	Tumour biology 	2016	14
27013234	L-Tyrosine	Li P	Œ±E-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway.	Genes & development	2016	15
27041571	L-Tyrosine	Zhang L	SHP-2-upregulated ZEB1 is important for PDGFRŒ±-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.	Oncogene	2016	13
27052656	L-Tyrosine	Chung JH	Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes.	Annals of oncology 	2016	10
27068398	L-Tyrosine	Dziadziuszko R	An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.	Journal of thoracic oncology 	2016	11
27071706	L-Tyrosine	Wang S	Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.	Journal of hematology & oncology	2016	52
27078022	L-Tyrosine	Awada A	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.	JAMA oncology	2016	11
27083334	L-Tyrosine	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	78
27127301	L-Tyrosine	Saba NS	Pathogenic role of B-cell receptor signaling and canonical NF-Œ∫B activation in mantle cell lymphoma.	Blood	2016	13
27158780	L-Tyrosine	Campbell JD	Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.	Nature genetics	2016	69
27166522	L-Tyrosine	Chen Y	Tyrosine kinase receptor EGFR regulates the switch in cancer cells between cell survival and cell death induced by autophagy in hypoxia.	Autophagy	2016	12
27196461	L-Tyrosine	Ding L	The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature.	Medicine	2016	11
27198718	L-Tyrosine	Winqvist M	Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.	Haematologica	2016	11
27216193	L-Tyrosine	Moores SL	A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.	Cancer research	2016	16
27223332	L-Tyrosine	Greenhalgh J	First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.	The Cochrane database of systematic reviews	2016	21
27225694	L-Tyrosine	Gainor JF	EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.	Clinical cancer research 	2016	61
27229180	L-Tyrosine	Tan DS	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.	Journal of thoracic oncology 	2016	27
27237825	L-Tyrosine	Jiang T	EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.	Journal of thoracic oncology 	2016	11
27245147	L-Tyrosine	Katoh M	FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).	International journal of molecular medicine	2016	14
27251275	L-Tyrosine	Mertins P	Proteogenomics connects somatic mutations to signalling in breast cancer.	Nature	2016	109
27257132	L-Tyrosine	Bersanelli M	L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.	Journal of thoracic oncology 	2016	13
27262212	L-Tyrosine	Noonan SA	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.	Journal of thoracic oncology 	2016	12
27277600	L-Tyrosine	Bedke J	Systemic therapy in metastatic renal cell carcinoma.	World journal of urology	2017	9
27279544	L-Tyrosine	Choueiri TK	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2016	53
27279912	L-Tyrosine	Wang C	Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3Œ≤/Œ≤-catenin Signaling.	Theranostics	2016	15
27281222	L-Tyrosine	Abraham SA	Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.	Nature	2016	23
27323238	L-Tyrosine	Kobayashi Y	Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.	Cancer science	2016	12
27343443	L-Tyrosine	Schrock AB	Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.	Journal of thoracic oncology 	2016	13
27354477	L-Tyrosine	Oxnard GR	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2016	79
27354483	L-Tyrosine	Yoshida T	Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2016	25
27362227	L-Tyrosine	Chen YN	Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.	Nature	2016	35
27368100	L-Tyrosine	Gao H	Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling.	Cell	2016	15
27390349	L-Tyrosine	Gasparotto D	Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome.	Clinical cancer research 	2017	9
27406346	L-Tyrosine	Park JW	Adaptive Randomization of Neratinib in Early Breast Cancer.	The New England journal of medicine	2016	22
27416909	L-Tyrosine	Eadie LN	The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.	Leukemia	2017	7
27448564	L-Tyrosine	Wang S	EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.	Journal of hematology & oncology	2016	20
27450722	L-Tyrosine	Shi P	Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.	Cancer letters	2016	13
27461391	L-Tyrosine	Simons M	Mechanisms and regulation of endothelial VEGF receptor signalling.	Nature reviews. Molecular cell biology	2016	46
27468937	L-Tyrosine	Reckamp KL	A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.	Journal of thoracic oncology 	2016	24
27468938	L-Tyrosine	Reck M	ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study.	Journal of thoracic oncology 	2016	14
27470968	L-Tyrosine	Seifert AM	PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.	Clinical cancer research 	2017	6
27479178	L-Tyrosine	Qorraj M	The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.	Leukemia	2017	5
27481709	L-Tyrosine	Heldin CH	Signaling Receptors for TGF-Œ≤ Family Members.	Cold Spring Harbor perspectives in biology	2016	14
27492973	L-Tyrosine	Jin B	Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/Œ≤-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.	Clinical cancer research 	2017	7
27535981	L-Tyrosine	Amin NA	Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.	Clinical cancer research 	2017	6
27542267	L-Tyrosine	Takahama T	Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).	Oncotarget	2016	11
27564113	L-Tyrosine	Li H	Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.	Oncotarget	2017	5
27590878	L-Tyrosine	Wu J	Second-generation inhibitors of Bruton tyrosine kinase.	Journal of hematology & oncology	2016	13
27595394	L-Tyrosine	Chen W	Targeting renal cell carcinoma with a HIF-2 antagonist.	Nature	2016	39
27601642	L-Tyrosine	Zhao X	TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease.	Proceedings of the National Academy of Sciences of the United States of America	2016	10
27605552	L-Tyrosine	Carter BZ	Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.	Science translational medicine	2016	10
27613527	L-Tyrosine	Yu HA	A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib.	Journal of thoracic oncology 	2017	5
27619632	L-Tyrosine	Zhou Q	Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.	Journal of hematology & oncology	2016	12
27633443	L-Tyrosine	Yue B	Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer.	Molecular therapy 	2016	22
27634334	L-Tyrosine	Kanu N	DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer.	Genome biology	2016	18
27637985	L-Tyrosine	O'Brien S	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.	The Lancet. Oncology	2016	14
27671334	L-Tyrosine	Balaji K	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.	Molecular cancer research 	2017	8
27732970	L-Tyrosine	Dancsok AR	Advances in sarcoma diagnostics and treatment.	Oncotarget	2017	7
27765535	L-Tyrosine	Lee CK	Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.	Journal of thoracic oncology 	2017	33
27770386	L-Tyrosine	Wang S	Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors.	Frontiers of medicine	2016	16
27783593	L-Tyrosine	Dong L	Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.	Nature	2016	22
27794501	L-Tyrosine	Drilon A	Targeting MET in Lung Cancer: Will Expectations Finally Be MET?	Journal of thoracic oncology 	2017	9
27825616	L-Tyrosine	Yoh K	Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.	The Lancet. Respiratory medicine	2017	21
27825638	L-Tyrosine	Neal JW	Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.	The Lancet. Oncology	2016	12
27840244	L-Tyrosine	Wang S	EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.	Cancer letters	2017	10
27841873	L-Tyrosine	Guryanova OA	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.	Nature medicine	2016	16
27843590	L-Tyrosine	Amatu A	NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.	ESMO open	2016	12
27844272	L-Tyrosine	Duran I	Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.	Targeted oncology	2017	7
27865871	L-Tyrosine	Rozenblum AB	Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.	Journal of thoracic oncology 	2017	5
27870571	L-Tyrosine	Roberts KG	High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.	Journal of clinical oncology 	2017	15
27872057	L-Tyrosine	Pratz KW	How I treat FLT3-mutated AML.	Blood	2017	6
27890936	L-Tyrosine	Ilander M	Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.	Leukemia	2017	9
27894077	L-Tyrosine	Boer JM	Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.	Oncotarget	2017	6
27904138	L-Tyrosine	Yu J	Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.	Leukemia	2017	7
27908881	L-Tyrosine	Lee LY	Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.	Blood	2017	10
27913578	L-Tyrosine	Kobayashi Y	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.	Molecular cancer therapeutics	2017	8
27923714	L-Tyrosine	Ho CC	Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib.	Journal of thoracic oncology 	2017	10
27959700	L-Tyrosine	Mok TS	Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.	The New England journal of medicine	2017	125
27977138	L-Tyrosine	Zhang ZY	Drugging the Undruggable: Therapeutic Potential of Targeting Protein Tyrosine Phosphatases.	Accounts of chemical research	2017	9
28007774	L-Tyrosine	D'Angelo SP	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.	Clinical cancer research 	2017	7
28011673	L-Tyrosine	Myklebust JH	Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.	Blood	2017	9
28017789	L-Tyrosine	Castellanos E	Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer.	Journal of thoracic oncology 	2017	8
28034907	L-Tyrosine	Patel V	Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.	Clinical cancer research 	2017	6
28040594	L-Tyrosine	Ma P	Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2017	5
28056412	L-Tyrosine	Kroeze SG	Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.	Cancer treatment reviews	2017	7
28064454	L-Tyrosine	Matsumoto K	Hepatocyte growth factor/MET in cancer progression and biomarker discovery.	Cancer science	2017	8
28065597	L-Tyrosine	Yao Z	A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome.	Molecular cell	2017	8
28072762	L-Tyrosine	Gay CM	Giving AXL the axe: targeting AXL in human malignancy.	British journal of cancer	2017	10
28073897	L-Tyrosine	Reguart N	Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.	Clinical chemistry	2017	7
28077173	L-Tyrosine	Liu X	Is CD47 an innate immune checkpoint for tumor evasion?	Journal of hematology & oncology	2017	8
28088512	L-Tyrosine	Lin JJ	ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.	Journal of thoracic oncology 	2017	9
28099915	L-Tyrosine	Huang WL	Liquid biopsy genotyping in lung cancer: ready for clinical utility?	Oncotarget	2017	7
28108460	L-Tyrosine	Zawistowski JS	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.	Cancer discovery	2017	13
28111464	L-Tyrosine	Deng J	Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.	Leukemia	2017	8
28113019	L-Tyrosine	Magnuson WJ	Management of Brain Metastases in Tyrosine Kinase Inhibitor-Na√Øve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.	Journal of clinical oncology 	2017	15
28114269	L-Tyrosine	Li C	A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis.	Nature cell biology	2017	18
28122866	L-Tyrosine	Lin JJ	Targeting ALK: Precision Medicine Takes on Drug Resistance.	Cancer discovery	2017	17
28167659	L-Tyrosine	Noy A	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.	Blood	2017	6
28184013	L-Tyrosine	Kasikara C	Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression.	Molecular cancer research 	2017	7
28199309	L-Tyrosine	Compagno M	Phosphatidylinositol 3-kinase Œ¥ blockade increases genomic instability in B cells.	Nature	2017	14
28209987	L-Tyrosine	Brown HA	Targeting phospholipase D in cancer, infection and neurodegenerative disorders.	Nature reviews. Drug discovery	2017	11
28213007	L-Tyrosine	Sesumi Y	Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.	Lung cancer	2017	5
28258690	L-Tyrosine	Akalu YT	TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.	Immunological reviews	2017	5
28271729	L-Tyrosine	Ahn MJ	EGFR TKI combination with immunotherapy in non-small cell lung cancer.	Expert opinion on drug safety	2017	10
28274957	L-Tyrosine	Hanker AB	An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.	Cancer discovery	2017	6
28331056	L-Tyrosine	Hovorkova L	Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.	Blood	2017	6
28355115	L-Tyrosine	Martinelli G	Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.	Journal of clinical oncology 	2017	9
28376152	L-Tyrosine	Chaib I	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.	Journal of the National Cancer Institute	2017	12
28407039	L-Tyrosine	Haratani K	Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.	Annals of oncology 	2017	9
28408243	L-Tyrosine	Rosell R	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.	The Lancet. Respiratory medicine	2017	17
28418267	L-Tyrosine	Woyach JA	BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.	Journal of clinical oncology 	2017	9
28420416	L-Tyrosine	Saygin C	Emerging therapies for acute myeloid leukemia.	Journal of hematology & oncology	2017	12
28426106	L-Tyrosine	Paz-Ares L	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.	Annals of oncology 	2017	20
28447912	L-Tyrosine	Gautschi O	Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.	Journal of clinical oncology 	2017	14
28462395	L-Tyrosine	Nussinov R	Calmodulin and PI3K Signaling in KRAS Cancers.	Trends in cancer	2017	5
28498782	L-Tyrosine	Lee JK	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.	Journal of clinical oncology 	2017	11
28526769	L-Tyrosine	Vouri M	TAM Receptor Tyrosine Kinases in Cancer Drug Resistance.	Cancer research	2017	6
28546144	L-Tyrosine	Levis M	Midostaurin approved for FLT3-mutated AML.	Blood	2017	11
28723893	L-Tyrosine	Manguso RT	In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.	Nature	2017	16
11149923	Vincristine	Chen S	Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription.	The Journal of cell biology	2001	103
11786909	Vincristine	Shipp MA	Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.	Nature medicine	2002	353
11807147	Vincristine	Coiffier B	CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.	The New England journal of medicine	2002	666
12393461	Vincristine	Bharti AC	Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis.	Blood	2003	132
15016643	Vincristine	Pfreundschuh M	Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.	Blood	2004	72
15295046	Vincristine	Holleman A	Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.	The New England journal of medicine	2004	114
15494430	Vincristine	Marcus R	CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.	Blood	2005	108
15591112	Vincristine	Dreyling M	Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.	Blood	2005	75
15668467	Vincristine	Lenz G	Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).	Journal of clinical oncology 	2005	89
15867204	Vincristine	Feugier P	Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.	Journal of clinical oncology 	2005	222
15933054	Vincristine	Farinha P	Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).	Blood	2005	85
15955905	Vincristine	Sehn LH	Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.	Journal of clinical oncology 	2005	144
16123223	Vincristine	Hiddemann W	Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.	Blood	2005	174
16648042	Vincristine	Pfreundschuh M	CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.	The Lancet. Oncology	2006	285
16720851	Vincristine	Bernstein M	Ewing's sarcoma family of tumors: current management.	The oncologist	2006	82
16754935	Vincristine	Habermann TM	Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.	Journal of clinical oncology 	2006	235
16873669	Vincristine	van Oers MH	Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.	Blood	2006	85
17692808	Vincristine	Deng J	BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.	Cancer cell	2007	183
17953712	Vincristine	Liu L	Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer.	Cancer science	2008	51
18226581	Vincristine	Pfreundschuh M	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).	The Lancet. Oncology	2008	154
18378569	Vincristine	Wilson WH	Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.	Journal of clinical oncology 	2008	58
18662969	Vincristine	Marcus R	Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.	Journal of clinical oncology 	2008	91
18756521	Vincristine	Castillo J	HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases.	American journal of hematology	2008	51
18978206	Vincristine	Hulleman E	Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells.	Blood	2009	49
19038878	Vincristine	Lenz G	Stromal gene signatures in large-B-cell lymphomas.	The New England journal of medicine	2008	349
19075267	Vincristine	Yeo W	Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.	Journal of clinical oncology 	2009	99
19124805	Vincristine	Huguet F	Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.	Journal of clinical oncology 	2009	71
19138562	Vincristine	Den Boer ML	A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study.	The Lancet. Oncology	2009	166
19704118	Vincristine	Savage KJ	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.	Blood	2009	112
19706817	Vincristine	Choi WW	A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.	Clinical cancer research 	2009	115
19901110	Vincristine	Wick W	NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.	Journal of clinical oncology 	2009	140
20160062	Vincristine	van den Bent MJ	IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.	Clinical cancer research 	2010	93
20162574	Vincristine	Zhu W	miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines.	International journal of cancer	2010	83
20385988	Vincristine	Ziepert M	Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.	Journal of clinical oncology 	2010	81
20423999	Vincristine	Keating AK	Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.	Molecular cancer therapeutics	2010	56
20439641	Vincristine	van Oers MH	Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.	Journal of clinical oncology 	2010	48
20498406	Vincristine	Barrans S	Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.	Journal of clinical oncology 	2010	77
20542985	Vincristine	Cho D	Cytotoxicity of activated natural killer cells against pediatric solid tumors.	Clinical cancer research 	2010	65
20548096	Vincristine	Coiffier B	Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.	Blood	2010	169
20660290	Vincristine	Schmitz N	Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.	Blood	2010	55
20922763	Vincristine	Kang MH	National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.	Pediatric blood & cancer	2011	41
21030533	Vincristine	Flowers CR	Improving outcomes for patients with diffuse large B-cell lymphoma.	CA	2010	55
21135273	Vincristine	Meyer PN	Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.	Journal of clinical oncology 	2011	78
21189393	Vincristine	Ruan J	Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.	Journal of clinical oncology 	2011	56
21258880	Vincristine	Zhu W	miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.	Medical oncology	2012	56
21261654	Vincristine	Gupta SC	Chemosensitization of tumors by resveratrol.	Annals of the New York Academy of Sciences	2011	60
21368834	Vincristine	Wertz IE	Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.	Nature	2011	238
21482186	Vincristine	Peyrade F	Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.	The Lancet. Oncology	2011	42
21960059	Vincristine	Nakatani F	miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.	The Journal of pathology	2012	48
22170099	Vincristine	Michaelis M	Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.	Cell death & disease	2011	58
22337718	Vincristine	M√ºller C	The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.	Blood	2012	37
22665537	Vincristine	Green TM	Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	Journal of clinical oncology 	2012	91
22851556	Vincristine	d'Amore F	Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.	Journal of clinical oncology 	2012	55
22851565	Vincristine	Johnson NA	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	Journal of clinical oncology 	2012	110
22911837	Vincristine	Li ZM	Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.	PloS one	2012	36
22955915	Vincristine	Xu-Monette ZY	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.	Blood	2012	51
23057966	Vincristine	Cang S	Novel CD20 monoclonal antibodies for lymphoma therapy.	Journal of hematology & oncology	2012	36
23233710	Vincristine	Press OW	Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.	Journal of clinical oncology 	2013	34
23449635	Vincristine	Hu S	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.	Blood	2013	85
23578722	Vincristine	Delarue R	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.	The Lancet. Oncology	2013	31
23615461	Vincristine	Cunningham D	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.	Lancet	2013	38
23666744	Vincristine	Tan TZ	Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer.	EMBO molecular medicine	2013	37
24045430	Vincristine	Pisco AO	Non-Darwinian dynamics in therapy-induced cancer drug resistance.	Nature communications	2013	41
24171516	Vincristine	Stiff PJ	Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.	The New England journal of medicine	2013	34
24220563	Vincristine	Huang X	Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP.	Journal of clinical oncology 	2013	35
24336156	Vincristine	Tzankov A	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.	Modern pathology 	2014	27
24506200	Vincristine	Perry AM	MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.	British journal of haematology	2014	32
24591201	Vincristine	Flinn IW	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.	Blood	2014	50
24831981	Vincristine	Vitolo U	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.	The Lancet. Oncology	2014	24
25006130	Vincristine	Ellin F	Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.	Blood	2014	22
25499448	Vincristine	Sehn LH	Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.	Blood	2015	50
25514302	Vincristine	Huang H	Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.	JAMA	2014	22
25605897	Vincristine	Poruchynsky MS	Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins.	Proceedings of the National Academy of Sciences of the United States of America	2015	25
25738670	Vincristine	Robak T	Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.	The New England journal of medicine	2015	37
26240231	Vincristine	Scott DW	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.	Journal of clinical oncology 	2015	26
26256760	Vincristine	Pastore A	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	The Lancet. Oncology	2015	40
26304893	Vincristine	Gaspar N	Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.	Journal of clinical oncology 	2015	46
28259608	Vincristine	Ladenstein R	Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.	The Lancet. Oncology	2017	8
8858151	L-Lysine	Parthun MR	The major cytoplasmic histone acetyltransferase in yeast: links to chromatin replication and histone metabolism.	Cell	1996	130
11641392	L-Lysine	Marchese A	Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting.	The Journal of biological chemistry	2001	136
11779497	L-Lysine	Wang H	Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase.	Molecular cell	2001	158
12121615	L-Lysine	Fang J	Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase.	Current biology 	2002	108
12123582	L-Lysine	Feng Q	Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain.	Current biology 	2002	241
12351676	L-Lysine	Cao R	Role of histone H3 lysine 27 methylation in Polycomb-group silencing.	Science	2002	1007
12408818	L-Lysine	Gr√∂nroos E	Control of Smad7 stability by competition between acetylation and ubiquitination.	Molecular cell	2002	89
12438235	L-Lysine	Nguyen CT	Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine.	Cancer research	2002	105
12624111	L-Lysine	Balasubramanyam K	Small molecule modulators of histone acetyltransferase p300.	The Journal of biological chemistry	2003	106
12820959	L-Lysine	Wu G	Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase.	Molecular cell	2003	219
14536086	L-Lysine	Wang H	mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression.	Molecular cell	2003	91
14960713	L-Lysine	Yang XJ	The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases.	Nucleic acids research	2004	140
14985713	L-Lysine	Gyory I	PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing.	Nature immunology	2004	121
15021886	L-Lysine	Pan ZQ	Nedd8 on cullin: building an expressway to protein destruction.	Oncogene	2004	129
15225548	L-Lysine	Cao R	SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex.	Molecular cell	2004	233
15235609	L-Lysine	Hamamoto R	SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.	Nature cell biology	2004	170
15386022	L-Lysine	Wang H	Role of histone H2A ubiquitination in Polycomb silencing.	Nature	2004	466
15632063	L-Lysine	Rozenblatt-Rosen O	The parafibromin tumor suppressor protein is part of a human Paf1 complex.	Molecular and cellular biology	2005	96
15988529	L-Lysine	Seligson DB	Global histone modification patterns predict risk of prostate cancer recurrence.	Nature	2005	273
15990871	L-Lysine	Wu L	The HRDC domain of BLM is required for the dissolution of double Holliday junctions.	The EMBO journal	2005	67
16079795	L-Lysine	Metzger E	LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription.	Nature	2005	471
16285929	L-Lysine	Cho DH	Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF.	Molecular cell	2005	116
16441421	L-Lysine	Hamamoto R	Enhanced SMYD3 expression is essential for the growth of breast cancer cells.	Cancer science	2006	68
16585178	L-Lysine	McGarvey KM	Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state.	Cancer research	2006	114
16618769	L-Lysine	Erickson HK	Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.	Cancer research	2006	70
16699007	L-Lysine	Lu F	Acetylation of the latency-associated nuclear antigen regulates repression of Kaposi's sarcoma-associated herpesvirus lytic transcription.	Journal of virology	2006	78
16717128	L-Lysine	Knights CD	Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate.	The Journal of cell biology	2006	84
16732292	L-Lysine	Klose RJ	The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36.	Nature	2006	214
16805913	L-Lysine	Brown MA	Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex.	Molecular cancer	2006	84
17145880	L-Lysine	Kahl P	Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.	Cancer research	2006	122
17242207	L-Lysine	Zhang R	Molecular dissection of formation of senescence-associated heterochromatin foci.	Molecular and cellular biology	2007	124
17277772	L-Lysine	Wissmann M	Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression.	Nature cell biology	2007	186
17283066	L-Lysine	Stankovic-Valentin N	An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity.	Molecular and cellular biology	2007	58
17363312	L-Lysine	Yamane K	PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.	Molecular cell	2007	156
17369352	L-Lysine	Rauch T	Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay.	Proceedings of the National Academy of Sciences of the United States of America	2007	103
17463086	L-Lysine	Huang Y	Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes.	Proceedings of the National Academy of Sciences of the United States of America	2007	107
17512414	L-Lysine	Barski A	High-resolution profiling of histone methylations in the human genome.	Cell	2007	2450
17611497	L-Lysine	Carpten JD	A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.	Nature	2007	387
17719542	L-Lysine	Tanaka T	hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes.	Cell	2007	71
17923702	L-Lysine	Sun Y	DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity.	Molecular and cellular biology	2007	106
17923864	L-Lysine	Xiang Y	JMJD3 is a histone H3K27 demethylase.	Cell research	2007	66
17957188	L-Lysine	Krivtsov AV	MLL translocations, histone modifications and leukaemia stem-cell development.	Nature reviews. Cancer	2007	342
17967868	L-Lysine	Gupta A	The mammalian ortholog of Drosophila MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis.	Molecular and cellular biology	2008	84
17994099	L-Lysine	Frescas D	JHDM1B/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes.	Nature	2007	77
18042461	L-Lysine	Li H	Structural basis for lower lysine methylation state-specific readout by MBT repeats of L3MBTL1 and an engineered PHD finger.	Molecular cell	2007	88
18048344	L-Lysine	Xiang Y	JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	105
18446223	L-Lysine	Kondo Y	Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells.	PloS one	2008	84
18471979	L-Lysine	Subramanian K	Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase.	Molecular cell	2008	92
18505931	L-Lysine	Zhou Q	Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells.	Molecular cancer research 	2008	56
18519590	L-Lysine	Herranz N	Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor.	Molecular and cellular biology	2008	122
18560578	L-Lysine	Fa√ßa VM	Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.	PloS one	2008	53
18716620	L-Lysine	Song MS	The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.	Nature	2008	144
18723033	L-Lysine	Simon JA	Roles of the EZH2 histone methyltransferase in cancer epigenetics.	Mutation research	2008	252
18787082	L-Lysine	Robertson AG	Genome-wide relationship between histone H3 lysine 4 mono- and tri-methylation and transcription factor binding.	Genome research	2008	88
18984585	L-Lysine	Beyer S	The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.	The Journal of biological chemistry	2008	102
19187761	L-Lysine	Southall SM	Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks.	Molecular cell	2009	85
19203578	L-Lysine	Stewart GS	The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage.	Cell	2009	268
19203579	L-Lysine	Doil C	RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins.	Cell	2009	320
19223552	L-Lysine	Schulte JH	Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy.	Cancer research	2009	125
19232136	L-Lysine	Tan Y	Transcriptional inhibiton of Hoxd4 expression by miRNA-10a in human breast cancer cells.	BMC molecular biology	2009	61
19258506	L-Lysine	Friedman JM	The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2.	Cancer research	2009	138
19261746	L-Lysine	Shao G	MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks.	Genes & development	2009	64
19270680	L-Lysine	Das C	CBP/p300-mediated acetylation of histone H3 on lysine 56.	Nature	2009	245
19340297	L-Lysine	Yang X	CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells.	PloS one	2009	55
19349354	L-Lysine	Seligson DB	Global levels of histone modifications predict prognosis in different cancers.	The American journal of pathology	2009	117
19366799	L-Lysine	Elsheikh SE	Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome.	Cancer research	2009	83
19423649	L-Lysine	Komatsu S	Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma.	Carcinogenesis	2009	51
19535349	L-Lysine	Slany RK	The molecular biology of mixed lineage leukemia.	Haematologica	2009	80
19577000	L-Lysine	Dekker FJ	Histone acetyl transferases as emerging drug targets.	Drug discovery today	2009	72
19703393	L-Lysine	Wang Y	LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer.	Cell	2009	174
19738071	L-Lysine	Escoubet-Lozach L	Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.	Cancer research	2009	56
19805273	L-Lysine	Teesalu T	C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.	Proceedings of the National Academy of Sciences of the United States of America	2009	116
19843958	L-Lysine	Yamazaki K	Two mechanistically and temporally distinct NF-kappaB activation pathways in IL-1 signaling.	Science signaling	2009	49
19885928	L-Lysine	Majid S	Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer.	Cancer	2010	44
19920177	L-Lysine	Harreman M	Distinct ubiquitin ligases act sequentially for RNA polymerase II polyubiquitylation.	Proceedings of the National Academy of Sciences of the United States of America	2009	51
19934284	L-Lysine	Huang Y	Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes.	Clinical cancer research 	2009	72
19956800	L-Lysine	Mueller D	Misguided transcriptional elongation causes mixed lineage leukemia.	PLoS biology	2009	79
20093773	L-Lysine	Jin S	c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.	The Journal of clinical investigation	2010	49
20118233	L-Lysine	Huang J	G9a and Glp methylate lysine 373 in the tumor suppressor p53.	The Journal of biological chemistry	2010	119
20129925	L-Lysine	Wen H	Recognition of histone H3K4 trimethylation by the plant homeodomain of PHF2 modulates histone demethylation.	The Journal of biological chemistry	2010	42
20208519	L-Lysine	Chen D	Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses.	Nature	2010	51
20208542	L-Lysine	Feng W	PHF8 activates transcription of rRNA genes through H3K4me3 binding and H3K9me1/2 demethylation.	Nature structural & molecular biology	2010	72
20228790	L-Lysine	Metzger E	Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4.	Nature	2010	96
20236313	L-Lysine	Ansari KI	Mixed lineage leukemia: roles in gene expression, hormone signaling and mRNA processing.	The FEBS journal	2010	49
20305384	L-Lysine	Komashko VM	5-azacytidine treatment reorganizes genomic histone modification patterns.	Epigenetics	2010	43
20568732	L-Lysine	Mimasu S	Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .	Biochemistry	2010	43
20601953	L-Lysine	Ernst T	Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.	Nature genetics	2010	304
20603076	L-Lysine	Lee JS	Negative regulation of hypoxic responses via induced Reptin methylation.	Molecular cell	2010	64
20614940	L-Lysine	Liu F	Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.	Journal of medicinal chemistry	2010	57
20736451	L-Lysine	Velichutina I	EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis.	Blood	2010	80
20818375	L-Lysine	Liu H	Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint.	Nature	2010	48
20930520	L-Lysine	Hung T	Long noncoding RNA in genome regulation: prospects and mechanisms.	RNA biology	2010	119
20951770	L-Lysine	Varier RA	Histone lysine methylation and demethylation pathways in cancer.	Biochimica et biophysica acta	2011	93
20974671	L-Lysine	Martinez-Garcia E	The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.	Blood	2011	98
21078963	L-Lysine	Sneeringer CJ	Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.	Proceedings of the National Academy of Sciences of the United States of America	2010	149
21115810	L-Lysine	Cho HS	Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells.	Cancer research	2011	47
21149657	L-Lysine	Okada H	Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.	Journal of clinical oncology 	2011	168
21175789	L-Lysine	Tsang DP	Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.	Journal of gastroenterology and hepatology	2011	39
21187428	L-Lysine	Fnu S	Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joining.	Proceedings of the National Academy of Sciences of the United States of America	2011	82
21217779	L-Lysine	Ogiwara H	Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors.	Oncogene	2011	93
21239496	L-Lysine	Yuan W	H3K36 methylation antagonizes PRC2-mediated H3K27 methylation.	The Journal of biological chemistry	2011	138
21245294	L-Lysine	McLaughlin-Drubin ME	Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming.	Proceedings of the National Academy of Sciences of the United States of America	2011	73
21256156	L-Lysine	Yoo BK	Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology.	Pharmacology & therapeutics	2011	41
21310926	L-Lysine	He J	KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.	Blood	2011	50
21317535	L-Lysine	Zhao R	Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers.	The Journal of clinical investigation	2011	39
21367748	L-Lysine	Chase A	Aberrations of EZH2 in cancer.	Clinical cancer research 	2011	152
21383063	L-Lysine	Ginjala V	BMI1 is recruited to DNA breaks and contributes to DNA damage-induced H2A ubiquitination and repair.	Molecular and cellular biology	2011	79
21385930	L-Lysine	Hudlebusch HR	The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors.	Clinical cancer research 	2011	36
21398221	L-Lysine	Jo SY	Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.	Blood	2011	69
21400613	L-Lysine	Kauffman EC	Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.	Molecular carcinogenesis	2011	47
21460034	L-Lysine	Smith E	The super elongation complex (SEC) and MLL in development and disease.	Genes & development	2011	124
21460794	L-Lysine	Chowdhury R	The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.	EMBO reports	2011	239
21489993	L-Lysine	Nady N	Recognition of multivalent histone states associated with heterochromatin by UHRF1 protein.	The Journal of biological chemistry	2011	58
21512140	L-Lysine	Cheng AS	EZH2-mediated concordant repression of Wnt antagonists promotes Œ≤-catenin-dependent hepatocarcinogenesis.	Cancer research	2011	61
21565980	L-Lysine	Audrito V	Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.	Cancer research	2011	39
21572997	L-Lysine	So AY	DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs.	PloS one	2011	41
21683433	L-Lysine	Ceccarelli DF	An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme.	Cell	2011	63
21693764	L-Lysine	Tatham MH	Comparative proteomic analysis identifies a role for SUMO in protein quality control.	Science signaling	2011	66
21725364	L-Lysine	Niu X	The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.	Oncogene	2012	48
21734013	L-Lysine	Suzuki H	Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer.	Cancer research	2011	53
21741597	L-Lysine	Bernt KM	MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.	Cancer cell	2011	221
21753189	L-Lysine	Mishima Y	The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis.	Blood	2011	39
21764752	L-Lysine	Wang L	The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation.	Science	2011	59
21777816	L-Lysine	Rajakumara E	PHD finger recognition of unmodified histone H3R2 links UHRF1 to regulation of euchromatic gene expression.	Molecular cell	2011	58
21780790	L-Lysine	Liu F	Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.	Journal of medicinal chemistry	2011	40
21782458	L-Lysine	Ferguson AD	Structural basis of substrate methylation and inhibition of SMYD2.	Structure	2011	53
21837672	L-Lysine	Huqun	Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.	Cancer	2012	31
21841822	L-Lysine	Wang F	Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation.	Oncogene	2012	57
21884981	L-Lysine	Wu MZ	Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition.	Molecular cell	2011	60
21890490	L-Lysine	Pereira F	KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells.	Human molecular genetics	2011	36
21892211	L-Lysine	Taniguchi H	Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer.	Oncogene	2012	32
21917920	L-Lysine	Geng H	HDAC4 protein regulates HIF1Œ± protein lysine acetylation and cancer cell response to hypoxia.	The Journal of biological chemistry	2011	44
21936852	L-Lysine	Platta HW	Nedd4-dependent lysine-11-linked polyubiquitination of the tumour suppressor Beclin 1.	The Biochemical journal	2012	34
21938566	L-Lysine	Shu L	Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells.	The AAPS journal	2011	37
21947282	L-Lysine	Peng L	SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities.	Molecular and cellular biology	2011	54
21963238	L-Lysine	Chu C	Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions.	Molecular cell	2011	323
21975933	L-Lysine	Wang J	Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties.	Cancer research	2011	62
22004789	L-Lysine	Hjerpe R	Changes in the ratio of free NEDD8 to ubiquitin triggers NEDDylation by ubiquitin enzymes.	The Biochemical journal	2012	35
22014572	L-Lysine	Cai C	Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.	Cancer cell	2011	131
22053108	L-Lysine	Score J	Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.	Blood	2012	43
22099308	L-Lysine	Kuo AJ	NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.	Molecular cell	2011	90
22190494	L-Lysine	Menssen A	The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop.	Proceedings of the National Academy of Sciences of the United States of America	2012	79
22211105	L-Lysine	Yoo KH	EZH2 methyltransferase and H3K27 methylation in breast cancer.	International journal of biological sciences	2012	40
22323599	L-Lysine	McCabe MT	Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).	Proceedings of the National Academy of Sciences of the United States of America	2012	115
22370893	L-Lysine	Au SL	Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.	Hepatology	2012	73
22389628	L-Lysine	Jain AK	p53 regulates cell cycle and microRNAs to promote differentiation of human embryonic stem cells.	PLoS biology	2012	72
22391571	L-Lysine	Kalvik TV	Protein N-terminal acetyltransferases in cancer.	Oncogene	2013	34
22402492	L-Lysine	Ismail IH	CBX4-mediated SUMO modification regulates BMI1 recruitment at sites of DNA damage.	Nucleic acids research	2012	34
22406531	L-Lysine	Dong C	G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer.	The Journal of clinical investigation	2012	125
22406747	L-Lysine	Schenk T	Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.	Nature medicine	2012	134
22419068	L-Lysine	Van Aller GS	Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation.	Epigenetics	2012	39
22447389	L-Lysine	Willmann D	Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.	International journal of cancer	2012	38
22536950	L-Lysine	Yuan Y	A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma.	ACS chemical biology	2012	40
22556262	L-Lysine	Takawa M	Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression.	Cancer research	2012	51
22585859	L-Lysine	Bellail AC	A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma.	Cancer discovery	2012	30
22586264	L-Lysine	Peng L	SIRT1 negatively regulates the activities, functions, and protein levels of hMOF and TIP60.	Molecular and cellular biology	2012	34
22683710	L-Lysine	Pe√±a-Llopis S	BAP1 loss defines a new class of renal cell carcinoma.	Nature genetics	2012	184
22711031	L-Lysine	Crea F	EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis.	Cancer metastasis reviews	2012	44
22722849	L-Lysine	Barber MF	SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation.	Nature	2012	111
22766277	L-Lysine	Holm K	Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.	Molecular oncology	2012	36
22787429	L-Lysine	Cho HS	RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation.	Neoplasia	2012	46
22797064	L-Lysine	Ezponda T	The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.	Oncogene	2013	29
22824796	L-Lysine	Wang P	Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.	Oncogene	2013	81
22909820	L-Lysine	Butler LR	The proteasomal de-ubiquitinating enzyme POH1 promotes the double-strand DNA break response.	The EMBO journal	2012	39
22948112	L-Lysine	Prud'homme GJ	Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity.	Oncotarget	2012	43
22961379	L-Lysine	Ameyar-Zazoua M	Argonaute proteins couple chromatin silencing to alternative splicing.	Nature structural & molecular biology	2012	91
22988081	L-Lysine	Axup JY	Synthesis of site-specific antibody-drug conjugates using unnatural amino acids.	Proceedings of the National Academy of Sciences of the United States of America	2012	89
22990868	L-Lysine	Cho HS	Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B.	Nature communications	2012	34
23001124	L-Lysine	Cowper-Sal lari R	Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression.	Nature genetics	2012	135
23023262	L-Lysine	Knutson SK	A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.	Nature chemical biology	2012	209
23043551	L-Lysine	Zheng W	Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2.	Journal of the American Chemical Society	2012	33
23054398	L-Lysine	Ferrari-Amorotti G	Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion.	Cancer research	2013	32
23071358	L-Lysine	Yang H	IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.	Clinical cancer research 	2012	55
23129632	L-Lysine	Luo W	Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression.	Proceedings of the National Academy of Sciences of the United States of America	2012	62
23175188	L-Lysine	Liu PY	The histone deacetylase SIRT2 stabilizes Myc oncoproteins.	Cell death and differentiation	2013	41
23184418	L-Lysine	Dubuc AM	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.	Acta neuropathologica	2013	39
23236167	L-Lysine	Qi W	Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.	Proceedings of the National Academy of Sciences of the United States of America	2012	158
23245831	L-Lysine	Mannava S	Depletion of deoxyribonucleotide pools is an endogenous source of DNA damage in cells undergoing oncogene-induced senescence.	The American journal of pathology	2013	32
23257913	L-Lysine	Shankar SR	G9a, a multipotent regulator of gene expression.	Epigenetics	2013	34
23273980	L-Lysine	Chocarro-Calvo A	Glucose-induced Œ≤-catenin acetylation enhances Wnt signaling in cancer.	Molecular cell	2013	32
23329852	L-Lysine	Hsiao KY	Histone H4 deacetylation facilitates 53BP1 DNA damage signaling and double-strand break repair.	Journal of molecular cell biology	2013	49
23345616	L-Lysine	J√∏rgensen S	Histone H4 lysine 20 methylation: key player in epigenetic regulation of genomic integrity.	Nucleic acids research	2013	70
23361907	L-Lysine	Deshpande AJ	Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.	Blood	2013	46
23404370	L-Lysine	Reuss DE	Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.	Acta neuropathologica	2013	26
23437046	L-Lysine	Kuo YM	Quantitating the specificity and selectivity of Gcn5-mediated acetylation of histone H3.	PloS one	2013	33
23486531	L-Lysine	Khan SN	Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.	Leukemia	2013	29
23508102	L-Lysine	van Nuland R	Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes.	Molecular and cellular biology	2013	55
23509280	L-Lysine	Wang D	Methylation of SUV39H1 by SET7/9 results in heterochromatin relaxation and genome instability.	Proceedings of the National Academy of Sciences of the United States of America	2013	32
23523103	L-Lysine	Zhao D	Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer.	Cancer cell	2013	48
23576758	L-Lysine	Xu J	Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A.	Proceedings of the National Academy of Sciences of the United States of America	2013	51
23624935	L-Lysine	Wang L	BRCA1 is a negative modulator of the PRC2 complex.	The EMBO journal	2013	38
23633675	L-Lysine	Ding X	Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis.	Science signaling	2013	27
23634848	L-Lysine	Pfeifer GP	5-hydroxymethylcytosine and its potential roles in development and cancer.	Epigenetics & chromatin	2013	39
23642229	L-Lysine	Patel DJ	Readout of epigenetic modifications.	Annual review of biochemistry	2013	81
23684752	L-Lysine	Amente S	The histone LSD1 demethylase in stemness and cancer transcription programs.	Biochimica et biophysica acta	2013	41
23686307	L-Lysine	Zou Z	Brd4 maintains constitutively active NF-Œ∫B in cancer cells by binding to acetylated RelA.	Oncogene	2014	51
23754963	L-Lysine	Fu H	Methylation of histone H3 on lysine 79 associates with a group of replication origins and helps limit DNA replication once per cell cycle.	PLoS genetics	2013	34
23764001	L-Lysine	Tiwari N	Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming.	Cancer cell	2013	95
23775793	L-Lysine	Menendez D	Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells.	Nucleic acids research	2013	63
23795291	L-Lysine	Kerenyi MA	Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation.	eLife	2013	55
23862699	L-Lysine	Henry RA	Differences in specificity and selectivity between CBP and p300 acetylation of histone H3 and H3/H4.	Biochemistry	2013	33
23863932	L-Lysine	F√ºllgrabe J	The histone H4 lysine 16 acetyltransferase hMOF regulates the outcome of autophagy.	Nature	2013	62
23868064	L-Lysine	Cheng Y	Interaction of Sirt3 with OGG1 contributes to repair of mitochondrial DNA and protects from apoptotic cell death under oxidative stress.	Cell death & disease	2013	39
23871696	L-Lysine	Black JC	KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors.	Cell	2013	64
23889988	L-Lysine	Emdad L	AEG-1/MTDH/LYRIC: signaling pathways, downstream genes, interacting proteins, and regulation of tumor angiogenesis.	Advances in cancer research	2013	30
23900215	L-Lysine	Ding J	LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer.	British journal of cancer	2013	31
23904475	L-Lysine	Wei H	PRMT5 dimethylates R30 of the p65 subunit to activate NF-Œ∫B.	Proceedings of the National Academy of Sciences of the United States of America	2013	41
23906982	L-Lysine	Eisinger-Mathason TS	Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis.	Cancer discovery	2013	53
24035499	L-Lysine	Hao R	Proteasomes activate aggresome disassembly and clearance by producing unanchored ubiquitin chains.	Molecular cell	2013	35
24049067	L-Lysine	Garc√≠a-Jim√©nez C	A new link between diabetes and cancer: enhanced WNT/Œ≤-catenin signaling by high glucose.	Journal of molecular endocrinology	2014	27
24065767	L-Lysine	Lalonde ME	Exchange of associated factors directs a switch in HBO1 acetyltransferase histone tail specificity.	Genes & development	2013	35
24076604	L-Lysine	Jaffe JD	Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.	Nature genetics	2013	66
24081332	L-Lysine	Hu D	The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers.	Molecular and cellular biology	2013	72
24102134	L-Lysine	Liu F	Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.	Journal of medicinal chemistry	2013	41
24133372	L-Lysine	Yuan H	The emerging and diverse roles of sirtuins in cancer: a clinical perspective.	OncoTargets and therapy	2013	49
24160699	L-Lysine	Sinclair DA	Small-molecule allosteric activators of sirtuins.	Annual review of pharmacology and toxicology	2014	54
24165275	L-Lysine	Zhang J	Long non-coding RNA HOTAIR in carcinogenesis and metastasis.	Acta biochimica et biophysica Sinica	2014	42
24183969	L-Lysine	Garapaty-Rao S	Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.	Chemistry & biology	2013	33
24196443	L-Lysine	Sharma N	USP3 counteracts RNF168 via deubiquitinating H2A and Œ≥H2AX at lysine 13 and 15.	Cell cycle	2014	27
24200691	L-Lysine	Wagner KW	KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.	The Journal of clinical investigation	2013	37
24207024	L-Lysine	Chen S	Repression of RNA polymerase I upon stress is caused by inhibition of RNA-dependent deacetylation of PAF53 by SIRT7.	Molecular cell	2013	32
24345883	L-Lysine	Li Z	The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer.	Oncotarget	2013	26
24362326	L-Lysine	Tan JZ	EZH2: biology, disease, and structure-based drug discovery.	Acta pharmacologica Sinica	2014	29
24486017	L-Lysine	Fan J	Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex.	Molecular cell	2014	38
24491801	L-Lysine	Kim JH	UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells.	Cancer research	2014	38
24496381	L-Lysine	Pastori C	BET bromodomain proteins are required for glioblastoma cell proliferation.	Epigenetics	2014	29
24503539	L-Lysine	Chen Y	Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer.	Cell death & disease	2014	28
24516139	L-Lysine	Gonzalez ME	EZH2 expands breast stem cells through activation of NOTCH1 signaling.	Proceedings of the National Academy of Sciences of the United States of America	2014	43
24518117	L-Lysine	Mattiroli F	The nucleosome acidic patch plays a critical role in RNF168-dependent ubiquitination of histone H2A.	Nature communications	2014	31
24526064	L-Lysine	Deb G	EZH2: not EZHY (easy) to deal.	Molecular cancer research 	2014	29
24561908	L-Lysine	Van der Meulen J	The H3K27me3 demethylase UTX in normal development and disease.	Epigenetics	2014	20
24563539	L-Lysine	Knutson SK	Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.	Molecular cancer therapeutics	2014	88
24568369	L-Lysine	Ember SW	Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.	ACS chemical biology	2014	29
24579949	L-Lysine	Johansson C	The roles of Jumonji-type oxygenases in human disease.	Epigenomics	2014	34
24634223	L-Lysine	Eram MS	Trimethylation of histone H3 lysine 36 by human methyltransferase PRDM9 protein.	The Journal of biological chemistry	2014	25
24656127	L-Lysine	Herz HM	Enhancer malfunction in cancer.	Molecular cell	2014	38
24656132	L-Lysine	Cheng J	A role for H3K4 monomethylation in gene repression and partitioning of chromatin readers.	Molecular cell	2014	50
24667498	L-Lysine	Wang F	JMJD6 promotes colon carcinogenesis through negative regulation of p53 by hydroxylation.	PLoS biology	2014	23
24726141	L-Lysine	Piao L	The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells.	Neoplasia	2014	28
24742640	L-Lysine	Tee AE	The histone demethylase JMJD1A induces cell migration and invasion by up-regulating the expression of the long noncoding RNA MALAT1.	Oncotarget	2014	25
24751816	L-Lysine	Filippakopoulos P	Targeting bromodomains: epigenetic readers of lysine acetylation.	Nature reviews. Drug discovery	2014	216
24769080	L-Lysine	Bose P	Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.	Pharmacology & therapeutics	2014	40
24769394	L-Lysine	Wang YP	Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress.	The EMBO journal	2014	34
24778210	L-Lysine	Li X	Histone demethylase KDM5B is a key regulator of genome stability.	Proceedings of the National Academy of Sciences of the United States of America	2014	25
24782567	L-Lysine	Tammsalu T	Proteome-wide identification of SUMO2 modification sites.	Science signaling	2014	59
24808134	L-Lysine	Thomson R	Evolution of the primate trypanolytic factor APOL1.	Proceedings of the National Academy of Sciences of the United States of America	2014	55
24816405	L-Lysine	Kryczek I	IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L.	Immunity	2014	59
24821572	L-Lysine	Xie P	The covalent modifier Nedd8 is critical for the activation of Smurf1 ubiquitin ligase in tumorigenesis.	Nature communications	2014	24
24843002	L-Lysine	Carvalho S	SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint.	eLife	2014	50
24844570	L-Lysine	Chiba T	Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.	International journal of cancer	2015	16
24847881	L-Lysine	Mazur PK	SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.	Nature	2014	64
24859458	L-Lysine	Thinnes CC	Targeting histone lysine demethylases - progress, challenges, and the future.	Biochimica et biophysica acta	2014	33
24927542	L-Lysine	Ayrapetov MK	DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin.	Proceedings of the National Academy of Sciences of the United States of America	2014	74
24936451	L-Lysine	Phillips S	Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation.	Stem cell reports	2014	25
24937458	L-Lysine	Yamamoto S	JARID1B is a luminal lineage-driving oncogene in breast cancer.	Cancer cell	2014	43
24963049	L-Lysine	Sankar S	Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.	Clinical cancer research 	2014	25
25111487	L-Lysine	McCabe MT	EZH2 as a potential target in cancer therapy.	Epigenomics	2014	28
25115397	L-Lysine	Chinaranagari S	EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer.	Oncotarget	2014	20
25136132	L-Lysine	Barsyte-Lovejoy D	(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells.	Proceedings of the National Academy of Sciences of the United States of America	2014	36
25188243	L-Lysine	Popovic R	Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.	PLoS genetics	2014	38
25263594	L-Lysine	Guo R	BS69/ZMYND11 reads and connects histone H3.3 lysine 36 trimethylation-decorated chromatin to regulated pre-mRNA processing.	Molecular cell	2014	45
25280969	L-Lysine	Saloura V	WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck.	Molecular cancer research 	2015	16
25341040	L-Lysine	Zhang Q	Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.	Cell death & disease	2014	24
25384215	L-Lysine	Zhao D	NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells.	The Journal of clinical investigation	2014	27
25391492	L-Lysine	Lamoliatte F	Large-scale analysis of lysine SUMOylation by SUMO remnant immunoaffinity profiling.	Nature communications	2014	30
25394790	L-Lysine	Mansour MR	Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.	Science	2014	127
25428914	L-Lysine	Zhang K	Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner.	Oncotarget	2015	53
25457180	L-Lysine	Bradley WD	EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.	Chemistry & biology	2014	36
25482560	L-Lysine	Cai C	Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity.	Cell reports	2014	24
25537518	L-Lysine	Liu L	Genetic alterations of histone lysine methyltransferases and their significance in breast cancer.	Oncotarget	2015	19
25557551	L-Lysine	Nakagawa T	CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases.	Molecular cell	2015	20
25582194	L-Lysine	Shakya A	Pluripotency transcription factor Oct4 mediates stepwise nucleosome demethylation and depletion.	Molecular and cellular biology	2015	15
25603177	L-Lysine	Hu Y	BRD4 inhibitor inhibits colorectal cancer growth and metastasis.	International journal of molecular sciences	2015	15
25611389	L-Lysine	Vishnubalaji R	Genome-wide mRNA and miRNA expression profiling reveal multiple regulatory networks in colorectal cancer.	Cell death & disease	2015	23
25614009	L-Lysine	Hamamoto R	Critical roles of non-histone protein lysine methylation in human tumorigenesis.	Nature reviews. Cancer	2015	55
25629630	L-Lysine	Fillmore CM	EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.	Nature	2015	59
25727006	L-Lysine	Niikura Y	CENP-A K124¬†Ubiquitylation Is Required for CENP-A Deposition at the Centromere.	Developmental cell	2015	18
25728682	L-Lysine	Kanu N	SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.	Oncogene	2015	24
25751058	L-Lysine	Sch√∂lz C	Acetylation site specificities of lysine deacetylase inhibitors in human cells.	Nature biotechnology	2015	42
25849938	L-Lysine	Fu LL	Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.	Oncotarget	2015	37
25925379	L-Lysine	Nakakido M	Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN.	Neoplasia	2015	16
25982114	L-Lysine	Roe JS	BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.	Molecular cell	2015	67
25998713	L-Lysine	Rao RC	Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.	Nature reviews. Cancer	2015	48
26008601	L-Lysine	Sun T	Acetylation of Beclin 1 inhibits autophagosome maturation and promotes tumour growth.	Nature communications	2015	24
26027790	L-Lysine	Xu B	Targeting EZH2 and PRC2 dependence as novel anticancer therapy.	Experimental hematology	2015	17
26073078	L-Lysine	Ho TH	High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.	Oncogene	2016	18
26172293	L-Lysine	Li H	LncRNA HOTAIR promotes human liver cancer stem cell malignant growth through downregulation of SETD2.	Oncotarget	2015	30
26175415	L-Lysine	Mohammad HP	A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.	Cancer cell	2015	48
26199140	L-Lysine	Cho MH	DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression.	Nature communications	2015	20
26376677	L-Lysine	Li H	miR675 upregulates long noncoding RNA H19 through activating EGR1 in human liver cancer.	Oncotarget	2015	18
26399631	L-Lysine	Castel D	Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.	Acta neuropathologica	2015	37
26457648	L-Lysine	Caye A	Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.	Nature genetics	2015	22
26469956	L-Lysine	Sun X	Long non-coding RNA HOTAIR regulates cyclin J via inhibition of microRNA-205 expression in bladder cancer.	Cell death & disease	2015	17
26503055	L-Lysine	Peng D	Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.	Nature	2015	84
26560027	L-Lysine	Oldridge DA	Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism.	Nature	2015	46
26567139	L-Lysine	Nagarsheth N	PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.	Cancer research	2016	16
26598975	L-Lysine	Eram MS	A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.	ACS chemical biology	2016	21
26645727	L-Lysine	Prieto-Granada CN	Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.	The American journal of surgical pathology	2016	14
26721883	L-Lysine	Sepuru KM	CXCL1/MGSA Is a Novel Glycosaminoglycan (GAG)-binding Chemokine: STRUCTURAL EVIDENCE FOR TWO DISTINCT NON-OVERLAPPING BINDING DOMAINS.	The Journal of biological chemistry	2016	13
26747897	L-Lysine	Li N	JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis.	Cancer research	2016	12
26748827	L-Lysine	Wienken M	MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53.	Molecular cell	2016	15
26750096	L-Lysine	Olsen JB	Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics.	Molecular & cellular proteomics 	2016	12
26755663	L-Lysine	Agarwal P	Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.	Oncotarget	2016	13
26757928	L-Lysine	Kim Y	Methylation-dependent regulation of HIF-1Œ± stability restricts retinal and tumour angiogenesis.	Nature communications	2016	12
26769278	L-Lysine	Kuntz KW	The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.	Journal of medicinal chemistry	2016	11
26774283	L-Lysine	Benarroch-Popivker D	TRF2-Mediated Control of Telomere DNA Topology as a Mechanism for Chromosome-End Protection.	Molecular cell	2016	28
26784169	L-Lysine	Su J	The Functional Analysis of Histone Acetyltransferase MOF in Tumorigenesis.	International journal of molecular sciences	2016	11
26805763	L-Lysine	Sada M	Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility.	Cancer letters	2016	10
26917489	L-Lysine	Bamodu OA	Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.	BMC cancer	2016	12
26970896	L-Lysine	Feng Z	Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.	Journal of hematology & oncology	2016	18
26983694	L-Lysine	Kurozumi A	Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma.	International journal of oncology	2016	15
27058665	L-Lysine	Shen H	Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex.	Cell	2016	21
27105114	L-Lysine	Li Y	Molecular Coupling of Histone Crotonylation and Active Transcription by AF9 YEATS Domain.	Molecular cell	2016	34
27135738	L-Lysine	Souroullas GP	An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.	Nature medicine	2016	19
27151432	L-Lysine	Arcipowski KM	Histone demethylases in physiology and cancer: a tale of two enzymes, JMJD3 and UTX.	Current opinion in genetics & development	2016	11
27154821	L-Lysine	Zhu L	ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.	Cancer discovery	2016	11
27195672	L-Lysine	Li W	Upregulated long non-coding RNA AGAP2-AS1 represses LATS2 and KLF2 expression through interacting with EZH2 and LSD1 in non-small-cell lung cancer cells.	Cell death & disease	2016	21
27212032	L-Lysine	Cao C	Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.	Oncogene	2017	8
27214401	L-Lysine	Vinogradova M	An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.	Nature chemical biology	2016	27
27222667	L-Lysine	Morera L	Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.	Clinical epigenetics	2016	34
27270439	L-Lysine	Ramadoss S	Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.	Oncogene	2017	11
27292261	L-Lysine	da Motta LL	The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.	Oncogene	2017	13
27335278	L-Lysine	Rau RE	DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.	Blood	2016	12
27452519	L-Lysine	Rada M	Human EHMT2/G9a activates p53 through methylation-independent mechanism.	Oncogene	2017	6
27518565	L-Lysine	Park IY	Dual Chromatin and Cytoskeletal Remodeling by SETD2.	Cell	2016	13
27721406	L-Lysine	Zou M	Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression.	Oncogene	2017	6
27775714	L-Lysine	Xiong X	Selective recognition of histone crotonylation by double PHD fingers of MOZ and DPF2.	Nature chemical biology	2016	12
27820805	L-Lysine	Kaczmarska Z	Structure of p300 in complex with acyl-CoA variants.	Nature chemical biology	2017	8
27845772	L-Lysine	Sun CC	Long Intergenic Noncoding RNA 00511 Acts as an Oncogene in Non-small-cell Lung Cancer by Binding to EZH2 and Suppressing p57.	Molecular therapy. Nucleic acids	2016	21
27845892	L-Lysine	Si X	LncRNA H19 confers chemoresistance in ERŒ±-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK.	Oncotarget	2016	13
27852821	L-Lysine	Terashima M	MEG3 Long Noncoding RNA Contributes to the Epigenetic Regulation of Epithelial-Mesenchymal Transition in Lung Cancer Cell Lines.	The Journal of biological chemistry	2017	12
27926873	L-Lysine	Jozwik KM	FOXA1 Directs H3K4 Monomethylation at Enhancers via Recruitment of the Methyltransferase MLL3.	Cell reports	2016	11
27974677	L-Lysine	Han M	Histone demethylase lysine demethylase 5B in development and cancer.	Oncotarget	2017	6
28112720	L-Lysine	Ding J	Long noncoding RNA HOXA-AS2 represses P21 and KLF2 expression transcription by binding with EZH2, LSD1 in colorectal cancer.	Oncogenesis	2017	5
28135237	L-Lysine	He Y	The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.	Nature chemical biology	2017	8
28241136	L-Lysine	Dran√© P	TIRR regulates 53BP1 by masking its histone methyl-lysine binding function.	Nature	2017	7
12942121	Pyruvic acid	Koukourakis MI	Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis.	British journal of cancer	2003	79
15822913	Pyruvic acid	DeSouza L	Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry.	Journal of proteome research	2005	75
16766262	Pyruvic acid	Fantin VR	Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance.	Cancer cell	2006	367
17149590	Pyruvic acid	Wang H	MAFA controls genes implicated in insulin biosynthesis and secretion.	Diabetologia	2007	62
17222789	Pyruvic acid	Bonnet S	A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.	Cancer cell	2007	391
17283074	Pyruvic acid	Hsu SC	Characterization of a novel tripartite nuclear localization sequence in the EGFR family.	The Journal of biological chemistry	2007	91
17785433	Pyruvic acid	Kim JW	Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1.	Molecular and cellular biology	2007	162
18191611	Pyruvic acid	Lee J	Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription.	The international journal of biochemistry & cell biology	2008	60
18446519	Pyruvic acid	Ganapathy V	Sodium-coupled monocarboxylate transporters in normal tissues and in cancer.	The AAPS journal	2008	54
18464261	Pyruvic acid	Wong TS	Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling.	International journal of cancer	2008	59
18718909	Pyruvic acid	Lu CW	Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance.	The Journal of biological chemistry	2008	75
19714445	Pyruvic acid	Marcus HJ	In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines.	Journal of neuro-oncology	2010	43
19826036	Pyruvic acid	Yang C	Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling.	Cancer research	2009	138
19826085	Pyruvic acid	Harris T	Kinetics of hyperpolarized 13C1-pyruvate transport and metabolism in living human breast cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	60
19942427	Pyruvic acid	Semenza GL	HIF-1: upstream and downstream of cancer metabolism.	Current opinion in genetics & development	2010	303
20005212	Pyruvic acid	Vander Heiden MG	Identification of small molecule inhibitors of pyruvate kinase M2.	Biochemical pharmacology	2010	70
20144215	Pyruvic acid	Zhou M	Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol.	Molecular cancer	2010	67
20228846	Pyruvic acid	Zhao F	Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.	Oncogene	2010	51
20861672	Pyruvic acid	Pavlides S	The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism.	Cell cycle	2010	96
20978194	Pyruvic acid	Chen M	Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA.	Cancer research	2010	46
21234284	Pyruvic acid	Erickson JW	Glutaminase: a hot spot for regulation of cancer cell metabolism?	Oncotarget	2010	53
21242296	Pyruvic acid	Wolf A	Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme.	The Journal of experimental medicine	2011	162
21516121	Pyruvic acid	Chen J	Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.	Oncogene	2011	66
21620138	Pyruvic acid	Luo W	Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1.	Cell	2011	308
21789790	Pyruvic acid	Bluemlein K	No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis.	Oncotarget	2011	72
21807103	Pyruvic acid	Chaumeil MM	Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma.	NeuroImage	2012	34
22056988	Pyruvic acid	Yang W	Nuclear PKM2 regulates Œ≤-catenin transactivation upon EGFR activation.	Nature	2011	239
22065843	Pyruvic acid	Draoui N	Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments.	Disease models & mechanisms	2011	54
22271574	Pyruvic acid	Goldberg MS	Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression.	The Journal of experimental medicine	2012	60
22307054	Pyruvic acid	Chen M	Concentration-dependent control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins.	Nature structural & molecular biology	2012	31
22407107	Pyruvic acid	Pinheiro C	Role of monocarboxylate transporters in human cancers: state of the art.	Journal of bioenergetics and biomembranes	2012	78
22509023	Pyruvic acid	Ye J	Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation.	Proceedings of the National Academy of Sciences of the United States of America	2012	84
22626471	Pyruvic acid	Chaneton B	Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer.	Trends in biochemical sciences	2012	67
22637725	Pyruvic acid	Lee SY	Wnt/Snail signaling regulates cytochrome C oxidase and glucose metabolism.	Cancer research	2012	42
22824010	Pyruvic acid	Luo W	Emerging roles of PKM2 in cell metabolism and cancer progression.	Trends in endocrinology and metabolism	2012	73
22895557	Pyruvic acid	Sun Y	miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect.	Oncology reports	2012	35
22901803	Pyruvic acid	Yang W	PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis.	Cell	2012	166
22922757	Pyruvic acid	Anastasiou D	Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.	Nature chemical biology	2012	151
23064226	Pyruvic acid	Chaneton B	Serine is a natural ligand and allosteric activator of pyruvate kinase M2.	Nature	2012	129
23086999	Pyruvic acid	Keller KE	SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions.	Science	2012	48
23178880	Pyruvic acid	Yang W	ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect.	Nature cell biology	2012	151
23204238	Pyruvic acid	Keshari KR	Hyperpolarized 13C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas.	Cancer research	2013	28
23470539	Pyruvic acid	Zhao Y	Targeting cellular metabolism to improve cancer therapeutics.	Cell death & disease	2013	208
23506875	Pyruvic acid	Halestrap AP	The SLC16 gene family - structure, role and regulation in health and disease.	Molecular aspects of medicine	2013	77
23685455	Pyruvic acid	Kaplon J	A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence.	Nature	2013	148
23791887	Pyruvic acid	Yang W	Regulation and function of pyruvate kinase M2 in cancer.	Cancer letters	2013	43
24013426	Pyruvic acid	Yang W	Nuclear PKM2 regulates the Warburg effect.	Cell cycle	2013	31
24023724	Pyruvic acid	Hill DK	Model free approach to kinetic analysis of real-time hyperpolarized 13C magnetic resonance spectroscopy data.	PloS one	2013	33
24077665	Pyruvic acid	Desai S	Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers.	Oncotarget	2014	32
24091747	Pyruvic acid	Jang M	Cancer cell metabolism: implications for therapeutic targets.	Experimental & molecular medicine	2013	57
24120138	Pyruvic acid	Israelsen WJ	PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells.	Cell	2013	105
24123565	Pyruvic acid	Prigione A	HIF1Œ± modulates cell fate reprogramming through early glycolytic shift and upregulation of PDK1-3 and PKM2.	Stem cells	2014	55
24265197	Pyruvic acid	Miao P	Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy.	IUBMB life	2013	45
24265240	Pyruvic acid	Halestrap AP	Monocarboxylic acid transport.	Comprehensive Physiology	2013	42
24316223	Pyruvic acid	Jiang Y	PKM2 regulates chromosome segregation and mitosis progression of tumor cells.	Molecular cell	2014	57
24344305	Pyruvic acid	Wang HJ	JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1Œ±-mediated glucose metabolism.	Proceedings of the National Academy of Sciences of the United States of America	2014	50
24361892	Pyruvic acid	Cheng P	Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE and AKT pathways.	Biochemical and biophysical research communications	2014	20
24395925	Pyruvic acid	Seiler SE	Obesity and lipid stress inhibit carnitine acetyltransferase activity.	Journal of lipid research	2014	24
24497069	Pyruvic acid	Feng W	Targeting unique metabolic properties of breast tumor initiating cells.	Stem cells	2014	34
24726384	Pyruvic acid	Xie H	Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells.	Cell metabolism	2014	83
24935220	Pyruvic acid	Chen B	MicroRNA-26a regulates glucose metabolism by direct targeting PDHX in colorectal cancer cells.	BMC cancer	2014	26
24951766	Pyruvic acid	Ryan JJ	The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.	Circulation research	2014	42
25266796	Pyruvic acid	Yang X	A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis.	Tumour biology 	2015	18
25313085	Pyruvic acid	Hamabe A	Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition.	Proceedings of the National Academy of Sciences of the United States of America	2014	30
25412762	Pyruvic acid	Jiang Y	PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells.	Nature communications	2014	26
25458841	Pyruvic acid	Schell JC	A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth.	Molecular cell	2014	56
25514599	Pyruvic acid	Liu WR	PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.	Oncotarget	2015	16
25576919	Pyruvic acid	Chen Z	Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.	Oncotarget	2015	19
25621950	Pyruvic acid	Fong MY	Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis.	Nature cell biology	2015	93
25770102	Pyruvic acid	Yang W	Pyruvate kinase M2 at a glance.	Journal of cell science	2015	19
25818238	Pyruvic acid	Taniguchi K	MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer.	Cancer letters	2015	25
25948776	Pyruvic acid	Luan W	PKM2 promotes glucose metabolism and cell growth in gliomas through a mechanism involving a let-7a/c-Myc/hnRNPA1 feedback loop.	Oncotarget	2015	17
26045167	Pyruvic acid	Izquierdo-Garcia JL	IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism.	Cancer research	2015	22
26113084	Pyruvic acid	Rajeshkumar NV	Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function.	Cancer research	2015	18
26234680	Pyruvic acid	Calabretta S	Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.	Oncogene	2016	18
26365179	Pyruvic acid	Dupuy F	PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer.	Cell metabolism	2015	51
26463117	Pyruvic acid	Arriola Apelo SI	Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system.	Aging cell	2016	21
26739387	Pyruvic acid	Azoitei N	PKM2 promotes tumor angiogenesis by regulating HIF-1Œ± through NF-Œ∫B activation.	Molecular cancer	2016	14
26745603	Pyruvic acid	Tang R	MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer.	Oncotarget	2016	17
26876154	Pyruvic acid	He CL	Pyruvate Kinase M2 Activates mTORC1 by Phosphorylating AKT1S1.	Scientific reports	2016	13
26993058	Pyruvic acid	P√©rez-Escuredo J	Monocarboxylate transporters in the brain and in cancer.	Biochimica et biophysica acta	2016	12
27573352	Pyruvic acid	Liang F	TSC22D2 interacts with PKM2 and inhibits cell growth in colorectal cancer.	International journal of oncology	2016	12
27856534	Pyruvic acid	Dayton TL	PKM2, cancer metabolism, and the road ahead.	EMBO reports	2016	18
27911861	Pyruvic acid	Zhu H	Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis.	Oncotarget	2017	7
28183841	Pyruvic acid	Lee M	Mathematical modeling links Wnt signaling to emergent patterns of metabolism in colon cancer.	Molecular systems biology	2017	6
11919237	Docetaxel	Esteva FJ	Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.	Journal of clinical oncology 	2002	99
15150302	Docetaxel	Pegram MD	Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.	Journal of the National Cancer Institute	2004	77
15735684	Docetaxel	He B	Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations.	Oncogene	2005	73
15911866	Docetaxel	Marty M	Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.	Journal of clinical oncology 	2005	271
15930421	Docetaxel	Martin M	Adjuvant docetaxel for node-positive breast cancer.	The New England journal of medicine	2005	141
16061678	Docetaxel	Li Y	Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.	Cancer research	2005	95
16391297	Docetaxel	Wedam SB	Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.	Journal of clinical oncology 	2006	131
16404427	Docetaxel	Arnould L	Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?	British journal of cancer	2006	120
16606824	Docetaxel	Farokhzad OC	Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2006	334
17308271	Docetaxel	Beer TM	Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.	Journal of clinical oncology 	2007	60
17602080	Docetaxel	Cobo M	Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.	Journal of clinical oncology 	2007	96
17606733	Docetaxel	Marangoni E	A new model of patient tumor-derived breast cancer xenografts for preclinical assays.	Clinical cancer research 	2007	119
17638896	Docetaxel	Araki S	Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer.	Cancer research	2007	87
17909051	Docetaxel	Loberg RD	Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.	Cancer research	2007	91
17920184	Docetaxel	Heidenreich A	EAU guidelines on prostate cancer.	European urology	2008	142
18024211	Docetaxel	Bonnefoi H	Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.	The Lancet. Oncology	2007	62
18056989	Docetaxel	Xie Y	The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells.	The Journal of biological chemistry	2008	60
18068131	Docetaxel	McGrogan BT	Taxanes, microtubules and chemoresistant breast cancer.	Biochimica et biophysica acta	2008	106
18258986	Docetaxel	Rastogi P	Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.	Journal of clinical oncology 	2008	259
18314475	Docetaxel	Merritt WM	Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.	Journal of the National Cancer Institute	2008	89
18420499	Docetaxel	Sparano JA	Weekly paclitaxel in the adjuvant treatment of breast cancer.	The New England journal of medicine	2008	136
18645028	Docetaxel	Meng Y	Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.	Molecular cancer therapeutics	2008	60
18674639	Docetaxel	Chen Y	Targeting the androgen receptor pathway in prostate cancer.	Current opinion in pharmacology	2008	143
18824702	Docetaxel	Tolcher AW	Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.	Journal of clinical oncology 	2008	65
18974132	Docetaxel	Risinger AL	The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.	Cancer research	2008	52
19147587	Docetaxel	Kim RH	Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.	Cancer research	2009	73
19150933	Docetaxel	Corkery B	Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.	Annals of oncology 	2009	74
19204201	Docetaxel	Jones S	Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.	Journal of clinical oncology 	2009	82
19230702	Docetaxel	Catalano V	Gastric cancer.	Critical reviews in oncology/hematology	2009	100
19237188	Docetaxel	Boren T	MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.	Gynecologic oncology	2009	50
19275762	Docetaxel	Morgan TM	Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.	Current cancer drug targets	2009	77
19339269	Docetaxel	Attard G	Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.	Cancer research	2009	174
19509167	Docetaxel	Yao E	Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.	Clinical cancer research 	2009	48
19666588	Docetaxel	Creighton CJ	Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.	Proceedings of the National Academy of Sciences of the United States of America	2009	438
19826044	Docetaxel	Gan L	Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.	Cancer research	2009	52
19917839	Docetaxel	Spielmann M	Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.	Journal of clinical oncology 	2009	59
20038723	Docetaxel	Douillard JY	Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.	Journal of clinical oncology 	2010	142
20100966	Docetaxel	Lynch TJ	Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.	Journal of clinical oncology 	2010	108
20145158	Docetaxel	Zoubeidi A	Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.	Clinical cancer research 	2010	40
20159814	Docetaxel	Danila DC	Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.	Journal of clinical oncology 	2010	113
20238327	Docetaxel	Wagner AD	Chemotherapy for advanced gastric cancer.	The Cochrane database of systematic reviews	2010	148
20308670	Docetaxel	Untch M	Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.	Journal of clinical oncology 	2010	97
20406831	Docetaxel	Riethdorf S	Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.	Clinical cancer research 	2010	111
20498403	Docetaxel	Miles DW	Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2010	205
20697801	Docetaxel	Huober J	Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.	Breast cancer research and treatment	2010	52
20733135	Docetaxel	Chi KN	Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2010	55
20842666	Docetaxel	Zhang HL	Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.	The Prostate	2011	89
20978165	Docetaxel	Thompson CB	Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models.	Molecular cancer therapeutics	2010	47
21121833	Docetaxel	Mart√≠n M	Adjuvant docetaxel for high-risk, node-negative breast cancer.	The New England journal of medicine	2010	46
21135276	Docetaxel	Dave B	Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.	Journal of clinical oncology 	2011	82
21149267	Docetaxel	Jeyapalan Z	Expression of CD44 3'-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis.	Nucleic acids research	2011	62
21149659	Docetaxel	Andersson M	Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.	Journal of clinical oncology 	2011	51
21177763	Docetaxel	Litzenburger BC	High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.	Clinical cancer research 	2011	40
21197560	Docetaxel	Xu B	miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS.	Molecular and cellular biochemistry	2011	53
21216939	Docetaxel	Carrasco RA	Antisense inhibition of survivin expression as a cancer therapeutic.	Molecular cancer therapeutics	2011	37
21233014	Docetaxel	Lorch JH	Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.	The Lancet. Oncology	2011	61
21233403	Docetaxel	Huang H	Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.	Clinical cancer research 	2011	43
21315502	Docetaxel	Mottet N	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.	European urology	2011	107
21373875	Docetaxel	Gl√ºck S	TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ¬± trastuzumab.	Breast cancer research and treatment	2012	62
21383283	Docetaxel	Robert NJ	RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.	Journal of clinical oncology 	2011	235
21471425	Docetaxel	Cheever MA	PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.	Clinical cancer research 	2011	98
21559013	Docetaxel	Lee HE	An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer.	British journal of cancer	2011	50
21612468	Docetaxel	de Bono JS	Abiraterone and increased survival in metastatic prostate cancer.	The New England journal of medicine	2011	837
21680543	Docetaxel	Massard C	Targeting continued androgen receptor signaling in prostate cancer.	Clinical cancer research 	2011	40
21826082	Docetaxel	Yap TA	The changing therapeutic landscape of castration-resistant prostate cancer.	Nature reviews. Clinical oncology	2011	52
21837479	Docetaxel	Loibl S	Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy.	Breast cancer research and treatment	2011	39
21918169	Docetaxel	Brunsvig PF	Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.	Clinical cancer research 	2011	40
21976132	Docetaxel	Araujo JC	Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.	Cancer	2012	54
21990397	Docetaxel	Brufsky AM	RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.	Journal of clinical oncology 	2011	90
21991949	Docetaxel	Slamon D	Adjuvant trastuzumab in HER2-positive breast cancer.	The New England journal of medicine	2011	395
22003071	Docetaxel	LoRusso PM	Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.	Clinical cancer research 	2011	71
22112969	Docetaxel	Sonpavde G	Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.	Annals of oncology 	2012	37
22139708	Docetaxel	Feng B	MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3.	Cancer	2012	38
22149875	Docetaxel	Baselga J	Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.	The New England journal of medicine	2012	444
22153890	Docetaxel	Gianni L	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2012	275
22188813	Docetaxel	Maira SM	Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.	Molecular cancer therapeutics	2012	132
22257523	Docetaxel	Untch M	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.	The Lancet. Oncology	2012	74
22264790	Docetaxel	Van der Veldt AA	Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.	Cancer cell	2012	95
22276820	Docetaxel	von Minckwitz G	Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.	The New England journal of medicine	2012	104
22276821	Docetaxel	Bear HD	Bevacizumab added to neoadjuvant chemotherapy for breast cancer.	The New England journal of medicine	2012	104
22294718	Docetaxel	Davies BR	Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.	Molecular cancer therapeutics	2012	69
22331954	Docetaxel	Bergh J	First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.	Journal of clinical oncology 	2012	58
22377126	Docetaxel	Pierga JY	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.	The Lancet. Oncology	2012	31
22387005	Docetaxel	Shien K	Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.	Lung cancer	2012	33
22411952	Docetaxel	Richards J	Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.	Cancer research	2012	57
22425996	Docetaxel	Chen Z	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.	Nature	2012	141
22454414	Docetaxel	Kelly WK	Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.	Journal of clinical oncology 	2012	143
22465195	Docetaxel	Murray S	Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.	Cancer treatment reviews	2012	49
22491949	Docetaxel	Hrkach J	Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.	Science translational medicine	2012	221
22558290	Docetaxel	Kirby BJ	Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.	PloS one	2012	61
22674438	Docetaxel	Antonarakis ES	An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.	Cancer	2012	33
22683778	Docetaxel	Balko JM	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.	Nature medicine	2012	53
22884505	Docetaxel	Ismael G	Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.	The Lancet. Oncology	2012	43
22907596	Docetaxel	Pienta KJ	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.	Investigational new drugs	2013	46
22952424	Docetaxel	Domanska UM	CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.	Neoplasia	2012	39
22972611	Docetaxel	Sehdev V	The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.	Cancer	2013	26
23032615	Docetaxel	Mamounas EP	Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.	Journal of clinical oncology 	2012	45
23041621	Docetaxel	Qiu M	Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells.	Cancer letters	2013	26
23102520	Docetaxel	Cervantes A	Current questions for the treatment of advanced gastric cancer.	Cancer treatment reviews	2013	35
23200175	Docetaxel	J√§nne PA	Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.	The Lancet. Oncology	2013	181
23246022	Docetaxel	Mackey JR	Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.	The Lancet. Oncology	2013	44
23340294	Docetaxel	Schott AF	Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.	Clinical cancer research 	2013	44
23368632	Docetaxel	Chen J	Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures.	BMC cell biology	2013	26
23382472	Docetaxel	Hurvitz SA	Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.	Journal of clinical oncology 	2013	80
23386691	Docetaxel	Shen H	Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.	Clinical cancer research 	2013	34
23422754	Docetaxel	Miles DW	Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.	British journal of cancer	2013	38
23475636	Docetaxel	Swain SM	Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.	The oncologist	2013	34
23576708	Docetaxel	Loriot Y	Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).	Annals of oncology 	2013	72
23587417	Docetaxel	Akinleye A	MEK and the inhibitors: from bench to bedside.	Journal of hematology & oncology	2013	72
23602601	Docetaxel	Swain SM	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.	The Lancet. Oncology	2013	161
23649003	Docetaxel	Aparicio AM	Platinum-based chemotherapy for variant castrate-resistant prostate cancer.	Clinical cancer research 	2013	42
23690416	Docetaxel	Bepler G	Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2013	40
23704196	Docetaxel	Schneeweiss A	Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).	Annals of oncology 	2013	94
23849416	Docetaxel	Schrader AJ	Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.	European urology	2014	62
23957948	Docetaxel	Sridhar SS	Castration-resistant prostate cancer: from new pathophysiology to new treatment.	European urology	2014	29
24002511	Docetaxel	von Minckwitz G	Response-guided neoadjuvant chemotherapy for breast cancer.	Journal of clinical oncology 	2013	38
24008666	Docetaxel	Liu P	Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.	British journal of cancer	2013	26
24048758	Docetaxel	Lordick F	Optimal chemotherapy for advanced gastric cancer: is there a global consensus?	Gastric cancer 	2014	23
24074764	Docetaxel	Bianchini D	Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.	European journal of cancer	2014	34
24136883	Docetaxel	Gerber B	Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).	Annals of oncology 	2013	26
24149323	Docetaxel	Yan W	Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer.	Epigenetics	2013	30
24200698	Docetaxel	van Soest RJ	Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.	European journal of cancer	2013	38
24276076	Docetaxel	Yin L	CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.	Nature reviews. Urology	2014	23
24282274	Docetaxel	Fitzgerald JB	MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.	Molecular cancer therapeutics	2014	26
24309006	Docetaxel	Stewart DJ	Wnt signaling pathway in non-small cell lung cancer.	Journal of the National Cancer Institute	2014	94
24321502	Docetaxel	Heidenreich A	EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.	European urology	2014	203
24387695	Docetaxel	Molife LR	Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.	Journal of hematology & oncology	2014	34
24478320	Docetaxel	Sternberg CN	Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.	Annals of oncology 	2014	29
24556717	Docetaxel	Thadani-Mulero M	Androgen receptor splice variants determine taxane sensitivity in prostate cancer.	Cancer research	2014	55
24616308	Docetaxel	Goldkorn A	Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2014	50
24685829	Docetaxel	Swain SM	Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.	Annals of oncology 	2014	22
24740322	Docetaxel	Liu C	Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.	Clinical cancer research 	2014	61
24740415	Docetaxel	Chen WX	Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs.	PloS one	2014	62
24806399	Docetaxel	Sonpavde G	Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.	Clinical genitourinary cancer	2014	22
24815864	Docetaxel	Palena C	Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.	Journal of the National Cancer Institute	2014	25
24836273	Docetaxel	Sartor O	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.	The Lancet. Oncology	2014	58
24928772	Docetaxel	Brana I	Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.	Targeted oncology	2015	17
24985346	Docetaxel	Ono M	Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells.	Science signaling	2014	105
25002723	Docetaxel	Harari PM	Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.	Journal of clinical oncology 	2014	22
25018038	Docetaxel	Azad AA	Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.	European urology	2015	26
25273343	Docetaxel	Gligorov J	Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	20
25301760	Docetaxel	James ND	Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).	European urology	2015	36
25310895	Docetaxel	Chen D	MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc.	European journal of cancer	2014	22
25359780	Docetaxel	Bhardwaj A	CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1.	Oncotarget	2014	20
25439694	Docetaxel	Hoskin P	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.	The Lancet. Oncology	2014	36
25454616	Docetaxel	Ferraldeschi R	PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.	European urology	2015	24
25547504	Docetaxel	Dang C	Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.	Journal of clinical oncology 	2015	18
25691773	Docetaxel	de Leeuw R	Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.	Clinical cancer research 	2015	22
25693012	Docetaxel	Swain SM	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.	The New England journal of medicine	2015	175
25771365	Docetaxel	Vallabhajosula S	Radioimmunotherapy of Metastatic Prostate Cancer with ¬π‚Å∑‚Å∑Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.	Current radiopharmaceuticals	2016	15
25787766	Docetaxel	Leverson JD	Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.	Science translational medicine	2015	71
25975632	Docetaxel	Earl HM	Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.	The Lancet. Oncology	2015	25
26074382	Docetaxel	Attard G	Prostate cancer.	Lancet	2016	92
26077235	Docetaxel	Sparano JA	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.	Journal of clinical oncology 	2015	16
26117829	Docetaxel	Nakazawa M	Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.	Annals of oncology 	2015	40
26125448	Docetaxel	J√§nne PA	Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.	British journal of cancer	2015	18
26178025	Docetaxel	Spagnuolo C	Genistein and cancer: current status, challenges, and future directions.	Advances in nutrition	2015	28
26181238	Docetaxel	Antonarakis ES	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.	JAMA oncology	2015	87
26196735	Docetaxel	Crawford ED	Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.	The Journal of urology	2015	24
26244877	Docetaxel	Sweeney CJ	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.	The New England journal of medicine	2015	132
26253814	Docetaxel	Prat A	Clinical implications of the intrinsic molecular subtypes of breast cancer.	Breast	2015	49
26510020	Docetaxel	Mateo J	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.	The New England journal of medicine	2015	185
26578067	Docetaxel	Mendes D	The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review.	Breast cancer research 	2015	20
26847057	Docetaxel	Von Hoff DD	Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.	Clinical cancer research 	2016	15
26859684	Docetaxel	Black M	Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.	Oncotarget	2016	19
26884577	Docetaxel	Melosky B	Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.	Journal of clinical oncology 	2016	11
26969107	Docetaxel	Abdel-Rahman O	Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis.	Critical reviews in oncology/hematology	2016	13
27400947	Docetaxel	Smith M	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.	Journal of clinical oncology 	2016	16
27506431	Docetaxel	Yadav MP	177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment.	European journal of nuclear medicine and molecular imaging	2017	9
27566568	Docetaxel	Chen J	Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells.	Oncotarget	2016	10
27591931	Docetaxel	Cornford P	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.	European urology	2017	44
27964843	Docetaxel	Luen SJ	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.	The Lancet. Oncology	2017	14
28133913	Docetaxel	Hanrahan K	The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.	Molecular oncology	2017	8
28398846	Docetaxel	Blum JL	Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).	Journal of clinical oncology 	2017	5
9267023	Hydroxyurea	Scully R	Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage.	Cell	1997	222
9427750	Hydroxyurea	Cliby WA	Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints.	The EMBO journal	1998	163
9774970	Hydroxyurea	Chen J	Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells.	Molecular cell	1998	152
10839545	Hydroxyurea	Wu X	ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response.	Nature	2000	100
10859164	Hydroxyurea	Liu Q	Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.	Genes & development	2000	525
11114888	Hydroxyurea	Tibbetts RS	Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress.	Genes & development	2000	124
11331310	Hydroxyurea	Rappold I	Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways.	The Journal of cell biology	2001	142
14729972	Hydroxyurea	Davies SL	Phosphorylation of the Bloom's syndrome helicase and its role in recovery from S-phase arrest.	Molecular and cellular biology	2004	87
15665856	Hydroxyurea	S√∏rensen CS	The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair.	Nature cell biology	2005	215
16325696	Hydroxyurea	Campbell PJ	Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.	Lancet	2005	87
17679088	Hydroxyurea	Zhang H	An AT-rich sequence in human common fragile site FRA16D causes fork stalling and chromosome breakage in S. cerevisiae.	Molecular cell	2007	56
17957241	Hydroxyurea	Cowell IG	gammaH2AX foci form preferentially in euchromatin after ionising-radiation.	PloS one	2007	71
18045533	Hydroxyurea	Yang YG	Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease.	Cell	2007	131
18250621	Hydroxyurea	Sidorova JM	The RecQ helicase WRN is required for normal replication fork progression after DNA damage or replication fork arrest.	Cell cycle	2008	75
18923083	Hydroxyurea	Singh TR	BLAP18/RMI2, a novel OB-fold-containing protein, is an essential component of the Bloom helicase-double Holliday junction dissolvasome.	Genes & development	2008	91
20188668	Hydroxyurea	Petermann E	Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair.	Molecular cell	2010	276
21220604	Hydroxyurea	Tefferi A	Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.	Journal of clinical oncology 	2011	63
21220747	Hydroxyurea	Warsch W	High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.	Blood	2011	60
21240188	Hydroxyurea	Suhasini AN	Interaction between the helicases genetically linked to Fanconi anemia group J and Bloom's syndrome.	The EMBO journal	2011	52
21565612	Hydroxyurea	Schlacher K	Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.	Cell	2011	263
21730979	Hydroxyurea	Peasland A	Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.	British journal of cancer	2011	46
21828134	Hydroxyurea	Braun T	Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.	Blood	2011	37
22863775	Hydroxyurea	Stewart JA	Human CST promotes telomere duplex replication and general replication restart after fork stalling.	The EMBO journal	2012	62
23216616	Hydroxyurea	Marchioli R	Cardiovascular events and intensity of treatment in polycythemia vera.	The New England journal of medicine	2013	64
23352430	Hydroxyurea	Barlow JH	Identification of early replicating fragile sites that contribute to genome instability.	Cell	2013	94
23695894	Hydroxyurea	Tefferi A	Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.	American journal of hematology	2013	29
23739289	Hydroxyurea	Tefferi A	Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.	Leukemia	2013	57
24258498	Hydroxyurea	Verstovsek S	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.	Cancer	2014	31
25472969	Hydroxyurea	Geyer HL	Therapy for myeloproliferative neoplasms: when, which agent, and how?	Blood	2014	23
25611051	Hydroxyurea	Tefferi A	Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.	American journal of hematology	2015	25
26182311	Hydroxyurea	Tefferi A	Myeloproliferative Neoplasms: A Contemporary Review.	JAMA oncology	2015	33
26811524	Hydroxyurea	Amadori S	Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial.	Journal of clinical oncology 	2016	12
27102499	Hydroxyurea	Verstovsek S	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.	Haematologica	2016	11
27245312	Hydroxyurea	Birendra KC	Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.	Clinical lymphoma, myeloma & leukemia	2016	10
27916398	Hydroxyurea	Passamonti F	Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.	The Lancet. Oncology	2017	12
27991718	Hydroxyurea	Tefferi A	Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.	American journal of hematology	2017	15
14514658	Sulforaphane	Singh AV	Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo.	Carcinogenesis	2004	94
15572695	Sulforaphane	Zhang DD	Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex.	Molecular and cellular biology	2004	342
15856023	Sulforaphane	Xu C	Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells.	Oncogene	2005	80
16203797	Sulforaphane	Fang MZ	Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.	Clinical cancer research 	2005	86
16280330	Sulforaphane	Myzak MC	Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.	Carcinogenesis	2006	86
16407454	Sulforaphane	Myzak MC	Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice.	FASEB journal 	2006	98
16951197	Sulforaphane	Keum YS	Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells.	Cancer research	2006	62
17259330	Sulforaphane	Myzak MC	Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.	Experimental biology and medicine	2007	101
17396224	Sulforaphane	Juge N	Molecular basis for chemoprevention by sulforaphane: a comprehensive review.	Cellular and molecular life sciences 	2007	138
19812222	Sulforaphane	Ho E	Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention.	The Journal of nutrition	2009	50
20013083	Sulforaphane	Cheung KL	Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention.	The AAPS journal	2010	111
20625516	Sulforaphane	Meeran SM	Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines.	PloS one	2010	89
21258631	Sulforaphane	Meeran SM	Epigenetic targets of bioactive dietary components for cancer prevention and therapy.	Clinical epigenetics	2010	58
21374800	Sulforaphane	Clarke JD	Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells.	Molecular nutrition & food research	2011	49
22558124	Sulforaphane	Li Y	Mechanism of chemical activation of Nrf2.	PloS one	2012	32
22578879	Sulforaphane	Dinkova-Kostova AT	Glucosinolates and isothiocyanates in health and disease.	Trends in molecular medicine	2012	53
23589329	Sulforaphane	Lau A	Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner.	Molecular and cellular biology	2013	36
24297178	Sulforaphane	Li Q	Characterization of a stem-like subpopulation in basal-like ductal carcinoma in situ (DCIS) lesions.	The Journal of biological chemistry	2014	29
24466240	Sulforaphane	Wong CP	Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells.	PloS one	2014	22
26970133	Sulforaphane	Yang L	Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane.	Seminars in oncology	2016	11
2260966	Estradiol	Veldscholte J	A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.	Biochemical and biophysical research communications	1990	155
7658481	Estradiol	Hankinson SE	Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women.	Journal of the National Cancer Institute	1995	147
8547832	Estradiol	Hankinson SE	Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period.	Cancer epidemiology, biomarkers & prevention 	1995	118
10579320	Estradiol	Hall JM	The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens.	Endocrinology	1999	193
10987273	Estradiol	Truica CI	Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.	Cancer research	2000	104
11032808	Estradiol	Migliaccio A	Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation.	The EMBO journal	2000	157
11146623	Estradiol	Mazumdar A	Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor.	Nature cell biology	2001	111
11826265	Estradiol	Simpson ER	Aromatase--a brief overview.	Annual review of physiology	2002	123
11959894	Estradiol	Key T	Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies.	Journal of the National Cancer Institute	2002	436
12743149	Estradiol	McTiernan A	Adiposity and sex hormones in postmenopausal breast cancer survivors.	Journal of clinical oncology 	2003	88
15199113	Estradiol	Dunning AM	Polymorphisms associated with circulating sex hormone levels in postmenopausal women.	Journal of the National Cancer Institute	2004	98
15328768	Estradiol	Kennedy GL Jr	The toxicology of perfluorooctanoate.	Critical reviews in toxicology	2004	90
15389572	Estradiol	Macheda ML	Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer.	Journal of cellular physiology	2005	223
15561802	Estradiol	Reed MJ	Steroid sulfatase: molecular biology, regulation, and inhibition.	Endocrine reviews	2005	68
16033851	Estradiol	Boulay A	Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.	Clinical cancer research 	2005	77
16112414	Estradiol	Tsuchiya Y	Cytochrome P450-mediated metabolism of estrogens and its regulation in human.	Cancer letters	2005	99
16306086	Estradiol	Harrington WR	Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action.	Molecular endocrinology	2006	99
16533767	Estradiol	Garofalo C	Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli.	Clinical cancer research 	2006	96
16675129	Estradiol	Cavalieri E	Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention.	Biochimica et biophysica acta	2006	124
17716297	Estradiol	Vona-Davis L	Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer.	Obesity reviews 	2007	70
17911176	Estradiol	Laughlin GA	Low serum testosterone and mortality in older men.	The Journal of clinical endocrinology and metabolism	2008	132
17986456	Estradiol	Bourdeau V	Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells.	Nucleic acids research	2008	50
18172327	Estradiol	Gunter MJ	Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women.	Cancer research	2008	71
18509001	Estradiol	Allen NE	Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC).	Endocrine-related cancer	2008	52
18645193	Estradiol	Attard G	Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.	Journal of clinical oncology 	2008	214
19657377	Estradiol	Clark JP	ETS gene fusions in prostate cancer.	Nature reviews. Urology	2009	89
19690310	Estradiol	Ellis MJ	Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.	JAMA	2009	77
20159820	Estradiol	Friedenreich CM	Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women.	Journal of clinical oncology 	2010	51
20348243	Estradiol	Cicatiello L	Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs.	The American journal of pathology	2010	68
21464939	Estradiol	Wen Z	Discovery of molecular mechanisms of traditional Chinese medicinal formula Si-Wu-Tang using gene expression microarray and connectivity map.	PloS one	2011	44
21771987	Estradiol	Del Mastro L	Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.	JAMA	2011	54
21772329	Estradiol	Endogenous Hormones and Breast Cancer Collaborative Group.	Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies.	British journal of cancer	2011	91
22232133	Estradiol	Fuhrman BJ	Estrogen metabolism and risk of breast cancer in postmenopausal women.	Journal of the National Cancer Institute	2012	55
22614972	Estradiol	Campbell KL	Reduced-calorie dietary weight loss, exercise, and sex hormones in postmenopausal women: randomized controlled trial.	Journal of clinical oncology 	2012	41
23219374	Estradiol	Allott EH	Obesity and prostate cancer: weighing the evidence.	European urology	2013	86
23435015	Estradiol	Slominski A	Steroidogenesis in the skin: implications for local immune functions.	The Journal of steroid biochemistry and molecular biology	2013	59
23607871	Estradiol	Falk RT	Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study.	Breast cancer research 	2013	32
24430863	Estradiol	Dewailly D	The physiology and clinical utility of anti-Mullerian hormone in women.	Human reproduction update	2014	60
24894716	Estradiol	De Francesco EM	GPER mediates activation of HIF1Œ±/VEGF signaling by estrogens.	Cancer research	2014	29
25846769	Estradiol	Sun H	H19 lncRNA mediates 17Œ≤-estradiol-induced cell proliferation in MCF-7 breast cancer cells.	Oncology reports	2015	18
25901081	Estradiol	Svensson S	CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer.	Clinical cancer research 	2015	20
26049025	Estradiol	Kuhn C	Emergence of sex differences in the development of substance use and abuse during adolescence.	Pharmacology & therapeutics	2015	20
12663709	L-Lactic acid	Halabi S	Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.	Journal of clinical oncology 	2003	160
14695409	L-Lactic acid	Attal M	Single versus double autologous stem-cell transplantation for multiple myeloma.	The New England journal of medicine	2003	135
15556624	L-Lactic acid	Svastov√° E	Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH.	FEBS letters	2004	97
16175178	L-Lactic acid	Cardone RA	The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis.	Nature reviews. Cancer	2005	162
16278308	L-Lactic acid	Gottfried E	Tumor-derived lactic acid modulates dendritic cell activation and antigen expression.	Blood	2006	75
16423989	L-Lactic acid	Koukourakis MI	Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma.	Cancer research	2006	121
16648500	L-Lactic acid	Donskov F	Impact of immune parameters on long-term survival in metastatic renal cell carcinoma.	Journal of clinical oncology 	2006	64
16696665	L-Lactic acid	Parvez S	Probiotics and their fermented food products are beneficial for health.	Journal of applied microbiology	2006	100
16888090	L-Lactic acid	Spoo AC	CXCR4 is a prognostic marker in acute myelogenous leukemia.	Blood	2007	70
17415526	L-Lactic acid	Swietach P	Regulation of tumor pH and the role of carbonic anhydrase 9.	Cancer metastasis reviews	2007	112
18188595	L-Lactic acid	Pinheiro C	Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas.	Virchows Archiv 	2008	64
18304378	L-Lactic acid	Young CD	Sugar and fat - that's where it's at: metabolic changes in tumors.	Breast cancer research 	2008	53
18711745	L-Lactic acid	Junn E	Mitochondrial localization of DJ-1 leads to enhanced neuroprotection.	Journal of neuroscience research	2009	80
19033652	L-Lactic acid	Semenza GL	Tumor metabolism: cancer cells give and take lactate.	The Journal of clinical investigation	2008	82
19082467	L-Lactic acid	Yao Y	The expression of CRM1 is associated with prognosis in human osteosarcoma.	Oncology reports	2009	51
19213602	L-Lactic acid	Scher HI	Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.	The Lancet. Oncology	2009	146
19224853	L-Lactic acid	Carreras J	High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.	Journal of clinical oncology 	2009	51
19286567	L-Lactic acid	Amann T	GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis.	The American journal of pathology	2009	59
19443657	L-Lactic acid	Bartel TB	F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.	Blood	2009	68
19628770	L-Lactic acid	Hou JM	Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.	The American journal of pathology	2009	61
19668225	L-Lactic acid	Zhao YH	Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.	Oncogene	2009	57
20021214	L-Lactic acid	Kennedy KM	Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation.	Future oncology	2010	60
20100866	L-Lactic acid	Fogal V	Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation.	Molecular and cellular biology	2010	77
20118770	L-Lactic acid	Snuderl M	B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.	The American journal of surgical pathology	2010	54
20147742	L-Lactic acid	Coumans FA	All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer.	Annals of oncology 	2010	63
20636790	L-Lactic acid	Pinheiro C	Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma.	Histopathology	2010	49
20864819	L-Lactic acid	Chiavarina B	HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis.	Cell cycle	2010	82
20961996	L-Lactic acid	Qing G	Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.	Cancer research	2010	46
21292778	L-Lactic acid	Dimopoulos M	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.	Blood	2011	64
21498634	L-Lactic acid	Zhao Y	Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism.	Cancer research	2011	49
21502956	L-Lactic acid	Lehmann S	Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.	Leukemia	2011	37
21521946	L-Lactic acid	Witkiewicz AK	Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers.	Cell cycle	2011	42
21558814	L-Lactic acid	Whitaker-Menezes D	Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts.	Cell cycle	2011	117
21632858	L-Lactic acid	Koukourakis MI	Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.	Clinical cancer research 	2011	38
21642515	L-Lactic acid	Pierga JY	High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients.	Annals of oncology 	2012	61
21726217	L-Lactic acid	Steyerberg EW	Assessing the incremental value of diagnostic and prognostic markers: a review and illustration.	European journal of clinical investigation	2012	34
21778829	L-Lactic acid	Martinez-Outschoorn UE	Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors.	Cell cycle	2011	76
21804546	L-Lactic acid	Locasale JW	Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.	Nature genetics	2011	271
22002575	L-Lactic acid	Li S	B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.	Modern pathology 	2012	37
22099611	L-Lactic acid	Armstrong AJ	Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.	European urology	2012	44
22124101	L-Lactic acid	Kim KB	BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.	Journal of clinical oncology 	2012	52
22129993	L-Lactic acid	Balliet RM	Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection.	Cell cycle	2011	41
22130161	L-Lactic acid	Joseph RW	Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.	Journal of immunotherapy	2012	34
22156391	L-Lactic acid	Leontieva OV	Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression.	Aging	2011	69
22156546	L-Lactic acid	Venkatesh HS	Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.	Neuro-oncology	2012	38
22180178	L-Lactic acid	Jakob JA	NRAS mutation status is an independent prognostic factor in metastatic melanoma.	Cancer	2012	112
22184616	L-Lactic acid	Boidot R	Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors.	Cancer research	2012	42
22313602	L-Lactic acid	Witkiewicz AK	Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers.	Cell cycle	2012	70
22640478	L-Lactic acid	Ascierto PA	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.	Journal of translational medicine	2012	31
22691140	L-Lactic acid	Gregersen LH	MicroRNA-143 down-regulates Hexokinase 2 in colon cancer cells.	BMC cancer	2012	32
22828443	L-Lactic acid	Tamura H	Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.	Leukemia	2013	40
22850421	L-Lactic acid	Fiaschi T	Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay.	Cancer research	2012	100
22874531	L-Lactic acid	Guido C	Metabolic reprogramming of cancer-associated fibroblasts by TGF-Œ≤ drives tumor growth: connecting TGF-Œ≤ signaling with "Warburg-like" cancer metabolism and L-lactate production.	Cell cycle	2012	50
22878233	L-Lactic acid	Guido C	Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth.	Oncotarget	2012	38
22891270	L-Lactic acid	Armstrong AJ	Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.	Journal of clinical oncology 	2012	39
22894905	L-Lactic acid	Chiavarina B	Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1Œ± and HIF2Œ± in tumor-associated fibroblasts and human breast cancer cells.	Cell cycle	2012	31
22961700	L-Lactic acid	Yao F	LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma.	Tumour biology 	2013	28
23043612	L-Lactic acid	Ho J	Importance of glycolysis and oxidative phosphorylation in advanced melanoma.	Molecular cancer	2012	33
23258846	L-Lactic acid	Miranda-Gon√ßalves V	Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets.	Neuro-oncology	2013	52
23295735	L-Lactic acid	Villamor N	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.	Leukemia	2013	28
23404405	L-Lactic acid	Rong Y	Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells.	Tumour biology 	2013	38
23574725	L-Lactic acid	Curry JM	Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.	Cell cycle	2013	40
23656776	L-Lactic acid	Fiaschi T	Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells.	Cell cycle	2013	29
23690483	L-Lactic acid	Besser MJ	Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.	Clinical cancer research 	2013	54
23897900	L-Lactic acid	Li B	Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer.	Clinical cancer research 	2013	25
23913718	L-Lactic acid	Luke JJ	Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.	Cancer	2013	39
24178759	L-Lactic acid	Maftouh M	Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.	British journal of cancer	2014	23
24277449	L-Lactic acid	Pola≈Ñski R	Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.	Clinical cancer research 	2014	36
24357148	L-Lactic acid	Meyer C	Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.	Cancer immunology, immunotherapy 	2014	66
24366912	L-Lactic acid	Chesnelong C	Lactate dehydrogenase A silencing in IDH mutant gliomas.	Neuro-oncology	2014	32
24449231	L-Lactic acid	Halabi S	Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.	Journal of clinical oncology 	2014	56
24486645	L-Lactic acid	Martinez-Outschoorn UE	Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth.	Seminars in cancer biology	2014	58
24496328	L-Lactic acid	Leontieva OV	M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue.	Cell cycle	2014	29
24634381	L-Lactic acid	Cui J	FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression.	Clinical cancer research 	2014	28
24695951	L-Lactic acid	Simeone E	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.	Cancer immunology, immunotherapy 	2014	33
24847880	L-Lactic acid	Madiraju AK	Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.	Nature	2014	164
24885701	L-Lactic acid	Girgis H	Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma.	Molecular cancer	2014	26
25017943	L-Lactic acid	Sounni NE	Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.	Cell metabolism	2014	34
25085000	L-Lactic acid	Idorn M	Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.	Cancer immunology, immunotherapy 	2014	28
25136121	L-Lactic acid	Crane CA	Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients.	Proceedings of the National Academy of Sciences of the United States of America	2014	28
25215489	L-Lactic acid	Wang YH	Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis.	Cell	2014	51
25273342	L-Lactic acid	von Minckwitz G	Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	28
25456395	L-Lactic acid	Kim Y	Expression of lactate/H‚Å∫ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses.	Human pathology	2015	25
25598765	L-Lactic acid	Bjerrum JT	Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals.	Metabolomics 	2015	19
25649018	L-Lactic acid	GuhaThakurta D	Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.	Clinical cancer research 	2015	27
25676469	L-Lactic acid	Al Shammari B	The Extracellular Matrix Regulates Granuloma Necrosis in Tuberculosis.	The Journal of infectious diseases	2015	21
25748677	L-Lactic acid	McCommis KS	Mitochondrial pyruvate transport: a historical perspective and future research directions.	The Biochemical journal	2015	18
25749524	L-Lactic acid	Ono S	A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients.	Oncotarget	2015	15
25862517	L-Lactic acid	Simkens LH	Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.	Lancet	2015	49
25917568	L-Lactic acid	Kondaveeti Y	Epithelial-mesenchymal transition induces similar metabolic alterations in two independent breast cancer cell lines.	Cancer letters	2015	20
25930027	L-Lactic acid	Stenmark KR	Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension.	Journal of applied physiology	2015	19
25997818	L-Lactic acid	Ramalingam S	A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).	Annals of oncology 	2015	18
26240224	L-Lactic acid	Palumbo A	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.	Journal of clinical oncology 	2015	80
26269128	L-Lactic acid	Valvona CJ	The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor.	Brain pathology	2016	18
26286636	L-Lactic acid	Bahadar H	Toxicity of Nanoparticles and an Overview of Current Experimental Models.	Iranian biomedical journal	2016	11
26362431	L-Lactic acid	Zhou M	Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.	Journal of experimental & clinical cancer research 	2015	50
26379078	L-Lactic acid	Punnoose EA	PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.	British journal of cancer	2015	17
26438120	L-Lactic acid	Scarisbrick JJ	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and S√©zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.	Journal of clinical oncology 	2015	18
26467665	L-Lactic acid	Tang LQ	Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma.	Journal of the National Cancer Institute	2016	23
26759242	L-Lactic acid	Lim SO	EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape.	Cancer research	2016	19
26775841	L-Lactic acid	Ju T	Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543.	Biochemical and biophysical research communications	2016	15
26787752	L-Lactic acid	Martens A	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.	Clinical cancer research 	2016	50
26794281	L-Lactic acid	Diem S	Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.	British journal of cancer	2016	22
26811525	L-Lactic acid	Long GV	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.	Journal of clinical oncology 	2016	36
26876179	L-Lactic acid	Hong CS	MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.	Cell reports	2016	15
26902416	L-Lactic acid	Xiao X	The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer.	Scientific reports	2016	14
27134168	L-Lactic acid	Pisarsky L	Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy.	Cell reports	2016	18
27178742	L-Lactic acid	Sade-Feldman M	Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.	Clinical cancer research 	2016	13
27587707	L-Lactic acid	Ferdinandus J	Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.	Journal of nuclear medicine 	2017	5
27591677	L-Lactic acid	Talasila KM	The angiogenic switch leads to a metabolic shift in human glioblastoma.	Neuro-oncology	2017	11
27993896	L-Lactic acid	San-Mill√°n I	Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect.	Carcinogenesis	2017	7
28246332	L-Lactic acid	Carmona-Fontaine C	Metabolic origins of spatial organization in the tumor microenvironment.	Proceedings of the National Academy of Sciences of the United States of America	2017	7
28475671	L-Lactic acid	Long GV	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.	Annals of oncology 	2017	10
3282647	D-Glucose	Jain RK	Determinants of tumor blood flow: a review.	Cancer research	1988	237
6949641	D-Glucose	Tsuchiya S	Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester.	Cancer research	1982	187
7738205	D-Glucose	Hotamisligil GS	Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.	The Journal of clinical investigation	1995	501
9408743	D-Glucose	Dunaif A	Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.	Endocrine reviews	1997	289
9749880	D-Glucose	Csermely P	The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review.	Pharmacology & therapeutics	1998	183
9916799	D-Glucose	Shayesteh L	PIK3CA is implicated as an oncogene in ovarian cancer.	Nature genetics	1999	205
10449430	D-Glucose	Su CG	A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response.	The Journal of clinical investigation	1999	128
10582706	D-Glucose	Zhong H	Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.	Cancer research	1999	534
10611972	D-Glucose	Semenza GL	Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1.	Annual review of cell and developmental biology	1999	395
10866690	D-Glucose	Yoon JC	Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation.	Molecular and cellular biology	2000	96
11171994	D-Glucose	Haase VH	Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.	Proceedings of the National Academy of Sciences of the United States of America	2001	167
11504627	D-Glucose	Lee AS	The glucose-regulated proteins: stress induction and clinical applications.	Trends in biochemical sciences	2001	247
11786564	D-Glucose	Bos R	Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.	Journal of clinical oncology 	2002	92
12203114	D-Glucose	Budanov AV	Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability.	Oncogene	2002	90
12360255	D-Glucose	De Meyts P	Structural biology of insulin and IGF1 receptors: implications for drug design.	Nature reviews. Drug discovery	2002	135
12569601	D-Glucose	Kunkel M	Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma.	Cancer	2003	78
12713871	D-Glucose	Shuda M	Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis.	Journal of hepatology	2003	106
13130303	D-Glucose	Semenza GL	Targeting HIF-1 for cancer therapy.	Nature reviews. Cancer	2003	1460
15059920	D-Glucose	Schwartzenberg-Bar-Yoseph F	The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression.	Cancer research	2004	160
15143161	D-Glucose	Salma N	Temporal recruitment of transcription factors and SWI/SNF chromatin-remodeling enzymes during adipogenic induction of the peroxisome proliferator-activated receptor gamma nuclear hormone receptor.	Molecular and cellular biology	2004	73
15172999	D-Glucose	Elstrom RL	Akt stimulates aerobic glycolysis in cancer cells.	Cancer research	2004	399
15199412	D-Glucose	Horie Y	Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.	The Journal of clinical investigation	2004	165
15231248	D-Glucose	Grommes C	Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.	The Lancet. Oncology	2004	101
15353558	D-Glucose	Barata JT	Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.	The Journal of experimental medicine	2004	87
15380518	D-Glucose	Arap MA	Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands.	Cancer cell	2004	116
15618010	D-Glucose	D√©ry MA	Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators.	The international journal of biochemistry & cell biology	2005	106
15653324	D-Glucose	Harrington LS	Restraining PI3K: mTOR signalling goes back to the membrane.	Trends in biochemical sciences	2005	127
15677538	D-Glucose	Vleugel MM	Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.	Journal of clinical pathology	2005	71
15806154	D-Glucose	Buzzai M	The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation.	Oncogene	2005	114
15837624	D-Glucose	Shankar DB	The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia.	Cancer cell	2005	65
16007182	D-Glucose	Porstmann T	PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP.	Oncogene	2005	104
16054085	D-Glucose	Lin J	Metabolic control through the PGC-1 family of transcription coactivators.	Cell metabolism	2005	546
16109759	D-Glucose	Sotiropoulou PA	Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells.	Stem cells	2006	115
16288285	D-Glucose	Testa JR	AKT signaling in normal and malignant cells.	Oncogene	2005	84
16311215	D-Glucose	Koerner A	Adipocytokines: leptin--the classical, resistin--the controversical, adiponectin--the promising, and more to come.	Best practice & research. Clinical endocrinology & metabolism	2005	79
16352795	D-Glucose	Stolzenberg-Solomon RZ	Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers.	JAMA	2005	108
16388523	D-Glucose	Basaria S	Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.	Cancer	2006	66
16426829	D-Glucose	Gunter MJ	Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes.	The Journal of nutritional biochemistry	2006	69
16434464	D-Glucose	Smith MR	Insulin sensitivity during combined androgen blockade for prostate cancer.	The Journal of clinical endocrinology and metabolism	2006	99
16470636	D-Glucose	Wolfram S	Anti-obesity effects of green tea: from bedside to bench.	Molecular nutrition & food research	2006	62
16570048	D-Glucose	Kelesidis I	Adiponectin and cancer: a systematic review.	British journal of cancer	2006	104
16707446	D-Glucose	Gatenby RA	Acid-mediated tumor invasion: a multidisciplinary study.	Cancer research	2006	164
16778202	D-Glucose	Carroll VA	Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.	Cancer research	2006	96
16839873	D-Glucose	Green DR	p53 and metabolism: Inside the TIGAR.	Cell	2006	63
16861902	D-Glucose	Fu Y	Glucose regulated proteins in cancer progression, drug resistance and immunotherapy.	Cancer biology & therapy	2006	74
16892082	D-Glucose	Robey RB	Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt.	Oncogene	2006	127
16894525	D-Glucose	Gurney JG	Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia.	Cancer	2006	64
16912156	D-Glucose	Lee E	GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer.	Cancer research	2006	75
17051221	D-Glucose	Shen Y	Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.	Nature	2006	101
17071576	D-Glucose	Cowey S	The metabolic syndrome: A high-risk state for cancer?	The American journal of pathology	2006	104
17313687	D-Glucose	Zhou W	The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer.	Nutrition & metabolism	2007	63
17481900	D-Glucose	Bensaad K	p53: new roles in metabolism.	Trends in cell biology	2007	93
17618108	D-Glucose	Galisteo M	Effects of dietary fibers on disturbances clustered in the metabolic syndrome.	The Journal of nutritional biochemistry	2008	58
17624581	D-Glucose	Gillies RJ	Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?	Journal of bioenergetics and biomembranes	2007	66
17640713	D-Glucose	Daneshmand S	Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.	Human pathology	2007	66
17646672	D-Glucose	Huang H	Dynamic FoxO transcription factors.	Journal of cell science	2007	344
17687336	D-Glucose	Gatenby RA	Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer.	British journal of cancer	2007	91
17889646	D-Glucose	Dai C	Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis.	Cell	2007	300
17932564	D-Glucose	Handschin C	Abnormal glucose homeostasis in skeletal muscle-specific PGC-1alpha knockout mice reveals skeletal muscle-pancreatic beta cell crosstalk.	The Journal of clinical investigation	2007	126
17942897	D-Glucose	Sato K	Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation.	Cancer research	2007	98
17991893	D-Glucose	Shani G	GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth.	Molecular and cellular biology	2008	62
18223655	D-Glucose	Danial NN	Dual role of proapoptotic BAD in insulin secretion and beta cell survival.	Nature medicine	2008	103
18281663	D-Glucose	Ligibel JA	Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors.	Journal of clinical oncology 	2008	53
18347614	D-Glucose	Lawrence MC	The roles of MAPKs in disease.	Cell research	2008	60
18414037	D-Glucose	Palomero T	The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia.	Cell cycle	2008	68
18465360	D-Glucose	Pisani P	Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies.	Archives of physiology and biochemistry	2008	80
18482745	D-Glucose	Zheng HC	Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas.	Human pathology	2008	53
18556422	D-Glucose	Kidd M	Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants.	American journal of physiology. Gastrointestinal and liver physiology	2008	50
18577716	D-Glucose	Maciver NJ	Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival.	Journal of leukocyte biology	2008	109
18633113	D-Glucose	Stefan N	Plasma fetuin-A levels and the risk of type 2 diabetes.	Diabetes	2008	74
18701488	D-Glucose	Kotliarova S	Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation.	Cancer research	2008	79
18974394	D-Glucose	Greenberger LM	A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth.	Molecular cancer therapeutics	2008	53
19075268	D-Glucose	Koschmieder S	Dysregulation of the C/EBPalpha differentiation pathway in human cancer.	Journal of clinical oncology 	2009	51
19143055	D-Glucose	Denko NC	Hypoxia, HIF1 and glucose metabolism in the solid tumour.	Nature reviews. Cancer	2008	331
19201187	D-Glucose	Tong X	The molecular determinants of de novo nucleotide biosynthesis in cancer cells.	Current opinion in genetics & development	2009	89
19223518	D-Glucose	Sir-Petermann T	Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome.	The Journal of clinical endocrinology and metabolism	2009	58
19272022	D-Glucose	Ooms LM	The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease.	The Biochemical journal	2009	72
19276390	D-Glucose	Robey IF	Bicarbonate increases tumor pH and inhibits spontaneous metastases.	Cancer research	2009	160
19357959	D-Glucose	Jensen RL	Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.	Journal of neuro-oncology	2009	81
19421146	D-Glucose	Kelber JA	Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways.	Oncogene	2009	48
19541609	D-Glucose	Shackelford DB	mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2009	78
19597332	D-Glucose	Gonzalez E	The Akt kinases: isoform specificity in metabolism and cancer.	Cell cycle	2009	141
19620249	D-Glucose	Vigneri P	Diabetes and cancer.	Endocrine-related cancer	2009	199
19625659	D-Glucose	Elmasri H	Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells.	FASEB journal 	2009	61
19629071	D-Glucose	Shackelford DB	The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.	Nature reviews. Cancer	2009	446
19641507	D-Glucose	Danial NN	BAD: undertaker by night, candyman by day.	Oncogene	2008	98
19647786	D-Glucose	Butkinaree C	O-linked beta-N-acetylglucosamine (O-GlcNAc): Extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress.	Biochimica et biophysica acta	2010	114
19649631	D-Glucose	Haluska P	Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.	Cancer chemotherapy and pharmacology	2010	46
19671047	D-Glucose	Semenza GL	HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery.	Current pharmaceutical design	2009	51
19723875	D-Glucose	Palmieri D	Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis.	Molecular cancer research 	2009	52
19774643	D-Glucose	Thibault R	Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency.	Inflammatory bowel diseases	2010	49
19881548	D-Glucose	DeBerardinis RJ	Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer.	Oncogene	2010	311
19883376	D-Glucose	Wang F	Brd2 disruption in mice causes severe obesity without Type 2 diabetes.	The Biochemical journal	2009	46
19884662	D-Glucose	Melmed S	Acromegaly pathogenesis and treatment.	The Journal of clinical investigation	2009	78
19897009	D-Glucose	Saji M	The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.	Molecular and cellular endocrinology	2010	47
19963098	D-Glucose	Gibbons JJ	Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.	Seminars in oncology	2009	81
20005308	D-Glucose	Dominy JE Jr	Nutrient-dependent regulation of PGC-1alpha's acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5.	Biochimica et biophysica acta	2010	53
20018949	D-Glucose	Santi SA	The Akt isoforms are present at distinct subcellular locations.	American journal of physiology. Cell physiology	2010	49
20022465	D-Glucose	Das UN	Obesity: genes, brain, gut, and environment.	Nutrition	2010	49
20027213	D-Glucose	Stocks T	Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts.	PLoS medicine	2009	56
20086171	D-Glucose	Dang CV	Rethinking the Warburg effect with Myc micromanaging glutamine metabolism.	Cancer research	2010	126
20159883	D-Glucose	Moran LJ	Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis.	Human reproduction update	2010	100
20185812	D-Glucose	Yang X	Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry.	Diabetes	2010	43
20190804	D-Glucose	Caldwell SA	Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1.	Oncogene	2010	106
20206201	D-Glucose	Ralph SJ	The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy.	Molecular aspects of medicine	2010	87
20215559	D-Glucose	Gonzalez-Angulo AM	Metformin: a therapeutic opportunity in breast cancer.	Clinical cancer research 	2010	58
20227367	D-Glucose	Godlewski J	MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells.	Molecular cell	2010	134
20227368	D-Glucose	Yan L	PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR.	Molecular cell	2010	49
20363910	D-Glucose	Baba Y	HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.	The American journal of pathology	2010	44
20376506	D-Glucose	Nicolucci A	Epidemiological aspects of neoplasms in diabetes.	Acta diabetologica	2010	48
20457610	D-Glucose	Li L	Regulation of mTORC1 by the Rab and Arf GTPases.	The Journal of biological chemistry	2010	51
20512147	D-Glucose	Zhu H	Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies.	Nature genetics	2010	103
20517722	D-Glucose	Fayard E	Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway.	Current topics in microbiology and immunology	2010	77
20647762	D-Glucose	Godlewski J	microRNA-451: A conditional switch controlling glioma cell proliferation and migration.	Cell cycle	2010	58
20692331	D-Glucose	Lu Y	Chronic alcohol-induced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knock-in mice.	Free radical biology & medicine	2010	57
20844768	D-Glucose	Chen JL	Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA.	PLoS genetics	2010	44
20932932	D-Glucose	Fenton TR	Functions and regulation of the 70kDa ribosomal S6 kinases.	The international journal of biochemistry & cell biology	2011	86
20937689	D-Glucose	Calori G	Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study.	Diabetes care	2011	65
20944545	D-Glucose	Yvan-Charvet L	Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity.	Kidney international	2011	40
20970497	D-Glucose	Zhang Y	Role of nuclear receptor SHP in metabolism and cancer.	Biochimica et biophysica acta	2011	66
21088486	D-Glucose	Cuf√≠ S	Metformin against TGFŒ≤-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.	Cell cycle	2010	75
21115858	D-Glucose	Duggan C	Associations of insulin resistance and adiponectin with mortality in women with breast cancer.	Journal of clinical oncology 	2011	65
21119005	D-Glucose	Lock R	Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation.	Molecular biology of the cell	2011	142
21208359	D-Glucose	Madsbad S	An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.	Diabetes, obesity & metabolism	2011	42
21291474	D-Glucose	Uchida Y	Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors.	Journal of neurochemistry	2011	93
21309747	D-Glucose	Ni M	Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting.	The Biochemical journal	2011	132
21329883	D-Glucose	Ou YH	TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation.	Molecular cell	2011	77
21343617	D-Glucose	Chen CH	ER stress inhibits mTORC2 and Akt signaling through GSK-3Œ≤-mediated phosphorylation of rictor.	Science signaling	2011	49
21363910	D-Glucose	Claus SP	Colonization-induced host-gut microbial metabolic interaction.	mBio	2011	99
21391816	D-Glucose	Hart GW	Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease.	Annual review of biochemistry	2011	314
21447859	D-Glucose	Apontes P	Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture.	Oncotarget	2011	103
21460621	D-Glucose	Egan D	The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR.	Autophagy	2011	103
21467168	D-Glucose	Dong D	A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis.	Cancer research	2011	48
21516129	D-Glucose	Lee C	Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients.	Oncogene	2011	74
21553294	D-Glucose	Lynch BM	Associations of objectively assessed physical activity and sedentary time with biomarkers of breast cancer risk in postmenopausal women: findings from NHANES (2003-2006).	Breast cancer research and treatment	2011	36
21622984	D-Glucose	Xu L	Phospholipase D mediates nutrient input to mammalian target of rapamycin complex 1 (mTORC1).	The Journal of biological chemistry	2011	43
21638209	D-Glucose	Samarakoon R	TGF-Œ≤1 ‚Üí SMAD/p53/USF2 ‚Üí PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis.	Cell and tissue research	2012	39
21670080	D-Glucose	Coloff JL	Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition.	Cancer research	2011	50
21805476	D-Glucose	Borena W	Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults.	International journal of cancer	2012	41
21811634	D-Glucose	Caillou B	Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma.	PloS one	2011	36
21865645	D-Glucose	Ravassard P	A genetically engineered human pancreatic Œ≤ cell line exhibiting glucose-inducible insulin secretion.	The Journal of clinical investigation	2011	90
21917523	D-Glucose	Diano S	Mitochondrial uncoupling protein 2 (UCP2) in glucose and lipid metabolism.	Trends in molecular medicine	2012	46
21962509	D-Glucose	Zhu H	The Lin28/let-7 axis regulates glucose metabolism.	Cell	2011	235
21968997	D-Glucose	Mauro C	NF-Œ∫B controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration.	Nature cell biology	2011	76
21978918	D-Glucose	Qin Z	The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculature.	Atherosclerosis	2012	62
22017876	D-Glucose	Zhao Y	DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(Œ≤TrCP) E3 ubiquitin ligase and regulates survival and autophagy.	Molecular cell	2011	81
22056763	D-Glucose	Tailleux A	Roles of PPARs in NAFLD: potential therapeutic targets.	Biochimica et biophysica acta	2012	52
22096029	D-Glucose	Mor I	Control of glycolysis through regulation of PFK1: old friends and recent additions.	Cold Spring Harbor symposia on quantitative biology	2011	38
22162232	D-Glucose	Li D	Diabetes and pancreatic cancer.	Molecular carcinogenesis	2012	55
22162568	D-Glucose	Goodwin PJ	Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.	Journal of clinical oncology 	2012	48
22162589	D-Glucose	Bendell JC	Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.	Journal of clinical oncology 	2012	200
22173168	D-Glucose	Bechmann LP	The interaction of hepatic lipid and glucose metabolism in liver diseases.	Journal of hepatology	2012	103
22237023	D-Glucose	Bostr√∂m P	A PGC1-Œ±-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.	Nature	2012	636
22248668	D-Glucose	Madan E	Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor.	Oncotarget	2011	46
22265971	D-Glucose	Fei X	MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression.	FEBS letters	2012	37
22275356	D-Glucose	Lynch TP	Critical role of O-Linked Œ≤-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis.	The Journal of biological chemistry	2012	70
22318237	D-Glucose	Peters JM	The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.	Nature reviews. Cancer	2012	103
22354042	D-Glucose	Jiang S	A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells.	The EMBO journal	2012	76
22355097	D-Glucose	Dowling RJ	Metformin in cancer: translational challenges.	Journal of molecular endocrinology	2012	77
22360558	D-Glucose	Dhup S	Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis.	Current pharmaceutical design	2012	65
22396530	D-Glucose	Ji Y	Activation of natural killer T cells promotes M2 Macrophage polarization in adipose tissue and improves systemic glucose tolerance via interleukin-4 (IL-4)/STAT6 protein signaling axis in obesity.	The Journal of biological chemistry	2012	60
22426159	D-Glucose	Li Z	Glucose regulated protein 78: a critical link between tumor microenvironment and cancer hallmarks.	Biochimica et biophysica acta	2012	33
22436747	D-Glucose	Rottiers V	MicroRNAs in metabolism and metabolic disorders.	Nature reviews. Molecular cell biology	2012	246
22452979	D-Glucose	McBrayer SK	Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy.	Blood	2012	36
22464321	D-Glucose	Dang CV	MYC on the path to cancer.	Cell	2012	542
22496159	D-Glucose	Cheng S	Metabolite profiling identifies pathways associated with metabolic risk in humans.	Circulation	2012	116
22508478	D-Glucose	Luo B	The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies.	Oncogene	2013	146
22513163	D-Glucose	Cariou B	Thiazolidinediones and PPARŒ≥ agonists: time for a reassessment.	Trends in endocrinology and metabolism	2012	79
22549948	D-Glucose	Imayama I	Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial.	Cancer research	2012	53
22564993	D-Glucose	Bonanni B	Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.	Journal of clinical oncology 	2012	66
22576210	D-Glucose	Ros S	Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival.	Cancer discovery	2012	60
22593586	D-Glucose	Fang R	MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene.	The Journal of biological chemistry	2012	57
22609541	D-Glucose	Matsubara T	FXR signaling in the enterohepatic system.	Molecular and cellular endocrinology	2013	53
22614056	D-Glucose	Enh√∂rning S	Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malm√∂ Diet and Cancer Study cardiovascular cohort.	International journal of obesity	2013	26
22632973	D-Glucose	Chan CH	The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis.	Cell	2012	97
22661548	D-Glucose	Tan MJ	Emerging roles of angiopoietin-like 4 in human cancer.	Molecular cancer research 	2012	34
22719752	D-Glucose	Hsieh MC	The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese.	Experimental diabetes research	2012	42
22751133	D-Glucose	Grkovic S	IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments.	Oncogene	2013	26
22766017	D-Glucose	Baptissart M	Bile acids: from digestion to cancers.	Biochimie	2013	25
22784697	D-Glucose	Thornton JE	How does Lin28 let-7 control development and disease?	Trends in cell biology	2012	100
22806397	D-Glucose	Goldinger SM	Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8‚Å∫ T-cell responses in melanoma patients.	European journal of immunology	2012	33
22864381	D-Glucose	Komurov K	The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.	Molecular systems biology	2012	34
22869720	D-Glucose	Chaika NV	MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer.	Proceedings of the National Academy of Sciences of the United States of America	2012	53
22892585	D-Glucose	Coric V	Safety and tolerability of the Œ≥-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.	Archives of neurology	2012	50
22915762	D-Glucose	Wang Y	The unfolded protein response induces the angiogenic switch in human tumor cells through the PERK/ATF4 pathway.	Cancer research	2012	36
22923583	D-Glucose	Yi W	Phosphofructokinase 1 glycosylation regulates cell growth and metabolism.	Science	2012	132
22960655	D-Glucose	Aggarwal G	Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in Œ≤ cells and mice.	Gastroenterology	2012	31
22961911	D-Glucose	Hu Y	Recent agents targeting HIF-1Œ± for cancer therapy.	Journal of cellular biochemistry	2013	25
22970944	D-Glucose	Pal A	PTEN mutations as a cause of constitutive insulin sensitivity and obesity.	The New England journal of medicine	2012	48
22984531	D-Glucose	Safdie F	Fasting enhances the response of glioma to chemo- and radiotherapy.	PloS one	2012	33
22999886	D-Glucose	Kung C	Small molecule activation of PKM2 in cancer cells induces serine auxotrophy.	Chemistry & biology	2012	39
23061800	D-Glucose	Passtoors WM	Gene expression analysis of mTOR pathway: association with human longevity.	Aging cell	2013	38
23063129	D-Glucose	Teperino R	Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat.	Cell	2012	65
23071360	D-Glucose	Meijer TW	Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy.	Clinical cancer research 	2012	80
23114091	D-Glucose	Lim SS	The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis.	Obesity reviews 	2013	35
23151455	D-Glucose	Rodriguez OC	Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy.	Cell cycle	2012	37
23159620	D-Glucose	Sinnett-Smith J	Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK.	Biochemical and biophysical research communications	2013	39
23164426	D-Glucose	Chen B	Roles of microRNA on cancer cell metabolism.	Journal of translational medicine	2012	42
23169792	D-Glucose	Ganeshan B	Non-small cell lung cancer: histopathologic correlates for texture parameters at CT.	Radiology	2013	52
23207292	D-Glucose	Djiogue S	Insulin resistance and cancer: the role of insulin and IGFs.	Endocrine-related cancer	2013	42
23236214	D-Glucose	Brauer HA	Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer.	Clinical cancer research 	2013	38
23249272	D-Glucose	Passos-Silva DG	Angiotensin-(1-7): beyond the cardio-renal actions.	Clinical science	2013	37
23262492	D-Glucose	Gammoh N	Interaction between FIP200 and ATG16L1 distinguishes ULK1 complex-dependent and -independent autophagy.	Nature structural & molecular biology	2013	47
23263486	D-Glucose	K√∂ttgen A	Genome-wide association analyses identify 18 new loci associated with serum urate concentrations.	Nature genetics	2013	139
23274086	D-Glucose	Faubert B	AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo.	Cell metabolism	2013	183
23315061	D-Glucose	Stepto NK	Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp.	Human reproduction	2013	67
23374352	D-Glucose	Ma L	Control of nutrient stress-induced metabolic reprogramming by PKCŒ∂ in tumorigenesis.	Cell	2013	52
23440242	D-Glucose	Ambrose M	Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions.	Blood	2013	39
23465396	D-Glucose	Jewell JL	Nutrient signaling to mTOR and cell growth.	Trends in biochemical sciences	2013	87
23466711	D-Glucose	Duggan C	Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma.	Clinical gastroenterology and hepatology 	2013	39
23493574	D-Glucose	Chen YH	miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance.	Diabetes	2013	35
23528347	D-Glucose	Sah RP	New insights into pancreatic cancer-induced paraneoplastic diabetes.	Nature reviews. Gastroenterology & hepatology	2013	45
23562747	D-Glucose	Newman G	Leptin-cytokine crosstalk in breast cancer.	Molecular and cellular endocrinology	2014	32
23636237	D-Glucose	Tanaka T	Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake.	The American journal of clinical nutrition	2013	48
23645884	D-Glucose	Nauck MA	A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks.	Diabetes care	2013	51
23645885	D-Glucose	Butler PC	A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?	Diabetes care	2013	62
23674815	D-Glucose	Clem BF	Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.	Molecular cancer therapeutics	2013	45
23746901	D-Glucose	Yang G	Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010.	Lancet	2013	276
23764390	D-Glucose	Croze ML	Potential role and therapeutic interests of myo-inositol in metabolic diseases.	Biochimie	2013	36
23797762	D-Glucose	Salani B	Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II.	Scientific reports	2013	26
23813974	D-Glucose	Bochenek G	The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10.	Human molecular genetics	2013	37
23859617	D-Glucose	Guo D	Targeting SREBP-1-driven lipid metabolism to treat cancer.	Current pharmaceutical design	2014	35
23906881	D-Glucose	Dang CV	MYC, metabolism, cell growth, and tumorigenesis.	Cold Spring Harbor perspectives in medicine	2013	140
23911236	D-Glucose	Patra KC	Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer.	Cancer cell	2013	136
23995067	D-Glucose	Flavahan WA	Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake.	Nature neuroscience	2013	83
24037093	D-Glucose	Taniguchi CM	Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes.	Nature medicine	2013	33
24091329	D-Glucose	Sukumar M	Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function.	The Journal of clinical investigation	2013	137
24140094	D-Glucose	Lee YS	Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.	Metabolism	2014	29
24141775	D-Glucose	Chen WT	GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN.	Oncogene	2014	24
24165795	D-Glucose	Lucas CL	Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110Œ¥ result in T cell senescence and human immunodeficiency.	Nature immunology	2014	100
24166096	D-Glucose	Yan JW	The emerging role of miR-375 in cancer.	International journal of cancer	2014	38
24184209	D-Glucose	Ellis BC	CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism.	Biochimica et biophysica acta	2014	41
24189526	D-Glucose	Anisimov VN	Metformin: do we finally have an anti-aging drug?	Cell cycle	2013	26
24388967	D-Glucose	Bryant KL	KRAS: feeding pancreatic cancer proliferation.	Trends in biochemical sciences	2014	99
24411942	D-Glucose	Roberts LD	Œ≤-Aminoisobutyric acid induces browning of white fat and hepatic Œ≤-oxidation and is inversely correlated with cardiometabolic risk factors.	Cell metabolism	2014	75
24423324	D-Glucose	Colao A	Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.	The Journal of clinical endocrinology and metabolism	2014	30
24423344	D-Glucose	O'Reilly MW	Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione.	The Journal of clinical endocrinology and metabolism	2014	25
24462370	D-Glucose	Holmes MV	Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis.	American journal of human genetics	2014	42
24469106	D-Glucose	Parmenter TJ	Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.	Cancer discovery	2014	54
24504108	D-Glucose	White NM	Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma.	Oncotarget	2014	28
24568896	D-Glucose	Bhindi B	Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.	European urology	2015	20
24613355	D-Glucose	Chen YJ	De novo formation of insulin-producing "neo-Œ≤ cell islets" from intestinal crypts.	Cell reports	2014	33
24662521	D-Glucose	Karnevi E	Tumour-educated macrophages display a mixed polarisation and enhance pancreatic cancer cell invasion.	Immunology and cell biology	2014	24
24662831	D-Glucose	Xiao L	Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy.	Oncogene	2014	30
24668104	D-Glucose	Emerging Risk Factors Collaboration.	Glycated hemoglobin measurement and prediction of cardiovascular disease.	JAMA	2014	35
24744147	D-Glucose	Olivier-Van Stichelen S	O-GlcNAcylation stabilizes Œ≤-catenin through direct competition with phosphorylation at threonine 41.	FASEB journal 	2014	23
24847886	D-Glucose	Deng D	Crystal structure of the human glucose transporter GLUT1.	Nature	2014	98
24890811	D-Glucose	Li Z	Long non-coding RNA UCA1 promotes glycolysis by upregulating hexokinase 2 through the mTOR-STAT3/microRNA143 pathway.	Cancer science	2014	43
24930970	D-Glucose	Macintyre AN	The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function.	Cell metabolism	2014	137
24990952	D-Glucose	Foster DA	Phospholipase D and the maintenance of phosphatidic acid levels for regulation of mammalian target of rapamycin (mTOR).	The Journal of biological chemistry	2014	32
24994904	D-Glucose	Eberlin LS	Alteration of the lipid profile in lymphomas induced by MYC overexpression.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
24997364	D-Glucose	Slominski A	The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1Œ± expression and HIF-dependent attendant pathways.	Archives of biochemistry and biophysics	2014	40
25002027	D-Glucose	Valencia T	Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis.	Cancer cell	2014	53
25038584	D-Glucose	Wahlstr√∂m T	Impact of MYC in regulation of tumor cell metabolism.	Biochimica et biophysica acta	2015	36
25041791	D-Glucose	Philip PA	Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).	Cancer	2014	27
25046320	D-Glucose	Wirth MD	Association of a dietary inflammatory index with inflammatory indices and metabolic syndrome among police officers.	Journal of occupational and environmental medicine	2014	65
25083993	D-Glucose	Henson SM	p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8‚Å∫ T cells.	The Journal of clinical investigation	2014	51
25102180	D-Glucose	Ng MC	Meta-analysis of genome-wide association studies in African Americans provides insights into the genetic architecture of type 2 diabetes.	PLoS genetics	2014	46
25105579	D-Glucose	Sancho R	Loss of Fbw7 reprograms adult pancreatic ductal cells into Œ±, Œ¥, and Œ≤ cells.	Cell stem cell	2014	26
25157349	D-Glucose	Pochini L	Membrane transporters for the special amino acid glutamine: structure/function relationships and relevance to human health.	Frontiers in chemistry	2014	33
25169894	D-Glucose	Rawlings-Goss RA	Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers.	BMC medical genomics	2014	27
25239226	D-Glucose	Liu X	IL-1Œ≤ induces IL-6 production in retinal M√ºller cells predominantly through the activation of p38 MAPK/NF-Œ∫B signaling pathway.	Experimental cell research	2015	17
25242225	D-Glucose	Soccio RE	Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.	Cell metabolism	2014	52
25262344	D-Glucose	Swerdlow DI	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.	Lancet	2015	82
25284588	D-Glucose	Jiang L	Metabolic reprogramming during TGFŒ≤1-induced epithelial-to-mesenchymal transition.	Oncogene	2015	26
25288136	D-Glucose	Coffee and Caffeine Genetics Consortium.	Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption.	Molecular psychiatry	2015	24
25304371	D-Glucose	Chen B	miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer.	Cancer letters	2015	21
25317558	D-Glucose	Gnad T	Adenosine activates brown adipose tissue and recruits beige adipocytes via A2A receptors.	Nature	2014	42
25352637	D-Glucose	Fuster JJ	Noncanonical Wnt signaling promotes obesity-induced adipose tissue inflammation and metabolic dysfunction independent of adipose tissue expansion.	Diabetes	2015	24
25399420	D-Glucose	Gao Y	The H19/let-7 double-negative feedback loop contributes to glucose metabolism in muscle cells.	Nucleic acids research	2014	42
25450819	D-Glucose	Janani C	PPAR gamma gene--a review.	Diabetes & metabolic syndrome	2015	45
25456737	D-Glucose	Foretz M	Metformin: from mechanisms of action to therapies.	Cell metabolism	2014	110
25476696	D-Glucose	Everard A	Intestinal epithelial MyD88 is a sensor switching host metabolism towards obesity according to nutritional status.	Nature communications	2014	42
25512540	D-Glucose	Hung CL	A long noncoding RNA connects c-Myc to tumor metabolism.	Proceedings of the National Academy of Sciences of the United States of America	2014	47
25525878	D-Glucose	Mashimo T	Acetate is a bioenergetic substrate for human glioblastoma and brain metastases.	Cell	2014	120
25528771	D-Glucose	Shibuya K	Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells.	Oncotarget	2015	28
25563886	D-Glucose	Goos JA	Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis.	Annals of surgery	2016	10
25576058	D-Glucose	Cifarelli V	Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms.	Diabetes	2015	21
25732824	D-Glucose	Zhang D	Metabolic reprogramming of cancer-associated fibroblasts by IDH3Œ± downregulation.	Cell reports	2015	27
25747274	D-Glucose	Monga SP	Œ≤-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis.	Gastroenterology	2015	58
25781552	D-Glucose	Booth A	Adipose tissue, obesity and adipokines: role in cancer promotion.	Hormone molecular biology and clinical investigation	2015	25
25789560	D-Glucose	Xue M	Chemical methods for the simultaneous quantitation of metabolites and proteins from single cells.	Journal of the American Chemical Society	2015	19
25796446	D-Glucose	Enzo E	Aerobic glycolysis tunes YAP/TAZ transcriptional activity.	The EMBO journal	2015	29
25870263	D-Glucose	Shen L	Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.	Proceedings of the National Academy of Sciences of the United States of America	2015	20
25887760	D-Glucose	Fu QF	Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway.	Journal of hematology & oncology	2015	25
25911689	D-Glucose	Senkowski W	Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer.	Molecular cancer therapeutics	2015	16
25919570	D-Glucose	Lin Y	MicroRNA-33b Inhibits Breast Cancer Metastasis by Targeting HMGA2, SALL4 and Twist1.	Scientific reports	2015	33
25937285	D-Glucose	Aird KM	ATM couples replication stress and metabolic reprogramming during cellular senescence.	Cell reports	2015	18
25956158	D-Glucose	Zadra G	Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies.	Molecular cancer research 	2015	24
26067718	D-Glucose	Pivonello R	The Treatment of Cushing's Disease.	Endocrine reviews	2015	24
26081915	D-Glucose	Penney NC	The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review.	International journal of obesity	2015	19
26179207	D-Glucose	Phan L	The cell cycle regulator 14-3-3œÉ opposes and reverses cancer metabolic reprogramming.	Nature communications	2015	19
26197299	D-Glucose	Flynn CR	Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery.	Nature communications	2015	19
26365896	D-Glucose	Baenke F	Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells.	Molecular oncology	2016	21
26387865	D-Glucose	Altman BJ	MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells.	Cell metabolism	2015	34
26399441	D-Glucose	Rao X	O-GlcNAcylation of G6PD promotes the pentose phosphate pathway and tumor growth.	Nature communications	2015	20
26433941	D-Glucose	Florath I	Type 2 diabetes and leucocyte DNA methylation: an epigenome-wide association study in over 1,500 older adults.	Diabetologia	2016	20
26437782	D-Glucose	Hochhaus A	Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.	Leukemia	2016	14
26443705	D-Glucose	Zhang H	Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1.	Science signaling	2015	24
26445512	D-Glucose	Kajimura S	Brown and Beige Fat: Physiological Roles beyond Heat Generation.	Cell metabolism	2015	88
26523864	D-Glucose	Zhao E	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.	Nature immunology	2016	51
26542580	D-Glucose	Perelis M	Pancreatic Œ≤ cell enhancers regulate rhythmic transcription of genes controlling insulin secretion.	Science	2015	49
26563978	D-Glucose	Allen DB	GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults.	European journal of endocrinology	2016	18
26587888	D-Glucose	Wibmer AG	Molecular Imaging of Prostate Cancer.	Radiographics 	2016	10
26621825	D-Glucose	Zaccardi F	Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective.	Postgraduate medical journal	2016	16
26636483	D-Glucose	P√©rez-Escuredo J	Lactate promotes glutamine uptake and metabolism in oxidative cancer cells.	Cell cycle	2016	18
26683796	D-Glucose	Mishra AK	Obesity: An overview of possible role(s) of gut hormones, lipid sensing and gut microbiota.	Metabolism	2016	15
26689977	D-Glucose	Lawman HG	Associations of Relative Handgrip Strength and Cardiovascular Disease Biomarkers in U.S. Adults, 2011-2012.	American journal of preventive medicine	2016	14
26704305	D-Glucose	Gwak H	Resveratrol triggers ER stress-mediated apoptosis by disrupting N-linked glycosylation of proteins in ovarian cancer cells.	Cancer letters	2016	11
26712688	D-Glucose	Iyengar NM	Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer.	Clinical cancer research 	2016	27
26724171	D-Glucose	Parks SK	Hypoxia optimises tumour growth by controlling nutrient import and acidic metabolite export.	Molecular aspects of medicine	2016	13
26773935	D-Glucose	Barron CC	Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment.	Metabolism	2016	20
26824656	D-Glucose	Hu H	Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton.	Cell	2016	30
26853146	D-Glucose	Redis RS	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2.	Molecular cell	2016	25
26859576	D-Glucose	Paolicchi E	Targeting hypoxic response for cancer therapy.	Oncotarget	2016	20
26950362	D-Glucose	Helman A	p16(Ink4a)-induced senescence of pancreatic beta cells enhances insulin secretion.	Nature medicine	2016	30
27027351	D-Glucose	D'Esposito V	Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5.	Oncotarget	2016	12
27088857	D-Glucose	Lien EC	Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer.	Nature cell biology	2016	16
27089238	D-Glucose	Lukey MJ	The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy.	Nature communications	2016	17
27106405	D-Glucose	Albert NL	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.	Neuro-oncology	2016	24
27238018	D-Glucose	Zhao X	Circadian Amplitude Regulation via FBXW7-Targeted REV-ERBŒ± Degradation.	Cell	2016	11
27343361	D-Glucose	Ferrer CM	O-GlcNAcylation in Cancer Biology: Linking Metabolism and Signaling.	Journal of molecular biology	2016	10
27347932	D-Glucose	Lagan√† AS	Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives.	International journal of molecular sciences	2016	12
27473078	D-Glucose	Polak K	New markers of insulin resistance in polycystic ovary syndrome.	Journal of endocrinological investigation	2017	6
27500523	D-Glucose	Zhou K	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.	Nature genetics	2016	13
27557514	D-Glucose	Zou ZW	LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells.	Oncotarget	2016	17
27557534	D-Glucose	Lien EC	Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer.	Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer	2016	11
27571186	D-Glucose	Dumesic DA	Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women.	The Journal of clinical endocrinology and metabolism	2016	11
27745828	D-Glucose	Rehman MB	Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.	Diabetes & metabolism	2017	5
27901631	D-Glucose	O'Reilly MW	11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome.	The Journal of clinical endocrinology and metabolism	2017	10
27908689	D-Glucose	Schmidt AF	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.	The lancet. Diabetes & endocrinology	2017	23
27931517	D-Glucose	Oh S	Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells.	BMB reports	2017	6
27935822	D-Glucose	Luo L	Adipose tissue in control of metabolism.	The Journal of endocrinology	2016	16
28199306	D-Glucose	Wolfson RL	KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1.	Nature	2017	19
28293093	D-Glucose	Rinaldi L	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis.	World journal of gastroenterology	2017	5
28314735	D-Glucose	Adams LA	Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.	Gut	2017	12
28351381	D-Glucose	von Ahrens D	The role of stromal cancer-associated fibroblasts in pancreatic cancer.	Journal of hematology & oncology	2017	10
28398233	D-Glucose	Colld√©n G	Therapeutic Potential of Targeting the Ghrelin Pathway.	International journal of molecular sciences	2017	5
28846098	D-Glucose	Emmerson PJ	The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL.	Nature medicine	2017	12
28854168	D-Glucose	Cohen LJ	Commensal bacteria make GPCR ligands that mimic human signalling molecules.	Nature	2017	9
10397265	Biotin	Chang SS	Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.	Cancer research	1999	123
14638862	Biotin	Christian S	Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels.	The Journal of cell biology	2003	114
18495537	Biotin	Bartolazzi A	Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study.	The Lancet. Oncology	2008	53
19509156	Biotin	Yamamichi N	Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development.	Clinical cancer research 	2009	66
23506878	Biotin	Zhao R	Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors.	Molecular aspects of medicine	2013	28
23933812	Biotin	Zhang Z	Negative regulation of lncRNA GAS5 by miR-21.	Cell death and differentiation	2013	72
25452129	Biotin	Dingar D	BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors.	Journal of proteomics	2015	25
25735706	Biotin	Jakobsen KR	Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma.	Journal of extracellular vesicles	2015	26
25900982	Biotin	Coyaud E	BioID-based Identification of Skp Cullin F-box (SCF)Œ≤-TrCP1/2 E3 Ligase Substrates.	Molecular & cellular proteomics 	2015	26
26086405	Biotin	Yang J	Global, in situ, site-specific analysis of protein S-sulfenylation.	Nature protocols	2015	24
26234674	Biotin	Phatak P	Overexpression of miR-214-3p in esophageal squamous cancer cells enhances sensitivity to cisplatin by targeting survivin directly and indirectly through CUG-BP1.	Oncogene	2016	15
28520103	Biotin	Han D	Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression.	Hepatology	2017	23
1557402	L-Cysteine	Wong AJ	Structural alterations of the epidermal growth factor receptor gene in human gliomas.	Proceedings of the National Academy of Sciences of the United States of America	1992	196
2158863	L-Cysteine	Schall TJ	Molecular cloning and expression of a receptor for human tumor necrosis factor.	Cell	1990	150
7652577	L-Cysteine	W√∂lfel T	A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.	Science	1995	187
7958843	L-Cysteine	Kumar S	Induction of apoptosis by the mouse Nedd2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1 beta-converting enzyme.	Genes & development	1994	120
8681377	L-Cysteine	Muzio M	FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex.	Cell	1996	479
9143692	L-Cysteine	Nakamura H	Redox regulation of cellular activation.	Annual review of immunology	1997	137
9600969	L-Cysteine	Babic AM	CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth.	Proceedings of the National Academy of Sciences of the United States of America	1998	113
10213689	L-Cysteine	Mannick JB	Fas-induced caspase denitrosylation.	Science	1999	128
10458605	L-Cysteine	Bromberg JF	Stat3 as an oncogene.	Cell	1999	799
10802708	L-Cysteine	Teitz T	Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN.	Nature medicine	2000	154
11104820	L-Cysteine	Chang HY	Proteases for cell suicide: functions and regulation of caspases.	Microbiology and molecular biology reviews 	2000	99
11441809	L-Cysteine	Powis G	Properties and biological activities of thioredoxins.	Annual review of biophysics and biomolecular structure	2001	87
11714645	L-Cysteine	Rabkin E	Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves.	Circulation	2001	148
12223280	L-Cysteine	East L	The mannose receptor family.	Biochimica et biophysica acta	2002	110
12235282	L-Cysteine	Baker AH	Metalloproteinase inhibitors: biological actions and therapeutic opportunities.	Journal of cell science	2002	213
12904165	L-Cysteine	Brigstock DR	The CCN family: a new stimulus package.	The Journal of endocrinology	2003	151
14871816	L-Cysteine	Caldwell GM	The Wnt antagonist sFRP1 in colorectal tumorigenesis.	Cancer research	2004	75
15094120	L-Cysteine	Bellail AC	Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion.	The international journal of biochemistry & cell biology	2004	124
15189137	L-Cysteine	Jiang X	Cytochrome C-mediated apoptosis.	Annual review of biochemistry	2004	282
15314073	L-Cysteine	Nylandsted J	Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization.	The Journal of experimental medicine	2004	130
15607806	L-Cysteine	Smyth MJ	Activation of NK cell cytotoxicity.	Molecular immunology	2005	94
16046058	L-Cysteine	Liaudet-Coopman E	Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis.	Cancer letters	2006	73
16389449	L-Cysteine	Johannessen M	The multifunctional roles of the four-and-a-half-LIM only protein FHL2.	Cellular and molecular life sciences 	2006	74
16481467	L-Cysteine	Gocheva V	Distinct roles for cysteine cathepsin genes in multistage tumorigenesis.	Genes & development	2006	129
16624823	L-Cysteine	Sandur SK	Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents.	The Journal of biological chemistry	2006	71
16722814	L-Cysteine	Gradishar WJ	Albumin-bound paclitaxel: a next-generation taxane.	Expert opinion on pharmacotherapy	2006	95
16818644	L-Cysteine	Rofstad EK	Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice.	Cancer research	2006	147
17235047	L-Cysteine	Infante JR	Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.	Journal of clinical oncology 	2007	118
17245112	L-Cysteine	Gocheva V	Cysteine cathepsins and the cutting edge of cancer invasion.	Cell cycle	2007	96
17311556	L-Cysteine	Vasiljeva O	Emerging roles of cysteine cathepsins in disease and their potential as drug targets.	Current pharmaceutical design	2007	90
17440104	L-Cysteine	Cohen CJ	Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.	Cancer research	2007	83
17545618	L-Cysteine	DeAlmeida VI	The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo.	Cancer research	2007	62
17893322	L-Cysteine	Atcha FA	A unique DNA binding domain converts T-cell factors into strong Wnt effectors.	Molecular and cellular biology	2007	57
18193050	L-Cysteine	Cai G	CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.	Nature immunology	2008	94
18508595	L-Cysteine	Turk V	Cystatins: biochemical and structural properties, and medical relevance.	Frontiers in bioscience 	2008	61
18614539	L-Cysteine	Roberts PJ	Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification.	The Journal of biological chemistry	2008	97
18824526	L-Cysteine	Gibbs GM	The CAP superfamily: cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins--roles in reproduction, cancer, and immune defense.	Endocrine reviews	2008	115
19381019	L-Cysteine	Qing J	Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.	The Journal of clinical investigation	2009	66
19426226	L-Cysteine	Cai G	The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.	Immunological reviews	2009	66
19567589	L-Cysteine	Lucio-Eterovic AK	Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.	Clinical cancer research 	2009	75
19671755	L-Cysteine	Colland F	Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells.	Molecular cancer therapeutics	2009	72
19788417	L-Cysteine	Allan LA	Apoptosis and autophagy: Regulation of caspase-9 by phosphorylation.	The FEBS journal	2009	55
20170166	L-Cysteine	Rauser S	Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry.	Journal of proteome research	2010	48
20213804	L-Cysteine	Sonnylal S	Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis.	Arthritis and rheumatism	2010	57
20226165	L-Cysteine	Salminen A	Celastrol: Molecular targets of Thunder God Vine.	Biochemical and biophysical research communications	2010	57
20385560	L-Cysteine	Doyle K	Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function.	The Journal of biological chemistry	2010	43
20414655	L-Cysteine	Ostrand-Rosenberg S	Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity.	Cancer immunology, immunotherapy 	2010	159
20421418	L-Cysteine	Lau A	A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62.	Molecular and cellular biology	2010	177
20480266	L-Cysteine	Ziyan W	MicroRNA-21 is involved in osteosarcoma cell invasion and migration.	Medical oncology	2011	48
20694660	L-Cysteine	Giudice A	Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents.	Methods in molecular biology	2010	51
20805300	L-Cysteine	Junutula JR	Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.	Clinical cancer research 	2010	50
21124317	L-Cysteine	Wang K	Integrative genomics identifies LMO1 as a neuroblastoma oncogene.	Nature	2011	95
21251164	L-Cysteine	Taguchi K	Molecular mechanisms of the Keap1‚ÄìNrf2 pathway in stress response and cancer evolution.	Genes to cells 	2011	237
21308479	L-Cysteine	Arvatz G	The heparanase system and tumor metastasis: is heparanase the seed and soil?	Cancer metastasis reviews	2011	39
21442631	L-Cysteine	Schrader J	Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells.	Hepatology	2011	81
21536738	L-Cysteine	Shochat C	Gain-of-function mutations in interleukin-7 receptor-Œ± (IL7R) in childhood acute lymphoblastic leukemias.	The Journal of experimental medicine	2011	98
21892159	L-Cysteine	Zenatti PP	Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.	Nature genetics	2011	98
21931545	L-Cysteine	Qu L	Disruption of TLR3 signaling due to cleavage of TRIF by the hepatitis A virus protease-polymerase processing intermediate, 3CD.	PLoS pathogens	2011	41
21969517	L-Cysteine	Von Hoff DD	Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.	Journal of clinical oncology 	2011	260
22015607	L-Cysteine	Dewson G	Bax dimerizes via a symmetric BH3:groove interface during apoptosis.	Cell death and differentiation	2012	61
22045338	L-Cysteine	Lynes EM	Palmitoylated TMX and calnexin target to the mitochondria-associated membrane.	The EMBO journal	2012	50
22056874	L-Cysteine	Harris LG	Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61.	Oncogene	2012	35
22093547	L-Cysteine	Victor BC	Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion.	Breast cancer research 	2011	36
22118673	L-Cysteine	Chen J	Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells.	Chemistry & biology	2011	46
22128301	L-Cysteine	Liu X	Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.	Clinical cancer research 	2012	41
22182510	L-Cysteine	King TD	Frizzled7 as an emerging target for cancer therapy.	Cellular signalling	2012	35
22200620	L-Cysteine	Raina D	Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells.	International journal of oncology	2012	33
22266111	L-Cysteine	Withana NP	Cathepsin B inhibition limits bone metastasis in breast cancer.	Cancer research	2012	44
22348534	L-Cysteine	Yoo NJ	Somatic mutations of the KEAP1 gene in common solid cancers.	Histopathology	2012	37
22710668	L-Cysteine	Kypta RM	Wnt/Œ≤-catenin signalling in prostate cancer.	Nature reviews. Urology	2012	63
23016862	L-Cysteine	Voronkov A	Wnt/beta-catenin signaling and small molecule inhibitors.	Current pharmaceutical design	2013	55
23174564	L-Cysteine	Goldsmith EC	Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression.	American journal of physiology. Cell physiology	2013	35
23203246	L-Cysteine	Cho SY	Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.	Journal of nuclear medicine 	2012	68
23219527	L-Cysteine	Bryan HK	The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation.	Biochemical pharmacology	2013	159
23333463	L-Cysteine	Wei Z	STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells.	Cellular signalling	2013	29
23386904	L-Cysteine	Magister S	Cystatins in immune system.	Journal of Cancer	2013	30
23407552	L-Cysteine	Meissner B	The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.	Blood	2013	28
23463012	L-Cysteine	Kulathu Y	Regulation of A20 and other OTU deubiquitinases by reversible oxidation.	Nature communications	2013	35
23646934	L-Cysteine	Greiner R	Polysulfides link H2S to protein thiol oxidation.	Antioxidants & redox signaling	2013	78
23690170	L-Cysteine	Neuzillet C	Stromal expression of SPARC in pancreatic adenocarcinoma.	Cancer metastasis reviews	2013	29
23770008	L-Cysteine	Yardley DA	nab-Paclitaxel mechanisms of action and delivery.	Journal of controlled release 	2013	48
23770776	L-Cysteine	Kung Sutherland MS	SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.	Blood	2013	65
23788041	L-Cysteine	Bullock MD	Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression.	Cell death & disease	2013	31
23881612	L-Cysteine	Hong KJ	RECK inhibits stemness gene expression and tumorigenicity of gastric cancer cells by suppressing ADAM-mediated Notch1 activation.	Journal of cellular physiology	2014	24
23902689	L-Cysteine	Brisson L	NaV1.5 Na‚Å∫ channels allosterically regulate the NHE-1 exchanger and promote the activity of breast cancer cell invadopodia.	Journal of cell science	2013	28
24078004	L-Cysteine	Zhao H	MiR-25 promotes gastric cancer cells growth and motility by targeting RECK.	Molecular and cellular biochemistry	2014	27
24080158	L-Cysteine	Xavier CP	Secreted Frizzled-related protein potentiation versus inhibition of Wnt3a/Œ≤-catenin signaling.	Cellular signalling	2014	21
24469331	L-Cysteine	Smit JJ	RBR E3-ligases at work.	EMBO reports	2014	21
24562449	L-Cysteine	Sinn M	SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.	Annals of oncology 	2014	24
24637463	L-Cysteine	Kratz F	A clinical update of using albumin as a drug vehicle - a commentary.	Journal of controlled release 	2014	23
24675529	L-Cysteine	Nagaraju GP	Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis.	Carcinogenesis	2014	26
24677670	L-Cysteine	Aggarwal N	Cathepsin B: multiple roles in cancer.	Proteomics. Clinical applications	2014	25
24683721	L-Cysteine	Thota R	Treatment of metastatic pancreatic adenocarcinoma: a review.	Oncology	2014	37
25030448	L-Cysteine	van den Boomen DJ	TMEM129 is a Derlin-1 associated ERAD E3 ligase essential for virus-induced degradation of MHC-I.	Proceedings of the National Academy of Sciences of the United States of America	2014	22
25043025	L-Cysteine	Kwiatkowski N	Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.	Nature	2014	101
25087232	L-Cysteine	Yoshie O	CCR4 and its ligands: from bench to bedside.	International immunology	2015	30
25159986	L-Cysteine	Heyninck K	Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKKŒ≤.	Biochemical pharmacology	2014	24
25172549	L-Cysteine	Le PN	Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.	Pharmacology & therapeutics	2015	34
25228770	L-Cysteine	Westphal D	Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane.	Proceedings of the National Academy of Sciences of the United States of America	2014	26
25460271	L-Cysteine	Malinauskas T	Extracellular modulators of Wnt signalling.	Current opinion in structural biology	2014	21
25579209	L-Cysteine	Neggers JE	Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.	Chemistry & biology	2015	27
25597503	L-Cysteine	Parent A	Mammalian frataxin directly enhances sulfur transfer of NFS1 persulfide to both ISCU and free thiols.	Nature communications	2015	21
25639489	L-Cysteine	Vanaja SK	Mechanisms of inflammasome activation: recent advances and novel insights.	Trends in cell biology	2015	60
25823923	L-Cysteine	Qin L	WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis.	Oncotarget	2015	23
26069305	L-Cysteine	Rowe SP	¬π‚Å∏F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.	Journal of nuclear medicine 	2015	36
26117331	L-Cysteine	Suzuki T	Molecular basis of the Keap1-Nrf2 system.	Free radical biology & medicine	2015	81
26169969	L-Cysteine	Hidalgo M	SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.	Clinical cancer research 	2015	30
26267657	L-Cysteine	Raina D	Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target.	PloS one	2015	17
26668317	L-Cysteine	Noy PJ	TspanC8 Tetraspanins and A Disintegrin and Metalloprotease 10 (ADAM10) Interact via Their Extracellular Regions: EVIDENCE FOR DISTINCT BINDING MECHANISMS FOR DIFFERENT TspanC8 PROTEINS.	The Journal of biological chemistry	2016	13
26791894	L-Cysteine	Zhang C	Œ†-Clamp-mediated cysteine conjugation.	Nature chemistry	2016	19
26805760	L-Cysteine	Zhang L	Unraveling the roles of Atg4 proteases from autophagy modulation to targeted cancer therapy.	Cancer letters	2016	10
26996066	L-Cysteine	Li S	MCP-1-induced ERK/GSK-3Œ≤/Snail signaling facilitates the epithelial-mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells.	Cellular & molecular immunology	2017	5
27312108	L-Cysteine	Dove KK	Molecular insights into RBR E3 ligase ubiquitin transfer mechanisms.	EMBO reports	2016	16
27497696	L-Cysteine	Dinkova-Kostova AT	Keap1, the cysteine-based mammalian intracellular sensor for electrophiles and oxidants.	Archives of biochemistry and biophysics	2017	6
27571479	L-Cysteine	Zhang T	Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.	Nature chemical biology	2016	17
27626662	L-Cysteine	Yan D	STAT3 and STAT6 Signaling Pathways Synergize to Promote Cathepsin Secretion from Macrophages via IRE1Œ± Activation.	Cell reports	2016	11
27705744	L-Cysteine	Luchetti G	Cholesterol activates the G-protein coupled receptor Smoothened to promote Hedgehog signaling.	eLife	2016	15
28287329	L-Cysteine	Skytte Rasmussen M	ATG4B contains a C-terminal LIR motif important for binding and efficient cleavage of mammalian orthologs of yeast Atg8.	Autophagy	2017	6
28336545	L-Cysteine	Karl JP	Changes in intestinal microbiota composition and metabolism coincide with increased intestinal permeability in young adults under prolonged physiological stress.	American journal of physiology. Gastrointestinal and liver physiology	2017	11
10235266	24,25-Dihydroxyvitamin D	Rachez C	Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex.	Nature	1999	186
10835626	24,25-Dihydroxyvitamin D	Albertson DG	Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene.	Nature genetics	2000	103
11470825	24,25-Dihydroxyvitamin D	P√°lmer HG	Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling.	The Journal of cell biology	2001	183
12016314	24,25-Dihydroxyvitamin D	Makishima M	Vitamin D receptor as an intestinal bile acid sensor.	Science	2002	189
14618623	24,25-Dihydroxyvitamin D	Tuohimaa P	Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries.	International journal of cancer	2004	90
15315818	24,25-Dihydroxyvitamin D	Uitterlinden AG	Genetics and biology of vitamin D receptor polymorphisms.	Gene	2004	229
15322538	24,25-Dihydroxyvitamin D	P√°lmer HG	The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer.	Nature medicine	2004	78
15905882	24,25-Dihydroxyvitamin D	H√∏yer-Hansen M	Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death.	Cell death and differentiation	2005	72
15958597	24,25-Dihydroxyvitamin D	John EM	Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer.	Cancer research	2005	66
15985530	24,25-Dihydroxyvitamin D	Gombart AF	Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3.	FASEB journal 	2005	223
16180015	24,25-Dihydroxyvitamin D	Anderson MG	Expression of VDR and CYP24A1 mRNA in human tumors.	Cancer chemotherapy and pharmacology	2006	64
16380576	24,25-Dihydroxyvitamin D	Garland CF	The role of vitamin D in cancer prevention.	American journal of public health	2006	200
16543149	24,25-Dihydroxyvitamin D	Shah S	The molecular basis of vitamin D receptor and beta-catenin crossregulation.	Molecular cell	2006	77
19221035	24,25-Dihydroxyvitamin D	Nowak D	Differentiation therapy of leukemia: 3 decades of development.	Blood	2009	79
19237542	24,25-Dihydroxyvitamin D	Novakovic B	Placenta-specific methylation of the vitamin D 24-hydroxylase gene: implications for feedback autoregulation of active vitamin D levels at the fetomaternal interface.	The Journal of biological chemistry	2009	59
19403841	24,25-Dihydroxyvitamin D	Raimondi S	Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk.	Carcinogenesis	2009	67
19437538	24,25-Dihydroxyvitamin D	Mohri T	MicroRNA regulates human vitamin D receptor.	International journal of cancer	2009	58
19701245	24,25-Dihydroxyvitamin D	Kaler P	Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3.	Oncogene	2009	67
19770375	24,25-Dihydroxyvitamin D	Newton-Bishop JA	Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma.	Journal of clinical oncology 	2009	79
20020487	24,25-Dihydroxyvitamin D	Janjetovic Z	20,23-dihydroxyvitamin D3, novel P450scc product, stimulates differentiation and inhibits proliferation and NF-kappaB activity in human keratinocytes.	Journal of cellular physiology	2010	44
20831823	24,25-Dihydroxyvitamin D	Lopes N	Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions.	BMC cancer	2010	48
21292298	24,25-Dihydroxyvitamin D	Bro≈ºyna AA	Expression of vitamin D receptor decreases during progression of pigmented skin lesions.	Human pathology	2011	42
21378269	24,25-Dihydroxyvitamin D	Touvier M	Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk.	Cancer epidemiology, biomarkers & prevention 	2011	47
21793032	24,25-Dihydroxyvitamin D	Gal-Tanamy M	Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes.	Hepatology	2011	37
22085499	24,25-Dihydroxyvitamin D	Welsh J	Cellular and molecular effects of vitamin D on carcinogenesis.	Archives of biochemistry and biophysics	2012	38
22108803	24,25-Dihydroxyvitamin D	Meyer MB	VDR/RXR and TCF4/Œ≤-catenin cistromes in colonic cells of colorectal tumor origin: impact on c-FOS and c-MYC gene expression.	Molecular endocrinology	2012	66
22270071	24,25-Dihydroxyvitamin D	Takai T	TSLP expression: cellular sources, triggers, and regulatory mechanisms.	Allergology international 	2012	36
22328083	24,25-Dihydroxyvitamin D	Alvarez-D√≠az S	MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells.	Human molecular genetics	2012	42
22498493	24,25-Dihydroxyvitamin D	Bristol ML	Dual functions of autophagy in the response of breast tumor cells to radiation: cytoprotective autophagy with radiation alone and cytotoxic autophagy in radiosensitization by vitamin D 3.	Autophagy	2012	33
22596255	24,25-Dihydroxyvitamin D	Rosen CJ	The nonskeletal effects of vitamin D: an Endocrine Society scientific statement.	Endocrine reviews	2012	115
22710573	24,25-Dihydroxyvitamin D	Majumdar A	Hepatic stem cells and transforming growth factor Œ≤ in hepatocellular carcinoma.	Nature reviews. Gastroenterology & hepatology	2012	32
22993313	24,25-Dihydroxyvitamin D	Slominski AT	Novel vitamin D hydroxyderivatives inhibit melanoma growth and show differential effects on normal melanocytes.	Anticancer research	2012	37
22995334	24,25-Dihydroxyvitamin D	Bro≈ºyna AA	Expression of the vitamin D-activating enzyme 1Œ±-hydroxylase (CYP27B1) decreases during melanoma progression.	Human pathology	2013	26
23150009	24,25-Dihydroxyvitamin D	Levin GP	Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes.	JAMA	2012	48
23188821	24,25-Dihydroxyvitamin D	Ting HJ	Identification of microRNA-98 as a therapeutic target inhibiting prostate cancer growth and a biomarker induced by vitamin D.	The Journal of biological chemistry	2013	29
23337117	24,25-Dihydroxyvitamin D	Grotsky DA	BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.	The Journal of cell biology	2013	26
23564710	24,25-Dihydroxyvitamin D	Jones G	Cytochrome P450-mediated metabolism of vitamin D.	Journal of lipid research	2014	40
23619147	24,25-Dihydroxyvitamin D	Padi SK	MicroRNA-627 mediates the epigenetic mechanisms of vitamin D to suppress proliferation of human colorectal cancer cells and growth of xenograft tumors in mice.	Gastroenterology	2013	29
23749111	24,25-Dihydroxyvitamin D	D'Orazio J	UV radiation and the skin.	International journal of molecular sciences	2013	71
23982684	24,25-Dihydroxyvitamin D	Schaap FG	Bile acid receptors as targets for drug development.	Nature reviews. Gastroenterology & hepatology	2014	61
24625454	24,25-Dihydroxyvitamin D	Vaidya R	Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.	Annals of oncology 	2014	21
24644045	24,25-Dihydroxyvitamin D	Fedirko V	Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: a nested case-control study.	Hepatology	2014	22
24974252	24,25-Dihydroxyvitamin D	Vimaleswaran KS	Association of vitamin D status with arterial blood pressure and hypertension risk: a mendelian randomisation study.	The lancet. Diabetes & endocrinology	2014	48
25002714	24,25-Dihydroxyvitamin D	Zgaga L	Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer.	Journal of clinical oncology 	2014	23
25259922	24,25-Dihydroxyvitamin D	Sherman MH	Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.	Cell	2014	124
25406188	24,25-Dihydroxyvitamin D	Afzal S	Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts.	BMJ	2014	40
25591978	24,25-Dihydroxyvitamin D	Song M	Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status.	Gut	2016	28
26506009	24,25-Dihydroxyvitamin D	Laurent MR	Muscle-bone interactions: From experimental models to the clinic? A critical update.	Molecular and cellular endocrinology	2016	13
27053631	24,25-Dihydroxyvitamin D	Ferrer-Mayorga G	Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer.	Gut	2017	5
28166722	24,25-Dihydroxyvitamin D	Singh PK	Integration of VDR genome wide binding and GWAS genetic variation data reveals co-occurrence of VDR and NF-Œ∫B binding that is linked to immune phenotypes.	BMC genomics	2017	7
28189050	24,25-Dihydroxyvitamin D	Chen S	H19 Overexpression Induces Resistance to 1,25(OH)2D3 by Targeting VDR Through miR-675-5p in Colon Cancer Cells.	Neoplasia	2017	6
28242709	24,25-Dihydroxyvitamin D	Tavera-Mendoza LE	Vitamin D receptor regulates autophagy in the normal mammary gland and in luminal breast cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2017	6
8093006	Sulfate	Hildebrand A	Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta.	The Biochemical journal	1994	199
9111868	Sulfate	Naor D	CD44: structure, function, and association with the malignant process.	Advances in cancer research	1997	194
15177029	Sulfate	Koziel L	Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification.	Developmental cell	2004	79
16024626	Sulfate	Capurro MI	Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.	Cancer research	2005	117
16331886	Sulfate	Morimoto-Tomita M	Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer.	Neoplasia	2005	65
16452201	Sulfate	Zetser A	Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation.	Cancer research	2006	83
17339423	Sulfate	Mahtouk K	Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.	Blood	2007	65
17347152	Sulfate	Yang Y	Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.	The Journal of biological chemistry	2007	97
17627539	Sulfate	Vlodavsky I	Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.	Current pharmaceutical design	2007	89
17635638	Sulfate	Vreys V	Mammalian heparanase: what is the message?	Journal of cellular and molecular medicine	2007	83
18467024	Sulfate	Murakami A	Multitargeted cancer prevention by quercetin.	Cancer letters	2008	60
18628464	Sulfate	Dhillon N	Phase II trial of curcumin in patients with advanced pancreatic cancer.	Clinical cancer research 	2008	216
18691882	Sulfate	Hawinkels LJ	VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis.	European journal of cancer	2008	56
18812315	Sulfate	Purushothaman A	Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.	The Journal of biological chemistry	2008	67
18829767	Sulfate	Day PM	Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids.	Journal of virology	2008	59
19360105	Sulfate	Zcharia E	Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases.	PloS one	2009	51
19466598	Sulfate	Iozzo RV	Basement membrane proteoglycans: modulators Par Excellence of cancer growth and angiogenesis.	Molecules and cells	2009	70
20097882	Sulfate	Purushothaman A	Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.	Blood	2010	80
20840586	Sulfate	Barash U	Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.	The FEBS journal	2010	71
21811836	Sulfate	Vlodavsky I	Significance of heparanase in cancer and inflammation.	Cancer microenvironment 	2012	59
22406535	Sulfate	Said N	RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration.	The Journal of clinical investigation	2012	41
22456598	Sulfate	Lepeule J	Chronic exposure to fine particles and mortality: an extended follow-up of the Harvard Six Cities study from 1974 to 2009.	Environmental health perspectives	2012	90
22573479	Sulfate	Ibrahim SA	Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism.	International journal of cancer	2012	34
22834835	Sulfate	Donato R	Functions of S100 proteins.	Current molecular medicine	2013	154
23374281	Sulfate	Ramani VC	The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.	The FEBS journal	2013	49
23792691	Sulfate	Biroccio A	TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells.	Nature cell biology	2013	27
24101524	Sulfate	Christianson HC	Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity.	Proceedings of the National Academy of Sciences of the United States of America	2013	124
24145152	Sulfate	Christianson HC	Heparan sulfate proteoglycan as a cell-surface endocytosis receptor.	Matrix biology 	2014	48
24441045	Sulfate	Webber JP	Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes.	Oncogene	2015	70
24768844	Sulfate	Urban S	Strategies to inhibit entry of HBV and HDV into hepatocytes.	Gastroenterology	2014	43
25063530	Sulfate	Wang X	Tumor necrosis factor-Œ±- and interleukin-1Œ≤-dependent matrix metalloproteinase-3 expression in nucleus pulposus cells requires cooperative signaling via syndecan 4 and mitogen-activated protein kinase-NF-Œ∫B axis: implications in inflammatory disc disease.	The American journal of pathology	2014	20
25282103	Sulfate	Wood AR	Defining the role of common variation in the genomic and biological architecture of adult human height.	Nature genetics	2014	348
25849134	Sulfate	Caruana I	Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.	Nature medicine	2015	51
26926788	Sulfate	Jung O	Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.	Oncogenesis	2016	10
27758044	Sulfate	Sanderson RD	Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.	The FEBS journal	2017	14
7972132	Cytidine	Lee WH	Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis.	Proceedings of the National Academy of Sciences of the United States of America	1994	134
12618505	Cytidine	Cheng JC	Inhibition of DNA methylation and reactivation of silenced genes by zebularine.	Journal of the National Cancer Institute	2003	96
12732658	Cytidine	Okazaki IM	Constitutive expression of AID leads to tumorigenesis.	The Journal of experimental medicine	2003	132
15019779	Cytidine	Beale RC	Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo.	Journal of molecular biology	2004	142
15911774	Cytidine	L√∂chelt M	The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein.	Proceedings of the National Academy of Sciences of the United States of America	2005	87
16501124	Cytidine	Tian C	Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.	Journal of virology	2006	75
16585222	Cytidine	Giovannetti E	Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.	Cancer research	2006	89
16729314	Cytidine	Bonvin M	Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.	Hepatology	2006	87
17126871	Cytidine	Xu H	Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.	Virology	2007	59
17299050	Cytidine	Derse D	Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.	Proceedings of the National Academy of Sciences of the United States of America	2007	64
17353367	Cytidine	Lenz G	Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma.	The Journal of experimental medicine	2007	58
17522216	Cytidine	Russell RA	Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.	Journal of virology	2007	124
17560275	Cytidine	Chaudhuri J	Evolution of the immunoglobulin heavy chain class switch recombination mechanism.	Advances in immunology	2007	123
18066064	Cytidine	Pasqualucci L	AID is required for germinal center-derived lymphomagenesis.	Nature genetics	2008	135
18403710	Cytidine	Vartanian JP	Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions.	Science	2008	102
18619467	Cytidine	He Z	Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.	Journal of molecular biology	2008	73
18678733	Cytidine	Takizawa M	AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development.	The Journal of experimental medicine	2008	71
18762567	Cytidine	de Y√©benes VG	miR-181b negatively regulates activation-induced cytidine deaminase in B cells.	The Journal of experimental medicine	2008	81
19109396	Cytidine	Pery E	Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.	Journal of virology	2009	54
19364882	Cytidine	Robert I	Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination.	The Journal of experimental medicine	2009	61
19941823	Cytidine	Robbiani DF	AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations.	Molecular cell	2009	100
19962179	Cytidine	Lin C	Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer.	Cell	2009	230
20219927	Cytidine	Mbisa JL	APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.	Journal of virology	2010	63
20308164	Cytidine	Refsland EW	Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.	Nucleic acids research	2010	154
20810283	Cytidine	De Carvalho DD	DNA methylation and cellular reprogramming.	Trends in cell biology	2010	62
21762814	Cytidine	Pavri R	AID targeting in antibody diversity.	Advances in immunology	2011	57
21962510	Cytidine	Klein IA	Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes.	Cell	2011	133
21962511	Cytidine	Chiarle R	Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells.	Cell	2011	147
22260300	Cytidine	Magrath I	Epidemiology: clues to the pathogenesis of Burkitt lymphoma.	British journal of haematology	2012	31
22343534	Cytidine	Lohr JG	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2012	260
22608084	Cytidine	Nik-Zainal S	Mutational processes molding the genomes of 21 breast cancers.	Cell	2012	444
23369223	Cytidine	Karahoca M	Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy.	Clinical epigenetics	2013	56
23604283	Cytidine	Khoddami V	Identification of direct targets and modified bases of RNA cytosine methyltransferases.	Nature biotechnology	2013	64
23852168	Cytidine	Burns MB	Evidence for APOBEC3B mutagenesis in multiple human cancers.	Nature genetics	2013	179
23852170	Cytidine	Roberts SA	An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.	Nature genetics	2013	237
23898051	Cytidine	Gnyszka A	DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer.	Anticancer research	2013	38
23995783	Cytidine	Weizman N	Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.	Oncogene	2014	45
24507154	Cytidine	Matthews AJ	Regulation of immunoglobulin class-switch recombination: choreography of noncoding transcription, targeted DNA deamination, and long-range DNA repair.	Advances in immunology	2014	32
24670820	Cytidine	Olivier M	Modelling mutational landscapes of human cancers in vitro.	Scientific reports	2014	20
24728294	Cytidine	Nik-Zainal S	Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.	Nature genetics	2014	70
25298230	Cytidine	Caval V	A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.	Nature communications	2014	33
25355878	Cytidine	Warren CJ	APOBEC3A functions as a restriction factor of human papillomavirus.	Journal of virology	2015	38
25483776	Cytidine	Meng FL	Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability.	Cell	2014	54
25483777	Cytidine	Qian J	B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity.	Cell	2014	71
25730878	Cytidine	Cescon DW	APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.	Proceedings of the National Academy of Sciences of the United States of America	2015	38
25898173	Cytidine	Sharma S	APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages.	Nature communications	2015	26
26255562	Cytidine	Nagathihalli NS	Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.	Gastroenterology	2015	16
26258849	Cytidine	Chan K	An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.	Nature genetics	2015	49
26296954	Cytidine	Issa JJ	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.	The Lancet. Oncology	2015	36
26608778	Cytidine	Knisbacher BA	DNA Editing by APOBECs: A Genomic Preserver and Transformer.	Trends in genetics 	2016	15
26638776	Cytidine	Kasar S	Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution.	Nature communications	2015	22
26755635	Cytidine	Seplyarskiy VB	APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication.	Genome research	2016	19
26832400	Cytidine	Hoopes JI	APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication.	Cell reports	2016	24
26898111	Cytidine	Casellas R	Mutations, kataegis and translocations in B cells: understanding AID promiscuous activity.	Nature reviews. Immunology	2016	23
27007129	Cytidine	Ciccolini J	Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.	Cancer chemotherapy and pharmacology	2016	14
27149507	Cytidine	Sharma S	Transient overexpression of exogenous APOBEC3A causes C-to-U RNA editing of thousands of genes.	RNA biology	2017	7
27798611	Cytidine	Hess GT	Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells.	Nature methods	2016	27
10766168	Sulfite	Ueki T	Hypermethylation of multiple genes in pancreatic adenocarcinoma.	Cancer research	2000	90
11984524	Sulfite	Hawkins N	CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability.	Gastroenterology	2002	97
15822191	Sulfite	Esteller M	Aberrant DNA methylation as a cancer-inducing mechanism.	Annual review of pharmacology and toxicology	2005	101
16174854	Sulfite	Shen L	MGMT promoter methylation and field defect in sporadic colorectal cancer.	Journal of the National Cancer Institute	2005	157
16251483	Sulfite	Chanda S	DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy.	Toxicological sciences 	2006	68
16645207	Sulfite	Ogino S	Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis.	The Journal of molecular diagnostics 	2006	156
16778214	Sulfite	Gore SD	Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.	Cancer research	2006	150
16951683	Sulfite	Chan TL	Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer.	Nature genetics	2006	68
17210699	Sulfite	Zinn RL	hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site.	Cancer research	2007	66
17408664	Sulfite	Park IY	Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein.	Gastroenterology	2007	73
17476321	Sulfite	Est√©cio MR	LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability.	PloS one	2007	107
17591937	Sulfite	Mikeska T	Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.	The Journal of molecular diagnostics 	2007	56
17875690	Sulfite	Taylor KH	Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing.	Cancer research	2007	77
17947473	Sulfite	Shen L	Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy.	Clinical cancer research 	2007	58
17967063	Sulfite	Shen L	Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters.	PLoS genetics	2007	134
18045775	Sulfite	Al-Mahdawi S	The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues.	Human molecular genetics	2008	90
18221536	Sulfite	Roll JD	DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines.	Molecular cancer	2008	54
19084528	Sulfite	Yu J	Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.	Gastroenterology	2009	53
19221000	Sulfite	Majid S	BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer.	Carcinogenesis	2009	60
19406918	Sulfite	deVos T	Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer.	Clinical chemistry	2009	106
19491193	Sulfite	Koga Y	Genome-wide screen of promoter methylation identifies novel markers in melanoma.	Genome research	2009	73
19535783	Sulfite	Melotte V	N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.	Journal of the National Cancer Institute	2009	50
19897574	Sulfite	Kanduri M	Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia.	Blood	2010	46
19906696	Sulfite	Serre D	MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome.	Nucleic acids research	2010	136
20696752	Sulfite	Ceppi P	Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer.	Molecular cancer research 	2010	92
21350001	Sulfite	Li D	Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer.	Clinical cancer research 	2011	94
21547903	Sulfite	Chen X	CpG island methylation status of miRNAs in esophageal squamous cell carcinoma.	International journal of cancer	2012	32
21772049	Sulfite	Kalac M	HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.	Blood	2011	37
21788354	Sulfite	Reinert T	Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers.	Clinical cancer research 	2011	49
21969817	Sulfite	He Y	Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma.	Neoplasia	2011	37
22083596	Sulfite	Kisiel JB	Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates.	Cancer	2012	35
22233696	Sulfite	Kimura T	A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma.	The American journal of gastroenterology	2012	32
22289355	Sulfite	Augoff K	miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer.	Molecular cancer	2012	81
22374981	Sulfite	Brennan K	Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk.	Cancer research	2012	49
22392079	Sulfite	Hoyo C	Association of cord blood methylation fractions at imprinted insulin-like growth factor 2 (IGF2), plasma IGF2, and birth weight.	Cancer causes & control 	2012	36
22395470	Sulfite	Yamazaki J	Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.	Epigenetics	2012	32
22534504	Sulfite	Pei L	Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia.	Epigenetics	2012	35
22551203	Sulfite	Intarasunanont P	Effects of arsenic exposure on DNA methylation in cord blood samples from newborn babies and in a human lymphoblast cell line.	Environmental health 	2012	42
22589488	Sulfite	Mahapatra S	Global methylation profiling for risk prediction of prostate cancer.	Clinical cancer research 	2012	39
22689435	Sulfite	Neumann O	Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors.	Hepatology	2012	42
22876840	Sulfite	Liu XH	MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5.	BMC cancer	2012	51
23049919	Sulfite	T√≥th K	Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers.	PloS one	2012	34
23056401	Sulfite	Takahashi M	The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer.	PloS one	2012	46
23064414	Sulfite	Kulis M	Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia.	Nature genetics	2012	148
23325432	Sulfite	Varley KE	Dynamic DNA methylation across diverse human cell lines and tissues.	Genome research	2013	214
23388414	Sulfite	Soubry A	Paternal obesity is associated with IGF2 hypomethylation in newborns: results from a Newborn Epigenetics Study (NEST) cohort.	BMC medicine	2013	52
23418553	Sulfite	Nye MD	Associations between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer.	PloS one	2013	32
23474808	Sulfite	Shim J	Detection and quantification of methylation in DNA using solid-state nanopores.	Scientific reports	2013	34
23593011	Sulfite	Garding A	Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB.	PLoS genetics	2013	31
23704319	Sulfite	Hur K	Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis.	Gut	2014	55
23871666	Sulfite	Hussain S	NSun2-mediated cytosine-5 methylation of vault noncoding RNA determines its processing into regulatory small RNAs.	Cell reports	2013	69
23918943	Sulfite	Haldrup C	DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.	Journal of clinical oncology 	2013	39
24059801	Sulfite	Ehrlich M	DNA methylation and differentiation: silencing, upregulation and modulation of gene expression.	Epigenomics	2013	28
24098911	Sulfite	Lu KH	Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression.	BMC cancer	2013	80
24158121	Sulfite	Soubry A	Newborns of obese parents have altered DNA methylation patterns at imprinted genes.	International journal of obesity	2015	49
24183680	Sulfite	Bender S	Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas.	Cancer cell	2013	114
24270890	Sulfite	Cruickshanks HA	Senescent cells harbour features of the cancer epigenome.	Nature cell biology	2013	64
24485021	Sulfite	Mitchell SM	A panel of genes methylated with high frequency in colorectal cancer.	BMC cancer	2014	36
24500968	Sulfite	Nones K	Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling.	International journal of cancer	2014	29
24504172	Sulfite	Kim HC	Collagen triple helix repeat containing 1 (CTHRC1) acts via ERK-dependent induction of MMP9 to promote invasion of colorectal cancer cells.	Oncotarget	2014	26
24659709	Sulfite	Liu MX	Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.	Oncotarget	2014	25
25608619	Sulfite	Zhang Z	microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma.	Molecular cancer	2015	20
25613496	Sulfite	Hu L	Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma.	Journal of experimental & clinical cancer research 	2015	52
25641194	Sulfite	Zhuo H	The aberrant expression of MEG3 regulated by UHRF1 predicts the prognosis of hepatocellular carcinoma.	Molecular carcinogenesis	2016	33
25663388	Sulfite	Steponaitiene R	Epigenetic silencing of miR-137 is a frequent event in gastric carcinogenesis.	Molecular carcinogenesis	2016	16
26062908	Sulfite	Silver MJ	Independent genomewide screens identify the tumor suppressor VTRNA2-1 as a human epiallele responsive to periconceptional environment.	Genome biology	2015	28
26206665	Sulfite	Wang K	MDGA2 is a novel tumour suppressor cooperating with DMAP1 in gastric cancer and is associated with disease outcome.	Gut	2016	10
26437030	Sulfite	Kretzmer H	DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control.	Nature genetics	2015	29
26680004	Sulfite	Chen K	Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer.	Cell research	2016	13
26707824	Sulfite	Fang S	Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells.	Laboratory investigation; a journal of technical methods and pathology	2016	13
26923874	Sulfite	Johann PD	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes.	Cancer cell	2016	31
26977886	Sulfite	Chun HE	Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways.	Cancer cell	2016	14
28215704	Sulfite	Spencer DH	CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.	Cell	2017	12
8194005	Cisplatin	Mandard AM	Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.	Cancer	1994	246
8673929	Cisplatin	Aas T	Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.	Nature medicine	1996	143
9053482	Cisplatin	-	International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.	Journal of clinical oncology 	1997	198
9176490	Cisplatin	Heise C	ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.	Nature medicine	1997	133
9270026	Cisplatin	Kool M	Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines.	Cancer research	1997	114
9704716	Cisplatin	Pegram MD	Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.	Journal of clinical oncology 	1998	115
9927204	Cisplatin	Blandino G	Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.	Oncogene	1999	97
10446958	Cisplatin	Yuan SS	BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.	Cancer research	1999	142
10606224	Cisplatin	Brown JM	The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.	Cancer research	1999	111
10673506	Cisplatin	Ara√∫jo SJ	Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK.	Genes & development	2000	93
11085525	Cisplatin	Plumb JA	Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.	Cancer research	2000	96
12114432	Cisplatin	Lord RV	Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.	Clinical cancer research 	2002	112
12524540	Cisplatin	Bergamaschi D	iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.	Nature genetics	2003	96
12637505	Cisplatin	Mansouri A	Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.	The Journal of biological chemistry	2003	85
12692539	Cisplatin	Taniguchi T	Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.	Nature medicine	2003	141
12698198	Cisplatin	Tassone P	BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.	British journal of cancer	2003	85
12726864	Cisplatin	Bergamaschi D	p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.	Cancer cell	2003	91
14612526	Cisplatin	Kim MS	Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.	Cancer research	2003	108
14645242	Cisplatin	Dan HC	Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP).	The Journal of biological chemistry	2004	122
14673047	Cisplatin	Ando N	Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.	Journal of clinical oncology 	2003	88
14702041	Cisplatin	Katayama H	Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53.	Nature genetics	2004	159
14977831	Cisplatin	Rosell R	Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.	Clinical cancer research 	2004	79
14998492	Cisplatin	Ren J	Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents.	Cancer cell	2004	114
15024021	Cisplatin	Ando K	Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation.	The Journal of biological chemistry	2004	74
15208673	Cisplatin	Altomare DA	AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.	Oncogene	2004	113
15317748	Cisplatin	Taron M	BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.	Human molecular genetics	2004	70
15469940	Cisplatin	Liu Q	Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215.	The Journal of biological chemistry	2004	85
15797377	Cisplatin	Beuvink I	The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.	Cell	2005	142
15811630	Cisplatin	Albertella MR	The overexpression of specialized DNA polymerases in cancer.	DNA repair	2005	75
16116421	Cisplatin	Bridge WL	The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair.	Nature genetics	2005	79
16289418	Cisplatin	Sieghart W	Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.	Journal of hepatology	2006	62
16314626	Cisplatin	Burtness B	Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.	Journal of clinical oncology 	2005	171
16357177	Cisplatin	Nawrocki ST	Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.	Cancer research	2005	95
16493006	Cisplatin	Taniguchi T	Molecular pathogenesis of Fanconi anemia: recent progress.	Blood	2006	124
16601104	Cisplatin	Dasgupta P	Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin.	Proceedings of the National Academy of Sciences of the United States of America	2006	84
16951222	Cisplatin	Sok JC	Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.	Clinical cancer research 	2006	141
16957145	Cisplatin	Olaussen KA	DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.	The New England journal of medicine	2006	355
16980606	Cisplatin	Ceppi P	ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.	Annals of oncology 	2006	67
17146434	Cisplatin	Ambrosini G	Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.	Oncogene	2007	55
17227995	Cisplatin	Lewis IJ	Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.	Journal of the National Cancer Institute	2007	64
17332336	Cisplatin	Hayes GM	Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas.	Cancer research	2007	56
17634556	Cisplatin	Mabuchi S	RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.	Clinical cancer research 	2007	62
17671210	Cisplatin	Jacquemont C	Proteasome function is required for DNA damage response and fanconi anemia pathway activation.	Cancer research	2007	73
17911266	Cisplatin	Lo AK	Modulation of LMP1 protein expression by EBV-encoded microRNAs.	Proceedings of the National Academy of Sciences of the United States of America	2007	127
17923843	Cisplatin	Li SD	Tumor-targeted delivery of siRNA by self-assembled nanoparticles.	Molecular therapy 	2008	95
17947225	Cisplatin	Rosell R	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.	Annals of oncology 	2008	61
18024870	Cisplatin	Tsao MS	Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.	Journal of clinical oncology 	2007	72
18199536	Cisplatin	Yang H	MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.	Cancer research	2008	355
18206965	Cisplatin	Lim ST	Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation.	Molecular cell	2008	151
18237851	Cisplatin	S√®ve P	Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?	The Lancet. Oncology	2008	88
18282805	Cisplatin	Koizumi W	S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.	The Lancet. Oncology	2008	325
18316592	Cisplatin	Ohta T	Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.	Cancer research	2008	174
18362892	Cisplatin	Tajeddine N	Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death.	Oncogene	2008	54
18451214	Cisplatin	Lee JW	Altered MicroRNA expression in cervical carcinomas.	Clinical cancer research 	2008	93
18469852	Cisplatin	Chekenya M	The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling.	Oncogene	2008	54
18495226	Cisplatin	Gotlieb WH	In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.	Gynecologic oncology	2008	67
18519691	Cisplatin	Zhang S	Identification and characterization of ovarian cancer-initiating cells from primary human tumors.	Cancer research	2008	391
18573234	Cisplatin	Kojima K	A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.	Biochemical and biophysical research communications	2008	53
18594319	Cisplatin	Ramlau R	A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.	Journal of thoracic oncology 	2008	52
18612434	Cisplatin	Chen YC	Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells.	PloS one	2008	141
18728788	Cisplatin	Levina V	Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties.	PloS one	2008	140
18823650	Cisplatin	Sorrentino A	Role of microRNAs in drug-resistant ovarian cancer cells.	Gynecologic oncology	2008	112
18829483	Cisplatin	Lo HW	Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.	Clinical cancer research 	2008	68
19318576	Cisplatin	Seiwert TY	The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.	Cancer research	2009	76
19360350	Cisplatin	Fujii H	Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines.	International journal of oncology	2009	50
19584296	Cisplatin	Arumugam T	Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.	Cancer research	2009	241
19706487	Cisplatin	Sayan AE	SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer.	Proceedings of the National Academy of Sciences of the United States of America	2009	48
19738048	Cisplatin	Drygin D	Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.	Cancer research	2009	91
19748363	Cisplatin	Ben-Yehoyada M	Checkpoint signaling from a single DNA interstrand crosslink.	Molecular cell	2009	57
19770374	Cisplatin	Allum WH	Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.	Journal of clinical oncology 	2009	131
19783996	Cisplatin	Gonfloni S	Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death.	Nature medicine	2009	79
19802016	Cisplatin	Abedini MR	Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.	Oncogene	2010	42
19818685	Cisplatin	Boku N	Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.	The Lancet. Oncology	2009	122
19881547	Cisplatin	Tesniere A	Immunogenic death of colon cancer cells treated with oxaliplatin.	Oncogene	2010	142
20028869	Cisplatin	Levina V	Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop.	Cancer research	2010	40
20051134	Cisplatin	Ban√°th JP	Residual gammaH2AX foci as an indication of lethal DNA lesions.	BMC cancer	2010	51
20068070	Cisplatin	Kwok JM	FOXM1 confers acquired cisplatin resistance in breast cancer cells.	Molecular cancer research 	2010	72
20074550	Cisplatin	Teng Y	Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells.	Biochemical and biophysical research communications	2010	67
20099276	Cisplatin	Pogribny IP	Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.	International journal of cancer	2010	94
20107315	Cisplatin	Hirai H	MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.	Cancer biology & therapy	2010	65
20170547	Cisplatin	Arrieta O	Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study.	BMC cancer	2010	42
20215556	Cisplatin	Sikora AG	Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy.	Clinical cancer research 	2010	43
20236757	Cisplatin	Wang Y	Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.	Cancer letters	2010	54
20371173	Cisplatin	Guo L	Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.	European journal of cancer	2010	48
20418188	Cisplatin	Arora S	Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.	DNA repair	2010	41
20564628	Cisplatin	Annunziata CM	Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer.	Cancer	2010	45
20670951	Cisplatin	Harrington KJ	Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.	Clinical cancer research 	2010	60
20697079	Cisplatin	Rischin D	Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.	Journal of clinical oncology 	2010	136
20728210	Cisplatin	Bang YJ	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.	Lancet	2010	1076
20943634	Cisplatin	Chan AT	Nasopharyngeal carcinoma.	Annals of oncology 	2010	48
20947521	Cisplatin	Hall CA	Hippo pathway effector Yap is an ovarian cancer oncogene.	Cancer research	2010	71
20956982	Cisplatin	Narod SA	BRCA mutations in the management of breast cancer: the state of the art.	Nature reviews. Clinical oncology	2010	41
21034966	Cisplatin	Smith J	The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.	Advances in cancer research	2010	268
21124918	Cisplatin	Leung EL	Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.	PloS one	2010	115
21151176	Cisplatin	Martins I	Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress.	Oncogene	2011	67
21205897	Cisplatin	Ren D	Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.	Proceedings of the National Academy of Sciences of the United States of America	2011	118
21224400	Cisplatin	Ye G	MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance.	Journal of cell science	2011	40
21248297	Cisplatin	Hamano R	Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.	Clinical cancer research 	2011	56
21257722	Cisplatin	Dickson MA	A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors.	Clinical cancer research 	2011	39
21266349	Cisplatin	Liccardi G	EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.	Cancer research	2011	73
21274007	Cisplatin	Huang Y	Phospho-ŒîNp63Œ± is a key regulator of the cisplatin-induced microRNAome in cancer cells.	Cell death and differentiation	2011	40
21325880	Cisplatin	O'Donovan TR	Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics.	Autophagy	2011	78
21327457	Cisplatin	Yang Z	Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation.	Annals of surgical oncology	2011	221
21329503	Cisplatin	Bian HB	Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549).	Journal of experimental & clinical cancer research 	2011	47
21334406	Cisplatin	Chen X	Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations.	Journal of hepatology	2011	38
21353530	Cisplatin	Otvos L Jr	Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer.	European journal of cancer	2011	38
21371883	Cisplatin	Yu H	p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins.	European journal of cancer	2011	37
21425153	Cisplatin	Hsu HS	Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27.	Cancer	2011	40
21489257	Cisplatin	Lister A	Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.	Molecular cancer	2011	52
21532889	Cisplatin	Rattan R	Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo.	Neoplasia	2011	85
21550168	Cisplatin	Noguchi S	MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells.	Cancer letters	2011	38
21633166	Cisplatin	Lehmann BD	Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.	The Journal of clinical investigation	2011	890
21684283	Cisplatin	Tan IB	Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy.	Gastroenterology	2011	73
21693595	Cisplatin	Wang Y	MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression.	Molecular cancer research 	2011	46
21702042	Cisplatin	Vinall RL	MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status.	International journal of cancer	2012	31
21725369	Cisplatin	Sun L	MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1.	Oncogene	2012	79
21726833	Cisplatin	Lee TK	CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation.	Cell stem cell	2011	148
21743489	Cisplatin	Zhang Y	NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response.	Oncogene	2012	43
21782507	Cisplatin	O'Byrne KJ	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.	The Lancet. Oncology	2011	58
21903745	Cisplatin	Curran WJ Jr	Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.	Journal of the National Cancer Institute	2011	174
21909139	Cisplatin	Yue P	Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.	Oncogene	2012	43
21993663	Cisplatin	Zhu W	miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.	Cancer chemotherapy and pharmacology	2012	58
22019520	Cisplatin	Quoix E	Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.	The Lancet. Oncology	2011	73
22104727	Cisplatin	Huang S	Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells.	Cancer letters	2012	31
22112324	Cisplatin	Kim CH	miRNA signature associated with outcome of gastric cancer patients following chemotherapy.	BMC medical genomics	2011	39
22114138	Cisplatin	Fraser M	PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.	Clinical cancer research 	2012	40
22178121	Cisplatin	Lee NY	Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.	The Lancet. Oncology	2012	61
22193543	Cisplatin	Donzelli S	MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.	Cell death and differentiation	2012	43
22249249	Cisplatin	Zeller C	Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.	Oncogene	2012	61
22261329	Cisplatin	Roos WP	DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis.	Cancer letters	2013	153
22278418	Cisplatin	Chen G	Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.	The Journal of clinical endocrinology and metabolism	2012	37
22291137	Cisplatin	Patel AG	Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.	Clinical cancer research 	2012	52
22302096	Cisplatin	Sehdev V	The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.	Molecular cancer therapeutics	2012	38
22308459	Cisplatin	Meirelles K	Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.	Proceedings of the National Academy of Sciences of the United States of America	2012	39
22371451	Cisplatin	Rajan A	A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.	Clinical cancer research 	2012	35
22396773	Cisplatin	Wan S	Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells.	PloS one	2012	36
22406827	Cisplatin	Guo XL	Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells.	Cancer letters	2012	44
22429801	Cisplatin	Haslehurst AM	EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.	BMC cancer	2012	64
22465665	Cisplatin	Fu X	Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells.	FEBS letters	2012	50
22467215	Cisplatin	Thiel KW	Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.	Nucleic acids research	2012	63
22473169	Cisplatin	Rossi A	Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.	Journal of clinical oncology 	2012	46
22473773	Cisplatin	Shan J	Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma.	Hepatology	2012	74
22498306	Cisplatin	Cheng W	MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.	The FEBS journal	2012	64
22576688	Cisplatin	Wang Y	Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer.	International journal of oncology	2012	46
22590557	Cisplatin	Wilkerson MD	Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.	PloS one	2012	50
22647982	Cisplatin	Zhou C	Monitoring autophagic flux by an improved tandem fluorescent-tagged LC3 (mTagRFP-mWasabi-LC3) reveals that high-dose rapamycin impairs autophagic flux in cancer cells.	Autophagy	2012	43
22665541	Cisplatin	Kindler HL	Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.	Journal of clinical oncology 	2012	43
22678161	Cisplatin	Chuang HC	Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.	Breast cancer research and treatment	2012	31
22710713	Cisplatin	Guo ST	MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.	Oncogene	2013	72
22761336	Cisplatin	Wang Y	MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition.	Cancer research	2012	35
22778317	Cisplatin	Gridelli C	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.	Journal of clinical oncology 	2012	64
22810206	Cisplatin	Enoiu M	Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis.	Nucleic acids research	2012	35
22847005	Cisplatin	Bourguignon LY	Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.	The Journal of biological chemistry	2012	64
22847808	Cisplatin	Sugimura K	Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma.	Clinical cancer research 	2012	39
22892391	Cisplatin	Ryan J	MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome.	British journal of cancer	2012	33
22893596	Cisplatin	Khorana AA	Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.	Cancer	2013	37
22927417	Cisplatin	Zoppoli G	Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.	Proceedings of the National Academy of Sciences of the United States of America	2012	42
22928012	Cisplatin	Lohberger B	Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma.	PloS one	2012	31
22955317	Cisplatin	Feng PH	CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.	American journal of respiratory and critical care medicine	2012	31
22987153	Cisplatin	Karanja KK	DNA2 and EXO1 in replication-coupled, homology-directed repair and in the interplay between HDR and the FA/BRCA network.	Cell cycle	2012	33
23050965	Cisplatin	Ali AY	Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum.	Annals of the New York Academy of Sciences	2012	32
23071587	Cisplatin	Gout S	Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma.	PloS one	2012	33
23251001	Cisplatin	Kimple RJ	Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts.	Clinical cancer research 	2013	31
23337879	Cisplatin	Wang F	MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells.	FEBS letters	2013	35
23372675	Cisplatin	Zhao G	MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma.	PloS one	2013	66
23382914	Cisplatin	Pan Y	Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma.	PloS one	2013	30
23449973	Cisplatin	Fortier AM	Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudin1 up-regulation.	The Journal of biological chemistry	2013	41
23461856	Cisplatin	Ma L	Cancer stem-like cell properties are regulated by EGFR/AKT/Œ≤-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.	The FEBS journal	2013	26
23466500	Cisplatin	Yang SM	miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN.	Toxicology	2013	45
23483142	Cisplatin	Xu Y	miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells.	Oncology reports	2013	39
23542177	Cisplatin	Mao B	SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma.	Oncogene	2014	30
23548269	Cisplatin	Huntoon CJ	ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.	Cancer research	2013	38
23563269	Cisplatin	Murtaza M	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.	Nature	2013	320
23610451	Cisplatin	Listerman I	The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis.	Cancer research	2013	32
23816960	Cisplatin	Sequist LV	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	472
23816967	Cisplatin	Yang JC	Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	59
23845449	Cisplatin	V√©layoudom-C√©phise FL	Are G3 ENETS neuroendocrine neoplasms heterogeneous?	Endocrine-related cancer	2013	31
23945651	Cisplatin	Maskey D	ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy.	Nature communications	2013	45
23967051	Cisplatin	Yasuda K	Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population.	PloS one	2013	29
24068565	Cisplatin	Cao W	miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.	Tumour biology 	2014	21
24077350	Cisplatin	Cardnell RJ	Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.	Clinical cancer research 	2013	56
24081734	Cisplatin	Fassnacht M	Update in adrenocortical carcinoma.	The Journal of clinical endocrinology and metabolism	2013	50
24099915	Cisplatin	Dong Z	MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9.	Cancer letters	2014	24
24155936	Cisplatin	Liu Z	The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression.	PloS one	2013	78
24165223	Cisplatin	Sun XP	Up-regulation of survivin by AKT and hypoxia-inducible factor¬†1Œ± contributes to cisplatin resistance in gastric cancer.	The FEBS journal	2014	20
24318570	Cisplatin	Liu SY	High aldehyde dehydrogenase activity identifies cancer stem cells in human cervical cancer.	Oncotarget	2013	29
24333218	Cisplatin	Wang H	Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/Œ≤-catenin/Snail signaling pathway.	European journal of pharmacology	2014	29
24407244	Cisplatin	Zhang P	Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.	Cell death & disease	2014	24
24439929	Cisplatin	Wu YL	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	282
24468065	Cisplatin	Zhou Y	miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.	Journal of experimental & clinical cancer research 	2014	45
24473399	Cisplatin	Kurokawa Y	Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).	British journal of cancer	2014	26
24495014	Cisplatin	Fan Y	Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling.	The FEBS journal	2014	79
24495516	Cisplatin	Xia JT	MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-Œ∫B signaling.	Journal of translational medicine	2014	23
24536047	Cisplatin	Lal S	HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.	Cancer research	2014	28
24554720	Cisplatin	Joshi PM	Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.	The Journal of biological chemistry	2014	24
24571667	Cisplatin	Ma J	NF-kappaB-dependent microRNA-425 upregulation promotes gastric cancer cell growth by targeting PTEN upon IL-1Œ≤ induction.	Molecular cancer	2014	21
24587643	Cisplatin	Orditura M	Treatment of gastric cancer.	World journal of gastroenterology	2014	84
24668391	Cisplatin	Tsuburaya A	Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.	The British journal of surgery	2014	23
24669930	Cisplatin	He C	Nanoscale metal-organic frameworks for the co-delivery of cisplatin and pooled siRNAs to enhance therapeutic efficacy in drug-resistant ovarian cancer cells.	Journal of the American Chemical Society	2014	31
24720540	Cisplatin	Guo S	Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation.	ACS nano	2014	22
24848258	Cisplatin	Shapiro IM	Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.	Science translational medicine	2014	44
24929024	Cisplatin	Hou√©d√© N	Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers.	Pharmacology & therapeutics	2015	19
24947926	Cisplatin	Yoon C	CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance.	Clinical cancer research 	2014	26
24960601	Cisplatin	Choi W	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.	Nature reviews. Urology	2014	40
24965569	Cisplatin	Iveson T	Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.	The Lancet. Oncology	2014	76
24989332	Cisplatin	Hassan R	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.	Cancer	2014	41
25026298	Cisplatin	Ha K	Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.	Oncotarget	2014	25
25104095	Cisplatin	Bryant C	Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.	BMC cancer	2014	23
25110412	Cisplatin	Grossi V	p38Œ± MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.	World journal of gastroenterology	2014	30
25114235	Cisplatin	Xue W	Small RNA combination therapy for lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	56
25128483	Cisplatin	Li J	miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells.	Molecular cancer	2014	31
25228385	Cisplatin	Tan X	miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.	Breast cancer research 	2014	30
25231400	Cisplatin	Hassan R	Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.	Clinical cancer research 	2014	31
25234467	Cisplatin	Guo J	MicroRNA-217 functions as a tumour suppressor gene and correlates with cell resistance to cisplatin in lung cancer.	Molecules and cells	2014	20
25249556	Cisplatin	Yu G	Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression.	Molecular cancer therapeutics	2014	44
25315138	Cisplatin	He C	Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer.	Biomaterials	2015	16
25316259	Cisplatin	Yamada Y	Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na√Øve patients with advanced gastric cancer.	Annals of oncology 	2015	37
25385148	Cisplatin	Dai T	Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma cell aggressiveness by activating the NF-Œ∫B pathway.	The Journal of pathology	2015	19
25426560	Cisplatin	Pan B	Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A.	Oncotarget	2015	16
25428916	Cisplatin	Desiderio V	Increased fucosylation has a pivotal role in invasive and metastatic properties of head and neck cancer stem cells.	Oncotarget	2015	19
25432176	Cisplatin	Kolev VN	PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.	Cancer research	2015	42
25504633	Cisplatin	Osman AA	Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.	Molecular cancer therapeutics	2015	20
25537512	Cisplatin	Chiu WT	FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.	Oncotarget	2015	35
25589191	Cisplatin	Yang JC	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.	The Lancet. Oncology	2015	226
25596659	Cisplatin	Giralt J	Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.	The Lancet. Oncology	2015	25
25596660	Cisplatin	Mes√≠a R	Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.	The Lancet. Oncology	2015	20
25607838	Cisplatin	Morigi M	Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury.	The Journal of clinical investigation	2015	35
25609015	Cisplatin	Litchfield K	Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours.	Nature communications	2015	18
25658419	Cisplatin	Xu J	Œ≤-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells.	PloS one	2015	18
25682441	Cisplatin	Fuse N	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.	Gastric cancer 	2016	21
25701171	Cisplatin	Paz-Ares L	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.	The Lancet. Oncology	2015	31
25721211	Cisplatin	Zhao Z	miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.	Cancer gene therapy	2015	15
25737278	Cisplatin	Guillemette S	Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4.	Genes & development	2015	17
25831546	Cisplatin	Srivastava AK	Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.	Proceedings of the National Academy of Sciences of the United States of America	2015	30
25832687	Cisplatin	Tan T	Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.	International journal of radiation oncology, biology, physics	2015	35
25867064	Cisplatin	Zhu X	miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.	Oncogene	2016	28
25868979	Cisplatin	Canino C	A STAT3-NFkB/DDIT3/CEBPŒ≤ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations.	Oncotarget	2015	15
25871967	Cisplatin	Li X	MicroRNA-449a inhibits proliferation and induces apoptosis by directly repressing E2F3 in gastric cancer.	Cellular physiology and biochemistry 	2015	16
25956062	Cisplatin	Zhang XW	Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance.	Biochemical and biophysical research communications	2015	32
25967360	Cisplatin	Wang F	Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells.	Neoplasma	2015	18
25972604	Cisplatin	Challagundla KB	Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy.	Journal of the National Cancer Institute	2015	50
25995442	Cisplatin	Liu G	Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.	Journal of the National Cancer Institute	2015	24
26020117	Cisplatin	Cioffi M	Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer.	Scientific reports	2015	22
26026166	Cisplatin	Tanaka K	miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts.	Carcinogenesis	2015	20
26045340	Cisplatin	Thatcher N	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.	The Lancet. Oncology	2015	69
26105600	Cisplatin	Wu YL	First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.	Annals of oncology 	2015	54
26178914	Cisplatin	Balermpas P	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG).	International journal of cancer	2016	27
26201611	Cisplatin	Wu HM	Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells.	Scientific reports	2015	18
26201895	Cisplatin	Han LP	MicroRNA-138 negatively regulates non-small cell lung cancer cells through the interaction with cyclin D3.	Tumour biology 	2016	10
26282001	Cisplatin	Xie J	MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.	Tumour biology 	2016	10
26325371	Cisplatin	Liu M	RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.	Oncotarget	2015	15
26341496	Cisplatin	Li J	Overexpression of long non-coding RNA HOTAIR leads to chemoresistance by activating the Wnt/Œ≤-catenin pathway in human ovarian cancer.	Tumour biology 	2016	17
26376998	Cisplatin	Li JH	Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.	Tumour biology 	2016	11
26462739	Cisplatin	Pariente R	Melatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: effects on oxidative stress and DNA fragmentation.	Journal of pineal research	2016	17
26497652	Cisplatin	Teschendorff AE	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.	Genome medicine	2015	26
26517239	Cisplatin	Vendetti FP	The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.	Oncotarget	2015	26
26595461	Cisplatin	Wanzel M	CRISPR-Cas9-based target validation for p53-reactivating model compounds.	Nature chemical biology	2016	12
26598503	Cisplatin	Gobbo J	Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer.	Journal of the National Cancer Institute	2016	13
26598537	Cisplatin	Cierna Z	Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.	Annals of oncology 	2016	16
26654944	Cisplatin	Choi EJ	FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.	Oncotarget	2016	12
26756568	Cisplatin	Zhou XL	High expression of long non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.	Molecular carcinogenesis	2016	16
26799420	Cisplatin	Su X	Overexpression of TRIM14 promotes tongue squamous cell carcinoma aggressiveness by activating the NF-Œ∫B signaling pathway.	Oncotarget	2016	12
26801672	Cisplatin	Liu S	NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.	Tumour biology 	2016	10
26822397	Cisplatin	Fujitani K	Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.	The Lancet. Oncology	2016	32
26909612	Cisplatin	Zhu X	miR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein.	Oncotarget	2016	14
26982250	Cisplatin	Czapar AE	Tobacco Mosaic Virus Delivery of Phenanthriplatin for Cancer therapy.	ACS nano	2016	14
26989074	Cisplatin	Shen H	MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer.	Oncotarget	2016	11
27013395	Cisplatin	Morrow CJ	Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.	Annals of oncology 	2016	14
27014910	Cisplatin	Chen QY	miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.	Oncotarget	2016	18
27071093	Cisplatin	Menghi F	The tandem duplicator phenotype as a distinct genomic configuration in cancer.	Proceedings of the National Academy of Sciences of the United States of America	2016	10
27102149	Cisplatin	Chong DQ	The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.	Oncotarget	2016	15
27199349	Cisplatin	Langsch S	miR-29b Mediates NF-Œ∫B Signaling in KRAS-Induced Non-Small Cell Lung Cancers.	Cancer research	2016	14
27287412	Cisplatin	Shintani Y	IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling.	Journal of thoracic oncology 	2016	17
27381626	Cisplatin	Ter Brugge P	Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.	Journal of the National Cancer Institute	2016	11
27440269	Cisplatin	Lok BH	PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.	Clinical cancer research 	2017	13
27591936	Cisplatin	Pan J	Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.	Cancer letters	2016	20
27609068	Cisplatin	Wang Y	Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis.	Cancer letters	2016	18
27694794	Cisplatin	Fang Q	Long Non-Coding RNA (LncRNA) Urothelial Carcinoma Associated 1 (UCA1) Increases Multi-Drug Resistance of Gastric Cancer via Downregulating miR-27b.	Medical science monitor 	2016	11
27776843	Cisplatin	Al-Batran SE	Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.	The Lancet. Oncology	2016	17
27803105	Cisplatin	Yokoyama Y	BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.	Cancer research	2016	13
27875524	Cisplatin	Li X	microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP.	British journal of cancer	2017	8
27888811	Cisplatin	Hientz K	The role of p53 in cancer drug resistance and targeted chemotherapy.	Oncotarget	2017	18
27900563	Cisplatin	Yan J	LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes.	Tumour biology 	2016	13
27911863	Cisplatin	Wang Q	Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma.	Oncotarget	2017	8
27935869	Cisplatin	Dai Y	The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer.	Oncotarget	2017	6
27939400	Cisplatin	Balar AV	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.	Lancet	2017	62
28027578	Cisplatin	Li D	Long noncoding RNA HULC modulates the phosphorylation of YB-1 through serving as a scaffold of extracellular signal-regulated kinase and YB-1 to enhance hepatocarcinogenesis.	Hepatology	2017	17
28163000	Cisplatin	Cunningham D	Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.	The Lancet. Oncology	2017	7
28192397	Cisplatin	Shi ZM	Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling.	Oncogene	2017	10
28196596	Cisplatin	Gardner EE	Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.	Cancer cell	2017	14
28214651	Cisplatin	Bellmunt J	A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.	Cancer treatment reviews	2017	14
28240761	Cisplatin	Elia G	Hepatocellular carcinoma and CXCR3 chemokines: a narrative review.	La Clinica terapeutica	2017	6
28285905	Cisplatin	Chen D	Targeting BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma.	Cell stem cell	2017	10
28612710	Cisplatin	Lee MR	YC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells.	BioMedicine	2017	7
8253089	Etoposide	Oberhammer F	Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation.	The EMBO journal	1993	127
9733516	Etoposide	Wang CY	NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.	Science	1998	515
10567338	Etoposide	Masumoto J	ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells.	The Journal of biological chemistry	1999	117
12065594	Etoposide	Robertson JD	Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis.	The Journal of biological chemistry	2002	89
12761490	Etoposide	Knuefermann C	HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.	Oncogene	2003	109
12773551	Etoposide	Zhu WG	Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter.	Molecular and cellular biology	2003	77
14612912	Etoposide	Robey RW	Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.	British journal of cancer	2003	89
15115387	Etoposide	Nikolovska-Coleska Z	Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database.	Journal of medicinal chemistry	2004	75
16569192	Etoposide	Fu X	Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1.	DNA and cell biology	2006	70
16707462	Etoposide	Zhao Y	Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.	Cancer research	2006	108
16847267	Etoposide	Monte M	MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.	Proceedings of the National Academy of Sciences of the United States of America	2006	65
17310986	Etoposide	Lue H	Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.	Oncogene	2007	89
17533374	Etoposide	Maxwell PJ	HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.	Oncogene	2007	67
17537913	Etoposide	Huang RS	A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity.	Proceedings of the National Academy of Sciences of the United States of America	2007	121
18381439	Etoposide	Hann CL	Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.	Cancer research	2008	69
18559509	Etoposide	Wang L	Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.	Cancer research	2008	61
18663354	Etoposide	Tagscherer KE	Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.	Oncogene	2008	63
19118018	Etoposide	Ara T	Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells.	Cancer research	2009	56
19920819	Etoposide	Reardon DA	Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.	British journal of cancer	2009	47
20434400	Etoposide	Issels RD	Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.	The Lancet. Oncology	2010	77
20534341	Etoposide	Pommier Y	DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.	Chemistry & biology	2010	313
20625515	Etoposide	Song J	Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling.	PloS one	2010	45
20973777	Etoposide	Kim JH	Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein.	British journal of pharmacology	2011	40
21212465	Etoposide	Leontieva OV	DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.	Aging	2010	96
21333317	Etoposide	Marquitz AR	The Epstein-Barr Virus BART microRNAs target the pro-apoptotic protein Bim.	Virology	2011	62
21455219	Etoposide	Laussmann MA	Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.	Cell death and differentiation	2011	37
21555371	Etoposide	Asiedu MK	TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype.	Cancer research	2011	76
21778401	Etoposide	Wu CC	Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.	Science	2011	79
21915098	Etoposide	Frankel LB	microRNA-101 is a potent inhibitor of autophagy.	The EMBO journal	2011	96
22249269	Etoposide	Yoon CH	c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells.	Oncogene	2012	37
22328513	Etoposide	Singh R	Downregulation of BCL2 by miRNAs augments drug-induced apoptosis--a combined computational and experimental approach.	Journal of cell science	2012	33
22508727	Etoposide	Do PM	Mutant p53 cooperates with ETS2 to promote etoposide resistance.	Genes & development	2012	53
22615413	Etoposide	Cowell IG	Model for MLL translocations in therapy-related leukemia involving topoisomerase IIŒ≤-mediated DNA strand breaks and gene proximity.	Proceedings of the National Academy of Sciences of the United States of America	2012	37
22847439	Etoposide	Leontieva OV	Hypoxia suppresses conversion from proliferative arrest to cellular senescence.	Proceedings of the National Academy of Sciences of the United States of America	2012	82
23255238	Etoposide	Gorlick R	Children's Oncology Group's 2013 blueprint for research: bone tumors.	Pediatric blood & cancer	2013	34
23437304	Etoposide	Wu CW	MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer.	PloS one	2013	29
23512991	Etoposide	Batey MA	Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.	Molecular cancer therapeutics	2013	32
23547842	Etoposide	Wei X	Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors.	Bioconjugate chemistry	2013	25
23774063	Etoposide	Nath S	MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes.	Oncogenesis	2013	35
23851503	Etoposide	Huang CK	Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-Œ∫B-mediated antiapoptotic pathway.	Oncogene	2014	22
25568070	Etoposide	Schweizer MT	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.	Science translational medicine	2015	40
25605014	Etoposide	Kirk JS	Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.	Oncotarget	2015	16
25639871	Etoposide	Seviour EG	Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.	Oncogene	2016	14
25675296	Etoposide	Moriwaki K	Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death.	Cell death & disease	2015	18
27247353	Etoposide	Polley E	Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.	Journal of the National Cancer Institute	2016	15
28533362	Etoposide	Yang H	cGAS is essential for cellular senescence.	Proceedings of the National Academy of Sciences of the United States of America	2017	20
7822316	Sirolimus	Sabers CJ	Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.	The Journal of biological chemistry	1995	184
10910062	Sirolimus	Sekuliƒá A	A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.	Cancer research	2000	168
11504908	Sirolimus	Neshat MS	Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.	Proceedings of the National Academy of Sciences of the United States of America	2001	217
11691836	Sirolimus	Gingras AC	Hierarchical phosphorylation of the translation inhibitor 4E-BP1.	Genes & development	2001	256
11778052	Sirolimus	Maeshima Y	Tumstatin, an endothelial cell-specific inhibitor of protein synthesis.	Science	2002	87
12039858	Sirolimus	Humar R	Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling.	FASEB journal 	2002	89
12045200	Sirolimus	Goncharova EA	Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).	The Journal of biological chemistry	2002	125
12172553	Sirolimus	Inoki K	TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.	Nature cell biology	2002	843
12271141	Sirolimus	Tee AR	Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.	Proceedings of the National Academy of Sciences of the United States of America	2002	212
12563289	Sirolimus	Jacinto E	Tor signalling in bugs, brain and brawn.	Nature reviews. Molecular cell biology	2003	151
12782577	Sirolimus	Choe G	Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo.	Cancer research	2003	109
12842888	Sirolimus	Castro AF	Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.	The Journal of biological chemistry	2003	109
12878853	Sirolimus	Huang S	Rapamycins: mechanism of action and cellular resistance.	Cancer biology & therapy	2003	80
12901945	Sirolimus	Huang S	Targeting mTOR signaling for cancer therapy.	Current opinion in pharmacology	2003	80
12906785	Sirolimus	Tee AR	Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.	Current biology 	2003	359
14561707	Sirolimus	Zhang H	Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.	The Journal of clinical investigation	2003	206
14607085	Sirolimus	Manning BD	Rheb fills a GAP between TSC and TOR.	Trends in biochemical sciences	2003	134
14729632	Sirolimus	Boulay A	Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.	Cancer research	2004	80
15028555	Sirolimus	Gao N	G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.	American journal of physiology. Cell physiology	2004	77
15071500	Sirolimus	Raught B	Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases.	The EMBO journal	2004	129
15094765	Sirolimus	Fingar DC	Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.	Oncogene	2004	333
15156201	Sirolimus	Majumder PK	mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways.	Nature medicine	2004	282
15325584	Sirolimus	Meijer AJ	Regulation and role of autophagy in mammalian cells.	The international journal of biochemistry & cell biology	2004	150
15342917	Sirolimus	Roux PP	Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.	Proceedings of the National Academy of Sciences of the United States of America	2004	235
15501954	Sirolimus	Zhou X	Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.	Clinical cancer research 	2004	90
15533996	Sirolimus	Manning BD	Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis.	The Journal of cell biology	2004	174
15550488	Sirolimus	R√©cher C	Antileukemic activity of rapamycin in acute myeloid leukemia.	Blood	2005	67
15624019	Sirolimus	Inoki K	Dysregulation of the TSC-mTOR pathway in human disease.	Nature genetics	2005	293
15641016	Sirolimus	Foulstone E	Insulin-like growth factor ligands, receptors, and binding proteins in cancer.	The Journal of pathology	2005	67
15647370	Sirolimus	Kang S	Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.	Proceedings of the National Academy of Sciences of the United States of America	2005	218
15659337	Sirolimus	Tee AR	mTOR, translational control and human disease.	Seminars in cell & developmental biology	2005	88
15718470	Sirolimus	Sarbassov DD	Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.	Science	2005	2058
15755954	Sirolimus	Inoki K	Signaling by target of rapamycin proteins in cell growth control.	Microbiology and molecular biology reviews 	2005	110
15805275	Sirolimus	Dasgupta B	Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.	Cancer research	2005	81
15833867	Sirolimus	Takeuchi H	Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.	Cancer research	2005	163
15840712	Sirolimus	Ramanathan A	Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements.	Proceedings of the National Academy of Sciences of the United States of America	2005	111
15890640	Sirolimus	Ghobrial IM	Targeting apoptosis pathways in cancer therapy.	CA	2005	187
15899889	Sirolimus	Chiang GG	Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase.	The Journal of biological chemistry	2005	163
15905173	Sirolimus	Holz MK	Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase.	The Journal of biological chemistry	2005	105
15916903	Sirolimus	Fuchs BC	Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?	Seminars in cancer biology	2005	131
15937108	Sirolimus	Johannessen CM	The NF1 tumor suppressor critically regulates TSC2 and mTOR.	Proceedings of the National Academy of Sciences of the United States of America	2005	158
15955899	Sirolimus	Chan S	Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2005	105
15983389	Sirolimus	Witzig TE	Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.	Journal of clinical oncology 	2005	117
16096426	Sirolimus	Morgensztern D	PI3K/Akt/mTOR pathway as a target for cancer therapy.	Anti-cancer drugs	2005	90
16267020	Sirolimus	Amornphimoltham P	Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.	Cancer research	2005	78
16341243	Sirolimus	Thomas GV	Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.	Nature medicine	2006	169
16432179	Sirolimus	Bader AG	Cancer-specific mutations in PIK3CA are oncogenic in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2006	122
16446424	Sirolimus	Furuya F	Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.	Proceedings of the National Academy of Sciences of the United States of America	2006	65
16453012	Sirolimus	Cully M	Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.	Nature reviews. Cancer	2006	341
16469695	Sirolimus	Wullschleger S	TOR signaling in growth and metabolism.	Cell	2006	1712
16489002	Sirolimus	Klos KS	ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.	Cancer research	2006	61
16585191	Sirolimus	Wang L	Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus.	Cancer research	2006	66
16636147	Sirolimus	Cai SL	Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning.	The Journal of cell biology	2006	122
16651424	Sirolimus	Mungamuri SK	Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.	Cancer research	2006	69
16715125	Sirolimus	Wang X	Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation.	Oncogene	2006	77
16740688	Sirolimus	Del Bufalo D	Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.	Cancer research	2006	63
16763566	Sirolimus	Shahbazian D	The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity.	The EMBO journal	2006	127
16799564	Sirolimus	Androutsellis-Theotokis A	Notch signalling regulates stem cell numbers in vitro and in vivo.	Nature	2006	271
16849518	Sirolimus	Koumenis C	"Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways.	Molecular cancer research 	2006	71
16849522	Sirolimus	Pore N	Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway.	Molecular cancer research 	2006	62
16883305	Sirolimus	Faivre S	Current development of mTOR inhibitors as anticancer agents.	Nature reviews. Drug discovery	2006	239
16904612	Sirolimus	Sodhi A	The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.	Cancer cell	2006	65
16904613	Sirolimus	Phung TL	Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.	Cancer cell	2006	152
16912159	Sirolimus	Wang MY	Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.	Cancer research	2006	100
16915281	Sirolimus	Bernardi R	PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.	Nature	2006	132
16915295	Sirolimus	Sabatini DM	mTOR and cancer: insights into a complex relationship.	Nature reviews. Cancer	2006	453
16951235	Sirolimus	Yee KW	Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.	Clinical cancer research 	2006	70
16959574	Sirolimus	Inoki K	TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.	Cell	2006	372
16968213	Sirolimus	Lee CH	mTOR pathway as a target in tissue hypertrophy.	Annual review of pharmacology and toxicology	2007	74
17010674	Sirolimus	Wei G	Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.	Cancer cell	2006	149
17028174	Sirolimus	Baba M	Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.	Proceedings of the National Academy of Sciences of the United States of America	2006	128
17031397	Sirolimus	Duran I	A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.	British journal of cancer	2006	76
17047067	Sirolimus	Cao C	Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.	Cancer research	2006	97
17052453	Sirolimus	Zhang HH	S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt.	Molecular cell	2006	103
17172425	Sirolimus	Kuo PL	Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells.	Molecular cancer therapeutics	2006	75
17210675	Sirolimus	Foster DA	Regulation of mTOR by phosphatidic acid?	Cancer research	2007	70
17234785	Sirolimus	Opel D	Activation of Akt predicts poor outcome in neuroblastoma.	Cancer research	2007	68
17253963	Sirolimus	Findlay GM	A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling.	The Biochemical journal	2007	100
17275731	Sirolimus	Tsang CK	Targeting mammalian target of rapamycin (mTOR) for health and diseases.	Drug discovery today	2007	109
17277121	Sirolimus	Zheng Y	A role for mammalian target of rapamycin in regulating T cell activation versus anergy.	Journal of immunology	2007	88
17332326	Sirolimus	Li M	Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.	Cancer research	2007	70
17334390	Sirolimus	Han EK	Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition.	Oncogene	2007	56
17361185	Sirolimus	Wilker EW	14-3-3sigma controls mitotic translation to facilitate cytokinesis.	Nature	2007	80
17363557	Sirolimus	Mabuchi S	RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.	Cancer research	2007	59
17363738	Sirolimus	Chan SM	Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia.	Blood	2007	89
17376031	Sirolimus	Proud CG	Signalling to translation: how signal transduction pathways control the protein synthetic machinery.	The Biochemical journal	2007	157
17395690	Sirolimus	Aoki H	Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways.	Molecular pharmacology	2007	130
17409454	Sirolimus	Petricoin EF 3rd	Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival.	Cancer research	2007	71
17419990	Sirolimus	Bhaskar PT	The two TORCs and Akt.	Developmental cell	2007	302
17440983	Sirolimus	Pantuck AJ	Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.	Cancer	2007	85
17452018	Sirolimus	Dann SG	mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer.	Trends in molecular medicine	2007	170
17465001	Sirolimus	Pazienza V	The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms.	Hepatology	2007	64
17545512	Sirolimus	Abraham RT	The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.	Clinical cancer research 	2007	62
17546049	Sirolimus	Bauer S	KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.	Oncogene	2007	60
17595159	Sirolimus	Chan EY	siRNA screening of the kinome identifies ULK1 as a multidomain modulator of autophagy.	The Journal of biological chemistry	2007	147
17599906	Sirolimus	Woo SY	PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.	The Journal of biological chemistry	2007	80
17613433	Sirolimus	Guertin DA	Defining the role of mTOR in cancer.	Cancer cell	2007	929
17616691	Sirolimus	Liu LZ	AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.	Cancer research	2007	67
17671177	Sirolimus	Ma L	Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.	Cancer research	2007	58
17680028	Sirolimus	Yang Q	Expanding mTOR signaling.	Cell research	2007	164
17684489	Sirolimus	Veverka V	Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR.	Oncogene	2008	56
17699757	Sirolimus	Armengol G	4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications.	Cancer research	2007	87
17785546	Sirolimus	Molinolo AA	Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.	Clinical cancer research 	2007	73
17786026	Sirolimus	Shinojima N	Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin-induced autophagy.	Autophagy	2007	84
17804702	Sirolimus	Fan QW	A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.	Cancer research	2007	66
17878402	Sirolimus	Tamburini J	Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.	Blood	2008	74
17905659	Sirolimus	Chiang GG	Targeting the mTOR signaling network in cancer.	Trends in molecular medicine	2007	91
17908983	Sirolimus	Lu CH	Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.	Clinical cancer research 	2007	71
18080139	Sirolimus	Martignoni G	PEComas: the past, the present and the future.	Virchows Archiv 	2008	93
18089801	Sirolimus	Masri J	mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor.	Cancer research	2007	92
18165616	Sirolimus	Lefranc F	Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.	The oncologist	2007	66
18166498	Sirolimus	LoPiccolo J	Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.	Drug resistance updates 	2008	192
18198340	Sirolimus	DeYoung MP	Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling.	Genes & development	2008	222
18296647	Sirolimus	Schmid T	Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion.	Cancer research	2008	53
18332467	Sirolimus	Tanaka C	Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.	Journal of clinical oncology 	2008	57
18332469	Sirolimus	Tabernero J	Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.	Journal of clinical oncology 	2008	152
18332470	Sirolimus	O'Donnell A	Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.	Journal of clinical oncology 	2008	120
18332865	Sirolimus	Steelman LS	Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.	Oncogene	2008	51
18342602	Sirolimus	Ozcan U	Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis.	Molecular cell	2008	165
18367868	Sirolimus	Mammucari C	Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle.	Autophagy	2008	76
18424697	Sirolimus	Basu S	Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin.	Journal of immunology	2008	57
18440854	Sirolimus	Jiang BH	Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment.	Drug resistance updates 	2008	73
18451242	Sirolimus	Rizzieri DA	A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.	Clinical cancer research 	2008	59
18460336	Sirolimus	Gulati P	Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34.	Cell metabolism	2008	131
18519641	Sirolimus	Dan HC	Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.	Genes & development	2008	150
18566586	Sirolimus	Facchinetti V	The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C.	The EMBO journal	2008	202
18570873	Sirolimus	Hong F	mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation.	Molecular cell	2008	98
18653228	Sirolimus	Motzer RJ	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.	Lancet	2008	689
18664580	Sirolimus	Mills JR	mTORC1 promotes survival through translational control of Mcl-1.	Proceedings of the National Academy of Sciences of the United States of America	2008	112
18669866	Sirolimus	Perrone F	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.	Annals of oncology 	2009	114
18679422	Sirolimus	Zhuang D	C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.	Oncogene	2008	56
18684977	Sirolimus	Golovina TN	CD28 costimulation is essential for human T regulatory expansion and function.	Journal of immunology	2008	55
18721898	Sirolimus	Yap TA	Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.	Current opinion in pharmacology	2008	146
18722871	Sirolimus	Curatolo P	Tuberous sclerosis.	Lancet	2008	171
18725988	Sirolimus	Carracedo A	Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.	The Journal of clinical investigation	2008	507
18725989	Sirolimus	Kinkade CW	Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.	The Journal of clinical investigation	2008	158
18725993	Sirolimus	Grant S	Cotargeting survival signaling pathways in cancer.	The Journal of clinical investigation	2008	60
18768809	Sirolimus	Fujishita T	Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.	Proceedings of the National Academy of Sciences of the United States of America	2008	57
18787170	Sirolimus	Mao JH	FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.	Science	2008	138
18794129	Sirolimus	Wang X	Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.	Cancer research	2008	59
18821591	Sirolimus	Llovet JM	Molecular targeted therapies in hepatocellular carcinoma.	Hepatology	2008	288
18846101	Sirolimus	Wouters BG	Hypoxia signalling through mTOR and the unfolded protein response in cancer.	Nature reviews. Cancer	2008	247
18922904	Sirolimus	Buck E	Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.	Cancer research	2008	82
18929564	Sirolimus	Villanueva A	Pivotal role of mTOR signaling in hepatocellular carcinoma.	Gastroenterology	2008	186
19018475	Sirolimus	Kreisl TN	A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).	Journal of neuro-oncology	2009	48
19029981	Sirolimus	Engelman JA	Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.	Nature medicine	2008	484
19033662	Sirolimus	Lu Z	The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells.	The Journal of clinical investigation	2008	117
19050071	Sirolimus	Sun Q	Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase.	Proceedings of the National Academy of Sciences of the United States of America	2008	187
19055754	Sirolimus	Marty B	Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.	Breast cancer research 	2008	63
19072831	Sirolimus	Vinciguerra M	Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes.	Hepatology	2009	53
19114562	Sirolimus	Toschi A	Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.	Molecular and cellular biology	2009	128
19164214	Sirolimus	Hildebrandt MA	Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.	Journal of clinical oncology 	2009	60
19166929	Sirolimus	Dunlop EA	Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms.	Cellular signalling	2009	92
19176518	Sirolimus	Fan QW	EGFR signals to mTOR through PKC and independently of Akt in glioma.	Science signaling	2009	66
19185849	Sirolimus	Guertin DA	mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.	Cancer cell	2009	149
19223493	Sirolimus	Yu G	Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer.	Clinical cancer research 	2009	51
19223496	Sirolimus	Lane HA	mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.	Clinical cancer research 	2009	53
19234517	Sirolimus	Hartman TR	The role of the Birt-Hogg-Dub√© protein in mTOR activation and renal tumorigenesis.	Oncogene	2009	62
19244117	Sirolimus	Copp J	TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2.	Cancer research	2009	132
19246562	Sirolimus	Cullion K	Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.	Blood	2009	50
19261747	Sirolimus	Puzio-Kuter AM	Inactivation of p53 and Pten promotes invasive bladder cancer.	Genes & development	2009	98
19264150	Sirolimus	Foster DA	Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.	Biochimica et biophysica acta	2009	78
19279323	Sirolimus	Young AR	Autophagy mediates the mitotic senescence transition.	Genes & development	2009	274
19282848	Sirolimus	Dankort D	Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.	Nature genetics	2009	324
19301157	Sirolimus	Zhou L	The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma.	Medical oncology	2010	44
19303758	Sirolimus	Bozulic L	PIKKing on PKB: regulation of PKB activity by phosphorylation.	Current opinion in cell biology	2009	68
19306412	Sirolimus	Amato RJ	A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.	Cancer	2009	45
19326431	Sirolimus	Narayanan NK	Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.	International journal of cancer	2009	60
19362054	Sirolimus	Weichhart T	The multiple facets of mTOR in immunity.	Trends in immunology	2009	74
19372546	Sirolimus	Breuleux M	Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.	Molecular cancer therapeutics	2009	75
19401449	Sirolimus	Wee S	PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.	Cancer research	2009	123
19410195	Sirolimus	Brems H	Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1.	The Lancet. Oncology	2009	70
19420259	Sirolimus	Di Nardo A	Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.	The Journal of neuroscience 	2009	63
19451225	Sirolimus	James MF	NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.	Molecular and cellular biology	2009	69
19451229	Sirolimus	L√≥pez-Lago MA	Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.	Molecular and cellular biology	2009	47
19501590	Sirolimus	Mueller MT	Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.	Gastroenterology	2009	81
19535919	Sirolimus	Zhu H	Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells.	Autophagy	2009	113
19543393	Sirolimus	Strauss L	Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin.	PloS one	2009	59
19553991	Sirolimus	Scott KL	GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer.	Nature	2009	106
19602587	Sirolimus	Huang J	Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.	Cancer research	2009	46
19625624	Sirolimus	Guo D	The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2009	84
19641186	Sirolimus	Gupta M	Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.	Blood	2009	58
19644473	Sirolimus	Liu P	Targeting the phosphoinositide 3-kinase pathway in cancer.	Nature reviews. Drug discovery	2009	563
19665249	Sirolimus	Newell P	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.	Journal of hepatology	2009	52
19706799	Sirolimus	Desbois-Mouthon C	Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.	Clinical cancer research 	2009	59
19771169	Sirolimus	Balgi AD	Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.	PloS one	2009	113
19773376	Sirolimus	Kim KW	Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.	Clinical cancer research 	2009	47
19789349	Sirolimus	Konstantinidou G	Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.	Cancer research	2009	56
19796751	Sirolimus	Rini BI	Resistance to targeted therapy in renal-cell carcinoma.	The Lancet. Oncology	2009	134
19817806	Sirolimus	Wong M	Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.	Epilepsia	2010	59
19834494	Sirolimus	Kang R	The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival.	Cell death and differentiation	2010	95
19838173	Sirolimus	Lee JS	FLIP-mediated autophagy regulation in cell death control.	Nature cell biology	2009	143
19843504	Sirolimus	Hudon V	Renal tumour suppressor function of the Birt-Hogg-Dub√© syndrome gene product folliculin.	Journal of medical genetics	2010	47
19860903	Sirolimus	Yuan R	Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.	Journal of hematology & oncology	2009	61
19875810	Sirolimus	Lieberthal W	The role of the mammalian target of rapamycin (mTOR) in renal disease.	Journal of the American Society of Nephrology 	2009	81
19917848	Sirolimus	Missiaglia E	Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.	Journal of clinical oncology 	2010	97
19920197	Sirolimus	Fu L	Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.	Cancer research	2009	53
19933912	Sirolimus	Yao JC	Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.	Journal of clinical oncology 	2010	121
19934294	Sirolimus	Gulhati P	Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.	Clinical cancer research 	2009	56
19934303	Sirolimus	Miller TW	Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.	Clinical cancer research 	2009	53
19935711	Sirolimus	Treins C	Rictor is a novel target of p70 S6 kinase-1.	Oncogene	2010	56
19945836	Sirolimus	Efeyan A	mTOR and cancer: many loops in one pathway.	Current opinion in cell biology	2010	138
19948145	Sirolimus	Laplante M	An emerging role of mTOR in lipid biosynthesis.	Current biology 	2009	156
19951971	Sirolimus	Park S	Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.	Haematologica	2010	58
19956179	Sirolimus	Menon S	Common corruption of the mTOR signaling network in human tumors.	Oncogene	2008	98
19995915	Sirolimus	Julien LA	mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.	Molecular and cellular biology	2010	141
20008935	Sirolimus	Olive V	miR-19 is a key oncogenic component of mir-17-92.	Genes & development	2009	235
20009104	Sirolimus	Guo D	EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.	Science signaling	2009	82
20022946	Sirolimus	Soliman GA	mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.	The Journal of biological chemistry	2010	81
20028765	Sirolimus	Mahalingam D	Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.	Clinical cancer research 	2010	40
20028853	Sirolimus	Baryawno N	Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.	Cancer research	2010	44
20038818	Sirolimus	Tsang CK	mTOR binds to the promoters of RNA polymerase I- and III-transcribed genes.	Cell cycle	2010	47
20042677	Sirolimus	Deng L	A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis.	The American journal of pathology	2010	57
20048174	Sirolimus	Wagner AJ	Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.	Journal of clinical oncology 	2010	66
20053782	Sirolimus	Koduru S	Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis.	Molecular cancer therapeutics	2010	44
20080688	Sirolimus	Hung KE	Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment.	Proceedings of the National Academy of Sciences of the United States of America	2010	80
20081105	Sirolimus	Nagaraja AK	A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.	Molecular endocrinology	2010	77
20117946	Sirolimus	Krycer JR	The Akt-SREBP nexus: cell signaling meets lipid metabolism.	Trends in endocrinology and metabolism	2010	58
20139716	Sirolimus	Blagosklonny MV	Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans).	Cell cycle	2010	85
20146692	Sirolimus	Orlova KA	The tuberous sclerosis complex.	Annals of the New York Academy of Sciences	2010	102
20154675	Sirolimus	Qin Y	Germline mutations in TMEM127 confer susceptibility to pheochromocytoma.	Nature genetics	2010	89
20157535	Sirolimus	Armour SM	Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy.	Aging	2009	65
20160026	Sirolimus	Pang X	Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway.	Cancer research	2010	44
20175032	Sirolimus	Hoshida Y	Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.	Seminars in liver disease	2010	94
20179189	Sirolimus	Workman P	Drugging the PI3 kinome: from chemical tools to drugs in the clinic.	Cancer research	2010	78
20190810	Sirolimus	Sato T	Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer.	Oncogene	2010	64
20227039	Sirolimus	Hsieh AC	Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E.	Cancer cell	2010	158
20229590	Sirolimus	Johnston PB	A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.	American journal of hematology	2010	51
20231677	Sirolimus	Doi T	Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.	Journal of clinical oncology 	2010	56
20233713	Sirolimus	Shor B	Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells.	The Journal of biological chemistry	2010	49
20299510	Sirolimus	Bhatt AP	Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.	Blood	2010	56
20360610	Sirolimus	Faoro L	EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.	The Journal of biological chemistry	2010	43
20371718	Sirolimus	Cirstea D	Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.	Molecular cancer therapeutics	2010	48
20384580	Sirolimus	Ciuffreda L	The mTOR pathway: a new target in cancer therapy.	Current cancer drug targets	2010	54
20399811	Sirolimus	Martelli AM	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis.	Biochimica et biophysica acta	2010	41
20406975	Sirolimus	Greshock J	Molecular target class is predictive of in vitro response profile.	Cancer research	2010	48
20421047	Sirolimus	Johnson SM	Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.	Journal of the American College of Surgeons	2010	44
20434451	Sirolimus	Mujumdar N	Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways.	Gastroenterology	2010	41
20460539	Sirolimus	Giovannetti E	MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.	Cancer research	2010	122
20472883	Sirolimus	Akhavan D	mTOR signaling in glioblastoma: lessons learned from bench to bedside.	Neuro-oncology	2010	50
20484036	Sirolimus	Doghman M	Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.	Cancer research	2010	66
20491627	Sirolimus	Zhou H	The complexes of mammalian target of rapamycin.	Current protein & peptide science	2010	42
20498635	Sirolimus	Heublein S	Proton-assisted amino-acid transporters are conserved regulators of proliferation and amino-acid-dependent mTORC1 activation.	Oncogene	2010	49
20498714	Sirolimus	Squarize CH	Accelerated wound healing by mTOR activation in genetically defined mouse models.	PloS one	2010	40
20501828	Sirolimus	Fornari F	MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.	Cancer research	2010	129
20530283	Sirolimus	Alvarez RH	Emerging targeted therapies for breast cancer.	Journal of clinical oncology 	2010	46
20563248	Sirolimus	Molina JR	Invasive glioblastoma cells acquire stemness and increased Akt activation.	Neoplasia	2010	62
20574048	Sirolimus	Isakson P	Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.	Blood	2010	69
20587533	Sirolimus	Voss V	The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma.	Molecular cancer research 	2010	49
20606035	Sirolimus	Cho DC	The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.	Clinical cancer research 	2010	78
20606252	Sirolimus	Korotchkina LG	The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.	Aging	2010	162
20616057	Sirolimus	Carayol N	Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.	Proceedings of the National Academy of Sciences of the United States of America	2010	70
20616807	Sirolimus	Kang YJ	The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis.	Cell death and differentiation	2011	42
20630061	Sirolimus	Javle MM	Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.	BMC cancer	2010	41
20634405	Sirolimus	Li X	The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.	Cancer research	2010	60
20639871	Sirolimus	Gao C	Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation.	Nature cell biology	2010	118
20664172	Sirolimus	Di Nicolantonio F	Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.	The Journal of clinical investigation	2010	117
20664473	Sirolimus	Boudreaux JP	The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.	Pancreas	2010	58
20668229	Sirolimus	Green AS	The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.	Blood	2010	53
20670887	Sirolimus	D√ºvel K	Activation of a metabolic gene regulatory network downstream of mTOR complex 1.	Molecular cell	2010	446
20671809	Sirolimus	Martelli AM	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.	Oncotarget	2010	76
20681032	Sirolimus	Slomovitz BM	A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.	Cancer	2010	45
20686120	Sirolimus	Hoang B	Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.	Blood	2010	42
20686178	Sirolimus	Andersen JN	Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.	Science translational medicine	2010	57
20704563	Sirolimus	Pearce LR	Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1).	The Biochemical journal	2010	82
20805416	Sirolimus	Haidinger M	A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation.	Journal of immunology	2010	63
20857497	Sirolimus	Sunayama J	Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.	Stem cells	2010	61
20860370	Sirolimus	Liu Q	Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzoh1,6naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.	Journal of medicinal chemistry	2010	68
20870173	Sirolimus	Powell JD	The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism.	Immunity	2010	152
20975068	Sirolimus	Andre F	Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.	Journal of clinical oncology 	2010	50
20978191	Sirolimus	Zhang F	mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis.	Cancer research	2010	49
21040901	Sirolimus	Lee JY	mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion.	Cell stem cell	2010	71
21047224	Sirolimus	Krueger DA	Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.	The New England journal of medicine	2010	226
21051933	Sirolimus	Leontieva OV	Weak p53 permits senescence during cell cycle arrest.	Cell cycle	2010	66
21115397	Sirolimus	Ehninger D	Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.	Trends in molecular medicine	2011	59
21135857	Sirolimus	Witzig TE	A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.	Leukemia	2011	65
21157483	Sirolimus	Zoncu R	mTOR: from growth signal integration to cancer, diabetes and ageing.	Nature reviews. Molecular cell biology	2011	1286
21179025	Sirolimus	Caron E	A comprehensive map of the mTOR signaling network.	Molecular systems biology	2010	67
21187475	Sirolimus	Gedaly R	PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.	Anticancer research	2010	45
21190521	Sirolimus	Zhou H	Role of mTOR signaling in tumor cell motility, invasion and metastasis.	Current protein & peptide science	2011	53
21228155	Sirolimus	Rieker C	Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling.	The Journal of neuroscience 	2011	42
21252315	Sirolimus	Jiao Y	DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.	Science	2011	363
21253593	Sirolimus	Golovina TN	Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells.	PloS one	2011	48
21289267	Sirolimus	Liu R	The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.	The Journal of clinical endocrinology and metabolism	2011	36
21289308	Sirolimus	Yoshimi A	Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.	Blood	2011	35
21306238	Sirolimus	Yao JC	Everolimus for advanced pancreatic neuroendocrine tumors.	The New England journal of medicine	2011	472
21325617	Sirolimus	Guevara-Aguirre J	Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans.	Science translational medicine	2011	183
21333749	Sirolimus	Zhang YJ	Targeting the mTOR kinase domain: the second generation of mTOR inhibitors.	Drug discovery today	2011	47
21339740	Sirolimus	Kim EK	Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.	Oncogene	2011	41
21346035	Sirolimus	Finley DS	Tumor biology and prognostic factors in renal cell carcinoma.	The oncologist	2011	39
21362200	Sirolimus	Sanchez CG	Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.	Breast cancer research 	2011	49
21376236	Sirolimus	Zinzalla V	Activation of mTORC2 by association with the ribosome.	Cell	2011	210
21406469	Sirolimus	Hernandez-Aya LF	Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.	The oncologist	2011	42
21413931	Sirolimus	Pearce LR	Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney.	The Biochemical journal	2011	53
21415215	Sirolimus	Altman JK	Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.	Clinical cancer research 	2011	37
21430067	Sirolimus	Gulhati P	mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.	Cancer research	2011	165
21436840	Sirolimus	Martelli AM	Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.	Leukemia	2011	52
21440577	Sirolimus	Hay N	Interplay between FOXO, TOR, and Akt.	Biochimica et biophysica acta	2011	67
21460630	Sirolimus	Dunlop EA	ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding.	Autophagy	2011	44
21460795	Sirolimus	Galan-Moya EM	Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway.	EMBO reports	2011	44
21470407	Sirolimus	Dowling RJ	Understanding the benefit of metformin use in cancer treatment.	BMC medicine	2011	100
21490404	Sirolimus	Wander SA	Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.	The Journal of clinical investigation	2011	138
21494257	Sirolimus	Steelman LS	Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.	Leukemia	2011	59
21501117	Sirolimus	Smith GI	Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia-hyperaminoacidaemia in healthy young and middle-aged men and women.	Clinical science	2011	45
21512002	Sirolimus	Narita M	Spatial coupling of mTOR and autophagy augments secretory phenotypes.	Science	2011	129
21548787	Sirolimus	Kim J	Amino acid signaling in TOR activation.	Annual review of biochemistry	2011	75
21564534	Sirolimus	Hippen KL	Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease.	American journal of transplantation 	2011	88
21707707	Sirolimus	Sun CH	Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.	Histopathology	2011	38
21730275	Sirolimus	Morrow PK	Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.	Journal of clinical oncology 	2011	65
21750201	Sirolimus	Naing A	Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.	Clinical cancer research 	2011	44
21779436	Sirolimus	Foster DA	Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s).	Genes & cancer	2010	57
21788564	Sirolimus	Oza AM	Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.	Journal of clinical oncology 	2011	59
21795477	Sirolimus	Uesugi A	The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer.	Cancer research	2011	74
21828076	Sirolimus	Rodr√≠guez-Escudero I	A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.	Human molecular genetics	2011	46
21841310	Sirolimus	Shuda M	Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator.	The Journal of clinical investigation	2011	100
21859846	Sirolimus	Schatz JH	Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.	The Journal of experimental medicine	2011	50
21862872	Sirolimus	Liu B	Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.	Cell cycle	2011	41
21876152	Sirolimus	Ilic N	PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.	Proceedings of the National Academy of Sciences of the United States of America	2011	86
21878637	Sirolimus	Li D	MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma.	The Journal of biological chemistry	2011	85
21878679	Sirolimus	Chan JC	AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.	Science signaling	2011	41
21907282	Sirolimus	Carson RP	Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.	Neurobiology of disease	2012	57
21930774	Sirolimus	Liu L	Review series: TOR kinase complexes and cell migration.	The Journal of cell biology	2011	36
21952069	Sirolimus	Coppin C	Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.	BJU international	2011	55
21963299	Sirolimus	Dazert E	mTOR signaling in disease.	Current opinion in cell biology	2011	140
21975930	Sirolimus	Patel V	Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.	Cancer research	2011	52
21993994	Sirolimus	Ho C	AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.	Hepatology	2012	55
21998291	Sirolimus	Wallin JJ	GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.	Molecular cancer therapeutics	2011	68
22025691	Sirolimus	Goto J	Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex.	Proceedings of the National Academy of Sciences of the United States of America	2011	61
22065737	Sirolimus	Shin S	Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation.	Proceedings of the National Academy of Sciences of the United States of America	2011	40
22067397	Sirolimus	Chawla SP	Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.	Journal of clinical oncology 	2012	59
22119496	Sirolimus	Pavel ME	Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.	Lancet	2011	163
22143671	Sirolimus	Willems L	The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.	Leukemia	2012	46
22144946	Sirolimus	Karar J	PI3K/AKT/mTOR Pathway in Angiogenesis.	Frontiers in molecular neuroscience	2011	131
22149876	Sirolimus	Baselga J	Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.	The New England journal of medicine	2012	561
22154278	Sirolimus	Reungwetwattana T	Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).	Clinical lung cancer	2012	30
22166724	Sirolimus	Blagosklonny MV	Hormesis does not make sense except in the light of TOR-driven aging.	Aging	2011	38
22171948	Sirolimus	Deng W	Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.	Pigment cell & melanoma research	2012	36
22186785	Sirolimus	Criollo A	Autophagy is required for the activation of NFŒ∫B.	Cell cycle	2012	31
22194965	Sirolimus	Atefi M	Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.	PloS one	2011	69
22215754	Sirolimus	Anderson KC	The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.	Journal of clinical oncology 	2012	42
22234835	Sirolimus	Fang Y	MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma.	Hepatology	2012	103
22239433	Sirolimus	Bartholomeusz C	Targeting the PI3K signaling pathway in cancer therapy.	Expert opinion on therapeutic targets	2012	55
22248718	Sirolimus	Korkmaz G	miR-376b controls starvation and mTOR inhibition-related autophagy by targeting ATG4C and BECN1.	Autophagy	2012	58
22261336	Sirolimus	Zaytseva YY	mTOR inhibitors in cancer therapy.	Cancer letters	2012	68
22271473	Sirolimus	Janku F	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.	Journal of clinical oncology 	2012	153
22310280	Sirolimus	Serrano I	Role of the integrin-linked kinase (ILK)/Rictor complex in TGFŒ≤-1-induced epithelial-mesenchymal transition (EMT).	Oncogene	2013	36
22349822	Sirolimus	Wen ZH	Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.	Oncogene	2013	29
22350330	Sirolimus	Willems L	PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.	Current oncology reports	2012	61
22354785	Sirolimus	Wiza C	Role of PRAS40 in Akt and mTOR signaling in health and disease.	American journal of physiology. Endocrinology and metabolism	2012	39
22357447	Sirolimus	Markman B	Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.	Annals of oncology 	2012	42
22394614	Sirolimus	Blagosklonny MV	Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging.	Aging	2012	130
22397650	Sirolimus	Gerlinger M	Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.	The New England journal of medicine	2012	1714
22402744	Sirolimus	Weeraratne SD	Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma.	Acta neuropathologica	2012	57
22408430	Sirolimus	P√≥pulo H	The mTOR signalling pathway in human cancer.	International journal of molecular sciences	2012	128
22409888	Sirolimus	Molinolo AA	mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.	Clinical cancer research 	2012	38
22425712	Sirolimus	Chen Z	Down-regulation of the microRNA-99 family members in head and neck squamous cell carcinoma.	Oral oncology	2012	44
22431589	Sirolimus	Suh SS	MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme.	Proceedings of the National Academy of Sciences of the United States of America	2012	41
22439642	Sirolimus	Vinci M	Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.	BMC biology	2012	138
22443084	Sirolimus	De Luca A	The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.	Expert opinion on therapeutic targets	2012	128
22449814	Sirolimus	Bakan I	Connecting mTORC1 signaling to SREBP-1 activation.	Current opinion in lipidology	2012	39
22457330	Sirolimus	Menon S	Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.	Science signaling	2012	51
22473468	Sirolimus	Song MS	The functions and regulation of the PTEN tumour suppressor.	Nature reviews. Molecular cell biology	2012	494
22473959	Sirolimus	Lee K	Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia.	The Journal of experimental medicine	2012	43
22474287	Sirolimus	Fonseca BD	Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling.	The Journal of biological chemistry	2012	41
22500797	Sirolimus	Laplante M	mTOR signaling in growth control and disease.	Cell	2012	2019
22504094	Sirolimus	Chang Y	miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions.	Gastroenterology	2012	53
22565002	Sirolimus	Bachelot T	Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.	Journal of clinical oncology 	2012	132
22574197	Sirolimus	√ñgmundsd√≥ttir MH	Proton-assisted amino acid transporter PAT1 complexes with Rag GTPases and activates TORC1 on late endosomal and lysosomal membranes.	PloS one	2012	48
22580614	Sirolimus	Ciechomska IA	Endoplasmic reticulum stress triggers autophagy in malignant glioma cells undergoing cyclosporine a-induced cell death.	Oncogene	2013	31
22585904	Sirolimus	Baird TD	Eukaryotic initiation factor 2 phosphorylation and translational control in metabolism.	Advances in nutrition	2012	119
22605338	Sirolimus	Wang Y	Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity.	The Journal of biological chemistry	2012	49
22641689	Sirolimus	Liu EY	Autophagy and cancer--issues we need to digest.	Journal of cell science	2012	51
22685175	Sirolimus	Tasian SK	Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.	Blood	2012	50
22749019	Sirolimus	Efeyan A	Amino acids and mTORC1: from lysosomes to disease.	Trends in molecular medicine	2012	126
22778315	Sirolimus	Busaidy NL	Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.	Journal of clinical oncology 	2012	41
22826565	Sirolimus	Zeng Z	Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.	Blood	2012	38
22834827	Sirolimus	Arora S	Honokiol: a novel natural agent for cancer prevention and therapy.	Current molecular medicine	2012	37
22859719	Sirolimus	Sun ZJ	Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.	Clinical cancer research 	2012	41
22872574	Sirolimus	Roberts PJ	Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.	Clinical cancer research 	2012	65
22889214	Sirolimus	Waickman AT	mTOR, metabolism, and the regulation of T-cell differentiation and function.	Immunological reviews	2012	77
22902833	Sirolimus	Singh BN	Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells.	Biochemical pharmacology	2012	44
22907434	Sirolimus	Du W	ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer.	Oncogene	2013	27
22923433	Sirolimus	Iyer G	Genome sequencing identifies a basis for everolimus sensitivity.	Science	2012	174
22924465	Sirolimus	Maiese K	Targeting disease through novel pathways of apoptosis and autophagy.	Expert opinion on therapeutic targets	2012	48
22958932	Sirolimus	Iglesias-Bartolome R	mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis.	Cell stem cell	2012	91
22980037	Sirolimus	Chong ZZ	Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin.	Progress in neurobiology	2012	49
22983984	Sirolimus	Iwaya T	Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway.	Carcinogenesis	2012	50
22990118	Sirolimus	Woods NT	Charting the landscape of tandem BRCT domain-mediated protein interactions.	Science signaling	2012	36
22994652	Sirolimus	Welker MW	Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.	Transplant international 	2013	35
23026799	Sirolimus	Zou Z	Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells.	Autophagy	2012	45
23123587	Sirolimus	Reith RM	Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex.	Neurobiology of disease	2013	42
23124837	Sirolimus	Hung CM	mTOR-dependent cell survival mechanisms.	Cold Spring Harbor perspectives in biology	2012	34
23152448	Sirolimus	Kaul A	Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner.	Genes & development	2012	33
23158522	Sirolimus	Franz DN	Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.	Lancet	2013	129
23173671	Sirolimus	Cui L	MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma.	BMC cancer	2012	31
23233719	Sirolimus	Wolff AC	Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.	Journal of clinical oncology 	2013	61
23238567	Sirolimus	Ben-Sahra I	Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death.	Cell death and differentiation	2013	38
23246968	Sirolimus	Beauchamp EM	The evolution of the TOR pathway and its role in cancer.	Oncogene	2013	42
23265840	Sirolimus	Maiese K	mTOR: on target for novel therapeutic strategies in the nervous system.	Trends in molecular medicine	2013	61
23271044	Sirolimus	Chiarini F	A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.	Oncotarget	2012	35
23312829	Sirolimus	Bissler JJ	Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.	Lancet	2013	136
23317514	Sirolimus	Cornu M	mTOR in aging, metabolism, and cancer.	Current opinion in genetics & development	2013	151
23319457	Sirolimus	Figlin RA	Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.	International journal of cancer	2013	29
23322078	Sirolimus	Tekirdag KA	MIR181A regulates starvation- and rapamycin-induced autophagy through targeting of ATG5.	Autophagy	2013	39
23431193	Sirolimus	Posch C	Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2013	70
23456430	Sirolimus	Bitting RL	Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.	Endocrine-related cancer	2013	63
23460185	Sirolimus	Alayev A	mTOR signaling for biological control and cancer.	Journal of cellular physiology	2013	36
23532336	Sirolimus	Casado P	Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells.	Science signaling	2013	41
23542178	Sirolimus	Ducker GS	Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.	Oncogene	2014	31
23554977	Sirolimus	Lau MT	Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells.	PloS one	2013	26
23581296	Sirolimus	Sommer EM	Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.	The Biochemical journal	2013	48
23582881	Sirolimus	Templeton AJ	Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).	European urology	2013	27
23601105	Sirolimus	Chang HH	A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity.	Cell host & microbe	2013	32
23624914	Sirolimus	Ye Q	ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.	Oncogene	2014	47
23633493	Sirolimus	Shen C	Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.	Cancer research	2013	30
23635776	Sirolimus	Serra V	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.	The Journal of clinical investigation	2013	28
23641065	Sirolimus	Laplante M	Regulation of mTORC1 and its impact on gene expression at a glance.	Journal of cell science	2013	147
23642907	Sirolimus	Khan KH	Targeting the PI3K-AKT-mTOR signaling network in cancer.	Chinese journal of cancer	2013	31
23643661	Sirolimus	Saini KS	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.	Cancer treatment reviews	2013	78
23644232	Sirolimus	Wong M	Mammalian target of rapamycin (mTOR) pathways in neurological diseases.	Biomedical journal	2013	32
23644661	Sirolimus	Loreni F	Translation factors and ribosomal proteins control tumor onset and progression: how?	Oncogene	2014	25
23671130	Sirolimus	Sun J	Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors.	Carcinogenesis	2013	25
23694989	Sirolimus	Kim SG	Nutrient regulation of the mTOR complex 1 signaling pathway.	Molecules and cells	2013	58
23715582	Sirolimus	Demetri GD	Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.	Journal of clinical oncology 	2013	45
23723238	Sirolimus	Bar-Peled L	A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1.	Science	2013	209
23745794	Sirolimus	Fowles JS	Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.	Veterinary and comparative oncology	2015	16
23778311	Sirolimus	McCubrey JA	Multifaceted roles of GSK-3 and Wnt/Œ≤-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.	Leukemia	2014	41
23792225	Sirolimus	Sun SY	mTOR kinase inhibitors as potential cancer therapeutic drugs.	Cancer letters	2013	46
23803853	Sirolimus	Pourdehnad M	Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers.	Proceedings of the National Academy of Sciences of the United States of America	2013	64
23818547	Sirolimus	Lu J	Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.	Blood	2013	36
23818640	Sirolimus	Meckes DG Jr	Modulation of B-cell exosome proteins by gamma herpesvirus infection.	Proceedings of the National Academy of Sciences of the United States of America	2013	57
23856247	Sirolimus	Cai J	miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer.	Cancer research	2013	44
23863154	Sirolimus	Howell JJ	A growing role for mTOR in promoting anabolic metabolism.	Biochemical Society transactions	2013	55
23872332	Sirolimus	Theodoropoulou M	Somatostatin receptors: from signaling to clinical practice.	Frontiers in neuroendocrinology	2013	35
23892718	Sirolimus	Neri LM	Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.	Leukemia	2014	23
23897969	Sirolimus	Iyer G	Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.	Journal of clinical oncology 	2013	64
23902785	Sirolimus	Op den Kamp CM	Nuclear transcription factor Œ∫ B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia.	The American journal of clinical nutrition	2013	27
23903756	Sirolimus	Elkabets M	mTORC1 inhibition is required for sensitivity to PI3K p110Œ± inhibitors in PIK3CA-mutant breast cancer.	Science translational medicine	2013	76
23911927	Sirolimus	Linares JF	K63 polyubiquitination and activation of mTOR by the p62-TRAF6 complex in nutrient-activated cells.	Molecular cell	2013	55
23929677	Sirolimus	Sinha RA	Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice.	Hepatology	2014	48
23953116	Sirolimus	Thedieck K	Inhibition of mTORC1 by astrin and stress granules prevents apoptosis in cancer cells.	Cell	2013	52
23973332	Sirolimus	Lamming DW	A Central role for mTOR in lipid homeostasis.	Cell metabolism	2013	72
23974099	Sirolimus	Leontieva OV	CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.	Cell cycle	2013	41
24011086	Sirolimus	Tsubaki M	Activation of NF-Œ∫B by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.	Journal of experimental & clinical cancer research 	2013	27
24043745	Sirolimus	Ohtsu A	Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.	Journal of clinical oncology 	2013	92
24092409	Sirolimus	Cabantous S	A new protein-protein interaction sensor based on tripartite split-GFP association.	Scientific reports	2013	29
24120665	Sirolimus	Stumpf CR	The translational landscape of the mammalian cell cycle.	Molecular cell	2013	61
24161930	Sirolimus	Liu P	Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis.	Nature cell biology	2013	72
24185040	Sirolimus	Francipane MG	Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.	Oncotarget	2013	29
24231729	Sirolimus	Matsubara S	mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions.	Scientific reports	2013	28
24270418	Sirolimus	Liu SC	Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance.	The Journal of clinical investigation	2013	29
24308993	Sirolimus	Matter MS	Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.	Journal of hepatology	2014	41
24311635	Sirolimus	Kahn J	The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.	Neuro-oncology	2014	23
24333502	Sirolimus	Polivka J Jr	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.	Pharmacology & therapeutics	2014	89
24336084	Sirolimus	Blagosklonny MV	TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.	Cell death & disease	2013	35
24336570	Sirolimus	Johnson BE	Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.	Science	2014	244
24367102	Sirolimus	Weiler M	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.	Proceedings of the National Academy of Sciences of the United States of America	2014	39
24393708	Sirolimus	Francipane MG	mTOR pathway in colorectal cancer: an update.	Oncotarget	2014	31
24401568	Sirolimus	Liu B	Hepatitis B virus X protein inhibits autophagic degradation by impairing lysosomal maturation.	Autophagy	2014	29
24440717	Sirolimus	Janku F	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.	Cell reports	2014	59
24445654	Sirolimus	Chang L	Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy.	Cancer metastasis reviews	2014	21
24469833	Sirolimus	Mathews Griner LA	High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.	Proceedings of the National Academy of Sciences of the United States of America	2014	73
24470531	Sirolimus	Farid M	Malignant peripheral nerve sheath tumors.	The oncologist	2014	23
24470557	Sirolimus	Wen PY	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.	Neuro-oncology	2014	30
24474794	Sirolimus	Liu X	Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK.	Proceedings of the National Academy of Sciences of the United States of America	2014	68
24480319	Sirolimus	Santoni M	Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma.	Biochimica et biophysica acta	2014	21
24481312	Sirolimus	Fruman DA	PI3K and cancer: lessons, challenges and opportunities.	Nature reviews. Drug discovery	2014	313
24532714	Sirolimus	Tcherkezian J	Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5'TOP mRNA translation.	Genes & development	2014	52
24556063	Sirolimus	Husseinzadeh N	mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.	Gynecologic oncology	2014	25
24590173	Sirolimus	Puustinen P	CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation.	The Journal of cell biology	2014	24
24603303	Sirolimus	Shimizu K	ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.	British journal of cancer	2014	25
24615500	Sirolimus	Rugo HS	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.	Annals of oncology 	2014	24
24631838	Sirolimus	Grabiner BC	A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.	Cancer discovery	2014	83
24685370	Sirolimus	Kaplan B	Strategies for the management of adverse events associated with mTOR inhibitors.	Transplantation reviews	2014	28
24698685	Sirolimus	Bar-Peled L	Regulation of mTORC1 by amino acids.	Trends in cell biology	2014	170
24700142	Sirolimus	Yang N	SOX2 promotes the migration and invasion of laryngeal cancer cells by induction of MMP-2 via the PI3K/Akt/mTOR pathway.	Oncology reports	2014	20
24713927	Sirolimus	Gu Y	MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.	Blood	2014	22
24717934	Sirolimus	Morran DC	Targeting mTOR dependency in pancreatic cancer.	Gut	2014	25
24764583	Sirolimus	Mittendorf EA	PD-L1 expression in triple-negative breast cancer.	Cancer immunology research	2014	102
24777052	Sirolimus	Ocana A	Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.	PloS one	2014	36
24780124	Sirolimus	Moschetta M	Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations.	British journal of pharmacology	2014	25
24791855	Sirolimus	Weisberg E	Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.	Leukemia	2015	18
24818748	Sirolimus	Xu Y	Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence.	Trends in biochemical sciences	2014	34
24841777	Sirolimus	Albiges L	A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.	European urology	2015	30
24863259	Sirolimus	Fumarola C	Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.	Biochemical pharmacology	2014	48
24889617	Sirolimus	Leontieva OV	Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program.	Proceedings of the National Academy of Sciences of the United States of America	2014	44
24900173	Sirolimus	Knight SD	Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.	ACS medicinal chemistry letters	2010	51
24910242	Sirolimus	Umemura A	Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.	Cell metabolism	2014	27
24931163	Sirolimus	Dodd KM	mTORC1 drives HIF-1Œ± and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3.	Oncogene	2015	24
24948110	Sirolimus	Burotto M	The MAPK pathway across different malignancies: a new perspective.	Cancer	2014	56
24954509	Sirolimus	Chou SD	HSF1 regulation of Œ≤-catenin in mammary cancer cells through control of HuR/elavL1 expression.	Oncogene	2015	21
24973821	Sirolimus	Mar√ßais A	The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells.	Nature immunology	2014	73
24990947	Sirolimus	Dan HC	Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IŒ∫B kinase Œ± (IKKŒ±).	The Journal of biological chemistry	2014	22
25037117	Sirolimus	Beck JT	Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.	Cancer treatment reviews	2014	23
25082895	Sirolimus	Cornu M	Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21.	Proceedings of the National Academy of Sciences of the United States of America	2014	34
25086744	Sirolimus	Li H	PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.	Archives of gynecology and obstetrics	2014	23
25115638	Sirolimus	Manfredi GI	PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy.	Endocrine	2015	22
25143389	Sirolimus	Nair V	Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors.	The Journal of biological chemistry	2014	30
25158238	Sirolimus	Dunlop EA	mTOR and autophagy: a dynamic relationship governed by nutrients and energy.	Seminars in cell & developmental biology	2014	67
25175012	Sirolimus	Zhu L	TSC1 controls macrophage polarization to prevent inflammatory disease.	Nature communications	2014	40
25253086	Sirolimus	Jia G	Overnutrition, mTOR signaling, and cardiovascular diseases.	American journal of physiology. Regulatory, integrative and comparative physiology	2014	31
25263562	Sirolimus	Chantranupong L	The Sestrins interact with GATOR2 to negatively regulate the amino-acid-sensing pathway upstream of mTORC1.	Cell reports	2014	83
25275598	Sirolimus	Chang L	PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways.	Cell death & disease	2014	48
25295501	Sirolimus	Wagle N	Response and acquired resistance to everolimus in anaplastic thyroid cancer.	The New England journal of medicine	2014	76
25307878	Sirolimus	Lee DH	Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.	International journal of cancer	2015	23
25344362	Sirolimus	Tolcher AW	A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.	Annals of oncology 	2015	20
25361980	Sirolimus	Treilleux I	Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.	Annals of oncology 	2015	18
25444920	Sirolimus	Zheng B	Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.	Cancer letters	2015	21
25446280	Sirolimus	Wagner LM	Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.	Pediatric blood & cancer	2015	18
25450580	Sirolimus	Xu K	mTOR signaling in tumorigenesis.	Biochimica et biophysica acta	2014	34
25464856	Sirolimus	Staron MM	The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection.	Immunity	2014	66
25477072	Sirolimus	Gao B	Translational control by oncogenic signaling pathways.	Biochimica et biophysica acta	2015	15
25497227	Sirolimus	Chiarini F	Current treatment strategies for inhibiting mTOR in cancer.	Trends in pharmacological sciences	2015	54
25512523	Sirolimus	Perry JA	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.	Proceedings of the National Academy of Sciences of the United States of America	2014	62
25522665	Sirolimus	Pollizzi KN	Regulation of T cells by mTOR: the known knowns and the known unknowns.	Trends in immunology	2015	31
25526733	Sirolimus	Ma DJ	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.	Neuro-oncology	2015	18
25531317	Sirolimus	Siu MK	Transforming growth factor-Œ≤ promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway.	Oncogene	2015	19
25532816	Sirolimus	Simpson DR	Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck.	Oral oncology	2015	21
25534823	Sirolimus	Kaul A	Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.	Neuro-oncology	2015	17
25556614	Sirolimus	Cheaib B	The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.	Chinese journal of cancer	2015	25
25557953	Sirolimus	Cornella H	Unique genomic profile of fibrolamellar hepatocellular carcinoma.	Gastroenterology	2015	20
25561726	Sirolimus	Marchand B	Glycogen synthase kinase-3 (GSK3) inhibition induces prosurvival autophagic signals in human pancreatic cancer cells.	The Journal of biological chemistry	2015	22
25567906	Sirolimus	Wang S	Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1.	Science	2015	152
25590164	Sirolimus	Morita M	mTOR coordinates protein synthesis, mitochondrial activity and proliferation.	Cell cycle	2015	42
25591831	Sirolimus	Curatolo P	Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.	Pediatric neurology	2015	16
25601637	Sirolimus	Kong B	A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.	Gut	2016	14
25657110	Sirolimus	Cao Y	Fibronectin promotes cell proliferation and invasion through mTOR signaling pathway activation in gallbladder cancer.	Cancer letters	2015	19
25677064	Sirolimus	Mabuchi S	The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.	Gynecologic oncology	2015	43
25682869	Sirolimus	Zhu M	Hepatitis B virus X protein induces expression of alpha-fetoprotein and activates PI3K/mTOR signaling pathway in liver cells.	Oncotarget	2015	20
25688110	Sirolimus	Cargnello M	The expanding role of mTOR in cancer cell growth and proliferation.	Mutagenesis	2015	23
25749036	Sirolimus	Yang H	FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells.	Oncotarget	2015	21
25752815	Sirolimus	Chen J	Signaling pathways in HPV-associated cancers and therapeutic implications.	Reviews in medical virology	2015	18
25813405	Sirolimus	Wang Y	CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling.	Cancer letters	2015	45
25834401	Sirolimus	Li JP	The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.	Drug design, development and therapy	2015	20
25844603	Sirolimus	Blagosklonny MV	Rejuvenating immunity: "anti-aging drug today" eight years later.	Oncotarget	2015	17
25877892	Sirolimus	McGranahan N	Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.	Science translational medicine	2015	78
25883264	Sirolimus	Shuda M	CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation.	Proceedings of the National Academy of Sciences of the United States of America	2015	19
25940091	Sirolimus	Fonseca BD	La-related Protein 1 (LARP1) Represses Terminal Oligopyrimidine (TOP) mRNA Translation Downstream of mTOR Complex 1 (mTORC1).	The Journal of biological chemistry	2015	26
25961916	Sirolimus	Shi Y	Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.	Oncogene	2016	14
26028026	Sirolimus	Ricoult SJ	Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP.	Oncogene	2016	24
26067126	Sirolimus	Curatolo P	Neurological and neuropsychiatric aspects of tuberous sclerosis complex.	The Lancet. Neurology	2015	37
26118643	Sirolimus	Egan DF	Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates.	Molecular cell	2015	63
26124089	Sirolimus	Caino MC	PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.	Proceedings of the National Academy of Sciences of the United States of America	2015	32
26156073	Sirolimus	Bissler JJ	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.	Nephrology, dialysis, transplantation 	2016	28
26177599	Sirolimus	Bendell JC	A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.	Cancer	2015	17
26253360	Sirolimus	Chang L	Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.	Critical reviews in oncology/hematology	2015	18
26277543	Sirolimus	Hsieh AL	MYC and metabolism on the path to cancer.	Seminars in cell & developmental biology	2015	31
26280535	Sirolimus	Herranz N	mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype.	Nature cell biology	2015	48
26310906	Sirolimus	Wong PM	Regulation of autophagy by coordinated action of mTORC1 and protein phosphatase 2A.	Nature communications	2015	31
26311737	Sirolimus	Tsai JP	Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.	Oncotarget	2015	22
26364551	Sirolimus	Powles T	A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.	European urology	2016	13
26364608	Sirolimus	Coarfa C	Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.	Oncogene	2016	21
26389641	Sirolimus	Park YY	Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.	Hepatology	2016	14
26476289	Sirolimus	Li L	Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.	Journal of hepatology	2016	12
26517881	Sirolimus	Siddiqui N	Signalling to eIF4E in cancer.	Biochemical Society transactions	2015	27
26540343	Sirolimus	Ji J	LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway.	Oncotarget	2015	33
26543160	Sirolimus	Ye J	GCN2 sustains mTORC1 suppression upon amino acid deprivation by inducing Sestrin2.	Genes & development	2015	34
26563133	Sirolimus	Brunstein CG	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.	Blood	2016	46
26565512	Sirolimus	Qiang L	Autophagy positively regulates DNA damage recognition by nucleotide excision repair.	Autophagy	2016	12
26678875	Sirolimus	Aylett CH	Architecture of human mTOR complex 1.	Science	2016	54
26735353	Sirolimus	Bournet B	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.	European journal of cancer	2016	19
26742086	Sirolimus	Carroll B	Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity.	eLife	2016	22
26779371	Sirolimus	Lee JJ	PI3K/Akt/mTOR inhibitors in breast cancer.	Cancer biology & medicine	2015	29
26818518	Sirolimus	Gentry EG	Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration.	The Journal of neuroscience 	2016	10
26826241	Sirolimus	Goh CC	Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN-Œ≥ Production by Altering Cellular Metabolism via Arginase-1.	Journal of immunology	2016	13
26878385	Sirolimus	Garros-Regulez L	mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.	Expert opinion on therapeutic targets	2016	14
26884601	Sirolimus	Viel S	TGF-Œ≤ inhibits the activation and functions of NK cells by repressing the mTOR pathway.	Science signaling	2016	24
26912861	Sirolimus	Ben-Sahra I	mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle.	Science	2016	59
26917778	Sirolimus	Yun S	4EBP1/c-MYC/PUMA and NF-Œ∫B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.	Blood	2016	12
26927950	Sirolimus	Curatolo P	The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.	Drugs	2016	11
26929424	Sirolimus	Kempf E	KRAS oncogene in lung cancer: focus on molecularly driven clinical trials.	European respiratory review 	2016	12
27076075	Sirolimus	Goberdhan DC	Amino Acid Sensing by mTORC1: Intracellular Transporters Mark the Spot.	Cell metabolism	2016	25
27161823	Sirolimus	Gaubitz C	TORC2 Structure and Function.	Trends in biochemical sciences	2016	29
27217461	Sirolimus	Rugo HS	Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.	Journal of clinical oncology 	2016	21
27226234	Sirolimus	Henske EP	Tuberous sclerosis complex.	Nature reviews. Disease primers	2016	22
27232329	Sirolimus	Welsh SJ	Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?	European journal of cancer	2016	18
27385099	Sirolimus	Zhu YR	The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models.	Oncotarget	2016	15
27465917	Sirolimus	Mao Y	IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.	Blood	2016	16
27503005	Sirolimus	Statz CM	mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review.	Targeted oncology	2017	7
27511728	Sirolimus	Siska PJ	Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia.	Journal of immunology	2016	14
27578176	Sirolimus	Yu JS	Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination.	Development	2016	21
27613521	Sirolimus	French JA	Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.	Lancet	2016	25
27621407	Sirolimus	LoRusso PM	Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.	Journal of clinical oncology 	2016	12
27628078	Sirolimus	McCormack FX	Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.	American journal of respiratory and critical care medicine	2016	13
27663511	Sirolimus	Riedl A	Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses.	Journal of cell science	2017	8
27668290	Sirolimus	Ilagan E	Emerging role of mTOR in the response to cancer therapeutics.	Trends in cancer	2016	19
27671674	Sirolimus	Clark CA	Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.	Cancer research	2016	18
27748764	Sirolimus	Kim LC	mTORC1 and mTORC2 in cancer and the tumor microenvironment.	Oncogene	2017	23
27751729	Sirolimus	Hsieh JJ	Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.	European urology	2017	13
27777238	Sirolimus	Tasian SK	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.	Blood	2017	15
27894091	Sirolimus	Lu XS	Preclinical study of cinobufagin as a promising anti-colorectal cancer agent.	Oncotarget	2017	11
28026112	Sirolimus	Wu J	Matrine induces Akt/mTOR signalling inhibition-mediated autophagy and apoptosis in acute myeloid leukaemia cells.	Journal of cellular and molecular medicine	2017	8
28027327	Sirolimus	Lefebvre C	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.	PLoS medicine	2016	20
28040803	Sirolimus	Tarrado-Castellarnau M	Oncogenic regulation of tumor metabolic reprogramming.	Oncotarget	2016	12
28079894	Sirolimus	Jin F	MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.	Cell death & disease	2017	16
28119806	Sirolimus	Zhao W	Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy.	Acta pharmaceutica Sinica. B	2017	6
28146265	Sirolimus	Calimeri T	m-TOR inhibitors and their potential role in haematological malignancies.	British journal of haematology	2017	7
28162974	Sirolimus	Vila IK	A UBE2O-AMPKŒ±2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy.	Cancer cell	2017	7
28165011	Sirolimus	Palmieri M	mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases.	Nature communications	2017	11
28283069	Sirolimus	Saxton RA	mTOR Signaling in Growth, Metabolism, and Disease.	Cell	2017	128
28292440	Sirolimus	Fan Q	A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.	Cancer cell	2017	7
28336668	Sirolimus	Castellano BM	Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex.	Science	2017	17
28658205	Sirolimus	Zabala-Letona A	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.	Nature	2017	8
11139588	Tamoxifen	Campbell RA	Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.	The Journal of biological chemistry	2001	191
12586780	Tamoxifen	Knowlden JM	Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.	Endocrinology	2003	123
14555514	Tamoxifen	Girault I	Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas.	Clinical cancer research 	2003	80
14701735	Tamoxifen	Zeisig BB	Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.	Molecular and cellular biology	2004	120
15197194	Tamoxifen	Metcalfe K	Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2004	113
15613444	Tamoxifen	Ring A	Mechanisms of tamoxifen resistance.	Endocrine-related cancer	2004	142
15756033	Tamoxifen	Cohen BD	Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.	Clinical cancer research 	2005	86
16088978	Tamoxifen	Kirkegaard T	AKT activation predicts outcome in breast cancer patients treated with tamoxifen.	The Journal of pathology	2005	76
16333527	Tamoxifen	Hiscox S	Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.	Breast cancer research and treatment	2006	66
16361630	Tamoxifen	Goetz MP	Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.	Journal of clinical oncology 	2005	166
16382061	Tamoxifen	Breast International Group (BIG) 1-98 Collaborative Group.	A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.	The New England journal of medicine	2005	307
16550168	Tamoxifen	Rodriguez-Antona C	Cytochrome P450 pharmacogenetics and cancer.	Oncogene	2006	95
16815318	Tamoxifen	Borges S	Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.	Clinical pharmacology and therapeutics	2006	117
16888645	Tamoxifen	Obexer P	FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells.	Cell death and differentiation	2007	62
17200148	Tamoxifen	Coates AS	Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.	Journal of clinical oncology 	2007	182
17417639	Tamoxifen	Holst F	Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.	Nature genetics	2007	77
17721435	Tamoxifen	Green KA	Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state.	Nature reviews. Cancer	2007	78
17993229	Tamoxifen	Gonzalez-Angulo AM	Overview of resistance to systemic therapy in patients with breast cancer.	Advances in experimental medicine and biology	2007	197
18001838	Tamoxifen	Ingelman-Sundberg M	Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.	Pharmacology & therapeutics	2007	161
18193062	Tamoxifen	Kouzine F	The functional response of upstream DNA to dynamic supercoiling in vivo.	Nature structural & molecular biology	2008	121
18458534	Tamoxifen	Mercier I	Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy.	Cancer biology & therapy	2008	53
18676830	Tamoxifen	Stemke-Hale K	An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.	Cancer research	2008	316
19005469	Tamoxifen	Hurtado A	Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.	Nature	2008	102
19074892	Tamoxifen	Law JH	Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.	Cancer research	2008	118
19139166	Tamoxifen	Pauklin S	Estrogen directly activates AID transcription and function.	The Journal of experimental medicine	2009	57
19549922	Tamoxifen	Lin BC	Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation.	Cancer research	2009	47
19657382	Tamoxifen	Hu G	Human disease-drug network based on genomic expression profiles.	PloS one	2009	95
19685490	Tamoxifen	L√≥pez-Knowles E	PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.	International journal of cancer	2010	66
19692688	Tamoxifen	BIG 1-98 Collaborative Group.	Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.	The New England journal of medicine	2009	106
19809024	Tamoxifen	Schroth W	Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.	JAMA	2009	118
20124171	Tamoxifen	Kiyotani K	Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.	Journal of clinical oncology 	2010	49
20215537	Tamoxifen	Cristofanilli M	Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.	Clinical cancer research 	2010	40
20224296	Tamoxifen	Dalby KN	Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer.	Autophagy	2010	135
20495363	Tamoxifen	Bonuccelli G	The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts.	Cell cycle	2010	73
21098263	Tamoxifen	Fillmore CM	Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling.	Proceedings of the National Academy of Sciences of the United States of America	2010	94
21150282	Tamoxifen	Trimmer C	Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts.	Cancer biology & therapy	2011	47
21393507	Tamoxifen	Shi W	MicroRNA-301 mediates proliferation and invasion in human breast cancer.	Cancer research	2011	72
21559019	Tamoxifen	Jerevall PL	Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.	British journal of cancer	2011	38
21768473	Tamoxifen	Irvin WJ Jr	Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.	Journal of clinical oncology 	2011	38
21922245	Tamoxifen	Livaudais JC	Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.	Breast cancer research and treatment	2012	30
22018631	Tamoxifen	Regan MM	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8¬∑1 years median follow-up.	The Lancet. Oncology	2011	73
22318280	Tamoxifen	van de Water W	Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.	JAMA	2012	32
22395644	Tamoxifen	Regan MM	CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.	Journal of the National Cancer Institute	2012	76
22508479	Tamoxifen	Ward A	Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer.	Oncogene	2013	73
22689091	Tamoxifen	Murphy CC	Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.	Breast cancer research and treatment	2012	83
23091108	Tamoxifen	Brauch H	Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.	Journal of clinical oncology 	2013	28
23143302	Tamoxifen	Nishio M	Cancer susceptibility and embryonic lethality in Mob1a/1b double-mutant mice.	The Journal of clinical investigation	2012	37
23292282	Tamoxifen	Muscat GE	Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer.	Molecular endocrinology	2013	27
23589310	Tamoxifen	Khurana SS	The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric epithelial progenitor cell proliferation.	The Journal of biological chemistry	2013	32
23968733	Tamoxifen	Hoppe R	Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.	European journal of cancer	2013	31
24746818	Tamoxifen	Luo X	Isolation and molecular characterization of circulating melanoma cells.	Cell reports	2014	32
24868023	Tamoxifen	Burstein HJ	Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.	Journal of clinical oncology 	2014	119
25007959	Tamoxifen	Wei Y	Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.	Breast cancer research and treatment	2014	39
25220225	Tamoxifen	Cheng SM	YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells.	British journal of pharmacology	2015	18
25332252	Tamoxifen	Sestak I	Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.	Journal of clinical oncology 	2015	28
25433206	Tamoxifen	Huang B	Estrogen receptors in breast carcinogenesis and endocrine therapy.	Molecular and cellular endocrinology	2015	29
25792709	Tamoxifen	Gougelet A	Antitumour activity of an inhibitor of miR-34a in liver cancer with Œ≤-catenin-mutations.	Gut	2016	13
25935792	Tamoxifen	Gnant M	Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.	Annals of oncology 	2015	15
25939896	Tamoxifen	Coates AS	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.	Annals of oncology 	2015	194
26092816	Tamoxifen	Bernhard J	Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.	The Lancet. Oncology	2015	21
26122181	Tamoxifen	Jeselsohn R	ESR1 mutations‚Äîa mechanism for acquired endocrine resistance in breast cancer.	Nature reviews. Clinical oncology	2015	45
26342236	Tamoxifen	Le Tourneau C	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.	The Lancet. Oncology	2015	94
26538583	Tamoxifen	Tran KA	Endothelial Œ≤-Catenin Signaling Is Required for Maintaining Adult Blood-Brain Barrier Integrity and Central Nervous System Homeostasis.	Circulation	2016	11
27264120	Tamoxifen	Goss PE	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.	The New England journal of medicine	2016	38
27521269	Tamoxifen	Schietinger A	Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.	Immunity	2016	20
27986463	Tamoxifen	Muluhngwi P	Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.	Cancer letters	2017	6
28063065	Tamoxifen	Zhang HY	Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205.	Cancer chemotherapy and pharmacology	2017	8
28063929	Tamoxifen	Chen MJ	MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM.	Biochemical and biophysical research communications	2017	6
28238593	Tamoxifen	Llombart-Cussac A	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.	The Lancet. Oncology	2017	8
28355176	Tamoxifen	Shimokawa M	Visualization and targeting of LGR5+ human colon cancer stem cells.	Nature	2017	23
1946433	Cytosine	Brash DE	A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	1991	261
9041175	Cytosine	Kane MF	Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines.	Cancer research	1997	308
11385577	Cytosine	Ogura Y	A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.	Nature	2001	997
12021783	Cytosine	Futscher BW	Role for DNA methylation in the control of cell type specific maspin expression.	Nature genetics	2002	101
12138111	Cytosine	Chen T	A novel Dnmt3a isoform produced from an alternative promoter localizes to euchromatin and its expression correlates with active de novo methylation.	The Journal of biological chemistry	2002	95
15324698	Cytosine	Cheng JC	Preferential response of cancer cells to zebularine.	Cancer cell	2004	71
15852235	Cytosine	Schmidt LS	Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dub√© syndrome.	American journal of human genetics	2005	88
16025112	Cytosine	Ting AH	Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation.	Nature genetics	2005	88
16204030	Cytosine	Karpf AR	Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells.	Cancer research	2005	77
16423997	Cytosine	Jair KW	De novo CpG island methylation in human cancer cells.	Cancer research	2006	62
16707479	Cytosine	Yang AS	DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.	Cancer research	2006	79
17283125	Cytosine	Valinluck V	Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1.	Cancer research	2007	169
17991895	Cytosine	Palii SS	DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.	Molecular and cellular biology	2008	99
18555005	Cytosine	Wang R	Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues.	Biochemical and biophysical research communications	2008	65
19047171	Cytosine	Jiang L	Global hypomethylation of genomic DNA in cancer-associated myofibroblasts.	Cancer research	2008	58
19303358	Cytosine	Liu M	Balancing AID and DNA repair during somatic hypermutation.	Trends in immunology	2009	70
20101446	Cytosine	Veeck J	Breast cancer epigenetics: from DNA methylation to microRNAs.	Journal of mammary gland biology and neoplasia	2010	50
20570896	Cytosine	Lin RK	Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer.	Cancer research	2010	50
21321201	Cytosine	Shock LS	DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria.	Proceedings of the National Academy of Sciences of the United States of America	2011	119
21844352	Cytosine	You JS	OCT4 establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic regulation of its target genes.	Proceedings of the National Academy of Sciences of the United States of America	2011	41
22511653	Cytosine	Breitling LP	Smoking, F2RL3 methylation, and prognosis in stable coronary heart disease.	European heart journal	2012	42
22722201	Cytosine	Stephens PJ	The landscape of cancer genes and mutational processes in breast cancer.	Nature	2012	500
22829908	Cytosine	Orr BA	Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma.	PloS one	2012	44
22980977	Cytosine	Lian CG	Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma.	Cell	2012	195
22999938	Cytosine	Hsu CH	TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases.	Cell reports	2012	78
23098078	Cytosine	Johnson AA	The role of DNA methylation in aging, rejuvenation, and age-related disease.	Rejuvenation research	2012	43
23249472	Cytosine	Lada AG	AID/APOBEC cytosine deaminase induces genome-wide kataegis.	Biology direct	2012	38
23382536	Cytosine	Hiatt JB	Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation.	Genome research	2013	81
23640996	Cytosine	Abdel-Wahab O	Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.	Blood	2013	47
23913415	Cytosine	Sharma S	Yeast Nop2 and Rcm1 methylate C2870 and C2278 of the 25S rRNA, respectively.	Nucleic acids research	2013	37
24134914	Cytosine	Bronner C	Increasing role of UHRF1 in the reading and inheritance of the epigenetic code as well as in tumorogenesis.	Biochemical pharmacology	2013	27
24373966	Cytosine	Madzo J	Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis.	Cell reports	2014	30
24910434	Cytosine	Henderson S	APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development.	Cell reports	2014	66
25063673	Cytosine	Blanco S	Aberrant methylation of tRNAs links cellular stress to neuro-developmental disorders.	The EMBO journal	2014	71
25411794	Cytosine	Refsland EW	Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.	PLoS genetics	2014	27
25425670	Cytosine	Gawad C	Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics.	Proceedings of the National Academy of Sciences of the United States of America	2014	46
25818029	Cytosine	Harris RS	APOBECs and virus restriction.	Virology	2015	62
25893293	Cytosine	Fan H	Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2.	Oncogene	2016	12
26091828	Cytosine	Swanton C	APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.	Cancer discovery	2015	56
26199412	Cytosine	Kang J	Simultaneous deletion of the methylcytosine oxidases Tet1 and Tet3 increases transcriptome variability in early embryogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2015	18
26420215	Cytosine	Leonard B	The PKC/NF-Œ∫B signaling pathway induces APOBEC3B expression in multiple human cancers.	Cancer research	2015	20
26436839	Cytosine	Okoye-Okafor UC	New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.	Nature chemical biology	2015	25
26586431	Cytosine	Zhao Z	Combined Loss of Tet1 and Tet2 Promotes B Cell, but Not Myeloid Malignancies, in Mice.	Cell reports	2015	22
27036965	Cytosine	Rasmussen KD	Role of TET enzymes in DNA methylation, development, and cancer.	Genes & development	2016	42
28471683	Cytosine	Brown RV	The Consequences of Overlapping G-Quadruplexes and i-Motifs in the Platelet-Derived Growth Factor Receptor Œ≤ Core Promoter Nuclease Hypersensitive Element Can Explain the Unexpected Effects of Mutations and Provide Opportunities for Selective Targeting of Both Structures by Small Molecules To Downregulate Gene Expression.	Journal of the American Chemical Society	2017	6
10029595	Melphalan	Damiano JS	Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.	Blood	1999	166
16530576	Melphalan	Palumbo A	Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.	Lancet	2006	102
18505783	Melphalan	Palumbo A	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.	Blood	2008	64
20368561	Melphalan	Mateos MV	Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.	Journal of clinical oncology 	2010	82
20739218	Melphalan	Mateos MV	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.	The Lancet. Oncology	2010	96
20940200	Melphalan	Palumbo A	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.	Journal of clinical oncology 	2010	73
21795746	Melphalan	Mailankody S	Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).	Blood	2011	38
24449241	Melphalan	Palumbo A	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.	Journal of clinical oncology 	2014	31
24833354	Melphalan	San-Miguel J	Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.	Blood	2014	21
26352815	Melphalan	Garfall AL	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.	The New England journal of medicine	2015	85
28295190	Melphalan	Shah N	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.	British journal of haematology	2017	5
12486230	Acetaldehyde	Duncan T	Reversal of DNA alkylation damage by two human dioxygenases.	Proceedings of the National Academy of Sciences of the United States of America	2002	120
15099407	Acetaldehyde	Crabb DW	Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology.	The Proceedings of the Nutrition Society	2004	86
15917471	Acetaldehyde	Pearce DJ	Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples.	Stem cells	2005	88
17116430	Acetaldehyde	Hazra TK	Oxidative DNA damage repair in mammalian cells: a new perspective.	DNA repair	2007	76
17920722	Acetaldehyde	Patel M	ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors.	Lung cancer	2008	61
18573038	Acetaldehyde	Douville J	ALDH1 as a functional marker of cancer stem and progenitor cells.	Stem cells and development	2009	97
18591932	Acetaldehyde	Korkaya H	HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.	Oncogene	2008	211
18790753	Acetaldehyde	Feldmann G	An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.	Molecular cancer therapeutics	2008	89
19072981	Acetaldehyde	Chu P	Characterization of a subpopulation of colon cancer cells with stem cell-like properties.	International journal of cancer	2009	51
19075754	Acetaldehyde	Moreb JS	Aldehyde dehydrogenase as a marker for stem cells.	Current stem cell research & therapy	2008	79
19188663	Acetaldehyde	Jones RJ	Circulating clonotypic B cells in classic Hodgkin lymphoma.	Blood	2009	56
19251410	Acetaldehyde	Chuthapisith S	Breast cancer chemoresistance: emerging importance of cancer stem cells.	Surgical oncology	2010	41
19258443	Acetaldehyde	Mullendore ME	Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer.	Clinical cancer research 	2009	67
19276181	Acetaldehyde	Jiang F	Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.	Molecular cancer research 	2009	235
19450560	Acetaldehyde	Chen YC	Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer.	Biochemical and biophysical research communications	2009	124
19509181	Acetaldehyde	Tanei T	Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.	Clinical cancer research 	2009	149
20010854	Acetaldehyde	Li T	ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome.	Laboratory investigation; a journal of technical methods and pathology	2010	111
20019840	Acetaldehyde	Vesuna F	Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression.	Neoplasia	2009	66
20028757	Acetaldehyde	Charafe-Jauffret E	Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.	Clinical cancer research 	2010	238
20142235	Acetaldehyde	Su Y	Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer.	Cancer epidemiology, biomarkers & prevention 	2010	69
20309879	Acetaldehyde	Wang L	Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity.	International journal of cancer	2011	37
20422001	Acetaldehyde	Deng S	Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.	PloS one	2010	153
20606680	Acetaldehyde	Lugli A	Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.	British journal of cancer	2010	67
20716638	Acetaldehyde	Keysar SB	More than markers: biological significance of cancer stem cell-defining molecules.	Molecular cancer therapeutics	2010	65
20959469	Acetaldehyde	Todaro M	Tumorigenic and metastatic activity of human thyroid cancer stem cells.	Cancer research	2010	60
21103958	Acetaldehyde	Ma I	The role of human aldehyde dehydrogenase in normal and cancer stem cells.	Stem cell reviews	2011	126
21224357	Acetaldehyde	Liu S	Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks.	Cancer research	2011	167
21280157	Acetaldehyde	Marcato P	Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis.	Stem cells	2011	129
21281815	Acetaldehyde	Lindgren D	Isolation and characterization of progenitor-like cells from human renal proximal tubules.	The American journal of pathology	2011	60
21304586	Acetaldehyde	Chen C	Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma.	PloS one	2011	79
21304978	Acetaldehyde	Shankar S	Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition.	PloS one	2011	79
21437268	Acetaldehyde	McKay JD	A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium.	PLoS genetics	2011	63
21552008	Acetaldehyde	Marcato P	Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform.	Cell cycle	2011	135
21695188	Acetaldehyde	Kim MP	ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.	PloS one	2011	105
21856769	Acetaldehyde	Visus C	Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8‚Å∫ T cells.	Clinical cancer research 	2011	48
21900397	Acetaldehyde	Lin L	STAT3 is necessary for proliferation and survival in colon cancer-initiating cells.	Cancer research	2011	70
22020330	Acetaldehyde	Canino C	SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells.	Oncogene	2012	33
22070916	Acetaldehyde	Zhang Z	The biology of head and neck cancer stem cells.	Oral oncology	2012	31
22102611	Acetaldehyde	Sarrio D	Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties.	Stem cells	2012	45
22124327	Acetaldehyde	Sun XX	Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1.	The EMBO journal	2012	48
22131125	Acetaldehyde	Eirew P	Aldehyde dehydrogenase activity is a biomarker of primitive normal human mammary luminal cells.	Stem cells	2012	34
22162267	Acetaldehyde	Tang AL	UM-SCC-104: a new human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoma cell line.	Head & neck	2012	32
22222226	Acetaldehyde	Wang YC	ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome.	The American journal of pathology	2012	53
22262762	Acetaldehyde	Gerber JM	A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.	Blood	2012	68
22438320	Acetaldehyde	Germann M	Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer.	Stem cells	2012	35
22730244	Acetaldehyde	Santini R	Hedgehog-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells.	Stem cells	2012	43
22733132	Acetaldehyde	Gong C	Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-like/progenitor cells.	Oncogene	2013	65
22846863	Acetaldehyde	Ji J	Clinical implications of cancer stem cell biology in hepatocellular carcinoma.	Seminars in oncology	2012	58
22887839	Acetaldehyde	Luo Y	ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.	Stem cells	2012	72
22890301	Acetaldehyde	Ho PL	Normal and neoplastic urothelial stem cells: getting to the root of the problem.	Nature reviews. Urology	2012	39
23091114	Acetaldehyde	Duru N	HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.	Clinical cancer research 	2012	47
23539445	Acetaldehyde	Xu C	Œ≤-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma.	Cancer research	2013	29
23586700	Acetaldehyde	Alamgeer M	Cancer stem cells in lung cancer: Evidence and controversies.	Respirology	2013	40
23721823	Acetaldehyde	Januchowski R	The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2013	31
23762304	Acetaldehyde	Kuroda T	ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis.	PloS one	2013	29
23975425	Acetaldehyde	Qian X	N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties.	Oncogene	2014	33
24037726	Acetaldehyde	Hira A	Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients.	Blood	2013	30
24043631	Acetaldehyde	Alam M	MUC1-C oncoprotein activates ERK‚ÜíC/EBPŒ≤ signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells.	The Journal of biological chemistry	2013	29
24116047	Acetaldehyde	Ueda K	Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line.	PloS one	2013	31
24129237	Acetaldehyde	Suman S	Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells.	British journal of cancer	2013	31
24201124	Acetaldehyde	Yang L	ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma.	Modern pathology 	2014	25
24210755	Acetaldehyde	Ajani JA	ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients.	Molecular oncology	2014	25
24225944	Acetaldehyde	Kanakry CG	Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide.	Science translational medicine	2013	55
24511467	Acetaldehyde	Liu S	Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts.	Stem cell reports	2014	177
24615157	Acetaldehyde	Liu L	Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-Œ∫B downregulation.	International journal of cancer	2014	29
24652403	Acetaldehyde	Panni RZ	Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer.	Cancer immunology, immunotherapy 	2014	28
24681955	Acetaldehyde	Santini R	SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells.	Oncogene	2014	48
24709421	Acetaldehyde	N√∂r C	Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.	Neoplasia	2014	37
24907115	Acetaldehyde	Shao C	Essential role of aldehyde dehydrogenase 1A3 for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway.	Clinical cancer research 	2014	34
25106087	Acetaldehyde	Marcato P	Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling.	Molecular oncology	2015	19
25150980	Acetaldehyde	Shimoda M	Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state.	Nature cell biology	2014	29
25151964	Acetaldehyde	Zhao D	VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.	Oncogene	2015	36
25155611	Acetaldehyde	Oberbeck N	Maternal aldehyde elimination during pregnancy preserves the fetal genome.	Molecular cell	2014	21
25670168	Acetaldehyde	Cojoc M	Aldehyde Dehydrogenase Is Regulated by Œ≤-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells.	Cancer research	2015	30
25827713	Acetaldehyde	Thiagarajan PS	Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer.	Stem cells	2015	18
25979230	Acetaldehyde	James MI	Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy.	Cancer letters	2015	16
26421710	Acetaldehyde	Farnie G	High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.	Oncotarget	2015	30
26458814	Acetaldehyde	Yang MC	Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine.	Molecular cancer	2015	25
26783961	Acetaldehyde	Tomita H	Aldehyde dehydrogenase 1A1 in stem cells and cancer.	Oncotarget	2016	47
27270422	Acetaldehyde	Lu J	MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1.	Oncogene	2017	8
27634934	Acetaldehyde	Keysar SB	Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.	Journal of the National Cancer Institute	2017	8
15169807	Carboplatin	Johnson DH	Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.	Journal of clinical oncology 	2004	314
15501983	Carboplatin	Mondesire WH	Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.	Clinical cancer research 	2004	91
16043828	Carboplatin	Eberhard DA	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.	Journal of clinical oncology 	2005	363
16129365	Carboplatin	Berthold F	Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.	The Lancet. Oncology	2005	70
16782917	Carboplatin	Robert N	Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.	Journal of clinical oncology 	2006	97
17140455	Carboplatin	Liu G	Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.	Molecular cancer	2006	509
17167137	Carboplatin	Sandler A	Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.	The New England journal of medicine	2006	1259
17925555	Carboplatin	Appleton K	Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.	Journal of clinical oncology 	2007	61
18264088	Carboplatin	Edwards SL	Resistance to therapy caused by intragenic deletion in BRCA2.	Nature	2008	233
18281656	Carboplatin	Edelman MJ	Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.	Journal of clinical oncology 	2008	70
18316562	Carboplatin	Dowlati A	Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.	Clinical cancer research 	2008	82
18612151	Carboplatin	Hirsch FR	Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.	Journal of clinical oncology 	2008	70
18936474	Carboplatin	Heymach JV	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2008	59
19692680	Carboplatin	Mok TS	Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.	The New England journal of medicine	2009	1723
19884554	Carboplatin	Reynolds C	Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.	Journal of clinical oncology 	2009	54
19917840	Carboplatin	Kies MS	Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.	Journal of clinical oncology 	2010	40
20085937	Carboplatin	Dahlberg SE	Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.	Journal of clinical oncology 	2010	54
20100958	Carboplatin	Khambata-Ford S	Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	65
20159815	Carboplatin	Soria JC	Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer.	Journal of clinical oncology 	2010	47
20952506	Carboplatin	Chen Z	Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.	Cancer research	2010	71
21051560	Carboplatin	Leskel√§ S	The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.	Endocrine-related cancer	2011	63
21102589	Carboplatin	Gualberto A	Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.	British journal of cancer	2011	37
21115860	Carboplatin	Valero V	Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.	Journal of clinical oncology 	2011	52
21183737	Carboplatin	Drew Y	Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.	Journal of the National Cancer Institute	2011	72
21555682	Carboplatin	Blumenschein GR Jr	Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.	Journal of clinical oncology 	2011	46
21618519	Carboplatin	Boyerinas B	Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.	International journal of cancer	2012	43
21670455	Carboplatin	Fukuoka M	Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).	Journal of clinical oncology 	2011	326
21900837	Carboplatin	Goto K	Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.	Journal of thoracic oncology 	2012	58
22010015	Carboplatin	Soria JC	Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	62
22011650	Carboplatin	Thongprasert S	Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).	Journal of thoracic oncology 	2011	35
22048815	Carboplatin	Weigman VJ	Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.	Breast cancer research and treatment	2012	43
22204724	Carboplatin	Burger RA	Incorporation of bevacizumab in the primary treatment of ovarian cancer.	The New England journal of medicine	2011	349
22204725	Carboplatin	Perren TJ	A phase 3 trial of bevacizumab in ovarian cancer.	The New England journal of medicine	2011	329
22665533	Carboplatin	Carey LA	TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.	Journal of clinical oncology 	2012	122
22753922	Carboplatin	Scagliotti GV	International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.	Journal of clinical oncology 	2012	51
22858559	Carboplatin	Reck M	Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.	Annals of oncology 	2013	101
23483678	Carboplatin	Vonderheide RH	Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.	Oncoimmunology	2013	34
24336327	Carboplatin	Li A	SALL4 is a new target in endometrial cancer.	Oncogene	2015	19
24888810	Carboplatin	Langer CJ	Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2014	45
25446896	Carboplatin	Ruffell B	Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.	Cancer cell	2014	85
25534375	Carboplatin	Denkert C	Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.	Journal of clinical oncology 	2015	123
25605928	Carboplatin	Heist RS	Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2015	29
25867061	Carboplatin	Xue J	MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.	Oncogene	2016	16
25893298	Carboplatin	He Y	Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.	Oncogene	2016	11
26025631	Carboplatin	Brozovic A	The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.	Molecular oncology	2015	15
26216383	Carboplatin	Dijkgraaf EM	A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-Œ±2b in patients with recurrent epithelial ovarian cancer.	Annals of oncology 	2015	19
26647384	Carboplatin	Rafehi S	TGFŒ≤ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids.	Endocrine-related cancer	2016	12
26928463	Carboplatin	Kumar A	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer.	Nature medicine	2016	55
27039845	Carboplatin	Noonan AM	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.	Molecular therapy 	2016	13
27406347	Carboplatin	Rugo HS	Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.	The New England journal of medicine	2016	40
27569215	Carboplatin	Bliss SA	Mesenchymal Stem Cell-Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow.	Cancer research	2016	20
27643638	Carboplatin	Svensson RU	Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models.	Nature medicine	2016	28
9918209	Curcumin	Wang W	The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.	Clinical cancer research 	1999	151
16387689	Curcumin	Shishodia S	Curcumin: getting back to the roots.	Annals of the New York Academy of Sciences	2005	90
17439648	Curcumin	Bisht S	Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy.	Journal of nanobiotechnology	2007	146
18577686	Curcumin	Kasinski AL	Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin.	Molecular pharmacology	2008	57
18834508	Curcumin	Sa G	Anti cancer effects of curcumin: cycle of life and death.	Cell division	2008	51
18844852	Curcumin	Haussler MR	Vitamin D receptor: molecular signaling and actions of nutritional ligands in disease prevention.	Nutrition reviews	2008	71
19278222	Curcumin	Ganta S	Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells.	Molecular pharmaceutics	2009	66
20215512	Curcumin	Lin L	Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.	Cancer research	2010	73
22637745	Curcumin	Soubani O	Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer.	Carcinogenesis	2012	30
22952749	Curcumin	Bao B	Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.	PloS one	2012	43
22992310	Curcumin	Roy S	Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF.	Journal of hematology & oncology	2012	44
23548270	Curcumin	Yu CC	miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.	Cancer research	2013	40
23894315	Curcumin	Roy S	Difluorinated-curcumin (CDF) restores PTEN expression in colon cancer cells by down-regulating miR-21.	PloS one	2013	27
25542083	Curcumin	Zanotto-Filho A	Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas.	Cancer letters	2015	23
25547723	Curcumin	Aggarwal BB	Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses.	Molecules	2014	20
25945832	Curcumin	Raninga PV	Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma.	Oncotarget	2015	18
26116834	Curcumin	Taverna S	Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21.	Oncotarget	2015	15
26703799	Curcumin	Suresh R	The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.	Advances in experimental medicine and biology	2016	14
27866850	Curcumin	Lim SO	Deubiquitination and Stabilization of PD-L1 by CSN5.	Cancer cell	2016	18
11426655	Temsirolimus	Hidalgo M	The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.	Oncogene	2000	113
15136596	Temsirolimus	Raymond E	Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.	Journal of clinical oncology 	2004	88
15728109	Temsirolimus	Vignot S	mTOR-targeted therapy of cancer with rapamycin derivatives.	Annals of oncology 	2005	126
16012795	Temsirolimus	Chang SM	Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.	Investigational new drugs	2005	94
16227402	Temsirolimus	Shi Y	Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.	Molecular cancer therapeutics	2005	126
17158546	Temsirolimus	Motzer RJ	Targeted therapy for metastatic renal cell carcinoma.	Journal of clinical oncology 	2006	67
20234352	Temsirolimus	Dancey J	mTOR signaling and drug development in cancer.	Nature reviews. Clinical oncology	2010	110
20940415	Temsirolimus	P√©rez-Gal√°n P	Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.	Blood	2011	89
21346036	Temsirolimus	Hutson TE	Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.	The oncologist	2011	48
21547705	Temsirolimus	Carew JS	Mechanisms of mTOR inhibitor resistance in cancer therapy.	Targeted oncology	2011	37
21690471	Temsirolimus	Spunt SL	Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.	Journal of clinical oncology 	2011	36
22056247	Temsirolimus	Rini BI	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.	Lancet	2011	329
22848625	Temsirolimus	Bray K	Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition.	PloS one	2012	46
23375551	Temsirolimus	Martelli M	Diffuse large B-cell lymphoma.	Critical reviews in oncology/hematology	2013	50
23477833	Temsirolimus	Schwartz GK	Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2013	46
23674493	Temsirolimus	Weigelt B	PI3K pathway dependencies in endometrioid endometrial cancer cell lines.	Clinical cancer research 	2013	33
23744866	Temsirolimus	Lauring J	The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.	Journal of the National Comprehensive Cancer Network 	2013	27
24422672	Temsirolimus	Subbiah V	Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.	Journal of hematology & oncology	2014	21
24991838	Temsirolimus	Rangwala R	Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.	Autophagy	2014	91
25724518	Temsirolimus	McKay RR	Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.	Clinical cancer research 	2015	16
11581376	Plerixafor	Gorry PR	Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity.	Journal of virology	2001	124
12220670	Plerixafor	Hatse S	Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.	FEBS letters	2002	111
12384559	Plerixafor	Scotton CJ	Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.	Cancer research	2002	118
15020611	Plerixafor	Devine SM	Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.	Journal of clinical oncology 	2004	89
15087398	Plerixafor	Tavor S	CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.	Cancer research	2004	78
15548713	Plerixafor	Marchesi F	Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4.	Cancer research	2004	91
15574767	Plerixafor	Smith MC	CXCR4 regulates growth of both primary and metastatic breast cancer.	Cancer research	2004	213
16489019	Plerixafor	Yasumoto K	Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.	Cancer research	2006	62
17119115	Plerixafor	Alsayed Y	Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.	Blood	2007	116
17893878	Plerixafor	Kajiyama H	Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.	International journal of cancer	2008	79
18043246	Plerixafor	Broxmeyer HE	Chemokines in hematopoiesis.	Current opinion in hematology	2008	52
18426988	Plerixafor	Devine SM	Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.	Blood	2008	74
18987663	Plerixafor	Burger JA	CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers.	Leukemia	2009	116
19588204	Plerixafor	Matsusue R	Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis.	Annals of surgical oncology	2009	45
19720922	Plerixafor	DiPersio JF	Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.	Journal of clinical oncology 	2009	102
19837984	Plerixafor	Kofuku Y	Structural basis of the interaction between chemokine stromal cell-derived factor-1/CXCL12 and its G-protein-coupled receptor CXCR4.	The Journal of biological chemistry	2009	49
20631066	Plerixafor	Kozin SV	Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation.	Cancer research	2010	82
21045835	Plerixafor	Singh S	CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.	British journal of cancer	2010	59
21349998	Plerixafor	Duda DG	CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?	Clinical cancer research 	2011	124
21618540	Plerixafor	Ping YF	The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling.	The Journal of pathology	2011	52
21699506	Plerixafor	Scholten DJ	Pharmacological modulation of chemokine receptor function.	British journal of pharmacology	2012	51
21742774	Plerixafor	Righi E	CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.	Cancer research	2011	51
22045709	Plerixafor	Gourni E	PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.	Journal of nuclear medicine 	2011	38
22370645	Plerixafor	Jung MJ	Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells.	Oncogene	2013	54
22648473	Plerixafor	Zhang Q	A microfluidic-based device for study of transendothelial invasion of tumor aggregates in realtime.	Lab on a chip	2012	31
22871210	Plerixafor	Zhang SS	CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients.	BMC medicine	2012	46
24157575	Plerixafor	Gatti M	Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity.	Toxicology	2013	27
24277834	Plerixafor	Feig C	Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.	Proceedings of the National Academy of Sciences of the United States of America	2013	169
25444927	Plerixafor	Guan G	The HIF-1Œ±/CXCR4 pathway supports hypoxia-induced metastasis of human osteosarcoma cells.	Cancer letters	2015	16
26414794	Plerixafor	Izumi D	CXCL12/CXCR4 activation by cancer-associated fibroblasts promotes integrin Œ≤1 clustering and invasiveness in gastric cancer.	International journal of cancer	2016	11
26517945	Plerixafor	Fontanella R	A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion.	Cancer letters	2016	10
26851944	Plerixafor	Teng F	Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.	Journal of hematology & oncology	2016	14
8379464	Hyaluronan	Lesley J	CD44 and its interaction with extracellular matrix.	Advances in immunology	1993	160
9887098	Hyaluronan	Yu Q	Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion.	Genes & development	1999	145
11325633	Hyaluronan	Pur√© E	A crucial role for CD44 in inflammation.	Trends in molecular medicine	2001	93
11731267	Hyaluronan	Csoka AB	The six hyaluronidase-like genes in the human and mouse genomes.	Matrix biology 	2001	112
15047232	Hyaluronan	Burleson KM	Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers.	Gynecologic oncology	2004	81
15784621	Hyaluronan	Misra S	Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2.	The Journal of biological chemistry	2005	67
17055233	Hyaluronan	Slevin M	Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways.	Matrix biology 	2007	86
17079438	Hyaluronan	G√∂tte M	Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective.	Cancer research	2006	100
17493932	Hyaluronan	Bourguignon LY	Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration.	The Journal of biological chemistry	2007	60
18547053	Hyaluronan	Platt VM	Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor.	Molecular pharmaceutics	2008	52
19047049	Hyaluronan	Bourguignon LY	Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells.	The Journal of biological chemistry	2009	51
19218337	Hyaluronan	Bharadwaj AG	Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing.	The American journal of pathology	2009	52
20008845	Hyaluronan	Toole BP	Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities.	Clinical cancer research 	2009	90
21278789	Hyaluronan	Kwak HJ	Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas.	Oncogene	2011	38
22753277	Hyaluronan	Auvinen P	Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer.	International journal of cancer	2013	27
23118219	Hyaluronan	Yang C	The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering.	The Journal of biological chemistry	2012	42
23760401	Hyaluronan	Bjorklund CC	Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.	Leukemia	2014	24
24145190	Hyaluronan	Ju SY	Maintenance of the stemness in CD44(+) HCT-15 and HCT-116 human colon cancer cells requires miR-203 suppression.	Stem cell research	2014	21
25081533	Hyaluronan	Bourguignon LY	Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression.	Advances in cancer research	2014	24
25157350	Hyaluronan	Tolg C	Hyaluronan and RHAMM in wound repair and the "cancerization" of stromal tissues.	BioMed research international	2014	22
25387851	Hyaluronan	Tiainen S	High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer.	Histopathology	2015	15
25550464	Hyaluronan	Wu M	A novel role of low molecular weight hyaluronan in breast cancer metastasis.	FASEB journal 	2015	19
26005723	Hyaluronan	Li L	Transforming growth factor-Œ≤1 induces EMT by the transactivation of epidermal growth factor signaling through HA/CD44 in lung and breast cancer cells.	International journal of molecular medicine	2015	19
14570950	Gefitinib	Kris MG	Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.	JAMA	2003	406
15623594	Gefitinib	Huang SF	High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.	Clinical cancer research 	2004	83
15696205	Gefitinib	Pao W	KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.	PLoS medicine	2005	415
15709185	Gefitinib	Tokumo M	The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.	Clinical cancer research 	2005	100
15886310	Gefitinib	J√§nne PA	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.	Journal of clinical oncology 	2005	88
15939921	Gefitinib	Baselga J	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.	Journal of clinical oncology 	2005	83
15998906	Gefitinib	Hirsch FR	Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.	Journal of clinical oncology 	2005	101
15998907	Gefitinib	Takano T	Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.	Journal of clinical oncology 	2005	142
16204011	Gefitinib	Bell DW	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.	Journal of clinical oncology 	2005	123
16278407	Gefitinib	Lassman AB	Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.	Clinical cancer research 	2005	68
16322287	Gefitinib	Haura EB	Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.	Clinical cancer research 	2005	73
16785471	Gefitinib	Inoue A	Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.	Journal of clinical oncology 	2006	119
16818686	Gefitinib	Jackman DM	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.	Clinical cancer research 	2006	129
16818687	Gefitinib	Kimura H	Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.	Clinical cancer research 	2006	71
16818711	Gefitinib	Erjala K	Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.	Clinical cancer research 	2006	64
16843264	Gefitinib	Zhou BB	Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.	Cancer cell	2006	123
16906227	Gefitinib	Engelman JA	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.	The Journal of clinical investigation	2006	153
17047648	Gefitinib	Asahina H	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.	British journal of cancer	2006	68
17075123	Gefitinib	Hirsch FR	Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2006	148
17189394	Gefitinib	Riely GJ	Update on epidermal growth factor receptor mutations in non-small cell lung cancer.	Clinical cancer research 	2006	101
17200208	Gefitinib	Zhang J	SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.	The American journal of pathology	2007	59
17317677	Gefitinib	Hirsch FR	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.	Annals of oncology 	2007	70
17332364	Gefitinib	Mulloy R	Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.	Cancer research	2007	64
17349580	Gefitinib	Yun CH	Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.	Cancer cell	2007	231
17440163	Gefitinib	Farnie G	Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways.	Journal of the National Cancer Institute	2007	101
17463250	Gefitinib	Engelman JA	MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.	Science	2007	1311
17473659	Gefitinib	Wu YL	Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.	Journal of thoracic oncology 	2007	63
17785570	Gefitinib	Riely GJ	Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.	Clinical cancer research 	2007	99
17848912	Gefitinib	Kimura H	Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).	British journal of cancer	2007	57
17973572	Gefitinib	Costa DB	BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.	PLoS medicine	2007	173
18283321	Gefitinib	Tamura K	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).	British journal of cancer	2008	58
18292095	Gefitinib	Soeda A	Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells.	The Journal of biological chemistry	2008	57
18304967	Gefitinib	Weiss GJ	EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.	Annals of oncology 	2008	74
18325048	Gefitinib	Taniguchi K	Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.	Cancer science	2008	65
18381447	Gefitinib	Fuchs BC	Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.	Cancer research	2008	94
18458038	Gefitinib	Sequist LV	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.	Journal of clinical oncology 	2008	246
18509184	Gefitinib	Yang CH	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.	Journal of clinical oncology 	2008	58
18676761	Gefitinib	Wu JY	Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.	Clinical cancer research 	2008	77
19147502	Gefitinib	Griffero F	Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.	The Journal of biological chemistry	2009	52
19224850	Gefitinib	Inoue A	First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.	Journal of clinical oncology 	2009	93
19276389	Gefitinib	Narayan M	Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.	Cancer research	2009	73
19349489	Gefitinib	Riely GJ	KRAS mutations in non-small cell lung cancer.	Proceedings of the American Thoracic Society	2009	154
19351754	Gefitinib	Kuang Y	Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.	Clinical cancer research 	2009	72
19435898	Gefitinib	Mukherjee B	EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.	Cancer research	2009	74
19447865	Gefitinib	Naumov GN	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.	Clinical cancer research 	2009	61
19680293	Gefitinib	Gazdar AF	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.	Oncogene	2009	191
19934277	Gefitinib	Akiyama T	Bim-targeted cancer therapy: a link between drug action and underlying molecular changes.	Molecular cancer therapeutics	2009	54
20118985	Gefitinib	Ercan D	Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.	Oncogene	2010	65
20351699	Gefitinib	Harris TJ	The molecular pathology of cancer.	Nature reviews. Clinical oncology	2010	58
21030498	Gefitinib	Heon S	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2010	50
21123652	Gefitinib	Tigno-Aranjuez JT	Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses.	Genes & development	2010	49
21220471	Gefitinib	J√§nne PA	Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.	Clinical cancer research 	2011	41
21248303	Gefitinib	Janjigian YY	Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.	Clinical cancer research 	2011	48
21482992	Gefitinib	Keedy VL	American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.	Journal of clinical oncology 	2011	132
21487020	Gefitinib	Huang WC	Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.	The Journal of biological chemistry	2011	61
21597390	Gefitinib	Suda K	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.	Journal of thoracic oncology 	2011	81
22281684	Gefitinib	Prahallad A	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.	Nature	2012	428
22414764	Gefitinib	Blivet-Van Eggelpo√´l MJ	Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.	Journal of hepatology	2012	39
22586683	Gefitinib	Cheung HW	Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.	Cancer discovery	2011	49
22752005	Gefitinib	Cao M	MiR-23a regulates TGF-Œ≤-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells.	International journal of oncology	2012	48
22802077	Gefitinib	Reinhold WC	CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.	Cancer research	2012	112
22810899	Gefitinib	Johnson ML	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.	Cancer	2013	34
23154553	Gefitinib	D'Angelo SP	Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.	Journal of thoracic oncology 	2012	39
23307622	Gefitinib	Cuf√≠ S	Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.	Oncotarget	2012	33
23555954	Gefitinib	Chen G	miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.	PloS one	2013	74
23816963	Gefitinib	Katakami N	LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.	Journal of clinical oncology 	2013	68
23873022	Gefitinib	Kim HP	Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.	Oncogene	2014	29
24108744	Gefitinib	Buonato JM	ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.	Cancer research	2014	39
24263064	Gefitinib	Douillard JY	First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.	British journal of cancer	2014	48
24486412	Gefitinib	Zhao D	Upregulation of HIF-2Œ± induced by sorafenib contributes to the resistance by activating the TGF-Œ±/EGFR pathway in hepatocellular carcinoma cells.	Cellular signalling	2014	25
24489728	Gefitinib	Murakami A	Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.	PloS one	2014	28
24983493	Gefitinib	Zhou JY	MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.	Cancer letters	2014	21
25058005	Gefitinib	Shen H	Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer.	PloS one	2014	22
25074459	Gefitinib	Janjigian YY	Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.	Cancer discovery	2014	89
25189483	Gefitinib	Kharbanda A	Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.	Clinical cancer research 	2014	25
25294908	Gefitinib	Capelletti M	Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.	Clinical cancer research 	2014	27
25349974	Gefitinib	D'Incecco A	PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.	British journal of cancer	2015	102
25359280	Gefitinib	Lin GN	Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.	Asia-Pacific journal of clinical oncology	2017	14
25795635	Gefitinib	Burotto M	Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.	The oncologist	2015	26
25928246	Gefitinib	Wen W	Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.	Molecular cancer	2015	15
26537995	Gefitinib	Minguet J	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.	International journal of cancer	2016	31
26646759	Gefitinib	Schuler M	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.	Annals of oncology 	2016	22
27198414	Gefitinib	Gibbons DL	57O Efficacy, safety and tolerability of MEDI4736 (durvalumab D), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-na√Øve patients (pts) with EGFR mutant NSCLC.	Journal of thoracic oncology 	2016	17
27409677	Gefitinib	Pan H	Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.	Oncotarget	2016	14
27435396	Gefitinib	Ballard P	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.	Clinical cancer research 	2016	32
27663586	Gefitinib	Scarborough HA	AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.	Clinical cancer research 	2017	5
28096505	Gefitinib	Gemmill RM	The neuropilin 2 isoform NRP2b uniquely supports TGFŒ≤-mediated progression in lung cancer.	Science signaling	2017	6
28103612	Gefitinib	Yang JJ	A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.	British journal of cancer	2017	9
18375904	Lapatinib	Kumar A	Structure and clinical relevance of the epidermal growth factor receptor in human cancer.	Journal of clinical oncology 	2008	61
18421051	Lapatinib	Lin NU	Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2008	101
19047149	Lapatinib	Saxena NK	Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.	Cancer research	2008	73
19179558	Lapatinib	Blackwell KL	Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.	Annals of oncology 	2009	51
19204209	Lapatinib	Sauter G	Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.	Journal of clinical oncology 	2009	107
19701706	Lapatinib	Weigelt B	HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.	Breast cancer research and treatment	2010	104
20581867	Lapatinib	Chakrabarty A	H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.	Oncogene	2010	44
20730488	Lapatinib	Junttila TT	Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.	Breast cancer research and treatment	2011	71
21245432	Lapatinib	Spraggs CF	HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.	Journal of clinical oncology 	2011	56
21342044	Lapatinib	Gajria D	HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.	Expert review of anticancer therapy	2011	83
21499296	Lapatinib	Rexer BN	Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.	Oncogene	2011	49
21699723	Lapatinib	Giuliano M	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.	Breast cancer research 	2011	46
21741829	Lapatinib	von Minckwitz G	Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.	European journal of cancer	2011	41
21840482	Lapatinib	Wilson TR	Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.	Cancer cell	2011	51
21847123	Lapatinib	Pandya K	Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.	British journal of cancer	2011	46
22248472	Lapatinib	McDonagh CF	Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.	Molecular cancer therapeutics	2012	79
22407832	Lapatinib	Garc√≠a-Garc√≠a C	Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.	Clinical cancer research 	2012	54
22493419	Lapatinib	Guarneri V	Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.	Journal of clinical oncology 	2012	64
22649126	Lapatinib	Krop IE	A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.	Journal of clinical oncology 	2012	63
22689807	Lapatinib	Blackwell KL	Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.	Journal of clinical oncology 	2012	115
22745588	Lapatinib	Clark PA	Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.	Neoplasia	2012	45
23020162	Lapatinib	Verma S	Trastuzumab emtansine for HER2-positive advanced breast cancer.	The New England journal of medicine	2012	432
23071597	Lapatinib	Nowsheen S	Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.	PloS one	2012	33
23149820	Lapatinib	Singh JK	Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.	Clinical cancer research 	2013	51
23173552	Lapatinib	Lambert JM	Drug-conjugated antibodies for the treatment of cancer.	British journal of clinical pharmacology	2013	31
23220880	Lapatinib	Bose R	Activating HER2 mutations in HER2 gene amplification negative breast cancer.	Cancer discovery	2013	160
23563986	Lapatinib	Boku N	HER2-positive gastric cancer.	Gastric cancer 	2014	33
23940356	Lapatinib	Hanker AB	Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.	Proceedings of the National Academy of Sciences of the United States of America	2013	43
24080156	Lapatinib	K√ºmler I	A systematic review of dual targeting in HER2-positive breast cancer.	Cancer treatment reviews	2014	36
24097864	Lapatinib	Phillips GD	Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.	Clinical cancer research 	2014	36
24222194	Lapatinib	Welslau M	Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.	Cancer	2014	22
24518603	Lapatinib	Liu YJ	HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.	British journal of cancer	2014	31
24656976	Lapatinib	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	45
24742739	Lapatinib	Andr√© F	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.	The Lancet. Oncology	2014	87
24793816	Lapatinib	Krop IE	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	75
24919460	Lapatinib	Balduzzi S	Trastuzumab-containing regimens for metastatic breast cancer.	The Cochrane database of systematic reviews	2014	27
24967516	Lapatinib	Lambert JM	Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.	Journal of medicinal chemistry	2014	38
25025958	Lapatinib	Singh JC	HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.	British journal of cancer	2014	25
25086636	Lapatinib	M√ºller V	Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.	Breast cancer research and treatment	2014	29
25199759	Lapatinib	Loibl S	PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.	Journal of clinical oncology 	2014	47
25355722	Lapatinib	Krop IE	Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.	Annals of oncology 	2015	24
25467182	Lapatinib	Scaltriti M	High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.	Clinical cancer research 	2015	18
25605838	Lapatinib	Pivot X	CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.	Journal of clinical oncology 	2015	23
25622903	Lapatinib	Zhang L	Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.	Neoplasia	2015	17
25667274	Lapatinib	Lopez-Chavez A	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.	Journal of clinical oncology 	2015	44
26022204	Lapatinib	Javle M	HER2/neu-directed therapy for biliary tract cancer.	Journal of hematology & oncology	2015	17
26204261	Lapatinib	Moasser MM	The Evolving Landscape of HER2 Targeting in Breast Cancer.	JAMA oncology	2015	15
26598547	Lapatinib	Mazi√®res J	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.	Annals of oncology 	2016	22
26598744	Lapatinib	Piccart-Gebhart M	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.	Journal of clinical oncology 	2016	25
26647992	Lapatinib	Wang M	N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells.	International journal of oncology	2016	21
26920887	Lapatinib	Baselga J	Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.	Clinical cancer research 	2016	19
27034004	Lapatinib	Li W	Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.	Oncotarget	2016	22
28112728	Lapatinib	Cancer Genome Atlas Research Network.	Integrated genomic and molecular characterization of cervical cancer.	Nature	2017	38
12384400	Lenalidomide	Richardson PG	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.	Blood	2002	116
17995965	Lenalidomide	Reddy N	Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.	British journal of haematology	2008	66
18551193	Lenalidomide	Ramsay AG	Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.	The Journal of clinical investigation	2008	145
18843284	Lenalidomide	Podar K	Bone marrow microenvironment and the identification of new targets for myeloma therapy.	Leukemia	2009	98
20460501	Lenalidomide	Benson DM Jr	The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.	Blood	2010	143
20651070	Lenalidomide	G√∂rg√ºn G	Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.	Blood	2010	51
21109694	Lenalidomide	van der Veer MS	Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.	Haematologica	2011	36
21519010	Lenalidomide	J√§dersten M	TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.	Journal of clinical oncology 	2011	76
22547582	Lenalidomide	Ramsay AG	Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.	Blood	2012	68
22966948	Lenalidomide	Zhu YX	Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.	Leukemia & lymphoma	2013	45
23321256	Lenalidomide	G√∂rg√ºn GT	Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.	Blood	2013	64
24328678	Lenalidomide	Gandhi AK	Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).	British journal of haematology	2014	67
24569262	Lenalidomide	Tai YT	Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.	Blood	2014	32
24682512	Lenalidomide	Saft L	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).	Haematologica	2014	26
25287778	Lenalidomide	Balasa B	Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-Œ± pathways.	Cancer immunology, immunotherapy 	2015	19
25510242	Lenalidomide	Nijhof IS	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.	Haematologica	2015	17
26308596	Lenalidomide	Lokhorst HM	Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.	The New England journal of medicine	2015	110
27127303	Lenalidomide	Tai YT	APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.	Blood	2016	12
9607760	L-Arginine	Storey A	Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.	Nature	1998	129
9891044	L-Arginine	Thomas M	Two polymorphic variants of wild-type p53 differ biochemically and biologically.	Molecular and cellular biology	1999	132
10983978	L-Arginine	Monsalve M	Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1.	Molecular cell	2000	112
11313365	L-Arginine	Persad S	Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343.	The Journal of biological chemistry	2001	122
12391027	L-Arginine	Tan K	Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication.	The Journal of cell biology	2002	81
14639602	L-Arginine	Pim D	p53 polymorphic variants at codon 72 exert different effects on cell cycle progression.	International journal of cancer	2004	79
16543241	L-Arginine	Li H	Ubiquitination of RIP is required for tumor necrosis factor alpha-induced NF-kappaB activation.	The Journal of biological chemistry	2006	75
16809279	L-Arginine	Li Y	Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection.	Journal of virology	2006	66
17088326	L-Arginine	Szyk A	Crystal structures of human alpha-defensins HNP4, HD5, and HD6.	Protein science 	2006	64
18347055	L-Arginine	Conze DB	Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-kappaB activation.	Molecular and cellular biology	2008	85
18436584	L-Arginine	Glinka Y	Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity.	Journal of leukocyte biology	2008	81
18694959	L-Arginine	Wang L	Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells.	Molecular and cellular biology	2008	75
19234465	L-Arginine	Zhao Q	PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing.	Nature structural & molecular biology	2009	149
19656869	L-Arginine	Diaz-Griffero F	A B-box 2 surface patch important for TRIM5alpha self-association, capsid binding avidity, and retrovirus restriction.	Journal of virology	2009	85
19736621	L-Arginine	Jones JE	Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential.	Current opinion in drug discovery & development	2009	61
20142433	L-Arginine	Gross S	Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.	The Journal of experimental medicine	2010	200
20351325	L-Arginine	Glazer ES	Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.	Journal of clinical oncology 	2010	48
20692206	L-Arginine	Dang L	IDH mutations in glioma and acute myeloid leukemia.	Trends in molecular medicine	2010	94
20706768	L-Arginine	Slack JL	Protein arginine deiminase 4: a target for an epigenetic cancer therapy.	Cellular and molecular life sciences 	2011	36
20951943	L-Arginine	Aggarwal P	Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase.	Cancer cell	2010	72
20972461	L-Arginine	Yen KE	Cancer-associated IDH mutations: biomarker and therapeutic opportunities.	Oncogene	2010	66
21063024	L-Arginine	Lin Y	Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma.	Blood	2011	47
21948231	L-Arginine	Sippel TR	Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I.	Clinical cancer research 	2011	41
21966470	L-Arginine	Ananiev G	Isogenic pairs of wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome patients as in vitro disease model.	PloS one	2011	72
22053001	L-Arginine	Wang Y	Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1.	Molecular endocrinology	2011	41
22215888	L-Arginine	Cairns RA	IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.	Blood	2012	92
22291079	L-Arginine	Marcucci G	Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.	Journal of clinical oncology 	2012	68
22431577	L-Arginine	Zhang SJ	Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.	Blood	2012	42
22461507	L-Arginine	Tsai WB	Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.	Cancer research	2012	39
22617883	L-Arginine	Abdelmohsen K	RNA-binding protein nucleolin in disease.	RNA biology	2012	53
22678168	L-Arginine	Visconte V	Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.	Leukemia	2012	34
22726390	L-Arginine	Wei TY	Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade.	Cancer science	2012	36
23175390	L-Arginine	Bicker KL	The protein arginine deiminases: Structure, function, inhibition, and disease.	Biopolymers	2013	35
23249737	L-Arginine	Dhar SS	Trans-tail regulation of MLL4-catalyzed H3K4 methylation by H4R3 symmetric dimethylation is mediated by a tandem PHD of MLL4.	Genes & development	2012	44
23328665	L-Arginine	Syed N	Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma.	Cell death & disease	2013	29
24013503	L-Arginine	Bezzi M	Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery.	Genes & development	2013	38
24076217	L-Arginine	Zheng S	Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1.	Molecular cell	2013	35
24463069	L-Arginine	Wang G	High-quality 3D structures shine light on antibacterial, anti-biofilm and antiviral activities of human cathelicidin LL-37 and its fragments.	Biochimica et biophysica acta	2014	32
24468535	L-Arginine	Wang J	Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer.	Cellular signalling	2014	26
24498420	L-Arginine	Poulard C	JMJD6 regulates ERŒ± methylation on arginine.	PloS one	2014	21
24807918	L-Arginine	Das S	Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer.	Molecular cancer research 	2014	39
25084831	L-Arginine	Darcy CJ	Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients.	Critical care	2014	30
25284789	L-Arginine	Takai H	5-Hydroxymethylcytosine plays a critical role in glioblastomagenesis by recruiting the CHTOP-methylosome complex.	Cell reports	2014	22
25381816	L-Arginine	Mavrou A	Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.	Oncogene	2015	24
25582697	L-Arginine	Li Y	PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers.	Cancer discovery	2015	20
25662273	L-Arginine	Stopa N	The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond.	Cellular and molecular life sciences 	2015	41
25737013	L-Arginine	Yang Y	PRMT9 is a type II methyltransferase that methylates the splicing factor SAP145.	Nature communications	2015	32
25792598	L-Arginine	Hu SB	Protein arginine methyltransferase CARM1 attenuates the paraspeckle-mediated nuclear retention of mRNAs containing IRAlus.	Genes & development	2015	17
25915199	L-Arginine	Chan-Penebre E	A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.	Nature chemical biology	2015	50
25970242	L-Arginine	Koh CM	MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis.	Nature	2015	46
26261309	L-Arginine	Zhang J	Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities.	Proceedings of the National Academy of Sciences of the United States of America	2015	27
26789238	L-Arginine	Hu H	Small Molecule Inhibitors of Protein Arginine Methyltransferases.	Expert opinion on investigational drugs	2016	20
26972053	L-Arginine	Chantranupong L	The CASTOR Proteins Are Arginine Sensors for the mTORC1 Pathway.	Cell	2016	79
27180064	L-Arginine	Li Y	SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.	European urology	2017	10
27270440	L-Arginine	Chen H	A TGFŒ≤-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.	Oncogene	2017	11
27400413	L-Arginine	McNee G	Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma.	Leukemia	2017	6
27406712	L-Arginine	Rabbani N	Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics.	Glycoconjugate journal	2016	17
27577262	L-Arginine	Larsen SC	Proteome-wide analysis of arginine monomethylation reveals widespread occurrence in human cells.	Science signaling	2016	18
27745970	L-Arginine	Geiger R	L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity.	Cell	2016	53
28076779	L-Arginine	Sridhara SC	Transcription Dynamics Prevent RNA-Mediated Genomic Instability through SRPK2-Dependent DDX23 Phosphorylation.	Cell reports	2017	9
28740232	L-Arginine	Cha-Molstad H	p62/SQSTM1/Sequestosome-1 is an N-recognin of the N-end rule pathway which modulates autophagosome biogenesis.	Nature communications	2017	9
1409633	L-Threonine	Cheng JQ	AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.	Proceedings of the National Academy of Sciences of the United States of America	1992	153
7657393	L-Threonine	Bellacosa A	Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.	International journal of cancer	1995	179
7666531	L-Threonine	Jowett JB	The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle.	Journal of virology	1995	205
7790358	L-Threonine	Golsteyn RM	Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function.	The Journal of cell biology	1995	143
8006002	L-Threonine	ten Dijke P	Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4.	The Journal of biological chemistry	1994	131
8047140	L-Threonine	Wrana JL	Mechanism of activation of the TGF-beta receptor.	Nature	1994	369
8538749	L-Threonine	Hannigan GE	Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase.	Nature	1996	245
8700231	L-Threonine	Nussenzweig A	Requirement for Ku80 in growth and immunoglobulin V(D)J recombination.	Nature	1996	184
8752209	L-Threonine	Eppert K	MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma.	Cell	1996	146
8893010	L-Threonine	Lagna G	Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways.	Nature	1996	175
8991084	L-Threonine	Lane HA	Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes.	The Journal of cell biology	1996	194
9069260	L-Threonine	Morrison DK	The complexity of Raf-1 regulation.	Current opinion in cell biology	1997	121
9334355	L-Threonine	Serra R	Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis.	The Journal of cell biology	1997	117
9335507	L-Threonine	Nakao A	Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling.	Nature	1997	366
9393997	L-Threonine	Heldin CH	TGF-beta signalling from cell membrane to nucleus through SMAD proteins.	Nature	1997	720
9425897	L-Threonine	Jenne DE	Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.	Nature genetics	1998	227
9561851	L-Threonine	Downward J	Mechanisms and consequences of activation of protein kinase B/Akt.	Current opinion in cell biology	1998	217
9606188	L-Threonine	Bischoff JR	A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers.	The EMBO journal	1998	301
9720756	L-Threonine	Kawabata M	Signal transduction by bone morphogenetic proteins.	Cytokine & growth factor reviews	1998	102
9759503	L-Threonine	Massagu√© J	TGF-beta signal transduction.	Annual review of biochemistry	1998	900
10391244	L-Threonine	Lu PJ	The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.	Nature	1999	169
10487205	L-Threonine	Tibbles LA	The stress-activated protein kinase pathways.	Cellular and molecular life sciences 	1999	108
10593858	L-Threonine	Piek E	Specificity, diversity, and regulation in TGF-beta superfamily signaling.	FASEB journal 	1999	125
10617621	L-Threonine	Kharbanda S	Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage.	The Journal of biological chemistry	2000	95
10879283	L-Threonine	Miyazono K	TGF-beta signaling by Smad proteins.	Advances in immunology	2000	93
10974075	L-Threonine	de Caestecker MP	Role of transforming growth factor-beta signaling in cancer.	Journal of the National Cancer Institute	2000	116
11085506	L-Threonine	Ahn JY	Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation.	Cancer research	2000	119
11106403	L-Threonine	Itoh S	Signaling of transforming growth factor-beta family members through Smad proteins.	European journal of biochemistry	2000	101
11237521	L-Threonine	Simpson L	PTEN: life as a tumor suppressor.	Experimental cell research	2001	134
11381269	L-Threonine	Howe JR	Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis.	Nature genetics	2001	154
11518967	L-Threonine	Dhanasekaran SM	Delineation of prognostic biomarkers in prostate cancer.	Nature	2001	372
11532975	L-Threonine	Kim D	Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production.	FASEB journal 	2001	110
11686294	L-Threonine	Lawlor MA	PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?	Journal of cell science	2001	231
11740489	L-Threonine	Hofmann TG	Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.	Nature cell biology	2002	156
11875759	L-Threonine	Waite KA	Protean PTEN: form and function.	American journal of human genetics	2002	96
11882383	L-Threonine	Nicholson KM	The protein kinase B/Akt signalling pathway in human malignancy.	Cellular signalling	2002	313
11891124	L-Threonine	Melo J	A unified view of the DNA-damage checkpoint.	Current opinion in cell biology	2002	160
11950587	L-Threonine	Jaffer ZM	p21-activated kinases: three more join the Pak.	The international journal of biochemistry & cell biology	2002	109
11956073	L-Threonine	Zhuang L	Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells.	Cancer research	2002	81
11978535	L-Threonine	Lu KP	Pinning down proline-directed phosphorylation signaling.	Trends in cell biology	2002	92
12019169	L-Threonine	Han H	Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.	Cancer research	2002	96
12058067	L-Threonine	D√≠az-Rodr√≠guez E	Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding.	Molecular biology of the cell	2002	103
12065756	L-Threonine	Inman GJ	SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.	Molecular pharmacology	2002	460
12068308	L-Threonine	Davies H	Mutations of the BRAF gene in human cancer.	Nature	2002	2142
12198493	L-Threonine	Vadlamudi RK	Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1.	Nature cell biology	2002	109
12244302	L-Threonine	Liang J	PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest.	Nature medicine	2002	251
12244303	L-Threonine	Viglietto G	Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.	Nature medicine	2002	158
12460919	L-Threonine	Naoki K	Missense mutations of the BRAF gene in human lung adenocarcinoma.	Cancer research	2002	81
12466191	L-Threonine	Firth SM	Cellular actions of the insulin-like growth factor binding proteins.	Endocrine reviews	2002	365
12531180	L-Threonine	West KA	Activation of the PI3K/Akt pathway and chemotherapeutic resistance.	Drug resistance updates 	2002	132
12538643	L-Threonine	Maddox AS	RhoA is required for cortical retraction and rigidity during mitotic cell rounding.	The Journal of cell biology	2003	83
12554650	L-Threonine	Dajani R	Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex.	The EMBO journal	2003	82
12559175	L-Threonine	Anand S	AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.	Cancer cell	2003	164
12623839	L-Threonine	Platanias LC	Map kinase signaling pathways and hematologic malignancies.	Blood	2003	84
12631597	L-Threonine	Li D	Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer.	Clinical cancer research 	2003	83
12684414	L-Threonine	Gritsko TM	Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer.	Clinical cancer research 	2003	86
12781369	L-Threonine	Mercer KE	Raf proteins and cancer: B-Raf is identified as a mutational target.	Biochimica et biophysica acta	2003	80
12796778	L-Threonine	Toyo-oka K	14-3-3epsilon is important for neuronal migration by binding to NUDEL: a molecular explanation for Miller-Dieker syndrome.	Nature genetics	2003	102
12805220	L-Threonine	Baas AF	Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD.	The EMBO journal	2003	115
12855641	L-Threonine	Kamai T	Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer.	Clinical cancer research 	2003	102
12884918	L-Threonine	Katayama H	The Aurora kinases: role in cell transformation and tumorigenesis.	Cancer metastasis reviews	2003	100
12941274	L-Threonine	Harvey KF	The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis.	Cell	2003	278
12971829	L-Threonine	Dittmer J	The biology of the Ets1 proto-oncogene.	Molecular cancer	2003	130
14500344	L-Threonine	Hingorani SR	Suppression of BRAF(V599E) in human melanoma abrogates transformation.	Cancer research	2003	107
14532005	L-Threonine	Elia AE	The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain.	Cell	2003	258
14645548	L-Threonine	Li L	Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A.	Molecular and cellular biology	2003	93
14647146	L-Threonine	Schlieman MG	Incidence, mechanism and prognostic value of activated AKT in pancreas cancer.	British journal of cancer	2003	80
14679157	L-Threonine	Maldonado JL	Determinants of BRAF mutations in primary melanomas.	Journal of the National Cancer Institute	2003	114
14695152	L-Threonine	Omholt K	NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.	Clinical cancer research 	2003	88
14871980	L-Threonine	Noh WC	Determinants of rapamycin sensitivity in breast cancer cells.	Clinical cancer research 	2004	86
14976311	L-Threonine	Raftopoulou M	Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.	Science	2004	108
14998489	L-Threonine	Chen W	Identification of specific PP2A complexes involved in human cell transformation.	Cancer cell	2004	96
15000151	L-Threonine	Byrd JC	Mucins and mucin binding proteins in colorectal cancer.	Cancer metastasis reviews	2004	110
15090593	L-Threonine	Dougherty MK	Unlocking the code of 14-3-3.	Journal of cell science	2004	108
15111319	L-Threonine	Bao L	Prevalent overexpression of prolyl isomerase Pin1 in human cancers.	The American journal of pathology	2004	96
15130563	L-Threonine	ten Dijke P	New insights into TGF-beta-Smad signalling.	Trends in biochemical sciences	2004	295
15208680	L-Threonine	Karasarides M	B-RAF is a therapeutic target in melanoma.	Oncogene	2004	100
15592499	L-Threonine	Collis SJ	The life and death of DNA-PK.	Oncogene	2005	111
15661531	L-Threonine	Janssens V	PP2A: the expected tumor suppressor.	Current opinion in genetics & development	2005	121
15694309	L-Threonine	Patton EE	BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.	Current biology 	2005	155
15722192	L-Threonine	Knippschild U	The casein kinase 1 family: participation in multiple cellular processes in eukaryotes.	Cellular signalling	2005	169
15735123	L-Threonine	Dai DL	Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.	Journal of clinical oncology 	2005	79
15780591	L-Threonine	Woodgett JR	Recent advances in the protein kinase B signaling pathway.	Current opinion in cell biology	2005	100
15784165	L-Threonine	Song G	The activation of Akt/PKB signaling pathway and cell survival.	Journal of cellular and molecular medicine	2005	348
15805470	L-Threonine	Zhang X	Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4.	Genes & development	2005	74
15806160	L-Threonine	Sutherland BW	Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells.	Oncogene	2005	67
15833840	L-Threonine	Clark DE	The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.	Cancer research	2005	67
15867923	L-Threonine	Wulf G	Phosphorylation-specific prolyl isomerization: is there an underlying theme?	Nature cell biology	2005	84
15907369	L-Threonine	Koivunen J	Protein kinase C (PKC) family in cancer progression.	Cancer letters	2006	60
15940637	L-Threonine	Kobayashi S	Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells.	Gastroenterology	2005	73
16046538	L-Threonine	Carter TA	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.	Proceedings of the National Academy of Sciences of the United States of America	2005	116
16094359	L-Threonine	Parsons DW	Colorectal cancer: mutations in a signalling pathway.	Nature	2005	175
16123807	L-Threonine	Javelaud D	Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis.	Oncogene	2005	112
16200194	L-Threonine	Amaravadi R	The survival kinases Akt and Pim as potential pharmacological targets.	The Journal of clinical investigation	2005	114
16236519	L-Threonine	Malumbres M	Mammalian cyclin-dependent kinases.	Trends in biochemical sciences	2005	262
16299534	L-Threonine	Arroyo JD	Involvement of PP2A in viral and cellular transformation.	Oncogene	2005	83
16678165	L-Threonine	Massagu√© J	The logic of TGFbeta signaling.	FEBS letters	2006	263
16707622	L-Threonine	Hearle N	Frequency and spectrum of cancers in the Peutz-Jeghers syndrome.	Clinical cancer research 	2006	129
16904831	L-Threonine	Pardali K	Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer.	Biochimica et biophysica acta	2007	176
17145803	L-Threonine	Carvajal RD	Aurora kinases: new targets for cancer therapy.	Clinical cancer research 	2006	61
17188038	L-Threonine	Lochhead PA	A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation.	Molecular cell	2006	76
17188549	L-Threonine	Bernard O	Lim kinases, regulators of actin dynamics.	The international journal of biochemistry & cell biology	2007	94
17291758	L-Threonine	Steegmaier M	BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.	Current biology 	2007	242
17379520	L-Threonine	Guo C	RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network.	Current biology 	2007	73
17496919	L-Threonine	Turjanski AG	MAP kinases and the control of nuclear events.	Oncogene	2007	118
17496923	L-Threonine	Roberts PJ	Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.	Oncogene	2007	696
17632053	L-Threonine	Mumby M	PP2A: unveiling a reluctant tumor suppressor.	Cell	2007	93
17635004	L-Threonine	Houghton PJ	Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.	Pediatric blood & cancer	2008	51
17643117	L-Threonine	Zippo A	PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation.	Nature cell biology	2007	107
17657516	L-Threonine	Voss K	CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations.	Neurogenetics	2007	60
17676035	L-Threonine	Ji H	LKB1 modulates lung cancer differentiation and metastasis.	Nature	2007	327
17785202	L-Threonine	Kang S	FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.	Cancer cell	2007	63
17849476	L-Threonine	Leivonen SK	Transforming growth factor-beta signaling in cancer invasion and metastasis.	International journal of cancer	2007	59
17988798	L-Threonine	Tarp MA	Mucin-type O-glycosylation and its potential use in drug and vaccine development.	Biochimica et biophysica acta	2008	72
18288941	L-Threonine	Tokunaga E	Deregulation of the Akt pathway in human cancer.	Current cancer drug targets	2008	58
18329957	L-Threonine	Westermarck J	Multiple pathways regulated by the tumor suppressor PP2A in transformation.	Trends in molecular medicine	2008	121
18347165	L-Threonine	Gautschi O	Aurora kinases as anticancer drug targets.	Clinical cancer research 	2008	110
18482698	L-Threonine	Reindl W	Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.	Chemistry & biology	2008	59
18504432	L-Threonine	Bleeker FE	AKT1(E17K) in human solid tumours.	Oncogene	2008	57
18588945	L-Threonine	Eichhorn PJ	Protein phosphatase 2A regulatory subunits and cancer.	Biochimica et biophysica acta	2009	174
18593906	L-Threonine	Morishita D	Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.	Cancer research	2008	89
18606491	L-Threonine	Luo J	Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy.	Cancer letters	2009	118
18627125	L-Threonine	Galea CA	Regulation of cell division by intrinsically unstructured proteins: intrinsic flexibility, modularity, and signaling conduits.	Biochemistry	2008	62
18775331	L-Threonine	Eisinger-Mathason TS	Codependent functions of RSK2 and the apoptosis-promoting factor TIA-1 in stress granule assembly and cell survival.	Molecular cell	2008	59
18806775	L-Threonine	Wang Z	Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.	Nature	2008	93
18808420	L-Threonine	Inoue Y	Regulation of TGF-beta family signaling by E3 ubiquitin ligases.	Cancer science	2008	74
18936157	L-Threonine	Chan EY	Kinase-inactivated ULK proteins inhibit autophagy via their conserved C-terminal domains using an Atg13-independent mechanism.	Molecular and cellular biology	2009	144
18955974	L-Threonine	Franke TF	PI3K/Akt: getting it right matters.	Oncogene	2008	195
19001320	L-Threonine	Di Nicolantonio F	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.	Journal of clinical oncology 	2008	425
19030025	L-Threonine	L√∂nn P	Regulating the stability of TGFbeta receptors and Smads.	Cell research	2009	61
19075230	L-Threonine	Rychahou PG	Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis.	Proceedings of the National Academy of Sciences of the United States of America	2008	65
19110052	L-Threonine	Chin YR	Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer.	Cellular signalling	2009	75
19130886	L-Threonine	Robey RB	Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis.	Seminars in cancer biology	2009	143
19165420	L-Threonine	Dummler B	Pak protein kinases and their role in cancer.	Cancer metastasis reviews	2009	99
19228372	L-Threonine	Gorin MA	Protein kinase C epsilon: an oncogene and emerging tumor biomarker.	Molecular cancer	2009	50
19237272	L-Threonine	Heldin CH	Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition.	Current opinion in cell biology	2009	215
19258318	L-Threonine	Ganley IG	ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy.	The Journal of biological chemistry	2009	359
19270695	L-Threonine	Gao D	Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction.	Nature cell biology	2009	108
19273207	L-Threonine	Reyland ME	Protein kinase C isoforms: Multi-functional regulators of cell life and death.	Frontiers in bioscience	2009	91
19276360	L-Threonine	Hoeflich KP	Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.	Cancer research	2009	55
19285938	L-Threonine	Virshup DM	From promiscuity to precision: protein phosphatases get a makeover.	Molecular cell	2009	222
19332717	L-Threonine	Meric-Bernstam F	Targeting the mTOR signaling network for cancer therapy.	Journal of clinical oncology 	2009	194
19372583	L-Threonine	Boisvert-Adamo K	Mcl-1 is required for melanoma cell resistance to anoikis.	Molecular cancer research 	2009	52
19386264	L-Threonine	ten Klooster JP	Mst4 and Ezrin induce brush borders downstream of the Lkb1/Strad/Mo25 polarization complex.	Developmental cell	2009	63
19401561	L-Threonine	Roccaro AM	MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.	Blood	2009	95
19445024	L-Threonine	Lee SY	Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma.	Cancer science	2009	56
19458359	L-Threonine	Tamburini J	Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.	Blood	2009	54
19474163	L-Threonine	Sch√∂ffski P	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.	The oncologist	2009	55
19481982	L-Threonine	Mohammad DH	14-3-3 proteins, FHA domains and BRCT domains in the DNA damage response.	DNA repair	2009	62
19490892	L-Threonine	Scholl C	Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.	Cell	2009	197
19538984	L-Threonine	Niture SK	Nrf2 signaling and cell survival.	Toxicology and applied pharmacology	2010	62
19666537	L-Threonine	Sinclair DA	Drosophila O-GlcNAc transferase (OGT) is encoded by the Polycomb group (PcG) gene, super sex combs (sxc).	Proceedings of the National Academy of Sciences of the United States of America	2009	86
19762341	L-Threonine	Miyazono K	Bone morphogenetic protein receptors and signal transduction.	Journal of biochemistry	2010	240
19855013	L-Threonine	Moustakas A	The regulation of TGFbeta signal transduction.	Development	2009	266
19879149	L-Threonine	Le Guezennec X	WIP1 phosphatase at the crossroads of cancer and aging.	Trends in biochemical sciences	2010	48
20005306	L-Threonine	Dowling RJ	Dissecting the role of mTOR: lessons from mTOR inhibitors.	Biochimica et biophysica acta	2010	118
20080624	L-Threonine	Hu H	ATM is down-regulated by N-Myc-regulated microRNA-421.	Proceedings of the National Academy of Sciences of the United States of America	2010	78
20087440	L-Threonine	Yang G	Smad4-mediated TGF-beta signaling in tumorigenesis.	International journal of biological sciences	2010	51
20166984	L-Threonine	Falasca M	PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs.	Current pharmaceutical design	2010	40
20188563	L-Threonine	Walsh DW	Extracellular BMP-antagonist regulation in development and disease: tied up in knots.	Trends in cell biology	2010	59
20409325	L-Threonine	Foley NH	MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2.	Molecular cancer	2010	55
20533398	L-Threonine	Trembley JH	Emergence of protein kinase CK2 as a key target in cancer therapy.	BioFactors	2010	47
20549472	L-Threonine	Vasudevan KM	AKT signaling in physiology and disease.	Current topics in microbiology and immunology	2010	40
20562913	L-Threonine	Gan Y	Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.	Oncogene	2010	78
20580720	L-Threonine	Lee G	Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis.	Gastroenterology	2010	57
20592472	L-Threonine	Zheng X	CCM3 signaling through sterile 20-like kinases plays an essential role during zebrafish cardiovascular development and cerebral cavernous malformations.	The Journal of clinical investigation	2010	47
20679220	L-Threonine	Ueda T	Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development.	Proceedings of the National Academy of Sciences of the United States of America	2010	51
20711193	L-Threonine	Li T	MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation.	Nature immunology	2010	79
20818157	L-Threonine	Voets E	MASTL is the human orthologue of Greatwall kinase that facilitates mitotic entry, anaphase and cytokinesis.	Cell cycle	2010	56
20818844	L-Threonine	Flaherty KT	Inhibition of mutated, activated BRAF in metastatic melanoma.	The New England journal of medicine	2010	991
20826764	L-Threonine	Jones S	Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.	Science	2010	351
20846000	L-Threonine	Pal SK	Akt inhibitors in clinical development for the treatment of cancer.	Expert opinion on investigational drugs	2010	89
20886116	L-Threonine	Wu WI	Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition.	PloS one	2010	54
21107320	L-Threonine	Johannessen CM	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.	Nature	2010	447
21145983	L-Threonine	Cheong JK	Casein kinase 1: Complexity in the family.	The international journal of biochemistry & cell biology	2011	66
21245096	L-Threonine	Murakami H	LATS2 is a tumor suppressor gene of malignant mesothelioma.	Cancer research	2011	51
21248166	L-Threonine	McCormick JA	The WNKs: atypical protein kinases with pleiotropic actions.	Physiological reviews	2011	78
21258406	L-Threonine	Ip CK	p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells.	Oncogene	2011	35
21266350	L-Threonine	Wang X	Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland.	Cancer research	2011	51
21321066	L-Threonine	Guzi TJ	Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.	Molecular cancer therapeutics	2011	54
21325073	L-Threonine	Mallon R	Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.	Clinical cancer research 	2011	39
21430779	L-Threonine	Ceol CJ	The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset.	Nature	2011	145
21440011	L-Threonine	Zhang X	Akt, FoxO and regulation of apoptosis.	Biochimica et biophysica acta	2011	162
21482786	L-Threonine	Ong CC	Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	68
21505451	L-Threonine	Vincent EE	Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer.	British journal of cancer	2011	43
21602880	L-Threonine	Hannigan GE	Integrin-linked kinase: not so 'pseudo' after all.	Oncogene	2011	39
21629263	L-Threonine	Mu Y	TRAF6 ubiquitinates TGFŒ≤ type I receptor to promote its cleavage and nuclear translocation in cancer.	Nature communications	2011	53
21638088	L-Threonine	Capper D	Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.	Acta neuropathologica	2011	79
21643690	L-Threonine	Heldin CH	Role of Smads in TGFŒ≤ signaling.	Cell and tissue research	2012	75
21682951	L-Threonine	Lee TH	Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease.	Expert reviews in molecular medicine	2011	43
21706049	L-Threonine	Gu Y	Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion.	Oncogene	2012	32
21718111	L-Threonine	Hawinkels LJ	Exploring anti-TGF-Œ≤ therapies in cancer and fibrosis.	Growth factors	2011	60
21742770	L-Threonine	Babij C	STK33 kinase activity is nonessential in KRAS-dependent cancer cells.	Cancer research	2011	42
21743487	L-Threonine	Thomas M	The proto-oncogene Pim-1 is a target of miR-33a.	Oncogene	2012	45
21850036	L-Threonine	Slawson C	O-GlcNAc signalling: implications for cancer cell biology.	Nature reviews. Cancer	2011	91
21908616	L-Threonine	Guo JP	IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation.	The Journal of biological chemistry	2011	45
21924349	L-Threonine	Contreras-Vallejos E	Going out of the brain: non-nervous system physiological and pathological functions of Cdk5.	Cellular signalling	2012	37
22025163	L-Threonine	Yap TA	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.	Journal of clinical oncology 	2011	175
22101766	L-Threonine	Robinson DR	Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer.	Nature medicine	2011	107
22356324	L-Threonine	Sosman JA	Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.	The New England journal of medicine	2012	522
22371497	L-Threonine	Fong JJ	Œ≤-N-Acetylglucosamine (O-GlcNAc) is a novel regulator of mitosis-specific phosphorylations on histone H3.	The Journal of biological chemistry	2012	40
22552284	L-Threonine	Turke AB	MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.	Cancer research	2012	84
22552290	L-Threonine	Saini S	miRNA-708 control of CD44(+) prostate cancer-initiating cells.	Cancer research	2012	38
22710160	L-Threonine	Cai J	BMP signaling in vascular diseases.	FEBS letters	2012	61
22842228	L-Threonine	Krauthammer M	Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.	Nature genetics	2012	315
22943793	L-Threonine	Kubiczkova L	TGF-Œ≤ - an excellent servant but a bad master.	Journal of translational medicine	2012	64
23041284	L-Threonine	Lin Y	Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells.	Molecular cell	2012	54
23087057	L-Threonine	Kalev P	Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition.	Cancer research	2012	33
23132929	L-Threonine	Fry AM	Cell cycle regulation by the NEK family of protein kinases.	Journal of cell science	2012	75
23162742	L-Threonine	Ye DZ	PAK signaling in cancer.	Cellular logistics	2012	41
23273981	L-Threonine	Peterson SE	Activation of DSB processing requires phosphorylation of CtIP by ATR.	Molecular cell	2013	37
23287572	L-Threonine	Korsse SE	Targeting LKB1 signaling in cancer.	Biochimica et biophysica acta	2013	28
23447565	L-Threonine	Haq R	BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2013	59
23454242	L-Threonine	Seshacharyulu P	Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.	Cancer letters	2013	67
23639323	L-Threonine	Perrotti D	Protein phosphatase 2A: a target for anticancer therapy.	The Lancet. Oncology	2013	92
23642195	L-Threonine	Bond MR	O-GlcNAc cycling: a link between metabolism and chronic disease.	Annual review of nutrition	2013	73
23644504	L-Threonine	Kim JS	Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways.	Nature immunology	2013	30
23649806	L-Threonine	Kleiblova P	Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.	The Journal of cell biology	2013	40
23737503	L-Threonine	Lim S	Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.	Proceedings of the National Academy of Sciences of the United States of America	2013	30
24121667	L-Threonine	Liang Q	CDK5 is essential for TGF-Œ≤1-induced epithelial-mesenchymal transition and breast cancer progression.	Scientific reports	2013	30
24140082	L-Threonine	McNeely S	CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.	Pharmacology & therapeutics	2014	39
24158481	L-Threonine	Nan X	Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling.	Proceedings of the National Academy of Sciences of the United States of America	2013	38
24333164	L-Threonine	Hwang J	STRIPAK complexes: structure, biological function, and involvement in human diseases.	The international journal of biochemistry & cell biology	2014	38
24338364	L-Threonine	Bruinsma W	Bora and Aurora-A continue to activate Plk1 in mitosis.	Journal of cell science	2014	25
24632603	L-Threonine	Goldenson B	The aurora kinases in cell cycle and leukemia.	Oncogene	2015	39
24705252	L-Threonine	Taylor KR	Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.	Nature genetics	2014	87
24769077	L-Threonine	Singh JP	O-GlcNAc signaling in cancer metabolism and epigenetics.	Cancer letters	2015	18
24771982	L-Threonine	Yang Y	Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses.	Mediators of inflammation	2014	43
24801365	L-Threonine	Souchet B	Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage.	Neurobiology of disease	2014	23
24931005	L-Threonine	McCubrey JA	GSK-3 as potential target for therapeutic intervention in cancer.	Oncotarget	2014	83
25010901	L-Threonine	Julian L	Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions.	Small GTPases	2014	62
25042806	L-Threonine	Goodwin JM	An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls Snail1 and metastatic potential.	Molecular cell	2014	32
25057166	L-Threonine	Missiaglia E	Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.	Annals of oncology 	2014	51
25200357	L-Threonine	Malumbres M	Aurora kinase A inhibitors: promising agents in antitumoral therapy.	Expert opinion on therapeutic targets	2014	23
25355599	L-Threonine	Chai J	MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase.	Tumour biology 	2015	17
25404613	L-Threonine	Zannini L	CHK2 kinase in the DNA damage response and beyond.	Journal of molecular cell biology	2014	33
25500543	L-Threonine	Lemieux E	Oncogenic KRAS signalling promotes the Wnt/Œ≤-catenin pathway through LRP6 in colorectal cancer.	Oncogene	2015	34
25541719	L-Threonine	Ortega CE	Mining CK2 in cancer.	PloS one	2014	34
25550082	L-Threonine	Jette N	The DNA-dependent protein kinase: A multifunctional protein kinase with roles in DNA double strand break repair and mitosis.	Progress in biophysics and molecular biology	2015	28
25684140	L-Threonine	Zhao D	Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation.	Oncogene	2015	20
25690731	L-Threonine	Kim EK	Compromised MAPK signaling in human diseases: an update.	Archives of toxicology	2015	50
25749412	L-Threonine	Warfel NA	PIM kinase (and Akt) biology and signaling in tumors.	Pharmacology & therapeutics	2015	29
25907074	L-Threonine	Perl A	mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.	Annals of the New York Academy of Sciences	2015	26
25931445	L-Threonine	Wong YL	Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4.	Science	2015	52
25971842	L-Threonine	Salton M	Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.	Nature communications	2015	15
25996294	L-Threonine	Fauster A	A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.	Cell death & disease	2015	20
26073081	L-Threonine	Fedorenko IV	Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.	Oncogene	2016	14
26388441	L-Threonine	Creixell P	Kinome-wide decoding of network-attacking mutations rewiring cancer signaling.	Cell	2015	27
26507691	L-Threonine	Sangodkar J	All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.	The FEBS journal	2016	32
26734566	L-Threonine	Bavetsias V	Aurora Kinase Inhibitors: Current Status and Outlook.	Frontiers in oncology	2015	22
26815163	L-Threonine	√Ökerstr√∂m T	Activating mutations in CTNNB1 in aldosterone producing adenomas.	Scientific reports	2016	15
26859459	L-Threonine	Kim SH	Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-Œ∫B-dependent Manner.	Cancer cell	2016	26
27107696	L-Threonine	Rang Z	miR-542-3p suppresses invasion and metastasis by targeting the proto-oncogene serine/threonine protein kinase, PIM1, in melanoma.	Biochemical and biophysical research communications	2016	13
27252362	L-Threonine	Katagiri T	Bone Morphogenetic Proteins.	Cold Spring Harbor perspectives in biology	2016	20
27487218	L-Threonine	Strilic B	Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis.	Nature	2016	19
27612668	L-Threonine	McCubrey JA	Effects of mutations in Wnt/Œ≤-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.	Biochimica et biophysica acta	2016	19
27959630	L-Threonine	Galluzzi L	Necroptosis: Mechanisms and Relevance to Disease.	Annual review of pathology	2017	13
28085182	L-Threonine	Buys SS	A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.	Cancer	2017	12
28847820	L-Threonine	Berger ND	ATM-dependent pathways of chromatin remodelling and oxidative DNA damage responses.	Philosophical transactions of the Royal Society of London. Series B, Biological sciences	2017	7
2014052	L-Serine	Garcia JV	Serine phosphorylation-independent downregulation of cell-surface CD4 by nef.	Nature	1991	272
3260265	L-Serine	Matsushima K	Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor.	The Journal of experimental medicine	1988	188
8521815	L-Serine	Kischkel FC	Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor.	The EMBO journal	1995	347
9212216	L-Serine	Andreasen PA	The urokinase-type plasminogen activator system in cancer metastasis: a review.	International journal of cancer	1997	220
9215638	L-Serine	Hayashi H	The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling.	Cell	1997	286
9312064	L-Serine	Orford K	Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin.	The Journal of biological chemistry	1997	184
9395435	L-Serine	Sells MA	Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells.	Current biology 	1997	206
9440696	L-Serine	Hemesath TJ	MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes.	Nature	1998	123
9753325	L-Serine	Lowe M	Cdc2 kinase directly phosphorylates the cis-Golgi matrix protein GM130 and is required for Golgi fragmentation in mitosis.	Cell	1998	108
10067896	L-Serine	Ulloa L	Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway.	Nature	1999	146
10197582	L-Serine	Korsmeyer SJ	BCL-2 gene family and the regulation of programmed cell death.	Cancer research	1999	123
10203785	L-Serine	Maehama T	PTEN: a tumour suppressor that functions as a phospholipid phosphatase.	Trends in cell biology	1999	123
10339577	L-Serine	Liu C	beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation.	Proceedings of the National Academy of Sciences of the United States of America	1999	111
10364156	L-Serine	Coussens LM	Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis.	Genes & development	1999	220
10442635	L-Serine	Bowden ET	An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation.	Oncogene	1999	112
10477747	L-Serine	Rogakou EP	Megabase chromatin domains involved in DNA double-strand breaks in vivo.	The Journal of cell biology	1999	701
10564676	L-Serine	Ali IU	Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.	Journal of the National Cancer Institute	1999	118
10576742	L-Serine	Zimmermann S	Phosphorylation and regulation of Raf by Akt (protein kinase B).	Science	1999	251
10617468	L-Serine	Brondello JM	Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation.	Science	1999	120
10724175	L-Serine	Lee JS	hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response.	Nature	2000	117
10802669	L-Serine	Gatei M	ATM-dependent phosphorylation of nibrin in response to radiation exposure.	Nature genetics	2000	114
10866664	L-Serine	Zhou M	Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription.	Molecular and cellular biology	2000	104
10913153	L-Serine	Ding VW	Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling.	The Journal of biological chemistry	2000	123
10938077	L-Serine	Wang D	Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II.	The Journal of biological chemistry	2000	113
10949579	L-Serine	Andreasen PA	The plasminogen activation system in tumor growth, invasion, and metastasis.	Cellular and molecular life sciences 	2000	193
11257227	L-Serine	Mowen KA	Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription.	Cell	2001	112
11259436	L-Serine	Madrid LV	Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38.	The Journal of biological chemistry	2001	163
11294823	L-Serine	Yousef GM	The new human tissue kallikrein gene family: structure, function, and association to disease.	Endocrine reviews	2001	94
11333986	L-Serine	Bulavin DV	Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase.	Nature	2001	128
11356985	L-Serine	Macfarlane SR	Proteinase-activated receptors.	Pharmacological reviews	2001	253
11404367	L-Serine	Opdenakker G	Gelatinase B functions as regulator and effector in leukocyte biology.	Journal of leukocyte biology	2001	103
11479199	L-Serine	Magee JA	Expression profiling reveals hepsin overexpression in prostate cancer.	Cancer research	2001	101
11520773	L-Serine	L√©vesque JP	Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor.	Blood	2001	107
11544179	L-Serine	Yamashita A	Human SMG-1, a novel phosphatidylinositol 3-kinase-related protein kinase, associates with components of the mRNA surveillance complex and is involved in the regulation of nonsense-mediated mRNA decay.	Genes & development	2001	120
11602612	L-Serine	Martins LM	The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif.	The Journal of biological chemistry	2002	84
11606375	L-Serine	Philp AJ	The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.	Cancer research	2001	134
11606597	L-Serine	Hegde R	Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction.	The Journal of biological chemistry	2002	117
11741534	L-Serine	M√ºller J	C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1.	Molecular cell	2001	87
11780126	L-Serine	D'Orazi G	Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.	Nature cell biology	2002	180
11784863	L-Serine	Crosio C	Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases.	Molecular and cellular biology	2002	184
11893489	L-Serine	Redon C	Histone H2A variants H2AX and H2AZ.	Current opinion in genetics & development	2002	180
12145307	L-Serine	Zipper LM	The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm.	The Journal of biological chemistry	2002	89
12236816	L-Serine	Sedelnikova OA	Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody.	Radiation research	2002	169
12525533	L-Serine	Balk SP	Biology of prostate-specific antigen.	Journal of clinical oncology 	2003	91
12527751	L-Serine	Wolf K	Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis.	The Journal of cell biology	2003	378
12535517	L-Serine	Basu S	Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis.	Molecular cell	2003	220
12551925	L-Serine	Corbit KC	Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein.	The Journal of biological chemistry	2003	93
12615961	L-Serine	Doble BW	GSK-3: tricks of the trade for a multi-tasking kinase.	Journal of cell science	2003	603
12629547	L-Serine	Plant PJ	A polarity complex of mPar-6 and atypical PKC binds, phosphorylates and regulates mammalian Lgl.	Nature cell biology	2003	105
12784997	L-Serine	Sidenius N	The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.	Cancer metastasis reviews	2003	86
14555991	L-Serine	Luciano F	Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.	Oncogene	2003	162
14701743	L-Serine	Zhang J	Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair.	Molecular and cellular biology	2004	99
14734469	L-Serine	Deng G	BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer.	Clinical cancer research 	2004	72
14754404	L-Serine	Duffy MJ	The urokinase plasminogen activator system: role in malignancy.	Current pharmaceutical design	2004	90
15077149	L-Serine	Saelens X	Toxic proteins released from mitochondria in cell death.	Oncogene	2004	150
15109565	L-Serine	Lampe PD	The effects of connexin phosphorylation on gap junctional communication.	The international journal of biochemistry & cell biology	2004	171
15466212	L-Serine	Ban√°th JP	Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines.	Cancer research	2004	88
15574592	L-Serine	Mehle A	Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.	Genes & development	2004	147
15710331	L-Serine	Puc J	Lack of PTEN sequesters CHK1 and initiates genetic instability.	Cancer cell	2005	100
15800615	L-Serine	Esashi F	CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair.	Nature	2005	142
15841306	L-Serine	Dellas C	Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease.	Thrombosis and haemostasis	2005	71
15841311	L-Serine	Dan√∏ K	Plasminogen activation and cancer.	Thrombosis and haemostasis	2005	86
16096270	L-Serine	Zabel BA	Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades.	The Journal of biological chemistry	2005	70
16226704	L-Serine	She QB	The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.	Cancer cell	2005	133
16474402	L-Serine	Sheng Y	Molecular recognition of p53 and MDM2 by USP7/HAUSP.	Nature structural & molecular biology	2006	70
16906133	L-Serine	Pellegrini M	Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo.	Nature	2006	62
17100578	L-Serine	Kockeritz L	Glycogen synthase kinase-3--an overview of an over-achieving protein kinase.	Current drug targets	2006	82
17101782	L-Serine	Tan Y	Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes.	Molecular and cellular biology	2007	89
17194196	L-Serine	Pogue-Geile KL	Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism.	PLoS medicine	2006	64
17259299	L-Serine	Rajput AB	Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.	Journal of clinical pathology	2007	59
17296736	L-Serine	Wang X	Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway.	Molecular and cellular biology	2007	58
17350576	L-Serine	Cai L	Coronin 1B coordinates Arp2/3 complex and cofilin activities at the leading edge.	Cell	2007	90
17434128	L-Serine	Huang WC	Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB.	Molecular cell	2007	91
17573418	L-Serine	Shaw JL	Distribution of 15 human kallikreins in tissues and biological fluids.	Clinical chemistry	2007	69
17632056	L-Serine	Junttila MR	CIP2A inhibits PP2A in human malignancies.	Cell	2007	181
17906618	L-Serine	Plun-Favreau H	The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.	Nature cell biology	2007	151
18023328	L-Serine	Takahashi-Yanaga F	GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy.	Cellular signalling	2008	82
18162327	L-Serine	Dass K	Evolving role of uPA/uPAR system in human cancers.	Cancer treatment reviews	2008	115
18227151	L-Serine	Lei QY	TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway.	Molecular and cellular biology	2008	251
18265945	L-Serine	Lu X	The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.	Cancer metastasis reviews	2008	77
18505969	L-Serine	Setlur SR	Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.	Journal of the National Cancer Institute	2008	110
18548086	L-Serine	Croucher DR	Revisiting the biological roles of PAI2 (SERPINB2) in cancer.	Nature reviews. Cancer	2008	50
19005492	L-Serine	Bonner WM	GammaH2AX and cancer.	Nature reviews. Cancer	2008	491
19091954	L-Serine	Wilsker D	Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control.	Proceedings of the National Academy of Sciences of the United States of America	2008	55
19200050	L-Serine	Ulisse S	The urokinase plasminogen activator system: a target for anti-cancer therapy.	Current cancer drug targets	2009	73
19329994	L-Serine	Eiseler T	Protein kinase D1 regulates cofilin-mediated F-actin reorganization and cell motility through slingshot.	Nature cell biology	2009	103
19409690	L-Serine	Tomlins SA	ETS gene fusions in prostate cancer: from discovery to daily clinical practice.	European urology	2009	102
19468302	L-Serine	Burkard ME	Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells.	PLoS biology	2009	69
19481526	L-Serine	Hutti JE	Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.	Molecular cell	2009	72
19573808	L-Serine	Miao H	EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.	Cancer cell	2009	121
19707781	L-Serine	Dickey JS	H2AX: functional roles and potential applications.	Chromosoma	2009	81
19818709	L-Serine	Kong M	Alpha4 is an essential regulator of PP2A phosphatase activity.	Molecular cell	2009	49
20036661	L-Serine	Blasi F	The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling.	FEBS letters	2010	74
20065038	L-Serine	Douglas P	Protein phosphatase 6 interacts with the DNA-dependent protein kinase catalytic subunit and dephosphorylates gamma-H2AX.	Molecular and cellular biology	2010	62
20103546	L-Serine	Lawrence MG	Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus.	Endocrine reviews	2010	50
20137952	L-Serine	Li A	The actin-bundling protein fascin stabilizes actin in invadopodia and potentiates protrusive invasion.	Current biology 	2010	94
20140016	L-Serine	Wang J	Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.	Oncogene	2010	46
20493860	L-Serine	Yuan J	Focus on histone variant H2AX: to be or not to be.	FEBS letters	2010	64
20514025	L-Serine	Puca R	Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.	Oncogene	2010	51
20543138	L-Serine	Kantidakis T	mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1.	Proceedings of the National Academy of Sciences of the United States of America	2010	65
20601956	L-Serine	Haffner MC	Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.	Nature genetics	2010	157
20651683	L-Serine	Choi JH	Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.	Nature	2010	247
20826466	L-Serine	Coombs GS	WLS-dependent secretion of WNT3A requires Ser209 acylation and vacuolar acidification.	Journal of cell science	2010	53
20980437	L-Serine	Gordon V	CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.	Molecular endocrinology	2010	49
21098708	L-Serine	Ustach CV	A novel signaling axis of matriptase/PDGF-D/√ü-PDGFR in human prostate cancer.	Cancer research	2010	41
21119616	L-Serine	Carr SM	Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein.	The EMBO journal	2011	37
21233335	L-Serine	Konicek BW	Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.	Cancer research	2011	52
21255644	L-Serine	Mi W	O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy.	Biochimica et biophysica acta	2011	64
21364033	L-Serine	Arastu-Kapur S	Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.	Clinical cancer research 	2011	94
21382551	L-Serine	Sun Y	Phosphorylation state of Olig2 regulates proliferation of neural progenitors.	Neuron	2011	41
21498570	L-Serine	Litovchick L	DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly.	Genes & development	2011	73
21538350	L-Serine	Thaiparambil JT	Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation.	International journal of cancer	2011	55
21577205	L-Serine	Maurer G	Raf kinases in cancer-roles and therapeutic opportunities.	Oncogene	2011	49
21668992	L-Serine	Lee HO	FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells.	BMC cancer	2011	48
21710321	L-Serine	Bidart M	BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain.	Cellular and molecular life sciences 	2012	34
21802835	L-Serine	Danila DC	TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.	European urology	2011	51
21805237	L-Serine	Seidah NG	The proprotein convertases, 20 years later.	Methods in molecular biology	2011	38
21813756	L-Serine	Tomlins SA	Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.	Science translational medicine	2011	107
21865393	L-Serine	Hyland PL	Evidence for alteration of EZH2, BMI1, and KDM6A and epigenetic reprogramming in human papillomavirus type 16 E6/E7-expressing keratinocytes.	Journal of virology	2011	37
22080055	L-Serine	Hoogland AM	ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.	Modern pathology 	2012	36
22128155	L-Serine	Ho KK	Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin.	The Journal of biological chemistry	2012	35
22205726	L-Serine	White D	The ATM substrate KAP1 controls DNA repair in heterochromatin: regulation by HP1 proteins and serine 473/824 phosphorylation.	Molecular cancer research 	2012	34
22275373	L-Serine	Chen S	Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation.	The Journal of biological chemistry	2012	32
22323494	L-Serine	Brennen WN	Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy.	Molecular cancer therapeutics	2012	53
22325354	L-Serine	Yata K	Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair.	Molecular cell	2012	46
22361354	L-Serine	Khoronenkova SV	ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage.	Molecular cell	2012	45
22392765	L-Serine	Hou J	Targeting Mnks for cancer therapy.	Oncotarget	2012	39
22509028	L-Serine	Devaiah BN	BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain.	Proceedings of the National Academy of Sciences of the United States of America	2012	87
22565321	L-Serine	Falck J	CDK targeting of NBS1 promotes DNA-end resection, replication restart and homologous recombination.	EMBO reports	2012	31
22605332	L-Serine	Ranuncolo SM	Evidence of the involvement of O-GlcNAc-modified human RNA polymerase II CTD in transcription in vitro and in vivo.	The Journal of biological chemistry	2012	43
22614006	L-Serine	Moleirinho S	KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.	Oncogene	2013	43
22623533	L-Serine	Zhang X	Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.	Proceedings of the National Academy of Sciences of the United States of America	2012	92
22695242	L-Serine	Choudhury AD	The role of genetic markers in the management of prostate cancer.	European urology	2012	32
22736790	L-Serine	Pettersson A	The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.	Cancer epidemiology, biomarkers & prevention 	2012	80
22942700	L-Serine	Dobolyi A	The neuroprotective functions of transforming growth factor beta proteins.	International journal of molecular sciences	2012	34
23045282	L-Serine	Hsu YL	Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/snail signaling pathway.	Oncogene	2013	28
23065822	L-Serine	Diamanti-Kandarakis E	Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.	Endocrine reviews	2012	128
23153585	L-Serine	Mizuno K	Signaling mechanisms and functional roles of cofilin phosphorylation and dephosphorylation.	Cellular signalling	2013	94
23201006	L-Serine	Tang L	The urokinase plasminogen activator system in breast cancer invasion and metastasis.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	2013	32
23208492	L-Serine	Casar B	In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated Œ≤1 integrin and induction of FAK/PI3K/Akt motility signaling.	Oncogene	2014	24
23209295	L-Serine	Zhu Y	Modulation of serines 17 and 24 in the LC3-interacting region of Bnip3 determines pro-survival mitophagy versus apoptosis.	The Journal of biological chemistry	2013	62
23277200	L-Serine	Barrett A	p130Cas: a key signalling node in health and disease.	Cellular signalling	2013	28
23306062	L-Serine	Laine A	Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.	Cancer discovery	2013	32
23449797	L-Serine	Jha HC	H2AX phosphorylation is important for LANA-mediated Kaposi's sarcoma-associated herpesvirus episome persistence.	Journal of virology	2013	33
23716601	L-Serine	Farrell AS	Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis.	Molecular and cellular biology	2013	25
23728337	L-Serine	Feng H	EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180.	Oncogene	2014	25
24040362	L-Serine	Zins K	A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice.	PloS one	2013	26
24101513	L-Serine	Adler JJ	Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.	Proceedings of the National Academy of Sciences of the United States of America	2013	38
24204027	L-Serine	Khanna A	Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.	Cancer research	2013	43
24366358	L-Serine	Martinod K	Thrombosis: tangled up in NETs.	Blood	2014	78
24373970	L-Serine	Niewiadomski P	Gli protein activity is controlled by multisite phosphorylation in vertebrate Hedgehog signaling.	Cell reports	2014	49
24469043	L-Serine	Sales KU	Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis.	Oncogene	2015	16
24488013	L-Serine	Miao H	EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties.	Oncogene	2015	30
24503642	L-Serine	Brosens JJ	Uterine selection of human embryos at implantation.	Scientific reports	2014	24
24591637	L-Serine	Wang S	Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	32
24657168	L-Serine	Rao F	Inositol pyrophosphates mediate the DNA-PK/ATM-p53 cell death pathway by regulating CK2 phosphorylation of Tti1/Tel2.	Molecular cell	2014	24
24760886	L-Serine	Masaki T	Involvement of hepatitis C virus NS5A hyperphosphorylation mediated by casein kinase I-Œ± in infectious virus production.	Journal of virology	2014	21
24927563	L-Serine	Janghorban M	Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	31
24949972	L-Serine	Eswarappa SM	Programmed translational readthrough generates antiangiogenic VEGF-Ax.	Cell	2014	42
25195567	L-Serine	Paulo JA	Effects of MEK inhibitors GSK1120212 and PD0325901 in vivo using 10-plex quantitative proteomics and phosphoproteomics.	Proteomics	2015	23
25220373	L-Serine	Marques RB	High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.	European urology	2015	17
25417107	L-Serine	Li Y	AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation.	Cell	2014	60
25457014	L-Serine	Loeb S	Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.	European urology	2015	22
25468710	L-Serine	Abdel-Fatah TM	Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.	Molecular oncology	2015	15
25497381	L-Serine	Koromilas AE	Roles of the translation initiation factor eIF2Œ± serine 51 phosphorylation in cancer formation and treatment.	Biochimica et biophysica acta	2015	25
25590801	L-Serine	Rajesh K	Phosphorylation of the translation initiation factor eIF2Œ± at serine 51 determines the cell fate decisions of Akt in response to oxidative stress.	Cell death & disease	2015	21
25601544	L-Serine	Zhang L	NDR functions as a physiological YAP1 kinase in the intestinal epithelium.	Current biology 	2015	22
25646088	L-Serine	Artym VV	Dense fibrillar collagen is a potent inducer of invadopodia via a specific signaling network.	The Journal of cell biology	2015	17
25658204	L-Serine	Serasinghe MN	Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors.	Molecular cell	2015	53
25698643	L-Serine	Prassas I	Unleashing the therapeutic potential of human kallikrein-related serine proteases.	Nature reviews. Drug discovery	2015	28
25795007	L-Serine	Bradley SD	BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma.	Cancer immunology research	2015	17
25855378	L-Serine	Virtakoivu R	Vimentin-ERK Signaling Uncouples Slug Gene Regulatory Function.	Cancer research	2015	21
25860938	L-Serine	Principe M	Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells.	Oncotarget	2015	24
25913390	L-Serine	Bostr√∂m PJ	Genomic Predictors of Outcome in Prostate Cancer.	European urology	2015	35
25998963	L-Serine	Voskoboinik I	Perforin and granzymes: function, dysfunction and human pathology.	Nature reviews. Immunology	2015	50
26279188	L-Serine	Chen FX	PAF1, a Molecular Regulator of Promoter-Proximal Pausing by RNA Polymerase II.	Cell	2015	36
26416733	L-Serine	Usami Y	SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef.	Nature	2015	54
26667094	L-Serine	Su SC	The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies.	Expert opinion on therapeutic targets	2016	18
26735014	L-Serine	Shu S	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.	Nature	2016	68
26811421	L-Serine	Moudry P	TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.	The Journal of cell biology	2016	12
27247400	L-Serine	Li H	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques.	Proceedings of the National Academy of Sciences of the United States of America	2016	26
27922627	L-Serine	Hendriks RJ	Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.	Prostate cancer and prostatic diseases	2017	6
28061466	L-Serine	Tanase CP	Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery.	Oncotarget	2017	7
28279977	L-Serine	Pan CW	AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction.	The EMBO journal	2017	7
28392147	L-Serine	Taabazuing CY	Pyroptosis and Apoptosis Pathways Engage in Bidirectional Crosstalk in Monocytes and Macrophages.	Cell chemical biology	2017	8
10728691	Celecoxib	Masferrer JL	Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.	Cancer research	2000	178
10874062	Celecoxib	Steinbach G	The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.	The New England journal of medicine	2000	344
11830509	Celecoxib	Leahy KM	Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.	Cancer research	2002	81
12559775	Celecoxib	Subbaramaiah K	Cyclooxygenase 2: a molecular target for cancer prevention and treatment.	Trends in pharmacological sciences	2003	86
15117884	Celecoxib	Warner TD	Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.	FASEB journal 	2004	103
15713944	Celecoxib	Solomon SD	Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.	The New England journal of medicine	2005	348
16707460	Celecoxib	Dohadwala M	Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.	Cancer research	2006	92
19218449	Celecoxib	Hu M	Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast.	Proceedings of the National Academy of Sciences of the United States of America	2009	68
19336730	Celecoxib	Bertagnolli MM	Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.	Cancer prevention research	2009	65
19822006	Celecoxib	Half E	Familial adenomatous polyposis.	Orphanet journal of rare diseases	2009	86
21115882	Celecoxib	Elmets CA	Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.	Journal of the National Cancer Institute	2010	46
21345578	Celecoxib	Jendrossek V	Targeting apoptosis pathways by Celecoxib in cancer.	Cancer letters	2013	43
21443470	Celecoxib	Khan Z	Biology of Cox-2: an application in cancer therapeutics.	Current drug targets	2011	37
23001726	Celecoxib	Saito Y	The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells.	International journal of cancer	2013	25
25470039	Celecoxib	Kurtova AV	Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.	Nature	2015	93
26261008	Celecoxib	Wang D	Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice.	Gastroenterology	2015	26
27769779	Celecoxib	Gowda R	Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.	Cancer letters	2017	7
1310350	All-trans-retinoic acid	Zhang XK	Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors.	Nature	1992	190
1652368	All-trans-retinoic acid	Kakizuka A	Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML.	Cell	1991	274
2673546	All-trans-retinoic acid	Chen PL	Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation.	Cell	1989	215
3520340	All-trans-retinoic acid	Bentley DL	A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells.	Nature	1986	257
8131741	All-trans-retinoic acid	Koken MH	The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion.	The EMBO journal	1994	121
8293467	All-trans-retinoic acid	Dyck JA	A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein.	Cell	1994	201
8622766	All-trans-retinoic acid	Zhang J	Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2.	Nature	1996	127
10669754	All-trans-retinoic acid	Li H	Sequestration and inhibition of Daxx-mediated transcriptional repression by PML.	Molecular and cellular biology	2000	99
10936180	All-trans-retinoic acid	Encinas M	Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells.	Journal of neurochemistry	2000	134
11196170	All-trans-retinoic acid	Z√∂chbauer-M√ºller S	Aberrant promoter methylation of multiple genes in non-small cell lung cancers.	Cancer research	2001	110
11491531	All-trans-retinoic acid	Steinle A	Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.	Immunogenetics	2001	97
11704856	All-trans-retinoic acid	Regad T	Role and fate of PML nuclear bodies in response to interferon and viral infections.	Oncogene	2001	103
11834837	All-trans-retinoic acid	Di Croce L	Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor.	Science	2002	144
15003116	All-trans-retinoic acid	Sempere LF	Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation.	Genome biology	2004	524
16179254	All-trans-retinoic acid	Epping MT	The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.	Cell	2005	95
16585524	All-trans-retinoic acid	Loo YM	Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.	Proceedings of the National Academy of Sciences of the United States of America	2006	171
17283129	All-trans-retinoic acid	Chen Y	Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.	Cancer research	2007	120
17297439	All-trans-retinoic acid	Welch C	MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells.	Oncogene	2007	259
17314394	All-trans-retinoic acid	Freberg CT	Epigenetic reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract.	Molecular biology of the cell	2007	61
17512406	All-trans-retinoic acid	Schug TT	Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors.	Cell	2007	219
17534450	All-trans-retinoic acid	Rhodes DR	Molecular concepts analysis links tumors, pathways, mechanisms, and drugs.	Neoplasia	2007	68
17560333	All-trans-retinoic acid	Villa R	Role of the polycomb repressive complex 2 in acute promyelocytic leukemia.	Cancer cell	2007	71
17906642	All-trans-retinoic acid	Altucci L	RAR and RXR modulation in cancer and metabolic disease.	Nature reviews. Drug discovery	2007	148
18024835	All-trans-retinoic acid	Chaturvedi P	Structure, evolution, and biology of the MUC4 mucin.	FASEB journal 	2008	67
18948594	All-trans-retinoic acid	Gack MU	Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction.	Proceedings of the National Academy of Sciences of the United States of America	2008	73
18978796	All-trans-retinoic acid	Poeck H	5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma.	Nature medicine	2008	90
19056420	All-trans-retinoic acid	Cheung YT	Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research.	Neurotoxicology	2009	71
19345331	All-trans-retinoic acid	Huang S	ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome.	Cancer cell	2009	51
19451695	All-trans-retinoic acid	Payton JE	High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples.	The Journal of clinical investigation	2009	64
19471102	All-trans-retinoic acid	Xia HF	MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf.	Cellular physiology and biochemistry 	2009	56
19625408	All-trans-retinoic acid	Wang N	Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells.	Journal of virology	2009	82
19656871	All-trans-retinoic acid	Pichlmair A	Activation of MDA5 requires higher-order RNA structures generated during virus infection.	Journal of virology	2009	124
19713529	All-trans-retinoic acid	Evangelisti C	MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness.	FASEB journal 	2009	46
19747919	All-trans-retinoic acid	Weiss FU	Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer.	Gastroenterology	2009	71
20212135	All-trans-retinoic acid	Jullien J	Characterization of somatic cell nuclear reprogramming by oocytes in which a linker histone is required for pluripotency gene reactivation.	Proceedings of the National Academy of Sciences of the United States of America	2010	40
20966922	All-trans-retinoic acid	de Th√© H	Acute promyelocytic leukaemia: novel insights into the mechanisms of cure.	Nature reviews. Cancer	2010	115
21212796	All-trans-retinoic acid	Foley NH	MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2.	Cell death and differentiation	2011	39
22134508	All-trans-retinoic acid	Pili R	Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.	British journal of cancer	2012	34
22493297	All-trans-retinoic acid	Wang XS	MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia.	Blood	2012	52
23325835	All-trans-retinoic acid	Muranski P	Essentials of Th17 cell commitment and plasticity.	Blood	2013	103
23375374	All-trans-retinoic acid	Kittler R	A comprehensive nuclear receptor network for breast cancer cells.	Cell reports	2013	31
23589106	All-trans-retinoic acid	Iclozan C	Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.	Cancer immunology, immunotherapy 	2013	76
23653115	All-trans-retinoic acid	Martin JC	Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid.	Mucosal immunology	2014	23
23699600	All-trans-retinoic acid	Kaiser MF	Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.	Blood	2013	41
23863747	All-trans-retinoic acid	Guilhamon P	Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.	Nature communications	2013	41
24078252	All-trans-retinoic acid	Akdemir KC	Genome-wide profiling reveals stimulus-specific functions of p53 during differentiation and DNA damage of human embryonic stem cells.	Nucleic acids research	2014	30
24360797	All-trans-retinoic acid	Hou J	Hepatic RIG-I predicts survival and interferon-Œ± therapeutic response in hepatocellular carcinoma.	Cancer cell	2014	32
24577401	All-trans-retinoic acid	Kojetin DJ	REV-ERB and ROR nuclear receptors as drug targets.	Nature reviews. Drug discovery	2014	58
24602822	All-trans-retinoic acid	Mincheva-Nilsson L	Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance.	Seminars in cancer biology	2014	25
24833036	All-trans-retinoic acid	Israelow B	HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection.	Hepatology	2014	23
24931123	All-trans-retinoic acid	Zhu J	Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor.	Immunity	2014	40
25231870	All-trans-retinoic acid	Perry JR	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche.	Nature	2014	93
25240927	All-trans-retinoic acid	Witty AD	Generation of the epicardial lineage from human pluripotent stem cells.	Nature biotechnology	2014	31
25363776	All-trans-retinoic acid	McCracken KW	Modelling human development and disease in pluripotent stem-cell-derived gastric organoids.	Nature	2014	99
25636082	All-trans-retinoic acid	Sosa MS	NR2F1 controls tumour cell dormancy via SOX9- and RARŒ≤-driven quiescence programmes.	Nature communications	2015	25
27590114	All-trans-retinoic acid	Bhattacharya N	Normalizing Microbiota-Induced Retinoic Acid Deficiency Stimulates Protective CD8(+) T Cell-Mediated Immunity in Colorectal Cancer.	Immunity	2016	11
28017614	All-trans-retinoic acid	Li Z	FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase.	Cancer cell	2017	31
28073693	All-trans-retinoic acid	Zevini A	Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways.	Trends in immunology	2017	14
12623848	Imatinib	Branford S	Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.	Blood	2003	115
12654249	Imatinib	Azam M	Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.	Cell	2003	144
14645423	Imatinib	Heinrich MC	Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.	Journal of clinical oncology 	2003	377
14737178	Imatinib	Steelman LS	JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.	Leukemia	2004	130
15306667	Imatinib	Jamieson CH	Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.	The New England journal of medicine	2004	408
15618470	Imatinib	Deininger M	The development of imatinib as a therapeutic agent for chronic myeloid leukemia.	Blood	2005	229
15685537	Imatinib	Debiec-Rychter M	Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.	Gastroenterology	2005	103
15781488	Imatinib	Blay JY	Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.	Annals of oncology 	2005	131
15867244	Imatinib	Cortes J	Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.	Clinical cancer research 	2005	77
15980154	Imatinib	Komarova NL	Drug resistance in cancer: principles of emergence and prevention.	Proceedings of the National Academy of Sciences of the United States of America	2005	96
16170379	Imatinib	Roman-Gomez J	Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia.	Oncogene	2005	71
16286244	Imatinib	Neviani P	The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.	Cancer cell	2005	159
16344315	Imatinib	Yanada M	High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.	Journal of clinical oncology 	2006	62
16477019	Imatinib	Radich JP	Gene expression changes associated with progression and response in chronic myeloid leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2006	136
16624552	Imatinib	Debiec-Rychter M	KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.	European journal of cancer	2006	171
16625094	Imatinib	Miettinen M	Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up.	The American journal of surgical pathology	2006	100
16908931	Imatinib	Curtin JA	Somatic activation of KIT in distinct subtypes of melanoma.	Journal of clinical oncology 	2006	284
16954519	Imatinib	Heinrich MC	Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.	Journal of clinical oncology 	2006	171
16973963	Imatinib	Rousselot P	Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.	Blood	2007	110
17114238	Imatinib	Puttini M	In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.	Cancer research	2006	75
17138817	Imatinib	Hochhaus A	Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.	Blood	2007	128
17185463	Imatinib	Cortes J	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.	Blood	2007	77
17189410	Imatinib	Soverini S	Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.	Clinical cancer research 	2006	109
17213283	Imatinib	J√∏rgensen HG	Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.	Blood	2007	84
17264298	Imatinib	Guilhot F	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.	Blood	2007	73
17284533	Imatinib	Venturini L	Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.	Blood	2007	88
17317857	Imatinib	Kantarjian H	Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.	Blood	2007	80
17457302	Imatinib	Weisberg E	Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.	Nature reviews. Cancer	2007	118
17496200	Imatinib	O'Hare T	Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.	Blood	2007	124
17496201	Imatinib	Ottmann O	Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.	Blood	2007	77
17605814	Imatinib	Deprimo SE	Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.	Journal of translational medicine	2007	91
17710227	Imatinib	Shah NP	Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.	The Journal of clinical investigation	2007	103
17761829	Imatinib	White DL	Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.	Blood	2007	60
17853901	Imatinib	Quint√°s-Cardama A	Flying under the radar: the new wave of BCR-ABL inhibitors.	Nature reviews. Drug discovery	2007	71
17907802	Imatinib	Swingler S	Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein.	PLoS pathogens	2007	66
18232728	Imatinib	Pietras K	Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.	PLoS medicine	2008	113
18235121	Imatinib	Blanke CD	Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.	Journal of clinical oncology 	2008	214
18401416	Imatinib	Hochhaus A	Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.	Leukemia	2008	88
18550829	Imatinib	Tarn C	Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.	Proceedings of the National Academy of Sciences of the United States of America	2008	71
18615679	Imatinib	Agaram NP	Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.	Genes, chromosomes & cancer	2008	70
18765229	Imatinib	Gal H	MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells.	Biochemical and biophysical research communications	2008	73
18772113	Imatinib	Dierks C	Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.	Cancer cell	2008	143
18818703	Imatinib	Hu Y	beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.	Leukemia	2009	65
18955458	Imatinib	Heinrich MC	Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.	Journal of clinical oncology 	2008	132
18980976	Imatinib	Beadling C	KIT gene mutations and copy number in melanoma subtypes.	Clinical cancer research 	2008	113
19061839	Imatinib	Shah NP	Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.	Cancer cell	2008	87
19091943	Imatinib	Luo B	Highly parallel identification of essential genes in cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2008	214
19169242	Imatinib	Zhao C	Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.	Nature	2009	240
19188143	Imatinib	Yang JY	A new fork for clinical application: targeting forkhead transcription factors in cancer.	Clinical cancer research 	2009	83
19303137	Imatinib	Dematteo RP	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.	Lancet	2009	270
19351841	Imatinib	M√©nard C	Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.	Cancer research	2009	54
19363496	Imatinib	Fan AC	Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens.	Nature medicine	2009	48
19369233	Imatinib	Quint√°s-Cardama A	Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy.	Blood	2009	52
19732723	Imatinib	Klemm L	The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia.	Cancer cell	2009	54
19779040	Imatinib	M√ºller MC	Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.	Blood	2009	67
19822896	Imatinib	Rosti G	Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.	Blood	2009	54
19878872	Imatinib	O'Hare T	AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.	Cancer cell	2009	235
19965620	Imatinib	Huang Y	Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type.	Blood	2010	50
20103647	Imatinib	Puissant A	Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.	Cancer research	2010	93
20124181	Imatinib	Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST).	Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.	Journal of clinical oncology 	2010	89
20139391	Imatinib	Shah NP	Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.	Haematologica	2010	55
20233975	Imatinib	Carette JE	Generation of iPSCs from cultured human malignant cells.	Blood	2010	75
20421539	Imatinib	White DL	Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.	Journal of clinical oncology 	2010	42
20660757	Imatinib	Gupta A	Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST).	Proceedings of the National Academy of Sciences of the United States of America	2010	64
21125679	Imatinib	Antonescu CR	The GIST paradigm: lessons for other kinase-driven cancers.	The Journal of pathology	2011	38
21157039	Imatinib	Corbin AS	Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.	The Journal of clinical investigation	2011	189
21228332	Imatinib	Matutes E	Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification.	Blood	2011	41
21422420	Imatinib	Hehlmann R	Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-Œ± in newly diagnosed chronic myeloid leukemia.	Journal of clinical oncology 	2011	62
21856226	Imatinib	Kantarjian HM	Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.	The Lancet. Oncology	2011	99
21865346	Imatinib	Cortes JE	Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.	Blood	2011	77
21873989	Imatinib	Balachandran VP	Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.	Nature medicine	2011	140
21931113	Imatinib	Fo√† R	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.	Blood	2011	61
22160483	Imatinib	Kantarjian HM	Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).	Blood	2012	117
22282465	Imatinib	Miranda C	KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.	Clinical cancer research 	2012	43
22331945	Imatinib	Stacchiotti S	Phase II study of imatinib in advanced chordoma.	Journal of clinical oncology 	2012	35
22453568	Imatinib	Joensuu H	One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.	JAMA	2012	151
22592606	Imatinib	Kumano K	Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples.	Blood	2012	44
22614970	Imatinib	George S	Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.	Journal of clinical oncology 	2012	48
22699418	Imatinib	Larson RA	Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.	Leukemia	2012	76
22745105	Imatinib	Heinrich MC	Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.	Clinical cancer research 	2012	45
22898035	Imatinib	Dickson MA	Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors.	Annals of oncology 	2013	29
23099009	Imatinib	Robertson KA	Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.	The Lancet. Oncology	2012	37
23177515	Imatinib	Demetri GD	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.	Lancet	2013	203
23505219	Imatinib	Cadamuro M	Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma.	Hepatology	2013	28
23704092	Imatinib	Ross DM	Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.	Blood	2013	92
23775962	Imatinib	Hodi FS	Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.	Journal of clinical oncology 	2013	51
24297946	Imatinib	Hehlmann R	Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.	Journal of clinical oncology 	2014	52
24335106	Imatinib	Hughes TP	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.	Blood	2014	42
24569263	Imatinib	Shah NP	Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.	Blood	2014	26
24577808	Imatinib	Gotlib J	World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.	American journal of hematology	2014	25
24638003	Imatinib	Corless CL	Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.	Journal of clinical oncology 	2014	40
24711084	Imatinib	Prendergast GC	Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.	Cancer immunology, immunotherapy 	2014	61
24778155	Imatinib	Herrmann H	Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.	Blood	2014	28
24789445	Imatinib	Pickard MR	Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy.	Breast cancer research and treatment	2014	36
24925196	Imatinib	von Mehren M	Gastrointestinal stromal tumors, version 2.2014.	Journal of the National Comprehensive Cancer Network 	2014	26
25515961	Imatinib	Wang LS	MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors.	Blood	2015	29
25871397	Imatinib	Liao H	MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.	Oncotarget	2015	18
27217448	Imatinib	Cortes JE	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na√Øve Chronic Myeloid Leukemia Patients Trial.	Journal of clinical oncology 	2016	27
27854515	Imatinib	Xiao Y	lncRNA UCA1 Contributes to Imatinib Resistance by Acting as a ceRNA Against miR-16 in Chronic Myeloid Leukemia Cells.	DNA and cell biology	2017	6
28095277	Imatinib	Etienne G	Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.	Journal of clinical oncology 	2017	14
28319085	Imatinib	Han K	Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.	Nature biotechnology	2017	14
28329763	Imatinib	Wylie AA	The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.	Nature	2017	6
12531805	Sunitinib	O'Farrell AM	SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.	Blood	2003	170
12538485	Sunitinib	Mendel DB	In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.	Clinical cancer research 	2003	393
15459012	Sunitinib	Fiedler W	A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.	Blood	2005	83
17512858	Sunitinib	Rubin BP	Gastrointestinal stromal tumour.	Lancet	2007	93
18310500	Sunitinib	Hipp MM	Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.	Blood	2008	71
19064974	Sunitinib	Golshayan AR	Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.	Journal of clinical oncology 	2009	51
19224847	Sunitinib	Feldman DR	Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	72
20006922	Sunitinib	Izzedine H	VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.	European journal of cancer	2010	42
20007803	Sunitinib	Pratz KW	FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.	Blood	2010	82
20103651	Sunitinib	Huang D	Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.	Cancer research	2010	114
20339913	Sunitinib	Barrios CH	Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.	Breast cancer research and treatment	2010	50
20368560	Sunitinib	Hainsworth JD	Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.	Journal of clinical oncology 	2010	49
20881001	Sunitinib	Amato RJ	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.	Clinical cancer research 	2010	47
21527770	Sunitinib	Rini BI	Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.	Journal of the National Cancer Institute	2011	122
21664867	Sunitinib	N√©grier S	Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.	The Lancet. Oncology	2011	38
21882181	Sunitinib	Kim JJ	Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.	Cancer	2012	37
22308314	Sunitinib	Conley SJ	Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.	Proceedings of the National Academy of Sciences of the United States of America	2012	160
23378344	Sunitinib	Hollier BG	FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.	Cancer research	2013	75
23630200	Sunitinib	Kummar S	Cediranib for metastatic alveolar soft part sarcoma.	Journal of clinical oncology 	2013	37
24482243	Sunitinib	Vasudev NS	Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.	Angiogenesis	2014	119
24589894	Sunitinib	Llovet JM	Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.	Clinical cancer research 	2014	78
25123505	Sunitinib	Mikami S	Expression of TNF-Œ± and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas.	International journal of cancer	2015	22
25361735	Sunitinib	Huang H	VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-Œ∫B-induced endothelial activation.	FASEB journal 	2015	22
25488966	Sunitinib	Hobday TJ	Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.	Journal of clinical oncology 	2015	19
25538263	Sunitinib	Choueiri TK	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.	Clinical cancer research 	2015	34
26626617	Sunitinib	Tannir NM	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.	European urology	2016	26
27297795	Sunitinib	Oppermann S	High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.	Blood	2016	11
27487138	Sunitinib	Goto Y	The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma.	Oncotarget	2016	15
28199818	Sunitinib	Choueiri TK	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.	Journal of clinical oncology 	2017	15
28445140	Sunitinib	Jitariu AA	Triple negative breast cancer: the kiss of death.	Oncotarget	2017	6
15956649	Erlotinib	Haas-Kogan DA	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.	Journal of the National Cancer Institute	2005	137
16014883	Erlotinib	Tsao MS	Erlotinib in lung cancer - molecular and clinical predictors of outcome.	The New England journal of medicine	2005	325
16230409	Erlotinib	Thomson S	Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.	Cancer research	2005	205
16282176	Erlotinib	Mellinghoff IK	Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.	The New England journal of medicine	2005	416
16361555	Erlotinib	Yauch RL	Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.	Clinical cancer research 	2005	171
16609043	Erlotinib	Sarkaria JN	Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.	Clinical cancer research 	2006	112
16730237	Erlotinib	Ji H	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.	Cancer cell	2006	130
16809731	Erlotinib	Philip PA	Phase II study of erlotinib in patients with advanced biliary cancer.	Journal of clinical oncology 	2006	71
17050876	Erlotinib	Dragovich T	Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.	Journal of clinical oncology 	2006	80
17121914	Erlotinib	Buck E	Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.	Molecular cancer therapeutics	2006	69
17228019	Erlotinib	Jackman DM	Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2007	84
17374728	Erlotinib	Tabernero J	The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.	Molecular cancer research 	2007	83
17452677	Erlotinib	Moore MJ	Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.	Journal of clinical oncology 	2007	876
18089817	Erlotinib	Deng J	Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.	Cancer research	2007	63
18281673	Erlotinib	Eberhard DA	Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.	Journal of clinical oncology 	2008	72
18309947	Erlotinib	Rudin CM	Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.	Journal of clinical oncology 	2008	59
18349398	Erlotinib	Miller VA	Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.	Journal of clinical oncology 	2008	73
18452692	Erlotinib	Molina JR	Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.	Mayo Clinic proceedings	2008	411
18626007	Erlotinib	Zhu CQ	Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.	Journal of clinical oncology 	2008	170
18698032	Erlotinib	Morgan MA	The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.	Clinical cancer research 	2008	56
18794081	Erlotinib	Riely GJ	Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.	Clinical cancer research 	2008	139
18955445	Erlotinib	Brown PD	Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.	Journal of clinical oncology 	2008	67
19075262	Erlotinib	Prados MD	Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.	Journal of clinical oncology 	2009	97
19139433	Erlotinib	Thomas MB	Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.	Journal of clinical oncology 	2009	83
19201650	Erlotinib	Cohen EE	Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.	The Lancet. Oncology	2009	56
19238632	Erlotinib	Tang Z	Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.	British journal of cancer	2008	59
19278961	Erlotinib	Ma WW	Novel agents on the horizon for cancer therapy.	CA	2009	80
19351834	Erlotinib	Sos ML	PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.	Cancer research	2009	134
19452131	Erlotinib	Li T	Skin toxicities associated with epidermal growth factor receptor inhibitors.	Targeted oncology	2009	52
19562254	Erlotinib	Reardon DA	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.	Journal of neuro-oncology	2010	65
19806209	Erlotinib	Gong Y	High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).	PloS one	2009	58
20142592	Erlotinib	Haura EB	Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	66
20595147	Erlotinib	Porta R	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.	The European respiratory journal	2011	68
20603615	Erlotinib	Ye X	An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies.	Oncogene	2010	71
20959484	Erlotinib	Yamamoto C	Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.	Cancer research	2010	43
21045158	Erlotinib	Shultz JC	Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.	Cancer research	2010	46
21130517	Erlotinib	Brevet M	Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.	Lung cancer	2011	40
21282542	Erlotinib	Natale RB	Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	71
21412767	Erlotinib	Zhang Y	Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway.	Journal of cellular physiology	2012	36
21422426	Erlotinib	Zander T	Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using (18)Ffluorodeoxyglucose and (18)Ffluorothymidine positron emission tomography.	Journal of clinical oncology 	2011	41
21430781	Erlotinib	Bivona TG	FAS and NF-Œ∫B signalling modulate dependence of lung cancers on mutant EGFR.	Nature	2011	112
21576636	Erlotinib	Spigel DR	Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	44
21636705	Erlotinib	Wick W	Pathway inhibition: emerging molecular targets for treating glioblastoma.	Neuro-oncology	2011	49
21865399	Erlotinib	Grommes C	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.	Neuro-oncology	2011	74
22025157	Erlotinib	Ramalingam SS	Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.	Journal of clinical oncology 	2011	62
22135231	Erlotinib	Chaft JE	Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.	Molecular cancer therapeutics	2012	58
22180495	Erlotinib	Yang H	Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.	Cancer research	2012	58
22203961	Erlotinib	Shi Q	Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells.	Proceedings of the National Academy of Sciences of the United States of America	2012	67
22440336	Erlotinib	Scagliotti GV	Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.	Clinical lung cancer	2012	47
22492982	Erlotinib	Punnoose EA	Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.	Clinical cancer research 	2012	91
22753918	Erlotinib	Ramalingam SS	Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2012	66
22961667	Erlotinib	Ercan D	Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.	Cancer discovery	2012	85
23172311	Erlotinib	Huang S	Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.	Cancer research	2013	37
23341526	Erlotinib	Welsh JW	Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.	Journal of clinical oncology 	2013	87
23341531	Erlotinib	Herman JM	Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.	Journal of clinical oncology 	2013	36
23460709	Erlotinib	Martins RG	Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.	Journal of clinical oncology 	2013	34
23894143	Erlotinib	Li R	Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.	Molecular cancer therapeutics	2013	41
23994953	Erlotinib	Vazquez-Martin A	IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations.	Scientific reports	2013	27
24101053	Erlotinib	Spigel DR	Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2013	115
24429876	Erlotinib	Oxnard GR	Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.	Clinical cancer research 	2014	147
24550739	Erlotinib	Borad MJ	Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.	PLoS genetics	2014	59
24687921	Erlotinib	Koeppen H	Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib¬±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.	Clinical cancer research 	2014	31
24773774	Erlotinib	Weber B	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.	BMC cancer	2014	32
24841974	Erlotinib	Kawaguchi T	Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).	Journal of clinical oncology 	2014	60
25009014	Erlotinib	Azuma K	Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.	Annals of oncology 	2014	91
25031274	Erlotinib	Lee SM	Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.	Journal of the National Cancer Institute	2014	26
25137181	Erlotinib	Marchetti A	Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.	PloS one	2014	44
25149530	Erlotinib	Xu J	MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.	Oncotarget	2014	24
25714397	Erlotinib	Stahlhut C	Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.	Cell cycle	2015	23
25897473	Erlotinib	Cook GJ	Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.	Radiology	2015	20
25964297	Erlotinib	Niederst MJ	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.	Clinical cancer research 	2015	60
26181014	Erlotinib	Karachaliou N	Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.	JAMA oncology	2015	50
26309190	Erlotinib	Hata A	Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI.	Journal of thoracic oncology 	2015	17
26540028	Erlotinib	William WN Jr	Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.	JAMA oncology	2016	13
26720423	Erlotinib	Park K	First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.	JAMA oncology	2016	28
26802155	Erlotinib	Carter CA	Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.	Annals of oncology 	2016	14
26891683	Erlotinib	Ramirez M	Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells.	Nature communications	2016	23
27281561	Erlotinib	Yanagita M	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.	Clinical cancer research 	2016	19
27409162	Erlotinib	Hsu PC	YAP promotes erlotinib resistance in human non-small cell lung cancer cells.	Oncotarget	2016	12
27803065	Erlotinib	Rosen LS	A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.	Clinical cancer research 	2017	6
28061471	Erlotinib	Li L	Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report.	Oncotarget	2017	6
9661897	Paclitaxel	Baselga J	Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.	Cancer research	1998	130
11248153	Paclitaxel	Slamon DJ	Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.	The New England journal of medicine	2001	1772
11861387	Paclitaxel	Hu L	Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.	Cancer research	2002	85
15136595	Paclitaxel	Ayers M	Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.	Journal of clinical oncology 	2004	76
15671559	Paclitaxel	Mozzetti S	Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.	Clinical cancer research 	2005	91
15738535	Paclitaxel	Buzdar AU	Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.	Journal of clinical oncology 	2005	185
15766661	Paclitaxel	Tan TT	Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.	Cancer cell	2005	81
15914550	Paclitaxel	Rouzier R	Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2005	77
16236738	Paclitaxel	Romond EH	Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.	The New England journal of medicine	2005	1023
16258083	Paclitaxel	Tan-Chiu E	Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.	Journal of clinical oncology 	2005	130
16322248	Paclitaxel	Isakoff SJ	Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.	Cancer research	2005	174
16585214	Paclitaxel	Kelly MG	TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.	Cancer research	2006	135
16809727	Paclitaxel	Perez EA	HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.	Journal of clinical oncology 	2006	87
16972248	Paclitaxel	Becker KA	Self-renewal of human embryonic stem cells is supported by a shortened G1 cell cycle phase.	Journal of cellular physiology	2006	142
17200359	Paclitaxel	Buzdar AU	Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.	Clinical cancer research 	2007	94
17234791	Paclitaxel	Hou DY	Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.	Cancer research	2007	146
17538177	Paclitaxel	Gerstner ER	Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.	Journal of clinical oncology 	2007	58
17611683	Paclitaxel	Kajiyama H	Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.	International journal of oncology	2007	127
17965935	Paclitaxel	Zhou J	NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells.	Breast cancer research and treatment	2008	55
18250349	Paclitaxel	Perez EA	Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.	Journal of clinical oncology 	2008	105
18366788	Paclitaxel	Fillmore CM	Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.	Breast cancer research 	2008	368
18375893	Paclitaxel	Seidman AD	Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.	Journal of clinical oncology 	2008	121
18451153	Paclitaxel	Shi J	Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.	Cancer research	2008	81
18676833	Paclitaxel	Ding Q	Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.	Cancer research	2008	53
18758960	Paclitaxel	Tsang WP	Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3.	Apoptosis 	2008	65
18824714	Paclitaxel	Schneider BP	Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.	Journal of clinical oncology 	2008	171
19491198	Paclitaxel	Walker SR	Reciprocal effects of STAT5 and STAT3 in breast cancer.	Molecular cancer research 	2009	53
19544473	Paclitaxel	Kurrey NK	Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells.	Stem cells	2009	191
19665763	Paclitaxel	Inaba T	Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma.	Gynecologic oncology	2009	47
19720913	Paclitaxel	Gray R	Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.	Journal of clinical oncology 	2009	56
19748175	Paclitaxel	Zhang Q	A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy.	Cancer letters	2010	56
19826413	Paclitaxel	Szajnik M	TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.	Oncogene	2009	55
20124458	Paclitaxel	Park ES	Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set.	Molecular cancer therapeutics	2010	43
20406806	Paclitaxel	Fujita Y	MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression.	The Journal of biological chemistry	2010	54
20530690	Paclitaxel	Carr JR	FoxM1 mediates resistance to herceptin and paclitaxel.	Cancer research	2010	71
20697084	Paclitaxel	Perez EA	HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.	Journal of clinical oncology 	2010	53
20709389	Paclitaxel	Loessner D	Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells.	Biomaterials	2010	102
20807808	Paclitaxel	Zhu ML	Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.	Cancer research	2010	87
20829329	Paclitaxel	Tabchy A	Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.	Clinical cancer research 	2010	56
21109570	Paclitaxel	Tamura K	FcŒ≥R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.	Annals of oncology 	2011	47
21189395	Paclitaxel	Press MF	Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.	Journal of clinical oncology 	2011	51
21270667	Paclitaxel	Zhang JG	MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.	Journal of thoracic oncology 	2011	54
21354697	Paclitaxel	Li J	miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression.	Cancer letters	2011	36
21768458	Paclitaxel	Perez EA	Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.	Journal of clinical oncology 	2011	155
21788566	Paclitaxel	Untch M	Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.	Journal of clinical oncology 	2011	77
21791703	Paclitaxel	Quintavalle M	A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion.	Science signaling	2011	36
22019123	Paclitaxel	Zhang Y	The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles.	Biomaterials	2012	36
22042958	Paclitaxel	Perez EA	Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.	Journal of clinical oncology 	2011	59
22184370	Paclitaxel	Karlan BY	Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.	Journal of clinical oncology 	2012	61
22245726	Paclitaxel	Akiyama K	Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment.	The American journal of pathology	2012	35
22335738	Paclitaxel	Stone RL	Paraneoplastic thrombocytosis in ovarian cancer.	The New England journal of medicine	2012	130
22768203	Paclitaxel	Singh S	Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.	PloS one	2012	35
22843789	Paclitaxel	Baldwin RM	A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.	Clinical cancer research 	2012	47
22932669	Paclitaxel	Sangai T	Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.	Clinical cancer research 	2012	45
22987084	Paclitaxel	Romond EH	Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.	Journal of clinical oncology 	2012	72
22987486	Paclitaxel	Thadani-Mulero M	Androgen receptor on the move: boarding the microtubule expressway to the nucleus.	Cancer research	2012	35
23074172	Paclitaxel	Cittelly DM	Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel.	Molecular cancer therapeutics	2012	39
23094027	Paclitaxel	Limame R	Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays.	PloS one	2012	58
23359505	Paclitaxel	Sevko A	Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.	Journal of immunology	2013	31
23391723	Paclitaxel	Bhola NE	TGF-Œ≤ inhibition enhances chemotherapy action against triple-negative breast cancer.	The Journal of clinical investigation	2013	106
23401453	Paclitaxel	Lambrechts D	Markers of response for the antiangiogenic agent bevacizumab.	Journal of clinical oncology 	2013	90
23514751	Paclitaxel	Khongkow M	SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.	Carcinogenesis	2013	29
23720768	Paclitaxel	Rajput S	TLR4 is a novel determinant of the response to paclitaxel in breast cancer.	Molecular cancer therapeutics	2013	28
23750239	Paclitaxel	Gao J	MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1.	PloS one	2013	34
23849556	Paclitaxel	Heinemann V	Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.	Cancer treatment reviews	2014	30
23871962	Paclitaxel	Swaminathan SK	CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer.	Journal of controlled release 	2013	27
23943797	Paclitaxel	Cieply B	Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2.	Cancer research	2013	39
24063698	Paclitaxel	Dent RA	Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.	Breast cancer research 	2013	34
24092940	Paclitaxel	Gebhart G	18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.	Journal of nuclear medicine 	2013	27
24095300	Paclitaxel	Robidoux A	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2013	61
24122958	Paclitaxel	Huang D	miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer.	Journal of cellular biochemistry	2014	26
24170767	Paclitaxel	Liu N	BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110Œ± and p110Œ¥ activities in tumor cell lines and xenograft models.	Molecular cancer therapeutics	2013	32
24360787	Paclitaxel	Earl HM	Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2√ó2 factorial randomised phase 3 trial.	The Lancet. Oncology	2014	23
24510775	Paclitaxel	Zhu X	miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.	International journal of cancer	2014	23
24599932	Paclitaxel	Abraham JE	Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.	Clinical cancer research 	2014	22
24669015	Paclitaxel	Gonzalez-Angulo AM	Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer‚Ä†.	Annals of oncology 	2014	22
24868024	Paclitaxel	Satoh T	Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.	Journal of clinical oncology 	2014	99
25104330	Paclitaxel	Stoeck A	Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.	Cancer discovery	2014	29
25130998	Paclitaxel	de Azambuja E	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.	The Lancet. Oncology	2014	50
25153722	Paclitaxel	Konno Y	MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells.	Oncotarget	2014	53
25239937	Paclitaxel	Alewine C	Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.	Molecular cancer therapeutics	2014	28
25240821	Paclitaxel	Wilke H	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.	The Lancet. Oncology	2014	246
25258543	Paclitaxel	Ding J	Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer.	OncoTargets and therapy	2014	28
25332249	Paclitaxel	Perez EA	Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.	Journal of clinical oncology 	2014	88
25564897	Paclitaxel	Tolaney SM	Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.	The New England journal of medicine	2015	67
25595279	Paclitaxel	Gonzalez-Villasana V	Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.	Clinical cancer research 	2015	19
25605244	Paclitaxel	Yang Q	MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.	Oncotarget	2015	27
25684390	Paclitaxel	Weiner-Gorzel K	Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.	Cancer medicine	2015	19
25761368	Paclitaxel	Colin DJ	Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins.	Open biology	2015	15
25818419	Paclitaxel	Jiang L	Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.	Biomaterials	2015	20
25918279	Paclitaxel	Heestand GM	Approach to patients with pancreatic cancer without detectable metastases.	Journal of clinical oncology 	2015	16
25934888	Paclitaxel	Yen WC	Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency.	Clinical cancer research 	2015	42
26092818	Paclitaxel	Hurvitz SA	Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.	The Lancet. Oncology	2015	47
26181252	Paclitaxel	Salgado R	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.	JAMA oncology	2015	46
26392097	Paclitaxel	Advani PP	Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.	Journal of clinical oncology 	2016	15
26469139	Paclitaxel	Perez EA	Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.	JAMA oncology	2016	16
26578779	Paclitaxel	Tolaney SM	Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2015	32
26830752	Paclitaxel	Kamisawa T	Pancreatic cancer.	Lancet	2016	93
26832791	Paclitaxel	Wengner AM	Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.	Molecular cancer therapeutics	2016	12
26869049	Paclitaxel	Untch M	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.	The Lancet. Oncology	2016	26
26883251	Paclitaxel	Chen YM	Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells.	Tumour biology 	2016	11
26908167	Paclitaxel	Ring BZ	Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.	BMC cancer	2016	11
26921339	Paclitaxel	Jiang YZ	Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value.	Cancer research	2016	16
26979998	Paclitaxel	Zhang H	Dorsal Root Ganglion Infiltration by Macrophages Contributes to¬†Paclitaxel Chemotherapy-Induced Peripheral Neuropathy.	The journal of pain 	2016	17
27021436	Paclitaxel	Au Yeung CL	Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.	Nature communications	2016	58
27393622	Paclitaxel	Nahleh ZA	SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.	Breast cancer research and treatment	2016	14
27556950	Paclitaxel	Jordan NV	HER2 expression identifies dynamic functional states within circulating breast cancer cells.	Nature	2016	23
27635089	Paclitaxel	Zhang J	Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response.	Clinical cancer research 	2017	6
27803006	Paclitaxel	Mart√≠n M	A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).	Annals of oncology 	2017	8
27817944	Paclitaxel	Miles D	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.	European journal of cancer	2017	10
27887917	Paclitaxel	Jeong JY	MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.	Cancer letters	2017	9
28135148	Paclitaxel	Symmans WF	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.	Journal of clinical oncology 	2017	11
28209618	Paclitaxel	Chen MW	The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer.	Cancer research	2017	7
28296507	Paclitaxel	Shen CJ	LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells.	Journal of drug targeting	2017	7
28406482	Paclitaxel	Wang L	Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.	Cell death & disease	2017	6
28428276	Paclitaxel	Wen D	Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.	Cancer research	2017	5
28679654	Paclitaxel	Karagiannis GS	Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism.	Science translational medicine	2017	7
17613437	Sorafenib	Ricci MS	Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.	Cancer cell	2007	87
18165647	Sorafenib	Choueiri TK	Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.	Journal of clinical oncology 	2008	89
18300768	Sorafenib	Fecher LA	The MAPK pathway in melanoma.	Current opinion in oncology	2008	67
18794803	Sorafenib	Smalley KS	CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.	Oncogene	2009	56
18955566	Sorafenib	Zeng Z	Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.	Blood	2009	150
19652060	Sorafenib	Rini BI	Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.	Journal of clinical oncology 	2009	82
19671763	Sorafenib	Woodman SE	Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.	Molecular cancer therapeutics	2009	51
19726678	Sorafenib	Bai S	MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.	The Journal of biological chemistry	2009	157
19844230	Sorafenib	Kumar R	Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.	British journal of cancer	2009	60
19862815	Sorafenib	Jonasch E	Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.	Cancer	2010	41
20059340	Sorafenib	Villanueva A	Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.	Annual review of medicine	2010	66
20347499	Sorafenib	Shimizu S	The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.	Journal of hepatology	2010	87
20351323	Sorafenib	Choueiri TK	Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.	Journal of clinical oncology 	2010	67
20538618	Sorafenib	Whittaker S	Gatekeeper mutations mediate resistance to BRAF-targeted therapies.	Science translational medicine	2010	61
20616044	Sorafenib	W√ºstehube J	Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling.	Proceedings of the National Academy of Sciences of the United States of America	2010	47
20651059	Sorafenib	Pe√±a C	Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.	Clinical cancer research 	2010	50
21263155	Sorafenib	Sato T	FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.	Blood	2011	61
21325076	Sorafenib	Ma XH	Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.	Clinical cancer research 	2011	67
21352471	Sorafenib	Meng F	Functional analysis of microRNAs in human hepatocellular cancer stem cells.	Journal of cellular and molecular medicine	2012	41
21368833	Sorafenib	Inuzuka H	SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.	Nature	2011	195
21538283	Sorafenib	Nault JC	Genetics of hepatobiliary carcinogenesis.	Seminars in liver disease	2011	50
21816126	Sorafenib	Sangro B	Radioembolization for hepatocellular carcinoma.	Journal of hepatology	2012	62
22067401	Sorafenib	Oberholzer PA	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.	Journal of clinical oncology 	2012	81
22314428	Sorafenib	Burrel M	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.	Journal of hepatology	2012	78
22322234	Sorafenib	Lachenmayer A	Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.	Journal of hepatology	2012	44
22414760	Sorafenib	Personeni N	Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.	Journal of hepatology	2012	40
22504140	Sorafenib	Metzelder SK	High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.	Leukemia	2012	40
22890726	Sorafenib	Arao T	FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.	Hepatology	2013	25
23316005	Sorafenib	Huang XY	Œ±B-crystallin complexes with 14-3-3Œ∂ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.	Hepatology	2013	38
23471579	Sorafenib	Xia H	MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.	Hepatology	2013	89
23835194	Sorafenib	Pez F	Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs.	Journal of hepatology	2013	56
23862748	Sorafenib	Yang F	MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.	Technology in cancer research & treatment	2014	26
23958557	Sorafenib	Govaere O	Keratin 19: a key role player in the invasion of human hepatocellular carcinomas.	Gut	2014	53
23980090	Sorafenib	Llovet JM	Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.	Journal of clinical oncology 	2013	107
24569458	Sorafenib	Imielinski M	Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.	The Journal of clinical investigation	2014	31
24651044	Sorafenib	Liu L	Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.	PloS one	2014	24
24700742	Sorafenib	Xiang Q	Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.	Clinical cancer research 	2014	26
24836552	Sorafenib	Takeda H	Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.	Liver international 	2015	17
24918061	Sorafenib	Takahashi K	Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer.	FEBS open bio	2014	72
25053293	Sorafenib	Fernando J	A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.	International journal of cancer	2015	23
25158999	Sorafenib	Fitzmorris P	Management of hepatocellular carcinoma.	Journal of cancer research and clinical oncology	2015	17
25216638	Sorafenib	Rudalska R	In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.	Nature medicine	2014	43
25633810	Sorafenib	Ohta K	MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.	Oncotarget	2015	34
25733155	Sorafenib	Makarova-Rusher OV	The yin and yang of evasion and immune activation in HCC.	Journal of hepatology	2015	21
25832714	Sorafenib	Delire B	The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.	European journal of clinical investigation	2015	20
25938543	Sorafenib	Dai W	By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice.	Oncotarget	2015	24
26045065	Sorafenib	Liu K	miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.	Oncology reports	2015	25
26099527	Sorafenib	Zucman-Rossi J	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.	Gastroenterology	2015	66
26154152	Sorafenib	Won C	Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma.	Hepatology	2015	21
26311740	Sorafenib	He C	MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.	Oncotarget	2015	22
26314551	Sorafenib	Ross JS	The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.	International journal of cancer	2016	21
26364606	Sorafenib	Mandal R	Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.	Oncogene	2016	13
26514126	Sorafenib	Lou G	Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.	Journal of hematology & oncology	2015	38
26566875	Sorafenib	Diamond EL	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.	Cancer discovery	2016	28
26592953	Sorafenib	Govaere O	Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche.	Journal of hepatology	2016	13
27100895	Sorafenib	Zhang PF	Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.	Cell death & disease	2016	15
27399335	Sorafenib	Tong J	FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.	Oncogene	2017	13
27732875	Sorafenib	Sauzay C	Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma.	Clinica chimica acta; international journal of clinical chemistry	2016	13
27849399	Sorafenib	Woo HY	New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?	Expert opinion on pharmacotherapy	2017	5
27849562	Sorafenib	Bollard J	Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.	Gut	2017	8
28147363	Sorafenib	Kudo M	Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.	Oncology	2017	17
28177886	Sorafenib	Zhang X	Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.	Oncotarget	2017	7
28344323	Sorafenib	Zhu YJ	New knowledge of the mechanisms of sorafenib resistance in liver cancer.	Acta pharmacologica Sinica	2017	12
28423574	Sorafenib	Cheng Y	Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma.	Oncotarget	2017	5
15256671	Dasatinib	Shah NP	Overriding imatinib resistance with a novel ABL kinase inhibitor.	Science	2004	350
16230377	Dasatinib	Nam S	Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.	Cancer research	2005	132
16469872	Dasatinib	Copland M	Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.	Blood	2006	149
17268817	Dasatinib	Finn RS	Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.	Breast cancer research and treatment	2007	117
17720881	Dasatinib	Rix U	Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.	Blood	2007	154
19363292	Dasatinib	Bellodi C	Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.	The Journal of clinical investigation	2009	156
19447874	Dasatinib	Tatarov O	SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.	Clinical cancer research 	2009	47
19690143	Dasatinib	Lu KV	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.	Cancer research	2009	60
19920114	Dasatinib	Yu EY	Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.	Clinical cancer research 	2009	71
20190765	Dasatinib	Li J	A chemical and phosphoproteomic characterization of dasatinib action in lung cancer.	Nature chemical biology	2010	95
20215510	Dasatinib	Choi YL	LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer.	Cancer research	2010	53
20303350	Dasatinib	Morton JP	Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma.	Gastroenterology	2010	46
20855820	Dasatinib	Johnson FM	Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	60
21282564	Dasatinib	Baker AM	The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer.	Journal of the National Cancer Institute	2011	43
21297102	Dasatinib	Li Q	3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen.	Journal of biomolecular screening	2011	36
21423210	Dasatinib	Dulak AM	HGF-independent potentiation of EGFR action by c-Met.	Oncogene	2011	45
21523734	Dasatinib	Kluger HM	A phase 2 trial of dasatinib in advanced melanoma.	Cancer	2011	40
21768775	Dasatinib	Martinez-Outschoorn UE	Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells.	Cell cycle	2011	42
22184410	Dasatinib	Hamilton A	Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.	Blood	2012	88
22586301	Dasatinib	Chan CM	Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.	Clinical cancer research 	2012	31
22645182	Dasatinib	Marin D	Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.	Blood	2012	30
23153538	Dasatinib	Bicocca VT	Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.	Cancer cell	2012	51
23947765	Dasatinib	Gomez-Casal R	Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes.	Molecular cancer	2013	46
25278616	Dasatinib	Savitski MM	Tracking cancer drugs in living cells by thermal profiling of the proteome.	Science	2014	57
25501949	Dasatinib	Martins MM	Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.	Cancer discovery	2015	17
26001294	Dasatinib	Srivastava K	p63 drives invasion in keratinocytes expressing HPV16 E6/E7 genes through regulation of Src-FAK signalling.	Oncotarget	2017	6
26321221	Dasatinib	Churchman ML	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia.	Cancer cell	2015	26
18772396	Isocitric acid	Parsons DW	An integrated genomic analysis of human glioblastoma multiforme.	Science	2008	1568
18985363	Isocitric acid	Balss J	Analysis of the IDH1 codon 132 mutation in brain tumors.	Acta neuropathologica	2008	234
19117336	Isocitric acid	Bleeker FE	IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.	Human mutation	2009	117
19636000	Isocitric acid	Sanson M	Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.	Journal of clinical oncology 	2009	197
19737147	Isocitric acid	Ohgaki H	Genetic alterations and signaling pathways in the evolution of gliomas.	Cancer science	2009	106
19805672	Isocitric acid	Weller M	Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.	Journal of clinical oncology 	2009	142
19903171	Isocitric acid	Capper D	Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.	Brain pathology	2010	89
19996293	Isocitric acid	Yan H	Mutant metabolic enzymes are at the origin of gliomas.	Cancer research	2009	46
20171147	Isocitric acid	Ward PS	The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.	Cancer cell	2010	461
20368543	Isocitric acid	Marcucci G	IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.	Journal of clinical oncology 	2010	189
20410924	Isocitric acid	Pardanani A	IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.	Leukemia	2010	43
20508616	Isocitric acid	Tefferi A	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.	Leukemia	2010	76
20567020	Isocitric acid	Paschka P	IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.	Journal of clinical oncology 	2010	167
20615753	Isocitric acid	Kloosterhof NK	Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?	The Lancet. Oncology	2011	47
20805365	Isocitric acid	Schnittger S	IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.	Blood	2010	43
20847235	Isocitric acid	Kranendijk M	IDH2 mutations in patients with D-2-hydroxyglutaric aciduria.	Science	2010	48
21163902	Isocitric acid	Christensen BC	DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.	Journal of the National Cancer Institute	2011	92
21446051	Isocitric acid	Huse JT	Molecular subclassification of diffuse gliomas: seeing order in the chaos.	Glia	2011	77
21596855	Isocitric acid	Green CL	The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.	Blood	2011	50
21912393	Isocitric acid	Tefferi A	IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.	Leukemia	2012	33
22034964	Isocitric acid	SongTao Q	IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.	Cancer science	2012	39
22166263	Isocitric acid	Luchman HA	An in vivo patient-derived model of endogenous IDH1-mutant glioma.	Neuro-oncology	2012	47
22180306	Isocitric acid	Borger DR	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.	The oncologist	2012	142
22270850	Isocitric acid	Bleeker FE	Recent advances in the molecular understanding of glioblastoma.	Journal of neuro-oncology	2012	44
22281806	Isocitric acid	Choi C	2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.	Nature medicine	2012	150
22343889	Isocitric acid	Turcan S	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.	Nature	2012	444
22430270	Isocitric acid	Gaidzik VI	TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.	Journal of clinical oncology 	2012	49
22688054	Isocitric acid	M√ºller T	Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas.	The American journal of pathology	2012	31
22898539	Isocitric acid	Shih AH	The role of mutations in epigenetic regulators in myeloid malignancies.	Nature reviews. Cancer	2012	204
22990979	Isocitric acid	Zhang W	Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme.	Cancer	2013	35
23104868	Isocitric acid	Kannan K	Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.	Oncotarget	2012	60
23204232	Isocitric acid	Jin G	Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.	Cancer research	2013	35
23264629	Isocitric acid	Ward PS	The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.	The Journal of biological chemistry	2013	40
23558169	Isocitric acid	Rohle D	An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.	Science	2013	275
23558173	Isocitric acid	Wang F	Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.	Science	2013	176
23604282	Isocitric acid	Hu J	Heterogeneity of tumor-induced gene expression changes in the human metabolic network.	Nature biotechnology	2013	85
23641016	Isocitric acid	DiNardo CD	Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.	Blood	2013	38
23801749	Isocitric acid	Hughes LA	The CpG island methylator phenotype: what's in a name?	Cancer research	2013	45
23904111	Isocitric acid	Wiestler B	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.	Acta neuropathologica	2013	51
23999439	Isocitric acid	Andronesi OC	Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.	The Journal of clinical investigation	2013	32
24019001	Isocitric acid	Chaumeil MM	Non-invasive in vivo assessment of IDH1 mutational status in glioma.	Nature communications	2013	38
24065766	Isocitric acid	Lu C	Induction of sarcomas by mutant IDH2.	Genes & development	2013	40
24068788	Isocitric acid	Wick W	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.	Neurology	2013	37
24344214	Isocitric acid	Janin M	Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.	Journal of clinical oncology 	2014	25
24478380	Isocitric acid	Borger DR	Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.	Clinical cancer research 	2014	24
24510240	Isocitric acid	Molenaar RJ	The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.	Neuro-oncology	2014	26
24699305	Isocitric acid	Im AP	DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.	Leukemia	2014	42
24880135	Isocitric acid	Molenaar RJ	The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.	Biochimica et biophysica acta	2014	33
25043045	Isocitric acid	Saha SK	Mutant IDH inhibits HNF-4Œ± to block hepatocyte differentiation and promote biliary cancer.	Nature	2014	66
25081751	Isocitric acid	Chan AK	TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.	Modern pathology 	2015	21
25132561	Isocitric acid	Huang Y	Connections between TET proteins and aberrant DNA modification in cancer.	Trends in genetics 	2014	48
25135958	Isocitric acid	Bao ZS	RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.	Genome research	2014	41
25182153	Isocitric acid	Shim EH	L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.	Cancer discovery	2014	45
25599133	Isocitric acid	Chan SM	Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.	Nature medicine	2015	55
25701198	Isocitric acid	Olar A	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.	Acta neuropathologica	2015	21
25783747	Isocitric acid	Weller M	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.	Acta neuropathologica	2015	28
26124478	Isocitric acid	Sandmann T	Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.	Journal of clinical oncology 	2015	48
26188014	Isocitric acid	Waitkus MS	Isocitrate dehydrogenase mutations in gliomas.	Neuro-oncology	2016	25
26268241	Isocitric acid	Wang C	IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.	Blood	2015	24
26534967	Isocitric acid	Andronesi OC	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.	Clinical cancer research 	2016	14
26691210	Isocitric acid	de la Fuente MI	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.	Neuro-oncology	2016	22
26945349	Isocitric acid	Chen JR	Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas.	Medicine	2016	13
26948350	Isocitric acid	Masui K	Molecular classification of gliomas.	Handbook of clinical neurology	2016	14
27005468	Isocitric acid	Dang L	IDH mutations in cancer and progress toward development of targeted therapeutics.	Annals of oncology 	2016	26
27353503	Isocitric acid	Zhang B	Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.	Neuro-oncology	2017	8
27370400	Isocitric acid	Garber ST	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.	Neuro-oncology	2016	11
27520294	Isocitric acid	Konopleva M	Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.	Cancer discovery	2016	34
27820599	Isocitric acid	Miroshnikova YA	Tissue mechanics promote IDH1-dependent HIF1Œ±-tenascin C feedback to regulate glioblastoma¬†aggression.	Nature cell biology	2016	12
28043904	Isocitric acid	Sia D	Liver Cancer Cell of Origin, Molecular Class, and Effects on¬†Patient Prognosis.	Gastroenterology	2017	17
28124097	Isocitric acid	Pusch S	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.	Acta neuropathologica	2017	7
28148839	Isocitric acid	Sulkowski PL	2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.	Science translational medicine	2017	18
28193778	Isocitric acid	Yen K	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.	Cancer discovery	2017	14
28202508	Isocitric acid	Lu Y	Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.	Cancer research	2017	11
28360267	Isocitric acid	Venteicher AS	Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.	Science	2017	29
28389139	Isocitric acid	Rizvi S	Emerging molecular therapeutic targets for cholangiocarcinoma.	Journal of hepatology	2017	7
28588019	Isocitric acid	Amatangelo MD	Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.	Blood	2017	10
11309634	Pteroyl-D-glutamic acid	Watanabe T	Molecular predictors of survival after adjuvant chemotherapy for colon cancer.	The New England journal of medicine	2001	177
12506171	Pteroyl-D-glutamic acid	Kabbinavar F	Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2003	255
15175435	Pteroyl-D-glutamic acid	Hurwitz H	Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.	The New England journal of medicine	2004	1926
15867200	Pteroyl-D-glutamic acid	Kabbinavar FF	Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.	Journal of clinical oncology 	2005	110
15908660	Pteroyl-D-glutamic acid	Hurwitz HI	Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.	Journal of clinical oncology 	2005	117
15998951	Pteroyl-D-glutamic acid	Ince WL	Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.	Journal of the National Cancer Institute	2005	70
16009958	Pteroyl-D-glutamic acid	Bosset JF	Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.	Journal of clinical oncology 	2005	75
16365183	Pteroyl-D-glutamic acid	Jubb AM	Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.	Journal of clinical oncology 	2006	106
16809730	Pteroyl-D-glutamic acid	Toffoli G	The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2006	67
18024868	Pteroyl-D-glutamic acid	Tabernero J	Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.	Journal of clinical oncology 	2007	64
19114683	Pteroyl-D-glutamic acid	Bokemeyer C	Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.	Journal of clinical oncology 	2009	387
19144677	Pteroyl-D-glutamic acid	Hurwitz HI	The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.	The oncologist	2009	50
19273709	Pteroyl-D-glutamic acid	Bertagnolli MM	Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.	Journal of clinical oncology 	2009	106
19339720	Pteroyl-D-glutamic acid	Van Cutsem E	Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.	The New England journal of medicine	2009	841
19364970	Pteroyl-D-glutamic acid	Cecchin E	Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.	Journal of clinical oncology 	2009	55
19934290	Pteroyl-D-glutamic acid	Ogino S	KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.	Clinical cancer research 	2009	66
20008624	Pteroyl-D-glutamic acid	Kopetz S	Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.	Journal of clinical oncology 	2010	120
20498393	Pteroyl-D-glutamic acid	Sargent DJ	Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.	Journal of clinical oncology 	2010	237
20921462	Pteroyl-D-glutamic acid	Peeters M	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2010	193
20921465	Pteroyl-D-glutamic acid	Douillard JY	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.	Journal of clinical oncology 	2010	370
21502544	Pteroyl-D-glutamic acid	Van Cutsem E	Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.	Journal of clinical oncology 	2011	383
21641636	Pteroyl-D-glutamic acid	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	219
22147942	Pteroyl-D-glutamic acid	Ogino S	Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.	Clinical cancer research 	2012	87
22474202	Pteroyl-D-glutamic acid	Alberts SR	Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.	JAMA	2012	99
22627104	Pteroyl-D-glutamic acid	R√∂del C	Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.	The Lancet. Oncology	2012	100
22949147	Pteroyl-D-glutamic acid	Van Cutsem E	Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.	Journal of clinical oncology 	2012	212
22965965	Pteroyl-D-glutamic acid	Hoff PM	Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).	Journal of clinical oncology 	2012	37
23045248	Pteroyl-D-glutamic acid	Gavin PG	Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.	Clinical cancer research 	2012	60
23182985	Pteroyl-D-glutamic acid	Peeters M	Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.	Journal of clinical oncology 	2013	67
23569301	Pteroyl-D-glutamic acid	Ye LC	Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.	Journal of clinical oncology 	2013	55
24019539	Pteroyl-D-glutamic acid	Sinicrope FA	Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.	Journal of clinical oncology 	2013	43
24024839	Pteroyl-D-glutamic acid	Douillard JY	Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.	The New England journal of medicine	2013	432
24687833	Pteroyl-D-glutamic acid	Schwartzberg LS	PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.	Journal of clinical oncology 	2014	117
24859205	Pteroyl-D-glutamic acid	Shiovitz S	CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.	Gastroenterology	2014	31
24928083	Pteroyl-D-glutamic acid	Taieb J	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	28
25337750	Pteroyl-D-glutamic acid	Loupakis F	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.	The New England journal of medicine	2014	110
25361982	Pteroyl-D-glutamic acid	Klingbiel D	Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.	Annals of oncology 	2015	20
25543664	Pteroyl-D-glutamic acid	Sun Z	Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.	World journal of surgical oncology	2014	22
25605843	Pteroyl-D-glutamic acid	Van Cutsem E	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.	Journal of clinical oncology 	2015	88
25877855	Pteroyl-D-glutamic acid	Tabernero J	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.	The Lancet. Oncology	2015	92
26189067	Pteroyl-D-glutamic acid	R√∂del C	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.	The Lancet. Oncology	2015	41
26338525	Pteroyl-D-glutamic acid	Cremolini C	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.	The Lancet. Oncology	2015	55
27055731	Pteroyl-D-glutamic acid	Nywening TM	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.	The Lancet. Oncology	2016	40
27575024	Pteroyl-D-glutamic acid	Stintzing S	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.	The Lancet. Oncology	2016	19
28069878	Pteroyl-D-glutamic acid	Li P	MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.	Molecular cancer therapeutics	2017	20
14993230	Irinotecan	Saltz LB	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.	Journal of clinical oncology 	2004	294
15269313	Irinotecan	Cunningham D	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.	The New England journal of medicine	2004	932
15677699	Irinotecan	Chung KY	Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.	Journal of clinical oncology 	2005	204
16723399	Irinotecan	Agrelo R	Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.	Proceedings of the National Academy of Sciences of the United States of America	2006	74
17050875	Irinotecan	Lenz HJ	Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.	Journal of clinical oncology 	2006	92
17060484	Irinotecan	Rubbia-Brandt L	Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.	Annals of oncology 	2007	62
17728214	Irinotecan	Hoskins JM	UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.	Journal of the National Cancer Institute	2007	109
17947719	Irinotecan	Vredenburgh JJ	Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.	Journal of clinical oncology 	2007	340
17998284	Irinotecan	De Roock W	KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.	Annals of oncology 	2008	211
18003960	Irinotecan	Jonker DJ	Cetuximab for the treatment of colorectal cancer.	The New England journal of medicine	2007	391
18182667	Irinotecan	Sathornsumetee S	Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.	Journal of clinical oncology 	2008	79
18390971	Irinotecan	Sobrero AF	EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2008	175
18560594	Irinotecan	Dylla SJ	Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy.	PloS one	2008	174
18842611	Irinotecan	Scartozzi M	Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.	Annals of oncology 	2009	79
19114685	Irinotecan	Hecht JR	A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.	Journal of clinical oncology 	2009	189
19164213	Irinotecan	Bibeau F	Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.	Journal of clinical oncology 	2009	129
19217207	Irinotecan	Costantino E	TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.	Cancer letters	2009	47
19332770	Irinotecan	Quant EC	Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.	Neuro-oncology	2009	51
19366826	Irinotecan	Prenen H	PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.	Clinical cancer research 	2009	86
19398573	Irinotecan	Loupakis F	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.	Journal of clinical oncology 	2009	126
19603018	Irinotecan	Loupakis F	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.	British journal of cancer	2009	139
19664991	Irinotecan	Hoey T	DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.	Cell stem cell	2009	110
19738126	Irinotecan	Jacobs B	Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2009	87
20068564	Irinotecan	Trarbach T	Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.	British journal of cancer	2010	47
20142816	Irinotecan	Vilar E	Microsatellite instability in colorectal cancer-the stable evidence.	Nature reviews. Clinical oncology	2010	120
20167811	Irinotecan	de Groot JF	Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.	Neuro-oncology	2010	166
20177422	Irinotecan	Graziano F	Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.	The pharmacogenomics journal	2010	41
20332776	Irinotecan	Fang DD	Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery.	British journal of cancer	2010	41
20498386	Irinotecan	Chung KY	Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.	Journal of clinical oncology 	2010	52
20530282	Irinotecan	McLeod HL	Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.	Journal of clinical oncology 	2010	50
22216841	Irinotecan	Ebert MP	TFAP2E-DKK4 and chemoresistance in colorectal cancer.	The New England journal of medicine	2012	34
22228631	Irinotecan	Spindler KL	Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.	Clinical cancer research 	2012	52
22825584	Irinotecan	Julien S	Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.	Clinical cancer research 	2012	77
23081779	Irinotecan	Kobayashi S	LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution.	Stem cells	2012	38
23168366	Irinotecan	Bennouna J	Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.	The Lancet. Oncology	2013	205
23725851	Irinotecan	Seymour MT	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.	The Lancet. Oncology	2013	74
23881988	Irinotecan	Hurwitz HI	Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.	The oncologist	2013	31
24119443	Irinotecan	Kjersem JB	Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.	Molecular oncology	2014	33
24138831	Irinotecan	Loupakis F	FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.	European journal of cancer	2014	22
24152956	Irinotecan	Mahaseth H	Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.	Pancreas	2013	35
24585723	Irinotecan	Goldstein J	Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).	Annals of oncology 	2014	32
24717919	Irinotecan	Primrose J	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.	The Lancet. Oncology	2014	46
24934408	Irinotecan	Al-Ahmadie H	Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.	Cancer discovery	2014	32
25589621	Irinotecan	Yaeger R	Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.	Clinical cancer research 	2015	47
26541320	Irinotecan	Goldstein DA	Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.	Clinical colorectal cancer	2016	11
26976423	Irinotecan	Herrlinger U	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.	Journal of clinical oncology 	2016	12
26989027	Irinotecan	Hsu HC	Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.	Oncotarget	2016	19
27729313	Irinotecan	Hong DS	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.	Cancer discovery	2016	18
7585573	Decitabine	Graff JR	E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas.	Cancer research	1995	167
7937876	Decitabine	Herman JG	Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	1994	241
9618505	Decitabine	Herman JG	Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	1998	372
10344734	Decitabine	Toyota M	Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification.	Cancer research	1999	104
10811911	Decitabine	Ferguson AT	High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2000	111
11196646	Decitabine	Soengas MS	Inactivation of the apoptosis effector Apaf-1 in malignant melanoma.	Nature	2001	164
11593392	Decitabine	Fulda S	Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer.	Oncogene	2001	88
12006535	Decitabine	Soria JC	Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.	Clinical cancer research 	2002	90
12482974	Decitabine	Kondo Y	Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer.	Molecular and cellular biology	2003	79
12496760	Decitabine	Robert MF	DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.	Nature genetics	2003	147
12498717	Decitabine	Yamashita K	Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma.	Cancer cell	2002	86
12839967	Decitabine	Sato N	Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays.	Cancer research	2003	99
15256437	Decitabine	Mazieres J	Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer.	Cancer research	2004	74
15824739	Decitabine	Schulmann K	Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.	Oncogene	2005	69
16007195	Decitabine	Niwa Y	Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma.	Oncogene	2005	93
16140943	Decitabine	Vatolin S	Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.	Cancer research	2005	70
16247458	Decitabine	Ying J	Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation.	Oncogene	2006	69
16367923	Decitabine	Yamashita S	Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.	Cancer science	2006	69
16449975	Decitabine	Veeck J	Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis.	Oncogene	2006	81
16645171	Decitabine	Zorn E	IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.	Blood	2006	189
16766263	Decitabine	Saito Y	Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.	Cancer cell	2006	392
16882708	Decitabine	Kantarjian H	Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.	Blood	2007	163
17079474	Decitabine	Wehbe H	Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression.	Cancer research	2006	60
17145863	Decitabine	Muthusamy V	Epigenetic silencing of novel tumor suppressors in malignant melanoma.	Cancer research	2006	64
17241887	Decitabine	Isomoto H	Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.	Gastroenterology	2007	66
17297461	Decitabine	Nojima M	Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer.	Oncogene	2007	62
17417771	Decitabine	Kumagai T	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.	International journal of cancer	2007	59
17621267	Decitabine	Meng F	Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes.	Oncogene	2008	85
17660710	Decitabine	Han L	DNA methylation regulates MicroRNA expression.	Cancer biology & therapy	2007	101
17875710	Decitabine	Iorio MV	MicroRNA signatures in human ovarian cancer.	Cancer research	2007	470
17948228	Decitabine	Lehmann U	Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer.	The Journal of pathology	2008	136
18286529	Decitabine	Feng W	Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.	Cancer	2008	64
18381414	Decitabine	Kozaki K	Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer.	Cancer research	2008	204
18430739	Decitabine	Fujii S	Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.	The Journal of biological chemistry	2008	67
18519671	Decitabine	Toyota M	Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.	Cancer research	2008	178
19407485	Decitabine	Lee KH	Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer.	Pancreatology 	2009	65
19503096	Decitabine	Saito Y	Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.	Oncogene	2009	54
20028768	Decitabine	Yagi K	Three DNA methylation epigenotypes in human colorectal cancer.	Clinical cancer research 	2010	81
20073067	Decitabine	Rauhala HE	miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer.	International journal of cancer	2010	41
20084174	Decitabine	Vrba L	Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells.	PloS one	2010	108
20126405	Decitabine	Hollenbach PW	A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.	PloS one	2010	75
20368434	Decitabine	Blum W	Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.	Proceedings of the National Academy of Sciences of the United States of America	2010	120
20924086	Decitabine	Suzuki H	Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect.	Carcinogenesis	2010	61
20975101	Decitabine	Costa VL	Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples.	Clinical cancer research 	2010	51
21349819	Decitabine	Suh SO	MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer.	Carcinogenesis	2011	64
21368160	Decitabine	Sproul D	Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2011	57
21368878	Decitabine	Bhatnagar N	Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells.	Cell death & disease	2010	63
21703189	Decitabine	Alpini G	Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer.	Journal of hepatology	2011	41
21747116	Decitabine	Stefanska B	Definition of the landscape of promoter DNA hypomethylation in liver cancer.	Cancer research	2011	57
21835883	Decitabine	Han H	DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter.	Human molecular genetics	2011	61
21960261	Decitabine	Tsai KW	Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer.	International journal of cancer	2011	59
21965114	Decitabine	Foulks JM	Epigenetic drug discovery: targeting DNA methyltransferases.	Journal of biomolecular screening	2012	36
22002305	Decitabine	Ramachandran I	Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.	Oncogene	2012	35
22124213	Decitabine	Metzeler KH	DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.	Leukemia	2012	50
22237753	Decitabine	Sun CY	Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation.	Kidney international	2012	35
22282464	Decitabine	Heller G	Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers.	Clinical cancer research 	2012	57
22517893	Decitabine	Aimiuwu J	RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.	Blood	2012	34
22821729	Decitabine	Wang F	SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer.	The Journal of pathology	2013	38
22900969	Decitabine	Zhang X	The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia.	Molecular cancer	2012	33
23079745	Decitabine	Kim JK	Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b.	Hepatology	2013	68
23144859	Decitabine	Kresse SH	Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.	PloS one	2012	34
23297133	Decitabine	Klco JM	Genomic impact of transient low-dose decitabine treatment on primary AML cells.	Blood	2013	51
23318422	Decitabine	Xiang Y	MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.	Oncogene	2014	49
23408834	Decitabine	Heuck CJ	Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.	Journal of immunology	2013	25
23667495	Decitabine	Hashimoto Y	Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer.	PloS one	2013	38
23856509	Decitabine	Koukos G	MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis.	Gastroenterology	2013	51
24030154	Decitabine	Steinhart L	Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.	Cell death & disease	2013	25
24045501	Decitabine	Traina F	Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.	Leukemia	2014	58
24077826	Decitabine	Turcan S	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.	Oncotarget	2013	49
24270737	Decitabine	Yang H	Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.	Leukemia	2014	67
24283360	Decitabine	Naito Y	MicroRNA-143 regulates collagen type III expression in stromal fibroblasts of scirrhous type gastric cancer.	Cancer science	2014	20
24481854	Decitabine	Li Z	DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer.	Gastric cancer 	2015	59
24484870	Decitabine	Ufkin ML	miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia.	Leukemia research	2014	22
24535937	Decitabine	Odunsi K	Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.	Cancer immunology research	2014	31
24622842	Decitabine	Roy DM	Driver mutations of cancer epigenomes.	Protein & cell	2014	28
25210796	Decitabine	Yan F	Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation.	Cell death & disease	2014	23
25224413	Decitabine	Bejar R	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.	Blood	2014	76
25822018	Decitabine	Meldi K	Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.	The Journal of clinical investigation	2015	25
26676363	Decitabine	Li J	Epigenetic repression of long non-coding RNA MEG3 mediated by DNMT1 represses the p53 pathway in gliomas.	International journal of oncology	2016	17
26859457	Decitabine	Grandin M	Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers.	Cancer cell	2016	13
26934121	Decitabine	Dong P	Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression.	Oncotarget	2016	11
27259275	Decitabine	Tagde A	MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.	Oncotarget	2016	12
27623509	Decitabine	Lucarini V	Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to Improve Anti-Tumor Response against Melanoma.	The Journal of investigative dermatology	2017	7
27624549	Decitabine	Blum W	Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).	Leukemia	2017	5
28359286	Decitabine	Wolff F	The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.	Cell communication and signaling 	2017	8
21177764	Everolimus	Quek R	Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.	Clinical cancer research 	2011	67
21725052	Everolimus	Guglielmelli P	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.	Blood	2011	39
22210877	Everolimus	Meadows SA	PI3KŒ¥ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.	Blood	2012	37
23209032	Everolimus	Endo M	Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.	Clinical cancer research 	2013	28
24518170	Everolimus	Cardamone M	Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.	The Journal of pediatrics	2014	22
24625776	Everolimus	Wagle N	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.	Cancer discovery	2014	80
24943720	Everolimus	Cholongitas E	Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.	Transplant international 	2014	22
25624430	Everolimus	Slomovitz BM	Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.	Journal of clinical oncology 	2015	21
26406148	Everolimus	Motzer RJ	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.	The New England journal of medicine	2015	528
26546619	Everolimus	Mo W	mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.	Clinical cancer research 	2016	10
26794930	Everolimus	Armstrong AJ	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.	The Lancet. Oncology	2016	25
27091708	Everolimus	Andr√© F	Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.	Journal of clinical oncology 	2016	17
27169994	Everolimus	Choueiri TK	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.	Clinical cancer research 	2016	16
27283863	Everolimus	Cella D	Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2016	20
15169797	Bortezomib	Papandreou CN	Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.	Journal of clinical oncology 	2004	104
16024630	Bortezomib	Qin JZ	Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.	Cancer research	2005	90
16024631	Bortezomib	Fern√°ndez Y	Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.	Cancer research	2005	69
16166592	Bortezomib	P√©rez-Gal√°n P	The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.	Blood	2006	134
16357160	Bortezomib	Nawrocki ST	Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.	Cancer research	2005	84
16397231	Bortezomib	Roccaro AM	Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.	Cancer research	2006	62
16507771	Bortezomib	Obeng EA	Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.	Blood	2006	284
17164350	Bortezomib	Bhardwaj A	Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.	Blood	2007	93
17227835	Bortezomib	P√©rez-Gal√°n P	The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.	Blood	2007	69
17299090	Bortezomib	Spisek R	Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.	Blood	2007	84
17371942	Bortezomib	Giuliani N	The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.	Blood	2007	58
17525289	Bortezomib	Davenport EL	Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells.	Blood	2007	80
17545623	Bortezomib	Gomez-Bougie P	Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.	Cancer research	2007	81
17906076	Bortezomib	Tai YT	Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.	Blood	2008	99
18006697	Bortezomib	Chauhan D	Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.	Blood	2008	63
18040043	Bortezomib	Nguyen M	Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.	Proceedings of the National Academy of Sciences of the United States of America	2007	222
18042711	Bortezomib	Nikiforov MA	Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2007	74
18057228	Bortezomib	Piva R	CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.	Blood	2008	53
18083845	Bortezomib	Liu S	Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.	Blood	2008	65
18565852	Bortezomib	Oerlemans R	Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.	Blood	2008	126
18818117	Bortezomib	McConkey DJ	Mechanisms of proteasome inhibitor action and resistance in cancer.	Drug resistance updates 	2008	83
19050304	Bortezomib	Kuhn DJ	Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.	Blood	2009	56
19164757	Bortezomib	Wang Q	ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	101
19170677	Bortezomib	Richardson PG	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.	British journal of haematology	2009	56
19308771	Bortezomib	Berg M	Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.	Cytotherapy	2009	75
19380866	Bortezomib	Dunleavy K	Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.	Blood	2009	111
19417138	Bortezomib	Milani M	The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.	Cancer research	2009	100
19436050	Bortezomib	Hideshima T	Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.	Blood	2009	105
19509147	Bortezomib	Soucy TA	Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.	Clinical cancer research 	2009	71
20022965	Bortezomib	Armstrong JL	Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells.	The Journal of biological chemistry	2010	50
20116451	Bortezomib	Dick LR	Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.	Drug discovery today	2010	58
20233973	Bortezomib	Dasmahapatra G	The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.	Blood	2010	48
20388793	Bortezomib	Grisendi G	Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.	Cancer research	2010	53
20505158	Bortezomib	Ikeda H	PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.	Blood	2010	65
20555361	Bortezomib	Ri M	Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.	Leukemia	2010	55
20729919	Bortezomib	Chen KF	CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.	Oncogene	2010	49
20805366	Bortezomib	Chauhan D	A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.	Blood	2010	48
21170083	Bortezomib	Chaturvedi MM	NF-Œ∫B addiction and its role in cancer: 'one size does not fit all'.	Oncogene	2011	136
21219297	Bortezomib	Richardson PG	Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.	British journal of haematology	2011	36
21247385	Bortezomib	Jia L	SCF E3 ubiquitin ligases as anticancer targets.	Current cancer drug targets	2011	48
21247388	Bortezomib	Chen D	Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.	Current cancer drug targets	2011	151
21626033	Bortezomib	Sayers TJ	Targeting the extrinsic apoptosis signaling pathway for cancer therapy.	Cancer immunology, immunotherapy 	2011	40
21900099	Bortezomib	Blad√© J	Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.	Journal of clinical oncology 	2011	44
21993678	Bortezomib	Ling SC	Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.	Haematologica	2012	32
22052418	Bortezomib	Terpos E	Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.	International journal of cancer	2012	37
22057347	Bortezomib	D'Arcy P	Inhibition of proteasome deubiquitinating activity as a new cancer therapy.	Nature medicine	2011	108
22204764	Bortezomib	Mujtaba T	Advances in the understanding of mechanisms and therapeutic use of bortezomib.	Discovery medicine	2011	39
22291084	Bortezomib	Jakubowiak AJ	Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.	Journal of clinical oncology 	2012	41
22362782	Bortezomib	Young MM	Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis.	The Journal of biological chemistry	2012	79
22393418	Bortezomib	Jia L	Blocking autophagy prevents bortezomib-induced NF-Œ∫B activation by reducing I-Œ∫BŒ± degradation in lymphoma cells.	PloS one	2012	31
22538852	Bortezomib	Mimura N	Blockade of XBP1 splicing by inhibition of IRE1Œ± is a promising therapeutic option in multiple myeloma.	Blood	2012	94
22677155	Bortezomib	Wang M	Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.	The Lancet. Oncology	2012	43
22685174	Bortezomib	Fang J	Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.	Blood	2012	38
22874878	Bortezomib	Magrangeas F	Minor clone provides a reservoir for relapse in multiple myeloma.	Leukemia	2013	27
22932796	Bortezomib	Kuhn DJ	Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.	Blood	2012	54
23151137	Bortezomib	Zhao Y	Cullin-RING Ligases as attractive anti-cancer targets.	Current pharmaceutical design	2013	50
23190608	Bortezomib	Amodio N	miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.	Cell death & disease	2012	51
23588715	Bortezomib	Tai YT	CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.	Leukemia	2014	69
23822887	Bortezomib	Shen M	Targeting the ubiquitin-proteasome system for cancer therapy.	Expert opinion on therapeutic targets	2013	39
23916134	Bortezomib	Br√ºning A	Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation.	Molecular oncology	2013	28
24029229	Bortezomib	Leung-Hagesteijn C	Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.	Cancer cell	2013	82
24055414	Bortezomib	Dimopoulos M	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.	The Lancet. Oncology	2013	49
24091729	Bortezomib	Amodio N	miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.	Cell cycle	2013	31
24171104	Bortezomib	Wiita AP	Global cellular response to chemotherapy-induced apoptosis.	eLife	2013	27
24755012	Bortezomib	Senapedis WT	Clinical translation of nuclear export inhibitors in cancer.	Seminars in cancer biology	2014	29
24928860	Bortezomib	Wang J	Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.	Blood	2014	48
25398450	Bortezomib	Nijhof IS	Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.	Clinical cancer research 	2015	17
25670156	Bortezomib	Niewerth D	Molecular basis of resistance to proteasome inhibitors in hematological malignancies.	Drug resistance updates 	2015	25
26258847	Bortezomib	Ungewickell A	Genomic analysis of mycosis fungoides and S√©zary syndrome identifies recurrent alterations in TNFR2.	Nature genetics	2015	33
26526987	Bortezomib	Weinhold N	Clinical value of molecular subtyping multiple myeloma using gene expression profiling.	Leukemia	2016	11
27016342	Bortezomib	Ramani VC	Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype.	Matrix biology 	2016	12
27857131	Bortezomib	Qin Y	Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma.	Leukemia	2017	6
27909306	Bortezomib	Hofman IJF	RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.	Leukemia	2017	6
27926488	Bortezomib	Zeng D	Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.	Oncotarget	2017	6
28186131	Bortezomib	Viziteu E	RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.	Leukemia	2017	5
12761494	Gemcitabine	Arlt A	Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.	Oncogene	2003	124
12941837	Gemcitabine	Maloney EK	An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.	Cancer research	2003	81
15051286	Gemcitabine	Li D	Pancreatic cancer.	Lancet	2004	470
15172981	Gemcitabine	Davidson JD	An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.	Cancer research	2004	83
15897578	Gemcitabine	Berberat PO	Inhibition of heme oxygenase-1 increases responsiveness of pancreatic cancer cells to anticancer treatment.	Clinical cancer research 	2005	67
16258101	Gemcitabine	Kindler HL	Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.	Journal of clinical oncology 	2005	107
16622265	Gemcitabine	Zhu AX	Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.	Journal of clinical oncology 	2006	75
16762633	Gemcitabine	Meng F	Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.	Gastroenterology	2006	296
16918309	Gemcitabine	Shao J	Ribonucleotide reductase inhibitors and future drug design.	Current cancer drug targets	2006	83
17131328	Gemcitabine	Nakahira S	Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.	International journal of cancer	2007	59
17332349	Gemcitabine	Feldmann G	Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.	Cancer research	2007	242
17404099	Gemcitabine	Nomi T	Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.	Clinical cancer research 	2007	211
17894887	Gemcitabine	Cho WC	OncomiRs: the discovery and progress of microRNAs in cancers.	Molecular cancer	2007	210
18245495	Gemcitabine	Hwang RF	Cancer-associated stromal fibroblasts promote pancreatic tumor progression.	Cancer research	2008	289
18316569	Gemcitabine	Laheru D	Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.	Clinical cancer research 	2008	106
18413796	Gemcitabine	Melisi D	LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.	Molecular cancer therapeutics	2008	93
18829536	Gemcitabine	Ramachandran V	Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival.	Cancer research	2008	51
18992248	Gemcitabine	Farrell JJ	Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.	Gastroenterology	2009	103
19047305	Gemcitabine	Wolpin BM	Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.	Journal of clinical oncology 	2009	78
19174553	Gemcitabine	Jimeno A	A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.	Molecular cancer therapeutics	2009	104
19366899	Gemcitabine	Beltran PJ	AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.	Molecular cancer therapeutics	2009	52
19435867	Gemcitabine	Moriyama T	MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance.	Molecular cancer therapeutics	2009	118
19549912	Gemcitabine	Banerjee S	Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer.	Cancer research	2009	48
19571674	Gemcitabine	Hochwald SN	A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.	Cell cycle	2009	61
19654003	Gemcitabine	Crawford M	MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer.	Biochemical and biophysical research communications	2009	60
19654291	Gemcitabine	Li Y	Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.	Cancer research	2009	252
19730150	Gemcitabine	Park JK	Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma.	Pancreas	2009	87
19948396	Gemcitabine	Hummel R	MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types.	European journal of cancer	2010	109
20501833	Gemcitabine	Morgan MA	Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.	Cancer research	2010	100
20606093	Gemcitabine	Philip PA	Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.	Journal of clinical oncology 	2010	167
20927319	Gemcitabine	Fujita H	Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.	Neoplasia	2010	46
21078544	Gemcitabine	Arlt A	Targeting apoptosis pathways in pancreatic cancer.	Cancer letters	2013	27
21081113	Gemcitabine	Kikuta K	Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells.	Biochemical and biophysical research communications	2010	54
21106054	Gemcitabine	Zhang XJ	Dysregulation of miR-15a and miR-214 in human pancreatic cancer.	Journal of hematology & oncology	2010	57
21135251	Gemcitabine	Villarroel MC	Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.	Molecular cancer therapeutics	2011	71
21148071	Gemcitabine	Dangi-Garimella S	Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.	Cancer research	2011	37
21163702	Gemcitabine	Jordheim LP	The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.	The Lancet. Oncology	2011	36
21177151	Gemcitabine	Bensouda Y	Treatment for metastatic nasopharyngeal carcinoma.	European annals of otorhinolaryngology, head and neck diseases	2011	46
21306953	Gemcitabine	Kindler HL	Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.	The Lancet. Oncology	2011	101
21376256	Gemcitabine	Dong J	Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells.	Archives of medical research	2011	35
21389100	Gemcitabine	Rajeshkumar NV	MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.	Clinical cancer research 	2011	71
21408027	Gemcitabine	Bao B	Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.	PloS one	2011	73
21436454	Gemcitabine	Beatty GL	CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.	Science	2011	405
21594619	Gemcitabine	Bodoky G	A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 ARRY-142886) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.	Investigational new drugs	2012	51
21709185	Gemcitabine	Crane CH	Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.	Journal of clinical oncology 	2011	68
21792083	Gemcitabine	Kimura Y	Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.	Pancreas	2012	30
21903606	Gemcitabine	Stokes JB	Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.	Molecular cancer therapeutics	2011	57
22056140	Gemcitabine	Lonardo E	Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.	Cell stem cell	2011	102
22072567	Gemcitabine	Wei D	Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.	Cancer research	2012	52
22086681	Gemcitabine	Bao B	Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.	Cancer prevention research	2012	101
22363658	Gemcitabine	Zhang G	DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.	PloS one	2012	39
22510406	Gemcitabine	Hamada S	Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells.	Biochemical and biophysical research communications	2012	46
22705007	Gemcitabine	Mar√©chal R	Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.	Gastroenterology	2012	60
22811078	Gemcitabine	Wang L	First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.	Cancer	2013	36
22825331	Gemcitabine	Prevo R	The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.	Cancer biology & therapy	2012	57
23177026	Gemcitabine	Wang P	The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL.	Molecular oncology	2013	38
23222511	Gemcitabine	Fokas E	Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.	Cell death & disease	2012	57
23402593	Gemcitabine	Lee GY	Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.	ACS nano	2013	47
23437065	Gemcitabine	Proctor E	Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma.	PloS one	2013	32
23547081	Gemcitabine	Ueno H	Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.	Journal of clinical oncology 	2013	89
23591198	Gemcitabine	Mitsunaga S	Serum levels of IL-6 and IL-1Œ≤ can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.	British journal of cancer	2013	28
23593991	Gemcitabine	Thompson R	The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design.	British journal of clinical pharmacology	2013	35
23983255	Gemcitabine	Beatty GL	A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.	Clinical cancer research 	2013	80
24075276	Gemcitabine	Yamada S	Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer.	Surgery	2013	31
24097873	Gemcitabine	Nixon AB	Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).	Clinical cancer research 	2013	33
24114124	Gemcitabine	King C	Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.	Investigational new drugs	2014	22
24147037	Gemcitabine	Okamoto K	miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.	PloS one	2013	28
24216611	Gemcitabine	Hamada S	MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX.	Cellular signalling	2014	25
24351397	Gemcitabine	Valle JW	Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.	Annals of oncology 	2014	52
24859161	Gemcitabine	Li L	Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and Œ≤-catenin signaling in pancreatic ductal adenocarcinoma cells.	Gastroenterology	2014	29
24915778	Gemcitabine	Infante JR	A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.	European journal of cancer	2014	46
24919854	Gemcitabine	Gelbert LM	Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.	Investigational new drugs	2014	57
25034785	Gemcitabine	Zeuner A	Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer.	Cell death and differentiation	2014	27
25056373	Gemcitabine	Koido S	Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.	Clinical cancer research 	2014	26
25117811	Gemcitabine	Hasegawa S	MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer.	British journal of cancer	2014	27
25156567	Gemcitabine	Franco J	CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer.	Oncotarget	2014	31
25277192	Gemcitabine	Khan S	MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer.	Oncotarget	2014	33
25311384	Gemcitabine	Fiorini C	Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.	Biochimica et biophysica acta	2015	21
25331547	Gemcitabine	Guo Y	Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis.	Journal of cellular and molecular medicine	2015	16
25402324	Gemcitabine	Hiroshima Y	Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models.	Oncotarget	2014	53
25473894	Gemcitabine	Suzuki S	JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells.	Oncotarget	2015	18
25609246	Gemcitabine	Fuchs CS	A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.	Annals of oncology 	2015	25
25632066	Gemcitabine	Chen JS	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.	Annals of oncology 	2015	21
25638153	Gemcitabine	Ma J	Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.	Oncotarget	2015	29
25717063	Gemcitabine	Cioffi M	Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms.	Clinical cancer research 	2015	20
25834145	Gemcitabine	Duluc C	Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour¬†chemoresistance.	EMBO molecular medicine	2015	20
25887381	Gemcitabine	Cioffi M	The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.	Gut	2015	24
25889214	Gemcitabine	Li Z	The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.	Journal of translational medicine	2015	45
26036346	Gemcitabine	Tr√©houx S	Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells.	Biochimica et biophysica acta	2015	20
26077591	Gemcitabine	Miller BW	Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.	EMBO molecular medicine	2015	33
26156960	Gemcitabine	Di Caro G	Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy.	Gut	2016	16
26179201	Gemcitabine	Valle JW	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.	The Lancet. Oncology	2015	23
26527777	Gemcitabine	Catenacci DV	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.	Journal of clinical oncology 	2015	30
26540314	Gemcitabine	Leone F	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).	Cancer	2016	11
26546043	Gemcitabine	Tyagi N	p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling.	Cancer letters	2016	13
26666820	Gemcitabine	Wu ZH	MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer.	Tumour biology 	2016	14
26725968	Gemcitabine	Tjensvoll K	Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer.	Molecular oncology	2016	20
26817584	Gemcitabine	Liu Y	MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.	Journal of experimental & clinical cancer research 	2016	11
26828016	Gemcitabine	Fan P	MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.	Cancer letters	2016	10
26862857	Gemcitabine	Khan K	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.	Oncotarget	2016	11
27216178	Gemcitabine	Schultz MJ	The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype.	Cancer research	2016	12
27669441	Gemcitabine	Richards KE	Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells.	Oncogene	2017	28
27742686	Gemcitabine	Ireland L	Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.	Cancer research	2016	16
28034748	Gemcitabine	Zhang Y	MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells.	Biochemical and biophysical research communications	2017	6
28381539	Gemcitabine	Vennin C	Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.	Science translational medicine	2017	11
9799222	Doxorubicin	J√§√§ttel√§ M	Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases.	The EMBO journal	1998	127
10446993	Doxorubicin	Chang BD	A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents.	Cancer research	1999	119
11948130	Doxorubicin	Park JW	Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.	Clinical cancer research 	2002	106
12676586	Doxorubicin	Dolma S	Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.	Cancer cell	2003	103
15053878	Doxorubicin	Campbell KJ	Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B.	Molecular cell	2004	113
16170171	Doxorubicin	Hershman D	Racial disparities in treatment and survival among women with early-stage breast cancer.	Journal of clinical oncology 	2005	93
16234567	Doxorubicin	Yeo W	A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.	Journal of the National Cancer Institute	2005	120
16258084	Doxorubicin	Ewer MS	Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.	Journal of clinical oncology 	2005	106
17135249	Doxorubicin	Sylvestre Y	An E2F/miR-20a autoregulatory feedback loop.	The Journal of biological chemistry	2007	215
17415413	Doxorubicin	Biswas S	Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.	The Journal of clinical investigation	2007	100
17823410	Doxorubicin	Corney DC	MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.	Cancer research	2007	223
17854227	Doxorubicin	Bagalkot V	Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.	Nano letters	2007	126
17875789	Doxorubicin	Stein R	CD74: a new candidate target for the immunotherapy of B-cell neoplasms.	Clinical cancer research 	2007	56
17891174	Doxorubicin	Ma S	CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.	Oncogene	2008	209
17965883	Doxorubicin	Clark JC	A review of clinical and molecular prognostic factors in osteosarcoma.	Journal of cancer research and clinical oncology	2008	62
18039953	Doxorubicin	Nefedova Y	Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy.	Blood	2008	54
18424910	Doxorubicin	Akar U	Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells.	Autophagy	2008	71
18441325	Doxorubicin	Bourguignon LY	Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells.	The Journal of biological chemistry	2008	122
18446337	Doxorubicin	Diaz-Montero CM	Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.	Cancer immunology, immunotherapy 	2009	342
18574145	Doxorubicin	Burgess DJ	Topoisomerase levels determine chemotherapy response in vitro and in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2008	87
18645006	Doxorubicin	Sullivan R	Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity.	Molecular cancer therapeutics	2008	53
18645025	Doxorubicin	Kovalchuk O	Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin.	Molecular cancer therapeutics	2008	147
19276287	Doxorubicin	Magnifico A	Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.	Clinical cancer research 	2009	81
19584283	Doxorubicin	Fornari F	MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.	Cancer research	2009	117
19805669	Doxorubicin	Emens LA	Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.	Journal of clinical oncology 	2009	74
19839049	Doxorubicin	Tryndyak VP	E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.	International journal of cancer	2010	62
19840887	Doxorubicin	Fleming GF	Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.	Gynecologic oncology	2010	43
19883630	Doxorubicin	Liang Z	Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1.	Biochemical pharmacology	2010	82
20098429	Doxorubicin	Li Y	Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer.	Nature medicine	2010	94
20179989	Doxorubicin	Valle JW	A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.	Investigational new drugs	2011	35
20181615	Doxorubicin	Chen WC	In vivo targeting of B-cell lymphoma with glycan ligands of CD22.	Blood	2010	51
20388796	Doxorubicin	Yoo BK	Molecular mechanism of chemoresistance by astrocyte elevated gene-1.	Cancer research	2010	46
20460510	Doxorubicin	Adhikari AS	CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance.	Cancer research	2010	80
20668064	Doxorubicin	Zhang X	Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway.	Cancer research	2010	48
20689555	Doxorubicin	Aoubala M	p53 directly transactivates Œî133p53Œ±, regulating cell fate outcome in response to DNA damage.	Cell death and differentiation	2011	36
21055388	Doxorubicin	Henry JC	miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines.	Biochemical and biophysical research communications	2010	48
21070600	Doxorubicin	Feng DD	Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia.	Journal of cellular and molecular medicine	2011	38
21342659	Doxorubicin	Savla R	Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer.	Journal of controlled release 	2011	47
21527554	Doxorubicin	Chen J	Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth.	Cancer research	2011	42
21562218	Doxorubicin	Buti L	Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host.	Proceedings of the National Academy of Sciences of the United States of America	2011	38
21627074	Doxorubicin	Xiong XB	Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin.	ACS nano	2011	55
21642992	Doxorubicin	Hung T	Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters.	Nature genetics	2011	323
21953503	Doxorubicin	Zhu Y	Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5.	Clinical cancer research 	2011	54
21996747	Doxorubicin	Lo PK	CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFŒ≤ signaling.	Oncogene	2012	53
22217342	Doxorubicin	Doublier S	HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast.	BMC cancer	2012	32
22281424	Doxorubicin	Xiao Y	Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging.	Biomaterials	2012	42
22521303	Doxorubicin	Bao L	Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298.	The American journal of pathology	2012	42
22673234	Doxorubicin	Shatz M	The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells.	Cancer research	2012	35
22698404	Doxorubicin	Jackson JG	p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.	Cancer cell	2012	72
22817844	Doxorubicin	Liu Z	Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro.	Journal of translational medicine	2012	30
22926690	Doxorubicin	Sparano JA	Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer.	Cancer	2012	49
22952218	Doxorubicin	Manzoor AA	Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors.	Cancer research	2012	61
23144294	Doxorubicin	Maire V	Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.	Cancer research	2013	40
23251413	Doxorubicin	Corcoran C	Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.	PloS one	2012	72
23277563	Doxorubicin	Hirsch HA	Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth.	Proceedings of the National Academy of Sciences of the United States of America	2013	106
23349734	Doxorubicin	Godugu C	AlgiMatrix‚Ñ¢ based 3D cell culture system as an in-vitro tumor model for anticancer studies.	PloS one	2013	33
23526568	Doxorubicin	Qu J	MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA.	Journal of cellular physiology	2015	16
23563091	Doxorubicin	Gao AM	Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway.	Carcinogenesis	2013	26
23715267	Doxorubicin	Pang B	Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.	Nature communications	2013	46
23723074	Doxorubicin	Dong Y	Tumor suppressor functions of miR-133a in colorectal cancer.	Molecular cancer research 	2013	31
23801752	Doxorubicin	Oehme I	Histone deacetylase 10 promotes autophagy-mediated cell survival.	Proceedings of the National Academy of Sciences of the United States of America	2013	35
23955273	Doxorubicin	Clozel T	Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.	Cancer discovery	2013	34
24136231	Doxorubicin	Fan YH	USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.	Cell death & disease	2013	30
24211739	Doxorubicin	Xu L	MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.	Journal of hepatology	2014	35
24292814	Doxorubicin	Ciszewski WM	DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.	Breast cancer research and treatment	2014	25
24565101	Doxorubicin	Zhao N	MicroRNA-26b suppresses the NF-Œ∫B signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3.	Molecular cancer	2014	32
24577057	Doxorubicin	Liu Y	Lack of correlation of stem cell markers in breast cancer stem cells.	British journal of cancer	2014	24
24708766	Doxorubicin	Zhang H	Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.	Breast cancer research 	2014	23
24788655	Doxorubicin	Ouyang M	MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.	PloS one	2014	38
24991836	Doxorubicin	Barnard RA	Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.	Autophagy	2014	41
25026284	Doxorubicin	Mendonca J	Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer.	Oncotarget	2014	21
25079333	Doxorubicin	Tavora B	Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy.	Nature	2014	21
25292190	Doxorubicin	Xu M	miR-382 inhibits osteosarcoma metastasis and relapse by targeting Y box-binding protein 1.	Molecular therapy 	2015	18
25330770	Doxorubicin	Liu JC	Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.	EMBO molecular medicine	2014	25
25368020	Doxorubicin	Park EY	Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance.	Cancer research	2014	38
25407491	Doxorubicin	Zhang Y	miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1.	Tumour biology 	2015	17
25445786	Doxorubicin	Kiran S	Sirtuin 7 promotes cellular survival following genomic stress by attenuation of DNA damage, SAPK activation and p53 response.	Experimental cell research	2015	17
25504623	Doxorubicin	Jiang T	Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene.	Advanced materials	2015	21
25512109	Doxorubicin	Amornsupak K	Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells.	BMC cancer	2014	26
25727016	Doxorubicin	Zhang Y	MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1.	Biochemical and biophysical research communications	2015	19
25789975	Doxorubicin	Hall JR	Long noncoding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes.	Cell death & disease	2015	16
25823028	Doxorubicin	Xi G	CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-Œ∫B pathway in multidrug-resistant glioblastoma cells in vitro.	Oncogene	2016	15
25840969	Doxorubicin	Yu SF	A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.	Clinical cancer research 	2015	16
25900794	Doxorubicin	Hu Y	miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.	Breast cancer research and treatment	2015	20
25909227	Doxorubicin	Go H	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.	Oncotarget	2015	20
25944566	Doxorubicin	Baker EK	BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells.	Scientific reports	2015	22
26028030	Doxorubicin	Niu J	Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer.	Oncogene	2016	19
26041409	Doxorubicin	Tan Q	Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy.	Cancer science	2015	19
26447779	Doxorubicin	Abegglen LM	Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans.	JAMA	2015	41
26552700	Doxorubicin	Picaud S	Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.	Cancer research	2015	36
26781446	Doxorubicin	Shang C	Long noncoding RNA HOTAIR is a prognostic biomarker and inhibits chemosensitivity to doxorubicin in bladder transitional cell carcinoma.	Cancer chemotherapy and pharmacology	2016	13
26809111	Doxorubicin	Lencioni R	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.	Journal of hepatology	2016	54
26876203	Doxorubicin	Zhang ZM	Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/Œ≤-catenin pathway.	Oncogene	2016	11
27286459	Doxorubicin	Murakami T	Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.	Oncotarget	2016	23
27432897	Doxorubicin	Meitinger F	53BP1 and USP28 mediate p53 activation and G1 arrest after centrosome loss or extended mitotic duration.	The Journal of cell biology	2016	17
27479180	Doxorubicin	Quotti Tubi L	Protein kinase CK2 regulates AKT, NF-Œ∫B and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.	Leukemia	2017	6
28126034	Doxorubicin	Xu J	Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.	Journal of experimental & clinical cancer research 	2017	9
28298546	Doxorubicin	Lee H	64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.	Clinical cancer research 	2017	10
28323030	Doxorubicin	Zhang CL	Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2.	Cancer letters	2017	11
14998849	Oxaliplatin	Rubbia-Brandt L	Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.	Annals of oncology 	2004	141
16857785	Oxaliplatin	Yang AD	Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.	Clinical cancer research 	2006	139
18272912	Oxaliplatin	Tol J	A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.	Annals of oncology 	2008	57
19147571	Oxaliplatin	Meng RD	gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.	Cancer research	2009	81
19196673	Oxaliplatin	Tol J	Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.	The New England journal of medicine	2009	301
19244128	Oxaliplatin	Dallas NA	Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.	Cancer research	2009	149
19786657	Oxaliplatin	Chibaudel B	Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.	Journal of clinical oncology 	2009	58
20194850	Oxaliplatin	G√©rard JP	Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.	Journal of clinical oncology 	2010	120
20421432	Oxaliplatin	Zitvogel L	Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway.	Clinical cancer research 	2010	85
20648559	Oxaliplatin	Ning Y	Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models.	International journal of cancer	2011	87
21606427	Oxaliplatin	Aschele C	Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.	Journal of clinical oncology 	2011	133
22172905	Oxaliplatin	Della Vittoria Scarpati G	A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.	International journal of radiation oncology, biology, physics	2012	43
22264850	Oxaliplatin	Gaya A	A preclinical and clinical review of aflibercept for the management of cancer.	Cancer treatment reviews	2012	30
22391039	Oxaliplatin	Ning Y	The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.	Molecular cancer therapeutics	2012	31
22473155	Oxaliplatin	Tveit KM	Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.	Journal of clinical oncology 	2012	111
22473163	Oxaliplatin	Dewdney A	Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).	Journal of clinical oncology 	2012	61
22698403	Oxaliplatin	O'Brien CA	ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21.	Cancer cell	2012	62
23017669	Oxaliplatin	Foxtrot Collaborative Group	Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.	The Lancet. Oncology	2012	42
23152059	Oxaliplatin	Sacconi A	miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer.	Cell death & disease	2012	54
23342249	Oxaliplatin	Fan F	Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells.	Cancer medicine	2012	58
23510984	Oxaliplatin	Cohn AL	A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.	Annals of oncology 	2013	30
23574723	Oxaliplatin	Qian X	MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers.	Cell cycle	2013	41
23811849	Oxaliplatin	Yamazaki T	Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.	Cell death and differentiation	2014	40
24225157	Oxaliplatin	Yamada Y	Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.	The Lancet. Oncology	2013	37
24277452	Oxaliplatin	Zeng ZL	Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer.	Clinical cancer research 	2014	23
24356622	Oxaliplatin	Peeters M	Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.	Annals of oncology 	2014	23
24465408	Oxaliplatin	Nangia-Makker P	Metformin: a potential therapeutic agent for recurrent colon cancer.	PloS one	2014	30
25446103	Oxaliplatin	Wan LY	miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1.	Biochemical and biophysical research communications	2015	16
25616665	Oxaliplatin	Zhang Y	MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.	The Journal of biological chemistry	2015	22
25778491	Oxaliplatin	Liu W	HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.	Cancer biology & therapy	2015	16
25918287	Oxaliplatin	Dienstmann R	Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.	Journal of clinical oncology 	2015	38
25924065	Oxaliplatin	Shalapour S	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.	Nature	2015	50
25938772	Oxaliplatin	Hu Y	Fibroblast-Derived Exosomes Contribute to Chemoresistance through Priming Cancer Stem Cells in Colorectal Cancer.	PloS one	2015	37
25943534	Oxaliplatin	Stewart R	Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.	Cancer immunology research	2015	20
26474521	Oxaliplatin	Garcia-Aguilar J	Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.	The Lancet. Oncology	2015	20
26527776	Oxaliplatin	Andr√© T	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.	Journal of clinical oncology 	2015	32
26626800	Oxaliplatin	Shitara K	Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.	Gastric cancer 	2017	7
26831668	Oxaliplatin	Zhijun H	Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.	Tumour biology 	2016	11
26872698	Oxaliplatin	Pfirschke C	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.	Immunity	2016	49
27729273	Oxaliplatin	Yin X	Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells.	Gene	2017	7
27856123	Oxaliplatin	Sunakawa Y	Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.	Clinical colorectal cancer	2017	5
11739416	Somatostatin	Brandi ML	Guidelines for diagnosis and therapy of MEN type 1 and type 2.	The Journal of clinical endocrinology and metabolism	2001	192
12920149	Somatostatin	Reubi JC	Peptide receptors as molecular targets for cancer diagnosis and therapy.	Endocrine reviews	2003	137
14769829	Somatostatin	Colao A	Systemic complications of acromegaly: epidemiology, pathogenesis, and management.	Endocrine reviews	2004	108
16253899	Somatostatin	Oberg K	Endocrine tumours of the pancreas.	Best practice & research. Clinical gastroenterology	2005	76
19845567	Somatostatin	Modlin IM	Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.	Alimentary pharmacology & therapeutics	2010	49
22737187	Somatostatin	Fani M	Radiolabeled peptides: valuable tools for the detection and treatment of cancer.	Theranostics	2012	40
24742460	Somatostatin	Vogt D	Lhx6 directly regulates Arx and CXCR7 to determine cortical interneuron fate and laminar position.	Neuron	2014	28
25698782	Somatostatin	Herrmann K	Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.	Journal of nuclear medicine 	2015	20
26087898	Somatostatin	Boora GK	Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.	Cancer genetics	2015	18
26731483	Somatostatin	Rinke A	Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.	Neuroendocrinology	2017	25
26843617	Somatostatin	Lapa C	68GaPentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.	Oncotarget	2016	17
19359544	Bicalutamide	Tran C	Development of a second-generation antiandrogen for treatment of advanced prostate cancer.	Science	2009	469
19365403	Bicalutamide	Bisson I	WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics.	Cell research	2009	95
22266222	Bicalutamide	Clegg NJ	ARN-509: a novel antiandrogen for prostate cancer treatment.	Cancer research	2012	107
23966621	Bicalutamide	Thomas C	Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.	Molecular cancer therapeutics	2013	36
24002508	Bicalutamide	Rathkopf DE	Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.	Journal of clinical oncology 	2013	41
24874833	Bicalutamide	Yu Z	Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.	Clinical cancer research 	2014	23
24888812	Bicalutamide	Arce-Salinas C	Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.	Journal of clinical oncology 	2016	15
25103565	Bicalutamide	Lehmann BD	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.	Breast cancer research 	2014	38
26774508	Bicalutamide	Shore ND	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.	The Lancet. Oncology	2016	20
26813233	Bicalutamide	Lallous N	Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.	Genome biology	2016	15
28146658	Bicalutamide	Shipley WU	Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.	The New England journal of medicine	2017	15
10411544	Fluorouracil	Ashkenazi A	Safety and antitumor activity of recombinant soluble Apo2 ligand.	The Journal of clinical investigation	1999	416
10700175	Fluorouracil	Scherf U	A gene expression database for the molecular pharmacology of cancer.	Nature genetics	2000	247
15774776	Fluorouracil	Ghadimi BM	Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.	Journal of clinical oncology 	2005	67
16246976	Fluorouracil	R√∂del C	Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.	Journal of clinical oncology 	2005	191
17212999	Fluorouracil	Shih T	Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.	Clinical therapeutics	2006	88
17228023	Fluorouracil	Kim GP	Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.	Journal of clinical oncology 	2007	87
17906203	Fluorouracil	Collette L	Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.	Journal of clinical oncology 	2007	71
19074875	Fluorouracil	Braun CJ	p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest.	Cancer research	2008	165
19276252	Fluorouracil	Sakamoto K	Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth.	Clinical cancer research 	2009	62
19439999	Fluorouracil	Takagi T	Decreased expression of microRNA-143 and -145 in human gastric cancers.	Oncology	2009	94
19470921	Fluorouracil	Willett CG	Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.	Journal of clinical oncology 	2009	155
19843160	Fluorouracil	Borralho PM	MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells.	The FEBS journal	2009	64
20081809	Fluorouracil	Ong CW	CD133 expression predicts for non-response to chemotherapy in colorectal cancer.	Modern pathology 	2010	44
20159816	Fluorouracil	Ajani JA	Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.	Journal of clinical oncology 	2010	101
20501503	Fluorouracil	Fari√±a-Sarasqueta A	The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.	Annals of oncology 	2010	77
20516444	Fluorouracil	de la Chapelle A	Clinical relevance of microsatellite instability in colorectal cancer.	Journal of clinical oncology 	2010	49
20585341	Fluorouracil	Boni V	Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.	The pharmacogenomics journal	2011	37
20737575	Fluorouracil	Zhang J	Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene.	Cancer	2011	41
21969819	Fluorouracil	Shibata T	NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.	Neoplasia	2011	40
22072615	Fluorouracil	Nie J	microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2.	Carcinogenesis	2012	57
22205702	Fluorouracil	Xiong H	Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition.	The Journal of biological chemistry	2012	72
22260991	Fluorouracil	Funkhouser WK Jr	Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology.	The Journal of molecular diagnostics 	2012	30
22302899	Fluorouracil	Sinicrope FA	Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications.	Clinical cancer research 	2012	53
22790872	Fluorouracil	Nikulenkov F	Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis.	Cell death and differentiation	2012	86
23167930	Fluorouracil	Svoboda M	MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.	Radiation oncology	2012	32
23684942	Fluorouracil	Lei Z	Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.	Gastroenterology	2013	62
23744359	Fluorouracil	Karaayvaz M	miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer.	Cell death & disease	2013	37
23746666	Fluorouracil	Vermorken JB	Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.	The Lancet. Oncology	2013	69
24018051	Fluorouracil	Chen Z	MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/Œ≤-catenin pathway in hepatocellular carcinoma cells.	Cellular signalling	2013	26
24446491	Fluorouracil	Shin JY	High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias.	The Journal of experimental medicine	2014	38
24590654	Fluorouracil	Rosmarin D	Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.	Journal of clinical oncology 	2014	33
25185971	Fluorouracil	Satoh T	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.	Gastric cancer 	2015	23
25712124	Fluorouracil	Prabhu VV	Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.	Cancer research	2015	30
25820415	Fluorouracil	Kawai T	Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma.	Clinical cancer research 	2015	23
26031544	Fluorouracil	Kawakami H	Microsatellite instability testing and its role in the management of colorectal cancer.	Current treatment options in oncology	2015	24
26494468	Fluorouracil	Alam SK	DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53.	Cell death and differentiation	2016	11
26603945	Fluorouracil	Meulendijks D	Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.	The Lancet. Oncology	2015	18
26673620	Fluorouracil	Wang L	MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1.	Oncotarget	2016	15
26967246	Fluorouracil	Gao D	The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.	Oncotarget	2016	16
28114937	Fluorouracil	Zhang JX	Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway.	Molecular cancer	2017	9
15041700	Temozolomide	Hegi ME	Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.	Clinical cancer research 	2004	146
15758010	Temozolomide	Hegi ME	MGMT gene silencing and benefit from temozolomide in glioblastoma.	The New England journal of medicine	2005	1193
16024643	Temozolomide	Trivedi RN	The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death.	Cancer research	2005	78
16618716	Temozolomide	Hunter C	A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.	Cancer research	2006	90
17404084	Temozolomide	Cahill DP	Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.	Clinical cancer research 	2007	91
17522861	Temozolomide	Jordan JT	Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.	Cancer immunology, immunotherapy 	2008	77
18082451	Temozolomide	Gorlia T	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.	The Lancet. Oncology	2008	95
18556773	Temozolomide	Vlassenbroeck I	Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.	The Journal of molecular diagnostics 	2008	54
18565887	Temozolomide	Murat A	Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.	Journal of clinical oncology 	2008	233
18757334	Temozolomide	Hegi ME	Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.	Journal of clinical oncology 	2008	179
19088037	Temozolomide	Pallini R	Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.	Clinical cancer research 	2008	95
19118063	Temozolomide	Kulke MH	O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.	Clinical cancer research 	2009	53
19188675	Temozolomide	Brandes AA	Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.	Journal of clinical oncology 	2009	52
19265662	Temozolomide	Bleau AM	PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.	Cell stem cell	2009	239
19269895	Temozolomide	Stupp R	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.	The Lancet. Oncology	2009	1345
19536096	Temozolomide	Dunn J	Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy.	British journal of cancer	2009	67
19841865	Temozolomide	Karayan-Tapon L	Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods.	Journal of neuro-oncology	2010	49
19934293	Temozolomide	Palma JP	ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.	Clinical cancer research 	2009	46
20146084	Temozolomide	Ardon H	Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.	Journal of neuro-oncology	2010	44
20167819	Temozolomide	De Witt Hamer PC	Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.	Neuro-oncology	2010	42
20388803	Temozolomide	Hattermann K	The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.	Cancer research	2010	81
20439646	Temozolomide	Stupp R	Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.	Journal of clinical oncology 	2010	99
20444541	Temozolomide	Ujifuku K	miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.	Cancer letters	2010	55
20530668	Temozolomide	McEllin B	PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.	Cancer research	2010	81
20855119	Temozolomide	Minniti G	Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.	Radiotherapy and oncology 	2010	40
20921459	Temozolomide	Sampson JH	Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.	Journal of clinical oncology 	2010	205
20935218	Temozolomide	Gaspar N	MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.	Cancer research	2010	44
20975057	Temozolomide	Houillier C	IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.	Neurology	2010	92
21135282	Temozolomide	Lai A	Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.	Journal of clinical oncology 	2011	140
21149254	Temozolomide	Sampson JH	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.	Neuro-oncology	2011	92
21156036	Temozolomide	Etcheverry A	DNA methylation in glioblastoma: impact on gene expression and clinical outcome.	BMC genomics	2010	58
21425258	Temozolomide	Felsberg J	Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.	International journal of cancer	2011	49
21499132	Temozolomide	Fadul CE	Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.	Journal of immunotherapy	2011	54
21606416	Temozolomide	de Groot JF	Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.	Journal of clinical oncology 	2011	47
21737504	Temozolomide	Grossman SA	Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.	Clinical cancer research 	2011	84
21768296	Temozolomide	Mitchell DA	Monoclonal antibody blockade of IL-2 receptor Œ± during lymphopenia selectively depletes regulatory T cells in mice and humans.	Blood	2011	45
21988793	Temozolomide	Beier D	Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.	Molecular cancer	2011	80
22035272	Temozolomide	Narayana A	A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.	Journal of neurosurgery	2012	39
22045118	Temozolomide	Johnson DR	Glioblastoma survival in the United States before and during the temozolomide era.	Journal of neuro-oncology	2012	152
22048237	Temozolomide	Kirkwood JM	Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.	Clinical cancer research 	2012	77
22156195	Temozolomide	Agnihotri S	Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.	The Journal of clinical investigation	2012	32
22197930	Temozolomide	Stark MS	Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.	Nature genetics	2011	74
22244911	Temozolomide	Silber JR	O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.	Biochimica et biophysica acta	2012	30
22383993	Temozolomide	Sampson JH	A pilot study of IL-2RŒ± blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.	PloS one	2012	33
22469979	Temozolomide	Wagner L	Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-Œ∫B-dependent manner.	Oncogene	2013	28
22532597	Temozolomide	Kohsaka S	STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.	Molecular cancer therapeutics	2012	31
22593187	Temozolomide	Janouskova H	Integrin Œ±5Œ≤1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.	Cancer research	2012	32
23047041	Temozolomide	Triscott J	Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.	Oncotarget	2012	33
23183822	Temozolomide	Asuthkar S	Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity.	Oncotarget	2012	49
23370117	Temozolomide	Curtin NJ	Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.	Molecular aspects of medicine	2013	75
23383259	Temozolomide	Knizhnik AV	Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage.	PloS one	2013	39
23792642	Temozolomide	Comincini S	microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells.	Cancer biology & therapy	2013	32
23908450	Temozolomide	Wieland A	Anticancer effects of niclosamide in human glioblastoma.	Clinical cancer research 	2013	30
24101040	Temozolomide	Gilbert MR	Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.	Journal of clinical oncology 	2013	119
24147153	Temozolomide	Quintavalle C	MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.	PloS one	2013	27
24469053	Temozolomide	Zhang LH	TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway.	Oncogene	2015	16
24552317	Temozolomide	Gilbert MR	A randomized trial of bevacizumab for newly diagnosed glioblastoma.	The New England journal of medicine	2014	381
24552318	Temozolomide	Chinot OL	Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.	The New England journal of medicine	2014	358
24608791	Temozolomide	Auffinger B	Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.	Cell death and differentiation	2014	58
24861879	Temozolomide	Shi Z	MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.	Neuro-oncology	2014	36
24912512	Temozolomide	Wick W	MGMT testing--the challenges for biomarker-based glioma treatment.	Nature reviews. Neurology	2014	59
24980823	Temozolomide	Wang L	MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.	Oncotarget	2014	43
24991839	Temozolomide	Rangwala R	Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.	Autophagy	2014	73
25093489	Temozolomide	Han S	Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin Œ≤1-ERK pathway.	British journal of cancer	2014	26
25140036	Temozolomide	Simon M	TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.	Neuro-oncology	2015	28
25163906	Temozolomide	Stupp R	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.	The Lancet. Oncology	2014	126
25364264	Temozolomide	Lee JK	Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling.	OncoTargets and therapy	2014	23
25411133	Temozolomide	Galldiks N	Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-18Ffluoroethyl)-L-tyrosine PET.	European journal of nuclear medicine and molecular imaging	2015	26
25586468	Temozolomide	Schuster J	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.	Neuro-oncology	2015	66
25605243	Temozolomide	Wang Z	Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.	Oncotarget	2015	18
25609769	Temozolomide	Suchorska B	Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.	Neurology	2015	17
25762461	Temozolomide	Nabors LB	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.	Neuro-oncology	2015	30
25959588	Temozolomide	Shao H	Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma.	Nature communications	2015	43
26373279	Temozolomide	Kim J	Spatiotemporal Evolution of the Primary Glioblastoma Genome.	Cancer cell	2015	32
26846818	Temozolomide	Phillips AC	ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.	Molecular cancer therapeutics	2016	15
27020328	Temozolomide	Pitter KL	Corticosteroids compromise survival in glioblastoma.	Brain 	2016	14
27503138	Temozolomide	Arita H	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.	Acta neuropathologica communications	2016	12
27503200	Temozolomide	Gojo I	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.	Clinical cancer research 	2017	7
27690220	Temozolomide	Kawaguchi K	Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.	Oncotarget	2016	26
28106277	Temozolomide	Kawaguchi K	Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.	Journal of cellular biochemistry	2017	15
28121023	Temozolomide	Liao Y	LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway.	Journal of cellular biochemistry	2017	9
28187000	Temozolomide	Chen W	MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.	Oncotarget	2017	8
28233083	Temozolomide	Ludwig K	Molecular markers in glioma.	Journal of neuro-oncology	2017	9
28622068	Temozolomide	Kawaguchi K	Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.	Cell cycle	2017	8
28668966	Temozolomide	Li H	Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.	Cellular physiology and biochemistry 	2017	7
28844499	Temozolomide	Weller M	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.	The Lancet. Oncology	2017	11
7792600	1-Phosphatidyl-D-myo-inositol	Savitsky K	A single ataxia telangiectasia gene with a product similar to PI-3 kinase.	Science	1995	485
9330874	1-Phosphatidyl-D-myo-inositol	Frisch SM	Integrins and anoikis.	Current opinion in cell biology	1997	229
9508771	1-Phosphatidyl-D-myo-inositol	Honda K	Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion.	The Journal of cell biology	1998	102
9766667	1-Phosphatidyl-D-myo-inositol	Sarkaria JN	Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin.	Cancer research	1998	151
9799739	1-Phosphatidyl-D-myo-inositol	Haas-Kogan D	Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.	Current biology 	1998	102
10051603	1-Phosphatidyl-D-myo-inositol	Ramaswamy S	Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.	Proceedings of the National Academy of Sciences of the United States of America	1999	179
10400993	1-Phosphatidyl-D-myo-inositol	Marsh DJ	PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome.	Human molecular genetics	1999	98
10625637	1-Phosphatidyl-D-myo-inositol	Petiot A	Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells.	The Journal of biological chemistry	2000	324
10749120	1-Phosphatidyl-D-myo-inositol	Zhong H	Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.	Cancer research	2000	317
10839544	1-Phosphatidyl-D-myo-inositol	Zhao S	Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products.	Nature	2000	109
10866658	1-Phosphatidyl-D-myo-inositol	Vazquez F	Phosphorylation of the PTEN tail regulates protein stability and function.	Molecular and cellular biology	2000	218
11280739	1-Phosphatidyl-D-myo-inositol	Asselin E	XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.	Cancer research	2001	87
11358816	1-Phosphatidyl-D-myo-inositol	Brognard J	Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.	Cancer research	2001	209
11404460	1-Phosphatidyl-D-myo-inositol	Lin HK	Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.	Proceedings of the National Academy of Sciences of the United States of America	2001	102
11406568	1-Phosphatidyl-D-myo-inositol	Cuello M	Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.	Cancer research	2001	88
11431323	1-Phosphatidyl-D-myo-inositol	Sonoda Y	Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.	Cancer research	2001	90
11457733	1-Phosphatidyl-D-myo-inositol	Jiang BH	Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1.	Cell growth & differentiation 	2001	110
11477064	1-Phosphatidyl-D-myo-inositol	Arico S	The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway.	The Journal of biological chemistry	2001	140
11477091	1-Phosphatidyl-D-myo-inositol	Re F	Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells.	The Journal of biological chemistry	2001	140
11479209	1-Phosphatidyl-D-myo-inositol	Bachelder RE	Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells.	Cancer research	2001	106
11507052	1-Phosphatidyl-D-myo-inositol	Zhang X	Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia.	Cancer research	2001	107
11689445	1-Phosphatidyl-D-myo-inositol	Castoria G	PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells.	The EMBO journal	2001	91
11884591	1-Phosphatidyl-D-myo-inositol	Kops GJ	Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors.	Molecular and cellular biology	2002	107
11994454	1-Phosphatidyl-D-myo-inositol	Stahl M	The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2.	Journal of immunology	2002	195
12094235	1-Phosphatidyl-D-myo-inositol	Vivanco I	The phosphatidylinositol 3-Kinase AKT pathway in human cancer.	Nature reviews. Cancer	2002	1428
12149254	1-Phosphatidyl-D-myo-inositol	Fukuda R	Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells.	The Journal of biological chemistry	2002	169
12167664	1-Phosphatidyl-D-myo-inositol	Dan HC	Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin.	The Journal of biological chemistry	2002	100
12351634	1-Phosphatidyl-D-myo-inositol	Modur V	FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer.	The Journal of biological chemistry	2002	113
12391153	1-Phosphatidyl-D-myo-inositol	Schmidt M	Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D.	Molecular and cellular biology	2002	139
12446712	1-Phosphatidyl-D-myo-inositol	Dawson CW	Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling.	The Journal of biological chemistry	2003	94
12682293	1-Phosphatidyl-D-myo-inositol	Sudhakar A	Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins.	Proceedings of the National Academy of Sciences of the United States of America	2003	111
12764143	1-Phosphatidyl-D-myo-inositol	Mottet D	Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells.	The Journal of biological chemistry	2003	87
12781366	1-Phosphatidyl-D-myo-inositol	Zhao JJ	Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase.	Cancer cell	2003	101
12897778	1-Phosphatidyl-D-myo-inositol	Matsunaga T	Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.	Nature medicine	2003	143
14663478	1-Phosphatidyl-D-myo-inositol	Cox AD	The dark side of Ras: regulation of apoptosis.	Oncogene	2003	117
14769856	1-Phosphatidyl-D-myo-inositol	Liu H	Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells.	The Journal of cell biology	2004	96
15023437	1-Phosphatidyl-D-myo-inositol	Fresno Vara JA	PI3K/Akt signalling pathway and cancer.	Cancer treatment reviews	2004	316
15132991	1-Phosphatidyl-D-myo-inositol	Chung TW	Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential.	FASEB journal 	2004	72
15143086	1-Phosphatidyl-D-myo-inositol	Chakravarti A	The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.	Journal of clinical oncology 	2004	91
15209375	1-Phosphatidyl-D-myo-inositol	Mora A	PDK1, the master regulator of AGC kinase signal transduction.	Seminars in cell & developmental biology	2004	227
15231645	1-Phosphatidyl-D-myo-inositol	Yang L	Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.	Cancer research	2004	142
15254419	1-Phosphatidyl-D-myo-inositol	Bachman KE	The PIK3CA gene is mutated with high frequency in human breast cancers.	Cancer biology & therapy	2004	183
15289301	1-Phosphatidyl-D-myo-inositol	Broderick DK	Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.	Cancer research	2004	84
15339911	1-Phosphatidyl-D-myo-inositol	Hu P	Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death.	The Journal of biological chemistry	2004	87
15465916	1-Phosphatidyl-D-myo-inositol	Ono A	Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane.	Proceedings of the National Academy of Sciences of the United States of America	2004	225
15467468	1-Phosphatidyl-D-myo-inositol	Samuels Y	Oncogenic mutations of PIK3CA in human cancers.	Cell cycle	2004	131
15494427	1-Phosphatidyl-D-myo-inositol	Yu JL	Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.	Blood	2005	118
15502842	1-Phosphatidyl-D-myo-inositol	Cheng KW	The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers.	Nature medicine	2004	152
15766664	1-Phosphatidyl-D-myo-inositol	Kim RH	DJ-1, a novel regulator of the tumor suppressor PTEN.	Cancer cell	2005	133
15864272	1-Phosphatidyl-D-myo-inositol	Platanias LC	Mechanisms of type-I- and type-II-interferon-mediated signalling.	Nature reviews. Immunology	2005	718
15930273	1-Phosphatidyl-D-myo-inositol	Ikenoue T	Functional analysis of PIK3CA gene mutations in human colorectal cancer.	Cancer research	2005	97
15942189	1-Phosphatidyl-D-myo-inositol	Nawshad A	Transforming growth factor-beta signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis.	Cells, tissues, organs	2005	95
15994075	1-Phosphatidyl-D-myo-inositol	Velho S	The prevalence of PIK3CA mutations in gastric and colon cancer.	European journal of cancer	2005	97
16103051	1-Phosphatidyl-D-myo-inositol	Sun SY	Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.	Cancer research	2005	277
16168105	1-Phosphatidyl-D-myo-inositol	Wu G	Somatic mutation and gain of copy number of PIK3CA in human breast cancer.	Breast cancer research 	2005	66
16261406	1-Phosphatidyl-D-myo-inositol	Lo HW	EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization.	Breast cancer research and treatment	2006	67
16288007	1-Phosphatidyl-D-myo-inositol	Garc√≠a-Rost√°n G	Mutation of the PIK3CA gene in anaplastic thyroid cancer.	Cancer research	2005	84
16322209	1-Phosphatidyl-D-myo-inositol	Oda K	High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.	Cancer research	2005	116
16324768	1-Phosphatidyl-D-myo-inositol	Tang JM	Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.	Lung cancer	2006	87
16339315	1-Phosphatidyl-D-myo-inositol	Zhao JJ	The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2005	128
16341064	1-Phosphatidyl-D-myo-inositol	Hennessy BT	Exploiting the PI3K/AKT pathway for cancer drug discovery.	Nature reviews. Drug discovery	2005	541
16341083	1-Phosphatidyl-D-myo-inositol	Bader AG	Oncogenic PI3K deregulates transcription and translation.	Nature reviews. Cancer	2005	200
16390869	1-Phosphatidyl-D-myo-inositol	Zeng X	Functional specificity of the mammalian Beclin-Vps34 PI 3-kinase complex in macroautophagy versus endocytosis and lysosomal enzyme trafficking.	Journal of cell science	2006	117
16397234	1-Phosphatidyl-D-myo-inositol	Sunters A	Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.	Cancer research	2006	79
16449998	1-Phosphatidyl-D-myo-inositol	Karakas B	Mutation of the PIK3CA oncogene in human cancers.	British journal of cancer	2006	110
16478915	1-Phosphatidyl-D-myo-inositol	Kakinuma T	Chemokines, chemokine receptors, and cancer metastasis.	Journal of leukocyte biology	2006	85
16543232	1-Phosphatidyl-D-myo-inositol	Misra UK	Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78.	The Journal of biological chemistry	2006	73
16731745	1-Phosphatidyl-D-myo-inositol	Smalley KS	Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.	Molecular cancer therapeutics	2006	150
16732316	1-Phosphatidyl-D-myo-inositol	Cheng JC	Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway.	Oncogene	2006	64
16847462	1-Phosphatidyl-D-myo-inositol	Engelman JA	The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.	Nature reviews. Genetics	2006	829
16874027	1-Phosphatidyl-D-myo-inositol	Furuya N	The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function.	Autophagy	2005	135
16880536	1-Phosphatidyl-D-myo-inositol	Kasper M	Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes.	Molecular and cellular biology	2006	71
16912192	1-Phosphatidyl-D-myo-inositol	Chesler L	Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.	Cancer research	2006	62
17060456	1-Phosphatidyl-D-myo-inositol	Kim JS	Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.	Molecular and cellular biology	2007	61
17068222	1-Phosphatidyl-D-myo-inositol	Ferretti C	Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts.	Human reproduction update	2007	98
17210696	1-Phosphatidyl-D-myo-inositol	Maroulakou IG	Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.	Cancer research	2007	108
17234779	1-Phosphatidyl-D-myo-inositol	Tabe Y	Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells.	Cancer research	2007	61
17302559	1-Phosphatidyl-D-myo-inositol	Gharbi SI	Exploring the specificity of the PI3K family inhibitor LY294002.	The Biochemical journal	2007	107
17317825	1-Phosphatidyl-D-myo-inositol	Hou P	Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.	Clinical cancer research 	2007	112
17332339	1-Phosphatidyl-D-myo-inositol	Campbell PM	K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.	Cancer research	2007	79
17341655	1-Phosphatidyl-D-myo-inositol	Blanco-Aparicio C	PTEN, more than the AKT pathway.	Carcinogenesis	2007	120
17363567	1-Phosphatidyl-D-myo-inositol	Saxena NK	Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.	Cancer research	2007	118
17372210	1-Phosphatidyl-D-myo-inositol	Mehrian-Shai R	Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.	Proceedings of the National Academy of Sciences of the United States of America	2007	62
17452451	1-Phosphatidyl-D-myo-inositol	Delpuech O	Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression.	Molecular and cellular biology	2007	71
17452630	1-Phosphatidyl-D-myo-inositol	Saal LH	Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.	Proceedings of the National Academy of Sciences of the United States of America	2007	184
17457303	1-Phosphatidyl-D-myo-inositol	Marinkovich MP	Tumour microenvironment: laminin 332 in squamous-cell carcinoma.	Nature reviews. Cancer	2007	83
17563745	1-Phosphatidyl-D-myo-inositol	Kikuno N	Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity.	Oncogene	2007	79
17574021	1-Phosphatidyl-D-myo-inositol	Boehm JS	Integrative genomic approaches identify IKBKE as a breast cancer oncogene.	Cell	2007	238
17646396	1-Phosphatidyl-D-myo-inositol	Lamouille S	Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway.	The Journal of cell biology	2007	177
17692802	1-Phosphatidyl-D-myo-inositol	Brugge J	A new mutational AKTivation in the PI3K pathway.	Cancer cell	2007	92
17872411	1-Phosphatidyl-D-myo-inositol	Stommel JM	Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.	Science	2007	349
17973573	1-Phosphatidyl-D-myo-inositol	Cragg MS	Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.	PLoS medicine	2007	118
18079394	1-Phosphatidyl-D-myo-inositol	Huang CH	The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.	Science	2007	152
18245460	1-Phosphatidyl-D-myo-inositol	Graff JR	Targeting the eukaryotic translation initiation factor 4E for cancer therapy.	Cancer research	2008	110
18299320	1-Phosphatidyl-D-myo-inositol	Havasi A	Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism.	The Journal of biological chemistry	2008	53
18349857	1-Phosphatidyl-D-myo-inositol	Turley EA	Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?	Nature clinical practice. Oncology	2008	93
18593924	1-Phosphatidyl-D-myo-inositol	Ammoun S	Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.	Cancer research	2008	53
18611860	1-Phosphatidyl-D-myo-inositol	Roca H	CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation.	The Journal of biological chemistry	2008	55
18625725	1-Phosphatidyl-D-myo-inositol	Wang SE	Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.	Molecular and cellular biology	2008	65
18644989	1-Phosphatidyl-D-myo-inositol	Toulany M	Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.	Molecular cancer therapeutics	2008	52
18663744	1-Phosphatidyl-D-myo-inositol	Guo C	The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.	Genes, chromosomes & cancer	2008	124
18754654	1-Phosphatidyl-D-myo-inositol	Folkes AJ	The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno3,2-dpyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .	Journal of medicinal chemistry	2008	192
18757405	1-Phosphatidyl-D-myo-inositol	Yamamoto H	PIK3CA mutations and copy number gains in human lung cancers.	Cancer research	2008	145
18794134	1-Phosphatidyl-D-myo-inositol	Rainey MD	Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation.	Cancer research	2008	59
18806760	1-Phosphatidyl-D-myo-inositol	Maiuri MC	Control of autophagy by oncogenes and tumor suppressor genes.	Cell death and differentiation	2009	125
18829572	1-Phosphatidyl-D-myo-inositol	Oda K	PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.	Cancer research	2008	59
18991571	1-Phosphatidyl-D-myo-inositol	Lin Y	Luteolin, a flavonoid with potential for cancer prevention and therapy.	Current cancer drug targets	2008	89
19002158	1-Phosphatidyl-D-myo-inositol	Guo X	Signaling cross-talk between TGF-beta/BMP and other pathways.	Cell research	2009	232
19088048	1-Phosphatidyl-D-myo-inositol	Solit DB	Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.	Clinical cancer research 	2008	70
19117997	1-Phosphatidyl-D-myo-inositol	Ihle NT	Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.	Cancer research	2009	113
19147560	1-Phosphatidyl-D-myo-inositol	Wang SE	Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton.	Cancer research	2009	50
19147570	1-Phosphatidyl-D-myo-inositol	Mirzoeva OK	Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.	Cancer research	2009	116
19176381	1-Phosphatidyl-D-myo-inositol	Almog N	Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype.	Cancer research	2009	73
19214224	1-Phosphatidyl-D-myo-inositol	Read RD	A drosophila model for EGFR-Ras and PI3K-dependent human glioma.	PLoS genetics	2009	54
19318560	1-Phosphatidyl-D-myo-inositol	Szczepanski MJ	Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.	Cancer research	2009	64
19371598	1-Phosphatidyl-D-myo-inositol	Morselli E	Anti- and pro-tumor functions of autophagy.	Biochimica et biophysica acta	2009	93
19435916	1-Phosphatidyl-D-myo-inositol	Hennessy BT	Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.	Cancer research	2009	263
19491896	1-Phosphatidyl-D-myo-inositol	Shoji K	The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.	British journal of cancer	2009	52
19567914	1-Phosphatidyl-D-myo-inositol	Schoeberl B	Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.	Science signaling	2009	114
19568240	1-Phosphatidyl-D-myo-inositol	Meng XN	Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion.	British journal of cancer	2009	56
19573809	1-Phosphatidyl-D-myo-inositol	Vasudevan KM	AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.	Cancer cell	2009	187
19638457	1-Phosphatidyl-D-myo-inositol	Sarker D	Targeting the PI3K/AKT pathway for the treatment of prostate cancer.	Clinical cancer research 	2009	93
19647222	1-Phosphatidyl-D-myo-inositol	Gewinner C	Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.	Cancer cell	2009	145
19671852	1-Phosphatidyl-D-myo-inositol	Kalinsky K	PIK3CA mutation associates with improved outcome in breast cancer.	Clinical cancer research 	2009	109
19789314	1-Phosphatidyl-D-myo-inositol	Platt FM	Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.	Clinical cancer research 	2009	71
19797076	1-Phosphatidyl-D-myo-inositol	Simonsen A	Coordination of membrane events during autophagy by multiple class III PI3-kinase complexes.	The Journal of cell biology	2009	159
19797085	1-Phosphatidyl-D-myo-inositol	Li X	beta-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt.	Molecular and cellular biology	2009	46
19805105	1-Phosphatidyl-D-myo-inositol	Mandelker D	A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.	Proceedings of the National Academy of Sciences of the United States of America	2009	96
19850932	1-Phosphatidyl-D-myo-inositol	Ng SS	Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade.	The Journal of biological chemistry	2009	52
19889969	1-Phosphatidyl-D-myo-inositol	van den Bout I	PIP5K-driven PtdIns(4,5)P2 synthesis: regulation and cellular functions.	Journal of cell science	2009	68
20081861	1-Phosphatidyl-D-myo-inositol	Houghton AM	Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth.	Nature medicine	2010	120
20085938	1-Phosphatidyl-D-myo-inositol	Courtney KD	The PI3K pathway as drug target in human cancer.	Journal of clinical oncology 	2010	325
20212113	1-Phosphatidyl-D-myo-inositol	Chagpar RB	Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.	Proceedings of the National Academy of Sciences of the United States of America	2010	61
20233997	1-Phosphatidyl-D-myo-inositol	Zhang J	Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.	Journal of the National Cancer Institute	2010	74
20388916	1-Phosphatidyl-D-myo-inositol	Poliseno L	Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation.	Science signaling	2010	166
20453058	1-Phosphatidyl-D-myo-inositol	O'Brien C	Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.	Clinical cancer research 	2010	87
20471940	1-Phosphatidyl-D-myo-inositol	Chin YR	The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.	Molecular cell	2010	55
20522708	1-Phosphatidyl-D-myo-inositol	Herman SE	Phosphatidylinositol 3-kinase-Œ¥ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.	Blood	2010	160
20535651	1-Phosphatidyl-D-myo-inositol	Samuels Y	Oncogenic mutations of PIK3CA in human cancers.	Current topics in microbiology and immunology	2010	43
20622047	1-Phosphatidyl-D-myo-inositol	Zhang S	PI(3)king apart PTEN's role in cancer.	Clinical cancer research 	2010	77
20643123	1-Phosphatidyl-D-myo-inositol	Thoresen SB	A phosphatidylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic.	Experimental cell research	2010	62
20864032	1-Phosphatidyl-D-myo-inositol	Horejs√≠ Z	CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability.	Molecular cell	2010	58
20959606	1-Phosphatidyl-D-myo-inositol	Lannutti BJ	CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.	Blood	2011	185
21216931	1-Phosphatidyl-D-myo-inositol	Vilar E	Pushing the envelope in the mTOR pathway: the second generation of inhibitors.	Molecular cancer therapeutics	2011	37
21320503	1-Phosphatidyl-D-myo-inositol	Ke AW	CD151 amplifies signaling by integrin Œ±6Œ≤1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells.	Gastroenterology	2011	43
21324922	1-Phosphatidyl-D-myo-inositol	Adams JR	Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.	Cancer research	2011	38
21447798	1-Phosphatidyl-D-myo-inositol	Little AS	Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.	Science signaling	2011	55
21596819	1-Phosphatidyl-D-myo-inositol	Murugan AK	Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.	Cancer research	2011	45
21628414	1-Phosphatidyl-D-myo-inositol	Kuchenbauer F	Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells.	Blood	2011	38
21779497	1-Phosphatidyl-D-myo-inositol	Castellano E	RAS Interaction with PI3K: More Than Just Another Effector Pathway.	Genes & cancer	2011	123
21818118	1-Phosphatidyl-D-myo-inositol	Qiang L	HIF-1Œ± is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway.	Cell death and differentiation	2012	59
21822287	1-Phosphatidyl-D-myo-inositol	Liu P	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.	Nature medicine	2011	93
21909130	1-Phosphatidyl-D-myo-inositol	Astle MV	AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.	Oncogene	2012	47
21984976	1-Phosphatidyl-D-myo-inositol	Cheung LW	High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.	Cancer discovery	2011	129
22002674	1-Phosphatidyl-D-myo-inositol	Florey O	Autophagy machinery mediates macroendocytic processing and entotic cell death by targeting single membranes.	Nature cell biology	2011	112
22065080	1-Phosphatidyl-D-myo-inositol	Koul D	Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.	Clinical cancer research 	2012	50
22133722	1-Phosphatidyl-D-myo-inositol	Roychowdhury S	Personalized oncology through integrative high-throughput sequencing: a pilot study.	Science translational medicine	2011	190
22247021	1-Phosphatidyl-D-myo-inositol	Ihle NT	Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.	Journal of the National Cancer Institute	2012	98
22453015	1-Phosphatidyl-D-myo-inositol	Davies MA	The role of the PI3K-AKT pathway in melanoma.	Cancer journal	2012	42
22471665	1-Phosphatidyl-D-myo-inositol	Sheppard K	Targeting PI3 kinase/AKT/mTOR signaling in cancer.	Critical reviews in oncogenesis	2012	70
22494966	1-Phosphatidyl-D-myo-inositol	Torsvik A	Mesenchymal stem cell signaling in cancer progression.	Cancer treatment reviews	2013	27
22588880	1-Phosphatidyl-D-myo-inositol	Ni J	Functional characterization of an isoform-selective inhibitor of PI3K-p110Œ≤ as a potential anticancer agent.	Cancer discovery	2012	56
22614243	1-Phosphatidyl-D-myo-inositol	Simioni C	Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.	Leukemia	2012	30
22619466	1-Phosphatidyl-D-myo-inositol	Wen PY	Current clinical development of PI3K pathway inhibitors in glioblastoma.	Neuro-oncology	2012	40
22692215	1-Phosphatidyl-D-myo-inositol	Huang W	The N-terminal phosphodegron targets TAZ/WWTR1 protein for SCFŒ≤-TrCP-dependent degradation in response to phosphatidylinositol 3-kinase inhibition.	The Journal of biological chemistry	2012	40
22713753	1-Phosphatidyl-D-myo-inositol	Huang J	SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane.	Nature communications	2012	50
22729222	1-Phosphatidyl-D-myo-inositol	Lindhurst MJ	Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA.	Nature genetics	2012	46
22936542	1-Phosphatidyl-D-myo-inositol	Rose DP	The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression.	Endocrine-related cancer	2012	33
22969158	1-Phosphatidyl-D-myo-inositol	Hoshino D	Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKCŒ± invasive signaling axis.	Science signaling	2012	33
23094721	1-Phosphatidyl-D-myo-inositol	Liao X	Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.	The New England journal of medicine	2012	225
23112296	1-Phosphatidyl-D-myo-inositol	Wang RC	Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation.	Science	2012	167
23236232	1-Phosphatidyl-D-myo-inositol	Sukawa Y	Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.	World journal of gastroenterology	2012	32
23348690	1-Phosphatidyl-D-myo-inositol	Ha GH	TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways.	Cancer letters	2013	28
23420005	1-Phosphatidyl-D-myo-inositol	Fu LL	Beclin-1: autophagic regulator and therapeutic target in cancer.	The international journal of biochemistry & cell biology	2013	42
23604117	1-Phosphatidyl-D-myo-inositol	Zhu X	Synergy between Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 and HIV-1 Nef protein in promotion of angiogenesis and oncogenesis: role of the AKT signaling pathway.	Oncogene	2014	21
23643389	1-Phosphatidyl-D-myo-inositol	Hao Y	Gain of interaction with IRS1 by p110Œ±-helical domain mutants is crucial for their oncogenic functions.	Cancer cell	2013	25
23658859	1-Phosphatidyl-D-myo-inositol	Martini M	Targeting PI3K in Cancer: Any Good News?	Frontiers in oncology	2013	36
24037752	1-Phosphatidyl-D-myo-inositol	Wright AA	Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.	Cancer	2013	43
24076665	1-Phosphatidyl-D-myo-inositol	Filbin MG	Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.	Nature medicine	2013	41
24261963	1-Phosphatidyl-D-myo-inositol	Akinleye A	Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.	Journal of hematology & oncology	2013	60
24387334	1-Phosphatidyl-D-myo-inositol	Dillon LM	Therapeutic targeting of cancers with loss of PTEN function.	Current drug targets	2014	29
24440701	1-Phosphatidyl-D-myo-inositol	Wang Y	MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.	Biochemical and biophysical research communications	2014	24
24450858	1-Phosphatidyl-D-myo-inositol	Gopal AK	PI3KŒ¥ inhibition by idelalisib in patients with relapsed indolent lymphoma.	The New England journal of medicine	2014	145
24533074	1-Phosphatidyl-D-myo-inositol	Wang L	PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.	PloS one	2014	28
24607406	1-Phosphatidyl-D-myo-inositol	Todaro M	CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.	Cell stem cell	2014	116
24615777	1-Phosphatidyl-D-myo-inositol	Brown JR	Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110Œ¥, for relapsed/refractory chronic lymphocytic leukemia.	Blood	2014	124
24762440	1-Phosphatidyl-D-myo-inositol	Yang Y	ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.	The Journal of clinical investigation	2014	40
24813945	1-Phosphatidyl-D-myo-inositol	Gelato KA	Accessibility of different histone H3-binding domains of UHRF1 is allosterically regulated by phosphatidylinositol 5-phosphate.	Molecular cell	2014	30
24867100	1-Phosphatidyl-D-myo-inositol	Wang F	MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma.	Tumour biology 	2014	22
24981249	1-Phosphatidyl-D-myo-inositol	Liu G	MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer.	Tumour biology 	2014	20
25001183	1-Phosphatidyl-D-myo-inositol	Hu J	microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.	European journal of cancer	2014	33
25183785	1-Phosphatidyl-D-myo-inositol	Rubashkin MG	Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate.	Cancer research	2014	41
25475121	1-Phosphatidyl-D-myo-inositol	Huang XP	MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.	The FEBS journal	2015	20
25503676	1-Phosphatidyl-D-myo-inositol	Wei JX	Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells.	Hepatology	2015	25
25544637	1-Phosphatidyl-D-myo-inositol	Costa C	Measurement of PIP3 levels reveals an unexpected role for p110Œ≤ in early adaptive responses to p110Œ±-specific inhibitors in luminal breast cancer.	Cancer cell	2015	46
25559818	1-Phosphatidyl-D-myo-inositol	Majewski IJ	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.	Journal of clinical oncology 	2015	46
25650317	1-Phosphatidyl-D-myo-inositol	Ghosh JC	Adaptive mitochondrial reprogramming and resistance to PI3K therapy.	Journal of the National Cancer Institute	2015	27
26117819	1-Phosphatidyl-D-myo-inositol	Yap TA	Drugging PI3K in cancer: refining targets and therapeutic strategies.	Current opinion in pharmacology	2015	40
26233890	1-Phosphatidyl-D-myo-inositol	Guo H	The PI3K/AKT Pathway and Renal Cell Carcinoma.	Journal of genetics and genomics = Yi chuan xue bao	2015	17
26404259	1-Phosphatidyl-D-myo-inositol	Faes S	PI3K and AKT: Unfaithful Partners in Cancer.	International journal of molecular sciences	2015	29
26926684	1-Phosphatidyl-D-myo-inositol	Desmedt C	Genomic Characterization of Primary Invasive Lobular Breast Cancer.	Journal of clinical oncology 	2016	18
26977882	1-Phosphatidyl-D-myo-inositol	Pei Y	HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.	Cancer cell	2016	19
27095788	1-Phosphatidyl-D-myo-inositol	Bojarczuk K	BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.	Blood	2016	15
27199435	1-Phosphatidyl-D-myo-inositol	Quail DF	The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.	Science	2016	42
27613818	1-Phosphatidyl-D-myo-inositol	Li T	Role of the PI3K-Akt Signaling Pathway in the Pathogenesis of Polycystic Ovary Syndrome.	Reproductive sciences	2017	6
28123856	1-Phosphatidyl-D-myo-inositol	Liu J	MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by targeting PIK3CA.	American journal of cancer research	2017	5
28518139	1-Phosphatidyl-D-myo-inositol	Li N	MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer.	Cell death & disease	2017	10
